{"docstore/metadata": {"d2018a0b-99a7-4de0-b35a-6db10cebcd76": {"doc_hash": "74565707c8d9a0356f1abb8a6d9c7ce122d35b8f84d41075b4bd9f6e47eba641"}, "4faa2b7c-5f02-4209-96be-16c4ee565c75": {"doc_hash": "cb8a2d4b25cb81f91a31307b0a31cce00e8b9bf7fede74f26beb7b9dcb92b972"}, "0c51c536-373b-498e-8826-f6146e4caaf0": {"doc_hash": "14886388cac80b43fa2be5fc8808dc4a1a65cf898a83fbbe3205fa6694a29ebd"}, "500320de-55c2-45fa-a58d-487bc0b2179c": {"doc_hash": "cf7c704e1adac0bc4ca8621dde71c3824af6bcc3f4376e8cad79e503e2828364"}, "25004ac4-94a1-4f23-9f07-6ef3e4b4e22d": {"doc_hash": "880c1c9e8982d3c038e12dce32f06a655dd428c8e161de6c41d08ea3268f6dec"}, "ddde90c3-b670-4525-ae1e-9a1da3042086": {"doc_hash": "04bf986d66e91011015ee62c7033e973bab217a09cb156753d26b536d84a1292"}, "d1e98709-babe-4168-8e3d-b01d49bdae84": {"doc_hash": "4cf06c270bbf89b2323ea94cd59aa6196d3ce5fd9f91381e2e0c4c46b33ae232"}, "4b54fbc9-05a8-4ebd-97df-cc37d32d7c73": {"doc_hash": "d39c951cdb80db32195f66716fcfdcd1719468cebfdd86cf5fdeb4ce54bf23ae"}, "0c032fed-74ec-416f-8aed-9a47cf07898c": {"doc_hash": "df0c97cb85e513f5fd4a370b506c341529eba2d046e90634111a5986789ee7ed"}, "91470221-06ff-482c-8ce7-889eb870df07": {"doc_hash": "9a95922d6553d49538abcc4fecce0bfb500d5ff3dd7c7e6cc113ea8fb3ebdb31"}, "9385da6c-c575-4c4b-bc41-8e08c17a3d81": {"doc_hash": "a5c953c4e60f8ef9a3c2344043d35a2890c894539ed2f5c3f5902a1686765c44"}, "28648416-88b7-4171-88cf-8bcec594df5c": {"doc_hash": "827176e0922de10f8b3587b5f758be7ac59f3b7eb23ff2fcd85463b7f7ac42a8"}, "b9068d91-e1f4-44f8-973f-cce4d54198dc": {"doc_hash": "4767edd0ca71e0c593f6adf65de7f55e526686d63dceb3abc108546d2d1fff52"}, "eb2d3c6b-4c1f-4771-936a-acdb71e35049": {"doc_hash": "c185a927411f7b9f4f7aed43f564769a66ea502de404172bb7b0c4890df44220"}, "978ed50c-f15e-4976-b3b8-78528ff00afa": {"doc_hash": "7498e6cf5143f4cf456b3bcfccb400462c245fd80f8779a976354a073640c5a2"}, "7c60562a-1161-44a9-b17b-eea513c59ccb": {"doc_hash": "cd824f243a478d90a447548ac4bd3a1d5e19b487b455b841e7f39716aab99103"}, "57c141a6-7490-4731-9da8-31c398d172a6": {"doc_hash": "5acf2df57c154a0faa5e89d492875bd7d9d2789a60bd599342ed2199ac9c2395"}, "4c61839e-63a8-4b1a-8b41-a6c4b39d229c": {"doc_hash": "6e21eb1453efc7711139dbefea2bdf121b89bf21809fc4d26ff2b44a9e3b2cc3"}, "d618ddfb-b57a-425c-8f3c-cdadb780f905": {"doc_hash": "f1c8cb8c250ef9a8be7e747baeeede970dd9fdaf8f714ac64cbc17947643dd16"}, "4354f20f-b099-4c4c-abae-bd50d7e5c5db": {"doc_hash": "843dc3e1b889a3f8bf8b0f6cc69eba3be4873f8c39337d132e30dfb5162282c8"}, "732d36ef-8c5d-4588-962d-c4dc4204f1d8": {"doc_hash": "cb9da7ec2786b1147d67c1eb465f3af8f67e04b9317bd69482b79bce53ef2aa2"}, "d71baa71-40d8-4aab-a8c7-ba6cbee55a69": {"doc_hash": "f58706d2ce887b4e87b91daa7fe87fc8c4681a9690d331b72c3cc6d7c5372436"}, "a7b50c76-9e54-4854-bd18-e3af5c016e41": {"doc_hash": "1fadb6fc6fec33b365257b6b1a0c200538769c3fee4252f2d66a2caa1a07ff06"}, "7270adbc-d000-4c2e-8351-acb5ff28e3b9": {"doc_hash": "9d46d62fb558230b187be2544419355b683238241bed7e35389af931776c1fb1"}, "f0950654-0b9e-47e7-acbd-2d780485001d": {"doc_hash": "52ea00d66c4e476902bb3a867c1d7297ee1ae565eb951b88017241680b51ca1f"}, "9208caf8-3de9-4cef-8a2e-49a8017f71b4": {"doc_hash": "357b428e48f71fffd81a2e9d119272c538f018cae0ea805122877c9db7f0bfec"}, "1b3d1945-0882-4162-bf8d-3a6834fb8fbb": {"doc_hash": "a8fd4bda01fcbcf5f1a873f3151755bfe8ed263acb7127d8896dd4390846b67d"}, "5fd22f96-9a35-4f85-9010-fbf0469d9fa7": {"doc_hash": "333ce573095cdc9d599e0ca5930d825e70e14388f92724a506bede4d5b63bc0f"}, "b9da6b8c-332e-4fe7-8f05-7a7f25d2fa67": {"doc_hash": "2b8430a2369100921f2a0be4a655a23602961c7d914947d77271e065efe5df47"}, "4a1be7b9-f3dd-43d7-a3ee-65352c2eee30": {"doc_hash": "7e31015549c74b58ab598614c328605c4289176d47b88022cc5a9a9545630d08"}, "31fd1866-f5e7-434f-8dae-c26972fde9a5": {"doc_hash": "8a20f5712c34685c3a7f2bbfb31139973433e66cb2982a37b558f8b5906e5615"}, "4469f94f-ee49-4d40-9fe7-1158afa84afe": {"doc_hash": "e9784f45f4e11983302557df6dfaa3a59ebb9ca3a4bf6e11099e7e31cd36424d"}, "fe46a362-7871-46bc-9d56-2a7f3396288f": {"doc_hash": "b477fd3599d562a0c6ca53231fad6462252a9ec456e59983da177d6d7d3b75ae"}, "8876b368-19a7-4502-aaa9-fc8a556abbfa": {"doc_hash": "269a2b60f4f20e8b9a92f7107145273c0138c93b1341fec5213a3c2cac202b7e"}, "1ae36d76-8e88-46f5-bd67-67be78e26f04": {"doc_hash": "461315d5ff01dd1863099f4b9f9e8a43b932adbab04987a15277df2ac398bc17"}, "acbced89-6a78-470f-a420-ae6270eaaa32": {"doc_hash": "f3e3b6c81601aaa9d8ee5d8f821d45bd59d3a3071c0c25ac0f20351b00fd7964"}, "72bf1cf0-9d16-40d5-8ee5-808edcfdad08": {"doc_hash": "585f69b9e2b11ec1909ca94c1f03766f2955aba243eba325e7b051589dbec6be"}, "3de89589-f389-4a0a-b91d-726e5db42433": {"doc_hash": "737398ffe9758ea072082a80eee34108f4223ccd7bcfe3e8e8aca37f29f42859"}, "50beb819-1b07-416c-a3ad-ef33c77c122c": {"doc_hash": "dd4bf6afdf011adff1e4c7a27a3eb7811b7cff5b5f8f8caf69f83e6a00969f39"}, "dae59523-8e69-483b-8677-6182b6742476": {"doc_hash": "66fbe2c92beb40b14c8b2ad4fe94b0b6523de35bbb5835bca5bfaa8fd3f25f09"}, "66d5f9dd-87a8-4e3b-9d0f-3f00f07bed8b": {"doc_hash": "0342b705ae17d3abb1598c853f4fe617c98215aa80c61e00c1a8f1133b8baeb5"}, "9f005ea6-598c-43fd-8d3d-391cb5fb6563": {"doc_hash": "ea1374df0d36c0050c998878cfc5a725f6c78b8bc8020cde36e2b5a0ffc18f3f"}, "8a5922cc-57db-492a-a06c-5af9acfc185f": {"doc_hash": "94df22d14e46d785af8e6057dca3d203d75d10ec252250e896c3c2f1b1bc5b14"}, "78b95546-d2da-4e4c-9867-d8be86dd08fc": {"doc_hash": "0a5c0905a9839bde7f31b7da6acd3d512a12283c62adf4275ff7e44f9728142f"}, "f2742f62-db69-4fbf-b8a2-21103d882643": {"doc_hash": "4d7d656753c18f3b7b5c27aa1d9b06b991f99cf67f5654ec46c2a8e806f20900"}, "601fe89c-ec16-42ba-b5a9-caddb108acd6": {"doc_hash": "ffa5066623d53c5146dda5bd217e7049211665e2104d40ac27d27c69cc1b83d8"}, "81eae37b-ccf3-4aa5-8e22-b1c75bf034bc": {"doc_hash": "7ce3a680a94dc72de7ffb68f73f31f392c0afffc798cb2f998c80a62bbcaa276"}, "4cc40bdd-3b88-451b-8008-e1a3b76a5612": {"doc_hash": "18dc294bdc6e5885997a62a0b0e64c381aab2ce69e95bea976973fb6d9d596a5"}, "7fddc816-947f-43c5-a2ce-f7e189b6c1ff": {"doc_hash": "5f690dd758d5e0d1dd74135e1a4b9e96d8eacdaf029ba8b3d64ddf2728bdc656"}, "9c603077-5325-4529-94b5-c53e270b5935": {"doc_hash": "3ed1e08b47e09e889822dce44a9376e0b3cbe4257a852d765e3dc3332ab3c9f7"}, "bd29e430-dd99-46a4-b025-8ccd04ffc7fb": {"doc_hash": "48fbe4fc90f4a7cd0b6c3d7e673a479780fb073077d59e083c638b3caa4854d4"}, "bccae22b-16b6-481b-b0cc-d625db6ca65f": {"doc_hash": "069985f69eec88a61beb7f04cd038ff6a807845d201e6d2423b00e1cb94c01e8"}, "efc2184b-6b98-42fe-8c89-a4da99c9f400": {"doc_hash": "001c0fcc2e02e741594c2d8a78447d92664ecc7bd4af2ae52b4b339a2f08ec81"}, "0db58665-1e8e-4c84-9173-ccc828c87871": {"doc_hash": "f8415537228069419c7d67bacd36d863f353c90124c33af68fbf5f582dc3c405"}, "79fdffcd-9489-4262-a81d-bcbe43beca14": {"doc_hash": "671d72bb27c43905ee430ec1637ac28628f248d5097b2f72c4ce206886fa0884"}, "8be2043a-23a5-499e-9c2e-0a960733f1e0": {"doc_hash": "4d9fddb435b7948c31d9eb352085fecc7fb642964d5e97172daff6acd3113653"}, "37c094c9-4ded-4b8f-a3d5-bd6187acc8d7": {"doc_hash": "e1983c848ea071c4f590e6ce03c395f8322c693241ef518e469b9738546100b3"}, "761bb3fe-8847-42e7-9d73-5d3d8abc6b6b": {"doc_hash": "fcb9630e17309080bbf6f53ac9708a63fdbf44ddd52f692584301f007e447f79"}, "56ff51f7-ccb5-4c78-8d0a-99145acf70e4": {"doc_hash": "624d55bf5486df7a263ab86d8a4536843acf45dd1dfa2b3212fbbe0964913d69"}, "5f99e93f-2d79-41b7-bf31-24037874c191": {"doc_hash": "e56dd24961bdfacfcb20b6906eae1520e7cfab3d425b1d0938cf058b02ee1b28"}, "a932a3d2-886d-4a41-b4eb-c9e7304ef568": {"doc_hash": "89e87dc62e093c4e34f1cc38a09334b8838587d01779ae8fab84549c458bd4cc"}, "fdaa53d7-c08b-4351-b327-0fea1e9db34b": {"doc_hash": "1164cdf6ae64c85b648c0d345f1fc92b094d8d68077c2abb53f58d7570d64d5f"}, "017b08de-905a-4437-b0a2-d21b6c4cde5d": {"doc_hash": "c1db0a076bd79315de61789242150dc1e7b7ec0514cd05fa7406b153c2cf3751"}, "fde648af-5d4d-4dae-b4e2-a4d334b16383": {"doc_hash": "bb842ef8925a3e021557e8e611cf5137c28568e0c57ad55083469e9a4d289489"}, "efdc7e73-93b5-4b14-8f55-54d4edd305b8": {"doc_hash": "258e321a642865cd5b2b9e7527e45a884d2c4ae18eb26f85bb4441eaff335d7e"}, "ef7a8cb3-c404-4478-bfd6-d48cc93996ff": {"doc_hash": "d18a07df6c5c3c397101ca7a308fb7ebf9a5894d2bda2a54f85b3f27541a1ca4"}, "27abbbdc-485a-4983-9ac7-0666588bd8f7": {"doc_hash": "a8cad37288a5659c5ea38d1a8f459db0c54cc486efb61c8b0d8b4fedf05f2c29"}, "793fdd24-7965-4ec3-b67b-002f28e312e3": {"doc_hash": "b2486298939ec5ef3139be58b8d79c4a3364a20bb2aeb6a6c4d23676af0a7168"}, "a5cb8601-86b0-4a92-983b-21f73c7f3edb": {"doc_hash": "cafff973f75d1e27ebbba0a4417e9f81bde61a2e042266f817ca7ac86ad2670d"}, "36ef91a0-45ad-4de5-b37f-0347da796824": {"doc_hash": "cd8bbbb4f1375cae3c075d6791b113afbe634ce49838a95de38fe82c10a034b7"}, "9fba4c60-5030-4e2d-a80a-dc88ba2d1be1": {"doc_hash": "c640a6c675caea2faad2dda4e6a94a40ec9e5901f927866a1f604b329209b647"}, "66af6b35-4748-45dc-b047-5db47c7454a6": {"doc_hash": "80b97cffae053ec2cf5e7cd0120774c52990f260cc57e8a4ee0d82dd1f279284"}, "1a5b021a-1251-462c-88b3-0441db498c9b": {"doc_hash": "75e3602f512ad96e7ba1cd00c2b37c8f26f256089b7a01c4b6bf71806d9b91ba"}, "65906fe0-97af-478d-89e7-6eb93bae2203": {"doc_hash": "cd85c6ed225bd9850177a1863ba8fa6178c1ba9f33cd51860e5efb8196247f9b"}, "bfaa9764-5597-4dd1-9ad9-b29835b17ea0": {"doc_hash": "3a7943ae0ea19d6e4c9c835408528275942222c84a5e4152b19cd942643bb13b"}, "b86e0623-b7c5-418e-af81-6f680a0cd825": {"doc_hash": "cd9db9eaf0f622e0c68acf84c73f50cb1a8a5ffa38e944de586610d143706b9d"}, "211ae5a8-aeaf-4f78-a2a1-9bf5cde183b7": {"doc_hash": "bc2246cee9fba476d00e8d2390350b3eacc036c10ff60ef2401eab07685a5171"}, "8ef58779-6977-4fb6-bb69-64d6dc4f6015": {"doc_hash": "d30b3c6324f1b4be19f848734eac6714cba1b45ea687536a1b2c40ea8523290d"}, "b78963f2-1427-4e4b-bd11-712b03dd4aa9": {"doc_hash": "c6786a2563e246676abb9cd6e9ea3378160a1ba3ee4588024886cf809dbd7973"}, "a2980ba1-b4f5-4bf3-acfc-46666d7c0419": {"doc_hash": "bb6a729009f40b581cb316723c03cec6e353f75dd7a948aabe2fc1768a45a514"}, "4298f04d-6f99-48e7-bb95-9f26e912c4e1": {"doc_hash": "3509c7ec1bd42f08a032285db00244e6ab4aa041194c03bcd3ff7294762e58a4"}, "807e3618-d7a6-4343-833b-06d85b548478": {"doc_hash": "c65639a4c58475d9484698fc3b72e4ef4784db215f2dd29f1e3e71229a8b52cc"}, "e041abad-2618-46dd-a041-1dbc2e08bfcd": {"doc_hash": "a94dd787316e0ab5cda3fac8e31ba9cde57f5fdc1c96595b2ad8e9c77beff89b"}, "c0f03fd7-3c41-4ff5-a615-578abb7836cb": {"doc_hash": "9a72d237982fbcfae28841c94c79ed38daf194c5b94e171523dfde59bf0acd8e"}, "587dc3cd-fde2-4c71-9b40-2473b771f4ce": {"doc_hash": "d0caab3a225473595dcee1775e2dcb361ac0c12192e28252cd2a3c74094cbef7"}, "98e95dbf-dafc-4247-b20b-a4d84fa6aa19": {"doc_hash": "07574c2e33364620d2a42d064ceeb0d622a5385e2d48a322546f2df27598b57f"}, "d9aebe03-7172-4603-a4b9-fc252f4f8120": {"doc_hash": "90ffcc5b0dd24b6fbd20d160153f2ea3a7b59689e2ad777a6304789ef31d9628"}, "3b2cf5c8-27eb-4c9f-adb7-bfb585a20e39": {"doc_hash": "ab128eeada50196a6cf0f2ba4f7a46cd8aff0a17fc5d673ade5ed532a4c2b52b"}, "69240135-82d6-4306-a1b8-5797f4d75cfd": {"doc_hash": "b5872cff7a6e6a915f91abe24708d89b69ac50583165170848aaf0dd83025e79"}, "cf63ca09-1733-45ca-8a29-5299aabac73e": {"doc_hash": "ccbdc581f4a8307efab6b13319c9bfe02b0b8172cc599bf787e5c1537dee0a07"}, "ab208677-7742-45fd-ac0a-4cce1ba8ded8": {"doc_hash": "8236c04858e7174c21051af10c309e722f6ed1625289082df1a9ba4353d01492"}, "d8fa741f-944a-4fa7-923c-79699ba8d751": {"doc_hash": "0783d52884e6631cf091f0f04e7dadf8e64e96a603487e8b5dcec0333b211310"}, "45c8bb38-02a6-4db8-a11e-c0451354b3fd": {"doc_hash": "98fde020e935bc77743c9bb17f90a7c1a802382c9ce509d77009ffd46f92c5bc"}, "ed0be872-0597-40be-a640-49c6a519b7af": {"doc_hash": "b9d8f8ac50cfbd28a640f640a7d0289b291d49c0dfbcf03469f634d5443013d7"}, "234e85aa-e810-4fe5-9151-925d4e029b6a": {"doc_hash": "12857ad022ab87278704bc128d8a9ee084a7c3beea80fdadda3caaed2cbe4700"}, "9365d75b-df22-4bb1-87b1-c8becc020be8": {"doc_hash": "e46d7068558276a44c2e6229759301840c7c40441f93d44289e27159fbffde5a"}, "ac87c0ae-85e3-4cf2-a730-61f926edf400": {"doc_hash": "8251d8cf0bc6a7bf4a6c61ff6a6e636131331c6fe1d8602c872b3258f50b838d"}, "3d644fb7-3fee-4891-ad11-4a3c02452a32": {"doc_hash": "c471eb3d0318d7c34a168bc45cd3ad5ee989627e415c6b3b6212777978375525"}, "35f0cc85-d0d6-45e8-b14f-549678a8827a": {"doc_hash": "47fc4f1b6292668804fe84643e32ef24c18ccf62cb82c2fa1e55901cd8b20711"}, "9f50783a-89b7-4389-9e19-116448179aec": {"doc_hash": "9f62200a82de3ce472e26fdc6c2d8ba78d6e627ccf23a22a9dbd5b32bc41ecc8"}, "96d19885-c85b-4254-80c4-3c172b24dc5b": {"doc_hash": "d13571f937a3a0bfbb833bd1789aa4d577e6af4bb753aa5079097cc290f8f32a"}, "1f79b2e0-32a2-45a8-b114-db0d43b38822": {"doc_hash": "118fb2b0a931f922dd85dd19b227151758d1aee9b4be64ba9299eedc40dde1d0"}, "ebe6da7b-2906-41d9-9edd-32ff3638114d": {"doc_hash": "c2ab1426ff8243f3ce70ce115ed992e6b7e49b6599b2e4a193416b0b9eb7a500"}, "5bab9eb1-2820-4291-945b-30ae3ce9e833": {"doc_hash": "66f5b69e4d117e786e597ec474c5a80278700a743569f0e203adb6b14da68056"}, "080f72b3-c692-44bf-8b6b-e35c0a8e24ff": {"doc_hash": "9129f40347fb39dc4cc87aeaac8e2cc0f609adbc11e506d91506161dbfca0ef5"}, "75455cda-720f-4281-ad8d-c459a128196e": {"doc_hash": "e15a74ddecd808fb0fb4c822003fe6631213d294d443a080b076ef7503e4d53e"}, "40a58b3d-7df0-4217-8a28-e348002a8d80": {"doc_hash": "8c1948b64aa6166b93879104e23ec9a563a8aada3f348d865a82a821f8fc94da"}, "c5f7a6a3-9008-43b6-9d62-bd8d67c3fb4e": {"doc_hash": "e8781b60361953c0213c1d6027e9a2eaf08dd9740ea630ce1bcca2f6d86b8802"}, "b5ea9a47-6efd-4bbb-a59f-d20d7c568fc0": {"doc_hash": "1792c248c4eb71672b0e1826c20a669447f9e3bc7e9a8ffac4b12f504c34486d"}, "dca39f39-0906-442f-a7e3-1281a5f2d30a": {"doc_hash": "95b92ea0e9a9908135da080e28e42529c4f3a8b751b3a365d9fef72dc6b1f461"}, "aac21c47-5379-4e51-86de-fe537032c27f": {"doc_hash": "81b634b9310f13e04584d40c8041a5f0a819595ec6bda9718d51cfc951330d42"}, "a844fd4c-b679-4cf6-b6f7-c4b6aa1923bb": {"doc_hash": "c1e5ea6ca7aab6104ebd4a95da300fa1136417bfdf231ed88c70fc49cff51b2d"}, "3539126f-3ec2-4806-9bd1-bd7333cf6313": {"doc_hash": "c5603c6f4fe985612d27b52ea7e9e6c31a379a1a5ac049726be20e0a67b089ae"}, "a1d7cf10-2bd5-4ce6-92e0-722bdf4869e1": {"doc_hash": "18f34fe1f3ca72007a5533a0742919d741d67ed1b48039bc3a94d039048aacc1"}, "a7f203c6-f1c6-4391-9a2f-93ecbac8d1dd": {"doc_hash": "650714bcd0126d9b0a50a2d63b2cae1d613f3497ec5a0eaeedfd2de114ca9d9f"}, "39481e14-6b63-4449-a5ee-4b06a012c44f": {"doc_hash": "90bed498b9bdb05c44f190186339d95412f6629f4e2aa67619be83c5cbd31f1e"}, "7827c7e0-209d-4f3c-98cd-4e7e5502aaa8": {"doc_hash": "8649a668a9b7dd6413fc4b59deddce3eee5e59d569e0f992f2e45b4b7389363d"}, "33045505-2c07-40e6-82b9-5f3306e83032": {"doc_hash": "e2c64b51c1fa408bfecb14973be1a6492b70524e5018fb271c3620e9e77de9cd"}, "dd91fae4-be27-449b-a248-277d07df1d2b": {"doc_hash": "2fde571f99712701b13aceb6c2fa2fbae066b2fce62a4e995aadc8f077a92a52"}, "e96eecb7-db70-42f3-9855-5a5d46be4548": {"doc_hash": "0011b4023ea45d4ec782b7cabd1ed91f834431bde0e0e2663f4443525222d6c8"}, "1182aac5-628f-4dfc-8301-7bcdceca52b4": {"doc_hash": "0eae57b0a4c45206d1a733535c646499e6085bcf608363f965acd11d6cc5cf64"}, "1c377ee8-1469-4e10-b0b8-ba80ff296a3a": {"doc_hash": "7ac508df555fe445bf10002ff518d4dbdb107418e4b327746880f7f06e9ed19c"}, "791a0f49-b547-4d2a-9f91-edfdf60f37bb": {"doc_hash": "2f087b04adce9e1a72454271e19b7b02e699740f6adca79e1fa45341a828218c"}, "10a724cc-bf62-43cb-92a1-a06be3357109": {"doc_hash": "a9cccba29496e0881b90828155a3f9dd72e742423230030fc6e9c20f99302116"}, "a5baa07e-5af2-46c6-a9a2-1afb1352c612": {"doc_hash": "f6ce2615a5c600725bafa23dd066a340d98446f496d9571e6c1508286f3bee08"}, "aecfdb3e-ff3d-4f2c-8cc1-48157ad3b135": {"doc_hash": "60630ad1c88e0e0a6605b0671c6e427c29dd122d4e24123d3584d1f1f56bd693"}, "a4a8ac4a-99d7-4810-ba3b-e6894f3e75ae": {"doc_hash": "26eed7792074b041557ab4c5656e445afcae93d592459fbe3b726d8585f64457"}, "a1d5c5e6-4e47-480d-8c2c-af946efb80fb": {"doc_hash": "38fe7a7d648f777a6c86352ee3a2f3b2099e04c1a51393ff55f28441db356400"}, "a1c087bc-2e51-4305-9201-5228bfb3c768": {"doc_hash": "ab021d8d7d942d59ff5f147abaec3a6001951f9071a9e92bd6217285176a7f3a"}, "4cb35e6b-30fc-4519-9aa4-975b4b57c0c8": {"doc_hash": "548fa27c914d4422e219d960004387faf9f9240e5498d95a12c70a8a7972337e"}, "4c17322b-c2e5-40ca-8710-f8857fb2cb81": {"doc_hash": "3e3d645441dd65cda2ac999304c366c66d8e4d145f46fb2819bd8040bf8a2790"}, "e5c7d5c0-71be-4ad5-9125-36dfd5ae13e4": {"doc_hash": "688dd1275fd26f2d21a2ff51796c4adafaf3e627e2b664c9d95601e358979664"}, "8e7c1b08-1d21-4307-abcc-1e340fabac0a": {"doc_hash": "49857bef9c6f01cb1249f98daabce8617e9937d7df979ee3d8a7081e06fbb40c"}, "56b81214-cfed-44aa-aaec-bdb3ee5d19e3": {"doc_hash": "510b557b9d5e7d6a1d30ff2d3bd781acb7a93c451aaba90d79ce2d8bffb62942"}, "6656a408-9072-424b-a574-b2d5d7ae23fa": {"doc_hash": "9aefe0faf15a2a411375b857b6d5244fd15fbccb371424924a00134b9447b35f"}, "96bbad54-f8ad-4af4-9292-0bc5be3d8462": {"doc_hash": "630495b358d33b476c863eadbd6b1c15f0aa4791400f72b6bc0cc175d89087c0"}, "35714a6b-6a03-414b-81b5-d7d8ae4d7c37": {"doc_hash": "4eb3c7cb047ff4511c13725ddc151f908ff2a6d1a1fc8c3dbcb7800cf004bb57"}, "7dd90457-d3c3-4ffb-b1a9-3ec1ccd68129": {"doc_hash": "3b21afd2198aab8fec5d51ffb06364405d5a3b771be3d4d5b808ae437f2d895d"}, "0aad7860-77ee-4e44-9e82-2117738954e5": {"doc_hash": "885383729ee819fb817857bc67ff3475c2012a9262a21064af1932bc53219ec3"}, "4949872a-97be-41da-9a52-628746554ae9": {"doc_hash": "393048fbae41dbd2a946eaf6c7f2361823ef01dbcd0139d83ca133d783087a70"}, "077e5723-f58f-475f-a396-04541c26005d": {"doc_hash": "343bec9b312cd5059cedb7ec30d0ec6d6c719f24b80540dff1121f541c142f42"}, "129c4513-5ba9-4033-88ee-4075365ae992": {"doc_hash": "8031a208cb1ae3da6d26ed5effd35a00828d309e5f4719222c1001bc36520b82", "ref_doc_id": "d2018a0b-99a7-4de0-b35a-6db10cebcd76"}, "7510bac0-f70b-44bc-acd3-8f89e0c8a90d": {"doc_hash": "e60e2a96b789c79c43e57bda6c7ce44ce668a4707e4f447b63be4d10eb0905ae", "ref_doc_id": "d2018a0b-99a7-4de0-b35a-6db10cebcd76"}, "fc95755d-72c3-4a8a-a6f8-0988fb5c6be7": {"doc_hash": "9d1918abf8e3b00a74ec8931da1183e22ae51e039676bebc8f6e40491d86e821", "ref_doc_id": "d2018a0b-99a7-4de0-b35a-6db10cebcd76"}, "69ffe363-7420-452f-b2ea-e4416a5d11bb": {"doc_hash": "b626c0c00c694cfa61077fe8f4bef126f4b3a225dd534c38f8e5ba7782e2570e", "ref_doc_id": "4faa2b7c-5f02-4209-96be-16c4ee565c75"}, "b50b479e-a74b-49b3-94f0-a7a58fdbc05f": {"doc_hash": "da597eff1e6ff3464e7e4e5177c0cb97c274876c1ba7d8e49a7a9ce2367f9ce1", "ref_doc_id": "4faa2b7c-5f02-4209-96be-16c4ee565c75"}, "fe6f8386-4593-4649-86bf-d731c3569a66": {"doc_hash": "ecadf1ed8708a9d0034e6faedabf5b9ed7af354a6e70961a647e5e28ead78383", "ref_doc_id": "4faa2b7c-5f02-4209-96be-16c4ee565c75"}, "fb2eaad1-718f-4616-8039-4654f96c3bf1": {"doc_hash": "aed76db20a6da48878458af1c7ddbf15d583a9c01dedf9d007cd45965f47034e", "ref_doc_id": "0c51c536-373b-498e-8826-f6146e4caaf0"}, "4a99ebdc-8662-4dba-858c-34f555358893": {"doc_hash": "b40661b56a397963f792828aeb419991c903f6bcda16a92808dbe085c8c652e0", "ref_doc_id": "0c51c536-373b-498e-8826-f6146e4caaf0"}, "9a6b75f9-834b-410f-9884-95af32de356d": {"doc_hash": "98f31de9d0c909e6abd5e38e198ecca5819bef35251058c5894c25a3b957f541", "ref_doc_id": "0c51c536-373b-498e-8826-f6146e4caaf0"}, "d52fa8ce-1533-4937-8fd4-5275d850a9a1": {"doc_hash": "2cc9a8bd6ad3933c5e36f049f836205ef91ab45538a3e12d108885c0b6c517ae", "ref_doc_id": "0c51c536-373b-498e-8826-f6146e4caaf0"}, "d5a01f15-61ef-457c-9cdf-6dbb464e9ee1": {"doc_hash": "94117699e7574d6f11bacb03f2f21d10b1847243360c3cd8527b9e8927234c9f", "ref_doc_id": "500320de-55c2-45fa-a58d-487bc0b2179c"}, "95a7c3ef-887d-4b09-bd0d-c0f7380ca67e": {"doc_hash": "32156e9c07cd8a3418cf91de40a0f4db8e8c4dc60309706fa56621b822350cc4", "ref_doc_id": "500320de-55c2-45fa-a58d-487bc0b2179c"}, "734f87bc-cb1f-4923-b589-409732467fe7": {"doc_hash": "949d6a2270b1db8f1e27a9cc6c7840747bda875f0adfde8f0b4f42ff8530087c", "ref_doc_id": "500320de-55c2-45fa-a58d-487bc0b2179c"}, "43a92508-3957-4e23-b58f-6e209f2b6c84": {"doc_hash": "666ffef87099d6de8a5f063b38dcc61017ca91292d1739d1a2332947129b52a4", "ref_doc_id": "500320de-55c2-45fa-a58d-487bc0b2179c"}, "e378d602-c32c-4169-ac8f-81cea7823ae9": {"doc_hash": "ed5a8668626e71846d54db085b633d4004b40c8b5776af9df05ebb7cb37b3658", "ref_doc_id": "25004ac4-94a1-4f23-9f07-6ef3e4b4e22d"}, "5575d336-dcad-4387-afd7-9cafce4f56ee": {"doc_hash": "f71f2d2efd71510c785c438a23e62845137f7297a859460730e59f4f4392322c", "ref_doc_id": "25004ac4-94a1-4f23-9f07-6ef3e4b4e22d"}, "f858374d-56da-4a0d-a4bf-b1f3db02652c": {"doc_hash": "0cec354440917a5cd4da6c578075bb54d5f7ce1e96a2925f415faa1137354ba0", "ref_doc_id": "25004ac4-94a1-4f23-9f07-6ef3e4b4e22d"}, "ee57848f-ca45-4e62-b6ad-09016a2a020b": {"doc_hash": "c2ce48c58a0bfeb7efd98463a19cb762df7cf34bec03556dcf0a5c3af5d3f7a0", "ref_doc_id": "25004ac4-94a1-4f23-9f07-6ef3e4b4e22d"}, "5cd5875e-44f2-4c28-9991-87329308be61": {"doc_hash": "f7722cbf5747c6a46fa5f30ffc7f319e033bd047ca3fcebf5858ab56d69084d6", "ref_doc_id": "ddde90c3-b670-4525-ae1e-9a1da3042086"}, "4fb65a98-6a97-4d53-a423-51d232904636": {"doc_hash": "45c4544fe9f55c7582e78d13629e36f045e612909ffa922864d22dd1e829fec8", "ref_doc_id": "ddde90c3-b670-4525-ae1e-9a1da3042086"}, "21c86e4f-d084-4811-9a9f-0966078b0c3e": {"doc_hash": "034f2146c80714204c199e3344c3e25fb97b4ec0dc8e5c9cf98f020c3b83d1fd", "ref_doc_id": "ddde90c3-b670-4525-ae1e-9a1da3042086"}, "b831a628-4982-477b-bec3-dd2f19cf7105": {"doc_hash": "ff7e5032e979bd7586bb216f51824a06cecde2b8b6c6796d6f23a9f8407d3b6e", "ref_doc_id": "ddde90c3-b670-4525-ae1e-9a1da3042086"}, "4c8db16d-c9f9-4935-aaee-f60d563322da": {"doc_hash": "98f499b1f41339048207b5b956942d836bfbf920aee5d9df5d35df817022964d", "ref_doc_id": "d1e98709-babe-4168-8e3d-b01d49bdae84"}, "17828a4a-2f98-4535-93e3-619cd77fc02e": {"doc_hash": "22e4b780a5cbd5bb23f8cd97d1744e9b3f6020d0ab732bca6ff1151443622d64", "ref_doc_id": "d1e98709-babe-4168-8e3d-b01d49bdae84"}, "e99e7c5a-2565-4d47-af8a-11c34e108d74": {"doc_hash": "fc11eef6aaae08ae4bfd8f8a22c103125430821a2437811af7a7c8f0558ccd0f", "ref_doc_id": "d1e98709-babe-4168-8e3d-b01d49bdae84"}, "44fbce5c-c656-44c8-a6dc-98f424dcfd5f": {"doc_hash": "a4a0761a5a301dc6ba709c9905b0cfe454d1fa24c2cd690fa4974252925c3fc8", "ref_doc_id": "d1e98709-babe-4168-8e3d-b01d49bdae84"}, "2726fcf8-e00a-4887-814b-efd62ac169ac": {"doc_hash": "9ba43bc3ac3704130b849b5b09f88b8656f737dd11a4d7f7651920b495acd7d2", "ref_doc_id": "4b54fbc9-05a8-4ebd-97df-cc37d32d7c73"}, "9f5eb2a2-a250-44a7-ad4b-a9d6cfffc8b1": {"doc_hash": "2c55e50dac17f642070c798ba149878babc98604b82dec04027ad969408b1165", "ref_doc_id": "4b54fbc9-05a8-4ebd-97df-cc37d32d7c73"}, "22613f8c-2fee-4a7d-ab61-63667f9d4efe": {"doc_hash": "f8d16bd607cda65c6d7001e1ec75d5379fd4312c1031354163484b4b76edeb3f", "ref_doc_id": "4b54fbc9-05a8-4ebd-97df-cc37d32d7c73"}, "52816838-5504-4684-9390-a9c8062c1a09": {"doc_hash": "ec72b0dfdb3155600cd11b4c49a4ad294dca108b49b3594d373f61d7b9c51721", "ref_doc_id": "0c032fed-74ec-416f-8aed-9a47cf07898c"}, "47ca947a-0d22-47a0-8b2f-b2390af5fc0f": {"doc_hash": "f47808937fec67a65e784235d2dfd71b62181f01c0b88c640ffbb6cfda570d98", "ref_doc_id": "91470221-06ff-482c-8ce7-889eb870df07"}, "38269845-35b4-43fb-bcab-8dccea5c4519": {"doc_hash": "b1c20a25382e5e47e24e5b7f4d10c036f30803b2bb47dd1c6ead1da0b97e4d93", "ref_doc_id": "91470221-06ff-482c-8ce7-889eb870df07"}, "2298167c-0cf2-4d72-b0ad-5ddc3ec50dfd": {"doc_hash": "3d2b2f51d7758a515f57f58203d1caaa16adb780dfffc42e82cdfeb8bf9b43cc", "ref_doc_id": "9385da6c-c575-4c4b-bc41-8e08c17a3d81"}, "8245ff4d-8f14-464d-97e1-4b3260a404cb": {"doc_hash": "9679813a0fce98b0f6b3b93c2cfbe2f6981611b83493ddeee6c9b06f3f4f8f4c", "ref_doc_id": "28648416-88b7-4171-88cf-8bcec594df5c"}, "1ea2b8db-17d4-48bc-a4e0-3420605b79fd": {"doc_hash": "c883fd918ad5f464280ab2fa8a8f9379c4078739fc76778c0135e9100cfacd1c", "ref_doc_id": "b9068d91-e1f4-44f8-973f-cce4d54198dc"}, "ae94bd68-8960-4a33-a289-66e0d9e447dd": {"doc_hash": "47e14c1ca07a8a9d51e5f14da2542c3b2d9c5c91be8b5e15721da3e1d3f18a9f", "ref_doc_id": "b9068d91-e1f4-44f8-973f-cce4d54198dc"}, "c592916b-bb28-414c-b334-9d97a75633a7": {"doc_hash": "c70d013d7d7e6654d724e69dd971799e4b737f22948c3c6d976572a709306986", "ref_doc_id": "b9068d91-e1f4-44f8-973f-cce4d54198dc"}, "e738d045-f56d-4b27-b3e0-f26272c079ca": {"doc_hash": "d55f4327ff59e37b546c551b0ba66703bf81ec0b93817c9b14088e517fb97145", "ref_doc_id": "eb2d3c6b-4c1f-4771-936a-acdb71e35049"}, "0e4399ed-9517-4375-ba41-512af0d3081e": {"doc_hash": "048ee4b217b6b23b753df6928eea743521b440e218a9640030f35f3360ad88fe", "ref_doc_id": "eb2d3c6b-4c1f-4771-936a-acdb71e35049"}, "23e20188-4ed8-4f40-88bc-122a700e77c1": {"doc_hash": "264e1e51fca2338cb2ff6c9347b6524329776be14605e38809d6f2c18562883b", "ref_doc_id": "eb2d3c6b-4c1f-4771-936a-acdb71e35049"}, "32762e5a-be01-421a-beba-d919b624ae58": {"doc_hash": "9c2d836fc338f453d3918b6aef53e6e5f66aa50757ea6cef86db466a0818f679", "ref_doc_id": "eb2d3c6b-4c1f-4771-936a-acdb71e35049"}, "ca570e49-246a-4370-86bc-4075bf22f270": {"doc_hash": "8044917806b24fe29861e97a741b75e930ae839b9458e2d0dbd0985f6c7b6d28", "ref_doc_id": "978ed50c-f15e-4976-b3b8-78528ff00afa"}, "0387bf00-2093-4745-8491-6814a34f8a7d": {"doc_hash": "157a125fb5f67e4a9a70c00900f5b16f101c36301ed24eaf01816d9ac9229a67", "ref_doc_id": "978ed50c-f15e-4976-b3b8-78528ff00afa"}, "0b026d65-5852-4739-af01-cd72f8dc336d": {"doc_hash": "dc1e5765d614852ab5cefc086addbf751e4c0fc600149265ab66604948b432b6", "ref_doc_id": "978ed50c-f15e-4976-b3b8-78528ff00afa"}, "4c9f8ed5-93bc-4b10-8523-a3ce12d73446": {"doc_hash": "baa41362525f30199d73070945adf2f66bb81e9123ad725775b46a234bd13e54", "ref_doc_id": "978ed50c-f15e-4976-b3b8-78528ff00afa"}, "70710840-8457-4145-9900-f1e37c5fa20c": {"doc_hash": "af2b2bef2119f14afcf513c979cb31aabbe67ea81b4e0d35f5dd9714d0b5ed3d", "ref_doc_id": "7c60562a-1161-44a9-b17b-eea513c59ccb"}, "37503145-951c-430b-9ec4-2174f4b12c7f": {"doc_hash": "cfd064ab79d668064a0f16e62a3f373782a5a5399ef948520af6ddd23441f3c6", "ref_doc_id": "7c60562a-1161-44a9-b17b-eea513c59ccb"}, "0ebd3a10-eb76-4604-9199-e16ecf786975": {"doc_hash": "8af0dc4695439a37e30b8eec61188953eb50297ac6a7fbda44a7cb82414b8ba4", "ref_doc_id": "7c60562a-1161-44a9-b17b-eea513c59ccb"}, "3346480a-047a-4667-aad4-a4f4e0894fff": {"doc_hash": "05af84383307eb5a2a7e3fd8a821a59a2c686b54844591654cfe22358abb23ef", "ref_doc_id": "57c141a6-7490-4731-9da8-31c398d172a6"}, "8a784e94-6226-4e65-bdc4-b3fb280cb95e": {"doc_hash": "bb127f76720c56a827424c790699568933b4a08f0d5dc2dfe4cdcb341103f086", "ref_doc_id": "57c141a6-7490-4731-9da8-31c398d172a6"}, "97d24af3-fef9-4879-9a1a-567f6cc5b254": {"doc_hash": "3c94a47a88fd1578d35136acc81e7a8f7479687821cc5855173168703121e283", "ref_doc_id": "57c141a6-7490-4731-9da8-31c398d172a6"}, "2683462d-3e8c-44ce-87f8-cd4e37d05301": {"doc_hash": "c7f7639d2aeb30dabd3e30bc9e9082721cb5194c399680d02b00e8be9024b75c", "ref_doc_id": "57c141a6-7490-4731-9da8-31c398d172a6"}, "94232a86-002f-483d-80ea-a14d2df453eb": {"doc_hash": "484fb66533256340a16a13667b951a3c61031a1b541d7d8419b77a12c5bf68af", "ref_doc_id": "57c141a6-7490-4731-9da8-31c398d172a6"}, "c97a00a2-10ac-452d-b739-c91d7fd59e02": {"doc_hash": "5bce9f4ba005b5ae507214a210e5b92c4b7b00133c560b24320e5447b1e5d2a7", "ref_doc_id": "57c141a6-7490-4731-9da8-31c398d172a6"}, "52e2273c-c61f-428b-8bca-3977e43dd55f": {"doc_hash": "090687589c8319c587834793bf716a8f0382e16ca6890a5b5db2676dc4485dc4", "ref_doc_id": "4c61839e-63a8-4b1a-8b41-a6c4b39d229c"}, "f414c691-707e-431a-a7ae-b51486e1e3ac": {"doc_hash": "419eecd06901356d9722d6a7513a36ea3dbc8a81fc26a4490124a7b23b4c2a28", "ref_doc_id": "4c61839e-63a8-4b1a-8b41-a6c4b39d229c"}, "0f06968e-1c02-4a16-b7ae-bd36840247cf": {"doc_hash": "a1c3ea6bbe1b6842921ffde94f9dd7e0a5c26dee5c18977ace6766266416fcf8", "ref_doc_id": "4c61839e-63a8-4b1a-8b41-a6c4b39d229c"}, "52d737c6-7b28-4e86-b401-8aaea5b65cab": {"doc_hash": "b85c62a8a616da6c13a2626dc91fb20811661da7ac5662878c0630c53f95c89b", "ref_doc_id": "4c61839e-63a8-4b1a-8b41-a6c4b39d229c"}, "f68bd455-9fcd-4f0b-be20-cf0e453be9c2": {"doc_hash": "0de88e34d561513461f2d36544b16833aa9f9567d73af7067d6a91eec47f9f55", "ref_doc_id": "4c61839e-63a8-4b1a-8b41-a6c4b39d229c"}, "376e8cc1-5d2d-462a-b847-f8fe2a0965e7": {"doc_hash": "c97364422e263820c82758ddc16fd830a4071884db26ffd043298d822c6bb2f6", "ref_doc_id": "4c61839e-63a8-4b1a-8b41-a6c4b39d229c"}, "411a98cc-0f8f-48e8-b757-e97a24ef9e81": {"doc_hash": "f48ddb7de88868cacd269f8d43277b930bf65789c1f7b407a722ba821755e0fc", "ref_doc_id": "4c61839e-63a8-4b1a-8b41-a6c4b39d229c"}, "498a18fb-79a4-48a2-b3d9-bae479162cf2": {"doc_hash": "c792d88aebee2bc487ab6d004d981753ef6338e9445de5a80248e965f8ab7d46", "ref_doc_id": "d618ddfb-b57a-425c-8f3c-cdadb780f905"}, "452ac336-0448-4c9f-af93-b6b0f3d2cb59": {"doc_hash": "a1ed5f905148af1da7601d76f21f6c59d40432b3cc5f587830082717e60784dc", "ref_doc_id": "d618ddfb-b57a-425c-8f3c-cdadb780f905"}, "9357125c-3523-4f3a-9018-6c08aa835279": {"doc_hash": "857fe5ef20a2f2c7bc8e216fca11cfc9b6539cb99bbfd9ba59f3ddae4de4ecc7", "ref_doc_id": "4354f20f-b099-4c4c-abae-bd50d7e5c5db"}, "b8e99569-7668-4b3a-91d0-dc3e0fa95aed": {"doc_hash": "7d971c3fe0fbd66c6576496d43f12814d7ba865b12736a1b3c042b9668ce863a", "ref_doc_id": "4354f20f-b099-4c4c-abae-bd50d7e5c5db"}, "cb02e3ef-40c0-451d-a4bb-14809f01bd1b": {"doc_hash": "1366e329cc459a8af22ac05bc330005cbaf3c5c1da876f1161b49a335bea32ac", "ref_doc_id": "4354f20f-b099-4c4c-abae-bd50d7e5c5db"}, "4e93c9be-4015-4e2f-962a-9d9bf9eeff9f": {"doc_hash": "b62b472de6a286efcf1fccdea092100fe39fa74b40ca309a0fcb329e2ec43636", "ref_doc_id": "732d36ef-8c5d-4588-962d-c4dc4204f1d8"}, "a1022cdb-2d5a-4f2a-98f9-43b0d8f7728b": {"doc_hash": "fc90f4feff53b533d9ba2fc688c2b684c84bc193da81a970b8fe81d251e7af2e", "ref_doc_id": "732d36ef-8c5d-4588-962d-c4dc4204f1d8"}, "0c185699-c838-435c-a450-466887b10bd2": {"doc_hash": "e1c1044e08bd0da59282a4cc902cefd326af9ac7e1ce084a924b936ff8e2b03c", "ref_doc_id": "732d36ef-8c5d-4588-962d-c4dc4204f1d8"}, "bbe4b789-2f81-4846-beff-7f53e87ce87a": {"doc_hash": "9f31db161f6f4c150022b8f06e143241885ec437d6bfc0d85b38874a95a4536e", "ref_doc_id": "732d36ef-8c5d-4588-962d-c4dc4204f1d8"}, "38c5f45c-4600-431e-b195-c2937e185441": {"doc_hash": "65846783015bd1afe66799b6903573429bcba7f0795ec4ecd6cc02d125831e47", "ref_doc_id": "d71baa71-40d8-4aab-a8c7-ba6cbee55a69"}, "49c02434-3b56-450b-b011-6147aaf38601": {"doc_hash": "22aa8b8472b4855e63b550645fc04633e1740287d0541dac7568bfc4fdaa3816", "ref_doc_id": "d71baa71-40d8-4aab-a8c7-ba6cbee55a69"}, "52f98438-c604-4e0b-9931-2cfeb63f68a0": {"doc_hash": "0d96a0275bb5fea0d733dff1954a0f683a4ef7d3f6998c8ec44dd42f4675a07d", "ref_doc_id": "a7b50c76-9e54-4854-bd18-e3af5c016e41"}, "919bc9bb-5de8-40de-b5e3-2a32a52815ea": {"doc_hash": "65af001cc206b59d1cb0fac202ba574f2beed1cecab2ea18455ed6d3311846a5", "ref_doc_id": "a7b50c76-9e54-4854-bd18-e3af5c016e41"}, "d70ef2db-73fb-4880-aec8-cbce10c7f33e": {"doc_hash": "d1f952a8cab39e1d3af9674acf85cbba1765c49dd40811ae99b0fbef345a1565", "ref_doc_id": "a7b50c76-9e54-4854-bd18-e3af5c016e41"}, "65f54425-2787-4a92-8ad0-0c9b5d39b3ec": {"doc_hash": "e310934269cab206f4dccbac868d55748f3b3ff4da498349edc38178c9938cf1", "ref_doc_id": "a7b50c76-9e54-4854-bd18-e3af5c016e41"}, "9a4ee123-20a8-4af6-92b2-934509548349": {"doc_hash": "d6698f7e7356e75e3c8c43562cfd62a7093019afaf6f90cf295fab61c953893b", "ref_doc_id": "7270adbc-d000-4c2e-8351-acb5ff28e3b9"}, "d4280a9f-cd09-4edc-9055-b2c26aad73b1": {"doc_hash": "a0a51a5e680062896619e94e71f3b770fe68774fb7b18c608debdf957acba648", "ref_doc_id": "7270adbc-d000-4c2e-8351-acb5ff28e3b9"}, "080b6dee-f2a0-4ae0-9bed-9e2e68969085": {"doc_hash": "c4f308d21b0a58bd9c78317297a44c1878a4a5011aaaa8aed26e2bfb662a9f06", "ref_doc_id": "7270adbc-d000-4c2e-8351-acb5ff28e3b9"}, "27779168-4216-4731-97c6-b4cd9fe2ddd1": {"doc_hash": "f57a494454af3ccd6f56e3d50eb6aad421aa31db562256c705ac98f1bd4a0600", "ref_doc_id": "7270adbc-d000-4c2e-8351-acb5ff28e3b9"}, "4fc2d9bf-6063-4668-ad85-e2d155197981": {"doc_hash": "463f541ac5012c38d663fa69b22460585b5c9fa32e16211b05324a82cde3958e", "ref_doc_id": "f0950654-0b9e-47e7-acbd-2d780485001d"}, "bce874a3-eb71-4f83-aa21-56cea029f3c7": {"doc_hash": "8086ee6049b5433420c56bc4fe72dad24bb34cff164872fc5cfd97e1dbf93b73", "ref_doc_id": "f0950654-0b9e-47e7-acbd-2d780485001d"}, "113ffa4a-6837-4a51-a8d0-3973a52ba263": {"doc_hash": "b5de815c1b061bf11c3bde337ab99e85a844039add6aa574e97985f6dd2ceffc", "ref_doc_id": "f0950654-0b9e-47e7-acbd-2d780485001d"}, "5251d44c-257e-43b4-8771-bd514de0bcd1": {"doc_hash": "ec0048f5e630438159178f58fe798c11f7a4abae3f76879c1a8fa80df8c7ca80", "ref_doc_id": "f0950654-0b9e-47e7-acbd-2d780485001d"}, "e51f3753-49f7-4f05-9829-0fa4fbc94aee": {"doc_hash": "8c8ce48227ddf19663d895d8a5d3582ff2fd155cab8dd8bc3721b5ee108d6783", "ref_doc_id": "9208caf8-3de9-4cef-8a2e-49a8017f71b4"}, "850dc40e-f518-42e1-8b40-a0125bb3e783": {"doc_hash": "b17268f1712d5ec950efc554fb8c1ebaede517b16a80d53c99012703caeea3d1", "ref_doc_id": "9208caf8-3de9-4cef-8a2e-49a8017f71b4"}, "c4dd69a6-1ae5-4f51-81fc-8688d6442fe0": {"doc_hash": "fa7b23741e9761198d27b1d8ddad0036e1de98dce0fac2e9931af1e471f5616e", "ref_doc_id": "1b3d1945-0882-4162-bf8d-3a6834fb8fbb"}, "a83ec709-f214-43f4-ae27-589575212b80": {"doc_hash": "99ef923a69611687b0cd424cc3bdcc114bac60108fb72e31c55b563ced3e8654", "ref_doc_id": "1b3d1945-0882-4162-bf8d-3a6834fb8fbb"}, "0ec99e8b-0b4f-4ad6-a271-ac3e3b276d29": {"doc_hash": "2b3d1e11a86d32f8473f5b08004cf54b1660f0fe4ff039111e1c48dcda056169", "ref_doc_id": "1b3d1945-0882-4162-bf8d-3a6834fb8fbb"}, "ed3094b4-02f4-43de-b3e3-b6a6497f80b9": {"doc_hash": "240cc8d993fb5c4f6634fb8dfb17df51fedda8d52cf19640b5d45749d2cee371", "ref_doc_id": "1b3d1945-0882-4162-bf8d-3a6834fb8fbb"}, "8d2dbb2a-cce0-48db-9bb9-c083a4a74e6a": {"doc_hash": "226b644069ea575236e4da90331f0fa3b651202076304ac026b557c28b609ba3", "ref_doc_id": "5fd22f96-9a35-4f85-9010-fbf0469d9fa7"}, "7321ef23-f825-43e9-b1de-267d1827cdd2": {"doc_hash": "9802de697b11da4458dd12755e1ee545b92e63fee6b1e6d6cd1253ed29673120", "ref_doc_id": "5fd22f96-9a35-4f85-9010-fbf0469d9fa7"}, "b6053ffd-5968-4596-af45-e1e403bc7b5d": {"doc_hash": "5a9717d3491597cc2f139fc8d0963ce7fc5684d8f48849e337828142986c7688", "ref_doc_id": "5fd22f96-9a35-4f85-9010-fbf0469d9fa7"}, "fd053964-35ce-48f8-b9d7-9a2bcdb9a194": {"doc_hash": "96b17c1c20414bb42e4327ee5b1dd9f9c8a5ee48146e270a0ccad1c996411226", "ref_doc_id": "5fd22f96-9a35-4f85-9010-fbf0469d9fa7"}, "d86e27ea-ca09-4c27-aa20-119d1cc3181f": {"doc_hash": "90b4c3aba3cd15223e884cba1a46c895f5d92ba480d86867392e6a24489347e1", "ref_doc_id": "b9da6b8c-332e-4fe7-8f05-7a7f25d2fa67"}, "8e61bd17-962d-4e2d-89c2-0fdd0d06aa03": {"doc_hash": "28c2af751f26a1f75fade39bd2f0fa6c4bf4ac16239a25b60e9306807019c74b", "ref_doc_id": "b9da6b8c-332e-4fe7-8f05-7a7f25d2fa67"}, "e35d5419-adc2-4718-a662-73161e91a49e": {"doc_hash": "3c81555ad9d939b617af7c7ecaed65ecde9e95b31080da45231a9d7d7e9c51ea", "ref_doc_id": "b9da6b8c-332e-4fe7-8f05-7a7f25d2fa67"}, "173af25e-6718-471c-9453-2755bbf24856": {"doc_hash": "7bb54e0d01479d7e76c6738f322be32c09c511dbb7fdd13d950f1697a4d478e7", "ref_doc_id": "4a1be7b9-f3dd-43d7-a3ee-65352c2eee30"}, "a0193a14-9560-478f-a10f-a6ff357cdc1b": {"doc_hash": "36a45c7038d47db3dca584337ecb2c37be64e78884fd3cd595c35c3383d8044d", "ref_doc_id": "4a1be7b9-f3dd-43d7-a3ee-65352c2eee30"}, "377d05f6-dbd8-4adf-a793-cf0e6eb492a7": {"doc_hash": "dd273a0fce7e4b22785ffa7f4a7750b63662a9d181a2b0fed1561e59580bbd5a", "ref_doc_id": "4a1be7b9-f3dd-43d7-a3ee-65352c2eee30"}, "0e9a08db-bd9f-4de7-9832-bf67acd8f1aa": {"doc_hash": "74a2215434214c9a80736c60450872820c58c2cdf3ff39c8b36adc5ef985d3ca", "ref_doc_id": "4a1be7b9-f3dd-43d7-a3ee-65352c2eee30"}, "1c69593e-dab1-4bf0-b41a-e15127693faf": {"doc_hash": "93105327b8afbad812aca6e70ea43311306b177fa997e0713a5129ce3ceb470b", "ref_doc_id": "31fd1866-f5e7-434f-8dae-c26972fde9a5"}, "c5219734-fcfc-45dd-b4e2-bff802f62d82": {"doc_hash": "390fb6dee96370f6c5337919bc86fedc3108f3bd02752f8bbfb35b09dfce3544", "ref_doc_id": "31fd1866-f5e7-434f-8dae-c26972fde9a5"}, "95b8fb2c-8110-411c-883d-9931bd220f6b": {"doc_hash": "3b8478c8bf03511c1f65c2894aed25f3914cd848ba0c84b9b56751ebe3d78dce", "ref_doc_id": "31fd1866-f5e7-434f-8dae-c26972fde9a5"}, "6b15ecfd-0471-4044-a275-b385ac6aac33": {"doc_hash": "be1ea6e94492d44d81246da330b427fc1726a0c88eabeec2cbb0a2788917eec4", "ref_doc_id": "4469f94f-ee49-4d40-9fe7-1158afa84afe"}, "e51b4e5d-ae69-4681-93df-62c0ccf0cd1c": {"doc_hash": "6b413a2e181f9eceed0f267febb9081fbb4574fc32c71c4b88e356168461724f", "ref_doc_id": "4469f94f-ee49-4d40-9fe7-1158afa84afe"}, "25b90b38-a924-452f-91bf-9ab1ba275dcd": {"doc_hash": "fdb59905e0a2ff67c313509d1284ff712fe38b729b9624b560187cd8cdd44a34", "ref_doc_id": "4469f94f-ee49-4d40-9fe7-1158afa84afe"}, "80d3ef30-a0aa-4c2d-9734-9317ee93f4b2": {"doc_hash": "c351a275f8609dba7574be4a5467248a073b758007d0c0009301a303b43e9a3f", "ref_doc_id": "fe46a362-7871-46bc-9d56-2a7f3396288f"}, "dd8fd21e-6aa6-41fb-a71e-c19ceeaea478": {"doc_hash": "e9e517404a881ce9961097929af51bb7321fca693b6065a904d1a10020f4f5e0", "ref_doc_id": "fe46a362-7871-46bc-9d56-2a7f3396288f"}, "01513411-0fc4-4312-8653-0fe7f1e8018a": {"doc_hash": "ba3347b2258a74a0be420451306df0f0d6e9f9a8b27948fe872d803a9fab50f7", "ref_doc_id": "fe46a362-7871-46bc-9d56-2a7f3396288f"}, "1abc359c-d314-4daa-b74c-c5084a96d351": {"doc_hash": "64ec574ead6ec60e0dbc80af657fc02bc22229f747fe12b5323acdf2e29005b0", "ref_doc_id": "8876b368-19a7-4502-aaa9-fc8a556abbfa"}, "1749a00f-65af-4822-b802-56040b98f1ef": {"doc_hash": "18bd84a5a2e16a532d7ac706760e0183bf5e7c327626357ff2f6ee073ada25c8", "ref_doc_id": "8876b368-19a7-4502-aaa9-fc8a556abbfa"}, "89fb493e-7f25-44f8-b315-b5d93164ad83": {"doc_hash": "bc67ee14783f3970c9295bb9d6be499dabe01bd90bdc5a35439adac160093ace", "ref_doc_id": "1ae36d76-8e88-46f5-bd67-67be78e26f04"}, "71de077d-89cd-499a-b2ac-63926f9c45b7": {"doc_hash": "62303148e37d6df5b230306892d366376167e9c019625c05b81c57e58475c917", "ref_doc_id": "1ae36d76-8e88-46f5-bd67-67be78e26f04"}, "20f8b5ba-e7b0-4a72-92d0-be6915b88963": {"doc_hash": "261043c250d37372c93bd05074456f023a57cc16883c5ce37ae41e1203d79669", "ref_doc_id": "1ae36d76-8e88-46f5-bd67-67be78e26f04"}, "11831bc9-8348-437c-9f5a-9a28f430d9bb": {"doc_hash": "056123aa6666fe47c05912f879bb8f14f608bfc76dcbd1c16a7f747c278d579f", "ref_doc_id": "1ae36d76-8e88-46f5-bd67-67be78e26f04"}, "e90a1229-f665-4ee0-9258-eb4ae09e61bd": {"doc_hash": "34303af768738b8861711918315cb3ea2f5bcfe5fa62d07b7d47a4bef4499646", "ref_doc_id": "acbced89-6a78-470f-a420-ae6270eaaa32"}, "3aac689d-6dc1-4c71-9127-34492b7a5f23": {"doc_hash": "de08b809d4882cd6f8bdcd97e33e5a72397b3dacc97c9c07de02cb59ce52f944", "ref_doc_id": "acbced89-6a78-470f-a420-ae6270eaaa32"}, "f1029f33-4d0e-4ebb-8ae1-06c4958fa132": {"doc_hash": "0905fd19bc11470a9be27b5f7d33235d6a61deef5e91b98eb714683e36c23162", "ref_doc_id": "72bf1cf0-9d16-40d5-8ee5-808edcfdad08"}, "b4849b4e-1c07-4af1-a991-748356e851cb": {"doc_hash": "c9f39c8488529038a9291ed52523aeaa2e56361032307ecb6933d594f76be286", "ref_doc_id": "72bf1cf0-9d16-40d5-8ee5-808edcfdad08"}, "4b3d62ad-9e2a-4e3e-8dee-201c2e444af6": {"doc_hash": "fae23e00c59d21680a0e40ddf1b9e834f2deb9f75b142651b448748092de656b", "ref_doc_id": "3de89589-f389-4a0a-b91d-726e5db42433"}, "277ee5cc-b685-479f-9049-5db40dcc5d72": {"doc_hash": "e3d4bf5746f2ff12b61704dc8e942f71a85959b7a76e51c17ab07189aa7cc133", "ref_doc_id": "3de89589-f389-4a0a-b91d-726e5db42433"}, "e5c76e65-8f47-44a9-aa9d-07b66c0d49ea": {"doc_hash": "05608cea0b6d0454adb73159c6d0cb6eaba5b321f2def183561c07a558f1b9a0", "ref_doc_id": "50beb819-1b07-416c-a3ad-ef33c77c122c"}, "94d1d91f-f86d-4b92-9ac8-800e764e1d85": {"doc_hash": "c486aa737122014df9950e86d1b653c828ca04dacfa5404237627d9d12ec0c57", "ref_doc_id": "50beb819-1b07-416c-a3ad-ef33c77c122c"}, "6285c43c-f238-4daf-b1c7-dd9cfa053881": {"doc_hash": "e15ef47a28dbfbbb35830b70d612e3fd06e789a34b854e43965dd717f30ffa98", "ref_doc_id": "50beb819-1b07-416c-a3ad-ef33c77c122c"}, "58186b1e-0a5c-4b20-a17a-131d1704cb7d": {"doc_hash": "e272bf8c90acb664175cb13e2ba896a5352050ee86027b54f73b802e6766fba6", "ref_doc_id": "50beb819-1b07-416c-a3ad-ef33c77c122c"}, "b2b0f19d-434b-43e3-a65a-377732015e79": {"doc_hash": "6e0c1824b1bced2dcffa04371b544ea3d3de4a2334225fad89b93e5d27b1d75c", "ref_doc_id": "dae59523-8e69-483b-8677-6182b6742476"}, "bf28ea60-28f6-4dbb-9630-b8f27f74e46f": {"doc_hash": "bebacb7b132967b42adc78e9867bc9722500ea7162348b2e99e9b1e42ca3dc9c", "ref_doc_id": "dae59523-8e69-483b-8677-6182b6742476"}, "21edad98-906a-4fc5-a307-7a5efe781042": {"doc_hash": "c6990b5f57c803acc209085cd75b80a380d21ed115a47cb7a1290d53569b285e", "ref_doc_id": "dae59523-8e69-483b-8677-6182b6742476"}, "c248cdc2-9ca8-45ca-bc7b-4cb489283a5d": {"doc_hash": "5f4980399bb8c3b1406dbd9ca44bfa6311559d24d845a8cb8cd101f79de06048", "ref_doc_id": "dae59523-8e69-483b-8677-6182b6742476"}, "ec94d3fe-330a-45e1-a133-0db27dd522dc": {"doc_hash": "68c3e1d44e2b1439b201ccd26a7186f8f8b9428e61dfee7f928dd479440b6af9", "ref_doc_id": "66d5f9dd-87a8-4e3b-9d0f-3f00f07bed8b"}, "c5dfe4c0-aa8a-4cc6-bbb8-05a44a77be5d": {"doc_hash": "eb4690ee5450dde5817dc6a1702d7436389dc947282df7f725f0a8cd08379891", "ref_doc_id": "66d5f9dd-87a8-4e3b-9d0f-3f00f07bed8b"}, "3e092391-3ecf-4e7b-b155-116d5202646c": {"doc_hash": "d72f7cedfeca5df7cf8f462f98413f4db716526ce496bb45546899d17273f899", "ref_doc_id": "66d5f9dd-87a8-4e3b-9d0f-3f00f07bed8b"}, "04219a09-6d7a-4e24-ad68-f8595be57223": {"doc_hash": "4b1c6705d9cf174e1aa127cb5b2ac3e43559ffa34d77af0ce8a25aa112d8c87b", "ref_doc_id": "9f005ea6-598c-43fd-8d3d-391cb5fb6563"}, "7c5956e3-39d4-4fa1-bb96-dacf24c7946b": {"doc_hash": "fb41017fd0a187af5f63d280801fd15a5137a952417045ae087877649d9622e3", "ref_doc_id": "9f005ea6-598c-43fd-8d3d-391cb5fb6563"}, "c57ca3ae-d1f8-476a-bad9-783c79203fe3": {"doc_hash": "080a54588b40e3e80861362d1b4e8338219aa117b9ad3bf7c5f2dec906e61208", "ref_doc_id": "8a5922cc-57db-492a-a06c-5af9acfc185f"}, "e51efee7-2d05-4d05-a528-e1cc0f517da6": {"doc_hash": "9569baffce39dee33b863d1b0fe6b679857d09fe8664590bcc5df1fe13baea7a", "ref_doc_id": "8a5922cc-57db-492a-a06c-5af9acfc185f"}, "5b8c7436-beb5-4d80-8974-897c750fd3a2": {"doc_hash": "d3402a37af8a733a7f8649334f7b3482613d0895e938cb90942ae65147da55f8", "ref_doc_id": "78b95546-d2da-4e4c-9867-d8be86dd08fc"}, "53568206-b006-4547-a6cc-ea40852d3af5": {"doc_hash": "cbddb71a1208a4ffb8dedb177668266feb582c17cca7e68c1f6f9d36fe26a5d8", "ref_doc_id": "78b95546-d2da-4e4c-9867-d8be86dd08fc"}, "0e5ebb3c-e5c2-471d-9f90-092864a5f866": {"doc_hash": "eee2eb00f301f649d5e1311dcb16e8d2d1b1a5193e5e285a15cf67c52b417ef0", "ref_doc_id": "78b95546-d2da-4e4c-9867-d8be86dd08fc"}, "5557fe64-448f-407a-8a25-29bfb54cc617": {"doc_hash": "75d0959f7cbf71dc24c20c0e2dbad9c91cdeaa0a636670bcc5640657a37722ce", "ref_doc_id": "f2742f62-db69-4fbf-b8a2-21103d882643"}, "05383286-0878-419d-9409-525ab75fe178": {"doc_hash": "8891c9ca40c36708289fe8275fa074672c733f6c74dec083a27ce9063a8612a1", "ref_doc_id": "f2742f62-db69-4fbf-b8a2-21103d882643"}, "f9e95eaa-0245-4b93-a38f-208efc1cae17": {"doc_hash": "3dbe1dd15a36b8e2151bd7de68c374533ac35163d6bf29118982cd179589ba7b", "ref_doc_id": "f2742f62-db69-4fbf-b8a2-21103d882643"}, "753b4e40-06ba-4159-81a0-d2013e02d22f": {"doc_hash": "992ac5a53c9b0bbba8ddef6d1e5428623f713338e2337aec1619fb241b6c1776", "ref_doc_id": "601fe89c-ec16-42ba-b5a9-caddb108acd6"}, "3d844ea4-0529-4216-a60f-9dfb8df21046": {"doc_hash": "f23c7c084b22d97123538a3f105a86baf4aad36c099044e8dcf19dd98beb74d5", "ref_doc_id": "601fe89c-ec16-42ba-b5a9-caddb108acd6"}, "8d3abd06-59fb-45fa-a74f-8135137ee775": {"doc_hash": "3bc64c60be48e2fddaebdee3999df0f355b583446923258c2184ed912ab9134b", "ref_doc_id": "601fe89c-ec16-42ba-b5a9-caddb108acd6"}, "5484a62d-001c-45a6-be9f-5384e7967524": {"doc_hash": "b24f21b0b81ebe9ee65dd0e14766f3a0d2e63176847020d2b7dc3b1243a4cdad", "ref_doc_id": "601fe89c-ec16-42ba-b5a9-caddb108acd6"}, "48101311-136a-4e6f-8111-e2259ca6061e": {"doc_hash": "54b4971fbfeb10d2f0674374b54d988c1ae55d72abfc1929db76a38edaed75ab", "ref_doc_id": "81eae37b-ccf3-4aa5-8e22-b1c75bf034bc"}, "e18002bb-73a2-4836-8959-69ebb283c763": {"doc_hash": "83d00c5cec069d4cda166c9467545bf132d22babe54ded6e11bef7fb30dcdf3a", "ref_doc_id": "81eae37b-ccf3-4aa5-8e22-b1c75bf034bc"}, "36c133f6-a883-4cc4-aa21-95dd939027a8": {"doc_hash": "a7109596166e02d59c4ba9e657c721de92c17b282d60d2a568a436fa24f19353", "ref_doc_id": "81eae37b-ccf3-4aa5-8e22-b1c75bf034bc"}, "04fc74ef-0aab-4e7c-9503-6ed3095cce93": {"doc_hash": "e760919ff9e003fbf0ed5a0d1411f574ea21fe189edff004de7669e75fab40e6", "ref_doc_id": "81eae37b-ccf3-4aa5-8e22-b1c75bf034bc"}, "f7d7e415-2ce9-43b4-b88a-64c1c54e396c": {"doc_hash": "76bf7b40969232466b52834f2b06f2de2230153983fbba56e4ddbe9084c434fa", "ref_doc_id": "4cc40bdd-3b88-451b-8008-e1a3b76a5612"}, "fa5dfc01-2216-49b1-b848-545766f156ec": {"doc_hash": "3661409b3d09c94666fc7c730b56a0d679e0a66e85d8892790a19d1b996c9bcc", "ref_doc_id": "4cc40bdd-3b88-451b-8008-e1a3b76a5612"}, "7c67e125-f50c-49de-af00-ef22d3c673c2": {"doc_hash": "7ecaf41871822f48f4167cd1164a45d11521d9f39c52f1398f33d1732e1e9c93", "ref_doc_id": "4cc40bdd-3b88-451b-8008-e1a3b76a5612"}, "9d481ff0-ce6d-43c3-9aed-f74d54089cda": {"doc_hash": "3da4cd381b5008a7557ff9bcb1af8132ef4fe03d2b5b878dc04ae04d73650418", "ref_doc_id": "7fddc816-947f-43c5-a2ce-f7e189b6c1ff"}, "72bc67fb-f715-421d-98d9-0f2d20a1b7bc": {"doc_hash": "9769f14898d01df5db69b50d5dab270d165684a717e115244f023d78fa7a0fd6", "ref_doc_id": "7fddc816-947f-43c5-a2ce-f7e189b6c1ff"}, "2a4f1451-4f6d-4612-b059-37c9dbb77ea1": {"doc_hash": "dc779ba9e7cb19de3f6eb0672dcaf95dee9dfa824bceb7673ba60aa57e0891df", "ref_doc_id": "7fddc816-947f-43c5-a2ce-f7e189b6c1ff"}, "c135bfab-49cc-4f57-b4b7-d22b49ab66e2": {"doc_hash": "8847b30c3c9bf6c6944abc6d98cfe457c3c46a47bd79bf9ffeb4742f4da187be", "ref_doc_id": "9c603077-5325-4529-94b5-c53e270b5935"}, "4dc56958-af0d-41bb-a8a5-f8a5d250a676": {"doc_hash": "f35cabf8dd2017abfbc18cd48eebd1bff51f2512c0e390c22e6f397f15b35a1a", "ref_doc_id": "9c603077-5325-4529-94b5-c53e270b5935"}, "3b567437-e044-42c0-87aa-7f16a6392b25": {"doc_hash": "5d12c6189b78475ed6b92d73d89a190527920c343383fcfe7ab0a0db65fa9a64", "ref_doc_id": "9c603077-5325-4529-94b5-c53e270b5935"}, "90ab7808-2842-4144-bc86-2d14dbcc2a88": {"doc_hash": "ff2124cfad054eb7bc2c21331a492b57618804fccaf11cd8343e0243d8d21cb8", "ref_doc_id": "bd29e430-dd99-46a4-b025-8ccd04ffc7fb"}, "26410019-c612-4421-822c-b8965ea68c03": {"doc_hash": "b22223cf0b4f34122a37bbc177bce6c4ca6cf0b3d42e2cf0392770d2c160b712", "ref_doc_id": "bd29e430-dd99-46a4-b025-8ccd04ffc7fb"}, "0cb3da40-c65c-4a91-beb4-6b33a56bc286": {"doc_hash": "da63cf284104f654470bc7ecf49ab677b926291013ca4787de75b268d9d2e1c7", "ref_doc_id": "bd29e430-dd99-46a4-b025-8ccd04ffc7fb"}, "ef2b8976-6944-4d88-9904-3e4a378ea616": {"doc_hash": "352494449290fe99efb10f34225bb16f6dcd5b1f968f5c7a8fd54223dbba218c", "ref_doc_id": "bccae22b-16b6-481b-b0cc-d625db6ca65f"}, "63c9d658-6c01-4ab5-a86f-65ee121f4116": {"doc_hash": "3e1498759cbd1ff1cab8981a6113e4a8bb443383238a4ec3320c0281e47b94e0", "ref_doc_id": "bccae22b-16b6-481b-b0cc-d625db6ca65f"}, "7457ec7c-4b87-4765-8a06-aed1a45137ea": {"doc_hash": "3b2ee42fad79ac408e0c909cc4092d295b8459bf2170eeaa9fda0d75e37af8db", "ref_doc_id": "efc2184b-6b98-42fe-8c89-a4da99c9f400"}, "657c8563-81ec-407d-8947-453f46e704fd": {"doc_hash": "bb3172e6f23c618cb9e3fdd985e80c49b92fdb483c5237405d775a7ee5702163", "ref_doc_id": "efc2184b-6b98-42fe-8c89-a4da99c9f400"}, "05507c24-4f7e-4222-93b5-9c446d1d4bf9": {"doc_hash": "f010c26d57ebbc7ffd1eb727c40476ed88cdec9a3801d8283e6e37975798be30", "ref_doc_id": "0db58665-1e8e-4c84-9173-ccc828c87871"}, "2b466e86-38aa-4e84-9437-402517c2d27f": {"doc_hash": "47021bb639459c694951346498a879d9ce6f0c541af76522e608a55ba221fc2a", "ref_doc_id": "0db58665-1e8e-4c84-9173-ccc828c87871"}, "6ba74a3e-edbe-4c2c-a315-ef59f232b4de": {"doc_hash": "6af1c24a70ee3edc00b407bbeecac61b5e4bb6f119da301fb13040ad491dd48e", "ref_doc_id": "79fdffcd-9489-4262-a81d-bcbe43beca14"}, "0b67ba50-2d70-4698-87b9-91f46f5d6f81": {"doc_hash": "110f36aa10b52be67f9bfc274e9d063e0ae8fa289e37d51b8c64b4b1e77bcd39", "ref_doc_id": "79fdffcd-9489-4262-a81d-bcbe43beca14"}, "ad03e95f-e539-4b21-9ab6-680d3e6c7cd8": {"doc_hash": "05c9cdef92c74b83f6212c216e865440d2911d5ce563cb3d330b71e8fa0dd207", "ref_doc_id": "79fdffcd-9489-4262-a81d-bcbe43beca14"}, "70e70abb-f1dd-4c06-b76c-0fe67463b262": {"doc_hash": "b912cd2129464f52bcdf2a5badfb29c316649f20cc922cbb9f1c1243eedecbcd", "ref_doc_id": "79fdffcd-9489-4262-a81d-bcbe43beca14"}, "48b6f1a3-a591-4faf-8416-1bf2db236587": {"doc_hash": "e510ba9d9022591cd80f51beed0ecd7b2ffba81a8e3fa062dfd8a3bad7c79da5", "ref_doc_id": "8be2043a-23a5-499e-9c2e-0a960733f1e0"}, "2fdf36ba-8f1f-4efa-9ce4-691e81026b8d": {"doc_hash": "967c0e7badec431ec650d7c4e1d802f70f0d54684697881f9741536e5d619885", "ref_doc_id": "8be2043a-23a5-499e-9c2e-0a960733f1e0"}, "b76cb0d6-8d86-4adf-920a-7c02794732cc": {"doc_hash": "dee768530354040a97d27ecc7a5b6af8b5a650af724ce8233fdcdc6f5b390812", "ref_doc_id": "8be2043a-23a5-499e-9c2e-0a960733f1e0"}, "6fbd3de0-94a0-4975-8ba1-c0f1f307ccdc": {"doc_hash": "a17e736f748c99f7ecf3a49106e1196e046bc94271aaf60c3a279a40362f7e13", "ref_doc_id": "8be2043a-23a5-499e-9c2e-0a960733f1e0"}, "f98e02de-48bd-46ac-b133-872bd562085d": {"doc_hash": "c00cbbdcf501965cdf64e03a56a0825febb4304c32dc04b5d4a93b62769b2e8c", "ref_doc_id": "8be2043a-23a5-499e-9c2e-0a960733f1e0"}, "c4394a4e-dfde-49c2-8adb-8d5c3d1068f7": {"doc_hash": "f6d0b726346441d6c95f8b99c75252bc350f02011ffd0b8d8022f25fd5b7c3a3", "ref_doc_id": "37c094c9-4ded-4b8f-a3d5-bd6187acc8d7"}, "e098b971-7ab2-4049-b0d8-dbcd0fb24a2b": {"doc_hash": "9c05d6383193e93da4a4d58efb10e6a79adbda7913fdad16c88a2c90d5c36d1d", "ref_doc_id": "37c094c9-4ded-4b8f-a3d5-bd6187acc8d7"}, "a546d785-06ff-40e9-8ca1-3f81a268015c": {"doc_hash": "07f85976cb2d446c8825c478cad937026aabac351d12942d5d12008b9c812c45", "ref_doc_id": "37c094c9-4ded-4b8f-a3d5-bd6187acc8d7"}, "35d12205-0bf0-4367-9963-f5a456bb95e0": {"doc_hash": "e75da743c3bf35c3e246929c811e4d8ac5cc7113b416af17bf26c0e0d7870a00", "ref_doc_id": "37c094c9-4ded-4b8f-a3d5-bd6187acc8d7"}, "75b217c5-cccc-4a3d-a4f4-4641c8bae85c": {"doc_hash": "e70f0d219a25fb448c585eee78310a80483ed75458e14d2b5454514cf6b24be9", "ref_doc_id": "37c094c9-4ded-4b8f-a3d5-bd6187acc8d7"}, "e2752690-4c04-4c72-94a1-d31306fc2ea1": {"doc_hash": "1b382f578ec402c7ea374b37a44368ab4929369631c0bb450fefac3dd011147b", "ref_doc_id": "37c094c9-4ded-4b8f-a3d5-bd6187acc8d7"}, "73f33687-ad78-4678-b4ee-e1fbee3c09cc": {"doc_hash": "f369644e89ff46122fe59b0d25d841e31683c537a21edc271950648950d7b5d7", "ref_doc_id": "37c094c9-4ded-4b8f-a3d5-bd6187acc8d7"}, "0147068f-2e07-42cc-802a-617be82b8f48": {"doc_hash": "d9c33ebcd4269342744bcf2051654d21da7ff9ce6191f3b6b892750aa349285f", "ref_doc_id": "761bb3fe-8847-42e7-9d73-5d3d8abc6b6b"}, "80824659-5661-44e0-ac9d-9ab644235cd6": {"doc_hash": "e3691286a78025a47572bb670a41ad632b507bfa3ae964fbb14077a7583a3b99", "ref_doc_id": "761bb3fe-8847-42e7-9d73-5d3d8abc6b6b"}, "e1887e6f-82a2-432b-9db6-ecb4139d36f7": {"doc_hash": "07beb4ce2cc63da76a5240b8285e721f7b53a912e04a557b97f2474aaa60f304", "ref_doc_id": "761bb3fe-8847-42e7-9d73-5d3d8abc6b6b"}, "dcd49bc2-c5d4-47a2-b545-5c6be08dcdfa": {"doc_hash": "4baf25836af0902a2cd3e8702a4e356effe67cc0ccfdeecd8d53ffd4f3b2825a", "ref_doc_id": "761bb3fe-8847-42e7-9d73-5d3d8abc6b6b"}, "81023747-298d-49e4-8db2-1a9cee50ba56": {"doc_hash": "44b6e4ad7a5482a051c9009425256eea527b0d7410c5b28f35730ff1da310d0f", "ref_doc_id": "761bb3fe-8847-42e7-9d73-5d3d8abc6b6b"}, "a9fe4749-a380-4572-9785-5af8f66781c1": {"doc_hash": "9f0e0eb60146ab102ea3b7b808cba4b94403ca378c70621367867c4fe5194c93", "ref_doc_id": "761bb3fe-8847-42e7-9d73-5d3d8abc6b6b"}, "1ae18566-0bb6-471b-bd78-d48005cd3f8a": {"doc_hash": "d6ba87bda5a742f6f9622d033f084130c8a736dc43e5038493c3e16f8e5e0e84", "ref_doc_id": "761bb3fe-8847-42e7-9d73-5d3d8abc6b6b"}, "d9047c34-a108-4353-92e4-3197817657a7": {"doc_hash": "2ce71430464b21260b47f663c6dbe26e2476983544271c2d44f65f2066c0d682", "ref_doc_id": "56ff51f7-ccb5-4c78-8d0a-99145acf70e4"}, "397999f0-6ea0-4738-b94c-fb53b29788c0": {"doc_hash": "f52b173d32018218c33937e1ec37ec1430bea82c1acc57ca40d4249736a3b134", "ref_doc_id": "56ff51f7-ccb5-4c78-8d0a-99145acf70e4"}, "2e11b28c-687d-4fd4-a9e9-6475b6df4cb3": {"doc_hash": "af4e3be3562e09087c3ce47753a4ca199343522f58b16c0b7d4f74b21fc61fc4", "ref_doc_id": "56ff51f7-ccb5-4c78-8d0a-99145acf70e4"}, "8495d7c4-7983-453b-b9db-9d79906e58d4": {"doc_hash": "95263dacf892dc2a64cdfb4fbc1f47b83f4590231d9712538d7001c450fe5a60", "ref_doc_id": "56ff51f7-ccb5-4c78-8d0a-99145acf70e4"}, "95de215d-2279-497c-9530-71d9e56a065b": {"doc_hash": "14d586c9da925c0ac83175c0e9063a29d05a9277e676849adc5a474c2b789c72", "ref_doc_id": "56ff51f7-ccb5-4c78-8d0a-99145acf70e4"}, "78a7702b-6022-4923-9d6f-00efdb029153": {"doc_hash": "7628f24ededa81dd6575b62489802edb4d8810eccc1f3445c1e3e10fd2614dbb", "ref_doc_id": "56ff51f7-ccb5-4c78-8d0a-99145acf70e4"}, "abaaf669-00c0-4ba9-80f2-3fe711e31f81": {"doc_hash": "4425564337f9e6f1eae1b72ceec652cbe0376be330f15427cc16f08e4e003d5d", "ref_doc_id": "56ff51f7-ccb5-4c78-8d0a-99145acf70e4"}, "a1a0c823-2afa-4689-ba11-37b67038c740": {"doc_hash": "f88fc929ccdbab53a24f72d9d5dc1292b857ed53fc6b53b36e511e79ad15db08", "ref_doc_id": "5f99e93f-2d79-41b7-bf31-24037874c191"}, "6f4a5510-bf53-47cc-9d18-bc9077062075": {"doc_hash": "8590f1e3800e4746dcefd7c5afc39940774cc998b56fb75985a543de50474e1b", "ref_doc_id": "5f99e93f-2d79-41b7-bf31-24037874c191"}, "ba9642e2-6f66-4c7d-a141-be0059d06144": {"doc_hash": "99c0e3a1397022a87124ee8cf76aea288dcf5545af57baba851a7460d0ea261a", "ref_doc_id": "5f99e93f-2d79-41b7-bf31-24037874c191"}, "77c83dc5-f3a4-4f2d-a215-0ab4fef80d41": {"doc_hash": "0a081dde9f4ac31e34b79bb32f8cd5a0449ea259021aba73ba2ab36f144e954b", "ref_doc_id": "5f99e93f-2d79-41b7-bf31-24037874c191"}, "0953e172-4ccb-4096-bbe4-c987beb20c4a": {"doc_hash": "265e90f68083adb9db42033d00f7caeec697a04a3bdf60b99985a180a5c7af21", "ref_doc_id": "5f99e93f-2d79-41b7-bf31-24037874c191"}, "0fc5b0e6-01f4-40b4-8c7a-5e8904f0b753": {"doc_hash": "f94d640d910ff38bdeee72c61b81a7e43b8b8158bcd7a110462526462bae607b", "ref_doc_id": "5f99e93f-2d79-41b7-bf31-24037874c191"}, "ff753d51-5234-4293-9c13-cd83a41377ea": {"doc_hash": "84e3b29150d74e64a87009c486f11b73f96c1542d823578b81a3be9386dc627f", "ref_doc_id": "5f99e93f-2d79-41b7-bf31-24037874c191"}, "1ac810cb-ebf1-4b5c-8944-5ad981734de0": {"doc_hash": "b525aab8715f6d2bc13a7a7a2ace522920f7f2966bee86d27ae8882a21d63b0e", "ref_doc_id": "a932a3d2-886d-4a41-b4eb-c9e7304ef568"}, "ff116434-58e2-4e06-a625-9bede3b4144f": {"doc_hash": "0b9f3faf6af30456aa19c54124f98bf467095474b04481f77d970417e01409a3", "ref_doc_id": "a932a3d2-886d-4a41-b4eb-c9e7304ef568"}, "bd8ec913-fbb1-4b25-bcf0-71401808fcf5": {"doc_hash": "76c4857ee6f49230c2d484b3a74c527300cccc4894b9c54b1496f205636fcc08", "ref_doc_id": "a932a3d2-886d-4a41-b4eb-c9e7304ef568"}, "f1a3766a-94e9-4ac2-955f-83dc8081fa4a": {"doc_hash": "e9228c669c26999c9ae4478597613fb2a24b5fb4fc04ddba1a71cb5c784028b3", "ref_doc_id": "a932a3d2-886d-4a41-b4eb-c9e7304ef568"}, "fa21fca5-b7a5-4ece-8e39-be8a13c92af4": {"doc_hash": "085ab75e5d2909d12d5e6121b86180c8712cb9662f8867d0acb2c53643affd8f", "ref_doc_id": "a932a3d2-886d-4a41-b4eb-c9e7304ef568"}, "85522ba5-68e3-49e1-853d-bc7b7fc4b540": {"doc_hash": "c726ab03012335c644d60fb3b5fa32deb8bc6b66304beebb10666180cdd57cf5", "ref_doc_id": "a932a3d2-886d-4a41-b4eb-c9e7304ef568"}, "7abf6e28-78e8-4e28-a22a-18814cb9bf62": {"doc_hash": "ab4b8472d9ad3e37a14c3365cc92f8a0ee767dd9e3fcbd0fecdced4aca08b296", "ref_doc_id": "a932a3d2-886d-4a41-b4eb-c9e7304ef568"}, "04007ba2-a955-474d-b2aa-7ee4dd6ae394": {"doc_hash": "697b669326964064180ad3a8f0842d9e5b202da2f299a9409c8627d116c39d8d", "ref_doc_id": "fdaa53d7-c08b-4351-b327-0fea1e9db34b"}, "5e672d68-e79d-437e-899a-7eb42fcd09e1": {"doc_hash": "51123ae5b9725e679fbe2b892568b85a1b0acf64486e927c1093aabd77c20fc3", "ref_doc_id": "fdaa53d7-c08b-4351-b327-0fea1e9db34b"}, "17ff836a-4198-418b-a03f-07a9995e5738": {"doc_hash": "7281a4ecc482a9cf43178a7d73db45e0d969429c09ce0bbd1f5cdb8e5359d61b", "ref_doc_id": "fdaa53d7-c08b-4351-b327-0fea1e9db34b"}, "8b83e115-7327-4950-ac95-470dec3a3065": {"doc_hash": "d46e1ad83db3e81d78d06d9b184181150f7d625dbbb690ef602be417d92e4a3e", "ref_doc_id": "fdaa53d7-c08b-4351-b327-0fea1e9db34b"}, "b5982d9f-8de0-48e7-873c-4745b0a9b979": {"doc_hash": "7d125ac51d1cb4b49bcd9e8605fab1041685f8a81e0cb07ead2a97d6d828c8a7", "ref_doc_id": "fdaa53d7-c08b-4351-b327-0fea1e9db34b"}, "35783b00-240f-4ce6-b647-0336187bfd0d": {"doc_hash": "3e4bf54727ea0cb1000de6dcd52960a8330e8e24e86f87ee781b719825e9956c", "ref_doc_id": "fdaa53d7-c08b-4351-b327-0fea1e9db34b"}, "efeb9872-ea92-4132-b8e0-21c1ddb6c497": {"doc_hash": "268fa02c9820297bb1335414c088c965a9641d9ccd26d24f33d79bab619ee7a1", "ref_doc_id": "fdaa53d7-c08b-4351-b327-0fea1e9db34b"}, "76064f35-8e07-4eb4-88fd-d4596e77ae08": {"doc_hash": "264c328cb4f07420d3906f187e6501e2817a1fbbfc85d9b68730dc31bdba045a", "ref_doc_id": "017b08de-905a-4437-b0a2-d21b6c4cde5d"}, "8c4b1c7c-dcf9-474d-b66e-42763db1532e": {"doc_hash": "a2fd11be57732e8ad646d981bf6a01810606bf31bf96f4c3e092da954836a0c6", "ref_doc_id": "017b08de-905a-4437-b0a2-d21b6c4cde5d"}, "26122383-65a0-4a19-97fc-26bd1a0c6e3c": {"doc_hash": "62193231c407b5ebf53b475e2a65530ed6d989ab6260b577a06541e040ac1198", "ref_doc_id": "017b08de-905a-4437-b0a2-d21b6c4cde5d"}, "a49d974f-4423-4cb8-8de9-dc003050a48c": {"doc_hash": "fef45001deb34cb48b7bdad55e188fb5c230812100b741dff3da51a92fb20cbf", "ref_doc_id": "017b08de-905a-4437-b0a2-d21b6c4cde5d"}, "19913503-6860-4554-b211-e3e6c41f5289": {"doc_hash": "b3a358a2b3e1678190c225c66bc895b998545d2bca88cc31a96f72d2cad6753b", "ref_doc_id": "017b08de-905a-4437-b0a2-d21b6c4cde5d"}, "4c0ae015-b12c-4c2d-8dd7-aa96eaadc319": {"doc_hash": "dc1c1f508558ca86210ed12e763bc83eeccbe22c3833866148ad5b5a72eb684a", "ref_doc_id": "017b08de-905a-4437-b0a2-d21b6c4cde5d"}, "d575e133-9931-4aa0-b0b1-fd6674198764": {"doc_hash": "5f70726e9f9b60ad3644a99c7791e53fbb26d9481c8e84bf6c1be20efd835ce6", "ref_doc_id": "017b08de-905a-4437-b0a2-d21b6c4cde5d"}, "0a23ccf6-773e-46bb-8c44-4914a99c1f15": {"doc_hash": "46e2a915bb2d06907f889948b8aa07cd2329a3d673f2c197c17e5f177891befc", "ref_doc_id": "fde648af-5d4d-4dae-b4e2-a4d334b16383"}, "36eb6093-0ec7-4855-99cc-331fb872b1c2": {"doc_hash": "a1190df0857893898cc4683ab493d059ee4905b3d2b861291922f20eb73c8e31", "ref_doc_id": "fde648af-5d4d-4dae-b4e2-a4d334b16383"}, "544028d4-67cf-4db2-a126-2ee01e438abb": {"doc_hash": "a20338851dc867974ad628ed2de5cf7b2b2c80b7fb8228d88eea64676f758287", "ref_doc_id": "fde648af-5d4d-4dae-b4e2-a4d334b16383"}, "f8b2839b-5060-48af-9ac5-854dd11470ed": {"doc_hash": "7ebaa841e18f4339fcef023af8fd01ded1c7922784cf1e268d0bd0a6630108c1", "ref_doc_id": "fde648af-5d4d-4dae-b4e2-a4d334b16383"}, "cb4ad102-0f04-415c-9c6b-be9c46edd8e6": {"doc_hash": "deb554880a5ffcab8275891262526eee132d962844a7f1b8aa19fa09926722a1", "ref_doc_id": "fde648af-5d4d-4dae-b4e2-a4d334b16383"}, "71a74f10-4890-41ea-84d8-8e9a62626825": {"doc_hash": "50c729c5d2644512a6b8ab78805461592294fee11a6f4d002bb81078b5f7453b", "ref_doc_id": "fde648af-5d4d-4dae-b4e2-a4d334b16383"}, "ae5d7bb6-8723-48c4-867d-ff5bb7fd1a5c": {"doc_hash": "f883595edf91799cab01545bcdecdfdeebea2fa84e19cc52d69ee9f847095a76", "ref_doc_id": "fde648af-5d4d-4dae-b4e2-a4d334b16383"}, "4f55e565-fc97-4a01-9f08-f8d64da59106": {"doc_hash": "eedf2392e292384e86a3c0b6df18d963a1fe6289fc2876f770fbe5f0af5c26a3", "ref_doc_id": "efdc7e73-93b5-4b14-8f55-54d4edd305b8"}, "f422e3e6-fd9b-4b87-a07b-a49307b5a5c6": {"doc_hash": "bb0afd97cb9c5e8449035f0f90b44925aeb12a02856567a440d636073d2a3fed", "ref_doc_id": "efdc7e73-93b5-4b14-8f55-54d4edd305b8"}, "13141e2a-e8ab-4a32-b621-3155812403f9": {"doc_hash": "c30dd53d24ca0a0165d240426bb46ef14d416c217dea2f973323b5f626495793", "ref_doc_id": "efdc7e73-93b5-4b14-8f55-54d4edd305b8"}, "261b2be3-e88a-4660-a2e7-4ed93f0cfa86": {"doc_hash": "2edb3346af586577a5ee3ead4a59c7cb45d504b0a213ef72649e3f0522a8ebd3", "ref_doc_id": "efdc7e73-93b5-4b14-8f55-54d4edd305b8"}, "cf27b335-c15e-40c5-95ff-fa067d425e28": {"doc_hash": "501b15c2cc2747087f6842afc2391c11e9f185f42f8350d844f6f681a488ce1f", "ref_doc_id": "efdc7e73-93b5-4b14-8f55-54d4edd305b8"}, "6599f5e6-15b3-4400-9298-35e6184639fa": {"doc_hash": "49346d000427c0b3f1053d7f051ae4575aee0a453451364ced9856bf4a5d2c7b", "ref_doc_id": "efdc7e73-93b5-4b14-8f55-54d4edd305b8"}, "58b04eb3-8626-4be7-9353-20523afad44a": {"doc_hash": "6987bc96f94468b279050113d3be9ae04c4a52ed713a39313a3c20ca356cf143", "ref_doc_id": "efdc7e73-93b5-4b14-8f55-54d4edd305b8"}, "4834e53d-2136-45a5-bee3-e350c25bc308": {"doc_hash": "decba4c4e37c3ba24df1bd17dbc62398795972f832405eec46e8b76729ec44c2", "ref_doc_id": "ef7a8cb3-c404-4478-bfd6-d48cc93996ff"}, "b0fa056b-b183-496b-8430-1f264752c904": {"doc_hash": "94abac957383abdcdd4a139a591ee73a6e2e177e3773785ab867d092962a3c2a", "ref_doc_id": "ef7a8cb3-c404-4478-bfd6-d48cc93996ff"}, "ad53ef8f-c34e-4a00-8735-654440ff0bcd": {"doc_hash": "22c0bb732ab40ea59d44f0400c7a43bb67e5018fc665ace20e17e0dcf0dec154", "ref_doc_id": "ef7a8cb3-c404-4478-bfd6-d48cc93996ff"}, "be6c3c81-dc82-429c-97a7-1b82b69f0e83": {"doc_hash": "ddd1be0e470e8e4463bb353b4eaeccd5cc28e659aa711d0ebe7b9caf7f8f3335", "ref_doc_id": "ef7a8cb3-c404-4478-bfd6-d48cc93996ff"}, "72b34996-2125-4abb-823e-d5865aed94db": {"doc_hash": "acb369a570e62e92bb56ff610996d7936b5c66b4a4ff59e3a2c534af9051cda6", "ref_doc_id": "ef7a8cb3-c404-4478-bfd6-d48cc93996ff"}, "31ba9be0-5c48-4471-9e98-73f85d7deebc": {"doc_hash": "e74007933ae893529e19f4183530fbc55c68bdf70d860b0a9fb8d52e284e7212", "ref_doc_id": "ef7a8cb3-c404-4478-bfd6-d48cc93996ff"}, "7b656c36-d895-42d5-a60a-1bd576b871bb": {"doc_hash": "c53e8e0e0a4f35ac0503d59e69b66d8b7708cfd442ecc0e862db6618919fdc7c", "ref_doc_id": "ef7a8cb3-c404-4478-bfd6-d48cc93996ff"}, "6bdff43a-0693-4707-8fb1-010e9a2cdcb2": {"doc_hash": "8c9906e9dccc2034c8f86243c541a4864ca2afa98dfd7bb0168983928ebc1806", "ref_doc_id": "27abbbdc-485a-4983-9ac7-0666588bd8f7"}, "f5f29c4e-0f26-44e5-a81c-3d879b5c49d6": {"doc_hash": "3de5313fae54ce1224d35ec94806bc078a48db95e41b382e033b75d8f88fbed4", "ref_doc_id": "27abbbdc-485a-4983-9ac7-0666588bd8f7"}, "2317ffc9-03ba-438a-9367-1968cac06888": {"doc_hash": "c7795af797ba08ec497b0a229609b6f55047e27581db857e5f3d7fe8fd2a559f", "ref_doc_id": "27abbbdc-485a-4983-9ac7-0666588bd8f7"}, "eefdf0d9-7940-427e-b6d9-95510bf42b21": {"doc_hash": "8168870479fd46c55443fccfc28cf004cec43adcd7f69e623e4ca1a875fe05c4", "ref_doc_id": "27abbbdc-485a-4983-9ac7-0666588bd8f7"}, "2bc5072d-d23f-47b4-b3cf-01a85ebe6aac": {"doc_hash": "8dd45dedefc1b6596200253c5726e4ff2c57cc42246ecd06576307b45d80d56c", "ref_doc_id": "27abbbdc-485a-4983-9ac7-0666588bd8f7"}, "d741d7e4-1e2f-4d12-9d21-699d0e754ec8": {"doc_hash": "5cc0ceb063e1e56c1bd98931ef34d25d5f9c5bcb826e2bf2b546685a971d8d6d", "ref_doc_id": "27abbbdc-485a-4983-9ac7-0666588bd8f7"}, "a42a0d5e-8326-4170-9c66-48a32c0ecf3c": {"doc_hash": "1db4d37ed7b3be3f6634f08a71cbfc7ada3f0e176316afe6d796d9a3334afa52", "ref_doc_id": "793fdd24-7965-4ec3-b67b-002f28e312e3"}, "872fcdb6-1dd8-4ee6-91bf-0d5ef3ea0518": {"doc_hash": "ed384623cd4c664288cec94f04c08b7e92cc536990dbeaf7a2f72af95a520e5e", "ref_doc_id": "793fdd24-7965-4ec3-b67b-002f28e312e3"}, "74c8a6c7-0f05-4240-840f-3f4803bd4d90": {"doc_hash": "e59894408bccf095ba0847f9c11b117eb6a7d737c2e673b9d959faacd9bd4dfb", "ref_doc_id": "793fdd24-7965-4ec3-b67b-002f28e312e3"}, "dd82aaed-e0ef-4be2-8b62-e7c69f37e87d": {"doc_hash": "7cbb6578450f6ee6476fc7a5253e1e52269ca7aec5d8de30f16278792e193653", "ref_doc_id": "a5cb8601-86b0-4a92-983b-21f73c7f3edb"}, "db4ad094-a2b3-4a9a-a2f5-79169853e8cc": {"doc_hash": "0934a43a7c177bba1412f5f5c3375a5cfe30823451b458f06b7d4df328aac6f5", "ref_doc_id": "a5cb8601-86b0-4a92-983b-21f73c7f3edb"}, "aa68ae17-9430-4503-b248-dbf996def1cc": {"doc_hash": "312d21568fb46063388f02f5d1dd7924342e664a274987a5553d5b85c02340f3", "ref_doc_id": "a5cb8601-86b0-4a92-983b-21f73c7f3edb"}, "5e14767c-7a3c-460f-8da4-7dee7e6f9d4c": {"doc_hash": "ed4085cfd547c07b56335bda01bad14ff0d8de047db32a3115a608c486c90040", "ref_doc_id": "a5cb8601-86b0-4a92-983b-21f73c7f3edb"}, "e3eb41ec-c251-4ed7-b6dc-fb04d525dc73": {"doc_hash": "e1b07e34b7422c9560d42a0536e9eff453bdf69235930a25c5a283bb78dac57e", "ref_doc_id": "36ef91a0-45ad-4de5-b37f-0347da796824"}, "d3d7351e-4e9b-4121-bea7-8309bb65e827": {"doc_hash": "5a1b582c1c5d4032d5595098e5bb413442ed8d198a9e640290d276bd879da608", "ref_doc_id": "9fba4c60-5030-4e2d-a80a-dc88ba2d1be1"}, "f1a416bc-5cce-4cb0-99a3-7f9c8c3b29d6": {"doc_hash": "02e2eb9b7d8da11e2413e6dc7c27400bb8f7a2e445c92c537575853f82ed4c52", "ref_doc_id": "9fba4c60-5030-4e2d-a80a-dc88ba2d1be1"}, "a4b9e899-3de5-405b-9d02-a1207b812d24": {"doc_hash": "2bbf94a9edcbed038030b83318011a985eb256bb94a305a2b757186aa69f2dd1", "ref_doc_id": "66af6b35-4748-45dc-b047-5db47c7454a6"}, "04e4edc3-8fa4-437f-9e3d-ccbf8812e7ff": {"doc_hash": "7abaca4ef8b6d8f902d825920f9aef42d43779dc3a68c9ca7d39e675071a67d1", "ref_doc_id": "66af6b35-4748-45dc-b047-5db47c7454a6"}, "a672ec12-7596-482e-99d9-dedb5d5a6c8f": {"doc_hash": "d8aa629ff56736b5664b824c2496bb00a8d645d2243ab0c5aa2d1b0415a2d1e5", "ref_doc_id": "1a5b021a-1251-462c-88b3-0441db498c9b"}, "67d15ed4-d9b4-434f-bcd6-65e6f0325a02": {"doc_hash": "ff11ea690ea7c4d7ee19fdcf288d183974d35510fcaa641bb0dcdf0d920978a9", "ref_doc_id": "1a5b021a-1251-462c-88b3-0441db498c9b"}, "240e5630-7082-4e0a-8116-f9b243f03da1": {"doc_hash": "05fe2a68aec70511bc1d3b31ffdcae934fd65b5d40f57e2895f23bd4aeaba92d", "ref_doc_id": "1a5b021a-1251-462c-88b3-0441db498c9b"}, "b313e9a0-aabf-46b2-b9f6-7764a29932f5": {"doc_hash": "3a35693e4a9223184de9a32fc852e0cf7a1d56f1beb470925e2a2e20b89d10a9", "ref_doc_id": "1a5b021a-1251-462c-88b3-0441db498c9b"}, "cc5cd277-9217-4bbb-965c-e216757e512a": {"doc_hash": "61480a96794a476279c599c351ccb49b5e8a6d2f859afacb207c366b78773a0a", "ref_doc_id": "65906fe0-97af-478d-89e7-6eb93bae2203"}, "097695a6-bd1f-4a70-9b89-136d149461bb": {"doc_hash": "df145b452569ecd6d13391d304916d55f070442ea108c979fa09840bde604bf5", "ref_doc_id": "65906fe0-97af-478d-89e7-6eb93bae2203"}, "7e243e1a-a30e-42d8-907d-853e8632bbeb": {"doc_hash": "665200ac75662bedfae8bff9a4442a041d0203f4295acf74f98db091e4ad2839", "ref_doc_id": "bfaa9764-5597-4dd1-9ad9-b29835b17ea0"}, "efe4bcbe-f8fc-4b43-b5a6-c74824608351": {"doc_hash": "ba12bb1be276078b5a1bc8f3ef8a81f3ccb7921cc1665214038018c82af8b155", "ref_doc_id": "bfaa9764-5597-4dd1-9ad9-b29835b17ea0"}, "9fb88f11-2b37-4938-8961-bb7e6b5fedad": {"doc_hash": "029ef6c8b320663db657fef50c8f10d307ddb78e806d6255d529e344fac98425", "ref_doc_id": "bfaa9764-5597-4dd1-9ad9-b29835b17ea0"}, "056517c2-e40e-42cc-8543-a2b839f432cd": {"doc_hash": "f58d26e4a593eed85c9aa0d65af96319a60e2ff03185045c9ba08db41a446907", "ref_doc_id": "bfaa9764-5597-4dd1-9ad9-b29835b17ea0"}, "d791dd64-03cf-4a28-84b3-73a4bf6a98fc": {"doc_hash": "0d09a882dd4f8f26de250e4dc6dfec9a8afc3b346c404649a002aca627a7d9cd", "ref_doc_id": "b86e0623-b7c5-418e-af81-6f680a0cd825"}, "9682222d-863f-4319-b8a2-40c271a72810": {"doc_hash": "2d3e1251a70d21a461de7ac0d58001f226b4c984b0db51ed8ca868e13222010c", "ref_doc_id": "b86e0623-b7c5-418e-af81-6f680a0cd825"}, "43d2c03e-3821-4049-ba1c-38429a38c5ec": {"doc_hash": "e0d37be6e3132b5465f40b9948427281e40e5ef17453f18c3b078bba522a0e7b", "ref_doc_id": "b86e0623-b7c5-418e-af81-6f680a0cd825"}, "4e73f7a5-2a72-45ce-b5f6-0ff1bcf1d94d": {"doc_hash": "9ed2060545e1d2d560d7fda869e16c2720dc13ccd7e94b980aa93efad91bda6f", "ref_doc_id": "b86e0623-b7c5-418e-af81-6f680a0cd825"}, "51838432-552c-41d1-9da9-8ecaffa95b4f": {"doc_hash": "c59da4e47cee2b6aed4aa1fa0260abe55a44a3996e1e1016fb93d24f268af2a3", "ref_doc_id": "211ae5a8-aeaf-4f78-a2a1-9bf5cde183b7"}, "ce3a7b34-3ffd-4a7d-a7c0-86debf453268": {"doc_hash": "3bd2b00cbd5501c96828712246a0e5e1dbda2c799a5a8ca4e049064c867bc900", "ref_doc_id": "211ae5a8-aeaf-4f78-a2a1-9bf5cde183b7"}, "0fb8196a-1e04-4d67-a31d-59eddc796253": {"doc_hash": "07c8c7e5b434358a8c7df5fb5cf6fe80041490fdbe75a4a21212acb99bca779c", "ref_doc_id": "211ae5a8-aeaf-4f78-a2a1-9bf5cde183b7"}, "8925c1bf-3e89-4ebf-8e63-5be315af0179": {"doc_hash": "bf7ef1485ff29c96ccc9862275988a6b5334afec710a167655113408bee8c921", "ref_doc_id": "211ae5a8-aeaf-4f78-a2a1-9bf5cde183b7"}, "be14fb39-8dd9-471d-baea-f11c7f5b05f8": {"doc_hash": "b145f5bdcefc84f39f1e679394411025556a494dc81ef22a42474bfc6f431ec9", "ref_doc_id": "8ef58779-6977-4fb6-bb69-64d6dc4f6015"}, "1dacee84-56c2-4829-a896-85985abb1444": {"doc_hash": "2d425a814ea8e49c3322cf2959b9d7d1e759abea607cf41b5309391328bc7aa4", "ref_doc_id": "8ef58779-6977-4fb6-bb69-64d6dc4f6015"}, "2d63a75e-0e47-4f72-920c-474e35d1c7d5": {"doc_hash": "86b9d0c8e9f8a50f2bf0a9216344f637ac539f3cf89e325ef19340ebbd34aad2", "ref_doc_id": "b78963f2-1427-4e4b-bd11-712b03dd4aa9"}, "75b8f2dd-5803-4d38-b795-8ea9c72c4978": {"doc_hash": "274540b2dad9f6056f6911188ca214af6f0a075d3830e31f6e9680ebe2f13a68", "ref_doc_id": "b78963f2-1427-4e4b-bd11-712b03dd4aa9"}, "4a633ea5-b255-408a-8925-b3ce3ec8bb8d": {"doc_hash": "ec113b19faeba4ab9d6b3532097033de8dfb9f562475c8ac8415bffa7bc014e0", "ref_doc_id": "b78963f2-1427-4e4b-bd11-712b03dd4aa9"}, "3da98959-7833-471c-8946-92563a61d93b": {"doc_hash": "ceed835c7b5af35e0a6f2618880a5631265e72bde29530883d5cdd973772184d", "ref_doc_id": "b78963f2-1427-4e4b-bd11-712b03dd4aa9"}, "51eafc70-f43e-4298-8687-2409c97f3a2f": {"doc_hash": "371f3eda5ca203e24595aaf55fa9a7a71d4a6e42b9566eda72ebd12e7020f172", "ref_doc_id": "a2980ba1-b4f5-4bf3-acfc-46666d7c0419"}, "19b7979c-cf21-43bd-9623-1247c8e3bc50": {"doc_hash": "3c62ae06e55009b624639ea30b1f9c505de6b083601c1478036017d7d85e5d32", "ref_doc_id": "a2980ba1-b4f5-4bf3-acfc-46666d7c0419"}, "7fee2ea4-22a8-4502-9efa-d14a97b0d633": {"doc_hash": "cee7a090c270811ff95ff3b537e1d39f82cda586fe42ebcf877797a817d6dcae", "ref_doc_id": "a2980ba1-b4f5-4bf3-acfc-46666d7c0419"}, "a56cc89d-18f9-485c-85c2-ef01d8974fea": {"doc_hash": "e6725b6ab3b186d98a2c820254f0f8a95befaf588d84e695a9c00e8201ada763", "ref_doc_id": "a2980ba1-b4f5-4bf3-acfc-46666d7c0419"}, "9b0234d0-94c3-4844-b52b-4f5046836b4c": {"doc_hash": "7a605e0c6da1e1f4bb5993e23a2ec2b568e03a825e23521e781060a0414d8f2e", "ref_doc_id": "4298f04d-6f99-48e7-bb95-9f26e912c4e1"}, "e7a6430e-652d-4768-acdb-141bd3422b5d": {"doc_hash": "b2e6d4832a6e824173fcfc9d8ffb57e8c0a7ab7892aba364ab02f004711a1eb5", "ref_doc_id": "4298f04d-6f99-48e7-bb95-9f26e912c4e1"}, "c2826f2a-699d-460e-9b8a-7be5b47a7856": {"doc_hash": "1ee78a8140efd6614fd89d719c6aa06a11a37354b03aa66e512cb6ea8240730a", "ref_doc_id": "4298f04d-6f99-48e7-bb95-9f26e912c4e1"}, "fad729ef-da8c-4365-9be1-54dd34011692": {"doc_hash": "32851d2b7232f37d7c281e5a1049bacf7a2d3ac6c020252e5cd751049d5c5b21", "ref_doc_id": "4298f04d-6f99-48e7-bb95-9f26e912c4e1"}, "1c302e1c-5c91-408d-a4ba-01e6c5dccd7b": {"doc_hash": "c59db8391a61fdf58785e52bc760e6b40119fd16faa118b285b3d3f6cca4132f", "ref_doc_id": "807e3618-d7a6-4343-833b-06d85b548478"}, "32a72e73-22c3-4743-a5a4-38d376c66bb6": {"doc_hash": "74c0cc04f18218cbe386c5de6b3193810cf378e427b477f247c4ba456e786582", "ref_doc_id": "807e3618-d7a6-4343-833b-06d85b548478"}, "aab5d28e-1b5f-45f9-bbc1-5c3c1719de4b": {"doc_hash": "df2bd2319a850a70db48974cbcff8246365600f44e1b94cc2738aeafa9bfb806", "ref_doc_id": "807e3618-d7a6-4343-833b-06d85b548478"}, "497cb895-c115-479d-94e7-c0c5c6a406a0": {"doc_hash": "c045595def34e97409c6a1160dfb7a7c5c0700ce152a148304a516c6aa74382b", "ref_doc_id": "e041abad-2618-46dd-a041-1dbc2e08bfcd"}, "b1324942-3a5b-4944-b531-a1c12e9eb11d": {"doc_hash": "dbdb29ce90790c98078d31a2de2bd9160c6d60f450f3877f77d4d4a3a56fe624", "ref_doc_id": "e041abad-2618-46dd-a041-1dbc2e08bfcd"}, "16ef63c1-1b3c-4b5b-9ada-5bae87f0e448": {"doc_hash": "edb7473b3f94d4c6cb8ede647571b802539f4a47584bed7f36ef53d8ab8b640c", "ref_doc_id": "e041abad-2618-46dd-a041-1dbc2e08bfcd"}, "7398bddd-d207-4501-8a69-003df36c13d9": {"doc_hash": "bdb1c53b210462e20d8e6a77e9f48c77f90890859720b4a684baf2bd3207f1b3", "ref_doc_id": "e041abad-2618-46dd-a041-1dbc2e08bfcd"}, "f09d1838-a681-4c76-893c-e5f5e69551f6": {"doc_hash": "aebc8078a0e9986057590e39bbe25641d80a3aa8c0ce9e307d04a35983702e43", "ref_doc_id": "c0f03fd7-3c41-4ff5-a615-578abb7836cb"}, "355e5c34-3d5a-4abe-80bf-6d706a01d29d": {"doc_hash": "11a4eba2b4327bf4b098dbdec5233034b2a7b8cae91deaa99eb5296971351831", "ref_doc_id": "c0f03fd7-3c41-4ff5-a615-578abb7836cb"}, "16dc24cd-81ef-4da7-a9bd-193de4d8e75c": {"doc_hash": "5bc1daedcef3e48b79dd3a20b464284b6f7af95370626490549499271a248a6f", "ref_doc_id": "c0f03fd7-3c41-4ff5-a615-578abb7836cb"}, "499d12d2-bcd0-4a92-9a46-be68bc255779": {"doc_hash": "6bd5331e7dd2384d7f292edeea3c9124874a82ee1f8badb348eb69d409574659", "ref_doc_id": "c0f03fd7-3c41-4ff5-a615-578abb7836cb"}, "c51fc633-364f-4aa8-a307-4266d6a20be4": {"doc_hash": "853b538f6c28040f6066882963f7d1f16bfe36fb3d02b57726ca77edf85aa6cd", "ref_doc_id": "587dc3cd-fde2-4c71-9b40-2473b771f4ce"}, "ae33e657-6d03-40de-81b3-86835125b63f": {"doc_hash": "d94bba748ba0854fc5acf6622ae12c76a1599f8fb6ca5a2402d16165d76b9ed2", "ref_doc_id": "587dc3cd-fde2-4c71-9b40-2473b771f4ce"}, "821b7fc2-f9e1-451f-8ddc-a4252d3932cd": {"doc_hash": "547a1aad5edc3f31dc13600ec84c05fd3df1b1e7e5c6d7652bc9e8c79b402aed", "ref_doc_id": "587dc3cd-fde2-4c71-9b40-2473b771f4ce"}, "0ef7773c-ac18-4dbb-83d1-5c81e5cec00c": {"doc_hash": "80be3997781eadaa61bf625e332a9ba27ba6d8658d1c09c8142695e2ad9da0d0", "ref_doc_id": "587dc3cd-fde2-4c71-9b40-2473b771f4ce"}, "e9d9c288-6dbd-40b6-83bd-b380240aaad1": {"doc_hash": "da60c6cac209464b777d716aa050c0f391368ed9fe8d8696d51c55e5d37b246e", "ref_doc_id": "98e95dbf-dafc-4247-b20b-a4d84fa6aa19"}, "44e061c9-c1cc-4064-9fbf-9fefb0e36448": {"doc_hash": "b96c19cc2a0523a1e7fcce63234d905ec29847439b2cd8292052970bac3ee6a1", "ref_doc_id": "98e95dbf-dafc-4247-b20b-a4d84fa6aa19"}, "d61e9618-b7c2-43ac-8c78-8c9e7c4d5b1a": {"doc_hash": "57ab57fe9f587e3d678347a3e4d0f17f37b876e5a3721a5b84ed161968bb6f74", "ref_doc_id": "98e95dbf-dafc-4247-b20b-a4d84fa6aa19"}, "754009c1-a993-4df4-9fd8-a3d2ef5a74be": {"doc_hash": "f1d4ddd45b59b29ac080a2d3f347c7c110ea413e8d4959d2b2ba4887741dec61", "ref_doc_id": "98e95dbf-dafc-4247-b20b-a4d84fa6aa19"}, "7d6ee201-e1cc-47e7-8a71-a21e3f00cead": {"doc_hash": "397b2edd67d3f1b583df1a48f8bea5af9ebba0bedded067b60ef1fe414aa7b69", "ref_doc_id": "d9aebe03-7172-4603-a4b9-fc252f4f8120"}, "b64592f1-7a14-416a-9c34-7268c4b1f72b": {"doc_hash": "93f66cbd3367e4ca6ec181bf18b9a58dc271f6c7a2719f2008ec9567f9b43f2f", "ref_doc_id": "d9aebe03-7172-4603-a4b9-fc252f4f8120"}, "813ca0b5-bbc1-41c6-b45b-fc6a86bc0f62": {"doc_hash": "3a241edc80d6b9877161bf91e9aae2f33919aa8826186e699faa47aca0b6cd05", "ref_doc_id": "d9aebe03-7172-4603-a4b9-fc252f4f8120"}, "d5099df0-2b78-417f-935c-5e9f174727f7": {"doc_hash": "e37607ee2264dd5b87456400c9a96f7f9b2101eb70bb144e8f9560cd69d5ae01", "ref_doc_id": "3b2cf5c8-27eb-4c9f-adb7-bfb585a20e39"}, "5a8afcab-3188-474d-90af-ebbc0375245d": {"doc_hash": "dbdbbd5fde43c49e2e15a04be6c9da985e59f9b93722cbf78bad09de4335cb2d", "ref_doc_id": "3b2cf5c8-27eb-4c9f-adb7-bfb585a20e39"}, "2810d43b-63e6-4a84-aa41-015fbc903e12": {"doc_hash": "2cf0074538362a4fa0d446567a50bf65a3ee0d7f575281254ac0afcc4499dd3c", "ref_doc_id": "3b2cf5c8-27eb-4c9f-adb7-bfb585a20e39"}, "4eb70702-545b-4370-be43-87482225df7d": {"doc_hash": "acff87db64e7fe32119975fba9c6a374258cd626144c85c9f87605f6aeeeccf5", "ref_doc_id": "69240135-82d6-4306-a1b8-5797f4d75cfd"}, "6069e7e2-0bb5-4312-91b7-42665316ee79": {"doc_hash": "501bfa608a84765f2860921d97a66775a5b9fbd476e785238ae02a06648e79cc", "ref_doc_id": "69240135-82d6-4306-a1b8-5797f4d75cfd"}, "825a8cdf-50ca-4072-b42c-334eba3edc8c": {"doc_hash": "405fc4b41bb4933d7cc530fc08bcd16a56dc586642ea7ad66585b0bb0537d625", "ref_doc_id": "69240135-82d6-4306-a1b8-5797f4d75cfd"}, "c1cd7434-5815-4c9e-a291-bb7aeebc40aa": {"doc_hash": "60f93e4a632f472209603b5801e3145b573525e52d1e857a871d1805f3994527", "ref_doc_id": "69240135-82d6-4306-a1b8-5797f4d75cfd"}, "a2e90743-be84-43ba-9a7b-e15d17d8d14a": {"doc_hash": "5d8bb19ec430a5576e0c82d62eb57e7a5088e5229afc951a8e85aa5ca0e02a23", "ref_doc_id": "cf63ca09-1733-45ca-8a29-5299aabac73e"}, "2ebe2db7-9480-4df8-baaf-3a2c839bc5fd": {"doc_hash": "89910e6a69228f69f5270cb3864486f23a871fa9c5e1dc16c5914bad2598acdb", "ref_doc_id": "cf63ca09-1733-45ca-8a29-5299aabac73e"}, "d0094173-0425-43c4-9e86-19a83eb1df01": {"doc_hash": "1c2e7252a0c79eb8d3527ff9b22ce804aac3fb256500a6fc02b2e2447faff856", "ref_doc_id": "cf63ca09-1733-45ca-8a29-5299aabac73e"}, "98cc149d-38ec-4a00-8450-0660f21c7f3c": {"doc_hash": "be1df9643d38b810463d62fc09e4c8dc069e6b2441e74896856466eee3241249", "ref_doc_id": "cf63ca09-1733-45ca-8a29-5299aabac73e"}, "3dea4933-ce0e-46cc-9260-d1a1ff7cbbc7": {"doc_hash": "031e61912ff7cb25e78279ef30489d1104ac08b98d7297ef927279e2182d30d4", "ref_doc_id": "ab208677-7742-45fd-ac0a-4cce1ba8ded8"}, "9bf4c4f0-985f-4a25-85f0-683694b7c8f8": {"doc_hash": "05f838ae1ff0468311f6db41a5bc97729dee8bcc145085cd0f7e9163eb086822", "ref_doc_id": "ab208677-7742-45fd-ac0a-4cce1ba8ded8"}, "c82ed998-695d-4f5f-856b-c9d8c48712e6": {"doc_hash": "e275bc3321841df37d1c652c11a883af7772aa636668ccf0a956ef93ea0921de", "ref_doc_id": "ab208677-7742-45fd-ac0a-4cce1ba8ded8"}, "e6943aab-f624-4a93-8cd9-ba817d835cca": {"doc_hash": "064148f5e0ac9476282f6607dff7fddb591f3f3eb7929eb42d81181f19c73f75", "ref_doc_id": "ab208677-7742-45fd-ac0a-4cce1ba8ded8"}, "c1c1556f-15af-4c1f-a048-8058fca21517": {"doc_hash": "9bb1b43d0eee50223ef9487b1ad954c9bfc54c1163718d8fc55349bcb0bc91ce", "ref_doc_id": "d8fa741f-944a-4fa7-923c-79699ba8d751"}, "6cc8055e-1837-4af9-aaa6-6c4cb5d6ff6d": {"doc_hash": "d95743a0a36260e0e00ac61634d94cff37fd5432a0fe4eb3345db76d81d6e284", "ref_doc_id": "d8fa741f-944a-4fa7-923c-79699ba8d751"}, "bda5a8a4-5fcf-4428-8f1f-289fe07a9d5d": {"doc_hash": "cb4237593d825a1a83ef4b7c8ebd677d0b329d29b40e914d7698a90acf701ae7", "ref_doc_id": "d8fa741f-944a-4fa7-923c-79699ba8d751"}, "00e8b91d-05b5-46d7-9734-735a8c8eb903": {"doc_hash": "bf76c13e05b33cedb8a305e3e6fbe05ac1b92a094d636a594cead73ae7188a5c", "ref_doc_id": "d8fa741f-944a-4fa7-923c-79699ba8d751"}, "604deddb-80b6-4476-bbd3-c194ea0df1e9": {"doc_hash": "44a7f6c455c8885a94f35614de21b48f50405d454d2ec41d6d1b16d6fd848c11", "ref_doc_id": "45c8bb38-02a6-4db8-a11e-c0451354b3fd"}, "5f428a5f-5cc0-4367-96ae-a0980abe883f": {"doc_hash": "ba56d569b27f8b3a0bb5ac20c0c4e331ada733576125c3d7732f07d4cf473fab", "ref_doc_id": "45c8bb38-02a6-4db8-a11e-c0451354b3fd"}, "6d8f1af7-9c2e-4bb5-90f0-7142fb2ea6e7": {"doc_hash": "c064f1ac780f3cc1545032f5404a21a3fc9cdeb351de032b985c39d6b76922f4", "ref_doc_id": "ed0be872-0597-40be-a640-49c6a519b7af"}, "562e797d-544e-4aeb-8b41-d5c1f1773239": {"doc_hash": "c5b30946d9e30dc996fbb819587c3172b08a0f94d644e385bdbcd25f6a9cbea8", "ref_doc_id": "ed0be872-0597-40be-a640-49c6a519b7af"}, "dba13983-679f-4202-a8ea-467308c322d5": {"doc_hash": "1cc04c84839165fb3f1a615f277f8022e1d6253ea54b15e05f779943670024c1", "ref_doc_id": "ed0be872-0597-40be-a640-49c6a519b7af"}, "3f8cab12-a567-467a-81ea-435ca37ce7ef": {"doc_hash": "5ed94741b70a66b45f037b0273dc2e1b35ae68639c4fbda11309127a987ce933", "ref_doc_id": "234e85aa-e810-4fe5-9151-925d4e029b6a"}, "76289406-e487-4837-82bc-71ef38a7dddf": {"doc_hash": "7598a392492b4e722abbefc2c2a6e3053e571c8a153282bb37e603c86a2bc477", "ref_doc_id": "234e85aa-e810-4fe5-9151-925d4e029b6a"}, "704c03a7-6576-4ae2-9c96-cc765762fcf5": {"doc_hash": "8df55248e5943d8590042222b1a3d35e813de9f3953e29eec02e1310336c6433", "ref_doc_id": "234e85aa-e810-4fe5-9151-925d4e029b6a"}, "12b48709-4a6d-4a50-88f1-1f47b1f0e595": {"doc_hash": "6378863329e16f938e6c36c2dc846fab8ea14bb13b0286de8dcb4aa394d074ac", "ref_doc_id": "234e85aa-e810-4fe5-9151-925d4e029b6a"}, "0e02a1e4-b826-4366-bf96-7d6402142030": {"doc_hash": "0943ceee579a662c56f3b359e138a400c226759bb2356fbf7119db795dbc06ce", "ref_doc_id": "234e85aa-e810-4fe5-9151-925d4e029b6a"}, "5b0a364e-a8fb-4562-af69-91614343d2fd": {"doc_hash": "6a1a9f8eeca05c30847c9d8d155f1cb7d4d6fd59bcd43b93ef2bf0e8dedf0927", "ref_doc_id": "9365d75b-df22-4bb1-87b1-c8becc020be8"}, "3c72cc7b-08c2-4a37-8fe4-9d6508dd1158": {"doc_hash": "3fb75bc002c5e83f7b622d7abc21ee363b57614a357c6baeb02dd83e513a82dc", "ref_doc_id": "9365d75b-df22-4bb1-87b1-c8becc020be8"}, "4e5ac5b4-e2ec-4289-8405-3923a4891d92": {"doc_hash": "4d83470fa2b4b40d185f3d69f673002ceefbb4fdcf36f463f9e6ce40e7c2a40c", "ref_doc_id": "9365d75b-df22-4bb1-87b1-c8becc020be8"}, "67c4f5b0-97fe-4f53-b74a-ae3bf41e473b": {"doc_hash": "e39422a390e51dad8ae702689c2df693597274e1b980c60f4c60a75a24d446f6", "ref_doc_id": "9365d75b-df22-4bb1-87b1-c8becc020be8"}, "55bac4dc-dd5e-40d5-a516-1b17df1f4cb5": {"doc_hash": "dd05f8d5f65e2a15ef348832c344ead535601a5bfac38f0974b875fc145573ad", "ref_doc_id": "9365d75b-df22-4bb1-87b1-c8becc020be8"}, "10d4d15f-2c73-4426-a50f-71ea7f5ea9fb": {"doc_hash": "eebdb52b0e75d03f5eefc85b0c16032590d5518fccf37489b3e8d39f4992e6bb", "ref_doc_id": "ac87c0ae-85e3-4cf2-a730-61f926edf400"}, "2e6fc93b-c553-43a8-ad66-44e29001d417": {"doc_hash": "3c959f2ed234efe9419bf5dcbef51dce92f775cfbcba573fc51b6b1cec1fdb75", "ref_doc_id": "ac87c0ae-85e3-4cf2-a730-61f926edf400"}, "a11d218c-03c3-4287-9eee-1c3152479208": {"doc_hash": "b36f121e2e8da8e05b671c92b348bccd19c4e8d525c83c8569d5fcaf6d976c33", "ref_doc_id": "ac87c0ae-85e3-4cf2-a730-61f926edf400"}, "38036193-c9c7-4342-8491-e9680c2b9ad1": {"doc_hash": "ec77fdd20d24c253d494254bdb791fffb3712090442b100adb267d9ccdb57730", "ref_doc_id": "ac87c0ae-85e3-4cf2-a730-61f926edf400"}, "7411954a-86d9-4afa-8e46-22d0b9684ea9": {"doc_hash": "f121e766496209f1cb89914e463f53b089a4abe71497460ca5ccea7c155fc7c0", "ref_doc_id": "ac87c0ae-85e3-4cf2-a730-61f926edf400"}, "a96347eb-b047-4b8b-9936-2264f2903860": {"doc_hash": "1a81d71aab99e1538b0959aa6612b861c0d85fb26b726bb430eec8ecf01ec2e3", "ref_doc_id": "3d644fb7-3fee-4891-ad11-4a3c02452a32"}, "ba1b3311-d8b5-4bb7-b815-180fa7982f00": {"doc_hash": "8463cfcc4b83541f17c3f1e446ae302df18867d86b3d5aaa4cb4c78c72e369f2", "ref_doc_id": "3d644fb7-3fee-4891-ad11-4a3c02452a32"}, "a2c40831-b334-4f94-9ef3-33b0ce88c725": {"doc_hash": "8a48993eff42ee6d582fa3fddaccaad7e6f2c441e8192b5f59f26f4851f2851d", "ref_doc_id": "3d644fb7-3fee-4891-ad11-4a3c02452a32"}, "5a77cd27-44d3-46b4-a875-5f3227d74f02": {"doc_hash": "18dca0980096a53e1814ed5bdbb6eb77d4a5022f27672872979a0936eeebaf2b", "ref_doc_id": "3d644fb7-3fee-4891-ad11-4a3c02452a32"}, "5686bf4d-0256-4464-8319-1b26b72344f7": {"doc_hash": "83e7979b318f1525a39b1f29c0f518a74325afe96d52546ef9915243ed002839", "ref_doc_id": "3d644fb7-3fee-4891-ad11-4a3c02452a32"}, "48bd918a-35c7-4c06-9dc7-23cf1aaedbcf": {"doc_hash": "9ea267c1d09a26936d09cb9f13963958fd39302362dbd1520ce20bfc6caf2d39", "ref_doc_id": "35f0cc85-d0d6-45e8-b14f-549678a8827a"}, "bf34aaee-81c0-402f-87c0-01e03e56d171": {"doc_hash": "59656f0d2781bb557b279e5861661037528ca02356ad9195ec0a08662f8724e8", "ref_doc_id": "35f0cc85-d0d6-45e8-b14f-549678a8827a"}, "0444363e-44b2-41ea-9752-86b51555eed7": {"doc_hash": "bb9553d4375bfaa73b4d3bdd2647b7ce491532ac741421eaf175d98b591ac9e0", "ref_doc_id": "35f0cc85-d0d6-45e8-b14f-549678a8827a"}, "8f6e5557-84db-4f5b-bd14-dec247b4c19e": {"doc_hash": "8bb5aa60f7a2578fd5ee261fb824a4c1117a988ecaf29d3e7f20f4a5dec65e2e", "ref_doc_id": "35f0cc85-d0d6-45e8-b14f-549678a8827a"}, "5121ae10-e390-4da7-9d34-7d68066a37ca": {"doc_hash": "50379f088db25dd0522db18bbf75e95b03413e0050dc95035751604901baa68f", "ref_doc_id": "35f0cc85-d0d6-45e8-b14f-549678a8827a"}, "c0cecdb4-4a48-4a78-8301-d3672d43571c": {"doc_hash": "ad90488577ea32eadb6322bb37ee2084ea15d7b1b39dbd75dbd31746c278bead", "ref_doc_id": "9f50783a-89b7-4389-9e19-116448179aec"}, "16eafa85-a586-436c-8df5-132ecca5371d": {"doc_hash": "102e9d890e10af4e43246429cc4bd498c065e85788f3430a7a3c90dccac03888", "ref_doc_id": "9f50783a-89b7-4389-9e19-116448179aec"}, "ace771a5-2f88-47d5-94a6-b20d6a50f760": {"doc_hash": "8d5b41f7665b0777ad4f4123c445bf7009a7a8ef770810baa8e4cd7c0478267f", "ref_doc_id": "9f50783a-89b7-4389-9e19-116448179aec"}, "9895a5c2-2c9d-4e27-8e53-22b6d44fd9fb": {"doc_hash": "c70107a85deaf39d4a20962ffba0d766c3c5c81047c408110d4c8f4abf67c911", "ref_doc_id": "9f50783a-89b7-4389-9e19-116448179aec"}, "4b3ea8f9-8ae0-42d9-812a-65ddf7cf34c7": {"doc_hash": "9f5d7eb0100dacb181e0c8c79129da65cfc0de304ac8442fff5d696cde483cb8", "ref_doc_id": "9f50783a-89b7-4389-9e19-116448179aec"}, "83d8ea37-cc5b-461f-928b-e902185e304c": {"doc_hash": "2506ffee92c7b30aa8bc4f6f6505f09f98f53b9262b3ab8fe8f16a1b48cd8dfc", "ref_doc_id": "96d19885-c85b-4254-80c4-3c172b24dc5b"}, "5225cc00-9503-44bd-a2c1-04a3c1cdb9dc": {"doc_hash": "330af8a279158809f6c4ad292798f7726ae76b78aefc3516827548711c3d87b8", "ref_doc_id": "96d19885-c85b-4254-80c4-3c172b24dc5b"}, "4d614c56-7196-484d-a8c0-b0ab7f0367b2": {"doc_hash": "0bf206858bfd140dc564ba11bd246323ad31b5ea8ca2ee8fb0c2dfaaee947113", "ref_doc_id": "96d19885-c85b-4254-80c4-3c172b24dc5b"}, "46aedb37-db5d-4362-babf-89be3e6f1435": {"doc_hash": "9dcd7c9d6ae5aa17e5447e8ff43e0aa5b2caf206fee8c47f22caac5e892099cc", "ref_doc_id": "96d19885-c85b-4254-80c4-3c172b24dc5b"}, "a8d1690c-0990-43ac-b8fd-514d8dd018fc": {"doc_hash": "214f949b5eb2c8f36ab6d9a42c8165d642819a8dbb3698cca71d7a812c32dcad", "ref_doc_id": "96d19885-c85b-4254-80c4-3c172b24dc5b"}, "016f89e3-237c-413d-8111-aa0f9a37ecd6": {"doc_hash": "9e5db9d80b710744812ad221102810db7333ae718549c45ab292d81d23403232", "ref_doc_id": "1f79b2e0-32a2-45a8-b114-db0d43b38822"}, "dbae4752-6df0-444c-bf7f-f728a713f3dd": {"doc_hash": "070e36a507bcf40443263d1cdff8d71339579b415e5900654369681abdd42335", "ref_doc_id": "1f79b2e0-32a2-45a8-b114-db0d43b38822"}, "6433faa6-dfdc-4130-ba33-1621c0c900eb": {"doc_hash": "47f6c220b16769ab14b37d800515effbb37e171ea180919c5897b369ba4346b9", "ref_doc_id": "1f79b2e0-32a2-45a8-b114-db0d43b38822"}, "67e4179a-c6ea-40a9-a364-5ffd6a5e9993": {"doc_hash": "6735900408ee0a21b6d72d095fa996fe00d1214ad67119126227c2ddea809586", "ref_doc_id": "1f79b2e0-32a2-45a8-b114-db0d43b38822"}, "bfb44bbc-7d0e-4ca6-a2db-643981e5d3be": {"doc_hash": "1c5d363874f49a2c1374a3c674c8ef03700f259663184cb885ad88af05f58b61", "ref_doc_id": "1f79b2e0-32a2-45a8-b114-db0d43b38822"}, "12cf5b7b-a7f0-4a11-8329-a5f3788912b5": {"doc_hash": "da956242805e757b64cb904b7d9f5056b6d069c48e538b0d99b7ae4986097afa", "ref_doc_id": "ebe6da7b-2906-41d9-9edd-32ff3638114d"}, "c122fe51-0a27-4b4e-9614-dcafea5fe866": {"doc_hash": "d3960e711104402e03dfd6563797274a729f8f3080269094ef930726a4713de0", "ref_doc_id": "ebe6da7b-2906-41d9-9edd-32ff3638114d"}, "0fc0d930-c092-440e-acd2-2e251160b7b7": {"doc_hash": "bfe225844003ce57a549336c28abb8bdc1375971f976d5dc9fe7cd2d553a8fa2", "ref_doc_id": "ebe6da7b-2906-41d9-9edd-32ff3638114d"}, "e5ad5ebf-9544-44ed-922e-2be7cfd98801": {"doc_hash": "e3b55264305b777b9b6729b5103cbc2699e6e3adbbc5329413473a946fecc89a", "ref_doc_id": "ebe6da7b-2906-41d9-9edd-32ff3638114d"}, "5e4e087e-6fa0-4818-b58d-115409f2e83c": {"doc_hash": "a1cf5aab6966bac10441da51c3fa7eb32a2198a8ed6697c5f5baaa5bf585bd89", "ref_doc_id": "ebe6da7b-2906-41d9-9edd-32ff3638114d"}, "23699c03-7a89-419d-af4d-9010634a5051": {"doc_hash": "89ee4e42be6cff4ec97034caac5896380d864810c8dab5d44daf58cafb2e4cc6", "ref_doc_id": "5bab9eb1-2820-4291-945b-30ae3ce9e833"}, "a612f6e9-e19f-49ee-b14b-b35a8582366e": {"doc_hash": "7cf941ab8f1a6147fa054aed7e201819fa447a9881123f43a81a5f4abac52a53", "ref_doc_id": "5bab9eb1-2820-4291-945b-30ae3ce9e833"}, "69ba9788-6c92-4601-b1ae-59266085788d": {"doc_hash": "ab5641e12d02bc277dbd74b5f28e4cd3ad911ea2edcc0323f68e08aa41bd13b0", "ref_doc_id": "5bab9eb1-2820-4291-945b-30ae3ce9e833"}, "9d87171e-e6cb-48ad-807b-d91c54c3f3cf": {"doc_hash": "46db26d7803dd964559e7aa0d0f49714015ff39bc198f7e30f958c8cbb819da6", "ref_doc_id": "5bab9eb1-2820-4291-945b-30ae3ce9e833"}, "a60ce069-2d6d-4c1e-8ea7-6f600b86c23a": {"doc_hash": "cfddf969ba1cc13402dd130632598435dd7e412994634e9ed703a264bcbb5feb", "ref_doc_id": "5bab9eb1-2820-4291-945b-30ae3ce9e833"}, "586a93da-6cc5-467b-ab20-9bf860fd26c3": {"doc_hash": "a455d26c0899f0d957ad5c5d440414b1d5c873481cdf65aac8e77a81e4d13035", "ref_doc_id": "080f72b3-c692-44bf-8b6b-e35c0a8e24ff"}, "b9fd9aab-7702-4258-a5ed-d2082b8d6964": {"doc_hash": "727bd1eb8e358d74f59b06adad703692caa647dc12c71dd6466380cc6c76aeac", "ref_doc_id": "080f72b3-c692-44bf-8b6b-e35c0a8e24ff"}, "f0dd57d1-1291-4488-bce6-38a30f81b82b": {"doc_hash": "15a6225041bcd9f46e5ce956b878775e5082e1b13b2f2f795de62bce83fa0bad", "ref_doc_id": "080f72b3-c692-44bf-8b6b-e35c0a8e24ff"}, "d1dd3c31-d761-4446-9874-c09a4a6180a9": {"doc_hash": "f1eb0e961e9d1f12f116d899c4a0d66995df50222ad7923fe4dfd87e812b85e7", "ref_doc_id": "080f72b3-c692-44bf-8b6b-e35c0a8e24ff"}, "70e143c6-8c14-4800-9b1e-7b31067054df": {"doc_hash": "a7e86a00e497c371cd299d92ddaddd73577e23ee07c92099bd610a07f5415bab", "ref_doc_id": "080f72b3-c692-44bf-8b6b-e35c0a8e24ff"}, "c24ed535-7f95-4b1b-8f59-cbee02fe50fd": {"doc_hash": "a727b80e84d1f5af270a304959b7370f2aa0fc8ce9ca32cd340dfb83df3cf1b3", "ref_doc_id": "75455cda-720f-4281-ad8d-c459a128196e"}, "32741c93-6b65-4ea4-a5bf-c7187f27ff03": {"doc_hash": "9b5efffc6aa4b1e1c54ae7431fc95fe86b7cf55196b9e6b37b3b718eb2eae28a", "ref_doc_id": "75455cda-720f-4281-ad8d-c459a128196e"}, "467104fb-f5db-4905-9bd1-e6f6ab56ae66": {"doc_hash": "6fb31fbe9c89134b77d12762b42804130a71e2079187b16b33019ec84e49d890", "ref_doc_id": "75455cda-720f-4281-ad8d-c459a128196e"}, "6675e023-60b6-4e44-898e-5d59f4c4f31e": {"doc_hash": "ee300150d38ac2224102a8b32811e928d536680e984acc022f084259d7318755", "ref_doc_id": "75455cda-720f-4281-ad8d-c459a128196e"}, "9a7e5805-f608-4691-bd9c-b0714a308818": {"doc_hash": "e901d7f7c67fe037bab2f5624062ed462018356d6aeff90308234b1440acecf8", "ref_doc_id": "75455cda-720f-4281-ad8d-c459a128196e"}, "09572bee-5327-49af-9760-3685b32ef464": {"doc_hash": "a5c868194712c87ba68ee7077c3ca870b98a767420fa2000b684ade249c77546", "ref_doc_id": "40a58b3d-7df0-4217-8a28-e348002a8d80"}, "552c93a8-2f38-47cc-b3aa-6c1eddf6297b": {"doc_hash": "d2989f087030fc6ae0ed6d56dce0b445118972cd09cbfd9ed6be3edeb2e4c170", "ref_doc_id": "40a58b3d-7df0-4217-8a28-e348002a8d80"}, "ca34776d-066a-4226-8723-2af30872f5e0": {"doc_hash": "dfe96898a228d0d139bed0030d88b6cf165ba85bc5287b391703e5724f3fca45", "ref_doc_id": "40a58b3d-7df0-4217-8a28-e348002a8d80"}, "fe080274-f7b4-4e97-900d-5c50cc802205": {"doc_hash": "d71222c2ed5fa3960970aadc379a3419e170fde9b504d13486ba0b68b6bf6e0e", "ref_doc_id": "40a58b3d-7df0-4217-8a28-e348002a8d80"}, "54509ef9-e00c-47c0-a106-6ec84e7fdfa4": {"doc_hash": "db1fe2808f0be452bb90f71869dc948fcd35145be04b00bfdb3d1c79b7b0012b", "ref_doc_id": "40a58b3d-7df0-4217-8a28-e348002a8d80"}, "e1b1819e-6c38-4e5d-bb5f-7776fddf1899": {"doc_hash": "2a661674257e1948ada5527ee50a56cf52f3578d92601426554cac130b780524", "ref_doc_id": "c5f7a6a3-9008-43b6-9d62-bd8d67c3fb4e"}, "eca16efd-d3d1-4110-81b8-0dd23cf8dd60": {"doc_hash": "f7a12a8b1992abb4285179235760910a8d4fa7f455a4a4f88033c8c4ef40b7b0", "ref_doc_id": "c5f7a6a3-9008-43b6-9d62-bd8d67c3fb4e"}, "c28979a0-a56d-455c-94f8-1eee57118566": {"doc_hash": "c42a837e809da9791829cf8e98cbd36872024b00eba84bcf7f135f4e8334fb60", "ref_doc_id": "c5f7a6a3-9008-43b6-9d62-bd8d67c3fb4e"}, "084760c7-1e6e-477f-8d56-866e153245be": {"doc_hash": "95345487e22679fcbe0eeb6bbe812e488299ac5cb9874f7da749ca37c4a4e44e", "ref_doc_id": "c5f7a6a3-9008-43b6-9d62-bd8d67c3fb4e"}, "55df77c4-2154-48a7-873d-7d2a379ab133": {"doc_hash": "b07cfbc32b24222da96b6865a80ab12e6a56055c7333fc9c86e819212402a8c0", "ref_doc_id": "b5ea9a47-6efd-4bbb-a59f-d20d7c568fc0"}, "08590a5c-4710-49d6-9590-49040107a158": {"doc_hash": "aa0208191867c68a25354e921ec927b39088c59aebc0cacbabe2ebeead4ca882", "ref_doc_id": "b5ea9a47-6efd-4bbb-a59f-d20d7c568fc0"}, "b9478731-1b40-46fc-b0d7-de120548439a": {"doc_hash": "b2d53a4ba1f1290f31dc519c9e9c05828d72617fcb3f24cc6998076e968ccb08", "ref_doc_id": "b5ea9a47-6efd-4bbb-a59f-d20d7c568fc0"}, "d85d410f-5469-4dc7-950e-55b38733ab8e": {"doc_hash": "4283126850079eb4c1b2cbc0df83672e9dff062b5941539b11d55dd27d049c32", "ref_doc_id": "b5ea9a47-6efd-4bbb-a59f-d20d7c568fc0"}, "35792614-9985-437c-a269-60be3cc60c4e": {"doc_hash": "8c6249484fe69a7ca8c89882d17a3acf9abed335f9bb17b631211307a00b6ef3", "ref_doc_id": "dca39f39-0906-442f-a7e3-1281a5f2d30a"}, "51172858-d7ee-4a8b-aa02-f564c201792e": {"doc_hash": "8dd276dbbde497380e98aa67cf5732ac1e1cb69cc7eadb22c46ab5ff9c728fb3", "ref_doc_id": "dca39f39-0906-442f-a7e3-1281a5f2d30a"}, "86e29728-680c-4951-817c-a38010f4fa7b": {"doc_hash": "e845d0878e668d75a67c1c6cae4e2514df19c53966ce91f667641f5d9549be52", "ref_doc_id": "aac21c47-5379-4e51-86de-fe537032c27f"}, "8155e70a-1c8c-4820-a5d5-cb600f880e2f": {"doc_hash": "25421f617a97a0da885802e84c73a592cd1669bf6ab65fca52f4564127d357f6", "ref_doc_id": "aac21c47-5379-4e51-86de-fe537032c27f"}, "9eea549a-7051-4428-8d41-c1bbb8d3455b": {"doc_hash": "d6db2d8f23ad40fa06e0ad1df4b8c072c673e1f0ca066ea83791835b9d408147", "ref_doc_id": "aac21c47-5379-4e51-86de-fe537032c27f"}, "414e5bfe-4872-42b5-9cd6-307662e6dc0b": {"doc_hash": "07d376dd5cba6c60a549dd64f89c92e6dd794677a561c1c66e327e5129bed45e", "ref_doc_id": "a844fd4c-b679-4cf6-b6f7-c4b6aa1923bb"}, "184b8647-d17e-466f-9ef2-7466476f8e0c": {"doc_hash": "c0e29bf747711f3d5aab24cdd956c32af67dc53a4fd62112a52ac03405b84cd7", "ref_doc_id": "a844fd4c-b679-4cf6-b6f7-c4b6aa1923bb"}, "47907812-53e5-43ec-95dd-44fe1b6cfea0": {"doc_hash": "88b65dc92586a8fd25dc4dd58a35dbd2604ab7b11584325be59315ed78b61e29", "ref_doc_id": "a844fd4c-b679-4cf6-b6f7-c4b6aa1923bb"}, "8fb71b35-2a1f-4ecc-a47b-c9b01968957f": {"doc_hash": "69bc20219cee29ab4f1ee2848f090d5244ea8bf100e1d23477328fa7b0982436", "ref_doc_id": "3539126f-3ec2-4806-9bd1-bd7333cf6313"}, "92f1a912-88bb-4d1b-ae5f-7dacd9a0e1e8": {"doc_hash": "eec3f86ae8ac0b67c895c9d4d669859090237a0be252d96f7b902356439e2f82", "ref_doc_id": "3539126f-3ec2-4806-9bd1-bd7333cf6313"}, "b669ff45-46b9-4e4d-98d1-f8eaf5ded86e": {"doc_hash": "8d4e66dd58c5cb2b42627a317f92dc646766e0f63bb78df24c38dd240c85f3d1", "ref_doc_id": "3539126f-3ec2-4806-9bd1-bd7333cf6313"}, "3963aa60-62f6-4aa0-bbf5-a376ac8c9630": {"doc_hash": "a841b57e6217caea419086fded2963c851511f68e37d8a034a940abd8f338d48", "ref_doc_id": "3539126f-3ec2-4806-9bd1-bd7333cf6313"}, "5aa4316d-0ebb-4717-b46f-49bd3cd4ca55": {"doc_hash": "2abfcda9e7275491575b8d6fa67d0b106574897f5b9fea9ea641809a3877247c", "ref_doc_id": "a1d7cf10-2bd5-4ce6-92e0-722bdf4869e1"}, "bca466cd-6cd6-4f38-b74a-de5195810b24": {"doc_hash": "9670e98e830107de839a14ceb606e51294b87e2eb4dbe872e3b2af4957da0bc9", "ref_doc_id": "a1d7cf10-2bd5-4ce6-92e0-722bdf4869e1"}, "e1c61976-c09b-4a76-b40b-d2419f725813": {"doc_hash": "dce71a92a60bf50b947c324f1845cc144e36000189479f24410993ee41d1a49d", "ref_doc_id": "a1d7cf10-2bd5-4ce6-92e0-722bdf4869e1"}, "1d79b886-737a-483d-a26d-376cfc48458f": {"doc_hash": "1703aca3a33c9e55853c97263fb174c7354b3d47db20f59f155cfd92928be071", "ref_doc_id": "a7f203c6-f1c6-4391-9a2f-93ecbac8d1dd"}, "a2a99af2-e4cc-432f-bce4-8edad3763e80": {"doc_hash": "c31664829ae11e92184cb4ffe953f6134b8b9c3f36bee9da7423554ef80e8cfb", "ref_doc_id": "a7f203c6-f1c6-4391-9a2f-93ecbac8d1dd"}, "3eafa7ba-56f5-4451-8785-c328b29ec380": {"doc_hash": "c3a1c226c7a6ce94244915e85da4345b28140957541080ecdf67a404928ae13b", "ref_doc_id": "a7f203c6-f1c6-4391-9a2f-93ecbac8d1dd"}, "f3aa6e5d-e0e8-4ee0-bc61-708245188420": {"doc_hash": "b1bfeaa7b5571a5f4f8ad25d7084be45bcf0a3d4de19298f185e033b10dfdaef", "ref_doc_id": "a7f203c6-f1c6-4391-9a2f-93ecbac8d1dd"}, "fe81ec9e-e6e6-4483-8856-a4e2850143c9": {"doc_hash": "e630de7bbdf8bdcb2b5aaceab3992a81b29e63d48d476a83c1c27f631089badf", "ref_doc_id": "a7f203c6-f1c6-4391-9a2f-93ecbac8d1dd"}, "ab368f89-f8c5-409b-9013-c183c28d1418": {"doc_hash": "3e8641d580338b3d995d4455d4fda8b16906a606e7584cc04fdb41f7afd62e82", "ref_doc_id": "39481e14-6b63-4449-a5ee-4b06a012c44f"}, "0dce0402-7f17-4b1f-a472-d6a3d72da830": {"doc_hash": "3e17398d41710cd54b0782370fbce16432eac504485f13bc3596c25e858b06e5", "ref_doc_id": "39481e14-6b63-4449-a5ee-4b06a012c44f"}, "e4fc74fc-a671-4d39-8083-3f025e8aeb39": {"doc_hash": "311eca1923d4e8884d1143c745fd47c080a84bec45bc20f5727087e62c878bfd", "ref_doc_id": "39481e14-6b63-4449-a5ee-4b06a012c44f"}, "ea34ce3d-650b-41d0-a490-b067537189c1": {"doc_hash": "3c804db6693d3bed26b876dc74665b00247c961aafd1a79b1584c61353977ff0", "ref_doc_id": "39481e14-6b63-4449-a5ee-4b06a012c44f"}, "e6839b33-cc71-42a9-96b6-c2314e023cbe": {"doc_hash": "e20b825bed5e668588c787a74ce99f555ffeea3745421fda326292839ad72fa8", "ref_doc_id": "39481e14-6b63-4449-a5ee-4b06a012c44f"}, "b6e2be3d-e2d6-4829-ad67-47a0c3d672cf": {"doc_hash": "ce3eb571efb12a3eab1d2eb72d9db94c1aa27567b6680cdda714c1aae0c6b883", "ref_doc_id": "39481e14-6b63-4449-a5ee-4b06a012c44f"}, "0dd99e3b-76c5-4a19-95f3-981e59f654b6": {"doc_hash": "30662a1aa38f59cc005bc5bfe1e66f4e0530d638dadba1b682e3d8d586b1eb74", "ref_doc_id": "39481e14-6b63-4449-a5ee-4b06a012c44f"}, "4b6b46c6-3d6a-4af0-ad3f-7b9a69e689d9": {"doc_hash": "9dca6e0a860c328e717e5c09f005139a697e4085db7038f9e1f2a6db435491a2", "ref_doc_id": "7827c7e0-209d-4f3c-98cd-4e7e5502aaa8"}, "e4140117-03cc-4202-b9f9-fffa9720af1b": {"doc_hash": "ab0ea8fe4addfca8f519cbf1af27307ea6fb22d9711ebc95502d19012ba4018a", "ref_doc_id": "7827c7e0-209d-4f3c-98cd-4e7e5502aaa8"}, "d6489447-2c60-4546-82bb-5727e8008381": {"doc_hash": "6194935d3efd0a09f6399d45a65cea572c5cfb6d7660bf20ba60cc88048b6540", "ref_doc_id": "7827c7e0-209d-4f3c-98cd-4e7e5502aaa8"}, "66532eb0-3541-4668-876a-8fd4e0346f49": {"doc_hash": "4d6d0dfd85b22af7c5e40112e7bea5ad7873045ab2591d58086c057924f30369", "ref_doc_id": "7827c7e0-209d-4f3c-98cd-4e7e5502aaa8"}, "71c79a8f-8287-4e48-a5d6-1ad1dabdc29a": {"doc_hash": "c42f7a34af17d21f3fd6204bde10462da7b1e2e9740ce75f5bf3e38ea6465f31", "ref_doc_id": "7827c7e0-209d-4f3c-98cd-4e7e5502aaa8"}, "953758ae-18d0-4aab-8c51-e0867a21c2b5": {"doc_hash": "656486cb6d50f3e914b4dd90c936173c8a07d95de39f733f16e1b964094b2adb", "ref_doc_id": "7827c7e0-209d-4f3c-98cd-4e7e5502aaa8"}, "752fdde1-5c2f-48e1-a8fd-049456f462ce": {"doc_hash": "aafd8e230a8114cb637a285c4e25d1e1bd290483e31b225880c2044d21c56934", "ref_doc_id": "7827c7e0-209d-4f3c-98cd-4e7e5502aaa8"}, "6a838443-b8b5-4cb7-a153-0a1ec754f796": {"doc_hash": "105b91f1577b72d2619515bd1c9e11b59a7b5ac7d5cb370184109bb863033279", "ref_doc_id": "33045505-2c07-40e6-82b9-5f3306e83032"}, "5be15974-4aa0-4328-abdd-2ab743e97e0b": {"doc_hash": "9e88ce15c0ea0e02819db60f4dd5ae5cfb041a1b47707c74083385d25457801d", "ref_doc_id": "33045505-2c07-40e6-82b9-5f3306e83032"}, "7866a12d-ea8e-4bda-a978-6372894c2c1b": {"doc_hash": "d9689373c3da71f1a1d77a102763c0414971a4b08ba236e1a03e4db5b6e9d0eb", "ref_doc_id": "dd91fae4-be27-449b-a248-277d07df1d2b"}, "16b8c2c7-c3a3-42c7-b179-2a778bbef49e": {"doc_hash": "314dd22ca1aae75718c322d24aa5d39eabf8f590e88b147cac056b537371cf22", "ref_doc_id": "dd91fae4-be27-449b-a248-277d07df1d2b"}, "80afa5aa-912c-4fd0-bb49-05fc5a3c142d": {"doc_hash": "6e26033950b23c8527b840d364c56459cc89b396582ebe95b4d5837c43eb0915", "ref_doc_id": "dd91fae4-be27-449b-a248-277d07df1d2b"}, "71f6c3d3-5174-4810-b031-f8452bf8f1d9": {"doc_hash": "f65d11fd9f80e4b20b631bd8e6cea21afa14645f1575ef0d02e9d87d5f71b613", "ref_doc_id": "e96eecb7-db70-42f3-9855-5a5d46be4548"}, "13cc55f7-6d02-4e6a-adc1-876b28b1978f": {"doc_hash": "dbccbb2524125e8b31f0738352d60524016aeb8c72493cbe181d2a22f7a4b420", "ref_doc_id": "e96eecb7-db70-42f3-9855-5a5d46be4548"}, "654a5b40-f7a2-4739-bfc9-7c34c1940a93": {"doc_hash": "24d947d289740257b358e547c3fd83b6739b006444434160fc86bd70ddf86c88", "ref_doc_id": "e96eecb7-db70-42f3-9855-5a5d46be4548"}, "de3de816-f2c3-4703-8b4e-f4550c230a41": {"doc_hash": "0c16d158711333115cc693dab5bccd9c37970d0dda9edc790e5f4f1373aea0ba", "ref_doc_id": "1182aac5-628f-4dfc-8301-7bcdceca52b4"}, "5a140d87-0202-43ed-a33d-d451e6603d91": {"doc_hash": "7ca700db2ac6b4d26487cea82a25170ea514a6ebcc2b73cdb06cb1aa45888292", "ref_doc_id": "1182aac5-628f-4dfc-8301-7bcdceca52b4"}, "c5bcad1f-9701-4136-8f47-f3a809c7d7d2": {"doc_hash": "c6f57d314f02c18232d2a0313d0251c9e1afe6c87fb6ce42e9cabbd8b691a642", "ref_doc_id": "1182aac5-628f-4dfc-8301-7bcdceca52b4"}, "3846a556-2d32-4516-a106-3072212efb6c": {"doc_hash": "fa1bb4f0988e2ecbcf8763f58c5e64b0d8ac0d6e3a41e3589fa9a3cf70c98345", "ref_doc_id": "1c377ee8-1469-4e10-b0b8-ba80ff296a3a"}, "d598ef87-fae1-4432-a1fe-21317eeb9186": {"doc_hash": "d3e7171326ae83264cca327b344ffcfa0b1f3b5bdac5b7fc7e24e57e81670642", "ref_doc_id": "1c377ee8-1469-4e10-b0b8-ba80ff296a3a"}, "27237d82-84ff-4a1b-b944-f5fafa775657": {"doc_hash": "e1480ac717d03270711814a67b9fd172e763a419fa31013da9e71774a9d71c7a", "ref_doc_id": "1c377ee8-1469-4e10-b0b8-ba80ff296a3a"}, "d5d4676e-b888-4b05-ba77-945f806a0550": {"doc_hash": "f9973cf4ac3efd956238281c906bc36a5cb19bad50e7c89a8909301a7c3356fa", "ref_doc_id": "791a0f49-b547-4d2a-9f91-edfdf60f37bb"}, "e023cf11-7e7a-43a2-8d7b-ec64206ea261": {"doc_hash": "a2bdb74b9365227f8116d89fe4bb5412bf970be83d4ba3de6428650e283e229e", "ref_doc_id": "791a0f49-b547-4d2a-9f91-edfdf60f37bb"}, "92648530-da59-40b6-82f1-4e7f40c3ff41": {"doc_hash": "ef65173348609d0726c86f9ff36c2f8f7bf120dbbc880fe816620cc68742c06b", "ref_doc_id": "791a0f49-b547-4d2a-9f91-edfdf60f37bb"}, "497852dc-ae34-4097-bd60-8f9def2d1b94": {"doc_hash": "262ba6906e46c97862c4f58b3cd07e093eebf519cc4c71f6cb1e9fa37bb27230", "ref_doc_id": "10a724cc-bf62-43cb-92a1-a06be3357109"}, "4e01d8e4-5747-4590-9030-b053b1624161": {"doc_hash": "10411a76a94c7b603fa483ccf1c4512a67585bcd2a312ec8a1c5802db28ffc50", "ref_doc_id": "10a724cc-bf62-43cb-92a1-a06be3357109"}, "59f7dca9-88f5-457f-8c8b-5a0e08c9f925": {"doc_hash": "34224a132fddc6a502200279245da7b2adf485cf09f6225255c9b2886de11d77", "ref_doc_id": "10a724cc-bf62-43cb-92a1-a06be3357109"}, "824d7b93-602b-46fe-9b10-4bfc25b204d2": {"doc_hash": "9803fa49f9850dd442dc7f86dfc59173b8d7a9b968a68c354f749b535fd2a7b7", "ref_doc_id": "a5baa07e-5af2-46c6-a9a2-1afb1352c612"}, "c2ccfc5a-0072-402e-ba0e-cffcf5cd1ea7": {"doc_hash": "0d427f62d2429056824f1f64ad8f75101bf57363b16aa032372cb6a67603bd25", "ref_doc_id": "a5baa07e-5af2-46c6-a9a2-1afb1352c612"}, "1e538796-df0c-4506-8a6c-36039334b143": {"doc_hash": "3e1c0330d179f5e90d30d4212e954dc9e96666a57e86cc27e6bc1b8dbbdb12c2", "ref_doc_id": "a5baa07e-5af2-46c6-a9a2-1afb1352c612"}, "41fde725-70c6-465a-a0e5-a02f9c112da8": {"doc_hash": "37e7e982a401d37b5f1d242394a82e589e9e67f7cc4dc3d0464fd5833c036b29", "ref_doc_id": "aecfdb3e-ff3d-4f2c-8cc1-48157ad3b135"}, "13456ae3-8aa7-4e2a-9037-18fe7a5ebcda": {"doc_hash": "ce1d3e1329909ff3b36d9e804d57886da1fff7a7e9a9fde52808c1ead71875a0", "ref_doc_id": "aecfdb3e-ff3d-4f2c-8cc1-48157ad3b135"}, "0138a9e3-a65c-4817-9a9e-e0cc78ce9191": {"doc_hash": "cc1c7c33579a8d68d49a0663c6a8312b4b752dcc3fdf3a9a6339aa4741d3b97d", "ref_doc_id": "aecfdb3e-ff3d-4f2c-8cc1-48157ad3b135"}, "bf796889-c1e7-4fd8-b0aa-517cd9178427": {"doc_hash": "67f5bcb89aa2ce8ea71e3d32ba8b15cff866264d65477d8bc3bd09d9387e74ec", "ref_doc_id": "aecfdb3e-ff3d-4f2c-8cc1-48157ad3b135"}, "b5e6becb-1df3-442d-bfb2-9bb3b61fb783": {"doc_hash": "5588030383940387d1105eec01cdb3a3d90f3eedbf9e563f5cd5461a0d1ebcd2", "ref_doc_id": "a4a8ac4a-99d7-4810-ba3b-e6894f3e75ae"}, "45133e3c-cd70-4d5d-a82c-afdbbe2385d7": {"doc_hash": "a322bf6dc78f4ed014d51c5503efe7cac9538b333b05bbab278e4a3b07730ce1", "ref_doc_id": "a4a8ac4a-99d7-4810-ba3b-e6894f3e75ae"}, "0ae5e854-fb4a-49a9-a284-ac5dfb4d6509": {"doc_hash": "c9c0c6e7ad81de19ac06553506050be151006137fd48011ba111ab743f20ba9d", "ref_doc_id": "a4a8ac4a-99d7-4810-ba3b-e6894f3e75ae"}, "6879715a-a8a2-421d-9290-66a7604a7e33": {"doc_hash": "15cf505edce2cb132fdfae8d3a8b364c237a2c176c21d5ec6c7123b2fbc32a04", "ref_doc_id": "a1d5c5e6-4e47-480d-8c2c-af946efb80fb"}, "498e746c-cefd-44f5-add4-c03336001e00": {"doc_hash": "ffbe60f82845395e26e0d159db50a1d37644d0f762b76acace12995d59c51ef7", "ref_doc_id": "a1d5c5e6-4e47-480d-8c2c-af946efb80fb"}, "dc1b7aa9-d0c4-48e2-a54d-cf43695252bf": {"doc_hash": "dc7da7b7eee5c6e0692f5e957e15bda0ac88f1499d907178a251d505e76bbb26", "ref_doc_id": "a1d5c5e6-4e47-480d-8c2c-af946efb80fb"}, "3b303a47-137a-41cd-be1a-f40037d3ff59": {"doc_hash": "e4d321bcb6b6d3624338d01d91906023b6b111c2e3c4c44bbadd253b7ceb328c", "ref_doc_id": "a1c087bc-2e51-4305-9201-5228bfb3c768"}, "35d67d94-f935-473d-a051-e812556f9355": {"doc_hash": "aa73f612246335edc8f3039b874aca72fb58e5ffd94e14ee3c60f90b8d3fcd03", "ref_doc_id": "a1c087bc-2e51-4305-9201-5228bfb3c768"}, "71cd2865-07a0-45d1-bcaa-d3ad396dd52d": {"doc_hash": "6a6215dc94738000733c05fa93a1bc7dd06f4b98066d9a17e44947cd72acd89a", "ref_doc_id": "a1c087bc-2e51-4305-9201-5228bfb3c768"}, "20106827-6f98-4085-a815-ed964909bcad": {"doc_hash": "c3c0d6a64301e09a1b8c4b261f90605301e4af3f28ac0629f218020f89ea655e", "ref_doc_id": "4cb35e6b-30fc-4519-9aa4-975b4b57c0c8"}, "a772ff8e-9458-45c8-9d0b-f4f20c78032f": {"doc_hash": "57803a338fd6196f733987e63626cf5c4be4cbcf44941446d994978b6777d11e", "ref_doc_id": "4cb35e6b-30fc-4519-9aa4-975b4b57c0c8"}, "03549e66-b6ba-41ad-8126-3c1b244583ce": {"doc_hash": "6de6c2fc385a4a9f3bab744ce99a884fc8d7b0408dac8701045c81df17eadcea", "ref_doc_id": "4cb35e6b-30fc-4519-9aa4-975b4b57c0c8"}, "cacc2a75-4d8e-476e-9aa9-c80c0716b262": {"doc_hash": "ec7e92f6bb5fef67ac751961b03ce7d9a40b96589e91fe58344d80f38362bb90", "ref_doc_id": "4c17322b-c2e5-40ca-8710-f8857fb2cb81"}, "a6620ad9-62c5-4854-a84e-e25dd8aa4d54": {"doc_hash": "37702d3c733d48ed3e6c341f7038878de5a1e666e943829510b5912a2c9afa4f", "ref_doc_id": "4c17322b-c2e5-40ca-8710-f8857fb2cb81"}, "05e4ef80-5524-42bd-9ab4-1057b69cf6fe": {"doc_hash": "bd5dbb9eb14cfabbfb33660c037ff2d5915fb929f46f6631d284fba6af99ccee", "ref_doc_id": "4c17322b-c2e5-40ca-8710-f8857fb2cb81"}, "68799a17-b209-44e9-8512-8d4f40cec8a2": {"doc_hash": "7310abaead31b7a524e96e3873fce481a8507839cd281682d6ba8e36a6bc920a", "ref_doc_id": "e5c7d5c0-71be-4ad5-9125-36dfd5ae13e4"}, "ad70c1d4-03e3-4afc-908b-e674f2c2bcda": {"doc_hash": "f67bc226b5358393415c17a0058d71b4c925d50975474743084679d923acb1e4", "ref_doc_id": "e5c7d5c0-71be-4ad5-9125-36dfd5ae13e4"}, "7d4f5ed1-ed0b-4932-b2bf-cd6cd364d03e": {"doc_hash": "67e6ae0c5183b0b36ec01019000b5483000b02a1ccb2b8fd6e563f36f9b5528e", "ref_doc_id": "e5c7d5c0-71be-4ad5-9125-36dfd5ae13e4"}, "e99027de-fc48-419e-8e16-9e8d1474b75d": {"doc_hash": "e22b53361051ff3e8661e9c494188b5dc1598e7f871a313a66d880ec4c470629", "ref_doc_id": "8e7c1b08-1d21-4307-abcc-1e340fabac0a"}, "1d4e135d-dfbf-4eda-9b58-35279bb92cad": {"doc_hash": "c0134b78a9ed2861ce89e52e121db92ef9605c1d50b9e3b1d27a998e124bcc47", "ref_doc_id": "8e7c1b08-1d21-4307-abcc-1e340fabac0a"}, "7d47a0da-dc5e-4a4b-a215-82096cf4fbda": {"doc_hash": "4516d36aa5a9242e7f2a4e5e8029dac76ce49eae323a80602029ceb5ff7fec00", "ref_doc_id": "8e7c1b08-1d21-4307-abcc-1e340fabac0a"}, "996d1ae0-b8f2-4bff-bb53-0fb42c8cc539": {"doc_hash": "a75425315653a8b048dd0733f20adf6aae240e4df076fe80314c3f08fd7c8a2a", "ref_doc_id": "56b81214-cfed-44aa-aaec-bdb3ee5d19e3"}, "10a69b3c-1745-4bc7-8685-073f0c1a09d3": {"doc_hash": "873621dc7cd526b212e327ef429903d7a54255460dd53886b58e820e5143699a", "ref_doc_id": "56b81214-cfed-44aa-aaec-bdb3ee5d19e3"}, "2efb6bb5-ee70-4803-b291-673b3279d5d4": {"doc_hash": "536a57f138f63eceb6c57baa7bfcb30092dfd8b34cb3cc0a7d0a731200b5c475", "ref_doc_id": "56b81214-cfed-44aa-aaec-bdb3ee5d19e3"}, "0a43f452-f539-4fe3-95b7-575d8dadbf30": {"doc_hash": "6908642aecc10d40d4cc9c95d72ebb37f2bcf30b33b6112ffb3909e43925209c", "ref_doc_id": "56b81214-cfed-44aa-aaec-bdb3ee5d19e3"}, "6f3216fa-99e0-4495-b69d-bb8eb06b0efb": {"doc_hash": "3db85ff490fc944fc2eef7ceed25e270b160112496ffa97e142229bf93b91f8b", "ref_doc_id": "6656a408-9072-424b-a574-b2d5d7ae23fa"}, "363349bf-8bdf-471c-ad57-ccd1f0a3933a": {"doc_hash": "b07b6bc85b8c8fa53f14d7aa8b36c2731c64d8564a93015ce54cf53f1477afb5", "ref_doc_id": "6656a408-9072-424b-a574-b2d5d7ae23fa"}, "a26b4899-0d39-4ddb-adf0-9bed04d7565f": {"doc_hash": "282f95770c36d6f933e33ff608d693e73b83a9810b7cb8031cda0fa12f30b801", "ref_doc_id": "6656a408-9072-424b-a574-b2d5d7ae23fa"}, "f8f188ae-091e-477f-b425-0ce420677492": {"doc_hash": "c6084799d66109c9b05f0697b08db71d328713806378aba8dd4cf05671b4e37f", "ref_doc_id": "6656a408-9072-424b-a574-b2d5d7ae23fa"}, "89cab3be-0e04-44ce-abe3-405a57c41158": {"doc_hash": "5960bc0c750834228725b855b641e0ff270db6f8f49012b3852ea55c07316630", "ref_doc_id": "96bbad54-f8ad-4af4-9292-0bc5be3d8462"}, "f70ec346-0b6e-48c5-99ba-99e9db14c076": {"doc_hash": "1021b3a2e747e231406323388492b928ebabd3bd884b678973651bd82320784c", "ref_doc_id": "96bbad54-f8ad-4af4-9292-0bc5be3d8462"}, "f55c21cd-439f-4bf5-9d28-65625c6b6150": {"doc_hash": "10f9f6a3be0105b6ad9c3ccd770060c79b8590673ad9cc10bc2aab485df3383c", "ref_doc_id": "96bbad54-f8ad-4af4-9292-0bc5be3d8462"}, "f9a66bb8-404d-4cea-8fb6-ab310583e9b3": {"doc_hash": "5f71d5b57399064be170f761b056081414c2dc290168b055f3e91706cfec1a80", "ref_doc_id": "96bbad54-f8ad-4af4-9292-0bc5be3d8462"}, "ef985fcc-2625-4241-817b-cdaa881c4689": {"doc_hash": "cea7a34aa7d10099232c7dd19eb475bda6bc939179596a7e64096809c190d3a7", "ref_doc_id": "35714a6b-6a03-414b-81b5-d7d8ae4d7c37"}, "54570a77-e1bf-4e4c-9fc4-9f76417f85d4": {"doc_hash": "e18f5a32c621bf3a40ca3b5d7eec6f0e3a1529242bfd9db5c2153fc7b2e9d57d", "ref_doc_id": "35714a6b-6a03-414b-81b5-d7d8ae4d7c37"}, "b8b12894-9b4b-4dac-8772-a6accb1a43f0": {"doc_hash": "ee2d45d1cf2207ba522736062fb6accbf64cd6740634112babad25f5503a3aa6", "ref_doc_id": "35714a6b-6a03-414b-81b5-d7d8ae4d7c37"}, "a35925db-c7f1-4a62-9124-c9221eab866f": {"doc_hash": "80dfef382eee784a9d4facf0933234c6eeaf19419d6ec17ffd3cf0ebb2fb8086", "ref_doc_id": "35714a6b-6a03-414b-81b5-d7d8ae4d7c37"}, "f343b160-28aa-4823-95a2-e9408e25c95f": {"doc_hash": "1cb8d26962c3936b9a6b28e6e76b11bc82d209c30b82f70e888c99ca8dc87d88", "ref_doc_id": "7dd90457-d3c3-4ffb-b1a9-3ec1ccd68129"}, "6b702833-fbdc-4732-ba97-bb023faa3e10": {"doc_hash": "0269a0c1a3ed64fc3ddf248a963992569066ec18198013c289f836dfa9ae8d27", "ref_doc_id": "7dd90457-d3c3-4ffb-b1a9-3ec1ccd68129"}, "0b425afd-fd6a-465d-9a28-cabda7071ac6": {"doc_hash": "3c7c5e2c4da5940c967977e6a1fdb28580fa0fe5987bf550b30f5277c2906c9a", "ref_doc_id": "7dd90457-d3c3-4ffb-b1a9-3ec1ccd68129"}, "42b1197e-485b-45b9-9b88-a4911a3021d2": {"doc_hash": "62fd425f8ee08a1b3e5f9e214ee0d1662a37a41696b729d5c693b5ae6b48035a", "ref_doc_id": "7dd90457-d3c3-4ffb-b1a9-3ec1ccd68129"}, "8d6226c1-2cbf-4d5d-90bf-eb2ec99f8156": {"doc_hash": "6f9a7654e5ea1d9c5ff72a3141bd5841c1cbee1eee275e7e7e4af399193178aa", "ref_doc_id": "0aad7860-77ee-4e44-9e82-2117738954e5"}, "5ab467e3-7122-4b75-a9e9-a3a697961efc": {"doc_hash": "e046ee6b652b6864b8a6ece03137a9eb82d05b62aac76e8174f84d7d97788b55", "ref_doc_id": "0aad7860-77ee-4e44-9e82-2117738954e5"}, "470c6f81-d686-4ef2-a5f1-2c7c1916c2a4": {"doc_hash": "e45efc8b50c3a101c5aae5ba5c42cc32d0d69ad9ac2da2f971726025c31f3f6b", "ref_doc_id": "0aad7860-77ee-4e44-9e82-2117738954e5"}, "9577ee16-f52b-44a2-b6c5-c21c86b600d4": {"doc_hash": "1c02fde0cc34bca5d8479cc928542fbcb7f9e57a4b2d31d306bfc2db6000fd46", "ref_doc_id": "0aad7860-77ee-4e44-9e82-2117738954e5"}, "a6913d12-efbe-4eef-8b55-e29523b00d94": {"doc_hash": "136e868da7e61cd055a738bb6f6546a004ffc55be67b9b23c1bb2bf3ab6cfcef", "ref_doc_id": "4949872a-97be-41da-9a52-628746554ae9"}, "2f2d25f0-3d35-44fc-8303-82b0baaa962d": {"doc_hash": "08f4ea85c9b7b995711d8dae27bd2a28b6c08448dd170cc589851c5365306ce0", "ref_doc_id": "4949872a-97be-41da-9a52-628746554ae9"}, "0e5717ae-80f7-4a3a-b895-e564d226412d": {"doc_hash": "faf817ccfe7904d54dca1c1a242220cf4a3e6e4d83535a8e8f9ee14f5a591424", "ref_doc_id": "4949872a-97be-41da-9a52-628746554ae9"}, "030f74e5-5423-4804-8aa2-aebaf1374913": {"doc_hash": "44b262f20f7b5c5a7cc2f6231dcdf8a947444c6fe9067c0c72f8a97a1f2a99e6", "ref_doc_id": "4949872a-97be-41da-9a52-628746554ae9"}, "e9309ab0-0931-4665-acaa-c8379e647e21": {"doc_hash": "2f38b893da05fae9a02a08ae92b2225447814cb313b09818bfc21a1c25ce3d89", "ref_doc_id": "077e5723-f58f-475f-a396-04541c26005d"}, "001586eb-5057-4760-8f56-7580a1b08c08": {"doc_hash": "7c97cf8bb8ccc66b5b08660f57f3513215fa2a1e1ed7de4e66786b2ac8352180", "ref_doc_id": "077e5723-f58f-475f-a396-04541c26005d"}, "40a81f9c-3cc7-486d-9e5b-e77d3e6d0afa": {"doc_hash": "093e8c167e575ca9f93a4b4713badfcb4d51c7794b22021d6d353d8360f18d49", "ref_doc_id": "077e5723-f58f-475f-a396-04541c26005d"}, "e89ce251-a2f9-414d-8406-8a28c5970410": {"doc_hash": "6e44426cef6a4300d460b1389210fa6b64ab5459e4be486f2f653ce563c584f1", "ref_doc_id": "077e5723-f58f-475f-a396-04541c26005d"}}, "docstore/data": {"129c4513-5ba9-4033-88ee-4075365ae992": {"__data__": {"id_": "129c4513-5ba9-4033-88ee-4075365ae992", "embedding": null, "metadata": {"page_label": "1", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "d2018a0b-99a7-4de0-b35a-6db10cebcd76", "node_type": "4", "metadata": {"page_label": "1", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "74565707c8d9a0356f1abb8a6d9c7ce122d35b8f84d41075b4bd9f6e47eba641", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7510bac0-f70b-44bc-acd3-8f89e0c8a90d", "node_type": "1", "metadata": {}, "hash": "ca7f81b71cf8948684b355dea68344ca85140efacbdaea164ccdc535cbcd6574", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "ORIGINAL RESEARCH\npublished: 11 November 2021\ndoi: 10.3389/fdgth.2021.739327\nFrontiers in Digital Health | www.frontiersin.org 1 November 2021 | Volume 3 | Article 739327\nEdited by:\nYiannis Kyratsis,\nVrije Universiteit\nAmsterdam, Netherlands\nReviewed by:\nNiamh Lennox-Chhugani,\nInternational Foundation for Integrated\nCare (IFIC), United Kingdom\nRam Bajpai,\nKeele University, United Kingdom\n*Correspondence:\nChristina Malamateniou\nchristina.malamateniou@city.ac.uk\n\u2020These authors have contributed\nequally to this work and share last\nauthorship\nSpecialty section:\nThis article was submitted to\nHealth Technology Innovation,\na section of the journal\nFrontiers in Digital Health\nReceived: 10 July 2021\nAccepted: 19 October 2021\nPublished: 11 November 2021\nCitation:\nRainey C, O\u2019Regan T, Matthew J,\nSkelton E, Woznitza N, Chu K-Y,\nGoodman S, McConnell J, Hughes C,\nBond R, McFadden S and\nMalamateniou C (2021) Beauty Is in\nthe AI of the Beholder: Are We Ready\nfor the Clinical Integration of Arti\ufb01cial\nIntelligence in Radiography? An\nExploratory Analysis of Perceived AI\nKnowledge, Skills, Con\ufb01dence, and\nEducation Perspectives of UK\nRadiographers.\nFront. Digit. Health 3:739327.\ndoi: 10.3389/fdgth.2021.739327\nBeauty Is in the AI of the Beholder:\nAre We Ready for the Clinical\nIntegration of Arti\ufb01cial Intelligence in\nRadiography?", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1327, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "7510bac0-f70b-44bc-acd3-8f89e0c8a90d": {"__data__": {"id_": "7510bac0-f70b-44bc-acd3-8f89e0c8a90d", "embedding": null, "metadata": {"page_label": "1", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "d2018a0b-99a7-4de0-b35a-6db10cebcd76", "node_type": "4", "metadata": {"page_label": "1", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "74565707c8d9a0356f1abb8a6d9c7ce122d35b8f84d41075b4bd9f6e47eba641", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "129c4513-5ba9-4033-88ee-4075365ae992", "node_type": "1", "metadata": {"page_label": "1", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "8031a208cb1ae3da6d26ed5effd35a00828d309e5f4719222c1001bc36520b82", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fc95755d-72c3-4a8a-a6f8-0988fb5c6be7", "node_type": "1", "metadata": {}, "hash": "e9df4ffe3873cb447f256a7dd306d55008c30af1356d005fe90c45d414639b44", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "An Exploratory\nAnalysis of Perceived AI Knowledge,\nSkills, Con\ufb01dence, and Education\nPerspectives of UK Radiographers\nClare Rainey1, Tracy O\u2019Regan2, Jacqueline Matthew3, Emily Skelton3,4 , Nick Woznitza5,6 ,\nKwun-Ye Chu7,8 , Spencer Goodman2, Jonathan McConnell9, Ciara Hughes1,\nRaymond Bond10, Sonyia McFadden1\u2020 and Christina Malamateniou3,4*\u2020\n1 Faculty of Life and Health Sciences, School of Health Scienc es, Ulster University, Newtownabbey, United Kingdom, 2 The\nSociety and College of Radiographers, London, United Kingd om, 3 School of Biomedical Engineering and Imaging Sciences,\nKing\u2019s College London, St Thomas\u2019 Hospital, London, United Kingdom, 4 Department of Radiography, Division of Midwifery\nand Radiography, School of Health Sciences, University of L ondon, London, United Kingdom, 5 University College London\nHospitals, London, United Kingdom, 6 School of Allied and Public Health Professions, Canterbury Christ Church University,\nCanterbury, United Kingdom, 7 Department of Oncology, Oxford Institute for Radiation Onco logy, University of Oxford, Oxford,\nUnited Kingdom, 8 Radiotherapy Department, Churchill Hospital, Oxford Univ ersity Hospitals NHS FT, Oxford,\nUnited Kingdom, 9 NHS Scotland, Greater Glasgow and Clyde, Glasgow, United Ki ngdom, 10 Faculty of Computing,\nEngineering and the Built Environment, School of Computing , Ulster University, Newtownabbey, United Kingdom\nIntroduction: The use of arti\ufb01cial intelligence (AI) in medical imaging an d radiotherapy\nhas been met with both scepticism and excitement. However, c linical integration of AI\nis already well-underway. Many authors have recently repor ted on the AI knowledge\nand perceptions of radiologists/medical staff and student s however there is a paucity of\ninformation regarding radiographers. Published literatu re agrees that AI is likely to have\nsigni\ufb01cant impact on radiology practice.", "mimetype": "text/plain", "start_char_idx": 1328, "end_char_idx": 3209, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "fc95755d-72c3-4a8a-a6f8-0988fb5c6be7": {"__data__": {"id_": "fc95755d-72c3-4a8a-a6f8-0988fb5c6be7", "embedding": null, "metadata": {"page_label": "1", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "d2018a0b-99a7-4de0-b35a-6db10cebcd76", "node_type": "4", "metadata": {"page_label": "1", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "74565707c8d9a0356f1abb8a6d9c7ce122d35b8f84d41075b4bd9f6e47eba641", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7510bac0-f70b-44bc-acd3-8f89e0c8a90d", "node_type": "1", "metadata": {"page_label": "1", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "e60e2a96b789c79c43e57bda6c7ce44ce668a4707e4f447b63be4d10eb0905ae", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Published literatu re agrees that AI is likely to have\nsigni\ufb01cant impact on radiology practice. As radiographers are at the forefront of radiology\nservice delivery, an awareness of the current level of their perceived knowledge, skills, and\ncon\ufb01dence in AI is essential to identify any educational nee ds necessary for successful\nadoption into practice.\nAim:The aim of this survey was to determine the perceived knowled ge, skills, and\ncon\ufb01dence in AI amongst UK radiographers and highlight prio rities for educational\nprovisions to support a digital healthcare ecosystem.\nMethods:A survey was created on Qualtrics\u00ae and promoted via social me dia\n(Twitter\u00ae/LinkedIn\u00ae). This survey was open to all UK radiog raphers, including students\nand retired radiographers. Participants were recruited by convenience, snowball\nsampling. Demographic information was gathered as well as d ata on the perceived,\nself-reported, knowledge, skills, and con\ufb01dence in AI of re spondents. Insight into what\nthe participants understand by the term \u201cAI\u201d was gained by me ans of a free text response.", "mimetype": "text/plain", "start_char_idx": 3114, "end_char_idx": 4190, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "69ffe363-7420-452f-b2ea-e4416a5d11bb": {"__data__": {"id_": "69ffe363-7420-452f-b2ea-e4416a5d11bb", "embedding": null, "metadata": {"page_label": "2", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "4faa2b7c-5f02-4209-96be-16c4ee565c75", "node_type": "4", "metadata": {"page_label": "2", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "cb8a2d4b25cb81f91a31307b0a31cce00e8b9bf7fede74f26beb7b9dcb92b972", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b50b479e-a74b-49b3-94f0-a7a58fdbc05f", "node_type": "1", "metadata": {}, "hash": "fbd1eb1872f17547781d0dc5de969293f11906b368a760ec3e6c1ea176339a64", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Rainey et al. AI-Related Survey of UK Radiographers\nQuantitative analysis was performed using SPSS\u00ae and qualit ative thematic analysis was\nperformed on NVivo\u00ae.\nResults:Four hundred and eleven responses were collected (80% from d iagnostic\nradiography and 20% from a radiotherapy background), broad ly representative of the\nworkforce distribution in the UK. Although many respondent s stated that they understood\nthe concept of AI in general (78.7% for diagnostic and 52.1% f or therapeutic radiography\nrespondents, respectively) there was a notable lack of suf\ufb01 cient knowledge of AI\nprinciples, understanding of AI terminology, skills, and c on\ufb01dence in the use of AI\ntechnology. Many participants, 57% of diagnostic and 49% ra diotherapy respondents,\ndo not feel adequately trained to implement AI in the clinica l setting. Furthermore 52%\nand 64%, respectively, said they have not developed any skil l in AI whilst 62% and 55%,\nrespectively, stated that there is not enough AI training fo r radiographers. The majority\nof the respondents indicate that there is an urgent need for f urther education (77.4% of\ndiagnostic and 73.9% of therapeutic radiographers feeling they have not had adequate\ntraining in AI), with many respondents stating that they had to educate themselves to\ngain some basic AI skills. Notable correlations between con \ufb01dence in working with AI\nand gender, age, and highest quali\ufb01cation were reported.\nConclusion:Knowledge of AI terminology, principles, and applications by healthcare\npractitioners is necessary for adoption and integration of AI applications. The results\nof this survey highlight the perceived lack of knowledge, sk ills, and con\ufb01dence for\nradiographers in applying AI solutions but also underline t he need for formalised\neducation on AI to prepare the current and prospective workf orce for the upcoming\nclinical integration of AI in healthcare, to safely and ef\ufb01c iently navigate a digital future.\nFocus should be given on different needs of learners dependi ng on age, gender, and\nhighest quali\ufb01cation to ensure optimal integration.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2078, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "b50b479e-a74b-49b3-94f0-a7a58fdbc05f": {"__data__": {"id_": "b50b479e-a74b-49b3-94f0-a7a58fdbc05f", "embedding": null, "metadata": {"page_label": "2", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "4faa2b7c-5f02-4209-96be-16c4ee565c75", "node_type": "4", "metadata": {"page_label": "2", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "cb8a2d4b25cb81f91a31307b0a31cce00e8b9bf7fede74f26beb7b9dcb92b972", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "69ffe363-7420-452f-b2ea-e4416a5d11bb", "node_type": "1", "metadata": {"page_label": "2", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "b626c0c00c694cfa61077fe8f4bef126f4b3a225dd534c38f8e5ba7782e2570e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fe6f8386-4593-4649-86bf-d731c3569a66", "node_type": "1", "metadata": {}, "hash": "256ad60ec8c59e18ed5ad3a9c8cc235ff0cd7edd812181e4e9e564dabafd6164", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Focus should be given on different needs of learners dependi ng on age, gender, and\nhighest quali\ufb01cation to ensure optimal integration.\nKeywords: arti\ufb01cial intelligence, AI, radiography, education, workforce training, digital health, radiotherapy,\nadoption\nINTRODUCTION AND BACKGROUND\nThe AI Accelerating Trajectory\nIn the last decade, Arti\ufb01cial Intelligence (AI) implementation\nhas accelerated but has also become an increasingly divisive\ntopic in medicine, particularly so within medical imaging. The\ndevelopment of more sophisticated computers with greater\nstorage capabilities and faster graphics processing units (GPUs)\nhave allowed systems architectures to develop in a way which\nwas not possible before (\n1). This has allowed convolutional\nneural networks (CNNs) in image recognition tasks to develo p.\nThese systems learn iteratively until acceptable performanc e\nis achieved relative to the previous interpretive standard\n(\n2). Wider availability of large medical imaging datasets\nand advancements in neuroscience further perpetuated AI\ntechnology advancement (\n3).\nWhile AI is considered to be a promising, fast changing\narea of healthcare innovation ( 4), able to revolutionise care\ndelivery, it is often seen with suspicion and mistrust by\nmany healthcare professionals working in radiology, leaving\nthem concerned about their future careers (\n5\u20137). In response\nto the impending digital healthcare revolution, the NHS has\nprioritised the development, testing, and validation of AI to ols\nand digital health systems as part of their long-term improvem ent\nplan (8).\nAI Implementation Creates Controversy\nAmong Medics, Including Radiologists\nDespite these technological advances, implementation of AI into\nthe clinical setting has been perceived di\ufb00erently across the\nmultidisciplinary team. Di\ufb00erence research projects surveyed\nradiologists and radiology trainees, the medical practitio ners\nwithin medical imaging. In 2019, Waymel et al. (\n9) surveyed\n270 senior radiologists and radiology registrars in France a nd\nreported an optimistic view as clinicians felt that implementat ion\nof AI will have a positive impact on clinical practise.", "mimetype": "text/plain", "start_char_idx": 1943, "end_char_idx": 4094, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "fe6f8386-4593-4649-86bf-d731c3569a66": {"__data__": {"id_": "fe6f8386-4593-4649-86bf-d731c3569a66", "embedding": null, "metadata": {"page_label": "2", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "4faa2b7c-5f02-4209-96be-16c4ee565c75", "node_type": "4", "metadata": {"page_label": "2", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "cb8a2d4b25cb81f91a31307b0a31cce00e8b9bf7fede74f26beb7b9dcb92b972", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b50b479e-a74b-49b3-94f0-a7a58fdbc05f", "node_type": "1", "metadata": {"page_label": "2", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "da597eff1e6ff3464e7e4e5177c0cb97c274876c1ba7d8e49a7a9ce2367f9ce1", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "(\n9) surveyed\n270 senior radiologists and radiology registrars in France a nd\nreported an optimistic view as clinicians felt that implementat ion\nof AI will have a positive impact on clinical practise. Respondents\nthought that AI will speed up reporting turnaround times, i.e.,the\ntime taken to produce a clinical diagnostic report, with a possib le\nreduction in the number of imaging-related medical errors a nd\nsubsequent increased contact time to enable more direct pati ent\ncare. Further work by Oh et al. in Korea (\n10), surveyed the\ncon\ufb01dence of 669 doctors and medical students when using\nAI, where 62% of respondents reiterated the perception that AI\nFrontiers in Digital Health | www.frontiersin.org 2 November 2021 | Volume 3 | Article 739327", "mimetype": "text/plain", "start_char_idx": 3893, "end_char_idx": 4645, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "fb2eaad1-718f-4616-8039-4654f96c3bf1": {"__data__": {"id_": "fb2eaad1-718f-4616-8039-4654f96c3bf1", "embedding": null, "metadata": {"page_label": "3", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "0c51c536-373b-498e-8826-f6146e4caaf0", "node_type": "4", "metadata": {"page_label": "3", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "14886388cac80b43fa2be5fc8808dc4a1a65cf898a83fbbe3205fa6694a29ebd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4a99ebdc-8662-4dba-858c-34f555358893", "node_type": "1", "metadata": {}, "hash": "1090c09e222445168dba734bfcf69a315d00697836c314f06bf60630be465693", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Rainey et al. AI-Related Survey of UK Radiographers\nwould speed the collection of clinical data. In Germany, 83% o f\n263 surveyed medical students felt that AI will never replace th e\nradiologist ( 11) however this is contradicted by reports ranging\nfrom 26 to 78% of respondents (doctors, nurses, and technicia ns)\nfearing that AI could replace them in their clinical role ( 10\u201313).\nA lack of trust and acceptance of AI systems is also apparent in\nthe literature (\n14, 15) with results in Korea reporting that 79% of\nrespondents would always favour the doctor\u2019s opinion over the\nAI when a con\ufb02ict arose. Whilst in Germany (\n10), 56% of 263\nsurveyed medical students, stated that AI would not be able t o\nestablish a de\ufb01nitive diagnosis ( 11). The perceived advantages of\nAI in the current evidence-base are clear; however contradi ctory\nviews exist internationally on how exactly AI will work in the\nclinical arena and whether it will lead to role depletion among\nphysicians/healthcare workers and students.\nThe AI Training Gap May Challenge AI\nImplementation Among Clinicians and\nPerpetuate Long-Standing Workforce\nShortages\nThe majority of published literature has further highlighted a\nlack of training to empower healthcare practitioners to optima lly\nuse the capabilities of AI, as well as the lack of regulatory\nframeworks of AI-enabled healthcare products (\n16, 17) and lack\nof thorough scrutiny of reported studies, ensuring a robust\nknowledge base (\n18). The majority of physicians feel they have\nreceived insu\ufb03cient previous information on AI and would\nconsider attending continuous medical education or technically\nadvanced training on AI, if available (\n9\u201312). Similarly medical\nstudents have reported either no AI training at all or insu\ufb03ci ent\ntraining in AI with many believing it should be taught at\nundergraduate level and be part of the compulsory curriculum\n(\n11, 19).", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1888, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "4a99ebdc-8662-4dba-858c-34f555358893": {"__data__": {"id_": "4a99ebdc-8662-4dba-858c-34f555358893", "embedding": null, "metadata": {"page_label": "3", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "0c51c536-373b-498e-8826-f6146e4caaf0", "node_type": "4", "metadata": {"page_label": "3", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "14886388cac80b43fa2be5fc8808dc4a1a65cf898a83fbbe3205fa6694a29ebd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fb2eaad1-718f-4616-8039-4654f96c3bf1", "node_type": "1", "metadata": {"page_label": "3", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "aed76db20a6da48878458af1c7ddbf15d583a9c01dedf9d007cd45965f47034e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9a6b75f9-834b-410f-9884-95af32de356d", "node_type": "1", "metadata": {}, "hash": "194e96ab2bd87564e8b95d2636162d7639c62691a582dfc4d772bd97cd289860", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Similarly medical\nstudents have reported either no AI training at all or insu\ufb03ci ent\ntraining in AI with many believing it should be taught at\nundergraduate level and be part of the compulsory curriculum\n(\n11, 19).\nLack of adequate training on AI to prepare clinicians and\nexplain basic AI concepts and applications may impact on the\nnumber of physicians choosing to specialise in radiology after\ngraduation, as was highlighted by recent research in the UK (\n20).\nA total of 19 medical schools participated in a survey assessin g\nattitudes of medical students toward AI, 49% of respondents\nreported that they would be less likely to consider specialising in\nradiology due to the impact of AI. A similar picture is emerging in\nthe United States, where 44% of 156 survey respondents reported\nthey would also be less likely to choose radiology as a specialty\ndue to the in\ufb02uence of AI (\n13).\nThe lack of knowledge of AI bene\ufb01ts and risks and the skills\ngap on using AI tools by clinicians needs to be urgently addres sed\nto cater for the workforce shortages in medical imaging and\nradiotherapy; the current Royal College of Radiologist statistics\nwhich state that \u201cthe NHS radiologist workforce is now short -\nsta\ufb00ed by 33% and needs at least another 1,939 consultants to\nmeet safe sta\ufb03ng levels and pre-coronavirus levels of demand\nfor scans\u201d (\n20). This sta\ufb03ng shortage in medical imaging is\nfurther compounded by the College of Radiographers census of\nthe diagnostic radiography workforce in the UK. Results reported\nthat the average current UK vacancy rate across respondents\nwas 10.5% at the census date of 1 November 2020 (\n21). It is\nimperative to use dedicated educational provisions to dispel the\nmisperception that \u201cAI will replace radiology sta\ufb00, or that AI\nmay deter sta\ufb00 from specialising in the role in the \ufb01rst place.\u201d\nFurther training is required not only on how to use AI itself\nbut also on the advantages, challenges, and issues surrounding\nAI implementation into clinical departments to ensure the\ncon\ufb01dence of clinicians interested into these careers increases.", "mimetype": "text/plain", "start_char_idx": 1674, "end_char_idx": 3752, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "9a6b75f9-834b-410f-9884-95af32de356d": {"__data__": {"id_": "9a6b75f9-834b-410f-9884-95af32de356d", "embedding": null, "metadata": {"page_label": "3", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "0c51c536-373b-498e-8826-f6146e4caaf0", "node_type": "4", "metadata": {"page_label": "3", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "14886388cac80b43fa2be5fc8808dc4a1a65cf898a83fbbe3205fa6694a29ebd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4a99ebdc-8662-4dba-858c-34f555358893", "node_type": "1", "metadata": {"page_label": "3", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "b40661b56a397963f792828aeb419991c903f6bcda16a92808dbe085c8c652e0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d52fa8ce-1533-4937-8fd4-5275d850a9a1", "node_type": "1", "metadata": {}, "hash": "90c0097e81c023f5f2b230ad63562e03c213c1b39c570702c89fa25473b9b122", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "The Impact of AI on Radiographers\nRadiographers are registered healthcare professionals who work\npredominantly and directly with patients, families, carers,\nand service users but very closely with Radiologists. In the\nUK, diagnostic and therapeutic radiographers form the largest\nproportion of the workforce in clinical imaging (radiology) and\nradiotherapy departments, respectively. There are more than\n30,000 members of the radiographers\u2019 professional body, the\nSociety of Radiographers (SoR) (2020) (\n22), and 36,941 currently\nregistered with the regulator for health and care profession s, the\nHealth and Care Professions Council in the UK ( 23). Collectively\ntheir roles encompass the provision of health screening servic es,\nclinical imaging for diagnosis, and imaging and therapeutic\nservices to facilitate curative, palliative, surveillance,end of life,\nand forensic examinations. Radiographers interact with and care\nfor thousands of people each day. This requires a wide and\nencompassing range of skills and knowledge and the ability to\nempower people in shared decision making. Radiographers work\non the interface between technology and service users in clinical\nimaging and radiotherapy. They operate the equipment, produce,\nand report on diagnostic images.\nRadiology and radiography, two interconnected but distinct\nprofessions, are traditionally considered to be early adopters of\nAI technology (\n24, 25), with computerised diagnosis used as early\nas the 1960s ( 8). Since then, there have been several periods of\nhigh activity in AI research and development with intervenin g\nperiods of lower activity, so-called AI \u201cwinters\u201d ( 26, 27). Pattern\nrecognition computer aided diagnosis (CAD) tools have been\npart of mammography image interpretation since the 1980s (\n28,\n29), some of which are extant today and perpetuate signi\ufb01cant\nhuman input due to high false positive rates ( 14, 30).", "mimetype": "text/plain", "start_char_idx": 3753, "end_char_idx": 5652, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "d52fa8ce-1533-4937-8fd4-5275d850a9a1": {"__data__": {"id_": "d52fa8ce-1533-4937-8fd4-5275d850a9a1", "embedding": null, "metadata": {"page_label": "3", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "0c51c536-373b-498e-8826-f6146e4caaf0", "node_type": "4", "metadata": {"page_label": "3", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "14886388cac80b43fa2be5fc8808dc4a1a65cf898a83fbbe3205fa6694a29ebd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9a6b75f9-834b-410f-9884-95af32de356d", "node_type": "1", "metadata": {"page_label": "3", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "98f31de9d0c909e6abd5e38e198ecca5819bef35251058c5894c25a3b957f541", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "While research related to radiologists\u2019 roles, clinical prac tise,\nand education in relation to AI has \ufb02ourished, as discussed i n the\nabovementioned paragraphs, very little research has consider ed\nthe impact of AI on radiographers and their perception of using it\nin clinical practise. The limited literature available wouldsuggest\nthat radiographers are keen to engage with AI but controversy\nstill exists whereby some radiographers feel that AI may deplete\nor threaten their jobs in the future whilst others think it may l ead\nto more advanced role developments (\n31\u201334). Abuzaid et al. ( 35)\nsurveyed the opinions of 34 radiologists and 119 radiographer s\nin the UAE on their willingness to accept AI into practise.\nSta\ufb00 were excited and ready to embrace AI, however 17% of\nrespondents stated they had no knowledge of AI, 40% were self-\ntaught, and 73% reported di\ufb03culty accessing training courses to\n\ufb01ll the knowledge gap for sta\ufb00. Further work by Botwe et al. (\n36)\nsurveyed 151 radiographers in Ghana. Most respondents (83%)\nwere positive and would embrace the implementation of AI\ninto practise, however 83% expressed concerns about AI related\nFrontiers in Digital Health | www.frontiersin.org 3 November 2021 | Volume 3 | Article 739327", "mimetype": "text/plain", "start_char_idx": 5653, "end_char_idx": 6899, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "d5a01f15-61ef-457c-9cdf-6dbb464e9ee1": {"__data__": {"id_": "d5a01f15-61ef-457c-9cdf-6dbb464e9ee1", "embedding": null, "metadata": {"page_label": "4", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "500320de-55c2-45fa-a58d-487bc0b2179c", "node_type": "4", "metadata": {"page_label": "4", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "cf7c704e1adac0bc4ca8621dde71c3824af6bcc3f4376e8cad79e503e2828364", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "95a7c3ef-887d-4b09-bd0d-c0f7380ca67e", "node_type": "1", "metadata": {}, "hash": "862c4901897c260415e9fe95f28b5097592c4c258fcb4e2f52fbb8aa2c62e760", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Rainey et al. AI-Related Survey of UK Radiographers\nerrors and job displacement. A further 69% felt that AI could\nlead to reductions in radiation dose whilst maintaining image\nquality. Overall, they concluded that there was a need for fu rther\neducation for radiographers to alleviate these fears. Simil ar fears\nand apprehensions regarding trust and knowledge gaps have been\nexpressed by radiographers in Canada, America, and Ireland\n(\n32\u201334). In particular the survey of 318 diagnostic and 77\ntherapeutic radiographers from Ireland has identi\ufb01ed resist ance\nof AI use in particular for patient facing roles. Respondents\nfelt that radiographers would always have a primary role when\ncaring for the patient and that AI would not be able to replace\nthat human touch. Similar to other studies,>50% respondents\nworried about changing roles and fewer jobs for radiographer s,\nas AI will take over clinical delivery. However this notion o f role\ndepletion was not universally supported in this survey as 47%\nof diagnostic and 38% of therapeutic radiographers felt AI will\ncreate new specialised/advanced roles in the future. This may\nmean the radiographers can work together with AI tools to ful\ufb01 l\nroles that address the ongoing sta\ufb00 shortages.\nThe Future of AI Within Medical Imaging\nand Radiotherapy: Challenges and\nOpportunities for Integration and the\nImportance of Education\nSarwar et al. (\n37) have predicted the full integration of AI in\nhealthcare in the next 5\u201310 years. Implementation of AI into\nthe clinical setting is not without barriers; these includea lack\nof trust and acceptance of the systems o\ufb00ered (\n9, 29), lack of\ntraining to empower healthcare practitioners to optimally use t he\ncapabilities of AI, as discussed above, the lack of standardi sed\nregulatory frameworks of AI enabled healthcare products ( 10, 12)\nand lack of thorough scrutiny of reported studies, ensuring a\nrobust knowledge base (\n15) to name just a few.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1940, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "95a7c3ef-887d-4b09-bd0d-c0f7380ca67e": {"__data__": {"id_": "95a7c3ef-887d-4b09-bd0d-c0f7380ca67e", "embedding": null, "metadata": {"page_label": "4", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "500320de-55c2-45fa-a58d-487bc0b2179c", "node_type": "4", "metadata": {"page_label": "4", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "cf7c704e1adac0bc4ca8621dde71c3824af6bcc3f4376e8cad79e503e2828364", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d5a01f15-61ef-457c-9cdf-6dbb464e9ee1", "node_type": "1", "metadata": {"page_label": "4", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "94117699e7574d6f11bacb03f2f21d10b1847243360c3cd8527b9e8927234c9f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "734f87bc-cb1f-4923-b589-409732467fe7", "node_type": "1", "metadata": {}, "hash": "7df08a1cb44feaaa7e457474edf0a1b0426d69666eecfbf4921c5f0430c51593", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "It is essential\nfor the design, validation, and adoption of AI that radiograph ers\nare knowledgeable, competent, con\ufb01dent, and well-trained t o be\nable to fully materialise the bene\ufb01ts of new technology whil e\nminimising risks but also to be in position to explain these\nbene\ufb01ts and risks to the patients; thus radiographers could be\ncontributing to and sustaining of a safe, e\ufb03cient medical imaging\nand radiotherapy service, one that is based on trust and resea rch\nevidence on the use of appropriate AI technology.\nA number of suggestions to allow AI systems to make\ntheir way into clinical application have been o\ufb00ered, such\nas various measures to make AI more interpretable or\nexplainable (\n38, 39). The users of AI technologies, for instance\nthe radiographers, radiologists, and oncologists and those\nresponsible for the procurement of AI for healthcare, need to\nhave adequate knowledge, and understanding of the functionality\nand applications of the proposed systems to enable unbiased\nselection, i.e., the best application choice for the intended\nfunction with an awareness of potential limitations and risks.\nThe Topol review (\n40) reiterates the need for education in AI\nto be integrated into preregistration programmes, and for the\nnecessity of upskilling the existing workforce in AI applications\nand technology. Recent draught HCPC guidelines (\n41) state\nthat radiographers should \u201cbe aware of the principles of AI\nand deep learning technology, and the methods of assessing t he\nperformance of AI algorithms\u201d (p. 45). Recent recommendations\nand standards jointly delivered by the International Society\nof Radiographers and Radiological Technologists (ISRRT) and\nEuropean Federation of Radiographer Societies (EFRS) (\n42), state\nthat radiographers need to have functional and performance\nassessment knowledge of AI systems. This can be described as\na form of \u201cAI literacy\u201d that should be included in both pre\nand post registration programmes, along with education for the\nwhole workforce. The Society and College of Radiographers\u2019\nAI Working Party has also recently o\ufb00ered recommendations\nfor education and training of radiographers on AI theory and\napplications (\n43).", "mimetype": "text/plain", "start_char_idx": 1941, "end_char_idx": 4121, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "734f87bc-cb1f-4923-b589-409732467fe7": {"__data__": {"id_": "734f87bc-cb1f-4923-b589-409732467fe7", "embedding": null, "metadata": {"page_label": "4", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "500320de-55c2-45fa-a58d-487bc0b2179c", "node_type": "4", "metadata": {"page_label": "4", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "cf7c704e1adac0bc4ca8621dde71c3824af6bcc3f4376e8cad79e503e2828364", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "95a7c3ef-887d-4b09-bd0d-c0f7380ca67e", "node_type": "1", "metadata": {"page_label": "4", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "32156e9c07cd8a3418cf91de40a0f4db8e8c4dc60309706fa56621b822350cc4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "43a92508-3957-4e23-b58f-6e209f2b6c84", "node_type": "1", "metadata": {}, "hash": "58890902f25c3b260fd871c9a29dbc6fa425a5e20928deb472a2d5cc4696a4ef", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "The Society and College of Radiographers\u2019\nAI Working Party has also recently o\ufb00ered recommendations\nfor education and training of radiographers on AI theory and\napplications (\n43).\nRationale, Aims, and Objectives\nThe paucity of information available on radiographers\nperceptions of AI and its implementation into daily\nclinical practise provides a strong rationale for the design\nof a dedicated study. As identi\ufb01ed by Lai et al. (\n44) AI\nin healthcare will only be accepted and satisfactory for\neveryone, if we invest on collaborative e\ufb00ort and include\neveryone within the multidisciplinary team in the decision-\nmaking process. Hence, this exploratory study aims to\nhighlight the perceived, self-reported, knowledge, skills,\nand con\ufb01dence of UK diagnostic and therapeutic radiographers\nin relation to AI. Further objectives were to investigate\nthe adequacy of training provisions currently available\nand to propose content and format of further education\non AI.\nMETHODS\nQuestionnaire Design\nA questionnaire was designed using the QualtricsR\u20dd survey\nplatform. This is an online survey builder which allows for ope n\ndissemination via an internet link, hence optimising participa nt\nreach (\n45). This voluntary, fully online survey was designed\nand reported to adhere to the Checklist for Reporting Results\nof Internet E-Surveys (CHERRIES) (\n46) and approved by City,\nUniversity of London, School of Health Sciences Research Ethi cs\nCommittee (ETH1920-1989). No incentives were o\ufb00ered to\ncomplete this survey.\nThis was a fully open survey, available from the 12th of\nFebruary 2021 to the 6th of April 2021, for everyone who had the\nlink. The survey was set to collect fully anonymous responses,\ntherefore neither IP addresses nor any other identifying\ninformation was collected from participants. An opening slide\ngave participants information on the study rationale and aim,\nprovided information on current literature on the subject,\ninformed participants of the approximate time commitment to\ncomplete the survey and gained consent to proceed.", "mimetype": "text/plain", "start_char_idx": 3941, "end_char_idx": 5985, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "43a92508-3957-4e23-b58f-6e209f2b6c84": {"__data__": {"id_": "43a92508-3957-4e23-b58f-6e209f2b6c84", "embedding": null, "metadata": {"page_label": "4", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "500320de-55c2-45fa-a58d-487bc0b2179c", "node_type": "4", "metadata": {"page_label": "4", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "cf7c704e1adac0bc4ca8621dde71c3824af6bcc3f4376e8cad79e503e2828364", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "734f87bc-cb1f-4923-b589-409732467fe7", "node_type": "1", "metadata": {"page_label": "4", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "949d6a2270b1db8f1e27a9cc6c7840747bda875f0adfde8f0b4f42ff8530087c", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "An opening slide\ngave participants information on the study rationale and aim,\nprovided information on current literature on the subject,\ninformed participants of the approximate time commitment to\ncomplete the survey and gained consent to proceed. A \ufb01nal\nsurvey slide noti\ufb01ed respondents of submission of responses,\nalthough a full review of responses was not given. Participants\nwere permitted to freely navigate back to previous questions a nd\nallowed to save responses and \ufb01nish the survey at a later time\nin order to maximise response completeness. All responses were\nFrontiers in Digital Health | www.frontiersin.org 4 November 2021 | Volume 3 | Article 739327", "mimetype": "text/plain", "start_char_idx": 5737, "end_char_idx": 6403, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "e378d602-c32c-4169-ac8f-81cea7823ae9": {"__data__": {"id_": "e378d602-c32c-4169-ac8f-81cea7823ae9", "embedding": null, "metadata": {"page_label": "5", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "25004ac4-94a1-4f23-9f07-6ef3e4b4e22d", "node_type": "4", "metadata": {"page_label": "5", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "880c1c9e8982d3c038e12dce32f06a655dd428c8e161de6c41d08ea3268f6dec", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5575d336-dcad-4387-afd7-9cafce4f56ee", "node_type": "1", "metadata": {}, "hash": "674efbfeac8ae5853b54cc9b76018eab840219595d4afd0e7c7195d603ecbfa2", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Rainey et al. AI-Related Survey of UK Radiographers\nincluded in data analysis, even if the survey was not complete.\nTime for completion of the survey was, therefore, not analysed.\nThe questions included in the survey were loosely based on\na previous, unpublished, survey undertaken by one of the co-\nauthors. These initial survey was further modi\ufb01ed and expanded\nwith new questions based on input from all listed authors,\nmany of whom are members of the \u201cSociety and College of\nRadiographers Arti\ufb01cial Intelligence Working Party, \u201d who have\na range of senior clinical and academic experience. The surve y\ncontent is drawing upon current research evidence as outline d in\nintroduction, as well as from the themes presented on the Soci ety\nof Radiographers (SCoR) AI guidance document for radiography\nprofessionals (\n43).\nThe Survey Instrument\nThe questionnaire consisted of 91 questions in total, divided into\n\ufb01ve main sections or \u201cblocks\u201d\u2014(i) participant demographics,\n(ii) AI knowledge, (iii) skills and con\ufb01dence in AI (including\nquestions on education provision), (iv) perceptions of the impa ct\nof AI on clinical practise (v) expectations for the future of\nradiography with AI and \ufb01nally, (vi) the e\ufb00ect AI may have\non image perception and reporting. Most questions were either\nmultiple choice format, with some free text options to allow\nfor more detailed responses or Likert scale questions. Only one\nquestion required a fully open response.\nThe demographic section included seven questions to gather\ndata on the age, number of years\u2019 experience, highest academi c\nquali\ufb01cation, region of the UK, clinical setting, and nature\nof current role. This information was requested to allow\ninvestigation of any relationship between these independent\nvariables and dependent variables of knowledge, skills and\ncon\ufb01dence in AI. An eligibility \ufb01ltering question placed at\nthe beginning of the survey enquired if the respondent was a\npractising or student radiographer; this was to ensure that anyone\nother than a radiographer did not complete the survey.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2050, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "5575d336-dcad-4387-afd7-9cafce4f56ee": {"__data__": {"id_": "5575d336-dcad-4387-afd7-9cafce4f56ee", "embedding": null, "metadata": {"page_label": "5", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "25004ac4-94a1-4f23-9f07-6ef3e4b4e22d", "node_type": "4", "metadata": {"page_label": "5", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "880c1c9e8982d3c038e12dce32f06a655dd428c8e161de6c41d08ea3268f6dec", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e378d602-c32c-4169-ac8f-81cea7823ae9", "node_type": "1", "metadata": {"page_label": "5", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "ed5a8668626e71846d54db085b633d4004b40c8b5776af9df05ebb7cb37b3658", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f858374d-56da-4a0d-a4bf-b1f3db02652c", "node_type": "1", "metadata": {}, "hash": "7101aca46dbcaa8544bcc5828d64c5c3e7d3f8412134f6db1f789479cb558b8f", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "An eligibility \ufb01ltering question placed at\nthe beginning of the survey enquired if the respondent was a\npractising or student radiographer; this was to ensure that anyone\nother than a radiographer did not complete the survey. If the\nparticipant responded that they are not a radiographer, they\nwere redirected to the end of the survey and no further data\nwas collected.\nOnly the results of the \ufb01rst three sections of the survey (i\u2013i ii)\nare discussed in this paper; the remaining will be presented in\ndi\ufb00erent publications given space limit and richness of \ufb01ndings.\nValidity and Reliability of the Survey\nInstrument\nFor each new survey face and content validity are vital measures\nof quality (\n47).\nFace and Content Validity\nFace validity, a subjective measure which concerns whether\nor not the instrument appears to potential test takers to be\nassessing what it intended to measure (\n48) has been assessed\nand ensured for our study (in terms of feasibility, readabil ity,\nconsistency of formatting, the clarity of the language used ),\nthrough the piloting phase of the survey ( 49). Content validity,\n\u201cthe degree to which items in an instrument re\ufb02ect the conten t\nuniverse to which the instrument will be generalised\u201d ( 50) was\nensured by the design and review of this work by the SCoR AI\nworking party and other AI radiography experts, the piloting\nwith another team of AI experts with varying demographics and\nprofessional backgrounds and by being grounded on relevant\nresearch evidence, including the SCoR AI guidance document\nfor radiographers, which outlined priorities for AI adoption\nwithin the radiography workforce in all areas of practise,\nincluding education (\n43). The validation of the questionnaire\nwas conducted by a panel of experts in the medical imaging and\nAI \ufb01eld, which included 12 quali\ufb01ed, practising radiographers,\nacademics, students, and clinical sta\ufb00, with a range of clinic al\nexperience from <1 year to >20 years. This tested both the\ntechnical aspects of the survey format (face validity) as well as the\nsuitability of the questions (content validity).", "mimetype": "text/plain", "start_char_idx": 1825, "end_char_idx": 3909, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "f858374d-56da-4a0d-a4bf-b1f3db02652c": {"__data__": {"id_": "f858374d-56da-4a0d-a4bf-b1f3db02652c", "embedding": null, "metadata": {"page_label": "5", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "25004ac4-94a1-4f23-9f07-6ef3e4b4e22d", "node_type": "4", "metadata": {"page_label": "5", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "880c1c9e8982d3c038e12dce32f06a655dd428c8e161de6c41d08ea3268f6dec", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5575d336-dcad-4387-afd7-9cafce4f56ee", "node_type": "1", "metadata": {"page_label": "5", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "f71f2d2efd71510c785c438a23e62845137f7297a859460730e59f4f4392322c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ee57848f-ca45-4e62-b6ad-09016a2a020b", "node_type": "1", "metadata": {}, "hash": "1cc92b2b1254fa4391233206755e248db8d5f112051ed4d1a750776069d74b10", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "This tested both the\ntechnical aspects of the survey format (face validity) as well as the\nsuitability of the questions (content validity). Minor form atting\nissues involving di\ufb03culty in navigating to the next questio n were\nreported and \ufb01xed before \ufb01nal dissemination of the survey.\nInternal Consistency\nCronbach\u2019s alpha was calculatedpost-hoc for the Likert scale\nquestions of this instrument to be able to con\ufb01rm internal\nconsistency (\n47). Acceptable internal reliability was found for the\nscale questions for both professions ( \u03b1 = 0.736 and \u03b1 = 0.777 for\ndiagnostic and therapeutic radiography, respectively).\nParticipants\nThis survey was intended to give a national (UK) perspective\non perception of knowledge, skills, con\ufb01dence, and educational\nneeds of both the diagnostic radiography and therapeutic\nradiography workforce in the \ufb01eld of AI. All radiographers\n(student and trainees, practising and retired, academic, and\nresearchers) across all sub-specialisation areas, including\nsonographers, were invited to participate. The survey was\ndisseminated via LinkedInR\u20dd and Twitter R\u20dd employing non-\nprobability snowball, sampling (\n51), and widely shared by\nthe authors through their radiography-speci\ufb01c professional\nnetworks, many of whom are members of the SCoR AI Working\nParty or hold di\ufb00erent AI leadership positions within decision\nmaking agencies. Academic colleagues were also approached\nto distribute within radiography academic communities\nand students.\nThe link to the survey was also sent to the leads of\nmany clinical centres throughout the UK for dissemination\nto all colleagues, therefore ensuring maximum reach to\nrelevant parties.\nData Analysis\nThe IBM SPSS (version 23) was used for analysis of the\ndata (\n52). Descriptive statistics, in the form of frequencies\nhave been reported for most of the responses. One question\nrequired an open-ended response, which has been analysed\nby thematic content analysis, using NVivo (version 12) (\n53).\nDescriptive and inferential statistics were calculated using SPSS\nand graphs produced within MS Excel R\u20dd (Microsoft, 2018).", "mimetype": "text/plain", "start_char_idx": 3770, "end_char_idx": 5858, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "ee57848f-ca45-4e62-b6ad-09016a2a020b": {"__data__": {"id_": "ee57848f-ca45-4e62-b6ad-09016a2a020b", "embedding": null, "metadata": {"page_label": "5", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "25004ac4-94a1-4f23-9f07-6ef3e4b4e22d", "node_type": "4", "metadata": {"page_label": "5", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "880c1c9e8982d3c038e12dce32f06a655dd428c8e161de6c41d08ea3268f6dec", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f858374d-56da-4a0d-a4bf-b1f3db02652c", "node_type": "1", "metadata": {"page_label": "5", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "0cec354440917a5cd4da6c578075bb54d5f7ce1e96a2925f415faa1137354ba0", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Descriptive and inferential statistics were calculated using SPSS\nand graphs produced within MS Excel R\u20dd (Microsoft, 2018).\nData was presented in percentages for single response question s\nand counts/frequency for questions where more than one\nresponse was permitted. There were no weightings applied to any\nquestions for analysis.\nFrontiers in Digital Health | www.frontiersin.org 5 November 2021 | Volume 3 | Article 739327", "mimetype": "text/plain", "start_char_idx": 5735, "end_char_idx": 6160, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "5cd5875e-44f2-4c28-9991-87329308be61": {"__data__": {"id_": "5cd5875e-44f2-4c28-9991-87329308be61", "embedding": null, "metadata": {"page_label": "6", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "ddde90c3-b670-4525-ae1e-9a1da3042086", "node_type": "4", "metadata": {"page_label": "6", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "04bf986d66e91011015ee62c7033e973bab217a09cb156753d26b536d84a1292", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4fb65a98-6a97-4d53-a423-51d232904636", "node_type": "1", "metadata": {}, "hash": "48eb2b8bb91b1f485265230c296ffe56cc1184360de36bdb30e7b54f50525f41", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Rainey et al. AI-Related Survey of UK Radiographers\nCombinations of some of the variables have been analysed to\ndetermine if any patterns emerged in order for hypotheses to be\nproposed for future studies (\n54). The correlations of independent\nvariables such as: years practising, highest academic quali\ufb01 cation,\nand age with dependent variables such as: understanding of AI ,\ncon\ufb01dence in AI, understanding of the underlying terminolo gy\nof AI, feelings of being well-trained in AI, and agreement th at\nthey have developed some skill in AI, were all explored and\nmeasured on either four-point or seven-point Likert scales, with\nthe exception of \u201cunderstanding of AI, \u201d which was measured on\na scale of zero to ten. Spearman\u2019s rank (rs) and Kendall\u2019s tau-b (v)\ncorrelations between ordinal data were run using IBM SPSS R\u20dd\n(\n55). Responses which did not \ufb01t with the ordinal classi\ufb01cation\nof the data were recategorised as \u201cmissing\u201d before calculat ion,\nsuch as level of highest quali\ufb01cation option \u201cother\u201d and year s\u2019\nexperience options \u201cI do not work in the clinical setting\u201d and \u201c I\nam in retirement.\u201d Missing data were excluded pairwise, meani ng\nthat data could be included even if the respondent did not ente r\na response to some other question. Bootstrapping was activated\nfor 1,000 samples at 95% con\ufb01dence levels. Subgroup analysis\nwas then carried out to better understand the reason for any\nstatistically signi\ufb01cant correlations between ordinal data.\nChi-square test for independence was run for comparisons\nbetween nominal and ordinal data. In many cases, assumptions\nnecessary to allow accurate interpretation of the Pearson\u2019schi-\nsquare were found to be violated, so the \u201clikelihood ratio Ch i-\nsquare\u201d statistic was used as an alternative.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1751, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "4fb65a98-6a97-4d53-a423-51d232904636": {"__data__": {"id_": "4fb65a98-6a97-4d53-a423-51d232904636", "embedding": null, "metadata": {"page_label": "6", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "ddde90c3-b670-4525-ae1e-9a1da3042086", "node_type": "4", "metadata": {"page_label": "6", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "04bf986d66e91011015ee62c7033e973bab217a09cb156753d26b536d84a1292", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5cd5875e-44f2-4c28-9991-87329308be61", "node_type": "1", "metadata": {"page_label": "6", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "f7722cbf5747c6a46fa5f30ffc7f319e033bd047ca3fcebf5858ab56d69084d6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "21c86e4f-d084-4811-9a9f-0966078b0c3e", "node_type": "1", "metadata": {}, "hash": "b0fd7697ba209eb739817dc2785eb7c383dff49706db1945599b8b45e82bdda8", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "In many cases, assumptions\nnecessary to allow accurate interpretation of the Pearson\u2019schi-\nsquare were found to be violated, so the \u201clikelihood ratio Ch i-\nsquare\u201d statistic was used as an alternative. The likelihoo d ratio\ncompares the likelihood of obtaining the observed data compar ed\nto the likelihood of obtaining the data if there is no signi\ufb01c ant\ndi\ufb00erence in the variables, i.e., the data which would have\nbeen observed if there is no statistically signi\ufb01cant relationship\nbetween variables ( p \u2264 0.05) (\n56). Cramer\u2019s V (V) was then\nperformed to quantify the magnitude of any relationship.\nThe resultant cross tabulations were interrogated to ident ify\nany major di\ufb00erences between observed and expected counts\nwithin subgroups for signi\ufb01cant \ufb01ndings. Subgroup analysis\nwas then carried out to better understand the reason for any\nstatistically signi\ufb01cant correlations.\nThematic analysis using NVivo R\u20dd was performed to analyse\nqualitative responses (\n52). Responses to the open-ended question\n\u201cCan you describe the term Arti\ufb01cial Intelligence in your own\nwords?\u201d were read and coded. Codes were reread and collated\ninto four key themes.\nRESULTS\nDemographic Information\nCleaning of the data removed any blank responses from the\ninitial participants. A total of 415 radiographers responded to\nthe survey. Four participants selected the option of \u201cno consent, \u201d\nleaving 411 survey responses for analysis.\nOf the total respondents, 66.4% stated that they were\npractising diagnostic radiography ( n = 273), 14.4% were\ndiagnostic radiography students ( n = 59), 16.1% stated they\nwere practising therapeutic radiography ( n = 66), and 2.7% were\ntherapeutic radiography students ( n = 11). This calculated to an\napproximate 1:4 ratio of therapeutic: diagnostic radiographer s,\nwhich broadly represents the UK workforce ratio of 3,794\ntherapeutic to 20,231 diagnostic radiographers (\n57).", "mimetype": "text/plain", "start_char_idx": 1550, "end_char_idx": 3442, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "21c86e4f-d084-4811-9a9f-0966078b0c3e": {"__data__": {"id_": "21c86e4f-d084-4811-9a9f-0966078b0c3e", "embedding": null, "metadata": {"page_label": "6", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "ddde90c3-b670-4525-ae1e-9a1da3042086", "node_type": "4", "metadata": {"page_label": "6", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "04bf986d66e91011015ee62c7033e973bab217a09cb156753d26b536d84a1292", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4fb65a98-6a97-4d53-a423-51d232904636", "node_type": "1", "metadata": {"page_label": "6", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "45c4544fe9f55c7582e78d13629e36f045e612909ffa922864d22dd1e829fec8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b831a628-4982-477b-bec3-dd2f19cf7105", "node_type": "1", "metadata": {}, "hash": "77f013d07d777c0293e9f73acd537557336d7bfd1a8c06f1f3a4b8d64b534175", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "This calculated to an\napproximate 1:4 ratio of therapeutic: diagnostic radiographer s,\nwhich broadly represents the UK workforce ratio of 3,794\ntherapeutic to 20,231 diagnostic radiographers (\n57). The most\nrecent data from the HCPC, stated above, is not broken\ndown into diagnostic and therapeutic radiography (\n23). Two\nrespondents indicated they were practising both diagnostic an d\ntherapeutic radiography.\nThere were responses from throughout the regions of the UK\nwith the exception of therapeutic radiographers in the Channel\nIslands (Table 1).\nA range of years of experience was indicated in both diagnostic\nradiography and radiotherapy. Visual inspection would indicat e\nthere is a similar distribution amongst respondents in each\nprofession (Table 1).\nThere was representation across all age groups except for the\nover 65 years old group in radiotherapy ( Table 1).\nOf the diagnostic radiography respondents (including\nstudents), 26% indicated they were male, 72.2% female, 0.6%\nnon-binary/third gender, and 1.2% preferred not to say. This\nis similar to the radiotherapy respondents of whom 22.4%\nresponded that they were male and 77.6% female, which is\nbroadly representative of the UK radiographer workforce, which\nhas an approximate 1:3 ratio of male to female (\n47).\nHighest Academic Quali\ufb01cation\nFor both diagnostic radiography and therapeutic radiography,\nmost respondents indicated their highest level of academic\nquali\ufb01cation as a BSc, with 24.2 and 35.5%, respectively.\nThere were fewer diagnostic radiographers who have attained\na MSc (19.6 and 36.8%) or doctoral level quali\ufb01cation (e.g.,\nPh.D., Ed.D.) (1.9 and 3.9%) than therapeutic radiographers,\nrespectively. Those with A-level or equivalent are assumed to be\nstudent radiographers. This data is represented in full in Table 1.", "mimetype": "text/plain", "start_char_idx": 3245, "end_char_idx": 5048, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "b831a628-4982-477b-bec3-dd2f19cf7105": {"__data__": {"id_": "b831a628-4982-477b-bec3-dd2f19cf7105", "embedding": null, "metadata": {"page_label": "6", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "ddde90c3-b670-4525-ae1e-9a1da3042086", "node_type": "4", "metadata": {"page_label": "6", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "04bf986d66e91011015ee62c7033e973bab217a09cb156753d26b536d84a1292", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "21c86e4f-d084-4811-9a9f-0966078b0c3e", "node_type": "1", "metadata": {"page_label": "6", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "034f2146c80714204c199e3344c3e25fb97b4ec0dc8e5c9cf98f020c3b83d1fd", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "(1.9 and 3.9%) than therapeutic radiographers,\nrespectively. Those with A-level or equivalent are assumed to be\nstudent radiographers. This data is represented in full in Table 1.\nThose who selected \u201cother\u201d were asked for further explanatio n,\nwith the majority of the respondents across both professions\nstating they hold a Diploma of the College of Radiographers\n(DCR) (n = 7). Other responses included conversion degrees\nsuch as MRad ( n = 2), or other types of master\u2019s degrees such\nas MEd ( n = 1) and MA ( n = 2).\nClinical Setting\nThe greatest proportion of participants from both professions\nindicated that they work in university teaching hospitals, closely\nfollowed by the district general hospital setting. Full detail s of\nother responses are given in Table 1.\nFor those who responded \u201cother\u201d in therapeutic radiography,\ntwo stated they worked in a foundation trust, three in a specia list\ncancer centre, two were students, and one stated they were a\nuniversity lecturer. Most free text responses from the diagnostic\nradiography participants indicated that they worked in the\nuniversity setting as either an academic or researcher (n = 15),\nfollowed by responses from students ( n = 10).\nRole Description\nMost of those in clinical practise from both professions\nindicated that they were practising as a clinical radiographer\n(39.1 and 38.2%, diagnostic radiography and radiotherapy,\nrespectively), followed by those choosing the \u201cadvanced\nFrontiers in Digital Health | www.frontiersin.org 6 November 2021 | Volume 3 | Article 739327", "mimetype": "text/plain", "start_char_idx": 4869, "end_char_idx": 6412, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "4c8db16d-c9f9-4935-aaee-f60d563322da": {"__data__": {"id_": "4c8db16d-c9f9-4935-aaee-f60d563322da", "embedding": null, "metadata": {"page_label": "7", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "d1e98709-babe-4168-8e3d-b01d49bdae84", "node_type": "4", "metadata": {"page_label": "7", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "4cf06c270bbf89b2323ea94cd59aa6196d3ce5fd9f91381e2e0c4c46b33ae232", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "17828a4a-2f98-4535-93e3-619cd77fc02e", "node_type": "1", "metadata": {}, "hash": "13843ac5c644a405aa1a5964100da25aca6ac2bfcd9426a0c83e67fdd8120657", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Rainey et al. AI-Related Survey of UK Radiographers\nTABLE 1 | Respondents\u2019 demographic details presented as percentage s (%) and\nfrequencies (n).\nDiagnostic\nradiography\nTherapeutic\nradiography\nRegion of UK where\nrespondents\ncurrently work\nEngland 56.7 ( n = 183) 88.2 ( n = 67)\nScotland 30 ( n = 97) 9.2 ( n = 7)\nWales 1.9 ( n = 6) 1.3 ( n = 1)\nNorthern Ireland 11.1 ( n = 36) 1.3 ( n = 1)\nChannel Islands 0.3 ( n = 1) 0 ( n = 0)\nYears practising\nradiography\n0\u20132 years 22.7 ( n = 75) 23.4 ( n = 18)\n3\u20135 years 10.6 ( n = 35) 16.9 ( n = 13)\n6\u201310 years 13.9 ( n = 46) 11.7 ( n = 9)\n11\u201320 years 23.0 ( n = 76) 23.4 ( n = 18)\n>20 years 27.5 ( n = 91) 22.1 ( n = 17)\nNot practising 1.2 ( n = 4) 1.3 ( n = 1)\nRetired 1.3 ( n = 4) 1.3 ( n = 1)\nAge range 18\u201325 years old 19.3 ( n = 63) 23.7 ( n = 18)\n26\u201335 years old 28.4 ( n = 93) 26.3 ( n = 20)\n36\u201345 years old 27.2 ( n = 89) 25.0 ( n = 19)\n46\u201355 years old 12.5 ( n = 41) 18.4 ( n = 14)\n56\u201365 years old 11.3 ( n = 37) 6.6 ( n = 5)\n>65 years old 1.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 990, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "17828a4a-2f98-4535-93e3-619cd77fc02e": {"__data__": {"id_": "17828a4a-2f98-4535-93e3-619cd77fc02e", "embedding": null, "metadata": {"page_label": "7", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "d1e98709-babe-4168-8e3d-b01d49bdae84", "node_type": "4", "metadata": {"page_label": "7", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "4cf06c270bbf89b2323ea94cd59aa6196d3ce5fd9f91381e2e0c4c46b33ae232", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4c8db16d-c9f9-4935-aaee-f60d563322da", "node_type": "1", "metadata": {"page_label": "7", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "98f499b1f41339048207b5b956942d836bfbf920aee5d9df5d35df817022964d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e99e7c5a-2565-4d47-af8a-11c34e108d74", "node_type": "1", "metadata": {}, "hash": "b4953ddac02278dd39704d185c35d3e0b2142d923194a623b1d93b668ad58b17", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "5 ( n = 41) 18.4 ( n = 14)\n56\u201365 years old 11.3 ( n = 37) 6.6 ( n = 5)\n>65 years old 1.2 ( n = 4) 0 ( n = 0)\nHighest academic\nquali\ufb01cation\nA-level 14.9 ( n = 48) 11.8 ( n = 9)\nBSc 24.2 ( n = 78) 35.5 ( n = 27)\nPgCert 19.9 ( n = 64) 1.3 ( n = 1)\nPgDip 13.0 ( n = 42) 6.6 ( n = 5)\nMSc 19.6 ( n = 63) 36.8 ( n = 28)\nPhD/EdD/DProf or\nequivalent\n1.9 ( n = 6) 3.9 ( n = 3)\nOther 6.5 ( n = 21) 3.9 ( n = 3)\nClinical\nsetting/counts\n(respondents were\npermitted more than\none selection)\nUniversity teaching\nhospital\nn = 195 n = 50\nDistrict general\nhospital\nn = 103 n = 19\nPrivate sector n = 12 n = 2\nPoly-trauma unit n = 30 n = 0\nMobile unit n = 4 n = 0\nOther n = 14 n = 5\nI do not work in the\nclinical setting\nn = 25 n = 4\nCurrent role Assistant practitioner\nradiographer\n1.2 ( n = 4) 0 ( n = 0)\nUndergraduate\nradiography student\n19.6 ( n = 63) 13.2 ( n = 10)\nClinical radiographer 39.1 ( n = 126) 38.2 ( n = 29)\nResearch\nradiographer\n0.9 ( n = 3) 2.6 ( n = 2)\nAdvanced practitioner 15.8 ( n = 51) 17.1 ( n = 13)\nPh.D. researcher\nradiographer\n0.", "mimetype": "text/plain", "start_char_idx": 903, "end_char_idx": 1939, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "e99e7c5a-2565-4d47-af8a-11c34e108d74": {"__data__": {"id_": "e99e7c5a-2565-4d47-af8a-11c34e108d74", "embedding": null, "metadata": {"page_label": "7", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "d1e98709-babe-4168-8e3d-b01d49bdae84", "node_type": "4", "metadata": {"page_label": "7", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "4cf06c270bbf89b2323ea94cd59aa6196d3ce5fd9f91381e2e0c4c46b33ae232", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "17828a4a-2f98-4535-93e3-619cd77fc02e", "node_type": "1", "metadata": {"page_label": "7", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "22e4b780a5cbd5bb23f8cd97d1744e9b3f6020d0ab732bca6ff1151443622d64", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "44fbce5c-c656-44c8-a6dc-98f424dcfd5f", "node_type": "1", "metadata": {}, "hash": "e2353a2bdf4ba16cd7417104c59df07a64d4043709a2c502f2d7c8437e58bab3", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "6 ( n = 2)\nAdvanced practitioner 15.8 ( n = 51) 17.1 ( n = 13)\nPh.D. researcher\nradiographer\n0.6 ( n = 2) 0 ( n = 0)\n(Continued)\nTABLE 1 | Continued\nDiagnostic\nradiography\nTherapeutic\nradiography\nOther 3.1 ( n = 10) 6.6 ( n = 5)\nAcademic in\nradiography: teaching\nonly\n0.9 ( n = 3) 1.3 ( n = 1)\nIndustry partner 0.3 ( n = 1) 1 ( n = 0)\nConsultant\nradiographer\n4.3 ( n = 14) 13.2 ( n = 10)\nClinical\nacademic/Lecturer:\npractitioner\n3.1 ( n = 10) 1.3 ( n = 1)\nRadiology/\nRadiographer/\nRadiotherapy\nmanager\n6.2 ( n = 20) 6.6 ( n = 5)\nRetired radiographer 0.9 ( n = 3) 0 ( n = 0)\nAcademic in\nradiography: teaching\nand research\n3.7 ( n = 12) 0 ( n = 0)\nDiagnostic\nradiographysub-\nspecialism/counts\n(respondents were\npermitted more than\none selection)\nGeneral radiography\nincluding emergency,\ntheatre, and\n\ufb02uoroscopy\nn = 207\nMammography n = 32\nMRI n = 56\nCT n = 100\nUltrasound n = 25\nInterventional n = 44\nPET/CT n = 3\nPET/MRI n = 1\nDEXA/DXA n = 5\nReporting n = 63\nRadiology manager n = 20\nPACS administrator n = 9\nEducation n = 54\nPolicy\nmaker/professional\nadvocate\nn = 11\nOther (diagnostic) n = 22\nTherapeutic\nradiographysub-\nspecialism/counts\n(respondents were\npermitted more than\none selection)\nPre-treatment,", "mimetype": "text/plain", "start_char_idx": 1844, "end_char_idx": 3049, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "44fbce5c-c656-44c8-a6dc-98f424dcfd5f": {"__data__": {"id_": "44fbce5c-c656-44c8-a6dc-98f424dcfd5f", "embedding": null, "metadata": {"page_label": "7", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "d1e98709-babe-4168-8e3d-b01d49bdae84", "node_type": "4", "metadata": {"page_label": "7", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "4cf06c270bbf89b2323ea94cd59aa6196d3ce5fd9f91381e2e0c4c46b33ae232", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e99e7c5a-2565-4d47-af8a-11c34e108d74", "node_type": "1", "metadata": {"page_label": "7", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "fc11eef6aaae08ae4bfd8f8a22c103125430821a2437811af7a7c8f0558ccd0f", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "simulation, contouring,\nimmobilisation\nn = 35\nTreatment planning n = 15\nTreatment delivery n = 54\nPatient\ninformation/support/review\nn = 23\nEducator n = 7\nResearch n = 7\nManagement n = 10\nQuality\nassurance/Quality\nimprovement\nn = 7\nDEXA/DXA clinical\napplications\nn = 0\nOther (therapeutic) n = 7\nFrontiers in Digital Health | www.frontiersin.org 7 November 2021 | Volume 3 | Article 739327", "mimetype": "text/plain", "start_char_idx": 3050, "end_char_idx": 3438, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "2726fcf8-e00a-4887-814b-efd62ac169ac": {"__data__": {"id_": "2726fcf8-e00a-4887-814b-efd62ac169ac", "embedding": null, "metadata": {"page_label": "8", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "4b54fbc9-05a8-4ebd-97df-cc37d32d7c73", "node_type": "4", "metadata": {"page_label": "8", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "d39c951cdb80db32195f66716fcfdcd1719468cebfdd86cf5fdeb4ce54bf23ae", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9f5eb2a2-a250-44a7-ad4b-a9d6cfffc8b1", "node_type": "1", "metadata": {}, "hash": "0442d2e04b2d1e5ce0406b6b137a6d54bd36ee9bd822c2e62b8c08953b1dc30a", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Rainey et al. AI-Related Survey of UK Radiographers\npractitioner\u201d option (15.8% and 17.1%, diagnostic radiography\nand therapeutic radiography, respectively). There are fewer\nconsultant radiographers responding to this survey in diagnostic\nthan therapeutic radiography (4.3 and 13.2%, respectively),\nalthough it should be noted that there were more options\navailable for the diagnostic radiography respondents. This was\nto best re\ufb02ect the speci\ufb01c career landscape in both professions\n(Table 1).\nArea of Expertise/Sub-Specialism\nRespondents were given the option of selecting up to three\noptions from the list, along with a free-text option for\nfurther explanation. Most diagnostic radiographers indicated\nthat they were involved in general radiography (32%) followed\nby CT (15%), followed closely by those working in reporting,\nMRI and education. The responses from respondents in the\nradiotherapy cohort indicated that the majority were involved in\ntreatment delivery (33%), followed by pre-treatment, simula tion,\ncontouring, and immobilisation (21%) ( Table 1).\nFrom those who selected \u201cother\u201d in diagnostic radiography,\nmost responses were cardiac catheterisation ( n = 4) and nuclear\nmedicine ( n = 3). Radiotherapy respondents indicated areas\nof sub-specialism in breast cancer ( n = 1), research ( n = 1),\nstereotactic radiosurgery ( n = 1), and Information management\nand technology ( n = 1).\nPerceived Knowledge, Skills, and\nCon\ufb01dence in AI\nAn understanding of perceived knowledge, skills and con\ufb01dence\nin AI was sought through an open question, asking respondents\nto describe the term \u201carti\ufb01cial intelligence\u201d in their own words\nand a number of Likert-scale questions.\nUnderstanding of the Term \u201cArti\ufb01cial Intelligence\u201d\nResponses were initially coded using thematic analysis for each\nof the professions, resulting in 21 codes ( Supplementary Table 1;\nSupplementary Figure 1 ). Most codes were common across both\nprofessions ( Supplementary Figure 2 ).", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1960, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "9f5eb2a2-a250-44a7-ad4b-a9d6cfffc8b1": {"__data__": {"id_": "9f5eb2a2-a250-44a7-ad4b-a9d6cfffc8b1", "embedding": null, "metadata": {"page_label": "8", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "4b54fbc9-05a8-4ebd-97df-cc37d32d7c73", "node_type": "4", "metadata": {"page_label": "8", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "d39c951cdb80db32195f66716fcfdcd1719468cebfdd86cf5fdeb4ce54bf23ae", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2726fcf8-e00a-4887-814b-efd62ac169ac", "node_type": "1", "metadata": {"page_label": "8", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "9ba43bc3ac3704130b849b5b09f88b8656f737dd11a4d7f7651920b495acd7d2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "22613f8c-2fee-4a7d-ab61-63667f9d4efe", "node_type": "1", "metadata": {}, "hash": "1bb0e1046e3ecfec2ccf15f34852c5ddfbba07f29d5f8908d6053ecd9dd97687", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Most codes were common across both\nprofessions ( Supplementary Figure 2 ). Four general themes\nemerged from thematic analysis: (i) clinical applications of AI,\n(ii) advantages of AI, (iii) disadvantages of AI, (iv) techn ical\ninformation of AI technology ( Supplementary Table 1).\nThe top three most frequent codes in the responses from the\ndiagnostic radiographers\u2019 cohort included:\n(i) understanding of AI as used in the identi\ufb01cation of\npathology or abnormality (clinical applications), for\nexample the following quotes are presented as relevant;\n\u201creporting, without a practitioner looking at the \ufb01lm. Used\nto detect cancers. . . \u201d\n\u201c. . . report diagnostic images\u201d\n(ii) statements regarding the AI tasks which would normally\nrequire human input for example, the following quotes are\npresented as relevant;\n\u201c. . . automated use of computers to perform human tasks.\u201d\n\u201c. . . computer algorithms performing tasks that usually rely\non human interaction.\u201d\n(iii) comments with evidence of deeper understanding of\n\u201cmodern\u201d AI systems, such as descriptions of systems which\nlearn from example and \u201ccomputer vision\u201d for example the\nfollowing quotes are presented as relevant;\n\u201c...machine learning.\u201d\n\u201c. . . can be programmed to develop themselves on their\nown writing their own code, developer might even cease to\nunderstand the code.\u201d\nThe top three codes from the therapeutic radiographers\u2019\nresponses were similar, with the majority of comments\nrelating to:\n(i) changing radiography work\ufb02ows (AI replacing or\naugmenting tasks which require human input) for\nexample the following quotes are presented as relevant;\n\u201c. . . the use of technology, reporting, and verify systems,\ntreatment planning systems to support patient pathway.\u201d\n(ii) technical description of \u201cmodern\u201d AI systems, for example\nthe following quotes are presented as relevant:\n\u201c. . . use of computer algorithms to do mundane tasks e.g.,\noutlining organs at risk (OAR).\u201d\n\u201cThe use of complex interconnecting self-designing\nalgorithms to achieve a speci\ufb01c outcome. . .", "mimetype": "text/plain", "start_char_idx": 1886, "end_char_idx": 3908, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "22613f8c-2fee-4a7d-ab61-63667f9d4efe": {"__data__": {"id_": "22613f8c-2fee-4a7d-ab61-63667f9d4efe", "embedding": null, "metadata": {"page_label": "8", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "4b54fbc9-05a8-4ebd-97df-cc37d32d7c73", "node_type": "4", "metadata": {"page_label": "8", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "d39c951cdb80db32195f66716fcfdcd1719468cebfdd86cf5fdeb4ce54bf23ae", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9f5eb2a2-a250-44a7-ad4b-a9d6cfffc8b1", "node_type": "1", "metadata": {"page_label": "8", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "2c55e50dac17f642070c798ba149878babc98604b82dec04027ad969408b1165", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": ". use of computer algorithms to do mundane tasks e.g.,\noutlining organs at risk (OAR).\u201d\n\u201cThe use of complex interconnecting self-designing\nalgorithms to achieve a speci\ufb01c outcome. . . \u201d\n(iii) clinical applications of AI in radiotherapy, such as\nsegmentation, planning, and/or contouring. The following\nquotes are presented as relevant:\n\u201cAutomated RT planning to standardise planning\u201d\n\u201cUsing software algorithms to calculate/determine\noutcomes previously determined manually, such\nas auto-contouring. . . \u201d\nFinally there were very few comments regarding the\ndisadvantages of AI systems in both professions, with only\ntwo comments from diagnostic radiography and one from the\ntherapeutic radiography cohort. A representative quote from the\ndiagnostic radiography is noted below:\n\u201cIts current role is very \u2018task dependent\u2019 and limited as it\nstruggles to understand poor quality images, artefacts, or\nnormal variants, or post-surgery image appearances, often\nit is classed the \u2018next best thing\u2019 but most likely it is the new\n\u2018emperors clothing\u201d\u2019\nAnother representative comment was o\ufb00ered by the\nradiotherapy respondents:\n\u201cHuman reliance on technology. . . create(s) more work to\nme at work for simple decision-making process.\u201d\nPerceived Knowledge and Understanding of AI\nTerminology\nExamples of terms associated with modern AI technology\nand development were provided in the question represented\ninFigure 1\u2014algorithms, deep learning, neural networks,\ncomputer-aided detection diagnosis, data mining, and over-\n\ufb01tting. The results demonstrate that 42.3% of diagnostic\nradiography and 50% of radiotherapy respondents\nwere not con\ufb01dent at all in the terminology used\nin AI.\nFrontiers in Digital Health | www.frontiersin.org 8 November 2021 | Volume 3 | Article 739327", "mimetype": "text/plain", "start_char_idx": 3725, "end_char_idx": 5485, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "52816838-5504-4684-9390-a9c8062c1a09": {"__data__": {"id_": "52816838-5504-4684-9390-a9c8062c1a09", "embedding": null, "metadata": {"page_label": "9", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "0c032fed-74ec-416f-8aed-9a47cf07898c", "node_type": "4", "metadata": {"page_label": "9", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "df0c97cb85e513f5fd4a370b506c341529eba2d046e90634111a5986789ee7ed", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Rainey et al. AI-Related Survey of UK Radiographers\nFIGURE 1 | Respondents\u2019 understanding of the terminology of modern AI.\nFIGURE 2 | Development of skill in AI.\nDevelopment of Skill in AI\nMost of both diagnostic radiography and radiotherapy\nrespondents indicated that they do not feel they have developed\nany skill in AI used in radiography (51.6 and 64.0% of total\nresponses, respectively) (Figure 2). Out of the other options\npresented, the majority in both professions indicated that an y\nskill has been developed from their own, self-directed learn ing\n(21.0%). In both professions, the fewest responses came from th e\n\u201cCPD in a higher education establishment\u201d option. The \u201cother \u201d\noption was selected by 40 respondents over the two professions.\nThe diagnostic radiography respondents indicated that they have\nundertaken assignments or dissertations in AI ( n = 8), have read\naround the subject or taken online courses ( n = 4), have had\nequipment training or in house training ( n = 4), contributed to\na research project conducted by someone else ( n = 3), listened\nto presentations at conferences ( n = 3), or had some form of\nAI training integrated into a postgraduate quali\ufb01cation ( n = 3).\nThe radiotherapy comments included, workplace/applications\ntraining or through current use (n = 4), knowledge from a\nprevious career ( n = 1), and one respondent stated that they\nwork for an AI company.\nCon\ufb01dence in Using AI in Radiography\nMore of the diagnostic radiography respondents indicated\nthat they understood the term AI than the radiotherapy\nrespondents (yes, no, unsure) (78.7 and 52.1%, respectively)\nFrontiers in Digital Health | www.frontiersin.org 9 November 2021 | Volume 3 | Article 739327", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1706, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "47ca947a-0d22-47a0-8b2f-b2390af5fc0f": {"__data__": {"id_": "47ca947a-0d22-47a0-8b2f-b2390af5fc0f", "embedding": null, "metadata": {"page_label": "10", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "91470221-06ff-482c-8ce7-889eb870df07", "node_type": "4", "metadata": {"page_label": "10", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "9a95922d6553d49538abcc4fecce0bfb500d5ff3dd7c7e6cc113ea8fb3ebdb31", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "38269845-35b4-43fb-bcab-8dccea5c4519", "node_type": "1", "metadata": {}, "hash": "9aecd8538d9ef303849a735e70157a764b1a5803eede1b03a294293cfc15728d", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Rainey et al. AI-Related Survey of UK Radiographers\nFIGURE 3 | Respondents\u2019 perception of understanding of the term \u201carti \ufb01cial intelligence\u201d [(A), diagnostic radiography, (B) therapeutic radiography].\nFIGURE 4 | Respondents\u2019 perceived con\ufb01dence in using AI technologies.\n(Figures 3A,B), although a slightly smaller percentage of\ndiagnostic radiographers stated that they felt con\ufb01dent in u sing\nAI technologies in radiography, compared to the radiotherapy\nresponses (28.2 and 33.8% con\ufb01dent or very con\ufb01dent,\nrespectively) (Figure 4). Respondents from both professions\nindicated a moderate understanding of AI and asked to rate\nit using a 0 to 10 scale, with 0 representing no knowledge at\nall and 10 representing \u201cexpert.\u201d A mean response of 5.5 and\n4.5 (0\u201310 scale) was reported for diagnostic radiography and\nradiotherapy, respectively.\nPerceived Acquired Skills in AI and Training\nto Support These Skills\nQuestions were posed to respondents regarding their perceived\nlevel of skill in AI, how they have developed this skill, the nature\nof any training they have received and how prepared they feel\ntheir skills or training has made them for the implementationof\nAI in the clinical setting.\nPerception of Availability of AI Training for\nRadiographers (Generic)\nThe majority of respondents from both professions either\ndisagree or strongly disagree with this statement, with a\n\u201cdisagreement\u201d aggregate (somewhat disagree, disagree, and\nstrongly disagree) of 77.4 and 73.9% and an agreement aggreg ate\n(somewhat agree, agree, and strongly agree) of only 6.7 and\n6.1% for diagnostic and therapeutic radiography, respectively\n(Figure 5).\nPerception of Adequacy of Training Provisions for AI\nImplementation\nBoth professions indicated they did not feel well-\ntrained to implement new technologies and AI,\nwith over half (56.5%) of diagnostic radiography\nrespondents indicating they either disagreed or\nstrongly disagreed with this statement. This proportion\nwas only slightly lower for radiotherapy (49.2%)\n(Figure 6).", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2016, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "38269845-35b4-43fb-bcab-8dccea5c4519": {"__data__": {"id_": "38269845-35b4-43fb-bcab-8dccea5c4519", "embedding": null, "metadata": {"page_label": "10", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "91470221-06ff-482c-8ce7-889eb870df07", "node_type": "4", "metadata": {"page_label": "10", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "9a95922d6553d49538abcc4fecce0bfb500d5ff3dd7c7e6cc113ea8fb3ebdb31", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "47ca947a-0d22-47a0-8b2f-b2390af5fc0f", "node_type": "1", "metadata": {"page_label": "10", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "f47808937fec67a65e784235d2dfd71b62181f01c0b88c640ffbb6cfda570d98", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "This proportion\nwas only slightly lower for radiotherapy (49.2%)\n(Figure 6).\nFrontiers in Digital Health | www.frontiersin.org 10 November 2021 | Volume 3 | Article 739327", "mimetype": "text/plain", "start_char_idx": 1940, "end_char_idx": 2111, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "2298167c-0cf2-4d72-b0ad-5ddc3ec50dfd": {"__data__": {"id_": "2298167c-0cf2-4d72-b0ad-5ddc3ec50dfd", "embedding": null, "metadata": {"page_label": "11", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "9385da6c-c575-4c4b-bc41-8e08c17a3d81", "node_type": "4", "metadata": {"page_label": "11", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "a5c953c4e60f8ef9a3c2344043d35a2890c894539ed2f5c3f5902a1686765c44", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Rainey et al. AI-Related Survey of UK Radiographers\nFIGURE 5 | Perception of AI training availability for radiographers.\nFIGURE 6 | Perception of \u2018adequacy of radiographers\u2019 AI training for c linical implementation.\nPerception of Skill Acquisition in AI Clinical\nApplications\nAn aggregate of responses in the disagree categories (somewhat\ndisagree, disagree, and strongly disagree) and agree categ ories\n(somewhat agree, agree, and strongly agree) from respondent s\nin both professions indicate that they did not feel they had\ndeveloped skill in AI, with \u201cdisagree\u201d in diagnostic radiography\nbeing higher than \u201cagree\u201d (54.2 vs. 30.3%). This is similar to the\nradiotherapy responses (50.8 vs. 27.7%) ( Figure 7).\nFuture Training Content and Format on\nAI-Enabled Technologies\nTo determine the type of training and education requirements\nneeded in radiography, two questions were asked. One question\nsought to gather information on the content of any training\u2014\nwhat topic areas radiographers felt should be included in any\ntraining delivered, and another question on how or in what\nformat this training might be best delivered in.\nTopic Areas Needed for Training\nMost respondents from both professions indicated that they\nwere interested in learning about potential applications of AI\nand AI technology, techniques, and terminology. Programming\nand computer science and AI development and entrepreneurship\nwere not popular choices (Figure 8). The \u201cother\u201d option was\nchosen by 16 respondents from the diagnostic radiography\ncohort and mostly included comments suggesting uncertainty\nFrontiers in Digital Health | www.frontiersin.org 11 November 2021 | Volume 3 | Article 739327", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1673, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "8245ff4d-8f14-464d-97e1-4b3260a404cb": {"__data__": {"id_": "8245ff4d-8f14-464d-97e1-4b3260a404cb", "embedding": null, "metadata": {"page_label": "12", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "28648416-88b7-4171-88cf-8bcec594df5c", "node_type": "4", "metadata": {"page_label": "12", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "827176e0922de10f8b3587b5f758be7ac59f3b7eb23ff2fcd85463b7f7ac42a8", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Rainey et al. AI-Related Survey of UK Radiographers\nFIGURE 7 | Perceptions of having developed/learned some skill in AI.\nFIGURE 8 | AI education topic preferences.\naround what should be included. Two comments suggested that\nit is too early to consider any education in AI.\nTraining Format Preferences\nMost respondents indicated that training would be best\ndelivered as part of a preregistration degree programme. E-\nlearning/webinars and study days also received a high proportion\nof the total responses. All options were selected by some\nrespondents (minimum respondent frequencyn = 92 counts)\n(Figure 9). Eight diagnostic radiography respondents selected\nthe \u201cother\u201d option. Suggestions included; annual CPD days fo r\nquali\ufb01ed sta\ufb00 and summer schools for pre and post registration\nradiographers to allow time for this training to take place in an\nalready busy academic year.\nCOMPARISONS\nOrdinal vs. Ordinal Comparisons\nA selection of ranked variables (ordinal data) were compared\nusing Spearman\u2019s rho (rs) and Kendall\u2019s tau ( v) to identify\nFrontiers in Digital Health | www.frontiersin.org 12 November 2021 | Volume 3 | Article 739327", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1137, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "1ea2b8db-17d4-48bc-a4e0-3420605b79fd": {"__data__": {"id_": "1ea2b8db-17d4-48bc-a4e0-3420605b79fd", "embedding": null, "metadata": {"page_label": "13", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "b9068d91-e1f4-44f8-973f-cce4d54198dc", "node_type": "4", "metadata": {"page_label": "13", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "4767edd0ca71e0c593f6adf65de7f55e526686d63dceb3abc108546d2d1fff52", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ae94bd68-8960-4a33-a289-66e0d9e447dd", "node_type": "1", "metadata": {}, "hash": "48f904909a94e9da3350dfdfe7ce4db0c26632be6a5970cba696bf3d712587d3", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Rainey et al. AI-Related Survey of UK Radiographers\nFIGURE 9 | Training delivery preferences.\nany correlations. The results are presented in full in\nSupplementary Table 2. There was only one combination\nof variables which produced statistically signi\ufb01cant resul ts in\nboth professions i.e., the relationship between highest lev el of\nacademic quali\ufb01cation and understanding of AI on a scale of\n0\u201310, where a medium strength positive correlation was found\nin both professions (\n54). Sub-group analysis revealed that for\nboth the diagnostic and therapeutic responses, there was a\ngeneral downward trend in the lower rating of con\ufb01dence (i.e.,\nscoring 0\u20133) as level of academic quali\ufb01cation increased, w ith\nthe reverse apparent for the higher ratings of con\ufb01dence (i.e. ,\nscore of 7\u201310), i.e., as level of highest academic achieveme nt\nincreased, the number of respondents reporting higher levels\nof con\ufb01dence increased. This data is presented in full in\nSupplementary Tables 3\u20136.\nIn the diagnostic radiography responses, there was also\na signi\ufb01cant positive relationship between highest level of\nacademic quali\ufb01cation and con\ufb01dence in AI terminology (rs\n= 0.151, v = 0.218, n = 271, p = 0.05), but this was not\nthe case in the radiotherapy cohort. Further analysis of the\ngroups reveals that very few respondents across all categories are\nvery con\ufb01dent, or con\ufb01dent enough and a general downward\ntrend in the \u201cnot con\ufb01dent at all\u201d selection, i.e., as level of\nhighest academic quali\ufb01cation increased, from undergradu ate to\nPh.D./Ed.D./D.Prof. or equivalent, the proportion of respond ents\nindicating that they were \u201cnot con\ufb01dent at all, \u201d decreased\n(Supplementary Table 7).", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1673, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "ae94bd68-8960-4a33-a289-66e0d9e447dd": {"__data__": {"id_": "ae94bd68-8960-4a33-a289-66e0d9e447dd", "embedding": null, "metadata": {"page_label": "13", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "b9068d91-e1f4-44f8-973f-cce4d54198dc", "node_type": "4", "metadata": {"page_label": "13", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "4767edd0ca71e0c593f6adf65de7f55e526686d63dceb3abc108546d2d1fff52", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1ea2b8db-17d4-48bc-a4e0-3420605b79fd", "node_type": "1", "metadata": {"page_label": "13", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "c883fd918ad5f464280ab2fa8a8f9379c4078739fc76778c0135e9100cfacd1c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c592916b-bb28-414c-b334-9d97a75633a7", "node_type": "1", "metadata": {}, "hash": "bd798a8541f4b3b6fa26521d699243478c87eb594ce0b3148025119278c03348", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "or equivalent, the proportion of respond ents\nindicating that they were \u201cnot con\ufb01dent at all, \u201d decreased\n(Supplementary Table 7).\nAdditionally, a signi\ufb01cant, medium strength positive\nassociation ( rs = 0.417, v = 0.313, n = 71, p = 0.01) was found\nin the radiotherapy responses between age and understanding\nof AI (scale 0\u201310) and respondents\u2019 years\u2019 experience and\nunderstanding of AI (scale 0\u201310) (rs = 0.437, v = 0.332, n =\n70, p = 0.01). This was not mirrored in the data obtained from\nthe diagnostic radiography responses ( Supplementary Table 2).\nVisual analysis of the subgroup data indicates that, there wa s a\ngeneral downward trend in the lower rating of con\ufb01dence (i.e .,\nscoring 0\u20133) as both age category and years practising increa sed,\nwith the exception of the 55\u201365 years age group, as demonstrated\nfully inSupplementary Tables 8\u201311.\nThere was no signi\ufb01cant correlation in any of the\nother comparisons.\nNominal vs. Ordinal Comparisons\nThere were no associations found between variables in the\nmajority of tests, presented in full inSupplementary Table 12.\nThere were four tests in diagnostic radiography and three\ntests in radiotherapy which showed a signi\ufb01cant relationship\nbetween variables.\nIn both professions there was a statistically relationship\nbetween gender and the con\ufb01dence in AI terminology, with a\nmedium and large magnitudes in diagnostic radiography and\ntherapeutic radiography, respectively.", "mimetype": "text/plain", "start_char_idx": 1543, "end_char_idx": 2968, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "c592916b-bb28-414c-b334-9d97a75633a7": {"__data__": {"id_": "c592916b-bb28-414c-b334-9d97a75633a7", "embedding": null, "metadata": {"page_label": "13", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "b9068d91-e1f4-44f8-973f-cce4d54198dc", "node_type": "4", "metadata": {"page_label": "13", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "4767edd0ca71e0c593f6adf65de7f55e526686d63dceb3abc108546d2d1fff52", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ae94bd68-8960-4a33-a289-66e0d9e447dd", "node_type": "1", "metadata": {"page_label": "13", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "47e14c1ca07a8a9d51e5f14da2542c3b2d9c5c91be8b5e15721da3e1d3f18a9f", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "In both professions there was a statistically relationship\nbetween gender and the con\ufb01dence in AI terminology, with a\nmedium and large magnitudes in diagnostic radiography and\ntherapeutic radiography, respectively.\nAdditionally, in diagnostic radiography, the \u201clikelihood C hi-\nsquared test\u201d showed a signi\ufb01cant relationship between:\n(i) gender and con\ufb01dence in using AI technologies a\nmedium association strength, where male respondent\nreport greater perceived con\ufb01dence than females\n(Supplementary Table 12),\n(ii) gender and con\ufb01dence in the terminology of AI with a\nmedium association strength, where male respondent\nreport greater perceived con\ufb01dence than females\n(Supplementary Table 12),\n(iii) radiographers\u2019 role and their perceptions of the adequac y\nof training available, with a medium association\nstrength, where perceptions of adequacy of training\nwas lowest in the student radiographer responses\n(Supplementary Table 12), and\nFrontiers in Digital Health | www.frontiersin.org 13 November 2021 | Volume 3 | Article 739327", "mimetype": "text/plain", "start_char_idx": 2754, "end_char_idx": 3787, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "e738d045-f56d-4b27-b3e0-f26272c079ca": {"__data__": {"id_": "e738d045-f56d-4b27-b3e0-f26272c079ca", "embedding": null, "metadata": {"page_label": "14", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "eb2d3c6b-4c1f-4771-936a-acdb71e35049", "node_type": "4", "metadata": {"page_label": "14", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "c185a927411f7b9f4f7aed43f564769a66ea502de404172bb7b0c4890df44220", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0e4399ed-9517-4375-ba41-512af0d3081e", "node_type": "1", "metadata": {}, "hash": "4dfcca25ce47690f62e57e5007fd8a17d7b872b2426d435e858ca44cfeb11105", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Rainey et al. AI-Related Survey of UK Radiographers\n(iv) UK region and con\ufb01dence in AI terminology with a\nsmall association strength, with no apparent pattern\n(Supplementary Table 12).\nIn radiotherapy, signi\ufb01cant relationships were found to\nexist between:\n(i) gender and understanding of AI with large association\nstrength, where male respondent report greater perceptions\nof understanding than females (Supplementary Table 12),\n(ii) gender and con\ufb01dence in the terminology of AI, where\nmale respondent report greater perceived con\ufb01dence than\nfemales (likelihood ratio with a large association strength;\nSupplementary Table 12),\n(iii) radiographers\u2019 role and understanding of AI with large\nassociation strength, where perceptions of understanding\nwas lowest in the student radiographer responses\n(Supplementary Table 12).\nDISCUSSION\nThe focus of this survey was to establish a \u201csnapshot\u201d of\nUK radiographers\u2019 perceived knowledge, skills and con\ufb01dence\nin AI and to establish the speci\ufb01c detail of the educational\nneed and preferences of this workforce, in line with AI\nradiography guidance and priorities (\n43). Furthermore, as an\nexploratory study it would help provide direction for future\ntargeted AI research projects in the under-researched \ufb01eld\nof radiography.\nPerceived Knowledge, Understanding, and\nCon\ufb01dence\nAlthough a large proportion of both professions indicated\nthat they understood AI in general, further speci\ufb01c responses\nfrom both professions made it clear that respondents were\nnot very con\ufb01dent when using AI technologies. There was\nalso a lack of understanding of the speci\ufb01c terminologies used\nin modern AI, such as \u201calgorithms, \u201d \u201cdeep learning, \u201d \u201cdata\nmining, \u201d \u201cover-\ufb01tting, \u201d and \u201cneural networks\u201d (Figure 1). This\nmay indicate that, perhaps, initial reported \u201ccon\ufb01dence\u201d was\nsurrounding AI in general rather than AI in radiography\nand modern AI. Abuzaid et al.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1885, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "0e4399ed-9517-4375-ba41-512af0d3081e": {"__data__": {"id_": "0e4399ed-9517-4375-ba41-512af0d3081e", "embedding": null, "metadata": {"page_label": "14", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "eb2d3c6b-4c1f-4771-936a-acdb71e35049", "node_type": "4", "metadata": {"page_label": "14", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "c185a927411f7b9f4f7aed43f564769a66ea502de404172bb7b0c4890df44220", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e738d045-f56d-4b27-b3e0-f26272c079ca", "node_type": "1", "metadata": {"page_label": "14", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "d55f4327ff59e37b546c551b0ba66703bf81ec0b93817c9b14088e517fb97145", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "23e20188-4ed8-4f40-88bc-122a700e77c1", "node_type": "1", "metadata": {}, "hash": "876ea73f0d1efdd053498d3910b73b3b23cf45f7058f75692a82b2cf7faec3e9", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "This\nmay indicate that, perhaps, initial reported \u201ccon\ufb01dence\u201d was\nsurrounding AI in general rather than AI in radiography\nand modern AI. Abuzaid et al. (\n35) surveyed radiographers\nand radiologists in the United Arab Emirates (UAE) and\nfound that 40% of respondents were not familiar with\nAI and a further 30% had merely a basic understanding.\nOther studies also report that there is a general lack of\nunderstanding of AI amongst radiologists (\n58, 59). The\nknowledge and understanding of AI at this level of detail is\nessential when engaging with literature around modern AI\n(\n60). Many applications of AI in medicine are currently in\nthe development stage and therefore it is imperative for all\nclinicians to understand the literature in order to have a critical\nappreciation of the \u201cpotentials, pitfalls, and risks\u201d of proposed\ntechnology as we move into the inevitable implementation\nphase (\n6).\nLevel of Skill and Importance of Education\nand Training\nA barrier to clinicians\u2019 con\ufb01dence and understanding may bethe\ndearth of education on the subject, with many radiographers i n\nboth diagnostic and therapeutic radiography stating that the y do\nnot consider themselves to have any skill in AI. Botwe et al. (\n36)\nconducted a survey of African radiographers on their perceptio n\nof AI in diagnostic imaging and reported that 82.2% of 151\nrespondents felt that a lack of knowledge will be a signi\ufb01cant\nbarrier to the implementation of AI in the clinical setting.\nThis is supported by the responses from our survey indicating\nthat very few respondents felt that they were well-trained to\nimplement AI and new technologies in the clinical setting and\nwhy both professions overwhelmingly agree that there is not\nenough education and training available in AI for radiographers\n(Figure 5). Abuzaid et al.", "mimetype": "text/plain", "start_char_idx": 1734, "end_char_idx": 3535, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "23e20188-4ed8-4f40-88bc-122a700e77c1": {"__data__": {"id_": "23e20188-4ed8-4f40-88bc-122a700e77c1", "embedding": null, "metadata": {"page_label": "14", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "eb2d3c6b-4c1f-4771-936a-acdb71e35049", "node_type": "4", "metadata": {"page_label": "14", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "c185a927411f7b9f4f7aed43f564769a66ea502de404172bb7b0c4890df44220", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0e4399ed-9517-4375-ba41-512af0d3081e", "node_type": "1", "metadata": {"page_label": "14", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "048ee4b217b6b23b753df6928eea743521b440e218a9640030f35f3360ad88fe", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "32762e5a-be01-421a-beba-d919b624ae58", "node_type": "1", "metadata": {}, "hash": "bd17d636bf175db80e4c47b8b9c709cb0241781d4ec458238155b90bc8cd7686", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Abuzaid et al. (\n35) further support this in their survey\nof radiographers and radiologists in the UAEs, reporting that\n74.5% of radiographers and radiologists responding to their\nsurvey had not studied AI as part of their degree, that 73.9%\nindicating that the availability of education and trainingwill be\na barrier to the implementation of AI and that 68.6% of clinical\nsta\ufb00 lack even a basic understanding of the technology.\nAs radiography is an evidence-based, applied science\nprofession our day-to-day learning is supported formally, and\ninformally, through our clinical placement and later on clinical\nroles (\n61). This is evidenced by the number of respondents,\nwho reported that, despite not always having been formally\ntrained, they did have some skill in AI, indicating that theyhad\nto seek out their own learning ( Figure 2) and that AI has started\nto permeate radiography practise. Abuzaid et al. (\n35) concur,\nwith 39.9% of respondents to their survey being self-taught i n\nAI. Radiographers tend to learn to work with the tools which\nare introduced into the clinical setting, perhaps without the\ntime or resources to fully understand the technology (\n62). This\nmay have implications when newer, more complex forms of AI\nare introduced, which need to be approached more critically\ndue to complex systems architectures and whose method of\ndecision making are not so humanly interpretable (\n2, 15, 38).\nBeing in position to know the theory behind the practise will\nenable healthcare professionals and radiographers to query,\ufb02ag,\nescalate, and troubleshoot concerns in the functionality o f AI\necosystems and intervene, as and when needed, with human\nintelligence, for the safety of the patients.\nSuggestions for the Type and Format of AI\nLearning\nThe radiographers responding to the survey indicate they wish\nto have education on potential AI applications, technology\n(technique and terminology), patient centeredness with AI,\nAI ethics, AI standards (quality assurance and control), and\nwork\ufb02ow improvements.", "mimetype": "text/plain", "start_char_idx": 3521, "end_char_idx": 5542, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "32762e5a-be01-421a-beba-d919b624ae58": {"__data__": {"id_": "32762e5a-be01-421a-beba-d919b624ae58", "embedding": null, "metadata": {"page_label": "14", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "eb2d3c6b-4c1f-4771-936a-acdb71e35049", "node_type": "4", "metadata": {"page_label": "14", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "c185a927411f7b9f4f7aed43f564769a66ea502de404172bb7b0c4890df44220", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "23e20188-4ed8-4f40-88bc-122a700e77c1", "node_type": "1", "metadata": {"page_label": "14", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "264e1e51fca2338cb2ff6c9347b6524329776be14605e38809d6f2c18562883b", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "These are areas which, perhaps, the\nworkforce foresees or even witnesses as being the most impacted\nby AI (\n63). These may also be the areas that radiographers\nfeel they can more easily relate to, and grasp given their\ntraining at level 6 (Bachelor\u2019s level) to allow for a smoother\ntransition into a new \ufb01eld. Other proposed topics included\nFrontiers in Digital Health | www.frontiersin.org 14 November 2021 | Volume 3 | Article 739327", "mimetype": "text/plain", "start_char_idx": 5543, "end_char_idx": 5978, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "ca570e49-246a-4370-86bc-4075bf22f270": {"__data__": {"id_": "ca570e49-246a-4370-86bc-4075bf22f270", "embedding": null, "metadata": {"page_label": "15", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "978ed50c-f15e-4976-b3b8-78528ff00afa", "node_type": "4", "metadata": {"page_label": "15", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "7498e6cf5143f4cf456b3bcfccb400462c245fd80f8779a976354a073640c5a2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0387bf00-2093-4745-8491-6814a34f8a7d", "node_type": "1", "metadata": {}, "hash": "b556721eb58382da87dd6c3970a14006a90f794197f3b68d610eb4513b0c735b", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Rainey et al. AI-Related Survey of UK Radiographers\napplied machine learning, programming and computer science,\nand AI development/entrepreneurship, although these subject\nchoices were less popular. The above list of topics is similar to\nthose identi\ufb01ed in the literature as important for inclusionin\nAI curricula, although it is also suggested that a more \ufb02exib le\ncurriculum should be o\ufb00ered to best suit the students\u2019 intere st\nand current developments in the \ufb01eld (\n64, 65). A minority (2.5%)\nof respondents across both professions indicated that they ha d\nreceived training as part of a CPD programme in a higher\neducation setting. This could lead to some national or global\ndisparity and variability in the type and standard of educatio n\nbeing delivered in AI knowledge in the future (\n35) and could\nimpact speed and quality of AI adoption and implementation\nas well as job satisfaction. The development of a standardised or\nrecommended AI curriculum, as suggested for radiology trai nees,\nmay provide a solution for this (\n16, 58, 59).\nThe respondents indicate that the best place for any\nAI training was in the pre-registration setting. This aligns\nwith the proposed changes to the HCPC Standards of\nPro\ufb01ciency (radiographers) which highlight the necessity for all\nradiographers to have an awareness of both the principles of\nAI, and of the methods of assessment of performance of any\nAI algorithm (\n41). If accepted, these changes would make it\nessential that all HCPC registrants and aspiring registrant s have\nthis knowledge, and therefore this learning must be front-lo aded\nin the radiography education, in both the pre-registration as\nwell as post-registration stages. The Topol review (\n40) supports\nthis by recommending that training in digital technologies\nand computer science should be integrated into undergraduate\neducation for health care professionals. A systematic revie w\nby Schuur et al.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1914, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "0387bf00-2093-4745-8491-6814a34f8a7d": {"__data__": {"id_": "0387bf00-2093-4745-8491-6814a34f8a7d", "embedding": null, "metadata": {"page_label": "15", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "978ed50c-f15e-4976-b3b8-78528ff00afa", "node_type": "4", "metadata": {"page_label": "15", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "7498e6cf5143f4cf456b3bcfccb400462c245fd80f8779a976354a073640c5a2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ca570e49-246a-4370-86bc-4075bf22f270", "node_type": "1", "metadata": {"page_label": "15", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "8044917806b24fe29861e97a741b75e930ae839b9458e2d0dbd0985f6c7b6d28", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0b026d65-5852-4739-af01-cd72f8dc336d", "node_type": "1", "metadata": {}, "hash": "30f08cd08a79b7df5b94d08110e4c6bea5384d6e022170ab7c684d5345b0b332", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "The Topol review (\n40) supports\nthis by recommending that training in digital technologies\nand computer science should be integrated into undergraduate\neducation for health care professionals. A systematic revie w\nby Schuur et al. (\n16) examines training opportunities in AI\nfor radiologists and found that there was an overwhelming\nprevalence of short courses o\ufb00ered, rather than those integrated\nfully into curricula, with education providers only involve d in\na limited capacity. Interestingly this is not fully supported in\nthe results from our study which found that, although the\nrespondents indicated they did not receive speci\ufb01c training in\nAI, there was a statistically signi\ufb01cant relationship betw een the\nlevel of highest academic quali\ufb01cation and understanding o f AI.\nThis suggests that the higher the level of academic quali\ufb01cat ion,\nthe greater the perception of understanding in AI. In the absen ce\nof speci\ufb01c AI training, this may be simply due to the way which\npostgraduate students are required to develop transferableskills\nas fully independent learners and the encouragement of those\nstudying for higher academic quali\ufb01cations to become agents\nof change and therefore actively investigate current and fu ture\ndevelopments (such as AI) for clinical practise themselves (\n66).\nGender, Age, Quali\ufb01cation, and Role\nCorrelations in Arti\ufb01cial Intelligence for\nRadiographers\nThe results from the analysis of the nominal data indicated that\nthere is a relationship between gender and con\ufb01dence in usin g\nAI terminology across both professions. Further exploration into\nthe reason for this relationship were investigated from the cross\ntabulations of the likelihood ratios. This found that, on th e whole,\nthe observed values (responses) from the male respondents\nwere higher than the expected values for \u201ccon\ufb01dent\u201d and \u201cvery\ncon\ufb01dent\u201d and the female respondents were generally the reverse.\nThe reason for this is unclear, although it should be noted\nthat there were fewer male respondents than female in both\nprofessions (approximately 1:3 male:female respondents from\nboth professions, which is representative of the workforce gender\ndistribution).", "mimetype": "text/plain", "start_char_idx": 1684, "end_char_idx": 3846, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "0b026d65-5852-4739-af01-cd72f8dc336d": {"__data__": {"id_": "0b026d65-5852-4739-af01-cd72f8dc336d", "embedding": null, "metadata": {"page_label": "15", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "978ed50c-f15e-4976-b3b8-78528ff00afa", "node_type": "4", "metadata": {"page_label": "15", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "7498e6cf5143f4cf456b3bcfccb400462c245fd80f8779a976354a073640c5a2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0387bf00-2093-4745-8491-6814a34f8a7d", "node_type": "1", "metadata": {"page_label": "15", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "157a125fb5f67e4a9a70c00900f5b16f101c36301ed24eaf01816d9ac9229a67", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4c9f8ed5-93bc-4b10-8523-a3ce12d73446", "node_type": "1", "metadata": {}, "hash": "17469d9344b72ae760f64dfaeb4a6900be6a732734d8a04f9d8a6d9596ccb065", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Studies indicate that AI and computer scienc e are\nmale dominated \ufb01elds (\n67), with only 18% of authors at AI\nconferences are considered female and that in general, fema les\nare less con\ufb01dent in using technology than males ( 68). This\nmay be an issue for the radiography workforce, where there is\na much greater proportion of females than males (\n57). This is\nin contrast to the radiology workforce demographics, where 6 0%\nof the workforce are male ( 69). According to the Dunner-Kruger\ne\ufb00ect (64), self-reported con\ufb01dence is no measure of competence.\nA possible explanation for the lower con\ufb01dence scores for women\nin our study may be due to the gender con\ufb01dence gap and the\ntendency for women to think less favourably about their scienti\ufb01c\nreasoning ability and underestimate their performance (\n65).\nStudies suggest that while there remains a gap in female\nperceived self-con\ufb01dence in AI technology related terminol ogy\nand tasks, there is no di\ufb00erence in performance or accuracy\nbetween genders (\n70). Kim Nilsson writes in \u201cForbes, \u201d that, to\nmitigate service inequalities, it is essential that those pr ofessionals\nworking in AI are representative of the population for which\nthe AI will be used (\n71). There therefore, may need to be\nmore targeted investigation into the causes for this disparit y\nto allow timely intervention in education, training, mento rship,\nand representation before further integration of AI into thi s\nfemale-dominated clinical setting.\nThe Digital Natives Report ( 72), a multi-generational survey\nof over 1,000 UK business decision makers reported that AI is\nused in the daily lives of those born after mid-1995, so-called\n\u201cGeneration Z, \u201d the youngest participants in the survey. The\nreport also found that those in this age category have a hunger\nfor new technology and are comfortable using it. The \ufb01ndings\nfrom our survey support this by the relationship found between\nthe diagnostic radiography respondents\u2019 role and the perception\nof adequacy of training available in AI.", "mimetype": "text/plain", "start_char_idx": 3847, "end_char_idx": 5859, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "4c9f8ed5-93bc-4b10-8523-a3ce12d73446": {"__data__": {"id_": "4c9f8ed5-93bc-4b10-8523-a3ce12d73446", "embedding": null, "metadata": {"page_label": "15", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "978ed50c-f15e-4976-b3b8-78528ff00afa", "node_type": "4", "metadata": {"page_label": "15", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "7498e6cf5143f4cf456b3bcfccb400462c245fd80f8779a976354a073640c5a2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0b026d65-5852-4739-af01-cd72f8dc336d", "node_type": "1", "metadata": {"page_label": "15", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "dc1e5765d614852ab5cefc086addbf751e4c0fc600149265ab66604948b432b6", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "The \ufb01ndings\nfrom our survey support this by the relationship found between\nthe diagnostic radiography respondents\u2019 role and the perception\nof adequacy of training available in AI. The greatest discre pancy\nbetween actual and expected responses, as determined by\nthe likelihood ratio, noted was in the student radiography\ncohort, with three times as many responses than predicted\ndisagreeing with the statement \u201cThere is enough training onAI\ncurrently available for radiographers.\u201d Additionally, ther e was a\nrelationship found between role and understanding of AI (ye s, no\nand unsure responses available). Interrogation of the respon ses\nwould indicate that student therapeutic radiographers were m ore\nlikely than expected, based on the likelihood ratio, to respond\nthat they did not understand AI, and less likely to respond\n\u201cyes\u201d (Supplementary Table 12). The young professionals, and\nradiography students, of today are ready to embrace technolo gy\nand education providers and employers should be in a position\nto maximise this potential.\nA positive correlation between respondents\u2019 age and perceived\ncon\ufb01dence in AI and years practising and perceived con\ufb01dence\nin AI was found in the radiotherapy responses, indicating that\nthose in the younger age categories and those with fewer years\u2019\nexperience felt less con\ufb01dent in AI, which to some extent\nFrontiers in Digital Health | www.frontiersin.org 15 November 2021 | Volume 3 | Article 739327", "mimetype": "text/plain", "start_char_idx": 5680, "end_char_idx": 7125, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "70710840-8457-4145-9900-f1e37c5fa20c": {"__data__": {"id_": "70710840-8457-4145-9900-f1e37c5fa20c", "embedding": null, "metadata": {"page_label": "16", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "7c60562a-1161-44a9-b17b-eea513c59ccb", "node_type": "4", "metadata": {"page_label": "16", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "cd824f243a478d90a447548ac4bd3a1d5e19b487b455b841e7f39716aab99103", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "37503145-951c-430b-9ec4-2174f4b12c7f", "node_type": "1", "metadata": {}, "hash": "42a408b8d0acc7e25cf65cb76a8f6fca0775059b175ddb89fad17a3e97018c94", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Rainey et al. AI-Related Survey of UK Radiographers\ncontradicts the literature referenced above. This may be du e to\nprogressively greater exposure to new technologies in the cli nical\nsetting over time ( 61). Also a positive correlation was found\nbetween con\ufb01dence on AI tems and applications and highest\nacademic degree, which suggests the need for a customised\napproach to AI learning provisions for di\ufb00erent healthcare\npractitioners depending on the level of their prior knowledge,\nas expected.\nFinally, a correlation was also found between diagnostic\nradiographers\u2019 UK region and con\ufb01dence in the terminology of\nAI, although interrogation of the crosstabulation revealed no\napparent pattern ( Supplementary Table 12).\nLIMITATIONS AND FUTURE RESEARCH\nThis exploratory study gathered responses from a diverse sample\nof diagnostic and therapeutic radiographers, focussing on the\nUK radiography workforce. The male to female ratio (1:3)\nand diagnostic-to-therapeutic radiographers ratio (4:1) within\nthe survey are representative of the actual UK radiography\nworkforce. However, given that the survey employs convenience\nsampling (\n53), the results cannot be generalisable to the wider\nUK radiography population. This might relate to selection bias\nin relation to IT literacy and interest and knowledge of AI, as\nthe participants were invited from the professional networks o f\nthe co-authors, many of which are established academics and\nresearchers in the AI \ufb01eld. In reality the results of this work\nmay possibly underestimate the lack of knowledge, skills, an d\ncon\ufb01dence about AI as the respondents may come from settings\nof more established AI cultures and environments. However,\nconvenience sampling remains an inexpensive sampling method\nfor hard-to-reach populations (\n53). The sample size and sampling\nmethod is also comparable with similar studies in the \ufb01eld of\nradiography in other countries (\n34, 35).\nLimited free response information was obtained as many of\nthe questions required Likert-scale or closed type responses .\nThe team is planning focus groups with purposive sampling to\nunderstand in greater depth the educational need and challenges\nfaced with the upcoming integration of clinical AI.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2213, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "37503145-951c-430b-9ec4-2174f4b12c7f": {"__data__": {"id_": "37503145-951c-430b-9ec4-2174f4b12c7f", "embedding": null, "metadata": {"page_label": "16", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "7c60562a-1161-44a9-b17b-eea513c59ccb", "node_type": "4", "metadata": {"page_label": "16", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "cd824f243a478d90a447548ac4bd3a1d5e19b487b455b841e7f39716aab99103", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "70710840-8457-4145-9900-f1e37c5fa20c", "node_type": "1", "metadata": {"page_label": "16", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "af2b2bef2119f14afcf513c979cb31aabbe67ea81b4e0d35f5dd9714d0b5ed3d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0ebd3a10-eb76-4604-9199-e16ecf786975", "node_type": "1", "metadata": {}, "hash": "3f2308ff09894077fc86583f45386dcea9b3282874f21b083ddc01cabf87acb7", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "The team is planning focus groups with purposive sampling to\nunderstand in greater depth the educational need and challenges\nfaced with the upcoming integration of clinical AI.\nThe study is exploratory in nature to set the basis for future\nstudies; hence a hypothesis was not used but an explicit aim\nwith objectives was stated alluding to workforce readinessfor\nAI adoption.\nFinally, the survey instrument used did not employ a validate d\nknowledge, skills, con\ufb01dence scale as the team wished to\ncontextualise and customise the survey to the priorities and\nneeds of the workforce and validated questionnaires do not\no\ufb00er that \ufb02exibility; instead survey questions were developed by\nprofessional experts to get the information required to infor m\npractise change in educational provisions in the near future.\nIt is hoped that this study will provide some useful material fo r\nfuture studies to build on.\nCONCLUSION\nThe results from this survey demonstrate that the UK\nradiography workforce is not yet knowledgeable, appropriately\nskilled, con\ufb01dent, or su\ufb03ciently educated for full integra tion\nof modern AI into the clinical setting. Some of the workforce\nare resorting to educating themselves on AI using short courses\nonline but there is a need to prioritise formalised education\nand mentoring at all levels of the profession. This should not\ndiscriminate against those who do not have or do not wish to\nhave postgraduate quali\ufb01cations but also should allow \ufb02exibility\nby availability of postgraduate and CPD provisions for those\nwho wish to keep abreast of technological developments after\ngraduation. Radiographers, as integral to patient care and as\ndirect consumers of AI technologies, need to be educated to\ncritically embrace the emerging technologies, to ensure optimal\npatient care and outcomes and to be able to lead the way toward\nan AI-enabled future in health care.\nRadiographers are usually the \ufb01rst and, many times, the only\npoint of patient contact in medical imaging or radiotherapy\nservice. Consequently, an imperative exists for all radiographers\nto be part of the conversation as equal members in the\ndecision making and co-designers of any new AI technological\ndevelopments in the clinical setting.", "mimetype": "text/plain", "start_char_idx": 2037, "end_char_idx": 4256, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "0ebd3a10-eb76-4604-9199-e16ecf786975": {"__data__": {"id_": "0ebd3a10-eb76-4604-9199-e16ecf786975", "embedding": null, "metadata": {"page_label": "16", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "7c60562a-1161-44a9-b17b-eea513c59ccb", "node_type": "4", "metadata": {"page_label": "16", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "cd824f243a478d90a447548ac4bd3a1d5e19b487b455b841e7f39716aab99103", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "37503145-951c-430b-9ec4-2174f4b12c7f", "node_type": "1", "metadata": {"page_label": "16", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "cfd064ab79d668064a0f16e62a3f373782a5a5399ef948520af6ddd23441f3c6", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Consequently, an imperative exists for all radiographers\nto be part of the conversation as equal members in the\ndecision making and co-designers of any new AI technological\ndevelopments in the clinical setting. In order to appropriately\nengage in these conversations, we need to have a workforce where\nall feel con\ufb01dent and adequately educated to be able to have a\ncritical appreciation of the technology, its capabilities, challenges,\nand risks. This should come naturally for the radiography\nworkforce, which has been traditionally trained on the interface\nbetween technological innovation and patient care. This doe s\nnot mean that radiographers need to become computer science\nexperts; but it does mean that they should be in position to safely\nand expertly apply AI solutions in clinical practise, be able to\nmeaningfully appraise, interpret, and apply the evidence from\nliterature for the bene\ufb01t of their patients and collaborate in the\ndesign of new AI solutions addressing clinical challenges. W ith\nthis realised, the radiographic profession would in a position to\nprocure, use, and validate the most clinically useful AI tools for\nthe context and patient population within which they operate,\nand additionally, in\ufb02uence the system interfaces to allow for\noptimal integration into current work\ufb02ows.\nDATA AVAILABILITY STATEMENT\nThe original contributions presented in the study are included\nin the article/ Supplementary Material, further inquiries can be\ndirected to the corresponding author.\nETHICS STATEMENT\nThe studies involving human participants were reviewed and\napproved by City, University of London SHS REC. The\npatients/participants provided their written informed consentto\nparticipate in this study. Electronic consenting format was use d\nin this online survey.\nAUTHOR CONTRIBUTIONS\nCM and SM have equally contributed to the conceptualisation\nand design of this study and are therefore sharing joint last\nFrontiers in Digital Health | www.frontiersin.org 16 November 2021 | Volume 3 | Article 739327", "mimetype": "text/plain", "start_char_idx": 4046, "end_char_idx": 6066, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "3346480a-047a-4667-aad4-a4f4e0894fff": {"__data__": {"id_": "3346480a-047a-4667-aad4-a4f4e0894fff", "embedding": null, "metadata": {"page_label": "17", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "57c141a6-7490-4731-9da8-31c398d172a6", "node_type": "4", "metadata": {"page_label": "17", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "5acf2df57c154a0faa5e89d492875bd7d9d2789a60bd599342ed2199ac9c2395", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8a784e94-6226-4e65-bdc4-b3fb280cb95e", "node_type": "1", "metadata": {}, "hash": "fa601c18ff0e5bb32d3886f2087ee72df9022302da49f921c65543ae16dd05b1", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Rainey et al. AI-Related Survey of UK Radiographers\nauthorship. CR, CM, SM, and TO\u2019R have contributed to di\ufb00erent\naspects of data analysis and write up. All authors contributedto\nthe design of the online survey, recruitment of study partici pants,\nreviewed di\ufb00erent drafts of this document, and approved the\n\ufb01nal draft.\nFUNDING\nWe would like to thank the City University Radiography\nResearch Fund 90020HY for covering the costs of dissemination\nfor this publication.\nACKNOWLEDGMENTS\nThe authors wish to thank the Society and College of\nRadiographers for promoting the survey through its\nmembership. We are also grateful to all the study participants\nfor their kind contributions in advancing our understanding of\nAI readiness in Radiography during a time the clinical demands\nfor frontline workers were increasing because of the ongoing\nCOVID-19 pandemic. We do hope these results will help better\nsupport and educate the radiography workforce to use new\ntechnologies in AI and help manage the increasing clinical\nworkload.\nSUPPLEMENTARY MATERIAL\nThe Supplementary Material for this article can be found\nonline at: https://www.frontiersin.org/articles/10.3389/fdgth.\n2021.739327/full#supplementary-material\nREFERENCES\n1. Shen D, Wu G, Suk H-I. Deep learning in medical image analysis. Annu\nRev Biomed Eng. (2017) 19:221\u201348. doi: 10.1146/annurev-bioeng-071516-0\n44442\n2. Erickson BJ. Ch 4: Deep learning and machine learning in imaging: b asic\nprinciples. In: Ranschaert ER, Morozov S, Algra PR, editors. Arti\ufb01cial\nIntelligence in Medical Imaging. Cham: Springer Nature Switzerland (2019).\np. 39\u201346. doi: 10.1007/978-3-319-94878-2_4\n3. Meijering M. A bird\u2019s-eye view of deep learning in bioimage analy sis.\nComput Struct Biotechnol J.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1733, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "8a784e94-6226-4e65-bdc4-b3fb280cb95e": {"__data__": {"id_": "8a784e94-6226-4e65-bdc4-b3fb280cb95e", "embedding": null, "metadata": {"page_label": "17", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "57c141a6-7490-4731-9da8-31c398d172a6", "node_type": "4", "metadata": {"page_label": "17", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "5acf2df57c154a0faa5e89d492875bd7d9d2789a60bd599342ed2199ac9c2395", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3346480a-047a-4667-aad4-a4f4e0894fff", "node_type": "1", "metadata": {"page_label": "17", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "05af84383307eb5a2a7e3fd8a821a59a2c686b54844591654cfe22358abb23ef", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "97d24af3-fef9-4879-9a1a-567f6cc5b254", "node_type": "1", "metadata": {}, "hash": "d0d1ee417ab564e46fe63c8113d6a8802cf8cd89c4779cc0d28139417cd4910c", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Meijering M. A bird\u2019s-eye view of deep learning in bioimage analy sis.\nComput Struct Biotechnol J. (2020) 18:2312\u201325. doi: 10.1016/j.csbj.2020.0\n8.003\n4. England JR, Cheng PM. Arti\ufb01cial intelligence for medical image a nalysis:\na guide for authors and reviewers. Am J Radiol. (2019) 212:513\u2013\n9. doi: 10.2214/AJR.18.20490\n5. Huisman M, Ranschaert E, Parker W, Mastrodicasa D, Koci M, Pinto de.\nSantos D, et al. An international survey on AI in radiology in 1,04 1 radiologists\nand radiology residents part 1: fear of replacement, knowledge, and att itude.\nEur Radiol. (2021) 31:7058\u201366. doi: 10.1007/s00330-021-07781-5\n6. Recht M, Bryan M. Arti\ufb01cial intelligence: threat or boon to radio logists? J\nAmer Coll Radiol. (2017) 14:11. doi: 10.1016/j.jacr.2017.07.007\n7. Chockley K, Emanuel E. The end of radiology? Three threats to\nthe future practice of radiology. J Amer Coll Radiol. (2016) 13:1415\u2013\n20. doi: 10.1016/j.jacr.2016.07.010\n8. NHS Long Term Plan (2019). Available online at: https://www.longtermplan.\nnhs.uk/ (accessed November 24, 2020).\n9. Waymel Q, Badr S, Demondion X, Cotten A, Jacques T. Impact of the ri se\nof arti\ufb01cial intelligence in radiology: what do radiologists think ? Diagn Interv\nImaging. (2019) 100:327\u201336.", "mimetype": "text/plain", "start_char_idx": 1635, "end_char_idx": 2867, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "97d24af3-fef9-4879-9a1a-567f6cc5b254": {"__data__": {"id_": "97d24af3-fef9-4879-9a1a-567f6cc5b254", "embedding": null, "metadata": {"page_label": "17", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "57c141a6-7490-4731-9da8-31c398d172a6", "node_type": "4", "metadata": {"page_label": "17", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "5acf2df57c154a0faa5e89d492875bd7d9d2789a60bd599342ed2199ac9c2395", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8a784e94-6226-4e65-bdc4-b3fb280cb95e", "node_type": "1", "metadata": {"page_label": "17", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "bb127f76720c56a827424c790699568933b4a08f0d5dc2dfe4cdcb341103f086", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2683462d-3e8c-44ce-87f8-cd4e37d05301", "node_type": "1", "metadata": {}, "hash": "039ba37f16ebd48023f418a9d605c0c6fc4814cfdcbf620cc0820c9adaefae46", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Diagn Interv\nImaging. (2019) 100:327\u201336. doi: 10.1016/j.diii.2019.03.015\n10. Oh S, Kim JH, Choi SW, Lee HJ, Hong J, Kwon SH. Physician con\ufb01den ce\nin arti\ufb01cial intelligence: an online mobile survey. J Med Internet Res. (2019)\n21:e12422. doi: 10.2196/12422\n11. Pinto Dos Santos D, Giese D, Brodehl S, Chon SH, Staab W, Klein ert R, et al.\nMedical students\u2019 attitude towards arti\ufb01cial intelligence: a mu lticentre survey.\nEur Radiol. (2019) 29:1640\u20136. doi: 10.1007/s00330-018-5601-1\n12. Abdullah R, Fakieh B. Health care employees\u2019 perceptions of the use o f\narti\ufb01cial intelligence applications: survey study. J Med Internet Res. (2020)\n22:e17620. doi: 10.2196/17620\n13. Park CJ, Yi PH, Siegel EL. Medical student perspectives on the impact of\narti\ufb01cial intelligence on the practice of medicine. Curr Probl Diagn Radiol.\n(2020). 50:614\u20139. doi: 10.1067/j.cpradiol.2020.06.011\n14. Philpotts L. Can computer-aided detection be detrimental to mammo graphic\ninterpretation? Radiology. (2009) 253:17\u201322. doi: 10.1148/radiol.2531090689\n15. Kitamura FC, Marques O. Trustworthiness of arti\ufb01cial intelligen ce models\nin radiology and the role of explainability. Amer Coll Radiol. (2021) 8:1160\u2013\n2. doi: 10.1016/j.jacr.2021.02.008\n16.", "mimetype": "text/plain", "start_char_idx": 2827, "end_char_idx": 4047, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "2683462d-3e8c-44ce-87f8-cd4e37d05301": {"__data__": {"id_": "2683462d-3e8c-44ce-87f8-cd4e37d05301", "embedding": null, "metadata": {"page_label": "17", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "57c141a6-7490-4731-9da8-31c398d172a6", "node_type": "4", "metadata": {"page_label": "17", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "5acf2df57c154a0faa5e89d492875bd7d9d2789a60bd599342ed2199ac9c2395", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "97d24af3-fef9-4879-9a1a-567f6cc5b254", "node_type": "1", "metadata": {"page_label": "17", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "3c94a47a88fd1578d35136acc81e7a8f7479687821cc5855173168703121e283", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "94232a86-002f-483d-80ea-a14d2df453eb", "node_type": "1", "metadata": {}, "hash": "e4b4c164014728d88c14f656308ce954c1d53f179115020c94a6a98b34a254b6", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Amer Coll Radiol. (2021) 8:1160\u2013\n2. doi: 10.1016/j.jacr.2021.02.008\n16. Schuur F, Mehrizi MHR, Ranschaert E. Training opportunities of a rti\ufb01cial\nintelligence (AI) in radiology: a systemic review. Eur Radiol. (2021) 31:6021\u2013\n29. doi: 10.1007/s00330-020-07621-y\n17. Kelly CJ, Karthikesalingam A, Suleyman M, Corrado G, King D. Key\nchallenges for delivering clinical impact with arti\ufb01cial intelligenc e. BMC Med.\n(2019) 17:195. doi: 10.1186/s12916-019-1426-2\n18. Nagendran M, Chen Y, Lovejoy CA, Gordon AC, Komorowski M, Harv ey\nH, et al. Arti\ufb01cial intelligence versus clinicians: systematic revi ew of design,\nreporting standards, and claims of deep learning studies. Brit Med J (2020)\n368:m689. doi: 10.1136/bmj.m689\n19. Sit C, Srinivasan R, Amlani A, Muthuswamy K, Azam A, Monzon L,\net al. Attitudes and perceptions of UK medical students towards arti \ufb01cial\nintelligence and radiology: a multicentre survey. Insights Imaging. (2020)\n11:14. doi: 10.1186/s13244-019-0830-7\n20. RCR New RCR Census Shows The NHS Needs Nearly 2,000 More Radiologi sts\n(2021). Available online at: https://www.rcr.ac.uk/posts/new- rcr-census-\nshows-nhs-needs-nearly-2000-more-radiologists (accessed Sept ember 1,\n2021).\n21. Society and College of Radiographers. Radiography Census Highlights Sta\ufb00\nBravery Amid Workforce Shortages .", "mimetype": "text/plain", "start_char_idx": 3976, "end_char_idx": 5285, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "94232a86-002f-483d-80ea-a14d2df453eb": {"__data__": {"id_": "94232a86-002f-483d-80ea-a14d2df453eb", "embedding": null, "metadata": {"page_label": "17", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "57c141a6-7490-4731-9da8-31c398d172a6", "node_type": "4", "metadata": {"page_label": "17", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "5acf2df57c154a0faa5e89d492875bd7d9d2789a60bd599342ed2199ac9c2395", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2683462d-3e8c-44ce-87f8-cd4e37d05301", "node_type": "1", "metadata": {"page_label": "17", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "c7f7639d2aeb30dabd3e30bc9e9082721cb5194c399680d02b00e8be9024b75c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c97a00a2-10ac-452d-b739-c91d7fd59e02", "node_type": "1", "metadata": {}, "hash": "938c2906e5a909ed8871844c5fbcf0100f4016e9c7397df3c1e9bc5b49c6a6a1", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "21. Society and College of Radiographers. Radiography Census Highlights Sta\ufb00\nBravery Amid Workforce Shortages . Available online at: Radiography census\nhighlights sta\ufb00 bravery amid workforce shortages | SoR (accessed S eptember\n1, 2021).\n22. The Society of Radiographers 2020 Annual Report A Century of Suc cess.\nLondon: Society of Radiographers (2020). Available online at: Ge tFile.aspx\n(https://www.sor.orgsor.org) (accessed July 8, 2021).\n23. HCPC. Registrant Snapshot (2021) . Available online at: https://www.hcpc-uk.\norg/about-us/insights-and-data/the-register/registrant- snapshot-may-2021/\n(accessed: June 25, 2021).\n24. Liew C. The future of radiology segmented with arti\ufb01cial\nintelligence: a strategy for success. Eur J Radiol. (2018) 102:152\u2013\n6. doi: 10.1016/j.ejrad.2018.03.019\n25. Hardy MA, Harvey H. Arti\ufb01cial intelligence in diagnostic imagi ng:\nimpact on the radiography profession. Br J Radiol. (2020)\n93:20190840. doi: 10.1259/bjr.20190840\n26. Duan Y, Edwards JS, Dwivedi Y. Arti\ufb01cial intelligence for dec ision making in\nthe era of Big Data \u2013 evolution, challenges and research agenda. Int J Inform\nManage. (2019) 48. doi: 10.1016/j.ijinfomgt.2019.01.021\n27. Chang A. Intelligence Based Medicine . London: Academic Press. (2020).\n28. Castellino RA. Computer aided detection (CAD): an overview. Cancer\nImaging. (2005) 5:17\u20139.", "mimetype": "text/plain", "start_char_idx": 5174, "end_char_idx": 6518, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "c97a00a2-10ac-452d-b739-c91d7fd59e02": {"__data__": {"id_": "c97a00a2-10ac-452d-b739-c91d7fd59e02", "embedding": null, "metadata": {"page_label": "17", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "57c141a6-7490-4731-9da8-31c398d172a6", "node_type": "4", "metadata": {"page_label": "17", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "5acf2df57c154a0faa5e89d492875bd7d9d2789a60bd599342ed2199ac9c2395", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "94232a86-002f-483d-80ea-a14d2df453eb", "node_type": "1", "metadata": {"page_label": "17", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "484fb66533256340a16a13667b951a3c61031a1b541d7d8419b77a12c5bf68af", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "London: Academic Press. (2020).\n28. Castellino RA. Computer aided detection (CAD): an overview. Cancer\nImaging. (2005) 5:17\u20139. doi: 10.1102/1470-7330.2005.0018\nFrontiers in Digital Health | www.frontiersin.org 17 November 2021 | Volume 3 | Article 739327", "mimetype": "text/plain", "start_char_idx": 6392, "end_char_idx": 6646, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "52e2273c-c61f-428b-8bca-3977e43dd55f": {"__data__": {"id_": "52e2273c-c61f-428b-8bca-3977e43dd55f", "embedding": null, "metadata": {"page_label": "18", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "4c61839e-63a8-4b1a-8b41-a6c4b39d229c", "node_type": "4", "metadata": {"page_label": "18", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "6e21eb1453efc7711139dbefea2bdf121b89bf21809fc4d26ff2b44a9e3b2cc3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f414c691-707e-431a-a7ae-b51486e1e3ac", "node_type": "1", "metadata": {}, "hash": "5fdbdbb220be8812e7bd0e7f4236dd2591bd5302dca1cf1746379a8659f76a19", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Rainey et al. AI-Related Survey of UK Radiographers\n29. Fazal MI, Patel ME, Tye J, Gupta Y. The past, present and future\nrole of arti\ufb01cial intelligence in imaging. Eur J Radiol. (2018) 105:246\u2013\n50. doi: 10.1016/j.ejrad.2018.06.020\n30. Langlotz CP , Allen B, Erickson BJ, Kalpathy-Cramer J, Bigelow K, Co ok TS,\net al. A roadmap for foundational research on arti\ufb01cial intelligenc e in medical\nimaging: from the 2018. NIH/RSNA/AC/The Academy Workshop. Radiology.\n(2019) 291:190613. doi: 10.1148/radiol.2019190613\n31. Chen Y, Stavropoulou C, Narasinkan R, Baker A, Scarbrough H. Prof essionals\u2019\nresponses to the introduction of AI innovations in radiology and t heir\nimplications for future adoption: a qualitative study. BMC Health Serv Res .\n(2021) 21:813. doi: 10.1186/s12913-021-06861-y\n32. Wong K, Gallant F, Szumacher E. Perceptions of Canadian radiat ion\noncologists, radiation physicists, radiation therapists and radi ation trainees\nabout the impact of AI in Radiation Oncology. J Med Imag Radiat Sci. (2021)\n52:44e8. doi: 10.1016/j.jmir.2020.11.013\n33. American Society of Radiologic Technologists. 2019 Arti\ufb01cial Intelligence\nSurvey. American Society of Radiologic Technologists (2019). Available\nonline at: https://www.asrt.org/docs/default-source/resear ch/2019-arti\ufb01cial-\nintelligence-survey.pdf?sfvrsnij95033fd0_4survey (acces sed June 10, 2021).\n34. Ryan ML, O\u2019Donovan T, McNulty JP.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1396, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "f414c691-707e-431a-a7ae-b51486e1e3ac": {"__data__": {"id_": "f414c691-707e-431a-a7ae-b51486e1e3ac", "embedding": null, "metadata": {"page_label": "18", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "4c61839e-63a8-4b1a-8b41-a6c4b39d229c", "node_type": "4", "metadata": {"page_label": "18", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "6e21eb1453efc7711139dbefea2bdf121b89bf21809fc4d26ff2b44a9e3b2cc3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "52e2273c-c61f-428b-8bca-3977e43dd55f", "node_type": "1", "metadata": {"page_label": "18", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "090687589c8319c587834793bf716a8f0382e16ca6890a5b5db2676dc4485dc4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0f06968e-1c02-4a16-b7ae-bd36840247cf", "node_type": "1", "metadata": {}, "hash": "84b269337ce06e78f6b41aa18f45a54411485bb0d121aa92fc555c29e2719a8d", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "34. Ryan ML, O\u2019Donovan T, McNulty JP. Arti\ufb01cial intelligence: th e opinions\nof radiographers and radiation therapists in Ireland. Radiography (2021)\n27(suppl. 1):74\u201382. doi: 10.1016/j.radi.2021.07.022\n35. Abuzaid MM, Elshami W, Tekin H, Issa B. Assessment of\nthe willingness of radiologists and radiographers to accept the\nintegration if arti\ufb01cial intelligence into radiology practice.Acad\nRadiol. (2020) 2020:S1076-6332(20)30553-5. doi: 10.1016/j.acra. 2020.\n09.014\n36. Botwe BO, Antwi WK, Arkoh S, Akudjedu TN. Radiographers\u2019 pers pectives\non the emerging integration of arti\ufb01cial intelligence into diagn ostic imaging:\nthe Ghana study. J Med Radiat Sci. (2021) 68:260\u20138. doi: 10.1002/jmrs.460\n37. Sarwar S, Dent A, Faust K, Richer M, Djuric U, Van Ommeren R, et al.\nPhysician perspectives on integration of arti\ufb01cial intelligence into diagnostic\npathology NPJ Digit Med. (2019) 2:28. doi: 10.1038/s41746-019-0106-0\n38. Kumar D, Wong A, Taylor GW. Explaining the Unexplained: A Class-\nEnhanced Attentive Response (CLEAR) Approach to Understand ing Deep\nNeural Networks (2018). Available online at: https://ieeexplore.ieee.org/\nXplore/home.jsp (accessed August 10, 2019). doi: 10.1109/CVPRW .2017.215\n39. Reyes M, Meier R, Pereira S, Silva CA, Dahlweid F-M, von Tengg-\nKobligk H, et al.", "mimetype": "text/plain", "start_char_idx": 1359, "end_char_idx": 2646, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "0f06968e-1c02-4a16-b7ae-bd36840247cf": {"__data__": {"id_": "0f06968e-1c02-4a16-b7ae-bd36840247cf", "embedding": null, "metadata": {"page_label": "18", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "4c61839e-63a8-4b1a-8b41-a6c4b39d229c", "node_type": "4", "metadata": {"page_label": "18", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "6e21eb1453efc7711139dbefea2bdf121b89bf21809fc4d26ff2b44a9e3b2cc3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f414c691-707e-431a-a7ae-b51486e1e3ac", "node_type": "1", "metadata": {"page_label": "18", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "419eecd06901356d9722d6a7513a36ea3dbc8a81fc26a4490124a7b23b4c2a28", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "52d737c6-7b28-4e86-b401-8aaea5b65cab", "node_type": "1", "metadata": {}, "hash": "00f7af11c669a462b523bce25dcdd8bb73a9e2ad8fcc4ad001b79ace8001ec7d", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Reyes M, Meier R, Pereira S, Silva CA, Dahlweid F-M, von Tengg-\nKobligk H, et al. On the interpretability of arti\ufb01cial intelligence in\nradiology: challenges and opportunities.Radiol Artif Intell. (2020)\n2:e190043. doi: 10.1148/ryai.2020190043\n40. NHS The Topol Review. Health Education England (2019). Available online\nat: https://topol.hee.nhs.uk/ (accessed May 5, 2021).\n41. HCPC. Proposed changes to the HCPC Standards of Pro\ufb01ciency\n(Radiographers) (2020). Available online at: https://www.hcpc-u k.org/\nglobalassets/consultations/2020/standards-of-pro\ufb01ciency/ra diographers/\ntable-of-proposed-changes---radiographers.pdf (accessed June 2 3, 2020).\n42. International Society of Radiographers and Radiological Te chnologists and\nthe European Federation of Radiographer Societies. Arti\ufb01cial int elligence and\nthe radiographer/radiological technologist profession: a joint sta tement of the\nInternational Society of Radiographers and Radiological Techn ologists and\nthe European Federation of Radiographer Societies. Radiography. (2020) 26,\n93\u20135. doi: 10.1016/j.radi.2020.03.007\n43. Malamateniou C, McFadden S, McQuinlan Y, England A, Woznitza\nN, Goldsworthy S, et al. Arti\ufb01cial intelligence: guidance for clini cal\nimaging and therapeutic radiography professionals, a summary by the\nSociety of Radiographers AI working group.Radiography. (2021). 27:1192\u2013\n202. doi: 10.1016/j.radi.2021.07.028\n44. La\u00ef MC, Brian M, Mamzer MF.", "mimetype": "text/plain", "start_char_idx": 2565, "end_char_idx": 3989, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "52d737c6-7b28-4e86-b401-8aaea5b65cab": {"__data__": {"id_": "52d737c6-7b28-4e86-b401-8aaea5b65cab", "embedding": null, "metadata": {"page_label": "18", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "4c61839e-63a8-4b1a-8b41-a6c4b39d229c", "node_type": "4", "metadata": {"page_label": "18", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "6e21eb1453efc7711139dbefea2bdf121b89bf21809fc4d26ff2b44a9e3b2cc3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0f06968e-1c02-4a16-b7ae-bd36840247cf", "node_type": "1", "metadata": {"page_label": "18", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "a1c3ea6bbe1b6842921ffde94f9dd7e0a5c26dee5c18977ace6766266416fcf8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f68bd455-9fcd-4f0b-be20-cf0e453be9c2", "node_type": "1", "metadata": {}, "hash": "40812efc5a022746ff525d1cfcdd187ccfa8a94cc4059f337c2f8ac5956641c5", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "(2021). 27:1192\u2013\n202. doi: 10.1016/j.radi.2021.07.028\n44. La\u00ef MC, Brian M, Mamzer MF. Perceptions of arti\ufb01cial intelligen ce in\nhealthcare: \ufb01ndings from a qualitative survey study among actors in France. J\nTransl Med. (2020) 18:14. doi: 10.1186/s12967-019-02204-y\n45. Evans JR, Mathur A. The value of online surveys. Internet Res. (2018)\n28:4. doi: 10.1108/IntR-03-2018-0089\n46. Eysenbach G. Improving the quality of web surveys: the Checkli st for\nReporting Results of Internet E-Surveys (CHERRIES). J Med Internet Res.\n(2004) 6:e34. doi: 10.2196/jmir.6.3.e34\n47. Tavakol M, Dennick R. Making sense of Cronbach\u2019s alpha. Int J Med Educ.\n(2011) 27:53\u20135. doi: 10.5116/ijme.4dfb.8dfd\n48. Streiner DL, Norman GR, Cairney J. Health Measurement Scales: A Practical\nGuide to their Development and Use . 5th ed. Oxford: Oxford University\nPress (2015).\n49. Oluwatayo J. Validity and reliability issues in educational re search. J Educ\nSoc Res. (2012) 2:391\u2013400. Available online at: https://www.richtmann.o rg/\njournal/index.php/jesr/article/view/11851\n50. Straub D, Boudreau M, Gefen D. Validation guidelines for IS\npositivist research. Commun Assoc Inform Syst. (2004) 13:380\u2013\n427. doi: 10.17705/1CAIS.01324\n51.", "mimetype": "text/plain", "start_char_idx": 3904, "end_char_idx": 5108, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "f68bd455-9fcd-4f0b-be20-cf0e453be9c2": {"__data__": {"id_": "f68bd455-9fcd-4f0b-be20-cf0e453be9c2", "embedding": null, "metadata": {"page_label": "18", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "4c61839e-63a8-4b1a-8b41-a6c4b39d229c", "node_type": "4", "metadata": {"page_label": "18", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "6e21eb1453efc7711139dbefea2bdf121b89bf21809fc4d26ff2b44a9e3b2cc3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "52d737c6-7b28-4e86-b401-8aaea5b65cab", "node_type": "1", "metadata": {"page_label": "18", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "b85c62a8a616da6c13a2626dc91fb20811661da7ac5662878c0630c53f95c89b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "376e8cc1-5d2d-462a-b847-f8fe2a0965e7", "node_type": "1", "metadata": {}, "hash": "71294fbf8d639085aca487d6f080a6d8b1cf76b92a39c5145c2bc3f4681d7694", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Commun Assoc Inform Syst. (2004) 13:380\u2013\n427. doi: 10.17705/1CAIS.01324\n51. Baltar F, Brunet I. Social research 20: virtual snowball sampling method using\nFacebook. Internet Res. (2012) 22:57\u201374. doi: 10.1108/10662241211199960\n52. NVivo Qualitative Data Analysis Software; QSR Internationa l Pty Ltd. Version\n12 (2018).\n53. Fricker RD Jr. Chapter 10: Sampling methods for online surveys. In : Fielding\nN, Lee RM, Blank G, editors. The SAGE Handbook of Online Research Methods.\n2nd ed. London: SAGE Publications (2017) 162\u201383. doi: 10.413 5/97814739579\n92.n10\n54. Pallant, J. SPSS Survival Manual. 3rd ed . Berkshire: Open University\nPress/McGraw-Hill (2007).\n55. IBM SPSS Statistical Package for Windows, Version 23 . Armonk, NY: IBM\nCorporation (2019).\n56. Field A. Discovering Statistics Using IBM SPSS Statistics. 4th ed . Sage:\nLondon (2013).\n57. HCPC. Number of therapeutic radiographers on the HCPC Register (2018).\nAvailable online at: https://www.hcpc-uk.org/resources/freedo m-of-\ninformation-requests/2018/number-of-therapeutic-radiographer s-on-\nthe-hcpc-register---may-2018/ (accessed June 15, 2021).\n58. Tejani AS. Identifying and addressing barriers to an arti\ufb01ci al intelligence\ncurriculum. Amer Coll Radiol. (2020) 18:4. doi: 10.1016/j.jacr.2020.1\n0.001\n59. SIIM Strategic Plan 2017\u20132020 (2017). Available online at: https://cdn.", "mimetype": "text/plain", "start_char_idx": 5033, "end_char_idx": 6378, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "376e8cc1-5d2d-462a-b847-f8fe2a0965e7": {"__data__": {"id_": "376e8cc1-5d2d-462a-b847-f8fe2a0965e7", "embedding": null, "metadata": {"page_label": "18", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "4c61839e-63a8-4b1a-8b41-a6c4b39d229c", "node_type": "4", "metadata": {"page_label": "18", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "6e21eb1453efc7711139dbefea2bdf121b89bf21809fc4d26ff2b44a9e3b2cc3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f68bd455-9fcd-4f0b-be20-cf0e453be9c2", "node_type": "1", "metadata": {"page_label": "18", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "0de88e34d561513461f2d36544b16833aa9f9567d73af7067d6a91eec47f9f55", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "411a98cc-0f8f-48e8-b757-e97a24ef9e81", "node_type": "1", "metadata": {}, "hash": "040ef44461ac0a278471748fc516e17e85abaa62a4d7a25449032667bbddc5a2", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "SIIM Strategic Plan 2017\u20132020 (2017). Available online at: https://cdn.\nymaws.com/siim.org/resource/resmgr/governance/strategic_plan_2017v22.\npdf (accessed June 16, 2021).\n60. Lindqwister AL, Hassanpour S, Lewis PJ, Sin JM. AI-RADS: a n\narti\ufb01cial intelligence curriculum for residents. Acad Radiol. (2020)\n20:1076\u20136332. doi: 10.1016/j.acra.2020.09.017\n61. Hafslund B, Clare J, Graverholt B. Wammen-Nortvedt, M. Evidence-\nbased radiography. Radiography. (2008) 14:4. doi: 10.1016/j.radi.200\n8.01.003\n62. Aarts S, Cornelis F, Zevenboom Y, Brokken P , van de Griend N, Spoo renberg\nM, et al. The opinions of radiographers, nuclear medicine technologi sts and\nradiation therapists regarding technology in healthcare: a qualitat ive study. J\nMed Radiat Sci. (2017) 64:3\u20139. doi: 10.1002/jmrs.207\n63. SECTRA: The Radiologist\u2019s Handbook for Future Excellence (2021). Available\nonline at: https://medical.sectra.com/resources/the-radiologis ts-handbook-\nfor-future-excellence-2021/ (accessed June 15, 2021).\n64. Dunning D. The Dunning-Kruger e\ufb00ect: on being ignorant of o ne\u2019s own\nignorance. In: Olsen JM, Zanna MP , editors. Advances in Experimental\nSocial Psychology, Vol. 44. Cambridge, MA: Academic Press (2011), 247\u2013\n96. doi: 10.1016/B978-0-12-385522-0.00005-6\n65.", "mimetype": "text/plain", "start_char_idx": 6307, "end_char_idx": 7567, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "411a98cc-0f8f-48e8-b757-e97a24ef9e81": {"__data__": {"id_": "411a98cc-0f8f-48e8-b757-e97a24ef9e81", "embedding": null, "metadata": {"page_label": "18", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "4c61839e-63a8-4b1a-8b41-a6c4b39d229c", "node_type": "4", "metadata": {"page_label": "18", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "6e21eb1453efc7711139dbefea2bdf121b89bf21809fc4d26ff2b44a9e3b2cc3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "376e8cc1-5d2d-462a-b847-f8fe2a0965e7", "node_type": "1", "metadata": {"page_label": "18", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "c97364422e263820c82758ddc16fd830a4071884db26ffd043298d822c6bb2f6", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "44. Cambridge, MA: Academic Press (2011), 247\u2013\n96. doi: 10.1016/B978-0-12-385522-0.00005-6\n65. Ehrlinger J, Dunning D. How chronic self-views in\ufb02uence (and\npotentially mislead) estimates of performance. J Pers Soc Psychol. (2003)\n84:1. doi: 10.1037/0022-3514.84.1.5\n66. Knowles MS. Andragogy in Action. Applying Modern Principles of Adult\nEducation. San Francisco, CA: Jossey Bass (1984).\n67. West SM, Whittaker M, Crawford K. Discriminating Systems: Gender, Race\nand Power in AI . AI Now Institute (2019). Available online at: https://\nainowinstitute.org/discriminatingsystems.html (accessed J une 16, 2021).\n68. Yau HK, Cheng ALF. Gender di\ufb00erence of con\ufb01dence in using te chnologyfor\nlearning. J Technol Stud. (2012) 38:74\u20139. doi: 10.21061/jots.v38i2.a.2\n69. Royal College of Radiologists. Clinical Radiology UK Workforce Census\n(2020). Available online at: https://www.rcr.ac.uk/system/\ufb01les /publication/\n\ufb01eld_publication_\ufb01les/clinical-radiology-uk-workforce-census -2020-report.\npdf (accessed June 15, 2021).\nFrontiers in Digital Health | www.frontiersin.org 18 November 2021 | Volume 3 | Article 739327", "mimetype": "text/plain", "start_char_idx": 7473, "end_char_idx": 8581, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "498a18fb-79a4-48a2-b3d9-bae479162cf2": {"__data__": {"id_": "498a18fb-79a4-48a2-b3d9-bae479162cf2", "embedding": null, "metadata": {"page_label": "19", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "d618ddfb-b57a-425c-8f3c-cdadb780f905", "node_type": "4", "metadata": {"page_label": "19", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "f1c8cb8c250ef9a8be7e747baeeede970dd9fdaf8f714ac64cbc17947643dd16", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "452ac336-0448-4c9f-af93-b6b0f3d2cb59", "node_type": "1", "metadata": {}, "hash": "185b4404b0ea9fc7b3fff39521eb14ad6c53dc596dd9d223ccce659d385a66da", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Rainey et al. AI-Related Survey of UK Radiographers\n70. Liberatore MJ, Wagner WP. Gender, performance, and\nself-e\ufb03cacy: a quasi-experimental \ufb01eld study. J Comput\nInform Syst. (2020). doi: 10.1080/08874417.2020.1717\n397\n71. Nilsson, K. Why AI needs more women. Forbes (2019). Available online at:\nhttps://www.forbes.com/sites/kimnilsson/2019/03/08/why-ai-needs-more-\nwomen/?sh=13a953577f90 (accessed June 19, 2021).\n72. Advanced. The Digital Natives Report (2019). Available online at: https://\nwww.oneadvanced.com/trends-report/digital-natives-report-201 9-2020/\n(accessed June 29, 2021).\nCon\ufb02ict of Interest: The authors declare that the research was conducted in the\nabsence of any commercial or \ufb01nancial relationships that could be c onstrued as a\npotential con\ufb02ict of interest.\nPublisher\u2019s Note:All claims expressed in this article are solely those of the authors\nand do not necessarily represent those of their a\ufb03liated organizat ions, or those of\nthe publisher, the editors and the reviewers. Any product that may b e evaluated in\nthis article, or claim that may be made by its manufacturer, is not gua ranteed or\nendorsed by the publisher.\nCopyright \u00a9 2021 Rainey, O\u2019Regan, Matthew, Skelton, Woznitza, Chu, Goodman,\nMcConnell, Hughes, Bond, McFadden and Malamateniou. This is an open-access\narticle distributed under the terms of the Creative Commons Attribution License (CC\nBY). The use, distribution or reproduction in other forums is permitted, provided\nthe original author(s) and the copyright owner(s) are credit ed and that the original\npublication in this journal is cited, in accordance with acc epted academic practice.\nNo use, distribution or reproduction is permitted which doe s not comply with these\nterms.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1726, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "452ac336-0448-4c9f-af93-b6b0f3d2cb59": {"__data__": {"id_": "452ac336-0448-4c9f-af93-b6b0f3d2cb59", "embedding": null, "metadata": {"page_label": "19", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "d618ddfb-b57a-425c-8f3c-cdadb780f905", "node_type": "4", "metadata": {"page_label": "19", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "f1c8cb8c250ef9a8be7e747baeeede970dd9fdaf8f714ac64cbc17947643dd16", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "498a18fb-79a4-48a2-b3d9-bae479162cf2", "node_type": "1", "metadata": {"page_label": "19", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "c792d88aebee2bc487ab6d004d981753ef6338e9445de5a80248e965f8ab7d46", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "No use, distribution or reproduction is permitted which doe s not comply with these\nterms.\nFrontiers in Digital Health | www.frontiersin.org 19 November 2021 | Volume 3 | Article 739327", "mimetype": "text/plain", "start_char_idx": 1636, "end_char_idx": 1821, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "9357125c-3523-4f3a-9018-6c08aa835279": {"__data__": {"id_": "9357125c-3523-4f3a-9018-6c08aa835279", "embedding": null, "metadata": {"page_label": "1", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "4354f20f-b099-4c4c-abae-bd50d7e5c5db", "node_type": "4", "metadata": {"page_label": "1", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "843dc3e1b889a3f8bf8b0f6cc69eba3be4873f8c39337d132e30dfb5162282c8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b8e99569-7668-4b3a-91d0-dc3e0fa95aed", "node_type": "1", "metadata": {}, "hash": "030d395b533e916dcc9cbaa6af9c8b13b7aa08db738791006fb7e035a89d748f", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "REVIEW Open Access\n\u00a9 The Author(s) 2024. Open Access  This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, \nsharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and \nthe source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this \narticle are included in the article\u2019s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included \nin the article\u2019s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will \nneed to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The \nCreative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available \nin this article, unless otherwise stated in a credit line to the data.\nLu et al. Journal of Hematology & Oncology           (2024) 17:16 \nhttps://doi.org/10.1186/s13045-024-01535-8\nIntroduction\nCancer cells are mainly suppressed by the complicated \nnetworks in the immune system, but tumors develop \nseveral mechanisms to evade anti-cancer immunity [ 1]. \nHence, cancer immunotherapy has been introduced as a \nnew mainstay to utilize the patient\u2019s own immune system \nin cancer cell eradication. The cancer immunotherapy \nconcept can be categorized into immune checkpoints-\ntargeted therapy and the adoptive transfer of manipu -\nlated immune cells. Both of these strategies contribute \nto improving the immune system\u2019s function in the iden -\ntification and eradication of cancer cells [2]. A number of \nJournal of Hematology & \nOncology\n\u2020Qiang Lu, Dongquan Kou and Shenghan Lou contributed equally \nto this work.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1951, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "b8e99569-7668-4b3a-91d0-dc3e0fa95aed": {"__data__": {"id_": "b8e99569-7668-4b3a-91d0-dc3e0fa95aed", "embedding": null, "metadata": {"page_label": "1", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "4354f20f-b099-4c4c-abae-bd50d7e5c5db", "node_type": "4", "metadata": {"page_label": "1", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "843dc3e1b889a3f8bf8b0f6cc69eba3be4873f8c39337d132e30dfb5162282c8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9357125c-3523-4f3a-9018-6c08aa835279", "node_type": "1", "metadata": {"page_label": "1", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "857fe5ef20a2f2c7bc8e216fca11cfc9b6539cb99bbfd9ba59f3ddae4de4ecc7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cb02e3ef-40c0-451d-a4bb-14809f01bd1b", "node_type": "1", "metadata": {}, "hash": "209fdaca49c5ccfd84a7b5cdd964d0f7df6f725dcbc5c43c5f13405cffca9844", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "A number of \nJournal of Hematology & \nOncology\n\u2020Qiang Lu, Dongquan Kou and Shenghan Lou contributed equally \nto this work.\n*Correspondence:\nGautam Sethi\nphcgs@nus.edu.sg\nZhennan Yuan\nyuanzhennan123@hrbmu.edu.cn\nPeng Han\nleospiv@hrbmu.edu.cn\nFull list of author information is available at the end of the article\nAbstract\nCancer immunotherapy and vaccine development have significantly improved the fight against cancers. Despite \nthese advancements, challenges remain, particularly in the clinical delivery of immunomodulatory compounds. \nThe tumor microenvironment (TME), comprising macrophages, fibroblasts, and immune cells, plays a crucial role \nin immune response modulation. Nanoparticles, engineered to reshape the TME, have shown promising results \nin enhancing immunotherapy by facilitating targeted delivery and immune modulation. These nanoparticles can \nsuppress fibroblast activation, promote M1 macrophage polarization, aid dendritic cell maturation, and encourage \nT cell infiltration. Biomimetic nanoparticles further enhance immunotherapy by increasing the internalization \nof immunomodulatory agents in immune cells such as dendritic cells. Moreover, exosomes, whether naturally \nsecreted by cells in the body or bioengineered, have been explored to regulate the TME and immune-related cells \nto affect cancer immunotherapy. Stimuli-responsive nanocarriers, activated by pH, redox, and light conditions, \nexhibit the potential to accelerate immunotherapy. The co-application of nanoparticles with immune checkpoint \ninhibitors is an emerging strategy to boost anti-tumor immunity. With their ability to induce long-term immunity, \nnanoarchitectures are promising structures in vaccine development. This review underscores the critical role of \nnanoparticles in overcoming current challenges and driving the advancement of cancer immunotherapy and TME \nmodification.", "mimetype": "text/plain", "start_char_idx": 1829, "end_char_idx": 3712, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "cb02e3ef-40c0-451d-a4bb-14809f01bd1b": {"__data__": {"id_": "cb02e3ef-40c0-451d-a4bb-14809f01bd1b", "embedding": null, "metadata": {"page_label": "1", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "4354f20f-b099-4c4c-abae-bd50d7e5c5db", "node_type": "4", "metadata": {"page_label": "1", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "843dc3e1b889a3f8bf8b0f6cc69eba3be4873f8c39337d132e30dfb5162282c8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b8e99569-7668-4b3a-91d0-dc3e0fa95aed", "node_type": "1", "metadata": {"page_label": "1", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "7d971c3fe0fbd66c6576496d43f12814d7ba865b12736a1b3c042b9668ce863a", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "This review underscores the critical role of \nnanoparticles in overcoming current challenges and driving the advancement of cancer immunotherapy and TME \nmodification.\nKeywords Bioengineered nanostructures; cancer immunotherapy, Immune evasion nanoparticles, Tumor \nmicroenvironment\nNanoparticles in tumor microenvironment \nremodeling and cancer immunotherapy\nQiang\u00a0Lu1\u2020, Dongquan\u00a0Kou2\u2020, Shenghan\u00a0Lou3\u2020, Milad\u00a0Ashrafizadeh4,5,6, Amir Reza\u00a0Aref7,8, Israel\u00a0Canadas9, Yu\u00a0Tian10, \nXiaojia\u00a0Niu11, Yuzhuo\u00a0Wang11, Pedram\u00a0Torabian12,13, Lingzhi\u00a0Wang14,15, Gautam\u00a0Sethi14,15*, Vinay\u00a0Tergaonkar16, \nFranklin\u00a0Tay17, Zhennan\u00a0Yuan18* and Peng\u00a0Han18,19*", "mimetype": "text/plain", "start_char_idx": 3545, "end_char_idx": 4184, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "4e93c9be-4015-4e2f-962a-9d9bf9eeff9f": {"__data__": {"id_": "4e93c9be-4015-4e2f-962a-9d9bf9eeff9f", "embedding": null, "metadata": {"page_label": "2", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "732d36ef-8c5d-4588-962d-c4dc4204f1d8", "node_type": "4", "metadata": {"page_label": "2", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "cb9da7ec2786b1147d67c1eb465f3af8f67e04b9317bd69482b79bce53ef2aa2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a1022cdb-2d5a-4f2a-98f9-43b0d8f7728b", "node_type": "1", "metadata": {}, "hash": "af8c500cd34efc0760ac29ef115a93089db1bbb2fcd87c8048d6cc61d07d6024", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Page 2 of 48\nLu et al. Journal of Hematology & Oncology            (2024) 17:16 \nimmune checkpoint inhibitors, including programmed \ncell death ligand 1 (PD-L1) or cytotoxic T-lymphocyte-\nassociated protein 4 (CTLA-4) antibodies and agonists of \ncostimulatory molecules have shown satisfactory results \nin clinics for the treatment of cancer patients, however, \nthey still have a number of troublesome problems includ -\ning low response rate, high cost and non-specific toxicity \n[3\u20135]. Another method is the adoptive transfer of cells, \nwhich uses genetically engineered cells such as chimeric \nantigen receptor (CAR)-T cells and others such as multi -\npotent mesenchymal stem cells to affect the expression of \na specific cytokine and other features of cells [ 6, 7]. Since \nthe promising application of immune checkpoint block -\nade and CAR-T cell therapy, cancer immunotherapy has \nundergone significant advances. Cancer immunotherapy \nis now considered a powerful and innovative strategy in \nclinics compared to other conventional treatments such \nas surgery, radiotherapy, and chemotherapy. The most \nrecent immunotherapeutic methods have utilized T cells \nfor the induction of adaptive immune responses. On the \nother hand, studies have shown that a number of innate \nimmune checkpoints with expression on the antigen-\npresenting cells (APCs) contribute to immune evasion. \nThese checkpoints are capable of detecting and eradicat -\ning tumor cells through phagocytosis and suppressing \ninnate immune response. The first line of the immune \ndefense system is provided by innate immune cells such \nas macrophages, monocytes, and dendritic cells that act \nas APCs. They induce pro-inflammatory reactions to \nforeign attacks and contribute to the repair of damaged \ntissues.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1777, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "a1022cdb-2d5a-4f2a-98f9-43b0d8f7728b": {"__data__": {"id_": "a1022cdb-2d5a-4f2a-98f9-43b0d8f7728b", "embedding": null, "metadata": {"page_label": "2", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "732d36ef-8c5d-4588-962d-c4dc4204f1d8", "node_type": "4", "metadata": {"page_label": "2", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "cb9da7ec2786b1147d67c1eb465f3af8f67e04b9317bd69482b79bce53ef2aa2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4e93c9be-4015-4e2f-962a-9d9bf9eeff9f", "node_type": "1", "metadata": {"page_label": "2", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "b62b472de6a286efcf1fccdea092100fe39fa74b40ca309a0fcb329e2ec43636", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0c185699-c838-435c-a450-466887b10bd2", "node_type": "1", "metadata": {}, "hash": "a62f21e4ca24d77de11e4d476690e57c6ba1aac2d553cae26a57b2536ede5739", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "They induce pro-inflammatory reactions to \nforeign attacks and contribute to the repair of damaged \ntissues. The cancer cells are able to express a number of \nsignals known as \u201cdo not eat me\u201d signals through expres -\nsion of CD47 [ 8], CD24 [ 9], PD-L1 [ 10], the beta-2 micro -\nglobulin (\u03b22M) subunit of MHC-I [ 11], stanniocalcin \n1 (STC-1) [ 12] and GD2 [ 13] to evade the macrophage-\nmediated phagocytosis.\nThe application of cancer immunotherapy has been of \nimportance in the treatment of both hematological and \nsolid tumors [ 14]. In fact, immunotherapy has revolu -\ntionized cancer therapy, and it aims to apply immune \ncheckpoint inhibitors, adoptive cell therapy, and vaccines \nto finally target the immune-oncology cycle for improv -\ning the activity of T lymphocytes in tumor suppression. \nAll of these regimens should be applied in a cycle to \naccelerate the tumor antigen presentation by APCs [ 15]. \nAPCs are the cells with the ability to capture, process, \nand present the exogenous antigens to T cells, and are \nprimarily recognized through the expression of MHC-\nII and other co-stimulatory molecules. APCs are mainly \ncomprised of dendritic cells, macrophages, and B cells. \nThere are also other cells with expression of MHC-II \nsuch as thymic epithelial cells. Moreover, there are also \nother kinds of cells, such as eosinophils and basophils, \nwith the ability of MHC-II expression upon stimulation \n[16, 17]. Regarding solid tumors, antigen uptake and \npresentation are mainly performed by macrophages and \ndendritic cells [ 18]. Although macrophages are the prev -\nalent phagocytic cells in cancers, they lack the ability to \nmigrate into lymph nodes and activate T cells [ 18].", "mimetype": "text/plain", "start_char_idx": 1669, "end_char_idx": 3371, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "0c185699-c838-435c-a450-466887b10bd2": {"__data__": {"id_": "0c185699-c838-435c-a450-466887b10bd2", "embedding": null, "metadata": {"page_label": "2", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "732d36ef-8c5d-4588-962d-c4dc4204f1d8", "node_type": "4", "metadata": {"page_label": "2", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "cb9da7ec2786b1147d67c1eb465f3af8f67e04b9317bd69482b79bce53ef2aa2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a1022cdb-2d5a-4f2a-98f9-43b0d8f7728b", "node_type": "1", "metadata": {"page_label": "2", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "fc90f4feff53b533d9ba2fc688c2b684c84bc193da81a970b8fe81d251e7af2e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bbe4b789-2f81-4846-beff-7f53e87ce87a", "node_type": "1", "metadata": {}, "hash": "ba6faf598abf8ae03405f515fb0bef2f0f02459893bd3602aea01f202cf51a3b", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Although macrophages are the prev -\nalent phagocytic cells in cancers, they lack the ability to \nmigrate into lymph nodes and activate T cells [ 18]. Note -\nworthy, macrophages are considered a factor in impair -\ning the T cell-mediated responses against tumors, and \nthey reduce the response to immune checkpoint block -\nade, chemotherapy, and radiotherapy [ 19, 20]. On the \nother hand, the dendritic cells have a significant ability \nin lymph node migration to induce T cells for immunity \n[18, 21\u201324]. Moreover, increasing evidence has shown \nthe ability of tumor-resident dendritic cells to stimulate T \ncell-mediated anti-cancer immune response [ 18, 24\u201328]. \nHowever, it should be noted that macrophages and other \ncells in the TME, including fibroblasts, can exert carci -\nnogenic activity upon induction and their regulation is \nof importance for maximizing cancer immunotherapy \n[19, 29\u201336]. Stimulation of TME remodeling represents \na beneficial strategy for cancer treatment and immuno -\ntherapy [ 37\u201343]. Although a significant number of stud -\nies advocate the potential of immunotherapy in cancer \nsuppression [ 44\u201348], immunotherapy has faced its own \nproblems, and the most prominent one is immune eva -\nsion. Regarding the mutations and dysregulation of \nmolecular pathways in human tumors, the oncogenic \npathways are activated, which can finally promote the \nsurvival of cancer cells and mediate their escape from \ncancer immunotherapy and immune surveillance.\nIn addition to immune resistance, current drugs \nused for cancer immunotherapy and TME remodeling \nlack targeting features. As a result, the nanoparticles \nhave been introduced to facilitate anti-cancer immu -\nnity. Nanostructures can improve the retention time \nand provide the targeted delivery [ 49]. Furthermore, \nnanoparticles are capable of TME remodeling to dis -\nrupt an immunosuppressive environment.", "mimetype": "text/plain", "start_char_idx": 3222, "end_char_idx": 5112, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "bbe4b789-2f81-4846-beff-7f53e87ce87a": {"__data__": {"id_": "bbe4b789-2f81-4846-beff-7f53e87ce87a", "embedding": null, "metadata": {"page_label": "2", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "732d36ef-8c5d-4588-962d-c4dc4204f1d8", "node_type": "4", "metadata": {"page_label": "2", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "cb9da7ec2786b1147d67c1eb465f3af8f67e04b9317bd69482b79bce53ef2aa2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0c185699-c838-435c-a450-466887b10bd2", "node_type": "1", "metadata": {"page_label": "2", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "e1c1044e08bd0da59282a4cc902cefd326af9ac7e1ce084a924b936ff8e2b03c", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Nanostructures can improve the retention time \nand provide the targeted delivery [ 49]. Furthermore, \nnanoparticles are capable of TME remodeling to dis -\nrupt an immunosuppressive environment. The distor -\ntion of blood vessels and high growth rate of tumor cells \ncause hypoxia in TME that mediates an immunosup -\npressive environment, characterized by an increase in \nthe accumulation of immunosuppressive cells, includ -\ning regulatory T cells (Tregs) and myeloid-derived sup -\npressor cells (MDSCs), as well as secretion of a number \nof factors including vascular endothelial growth fac -\ntor (VEGF) and transforming growth factor \u03b2 (TGF-\u03b2). \nAs a result, the function of dendritic cells is suppressed \nand macrophages are polarized into M2 phenotype. The \nnanoparticles can be specifically developed to target \nTME components and disrupt the immunosuppressive \nTME to improve the function in cancer immunotherapy. \nMoreover, nanoparticles can be considered as nano-scale \ndelivery systems for drugs [ 50]. They can selectively accu -\nmulate in tumor tissue and enhance the retention time of \ndrugs. Moreover, nanostructures demonstrate enhanced", "mimetype": "text/plain", "start_char_idx": 4919, "end_char_idx": 6069, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "38c5f45c-4600-431e-b195-c2937e185441": {"__data__": {"id_": "38c5f45c-4600-431e-b195-c2937e185441", "embedding": null, "metadata": {"page_label": "3", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "d71baa71-40d8-4aab-a8c7-ba6cbee55a69", "node_type": "4", "metadata": {"page_label": "3", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "f58706d2ce887b4e87b91daa7fe87fc8c4681a9690d331b72c3cc6d7c5372436", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "49c02434-3b56-450b-b011-6147aaf38601", "node_type": "1", "metadata": {}, "hash": "1b018591865f5843fc9a09552c9bdf34ded6b0dda0291c985f77c33ad56ba7db", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Page 3 of 48\nLu et al. Journal of Hematology & Oncology            (2024) 17:16 \npermeability and retention (EPR) effect, improving their \naccumulation in tumor sites because of leaky tumor vas -\nculature and damaged lymphatic drainage [ 51, 52]. Fur -\nthermore, nanostructures can be functionalized with \nligands, to specifically target the tumor and even the \nTME components [ 53\u201355]. As a result, nanoparticles \nhave been introduced as new structures for potentiating \ncancer immunotherapy and overcoming immune evasion \n[56\u201363].\nAmidst the current challenges in cancer immunother -\napy, the need for improving cancer immunotherapy, and \nthe promise of nanoparticles, the use of targeting sys -\ntems has emerged as a novel strategy for immunotherapy \nenhancement and TME remodeling. The development \nof nanoparticles based on targeting TME and improv -\ning cancer immunotherapy can strengthen the potential \nfor tumor eradication. Since the TME modulators suf -\nfer from targeted action, it is preferred to use targeted \nnon-scale delivery systems for the regulation of TME and \nimproving cancer immunotherapy. The present review \nfocuses on the application of nanoparticles for TME \nremodeling and boosting cancer immunotherapy. The \ncurrent review will first provide a comprehensive outline \nregarding TME components and then, immune evasion is \ndiscussed. Then, the potential of nanoparticles for TME \nre-education through targeting its components, includ -\ning macrophages, is described. Moreover, biomimetic \nnanoparticles and their stimuli-responsive kinds for bet -\nter tumor targeting are described. Since exosomes have \nemerged recently in cancer immunotherapy, the role of \nexosomes, both endogenous and bioengineered, in the \nregulation of the immune system for tumor suppres -\nsion is discussed. Figure\u00a0 1 provides an overview of using \nnanoparticles for cancer immunotherapy.\nTumor microenvironment components\nMacrophages\nMacrophages, renowned for their phagocytic nature, play \na crucial role in the immune system. They participate in \nvarious physiological processes, including development \nFig.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2113, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "49c02434-3b56-450b-b011-6147aaf38601": {"__data__": {"id_": "49c02434-3b56-450b-b011-6147aaf38601", "embedding": null, "metadata": {"page_label": "3", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "d71baa71-40d8-4aab-a8c7-ba6cbee55a69", "node_type": "4", "metadata": {"page_label": "3", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "f58706d2ce887b4e87b91daa7fe87fc8c4681a9690d331b72c3cc6d7c5372436", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "38c5f45c-4600-431e-b195-c2937e185441", "node_type": "1", "metadata": {"page_label": "3", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "65846783015bd1afe66799b6903573429bcba7f0795ec4ecd6cc02d125831e47", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Tumor microenvironment components\nMacrophages\nMacrophages, renowned for their phagocytic nature, play \na crucial role in the immune system. They participate in \nvarious physiological processes, including development \nFig. 1 An overview of using nanoparticles in cancer immunotherapy. The nanoparticles circulate in blood, and upon reaching the tumor site, they re-\neducate several tumor microenvironment components, including cancer-associated fibroblasts and tumor-associated macrophages, to finally activate \nthe immune system. Moreover, nanoparticles can stimulate immunogenic cell death to enhance the maturation of dendritic cells for the activation of \nimmune cells, such as T cells, to enhance cancer immunotherapy. The co-application of nanoparticles with immune checkpoint inhibitors, such as PD-L1 \nblockers, can augment the potential of cancer immunotherapy", "mimetype": "text/plain", "start_char_idx": 1892, "end_char_idx": 2760, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "52f98438-c604-4e0b-9931-2cfeb63f68a0": {"__data__": {"id_": "52f98438-c604-4e0b-9931-2cfeb63f68a0", "embedding": null, "metadata": {"page_label": "4", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a7b50c76-9e54-4854-bd18-e3af5c016e41", "node_type": "4", "metadata": {"page_label": "4", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "1fadb6fc6fec33b365257b6b1a0c200538769c3fee4252f2d66a2caa1a07ff06", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "919bc9bb-5de8-40de-b5e3-2a32a52815ea", "node_type": "1", "metadata": {}, "hash": "ae88d20a00b9c5cfc3979715191125f6097c9dece39c980fa966b18111b43f7e", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Page 4 of 48\nLu et al. Journal of Hematology & Oncology            (2024) 17:16 \nand homeostasis. The phenotype and function of mac -\nrophages are intricately determined by their origin and \npolarization [ 64]. Initially believed to originate from \nhematopoietic stem cells and circulating monocytes [ 65], \nthe recent studies reported that macrophages have an \nembryo-derived lineage, with precursors derived from \nerythro-myeloid progenitors in yolk sacs and fetal liver \n[65, 66]. Maintaining or enhancing the macrophage pop -\nulation is essential for these cells to function effectively \n[67, 68]. There are two strategies for the replenishment of \nmacrophages: monocyte recruitment and increased pro -\nliferation in the form of tissue-resident macrophages for \nelevating self-renewal ability [ 67, 69].\nIn the TME, macrophages are referred to as tumor-\nassociated macrophages (TAMs), constituting 50% of the \ntumor mass [ 70]. The TAMs engage in intricate interac -\ntions not only with cancer cells but also with natural killer \n(NK) cells, T cells, endothelial cells, and fibroblasts. The \nroles of TAMs extend to the regulation of cancer prolifer -\nation, invasion, and angiogenesis [ 71\u201373]. Macrophages \nhave also been associated with the development of resis -\ntance to cancer therapies [ 74]. The TAMs primarily origi -\nnate from the bone marrow or the yolk sac [ 75]. They can \nbe polarized into two phenotypes. The M1 macrophages, \ninduced by lipopolysaccharide and type 1 T helper cell \n(Th1)-derived cytokines, exhibit pro-inflammatory \nand anti-cancer functions [ 76]. The M2 macrophages, \ninduced by Th2-derived cytokines like interleukin-4 (IL-\n4), IL-10, and IL-13, promote proliferation, invasion, and \nangiogenesis [ 76].", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1742, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "919bc9bb-5de8-40de-b5e3-2a32a52815ea": {"__data__": {"id_": "919bc9bb-5de8-40de-b5e3-2a32a52815ea", "embedding": null, "metadata": {"page_label": "4", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a7b50c76-9e54-4854-bd18-e3af5c016e41", "node_type": "4", "metadata": {"page_label": "4", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "1fadb6fc6fec33b365257b6b1a0c200538769c3fee4252f2d66a2caa1a07ff06", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "52f98438-c604-4e0b-9931-2cfeb63f68a0", "node_type": "1", "metadata": {"page_label": "4", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "0d96a0275bb5fea0d733dff1954a0f683a4ef7d3f6998c8ec44dd42f4675a07d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d70ef2db-73fb-4880-aec8-cbce10c7f33e", "node_type": "1", "metadata": {}, "hash": "5310eb95cc8cc212fb177524b85918df545c81f2cdb0c2fcf31d95898adec073", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "The M2 macrophages, \ninduced by Th2-derived cytokines like interleukin-4 (IL-\n4), IL-10, and IL-13, promote proliferation, invasion, and \nangiogenesis [ 76]. A delicate balance exists between M1 \nand M2 macrophages in vivo, influencing tumorigenesis \nand treatment outcomes [ 77, 78]. The anti-inflammatory \nnature of M2 macrophages accelerates cancer progres -\nsion. The regulation of TAMs has been of importance \nfor cancer immunotherapy. Currently, the strategies \nfor targeting TMAs are based on controlling the ori -\ngin, functional polarization, and phagocytic function of \nTAMs. Moreover, macrophages and monocytes have \nbeen engineered to mediate anti-cancer immunity. For \nthis purpose, four distinct strategies have been exploited, \nincluding a decrease in TAM population, switching from \nM2 polarization into M1 phenotypes, controlling mac -\nrophage phagocytic signal, and bioengineering of mac -\nrophages for increasing phagocytosis [ 79]. Currently, the \nnanostructures have been widely applied to re-educate \nTAMs [ 80], change phagocytosis ability [ 81], suppress \nTAMs [ 82] and deliver drugs to TAMs [ 83] for cancer \nimmunotherapy.\nCancer-associated fibroblasts\nCancer-associated fibroblasts (CAFs) represent a diverse \ngroup of cells that infiltrate the TME. The CAFs are dis -\ntinct from normal fibroblasts [ 84]. These cells play a \npivotal role in tumorigenesis by inducing biochemical \nalterations and signaling network changes that acceler -\nate tumor development [ 85]. Under specific conditions, \nCAFs may exhibit anti-cancer activities, contributing to \ntumor suppression [ 86].\nThe heterogeneity of CAFs arises from their diverse \norigins, including normal fibroblasts, epithelial cells, \nendothelial cells, peritumoral adipocytes, pericytes, \nhematopoietic stem cells, mesenchymal stem cells, and \ncancer stem cells [ 87].", "mimetype": "text/plain", "start_char_idx": 1585, "end_char_idx": 3436, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "d70ef2db-73fb-4880-aec8-cbce10c7f33e": {"__data__": {"id_": "d70ef2db-73fb-4880-aec8-cbce10c7f33e", "embedding": null, "metadata": {"page_label": "4", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a7b50c76-9e54-4854-bd18-e3af5c016e41", "node_type": "4", "metadata": {"page_label": "4", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "1fadb6fc6fec33b365257b6b1a0c200538769c3fee4252f2d66a2caa1a07ff06", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "919bc9bb-5de8-40de-b5e3-2a32a52815ea", "node_type": "1", "metadata": {"page_label": "4", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "65af001cc206b59d1cb0fac202ba574f2beed1cecab2ea18455ed6d3311846a5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "65f54425-2787-4a92-8ad0-0c9b5d39b3ec", "node_type": "1", "metadata": {}, "hash": "5e242dc0ebad73dcf5924694b4d58717d2f077ad80a5e44668e17be04ae184a0", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Based on their functions, CAFs \nmay be categorized into two groups: carcinogenic and \nanti-carcinogenic CAFs [ 88, 89]. Ohlund and colleagues \nidentified two distinct subtypes of CAFs in pancreatic \ncancer: myofibroblasts (myCAFs) and inflammatory \nCAFs (iCAFs) [ 90]. The myCAFs, located near cancer \ncells, are stimulated by transforming growth factor-beta \n(TGF-\u03b2) and exhibit high levels of alpha-smooth muscle \nactin (\u03b1-SMA). In contrast, iCAFs are positioned fur -\nther away from cancer cells. They demonstrate elevated \n\u03b1-SMA levels and the ability to secrete IL-6 and leukemia \ninhibitory factor [ 91].\nAnother subclass of CAFs, antigen-presenting CAFs \n(apCAFs), express biomarkers related to the MHC-II \nclass and CD44, enabling them to stimulate CD 4+ T cells \nin an antigen-dependent manner [ 92]. Additionally, there \nis a subtype known as restraining CAFs (rCAFs). Each of \nthese subpopulations plays a distinct role in cancer. For \nexample, iCAFs and myCAFs contribute to metabolic \nreprogramming and angiogenesis in cancer, respectively. \nThe iCAFs can secrete growth factors, cytokines, and \nchemokines, including PD-L1/L2, Fas ligand, and oth -\ners, that influence the regulation of the immune system. \nThe myCAFs, on the other hand, contribute to extracel -\nlular matrix remodeling by enhancing collagen synthesis. \nThe apCAFs are involved in stimulating CD 4+ T cells for \nimmune cell regulation, while rCAFs exhibit the ability to \nsuppress tumorigenesis [ 93]. Regarding the importance \nof CAFs in tumorigenesis, targeting CAFs for cancer \nimmunotherapy has been of importance. The nanostruc -\ntures demonstrate high penetration and permeability in \ntumor sites, and can be utilized to regulate CAFs [ 94].", "mimetype": "text/plain", "start_char_idx": 3437, "end_char_idx": 5165, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "65f54425-2787-4a92-8ad0-0c9b5d39b3ec": {"__data__": {"id_": "65f54425-2787-4a92-8ad0-0c9b5d39b3ec", "embedding": null, "metadata": {"page_label": "4", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a7b50c76-9e54-4854-bd18-e3af5c016e41", "node_type": "4", "metadata": {"page_label": "4", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "1fadb6fc6fec33b365257b6b1a0c200538769c3fee4252f2d66a2caa1a07ff06", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d70ef2db-73fb-4880-aec8-cbce10c7f33e", "node_type": "1", "metadata": {"page_label": "4", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "d1f952a8cab39e1d3af9674acf85cbba1765c49dd40811ae99b0fbef345a1565", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "The nanostruc -\ntures demonstrate high penetration and permeability in \ntumor sites, and can be utilized to regulate CAFs [ 94]. \nMoreover, nanoparticles can be utilized to engineer \nCAFs to act as APCs and stimulate antigen-specific CD 8+ \nT cells in cancer immunotherapy [ 95]. Nanostructures \ncan trigger clearance of activated and senescent CAFs \n[96], and regulation of CAFs by nanoparticles can disrupt \ncancer metastasis and invasion [ 97].\nNeutrophils\nUp to 70% of circulating leukocytes are comprised of neu -\ntrophils [ 98], and are considered a first-line against patho -\ngens [ 99]. Neutrophils have a short life and can persist in \ncirculation for five days [ 100]. When there is tissue dam -\nage or infection, the epithelial cells secrete chemokines \nto recruit neutrophils. Upon this, neutrophils extravasate", "mimetype": "text/plain", "start_char_idx": 5037, "end_char_idx": 5860, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "9a4ee123-20a8-4af6-92b2-934509548349": {"__data__": {"id_": "9a4ee123-20a8-4af6-92b2-934509548349", "embedding": null, "metadata": {"page_label": "5", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "7270adbc-d000-4c2e-8351-acb5ff28e3b9", "node_type": "4", "metadata": {"page_label": "5", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "9d46d62fb558230b187be2544419355b683238241bed7e35389af931776c1fb1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d4280a9f-cd09-4edc-9055-b2c26aad73b1", "node_type": "1", "metadata": {}, "hash": "2bad51ac10b7b18be1519fda90bc211f6647244cd2312b87818d82fcd6a0152f", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Page 5 of 48\nLu et al. Journal of Hematology & Oncology            (2024) 17:16 \nthe blood circulation, enter damaged tissue to secrete \na number of inflammatory cytokines, release neutro -\nphil extracellular traps (NETs), and finally, phagocytose \nthe pathogens or invading microorganisms [ 101]. NETs \nare vehicles for anti-microbial peptides and toxins [ 102, \n103]. In cancer, there are two categories of tumor-associ -\nated neutrophils (TANs) similar to the Th1/Th2 pattern, \nincluding N1 and N2 with tumor-suppressor and tumor-\npromoting function, respectively. Tumor type and stage \ndetermine the phenotype of neutrophils in TME. During \nthe first stages of tumorigenesis, neutrophils demonstrate \nan inflammatory phenotype, and as the cancer advances, \nthe neutrophils achieve an immunosuppression pheno -\ntype [ 104]. Neutrophil-mediated inflammation regula -\ntion relies on the secretion of ROS and RNS. Moreover, \nthe extracellular matrix can be re-configured by the \nneutrophils through the secretion of neutrophil elastase \nand matrix metalloproteinases. The neutrophils display \nthe ability to stimulate angiogenesis through oncostatin-\nM, increase carcinogenesis through PGE2, and enhance \nmetastasis of cancer through the release of ROS, RNS, \nNE and MMP-9. Noteworthy, the NETs have consisted of \nMMPs, cathepsin G, and NE [ 105, 106]. The function of \nthese proteases is to mediate pro-inflammatory cytokine \ndegradation and re-accumulate in TME for enhancement \nin tumorigenesis and metastasis [ 107]. In cancer patients, \nthe plasticity of circulating neutrophils is of importance, \nknown as high-density neutrophils (HDNs) or low-den -\nsity neutrophils (LDNs), corresponding to N1 and N2 \nphenotypes, respectively.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1735, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "d4280a9f-cd09-4edc-9055-b2c26aad73b1": {"__data__": {"id_": "d4280a9f-cd09-4edc-9055-b2c26aad73b1", "embedding": null, "metadata": {"page_label": "5", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "7270adbc-d000-4c2e-8351-acb5ff28e3b9", "node_type": "4", "metadata": {"page_label": "5", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "9d46d62fb558230b187be2544419355b683238241bed7e35389af931776c1fb1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9a4ee123-20a8-4af6-92b2-934509548349", "node_type": "1", "metadata": {"page_label": "5", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "d6698f7e7356e75e3c8c43562cfd62a7093019afaf6f90cf295fab61c953893b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "080b6dee-f2a0-4ae0-9bed-9e2e68969085", "node_type": "1", "metadata": {}, "hash": "91f468799eae3c49000fad556a2cc2a3eaa80754d33b7a26d817901a87ddfd3a", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "LDNs that have an immature \nphenotype, show prevalence in the circulation of many \ncancers and participate in carcinogenesis and metastasis \n[100]. In the field of cancer immunotherapy, the stimula -\ntion of N1 neutrophils can mediate toxic impacts on can -\ncer cells [ 108]. Furthermore, the stimulation of Ly6Ehi \nneutrophils through the STING pathway can enhance \nsensitivity to anti-PD-1 therapy, and they can be utilized \nas predictors of cancer immunotherapy [ 109]. Therefore, \nthe development of nanoparticles for targeting neutro -\nphils in cancer immunotherapy is important.\nNatural killer cells and T cells\nAs innate lymphocytes, NK cells exhibit a shorter half-life \ncompared to B and T cells, necessitating their replenish -\nment from bone marrow progenitors [ 110]. The NK cells \nundergo linear differentiation, with highly proliferative \nimmature NK cells differentiating into fully functional \nand granular effectors [ 111\u2013113]. Enhancing the fre -\nquency, infiltration, and function of NK cells contributes \nto the improved survival of cancer patients [ 114\u2013117]. \nThis renders NK cells valuable in cancer immunotherapy. \nThese group I innate lymphoid cells can rapidly target \ncells without prior sensitization [ 118], and express T-bet \nand Th1-related cytokines, including IFN-\u03b3 [ 119\u2013121].\nUpon maturation, NK cells migrate from the bone mar -\nrow to the blood and subsequently reside in peripheral \ntissues. Because of their capacity to move between lym -\nphatic and non-lymphatic tissues, NK cells are distrib -\nuted in numerous organs and tissues [ 122\u2013124]. Mature \nNK cells acquire the capability to exert cytotoxic impacts \non cancer cells or virus-infected cells [ 125]. Serving as \ncontributors to the adaptive immune system, NK cells \ninteract with other immune cells through the secretion of \ncytokines, growth factors, and chemokines [ 125]. These \neffects position NK cells as effective effectors in diseases \nsuch as cancer, infectious diseases, autoimmunity, and \nchronic inflammation [ 126\u2013129].", "mimetype": "text/plain", "start_char_idx": 1736, "end_char_idx": 3767, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "080b6dee-f2a0-4ae0-9bed-9e2e68969085": {"__data__": {"id_": "080b6dee-f2a0-4ae0-9bed-9e2e68969085", "embedding": null, "metadata": {"page_label": "5", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "7270adbc-d000-4c2e-8351-acb5ff28e3b9", "node_type": "4", "metadata": {"page_label": "5", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "9d46d62fb558230b187be2544419355b683238241bed7e35389af931776c1fb1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d4280a9f-cd09-4edc-9055-b2c26aad73b1", "node_type": "1", "metadata": {"page_label": "5", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "a0a51a5e680062896619e94e71f3b770fe68774fb7b18c608debdf957acba648", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "27779168-4216-4731-97c6-b4cd9fe2ddd1", "node_type": "1", "metadata": {}, "hash": "18bfec55bdfca17c3d5305178684ea39d1acef4c6034aa22cd0d883a0ae7de85", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "These \neffects position NK cells as effective effectors in diseases \nsuch as cancer, infectious diseases, autoimmunity, and \nchronic inflammation [ 126\u2013129].\nMoreover, NK cells play a significant role in the innate \nimmune system, providing surveillance in hemato -\nlogical cancers and cancer metastasis [ 110, 130, 131]. \nThe increased infiltration of NK cells into the TME is \npositively associated with the prognosis of various can -\ncer types, including melanoma, renal cell cancer, liver \ntumors, and breast cancer, among others [ 132\u2013136].\nThe adaptive immune system is primarily shaped by T \ncells, providing effective defense against pathogens and \ncancers. Upon exposure to cytokines and co-stimulatory \nsignals, na\u00efve T cells undergo proliferation, differentiat -\ning into effector cells. Na\u00efve CD 4+ T cells can differenti -\nate into T helper cells, including TH1, TH2, TH17, and \nTFH cells, to exert immune functions. The differentiation \nof na\u00efve CD 8+ T cells into effective CD 8+ T cells enables \nthese cells to combat infections and cancers through the \nrelease of IFN-\u03b3, TNF-\u03b1, and cytotoxic molecules [ 137].\nA challenge in cancer arises from T cell exhaustion. \nThis phenomenon is mediated by various mechanisms, \nwith the PD-1 axis being the most prominent. Upon anti -\ngen exposure, na\u00efve T cells transform into effector T cells, \nwith some undergoing cell death and others participat -\ning in tumor elimination. Antigen presentation can lead \nto the formation of stem cell memory T (TSCM) cells, \nwhich convert into TCM, TEM, and TRM. The TRM \ncells reside in the tissue, ready to respond to secondary \nstimulation, while TSCM and TCM possess self-renewal \ncapacity, generating TEM and TE upon re-stimulation \n[138].\nSigns of T cell exhaustion include the expression of \ninhibitory receptors, reduction in T cell function, and \ndecreased proliferation. Exhausted T cells exhibit a \nunique epigenetic profile that may result in a differen -\ntial or poor response to immunotherapy.", "mimetype": "text/plain", "start_char_idx": 3610, "end_char_idx": 5611, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "27779168-4216-4731-97c6-b4cd9fe2ddd1": {"__data__": {"id_": "27779168-4216-4731-97c6-b4cd9fe2ddd1", "embedding": null, "metadata": {"page_label": "5", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "7270adbc-d000-4c2e-8351-acb5ff28e3b9", "node_type": "4", "metadata": {"page_label": "5", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "9d46d62fb558230b187be2544419355b683238241bed7e35389af931776c1fb1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "080b6dee-f2a0-4ae0-9bed-9e2e68969085", "node_type": "1", "metadata": {"page_label": "5", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "c4f308d21b0a58bd9c78317297a44c1878a4a5011aaaa8aed26e2bfb662a9f06", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Exhausted T cells exhibit a \nunique epigenetic profile that may result in a differen -\ntial or poor response to immunotherapy. Additionally, \nexhausted T cells experience metabolic dysregulation, \nincluding mitochondrial suppression and glycolysis inhi -\nbition [ 139]. The challenge in cancer therapy extends \nbeyond T cell exhaustion, as their death and reduced \nproliferation can impair immune reactions. Targeting \nNK and T cells with nanoparticles has strengthened can -\ncer immunotherapy. The nanoparticles with high uptake", "mimetype": "text/plain", "start_char_idx": 5485, "end_char_idx": 6014, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "4fc2d9bf-6063-4668-ad85-e2d155197981": {"__data__": {"id_": "4fc2d9bf-6063-4668-ad85-e2d155197981", "embedding": null, "metadata": {"page_label": "6", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "f0950654-0b9e-47e7-acbd-2d780485001d", "node_type": "4", "metadata": {"page_label": "6", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "52ea00d66c4e476902bb3a867c1d7297ee1ae565eb951b88017241680b51ca1f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bce874a3-eb71-4f83-aa21-56cea029f3c7", "node_type": "1", "metadata": {}, "hash": "fd5ee2f211f4f67cf7613c62c46c3313bc62943ee31ebb0965b9913fd1e33320", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Page 6 of 48\nLu et al. Journal of Hematology & Oncology            (2024) 17:16 \nin NK cells, such as lipid-based nanoparticles, can be \nutilized to engineer NK cells [ 140]. Furthermore, nano -\nstructures can be utilized for non-invasive tracking of \nNK cells, including their migration and biodistribution \nin tumor regions [ 141]. The expression levels of CCR4 \nand CXCR4 on the surface of NK cells can be changed \nby nanoparticles to improve their interaction with can -\ncer cells [ 142]. Noteworthy, the nanoparticles can be \ndesigned to stimulate both NK and CD 8+ T cells in can -\ncer immunotherapy [ 143].\nEndothelial cells and pericytes\nEndothelial cells form the inner lining of blood vessels. \nThe biological functions of endothelial cells are crucial \nfor preserving normal physiological conditions [ 144]. \nThese cells play important roles in regulating blood clot -\nting, vessel size, and immune functions to enhance blood \nfluidity, oxygen distribution, cell transport, and nutri -\nent supply. Endothelial cells continuously secrete anti -\ncoagulant proteins to prevent clotting in vascular beds, \nmaintaining homeostasis and ensuring blood flow and \npressure at an appropriate level to deliver oxygen and \nnutrients to tissues [ 145\u2013149].\nDespite their essential physiological functions, endo -\nthelial cells have been implicated in cancer progression. \nRecent reviews have highlighted the role of endothelial \ncells in the tumor stroma [ 150, 151]. In the initial stages, \nendothelial cells induce angiogenesis to increase the pres -\nence of blood vessels in the primary tumor. These cells \nalso function as a platform and site for membrane-bound \nfactors and proteins, creating a TME conducive to can -\ncer progression. These localized functions of endothelial \ncells also play a role in regulating angiocrine signaling at \ndistant sites, influencing organ function. Furthermore, \nfactors and proteins secreted by tumor cells can extend \nbeyond tumor boundaries, affecting endothelial cells at \ndistant sites and exerting systematic functions [ 152].", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2068, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "bce874a3-eb71-4f83-aa21-56cea029f3c7": {"__data__": {"id_": "bce874a3-eb71-4f83-aa21-56cea029f3c7", "embedding": null, "metadata": {"page_label": "6", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "f0950654-0b9e-47e7-acbd-2d780485001d", "node_type": "4", "metadata": {"page_label": "6", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "52ea00d66c4e476902bb3a867c1d7297ee1ae565eb951b88017241680b51ca1f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4fc2d9bf-6063-4668-ad85-e2d155197981", "node_type": "1", "metadata": {"page_label": "6", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "463f541ac5012c38d663fa69b22460585b5c9fa32e16211b05324a82cde3958e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "113ffa4a-6837-4a51-a8d0-3973a52ba263", "node_type": "1", "metadata": {}, "hash": "9b57aa3512bb74691bb1be2d854a880f1fd90a0ce46f9c69b71774bf3a839d09", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Furthermore, \nfactors and proteins secreted by tumor cells can extend \nbeyond tumor boundaries, affecting endothelial cells at \ndistant sites and exerting systematic functions [ 152].\nUnderstanding the functions and regulatory impacts \nof tumors beyond their sites is crucial, given that most \ncancer-related deaths result from invasion, thrombosis, \nand cachexia [ 153\u2013155]. Proteins and factors secreted \nby tumor cells can induce changes in endothelial cells in \nthe pre-metastatic niche, enhancing the dissemination \nof cancer cells and mediating angiogenesis. Additionally, \nthese factors can lead to thrombosis in distant vascula -\nture [ 156]. Endothelial pericytes have been recognized \nmore than a century ago as microvasculature-associated \nmural cells [ 157]. These perivascularly positioned cells \n[158\u2013160] are ubiquitously distributed in all vascular -\nized tissues [ 161, 162]. Identification of pericytes requires \nimmunostaining and the use of biomarkers and antigens \nto differentiate them from vascular smooth muscle cells, \nfibroblasts, and mesenchymal cells [ 157]. Initially consid -\nered inert cells contributing to physical vascular stability \n[163, 164], recent advances have illuminated their roles in \nboth physiological and pathological conditions.\nPericytes play a crucial role in regulating blood vessel \ndevelopment and modulating blood flow, coagulation, \nand vascular permeability [ 165]. The structure of capil -\nlaries includes endothelial cells, pericytes, the basement \nmembrane, and vascular smooth muscle cells [ 166]. The \nprimary function of pericyte function in cancer progres -\nsion is stimulating angiogenesis in the TME [ 167]. The \nCD248 is capable of Wnt upregulation and increasing \nthe levels of OPN and SERPINE1 in pericytes to cause \nangiogenesis and expedite cancer progression [ 168]. \nAdditionally, pericyte contractility can be induced by the \nenzyme hexokinase 2 in glycolysis, leading to abnormali -\nties in tumor blood vessels [ 169].", "mimetype": "text/plain", "start_char_idx": 1885, "end_char_idx": 3877, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "113ffa4a-6837-4a51-a8d0-3973a52ba263": {"__data__": {"id_": "113ffa4a-6837-4a51-a8d0-3973a52ba263", "embedding": null, "metadata": {"page_label": "6", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "f0950654-0b9e-47e7-acbd-2d780485001d", "node_type": "4", "metadata": {"page_label": "6", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "52ea00d66c4e476902bb3a867c1d7297ee1ae565eb951b88017241680b51ca1f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bce874a3-eb71-4f83-aa21-56cea029f3c7", "node_type": "1", "metadata": {"page_label": "6", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "8086ee6049b5433420c56bc4fe72dad24bb34cff164872fc5cfd97e1dbf93b73", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5251d44c-257e-43b4-8771-bd514de0bcd1", "node_type": "1", "metadata": {}, "hash": "24dd61bdf4727f95445c139b6f9b800f0168d90f46d404a62f57148cd0d24ffd", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Additionally, pericyte contractility can be induced by the \nenzyme hexokinase 2 in glycolysis, leading to abnormali -\nties in tumor blood vessels [ 169]. When present in the \ntumor site, RGS5-TGF\u03b2-Smad2/3 creates an anti-apop -\ntotic environment that accelerates cancer cell growth \n[170]. Figure\u00a0 2 is a schematic representation of TME \ncomponents.\nMyeloid-derived suppressor cells\nThe Myeloid-derived suppressor cells (MDSCs) are \nanother type of cell present in TME. There are a num -\nber of arguments that MDSCs are a subtype of neutro -\nphils [ 104] due to the presence of overlapping markers \namong MDSCs and TANs, making it challenging and \nproblematic to distinguish them. There is still contro -\nversy regarding whether MDSCs represent a separate \nlineage of cells or are polarized immature neutrophils \n[171]. Overall, MDSCs are considered a heterogeneous \npopulation of cells with myeloid origin [ 172]. In spite of \norigination from myeloid progenitor cells, MDSCs and \nTANs are considered different cell types. Furthermore, \nMDSCs demonstrate several distinct features from neu -\ntrophils, including downregulation of CD16 and CD621 \nand upregulation of Arg1, CD66B, and CD11b [ 173, 174]. \nFurthermore, the studies have shown other subtypes \nof MDSCs including monocytic MDSCs (M-MDSCs), \nwhich are distinguished by a CD11b hi, LY6C hi, and \nLY6G lo phenotype, polymorphonuclear MDSCs (PMN-\nMDSCs), which display a CD11b hi, LY6C lo, and LY6G \nhi phenotype, and early stage MDSCs (eMDSCs) which \nare CD13- and CD14-, and CD33 + in humans [ 175, 176].", "mimetype": "text/plain", "start_char_idx": 3724, "end_char_idx": 5288, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "5251d44c-257e-43b4-8771-bd514de0bcd1": {"__data__": {"id_": "5251d44c-257e-43b4-8771-bd514de0bcd1", "embedding": null, "metadata": {"page_label": "6", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "f0950654-0b9e-47e7-acbd-2d780485001d", "node_type": "4", "metadata": {"page_label": "6", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "52ea00d66c4e476902bb3a867c1d7297ee1ae565eb951b88017241680b51ca1f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "113ffa4a-6837-4a51-a8d0-3973a52ba263", "node_type": "1", "metadata": {"page_label": "6", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "b5de815c1b061bf11c3bde337ab99e85a844039add6aa574e97985f6dd2ceffc", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "In TME, it is possible to observe both M-MDSCs and \nPMN-MDSCs, and compared to MDSCs, they demon -\nstrate a suppressive phenotype [ 177]. The MDSCs sup -\npress T cells and the innate immune system to create an \nimmunosuppressive phenotype in TME [ 177]. MDSCs \nalso contribute to the formation of pre-metastatic niches, \ncan elevate stemness and angiogenesis, and promote \nmetastasis through EMT induction and enhancing IL-6 \nsecretion [ 178, 179]. There are also other factors in TME \nthat can affect MDSCs. The HIF-1\u03b1, a marker of hypoxic \nTME, stimulates the differentiation of MDSCs into", "mimetype": "text/plain", "start_char_idx": 5290, "end_char_idx": 5881, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "e51f3753-49f7-4f05-9829-0fa4fbc94aee": {"__data__": {"id_": "e51f3753-49f7-4f05-9829-0fa4fbc94aee", "embedding": null, "metadata": {"page_label": "7", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "9208caf8-3de9-4cef-8a2e-49a8017f71b4", "node_type": "4", "metadata": {"page_label": "7", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "357b428e48f71fffd81a2e9d119272c538f018cae0ea805122877c9db7f0bfec", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "850dc40e-f518-42e1-8b40-a0125bb3e783", "node_type": "1", "metadata": {}, "hash": "69900e3527fc368ddd6cb4015ad7e02c49b981ab8f2e686b5ddd16bf1acafc83", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Page 7 of 48\nLu et al. Journal of Hematology & Oncology            (2024) 17:16 \nTAMs with carcinogenic function [ 180]. The metabo -\nlism of MDSCs in TME can be changed towards stimula -\ntion of fatty acid oxidation to enhance levels of Arg1 and \nNOS2 [ 181]. For cancer immunotherapy, the regulation \nof MDSCs can provide new insights, such as the down -\nregulation of CCRK that disrupts the immunosuppres -\nsion activity of MDSCs and promotes the potential of \nimmune-checkpoint blockade therapy [ 182]. The nano -\nstructures are able to reduce the population and function \nof MDSCs, impair MDSC-mediated immunosuppression \nand cause MDSC repolarization [ 183\u2013185].\nCytokines, chemokines and other factors\nThe immune cells present in the TME use the cytokines \nto send messages to other cells in an endocrine, para -\ncrine or autocrine manner and provide intercellular \ncommunication [ 186]. Cytokines, also known as immu -\nnomodulatory agents, can be produced in physiological \nand pathological status, and various classes of cells, \nincluding adipocytes and tumor cells, can secrete them. \nThe cytokines contribute to the cellular (type 1) and \nantibody-mediated (type 2) immunity as anti/pro-\ninflammatory and pro/anti-tumorigenic effectors that \nalso rely on the TME. Cytokines can bind to the recep -\ntor on the surface of other cells to regulate their action \nand change the molecular pathways. There are different \nkinds of cytokines in TME, including chemokines, inter -\nleukins, adipokines, transforming growth factors (TGFs), \ntumor necrosis factor (TNF), colony-stimulating factors \n(CSFs), and interferons (IFN) that can act alone or in a \nsynergistic way to affect immune system [ 187].", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1702, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "850dc40e-f518-42e1-8b40-a0125bb3e783": {"__data__": {"id_": "850dc40e-f518-42e1-8b40-a0125bb3e783", "embedding": null, "metadata": {"page_label": "7", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "9208caf8-3de9-4cef-8a2e-49a8017f71b4", "node_type": "4", "metadata": {"page_label": "7", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "357b428e48f71fffd81a2e9d119272c538f018cae0ea805122877c9db7f0bfec", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e51f3753-49f7-4f05-9829-0fa4fbc94aee", "node_type": "1", "metadata": {"page_label": "7", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "8c8ce48227ddf19663d895d8a5d3582ff2fd155cab8dd8bc3721b5ee108d6783", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Chemo -\nkines are considered as chemoattractant cytokines for the \nrecruitment of inflammatory cells, including leukocytes \n(monocytes, neutrophils), along with other kinds of cells, \nsuch as endothelial and epithelial cells [ 188]. Depending \non the position of conserved cysteine residues, there are \nFig. 2 Cellular components that influence the tumor microenvironment (TME). Interactions within the TME play a crucial role in accelerating cancer \nprogression. Cancer cells activate the PD-L1/PD-1 axis, leading to T cell exhaustion and impairment of T cell function. In addition, cancer cell-secreted exo-\nsomes that carry PD-1 contribute to T cell dysfunction, reducing proliferation and hindering proper function. Natural killer cells counteract tumorigenesis \nby secreting perforin and granular enzymes. Increased infiltration of Treg cells in the TME secretes TGF-\u03b2, inducing fibroblast transformation into cancer-\nassociated fibroblasts (CAFs), promoting extracellular matrix deposition, and causing T cell dysfunction. Myeloid-derived suppressor cells (MDSCs) induce \nTreg cell formation in the TME through the secretion of PGE-2, IL-10, and TGF-\u03b2. Regulatory T cells (Treg), in turn, suppress the function of dendritic cells \n(DCs) by secreting perforin, leading to DC cell apoptosis. M2-polarized macrophages secrete TGF-\u03b2 and IL-10, disrupting DC cell function. The interaction \nbetween endothelial cells and cancer cells results in angiogenesis, further enhancing cancer progression (created by Biorender.com)", "mimetype": "text/plain", "start_char_idx": 1703, "end_char_idx": 3226, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "c4dd69a6-1ae5-4f51-81fc-8688d6442fe0": {"__data__": {"id_": "c4dd69a6-1ae5-4f51-81fc-8688d6442fe0", "embedding": null, "metadata": {"page_label": "8", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "1b3d1945-0882-4162-bf8d-3a6834fb8fbb", "node_type": "4", "metadata": {"page_label": "8", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "a8fd4bda01fcbcf5f1a873f3151755bfe8ed263acb7127d8896dd4390846b67d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a83ec709-f214-43f4-ae27-589575212b80", "node_type": "1", "metadata": {}, "hash": "aae3c218e682a2bbc770ce096cc272a87017e3eb1e04cbdc835cf770b57416ef", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Page 8 of 48\nLu et al. Journal of Hematology & Oncology            (2024) 17:16 \nvarious classes of cytokines including CX3C, CXC, CC, \nor C chemokines [ 189]. Moreover, chemokines are able to \ninteract with the G protein-linked transmembrane recep -\ntors known as chemokine receptors [ 190]. A number of \nchemokines, such as CXCL8 and CCL3, have an inflam -\nmatory function, and they recruit the cells via the inflam -\nmatory signs or/and homeostatic [ 191]. Interleukins (ILs) \npossess a low molecular weight and demonstrate pro- \nand anti-inflammatory functions. The immunocompetent \ncells, including T cells, granulocytes, monocytes, mac -\nrophages, adipocytes, and endothelial cells, can secrete \nILs [ 192]. The ILs play a critical role in the development, \ndifferentiation, induction, maturation, migration, and \nadhesion of immune cells [ 193]. Adipokines (also known \nas adipocytokines) are cytokines that can be secreted by \nadipose tissue and consist of adipocytes, pre-adipocytes, \nmacrophages, stromal cells, fibroblasts, and endothe -\nlial cells [ 194]. The adipokines are comprised of adipose \ntissue-specific cytokines (adiponectin, leptin) and other \ncategories, including ILs, TNFs, and chemokines. More -\nover, inflammation, energy metabolism, and fat dis -\ntribution can be controlled by adipokines [ 195]. The \nadipokines also contribute to obesity-related inflamma -\ntion to regulate metabolic diseases [ 196]. Adipocytes are \ncritical regulators of tumorigenesis and metastasis [ 197].", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1508, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "a83ec709-f214-43f4-ae27-589575212b80": {"__data__": {"id_": "a83ec709-f214-43f4-ae27-589575212b80", "embedding": null, "metadata": {"page_label": "8", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "1b3d1945-0882-4162-bf8d-3a6834fb8fbb", "node_type": "4", "metadata": {"page_label": "8", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "a8fd4bda01fcbcf5f1a873f3151755bfe8ed263acb7127d8896dd4390846b67d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c4dd69a6-1ae5-4f51-81fc-8688d6442fe0", "node_type": "1", "metadata": {"page_label": "8", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "fa7b23741e9761198d27b1d8ddad0036e1de98dce0fac2e9931af1e471f5616e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0ec99e8b-0b4f-4ad6-a271-ac3e3b276d29", "node_type": "1", "metadata": {}, "hash": "1dceabee9fd2a77d52defd28f3ae021af7ecb9ed1c6d907c48be3a0dbb5f5ec8", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "The \nadipokines also contribute to obesity-related inflamma -\ntion to regulate metabolic diseases [ 196]. Adipocytes are \ncritical regulators of tumorigenesis and metastasis [ 197]. \nAccording to the impact of adipokines on the immune \nsystem, there are two kinds, including pro-inflammatory, \nsuch as leptin, TNF\u03b1, interleukin-1\u03b2 (IL-1\u03b2), interleu -\nkin-6 (IL-6), and interleukin-8 (IL-8), potentially linking \nadiposity and inflammation, and anti-inflammatory, such \nas interleukin-10 (IL-10) and adiponectin [ 197, 198]. A \nnumber of adipokines, such as adiponectin, demonstrate \nanti-carcinogenic function [ 198], while others, such as \nleptin, demonstrate carcinogenic function [ 199]. TGFs \nare a number of protein hormones that are overexpressed \nin human cancers and can modulate tumorigenesis and \ncancer growth. TGF\u03b1 is a member of the EGF family \nwith the potential to regulate epithelial development and \ncell proliferation and can modulate carcinogenesis and \nangiogenesis [ 200]. M2 macrophages and other kinds of \ncells, including cancer cells, can secrete TGF-\u03b2 to modu -\nlate the function of T cells, NK cells, and macrophages \npresent in TME, disrupting anti-cancer immunity and \nenhancing carcinogenesis [ 201]. IFN was discovered \nupon its function to interfere with viral growth [ 202]. The \nhost cells secret IFNs, and they can regulate the immune \nsystem. The fibroblasts and monocytes are able to secrete \ntype I IFNs such as IFN-\u03b1 and IFN-\u03b2 during the viral \nattack. Then, the expression of proteins with the ability \nto impair RNA and DNA replication is upregulated.", "mimetype": "text/plain", "start_char_idx": 1327, "end_char_idx": 2919, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "0ec99e8b-0b4f-4ad6-a271-ac3e3b276d29": {"__data__": {"id_": "0ec99e8b-0b4f-4ad6-a271-ac3e3b276d29", "embedding": null, "metadata": {"page_label": "8", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "1b3d1945-0882-4162-bf8d-3a6834fb8fbb", "node_type": "4", "metadata": {"page_label": "8", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "a8fd4bda01fcbcf5f1a873f3151755bfe8ed263acb7127d8896dd4390846b67d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a83ec709-f214-43f4-ae27-589575212b80", "node_type": "1", "metadata": {"page_label": "8", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "99ef923a69611687b0cd424cc3bdcc114bac60108fb72e31c55b563ced3e8654", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ed3094b4-02f4-43de-b3e3-b6a6497f80b9", "node_type": "1", "metadata": {}, "hash": "3eeda484099237200309e09adc6ba4a6b81596e46b3f4ca9ec0fd9606589348f", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Then, the expression of proteins with the ability \nto impair RNA and DNA replication is upregulated. The \ntype II IFNs, including IFN-\u03b3 can be released by CD 8+ T \nand Th1 cells to induce a number of cells, including NK \ncells, M1 macrophages, and CD 8+ T cells for enhancing \nMHC I and II presentation, promoting the anti-cancer \nimmunity [ 203].\nEnzymes\nThe changes in the expression level of enzymes are a fea -\nture of TME, and it can be exploited in a rational way to \ntreat cancer [ 204]. Enzymes are a kind of protein or RNA \nthat can facilitate chemical reactions [ 205]. The enzymes \nfor catalyzing reactions are highly selective and under \nmild conditions, demonstrate the specific substrates to \nmodulate biological and metabolic mechanisms [ 206]. \nThe enzymes display a number of changes in expres -\nsion in diseases such as TME [ 207]. The TME shows \nseveral enzyme secretions consisting of MMPs, hyal -\nuronidase, \u03b3-glutamyl transpeptidase, and esterase with \nhigher expression in tumors compared to normal tissues \n[208, 209]. The proteases contribute to the degradation \nof proteins or peptide substrates. The oxidoreductases \ncan mediate the catalysis of electron transfer from the \nreductant to the oxidant. Kinases provide phosphoryla -\ntion to affect protein activity and phosphatases mediate \ndephosphorylation. A number of enzymes demonstrate \nupregulation such as MMP-2 [ 210]. In bladder tumors, \nthe expression of HAse is enhanced compared to the nor -\nmal tissues [ 211].\nExtracellular matrix components\nThe extracellular matrix (ECM) is comprised of colla -\ngen, fibronection, laminin, vitronectin, elastin, and other \nfactors including growth factors, cytokines, and matrix \nmetalloproteinases that contribute to the support of the \nepithelial cell structure [ 212, 213].", "mimetype": "text/plain", "start_char_idx": 2819, "end_char_idx": 4619, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "ed3094b4-02f4-43de-b3e3-b6a6497f80b9": {"__data__": {"id_": "ed3094b4-02f4-43de-b3e3-b6a6497f80b9", "embedding": null, "metadata": {"page_label": "8", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "1b3d1945-0882-4162-bf8d-3a6834fb8fbb", "node_type": "4", "metadata": {"page_label": "8", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "a8fd4bda01fcbcf5f1a873f3151755bfe8ed263acb7127d8896dd4390846b67d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0ec99e8b-0b4f-4ad6-a271-ac3e3b276d29", "node_type": "1", "metadata": {"page_label": "8", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "2b3d1e11a86d32f8473f5b08004cf54b1660f0fe4ff039111e1c48dcda056169", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Various cells have the \nability to secrete ECM components but they are mainly \nsecreted by fibroblasts [ 214]. During cancer progression, \nECM can be considered as an initiation factor. The com -\nposition of ECM can be different based on the type of \ncancer, such as gastric tumors, in which a lower degree \nof differentiation improves the abundance of ECM com -\nponents, heightens cell metabolism, and increases meta -\nbolic reprogramming [ 215]. According to the proteomic \nanalysis, there is no difference between ECM compo -\nnents in tumor and normal tissues, while their levels \ndemonstrate changes that are manifested by enhance -\nment in ECM proteins and reduction in basement mem -\nbrane components modulating tumor angiogenesis, \nmetastasis, and invasion [ 216]. The density of ECM com -\nponents increases during tumor progression, and a num -\nber of factors, such as E-cadherin/\u03b2-catenin, demonstrate \nreduction, enhancing proliferation and metastasis of can -\ncer cells [ 217]. The increase in matrix density can cause a \nkind of environmental stress to enhance carcinogenesis. \nThe high-strength ECM can stimulate EMT to increase \ncancer progression and promote the infiltration of M2", "mimetype": "text/plain", "start_char_idx": 4620, "end_char_idx": 5816, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "8d2dbb2a-cce0-48db-9bb9-c083a4a74e6a": {"__data__": {"id_": "8d2dbb2a-cce0-48db-9bb9-c083a4a74e6a", "embedding": null, "metadata": {"page_label": "9", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "5fd22f96-9a35-4f85-9010-fbf0469d9fa7", "node_type": "4", "metadata": {"page_label": "9", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "333ce573095cdc9d599e0ca5930d825e70e14388f92724a506bede4d5b63bc0f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7321ef23-f825-43e9-b1de-267d1827cdd2", "node_type": "1", "metadata": {}, "hash": "0df91a915cadc1233de26a4c3b77fc96f118e9d56d4f0d9a84761e3f99e661fd", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Page 9 of 48\nLu et al. Journal of Hematology & Oncology            (2024) 17:16 \npolarized macrophages while it suppresses the function \nof CD 8+ T cells [ 218, 219].\nHypoxia\nThe presence of hypoxia is another feature of TME result -\ning from the high proliferation of tumor cells. The altera -\ntions in interstitial fluid pressure, decrease in pH, and \nenhancement in ROS generation can result from hypoxia \n[220]. In regions with hypoxia, there is high interstitial \nfluid pressure due to leaky vasculature and abnormal \nlymphatic drainage in the tumor [ 221]. Moreover, the \nhypoxia in TME can enhance the generation of lactic \nacid and carbonic acid through glycolysis induction, pro -\nviding an acidic pH. The hypoxia-inducible factor (HIF) \ncan induce carbonic anhydrase IX or XII to transform \ncarbon dioxide and water into HCO3\u2013 that, upon diffu -\nsion out of the cell membrane, it enhances HCO3\u2013 lev -\nels in TME. Furthermore, the endosomal and lysosomal \nvesicles in tumor cells demonstrate more acidic pH com -\npared to cytosolic pH [ 222]. The hypoxia TME displays \na redox potential difference between intracellular space \n(reducing) and extracellular space (oxidizing). Such redox \npotential is vital for the development of smart and selec -\ntive delivery of therapeutics [ 223]. The enzymatic reduc -\ntion during hypoxia in TME can cause the metabolism \nof chemical factors, including nitro, quinones, aromatic \nN-oxides, aliphatic N-oxides, and transition metals [ 224]. \nSuch a feature can be utilized to develop hypoxia-respon -\nsive structures for exploiting the hypoxic regions [ 225].\nMechanisms of immune evasion in cancer and \nunanswered questions in cancer immunotherapy\nThe immune system has undergone a transforma -\ntive evolution to combat cancer progression.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1786, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "7321ef23-f825-43e9-b1de-267d1827cdd2": {"__data__": {"id_": "7321ef23-f825-43e9-b1de-267d1827cdd2", "embedding": null, "metadata": {"page_label": "9", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "5fd22f96-9a35-4f85-9010-fbf0469d9fa7", "node_type": "4", "metadata": {"page_label": "9", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "333ce573095cdc9d599e0ca5930d825e70e14388f92724a506bede4d5b63bc0f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8d2dbb2a-cce0-48db-9bb9-c083a4a74e6a", "node_type": "1", "metadata": {"page_label": "9", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "226b644069ea575236e4da90331f0fa3b651202076304ac026b557c28b609ba3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b6053ffd-5968-4596-af45-e1e403bc7b5d", "node_type": "1", "metadata": {}, "hash": "16a13a350602b623e77af2b9f97353f71899e617618363269cc257b5d1790c86", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Mechanisms of immune evasion in cancer and \nunanswered questions in cancer immunotherapy\nThe immune system has undergone a transforma -\ntive evolution to combat cancer progression. However, \nimmune responses can be suppressed, and tumor cells \noften employ mechanisms to evade these responses, a \nconcept known as immune evasion. Recent studies have \nshed light on the major mechanisms contributing to the \nimmune evasion of cancer cells.\nMutations within tumor cells can facilitate immune \nevasion. This is evidenced by the dysregulation of CD 8+ \nT cells observed in clinical specimens harvested from \novarian cancer patients, accompanied by the activation \nof immunosuppressive signaling through TGF-\u03b2 [ 226]. A \nwell-known mechanism for inducing immune evasion is \nthe upregulation of PD-L1. In hepatocellular carcinoma, \nUSP22 expression increases via PRDM1, leading to \ndiminished SPI1 degradation through USP22 upregula -\ntion. This, in turn, results in increased PD-L1 expression, \npromoting immune evasion [ 227].\nEfforts to suppress PD-L1 have shown promise in \ndisrupting immune evasion. RNF31, with its ability to \ndownregulate PD-L1 by enhancing ubiquitination and \ndegradation of YAP , improves the function of CD 8+ T \ncells, offering potential in cancer immunotherapy [ 228]. \nWhile immune checkpoint inhibitors have significantly \nimproved tumor suppression and immunotherapy poten -\ntial, the efficacy of these treatments is compromised by \nmechanisms related to immune evasion.\nIn addition to the previously discussed mechanisms, \nChoi and colleagues [ 229] proposed that lactic acid, a \nbyproduct of cancer cell metabolism, plays a crucial \nrole in suppressing anti-cancer immunity. This hypoth -\nesis has been substantiated by further research, notably \nin the comprehensive review by Wang and colleagues \n[230]. Their findings indicate that the accumulation of \nlactic acid and the resulting acidic tumor microenviron -\nment (TME) significantly impair anti-cancer immune \nresponses. Notably, it has been demonstrated that the \npresence of lactic acid and the acidic conditions within \nthe TME inhibit the function of various immune cells, \nincluding T cells and dendritic cells.", "mimetype": "text/plain", "start_char_idx": 1606, "end_char_idx": 3806, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "b6053ffd-5968-4596-af45-e1e403bc7b5d": {"__data__": {"id_": "b6053ffd-5968-4596-af45-e1e403bc7b5d", "embedding": null, "metadata": {"page_label": "9", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "5fd22f96-9a35-4f85-9010-fbf0469d9fa7", "node_type": "4", "metadata": {"page_label": "9", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "333ce573095cdc9d599e0ca5930d825e70e14388f92724a506bede4d5b63bc0f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7321ef23-f825-43e9-b1de-267d1827cdd2", "node_type": "1", "metadata": {"page_label": "9", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "9802de697b11da4458dd12755e1ee545b92e63fee6b1e6d6cd1253ed29673120", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fd053964-35ce-48f8-b9d7-9a2bcdb9a194", "node_type": "1", "metadata": {}, "hash": "2019f78d435ad7e89dd87c75ea985b154887fb86465110c986efbeee8a83af05", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Notably, it has been demonstrated that the \npresence of lactic acid and the acidic conditions within \nthe TME inhibit the function of various immune cells, \nincluding T cells and dendritic cells. This leads to an \nimmunosuppressive environment that promotes tumor \ngrowth and metastasis. Such insights underscore the \ncomplex interplay between cancer cell metabolism and \nimmune evasion, emphasizing the pivotal role of lactic \nacid and the acidic TME as key contributors to cancer \nprogression.\nUpregulation of inhibitors such as SUSD6, TMEM127, \nand WWP2 in MHC-I has been implicated in immune \nevasion. Downregulation of SUSD6 increases MHC-I \nantigen presentation, suppressing cancer progression in a \nCD 8+ T cell-dependent manner. The mechanism involves \nSUSD6 forming a complex with TMEM127 and MHC-I \nto recruit WWP2 for lysosomal degradation of MHC-I, \nfacilitating immune evasion [ 231].\nMHC-I, a key factor in immune evasion, undergoes \ninternalization and degradation by CEMIP , further \nreducing immune surveillance [ 232]. In addition, SOX4-\ninduced T cell exhaustion mediated immune evasion. \nThe interaction between cancer cells and CD 8+ T cells, \nfacilitated by Midkine, alters immune system responses \n[233]. In PTEN-deficient animal models, PI3K\u03b2 down -\nregulation results in STAT3 suppression, accelerating \nimmune responses and revealing the potential of PI3K\u03b2 \nin causing immune tolerance and evasion [ 234].\nChromosomal changes and deletions also play a role in \nimmune evasion. Homozygous deletions affecting chro -\nmosome 9q21.3 impair the function of CDKN2A/B, has -\ntening carcinogenesis. Half of these deletions affect the \nIFN gene cluster on chromosome 9q21.3, increasing the \nescape of tumor cells from CD 8+ T cell surveillance [ 235].\nMaintaining the balance of interferon responses is vital \nfor cancer immunotherapy, as alterations in interferon \nand T cell levels can induce immune evasion.", "mimetype": "text/plain", "start_char_idx": 3611, "end_char_idx": 5538, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "fd053964-35ce-48f8-b9d7-9a2bcdb9a194": {"__data__": {"id_": "fd053964-35ce-48f8-b9d7-9a2bcdb9a194", "embedding": null, "metadata": {"page_label": "9", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "5fd22f96-9a35-4f85-9010-fbf0469d9fa7", "node_type": "4", "metadata": {"page_label": "9", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "333ce573095cdc9d599e0ca5930d825e70e14388f92724a506bede4d5b63bc0f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b6053ffd-5968-4596-af45-e1e403bc7b5d", "node_type": "1", "metadata": {"page_label": "9", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "5a9717d3491597cc2f139fc8d0963ce7fc5684d8f48849e337828142986c7688", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Maintaining the balance of interferon responses is vital \nfor cancer immunotherapy, as alterations in interferon \nand T cell levels can induce immune evasion. mTORC1 \nenhances B7-H3 expression, reducing T cell function and \nIFN-\u03b3 responses while increasing MHC-II expression \n[236]. One mechanism causing immune escape involves", "mimetype": "text/plain", "start_char_idx": 5380, "end_char_idx": 5707, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "d86e27ea-ca09-4c27-aa20-119d1cc3181f": {"__data__": {"id_": "d86e27ea-ca09-4c27-aa20-119d1cc3181f", "embedding": null, "metadata": {"page_label": "10", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "b9da6b8c-332e-4fe7-8f05-7a7f25d2fa67", "node_type": "4", "metadata": {"page_label": "10", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "2b8430a2369100921f2a0be4a655a23602961c7d914947d77271e065efe5df47", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8e61bd17-962d-4e2d-89c2-0fdd0d06aa03", "node_type": "1", "metadata": {}, "hash": "ee40d56b7a7820ba507667679e4e54b07a8828215783b97fed1772a872111337", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Page 10 of 48\nLu et al. Journal of Hematology & Oncology            (2024) 17:16 \nreducing the number of T cells, mediated by apoptosis \ninduction. Extracellular galectin 4 stimulates T cell apop -\ntosis, diminishing immune surveillance. Conversely, the \ndownregulation of galectin 4 promotes M1 polarization \nof macrophages and enhances T cells and dendritic cells, \ndisrupting immune escape [ 237].\nThe immune cells have shown potential in the identi -\nfication and recognition of neoplastic cells possessing \ninitiation mutations to suppress tumorigenesis [ 238]. \nAlthough the origination of a tumor is from a single \ntransformed cell, the presence of genomic instability can \ncause the generation of cancer cells that are genetically \nheterogeneous with unique morphological and physi -\nological characteristics. Moreover, the tumor cells have \nshown significant features in terms of surface molecule \nexpression, proliferation and angiogenesis [ 239] resulting \nfrom the morphological and epigenetic plasticity. Hence, \nthe cancer cells demonstrate expression of different anti -\ngens that may be tumor-specific or tumor-associated, \ndifferentiation antigens, and lectin-binding sites. Such \nantigens display uneven distribution on tumor subpop -\nulations and can stimulate various immune responses \n[240]. Such tumor heterogeneity can significantly affect \nthe genotype, gene expression, cellular morphology, \nmetabolic activity, motility, and behaviors, including \nproliferation, antigen presentation, drug response, and \nmetabolism [ 241]. Furthermore, this heterogeneity can be \nutilized for the diagnosis, therapeutic efficacy, and recog -\nnition of promising targets [ 242]. Such a heterogeneous \nnature of cancer cells can provide significant opportu -\nnities to escape from the function of immune cells. The \ntumor cells significantly proliferate in TME, which can \ncause hypoxia. The presence of hypoxia in TME recruits \nMDSCs and impairs the function of NK cells to provide \na pre-metastatic niche [ 243], showing that cancer cells \nmetastasize through suppressing immune surveillance.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2101, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "8e61bd17-962d-4e2d-89c2-0fdd0d06aa03": {"__data__": {"id_": "8e61bd17-962d-4e2d-89c2-0fdd0d06aa03", "embedding": null, "metadata": {"page_label": "10", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "b9da6b8c-332e-4fe7-8f05-7a7f25d2fa67", "node_type": "4", "metadata": {"page_label": "10", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "2b8430a2369100921f2a0be4a655a23602961c7d914947d77271e065efe5df47", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d86e27ea-ca09-4c27-aa20-119d1cc3181f", "node_type": "1", "metadata": {"page_label": "10", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "90b4c3aba3cd15223e884cba1a46c895f5d92ba480d86867392e6a24489347e1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e35d5419-adc2-4718-a662-73161e91a49e", "node_type": "1", "metadata": {}, "hash": "153a407660dac4e322cdfe00d59852e4c2ebca9f32251ac40dbc102b2be8aad4", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Upon surgical resection, the cancer cells undergo trauma, \nand such tumor cells can enhance the generation of cyto -\nkines and other factors, including IL-6, C-reactive pro -\ntein (CRP), TNF-\u03b1, IL-1\u03b2 to affect the immune system \n[244]. Therefore, the application of conventional thera -\npies and the heterogeneous nature of cancer cells should \nbe considered in immune evasion. The immune cells are \nable to suppress vulnerable cancer cells presenting tumor \nantigens [ 245], while the heterogeneous nature of cancer \ncells allows them to escape such action of the immune \nsystem. Furthermore, the tumor cells have shown capac -\nity to induce apoptosis in tumor-specific cytotoxic T lym -\nphocytes [ 246].\nTherefore, since immune evasion commonly occurs \nin cancer, cancer immunotherapy has been introduced. \nRegarding cancer immunotherapy, there are a number of \nchallenges that should be addressed. The first and most \nimportant challenge is regarding the fact that dominant \ndrivers of cancer immunity should be highlighted. More -\nover, more investigation should be directed towards \nunderstanding the function of organ-specific tumor \nimmune context. Checkpoint inhibitors are commonly \nutilized for the treatment of human cancers, but there \nis still a long way towards understanding the molecular \nlandscape of factors regulating primary versus secondary \nimmune escape. There is a big question about whether \nit is better to use endogenous or synthetic immunity for \nthe treatment of human cancers. Moreover, since cancer \nimmunotherapy has been applied in clinics, there are also \nquestions regarding the effective evaluation of cancer \nimmunotherapy in clinical studies. One of the hopes is \nthe advances in the field of biology highlighting the appli -\ncation of biomarkers and signatures for cancer immuno -\ntherapy. Therefore, precision medicine can significantly \nbenefit by highlighting the signatures and developing \nstrategies based on targeting accurate and efficient sig -\nnatures for cancer immunotherapy. Another question \nis that various types of regimens for cancer immuno -\ntherapy have been developed, and comprehensive stud -\nies are required to be performed in improving long-term \nsurvival through a combination of such regimens.", "mimetype": "text/plain", "start_char_idx": 2103, "end_char_idx": 4360, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "e35d5419-adc2-4718-a662-73161e91a49e": {"__data__": {"id_": "e35d5419-adc2-4718-a662-73161e91a49e", "embedding": null, "metadata": {"page_label": "10", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "b9da6b8c-332e-4fe7-8f05-7a7f25d2fa67", "node_type": "4", "metadata": {"page_label": "10", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "2b8430a2369100921f2a0be4a655a23602961c7d914947d77271e065efe5df47", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8e61bd17-962d-4e2d-89c2-0fdd0d06aa03", "node_type": "1", "metadata": {"page_label": "10", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "28c2af751f26a1f75fade39bd2f0fa6c4bf4ac16239a25b60e9306807019c74b", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Another question \nis that various types of regimens for cancer immuno -\ntherapy have been developed, and comprehensive stud -\nies are required to be performed in improving long-term \nsurvival through a combination of such regimens. In \norder to optimize the process of cancer immunotherapy, \nresponding to such concerns and questions can improve \nthe potential for the treatment of cancer patients [ 247].\nNanoparticles targeting tumor microenvironment \ncomponents in cancer immunotherapy\nNanoparticles targeting tumor-associated macrophages\nTo address the immunosuppressive role played by \nM2-polarized macrophages, the stimulation of M1 polar -\nization through nanostructures emerges as a promising \navenue for enhancing immunotherapy. A pivotal mecha -\nnism involves the development of genetically modified \npristine cells, whose extracted cell membrane is uti -\nlized to coat and functionalize nanoparticles in cancer \ntherapy. Biomimetic magnetic nanoparticles featuring \ngene-edited cell membranes demonstrate the capacity to \ntarget multiple pathways, thereby regulating macrophage \npolarization and suppressing tumorigenesis. Specifically, \nthe presence of gene-edited cell membranes suppresses \nthe CD44/SIRP\u03b1 axis by upregulating SIRP\u03b1 variants. \nMagnetic nanoparticles, forming the core, play a crucial \nrole in re-educating and reprogramming macrophages, \nthereby accelerating cancer immunotherapy [ 248].\nChanges in macrophages extend beyond polarization, \nand their role in regulating antigen processing is also \nsignificant. Certain clinically important pathways, such \nas STING, pose a challenge for targeting at the clini -\ncal level due to a lack of targeted delivery. By function -\ning as a STING agonist, ZnCDA encapsulates CDA and \ndisrupts the endothelial barrier in cancer vasculature, \nfacilitating penetration into the TME and tumor site.", "mimetype": "text/plain", "start_char_idx": 4129, "end_char_idx": 5992, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "173af25e-6718-471c-9453-2755bbf24856": {"__data__": {"id_": "173af25e-6718-471c-9453-2755bbf24856", "embedding": null, "metadata": {"page_label": "11", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "4a1be7b9-f3dd-43d7-a3ee-65352c2eee30", "node_type": "4", "metadata": {"page_label": "11", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "7e31015549c74b58ab598614c328605c4289176d47b88022cc5a9a9545630d08", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a0193a14-9560-478f-a10f-a6ff357cdc1b", "node_type": "1", "metadata": {}, "hash": "930898698277cd1202222f63cb2a81f70d4b819a5e8cee5837158cc167675475", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Page 11 of 48\nLu et al. Journal of Hematology & Oncology            (2024) 17:16 \nThese nanoparticles target macrophages, enhancing anti -\ngen processing and expediting T-cell-related responses in \ncancer immunotherapy [ 249]. A number of nanoparticles \nhave shown potential in changing the polarization of \nTAMs. In the context of M1 polarization of macrophages, \ndifferent mechanisms are available for the induction of \npolarization of macrophages into the M1 phenotype. \nGinseng-derived nanostructures with extracellular vesi -\ncle-like properties can stimulate the TLR4/MyD88 axis, \nresulting in increased M1 polarization of macrophages, \nelevated ROS levels, and induction of apoptosis in mela -\nnoma [ 250]. In fact, the M1 polarization of macrophages \nhas been accompanied by apoptosis induction.\nAlthough the primary focus of this section is to evalu -\nate the role of nanoparticles in macrophage re-educa -\ntion, studies have demonstrated that membranes can \nbe extracted from macrophages to coat and functional -\nize nanoparticles. This approach results in the develop -\nment of biocompatible structures with stealth properties \n[251]. Such an approach can be used mutually in which \nnanoparticles are functionalized with macrophage mem -\nbrane to improve their targeting ability towards mac -\nrophages and TME, and on the other hand, they can \nbe designed for re-education of macrophages into M1 \nphenotype.\nTargeting macrophages in cancer treatment is pri -\nmarily driven by their immunosuppressive function. \nDespite the development of various immune response \nregulation strategies, such as phototherapy-induced \nimmunotherapy, concerns persist regarding immuno -\ngenicity and inflammation induction. Therefore, it is \ncrucial for nanoparticles to employ safe and biocompat -\nible mechanisms to counteract macrophage-mediated \nimmunosuppression.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1859, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "a0193a14-9560-478f-a10f-a6ff357cdc1b": {"__data__": {"id_": "a0193a14-9560-478f-a10f-a6ff357cdc1b", "embedding": null, "metadata": {"page_label": "11", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "4a1be7b9-f3dd-43d7-a3ee-65352c2eee30", "node_type": "4", "metadata": {"page_label": "11", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "7e31015549c74b58ab598614c328605c4289176d47b88022cc5a9a9545630d08", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "173af25e-6718-471c-9453-2755bbf24856", "node_type": "1", "metadata": {"page_label": "11", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "7bb54e0d01479d7e76c6738f322be32c09c511dbb7fdd13d950f1697a4d478e7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "377d05f6-dbd8-4adf-a793-cf0e6eb492a7", "node_type": "1", "metadata": {}, "hash": "11ceab9971131d85f096be0cf100f85a26cd7ad1df64ac8a8f60cb846ef35ba8", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Therefore, it is \ncrucial for nanoparticles to employ safe and biocompat -\nible mechanisms to counteract macrophage-mediated \nimmunosuppression. The biomimetic Fe 3O4-SAS@PLT \nnanostructures, derived from sulfasalazine-loaded meso -\nporous magnetic nanostructures and functionalized with \nplatelets, have been designed to suppress the glutamate-\ncystine antiporter system Xc-pathway in ferroptosis \ninduction. This ferroptosis induction demonstrates syn -\nergistic effects with PD-L1 immune checkpoint immu -\nnotherapy, as observed in animal models. Notably, these \nbiomimetic nanostructures induce ferroptosis, promot -\ning M1 polarization of macrophages and disrupting the \nimmunosuppressive TME [ 252].\nWhen considering nanoparticles for modulating mac -\nrophages, especially for potential use in cancer immu -\nnotherapy at the clinical level, biocompatibility is as \nimportant as functionality. Lipid nanoparticles with cat -\nionic features have shown promise as carriers, delivering \nmRNA to targeted sites. Loading mRNA for re-educating \nmacrophage polarization onto lipid nanoparticles cre -\nates safe and biocompatible nanostructures for cancer \nimmunotherapy [ 253]. A significant advancement in \nutilizing nanoparticles for macrophage re-education \ninvolves functionalizing them with macrophage mem -\nbranes to enhance efficacy. This hypothesis has been \ntested in experiments, demonstrating the potential of \nmembranes derived from tumor-associated macro -\nphages with immunomodulatory functions and anti -\ngen-homing affinity. These membranes were employed \nto functionalize upconversion nanostructures loaded \nwith photosensitizers. Notably, tumor-associated mac -\nrophage membrane-functionalized nanoparticles sup -\npress CSF1 and interactions between cancer cells and \nthe tumor microenvironment, impairing tumorigenesis. \nMoreover, these nanoparticles stimulate photodynamic \ntherapy by suppressing the M2 phenotype, enhancing \nM1 macrophage polarization, inducing immunogenic cell \ndeath, and improving the generation of T cells through \nenhanced antigen presentation [ 254].", "mimetype": "text/plain", "start_char_idx": 1715, "end_char_idx": 3807, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "377d05f6-dbd8-4adf-a793-cf0e6eb492a7": {"__data__": {"id_": "377d05f6-dbd8-4adf-a793-cf0e6eb492a7", "embedding": null, "metadata": {"page_label": "11", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "4a1be7b9-f3dd-43d7-a3ee-65352c2eee30", "node_type": "4", "metadata": {"page_label": "11", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "7e31015549c74b58ab598614c328605c4289176d47b88022cc5a9a9545630d08", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a0193a14-9560-478f-a10f-a6ff357cdc1b", "node_type": "1", "metadata": {"page_label": "11", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "36a45c7038d47db3dca584337ecb2c37be64e78884fd3cd595c35c3383d8044d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0e9a08db-bd9f-4de7-9832-bf67acd8f1aa", "node_type": "1", "metadata": {}, "hash": "1b84f39a733f1342a112b26482717895c0edd83b8c290447049f04176a6ca115", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Moreover, these nanoparticles stimulate photodynamic \ntherapy by suppressing the M2 phenotype, enhancing \nM1 macrophage polarization, inducing immunogenic cell \ndeath, and improving the generation of T cells through \nenhanced antigen presentation [ 254].\nReorienting macrophages toward the M2 pheno -\ntype presents a hurdle in achieving successful immu -\nnotherapy. This polarization is chiefly instigated by \ntumor cell-secreted MCSF, resulting in the elevation of \nCSF1-R. Moreover, the heightened expression of SIRP\u03b1 \non myeloid cell surfaces activates SHP-1 and SHP-2 in \nmacrophages, impeding immunotherapy by hampering \nphagocytosis. Moving beyond macrophage polarization, \nefforts are redirected to address macrophage activity \nfailure. To augment macrophage phagocytosis, promis -\ning strategies involve the regulation of CSF1R and SHP2. \nNanoparticles laden with CSF1R and SHP2 suppressors \ninduce M1 macrophage polarization, boosting phagocy -\ntosis to impede tumorigenesis [ 255].\nAfter elucidating the key mechanisms governing mac -\nrophage polarization and activity, the subsequent focus \ninvolves exploring nanoparticles with potential clinical \napplications. The FDA-approved ferumoxytol, an iron \nsupplement and iron oxide nanostructure, serves dual \nroles as a drug delivery system and imaging agent. When \nco-cultured with macrophages for treating lung cancer \nmetastasis, ferumoxytol upregulates caspase-3, inducing \nmacrophages to express mRNAs for pro-inflammatory \nTh1-related responses. Ferumoxytol effectively sup -\npresses tumor metastasis and proliferation while promot -\ning M1 macrophage polarization to enhance the quality \nof cancer immunotherapy [ 256].\nA growing body of evidence supports the poten -\ntial involvement of tumor-associated macrophages in \nthe development of drug resistance [ 257, 258]. These \nmacrophages play a role beyond immune system regu -\nlation, influencing the response to chemotherapy.", "mimetype": "text/plain", "start_char_idx": 3553, "end_char_idx": 5495, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "0e9a08db-bd9f-4de7-9832-bf67acd8f1aa": {"__data__": {"id_": "0e9a08db-bd9f-4de7-9832-bf67acd8f1aa", "embedding": null, "metadata": {"page_label": "11", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "4a1be7b9-f3dd-43d7-a3ee-65352c2eee30", "node_type": "4", "metadata": {"page_label": "11", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "7e31015549c74b58ab598614c328605c4289176d47b88022cc5a9a9545630d08", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "377d05f6-dbd8-4adf-a793-cf0e6eb492a7", "node_type": "1", "metadata": {"page_label": "11", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "dd273a0fce7e4b22785ffa7f4a7750b63662a9d181a2b0fed1561e59580bbd5a", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "These \nmacrophages play a role beyond immune system regu -\nlation, influencing the response to chemotherapy. Furin-\nbased aggregated gold nanostructures capitalize on the \n\u201cenhanced permeability and retention\u201d effect, aggregating \nin breast cancer due to furin upregulation. This process \nsuppresses exocytosis, leading to increased preferential \naccumulation at the tumor site. These nanoparticles also \ninhibit autophagy, promoting M1 macrophage education", "mimetype": "text/plain", "start_char_idx": 5387, "end_char_idx": 5844, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "1c69593e-dab1-4bf0-b41a-e15127693faf": {"__data__": {"id_": "1c69593e-dab1-4bf0-b41a-e15127693faf", "embedding": null, "metadata": {"page_label": "12", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "31fd1866-f5e7-434f-8dae-c26972fde9a5", "node_type": "4", "metadata": {"page_label": "12", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "8a20f5712c34685c3a7f2bbfb31139973433e66cb2982a37b558f8b5906e5615", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c5219734-fcfc-45dd-b4e2-bff802f62d82", "node_type": "1", "metadata": {}, "hash": "0b9db6bfc2cdf6cbed5cdebab26206f8b3d6b33054313f0d11cc700ce590abaf", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Page 12 of 48\nLu et al. Journal of Hematology & Oncology            (2024) 17:16 \nto counteract drug resistance [ 259]. Table\u00a0 1 provides a \nconcise overview of the applications of nanoparticles in \nmacrophage re-education for cancer immunotherapy. \nFigure\u00a03 provides an overview of the regulation of tumor-\nassociated macrophages by nanoparticles in cancer \nimmunotherapy.\nNanoparticles targeting cancer-associated fibroblasts\nNanoparticles play a crucial role in influencing cancer-\nassociated fibroblasts (CAFs) within the cancer treatment \nlandscape. Interactions between cancer cells and CAFs in \nthe TME contribute to tumorigenesis, making it essential \nto explore nanoparticle applications in suppressing these \ninteractions and impeding cancer progression. In ovar -\nian cancer, ovarian cancer cells and TME cells promote \nthe activation of ovarian CAFs. Gold nanoparticles with a \nsize of 20\u00a0nm effectively disrupted this interaction, inhib -\niting CAF activation and offering potential in the treat -\nment of ovarian cancer [ 275].\nCAFs play a supportive role in tumor metastasis. \nCore-shell nanoparticles, with gold as the core and sil -\nver as the shell, were effective in suppressing osteopontin \nexpression in CAFs, hindering cancer progression with -\nout impacting CAF biomarker expression [ 276]. Besides \nmodulating CAF activation and secretions, nanostruc -\ntures may also be used for targeted CAF destruction. \nUltra-small iron oxide nanocarriers (6\u00a0 nm in diameter) \ncombined with low-frequency rotating magnetic fields \ninduce mechanical forces, leading to CAF death and \nlysosomal disruption [ 277]. Targeting CAFs for destruc -\ntion enhances nanoparticle internalization. Such a strat -\negy addresses the challenge of a dense TME that hinders \nnanoparticle penetration. Ferritin nanocages loaded with \nthe photosensitizer ZnF16Pc and modified with a single-\nchain variable fragment that targeted fibroblast activa -\ntion protein, facilitated phototherapy to reduce CAFs \nand improve nanoparticle penetration into the tumor site \n[278].", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2059, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "c5219734-fcfc-45dd-b4e2-bff802f62d82": {"__data__": {"id_": "c5219734-fcfc-45dd-b4e2-bff802f62d82", "embedding": null, "metadata": {"page_label": "12", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "31fd1866-f5e7-434f-8dae-c26972fde9a5", "node_type": "4", "metadata": {"page_label": "12", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "8a20f5712c34685c3a7f2bbfb31139973433e66cb2982a37b558f8b5906e5615", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1c69593e-dab1-4bf0-b41a-e15127693faf", "node_type": "1", "metadata": {"page_label": "12", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "93105327b8afbad812aca6e70ea43311306b177fa997e0713a5129ce3ceb470b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "95b8fb2c-8110-411c-883d-9931bd220f6b", "node_type": "1", "metadata": {}, "hash": "e3e1c4a024f3f2167623364a65eefaf0379c41d6cced9c17d2c7a0a561bb4fe4", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Nanoparticles can serve dual functions in regulating \nCAFs and modulating immune responses. Poly(lactic-\nco-glycolic acid) (PLGA) nanoparticles functionalized \nwith cancer cell membrane not only enhanced cancer \ncell-CAF interactions, but also increased antigen uptake, \nstimulating CD 8+ and CD 4+ T cells through MHC-I and \nMHC-II, thus promoting cancer immunotherapy [ 279]. \nThe fibroblast activation protein, upregulated on CAF \nsurfaces, represents a promising target in cancer immu -\nnotherapy. Nanoparticles functionalized with a single-\nchain variable fragment for ZnF16Pc delivery in cancer \nphototherapy lacked systemic toxicity. These function -\nalized nanoparticles suppressed cancer progression in \nboth primary and distant sites by accelerating immune \nresponses and promoting anti-CAF immunity [ 280].\nSome nanoparticles are designed to respond to fibro -\nblast activation protein as a CAF biomarker. Albumin \nnanostructures encapsulating paclitaxel and functional -\nized with CAP showed promise in targeting fibroblast \nactivation protein in CAFs. Incorporation of the photo -\nsensitive compound IR-780 further enabled near-infra -\nred laser irradiation for photothermal therapy, resulting \nin tumor suppression and improved deep tumor pen -\netration [ 281]. The concept of specifically targeting \nCAFs using their biomarkers has significant potential in \nenhancing the fight against cancer.\nNanoparticles targeting T cells\nNanoparticles, through targeted regulation of T cells, \nhave emerged as a promising avenue for effective cancer \nimmunotherapy [ 282\u2013288]. Increasing the infiltration \nof CD 8+ T cells and T helper cells in the TME is crucial \nfor TME remodeling and activating the immune system \nagainst cancer progression. Nanoparticles such as man -\nganese zinc sulfide nanostructures play a pivotal role in \nmediating this effect [ 289]. A noteworthy trend in recent \nyears involves the integration of immunotherapy with \nother therapeutic modalities like chemotherapy or pho -\ntotherapy. Hybrid prodrug nanocarriers carrying cispla -\ntin and camptothecin, stimulate the cGAS/STING axis \nand induce DNA damage.", "mimetype": "text/plain", "start_char_idx": 2060, "end_char_idx": 4198, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "95b8fb2c-8110-411c-883d-9931bd220f6b": {"__data__": {"id_": "95b8fb2c-8110-411c-883d-9931bd220f6b", "embedding": null, "metadata": {"page_label": "12", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "31fd1866-f5e7-434f-8dae-c26972fde9a5", "node_type": "4", "metadata": {"page_label": "12", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "8a20f5712c34685c3a7f2bbfb31139973433e66cb2982a37b558f8b5906e5615", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c5219734-fcfc-45dd-b4e2-bff802f62d82", "node_type": "1", "metadata": {"page_label": "12", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "390fb6dee96370f6c5337919bc86fedc3108f3bd02752f8bbfb35b09dfce3544", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Hybrid prodrug nanocarriers carrying cispla -\ntin and camptothecin, stimulate the cGAS/STING axis \nand induce DNA damage. Additionally, these prodrug \nnanocarriers enhance CD 8+ T cell infiltration in the \nTME, improving immunotherapy outcomes for colorec -\ntal cancer. These hybrid nanocarriers possess a respon -\nsive feature to reactive oxygen species (ROS) and are \nconstructed from mPEG2k-DSPE and other polymers \n[290]. The mPEG/PLGA/PLL nanocarriers, delivering \nCD155-siRNA and modified with PD-L1 antibodies, \ncan simultaneously suppress CD155 and PD-L1, avoid -\ning immune evasion. They enhance CD 8+ T cell infiltra -\ntion and induce immunogenic cell death in breast cancer \ntherapy [ 291].\nDeveloping an effective anti-cancer vaccine requires \nnanoparticles that can induce systemic immunity. \nMnO2-melittin nanostructures, responsive to changes \nin the TME, serve as promising vaccines by trigger -\ning systemic immune responses. These nanostructures \ninduce cancer cell death through the Fenton reaction in \nthe TME, activate the cGAS/STING axis, and enhance \nantigen-presenting cell maturation. Furthermore, MnO2-\nmelittin nanoparticles stimulate systemic immune reac -\ntions, including the promotion of T cells and increased \nlevels of pro-inflammatory cytokines and chemokines \n[292].\nCombining chemotherapy with phototherapy is \nanother strategy to expedite tumor suppression. Pro -\ndrug nanocarriers, developed from hyaluronic acid and \nadamantine-conjugated heterodimers of PPa and JQ1, \ntarget CD44-overexpressed pancreatic cancer cells.", "mimetype": "text/plain", "start_char_idx": 4077, "end_char_idx": 5635, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "6b15ecfd-0471-4044-a275-b385ac6aac33": {"__data__": {"id_": "6b15ecfd-0471-4044-a275-b385ac6aac33", "embedding": null, "metadata": {"page_label": "13", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "4469f94f-ee49-4d40-9fe7-1158afa84afe", "node_type": "4", "metadata": {"page_label": "13", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "e9784f45f4e11983302557df6dfaa3a59ebb9ca3a4bf6e11099e7e31cd36424d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e51b4e5d-ae69-4681-93df-62c0ccf0cd1c", "node_type": "1", "metadata": {}, "hash": "e42cf4352b939c05c486208c9c55b60fa12b990c7426242be858e05450bad024", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Page 13 of 48\nLu et al. Journal of Hematology & Oncology            (2024) 17:16 \nNanoparticle Cancer type/Cell \nline\nSize (nm)/Zeta \npotential (mV)\nOutcome Refer -\nence\nPEGylated \nliposomes\nBreast cancer/4T1 \ncells\nPancreatic cancer/ \nmurine KPC1245 \nand KPC1242 cells\n75\u00a0nm Delivery of mannose and levamisole hydrochloride for glycolysis suppression and reducing mitochondrial energy metabolism\nSuppression of cancer proliferation\nCombination with radiotherapy impairs M2 polarization of macrophages and increases immune responses\n [260]\nProdrug \nnanoparticles\nColorectal cancer/\nMC38 cells\nBreast cancer/\nMCF-7 cells\n39\u00a0nm/-8.23 mV\n263.2\u00a0nm/less than \n\u2212 5 mV\nCo-delivery of doxorubicin and R848\nModification of nanoparticles with bifunctional PD-1/PD-L1 peptide antagonist PCP\nCleavage of nanoparticles with FAP-\u03b1 in the tumor stroma\nRelease of cargo in the tumor site stimulates immunogenic cell death and causes macrophage reprogramming\n [261]\nLipid \nnanoparticles\nPancreatic cancer/\nKPC cells\n122.4\u00a0nm/+27.82 \nmV\nLoading lipid nanoparticles in injectable hydrogels\nDelivery of CCL5-siRNA by lipid nanoparticles to induce M1 polarization of macrophages and enhance T cell-induced immune \nresponses\n [262]\nUpconversion \nnanostructures\nBreast cancer/4T1 \ncells\n39.5\u00a0\u00b1\u00a01.1 and \n54.1\u00a0\u00b1\u00a01.3\u00a0nm/-19.7 \nmV and \u2212 4.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1312, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "e51b4e5d-ae69-4681-93df-62c0ccf0cd1c": {"__data__": {"id_": "e51b4e5d-ae69-4681-93df-62c0ccf0cd1c", "embedding": null, "metadata": {"page_label": "13", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "4469f94f-ee49-4d40-9fe7-1158afa84afe", "node_type": "4", "metadata": {"page_label": "13", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "e9784f45f4e11983302557df6dfaa3a59ebb9ca3a4bf6e11099e7e31cd36424d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6b15ecfd-0471-4044-a275-b385ac6aac33", "node_type": "1", "metadata": {"page_label": "13", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "be1ea6e94492d44d81246da330b427fc1726a0c88eabeec2cbb0a2788917eec4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "25b90b38-a924-452f-91bf-9ab1ba275dcd", "node_type": "1", "metadata": {}, "hash": "bff322ad232d29673ee3db6d160fca6b9934516a5f712fb7b5f207385e5628d3", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "5\u00a0\u00b1\u00a01.1 and \n54.1\u00a0\u00b1\u00a01.3\u00a0nm/-19.7 \nmV and \u2212 4.1 mV\nIntroduction of upconversion nanoparticles co-doped with perfluorocarbon (PFC)/chlorin e6 (Ce6)\nTargeted delivery of paclitaxel as a chemotherapy drug\nIncreasing singlet oxygen production\nStimulating M1 polarization of macrophage in accelerating pro-inflammatory cytokine release to impair breast cancer progression\n [263]\nIron-chelated \nmelanin-like \nnanocarriers\nColon and breast \ncancers/ CT26 and \n4T1 cells\n150\u00a0nm Stimulating M1 polarization of macrophages and providing photothermal therapy, they accelerated tumor-associated antigen \nrelease to improve cancer immunotherapy\n [264]\nSupramolecular \nnanoparticles\nBreast cancer/4T1 \ncells\n190.1\u00a0nm/-17.1 mV Suppression of CSF1R and MAPK to stimulate M1 polarization of macrophages  [265]\nMIP-3\u03b2 plasmid Breast cancer/4T1 \ncells\n90\u00a0nm/-2.1 mV Increasing dendritic cell maturation and suppressing M2 polarization of macrophages  [266]\nAu@PG \nnanocarriers\nLung cancer/ \nLewis lung carci-\nnoma cells\n32.2\u00a0nm at 2.5 mM \nONPG, 29.8\u00a0nm at \n10 mM, 26.4\u00a0nm \nat 50 mM, and \n18.3\u00a0nm at 75 mM\nPolyaniline-based glycol-condensation on the nanostructures\nSwitching M2 polarized macrophages into M1 polarized macrophages\nNanoparticles with smaller sizes demonstrate higher efficacy in the macrophage re-education\n [267]\nCaCO3-loaded Au \nnanostructures\nMacrophages/\nRAW 264.7 cells\n32\u00a0nm Elongating macrophage cell morphology\nStimulation of M1 biomarker and inflammatory cytokines\nInducing M2 polarization of macrophages\n [268]\nPolymeric \nnanocarriers\nOsteosarcoma/\nK7M2 cells\n98.4\u00a0nm/-14.", "mimetype": "text/plain", "start_char_idx": 1267, "end_char_idx": 2844, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "25b90b38-a924-452f-91bf-9ab1ba275dcd": {"__data__": {"id_": "25b90b38-a924-452f-91bf-9ab1ba275dcd", "embedding": null, "metadata": {"page_label": "13", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "4469f94f-ee49-4d40-9fe7-1158afa84afe", "node_type": "4", "metadata": {"page_label": "13", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "e9784f45f4e11983302557df6dfaa3a59ebb9ca3a4bf6e11099e7e31cd36424d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e51b4e5d-ae69-4681-93df-62c0ccf0cd1c", "node_type": "1", "metadata": {"page_label": "13", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "6b413a2e181f9eceed0f267febb9081fbb4574fc32c71c4b88e356168461724f", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "4\u00a0nm/-14.3 mV Biodegradable nanoparticles for delivery of regorafenib as vascular normalization compound\nRelease of cargo upon laser irradiation of 808\u00a0nm and increasing hypoxia in TME\nInduction of the release of reactive oxygen species and mediation of immunogenic cell death\nStimulation of M1 polarization of macrophages\n [269]\nGadofullerene \nnanocarriers\nBreast cancer/4T1 \ncells\n68.1\u00a0nm/-37.7 mV M1 polarization of macrophages and increasing infiltration of T lymphocytes in the TME for cancer suppression  [270]\nDGL-ZA \nnanoparticles\nBreast cancer/4T1 \ncells\n123.1\u00a0nm/-13.4 mV Potential cancer biodistribution, extravasation, and high tumor penetration\nConjugation of dendrigraft poly-L-lysines as inducers of autophagy\nMacrophage regulation and increasing tumor-suppressor activity\n [271]\nTable 1 Nanoparticle-induced cancer immunotherapy through targeting macrophages", "mimetype": "text/plain", "start_char_idx": 2835, "end_char_idx": 3709, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "80d3ef30-a0aa-4c2d-9734-9317ee93f4b2": {"__data__": {"id_": "80d3ef30-a0aa-4c2d-9734-9317ee93f4b2", "embedding": null, "metadata": {"page_label": "14", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "fe46a362-7871-46bc-9d56-2a7f3396288f", "node_type": "4", "metadata": {"page_label": "14", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "b477fd3599d562a0c6ca53231fad6462252a9ec456e59983da177d6d7d3b75ae", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dd8fd21e-6aa6-41fb-a71e-c19ceeaea478", "node_type": "1", "metadata": {}, "hash": "ade8880d6276f656253cd78f1d840d5fd3a00120390599c340502b274dbda8d4", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Page 14 of 48\nLu et al. Journal of Hematology & Oncology            (2024) 17:16 \nThis combination of phototherapy and immunotherapy \nincreases T lymphocyte infiltration. Moreover, JQ1 sup -\npresses phototherapy-induced immune evasion by down -\nregulating c-Myc and PD-L1, resulting in significant \ntumor suppression [ 293].\nAs cancer development is a gradual process, effec -\ntive treatment should focus on providing long-term \nimmunity. The use of cancer vaccines has significantly \nincreased in recent years; however, a major challenge \nremains in the targeted delivery of cargo, including anti -\ngens and adjuvants. To address this issue, glycosylated \npoly(lactic-co-glycolic acid) (PLGA) nanocarriers have \nbeen developed for the delivery of the ovalbumin antigen \nand CpG as an adjuvant in cancer vaccination. The sur -\nface of the nanostructures is modified with galactose or \nmannose. These nanoparticles possess high loading abil -\nity and sustained release, which are key features for the \ndevelopment of cancer vaccines. They stimulate dendritic \ncell maturation, promote antigen uptake, and enhance \nCD 4+ T cell levels, leading to increased infiltration of \nCD 8+ T cells in cancer immunotherapy [ 294].\nAn innovative approach in cancer therapy involves \ndeveloping nanoparticles that mimic pathogens to induce \na robust immune response. Saccharomyces cerevisiae  \n(yeast)-based nanocarriers function as nano-patho -\ngen-associated molecular patterns (nano-PAMPs) and, \nthrough the induction of Dectin-2 and TLR-4, enhance \nTH17 responses, contributing to anti-cancer immunity \n[295]. Stimulation of T helper cells has proven effective \nin cancer immunotherapy. Chondroitin sulfate-modified \nnanostructures conjugated with glycolic acid or man -\nnose, along with cationic liposomes loaded with ovalbu -\nmin, can stimulate the maturation of dendritic cells and \nevoke T helper type I and II responses [ 296].", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1921, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "dd8fd21e-6aa6-41fb-a71e-c19ceeaea478": {"__data__": {"id_": "dd8fd21e-6aa6-41fb-a71e-c19ceeaea478", "embedding": null, "metadata": {"page_label": "14", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "fe46a362-7871-46bc-9d56-2a7f3396288f", "node_type": "4", "metadata": {"page_label": "14", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "b477fd3599d562a0c6ca53231fad6462252a9ec456e59983da177d6d7d3b75ae", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "80d3ef30-a0aa-4c2d-9734-9317ee93f4b2", "node_type": "1", "metadata": {"page_label": "14", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "c351a275f8609dba7574be4a5467248a073b758007d0c0009301a303b43e9a3f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "01513411-0fc4-4312-8653-0fe7f1e8018a", "node_type": "1", "metadata": {}, "hash": "4410593d210a22113327430380d15ab77d6fe2b2ecb2bf2f450eeab8df3f99ee", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "In many \ncases, nanoparticles not only stimulate T cell infiltra -\ntion, but also accelerate the maturation of dendritic cells, \ncontributing to cancer immunotherapy [ 297]. Recogniz -\ning the role of epigenetic changes in immune dysfunc -\ntion, the delivery of miRNAs has been explored in cancer \nimmunotherapy. Lipid nanoparticles delivering anti-\nmiR-21 have demonstrated the ability to stimulate M1 \npolarization of macrophages and enhance the infiltration \nof CD 8+ T cells [ 298].\nNanoparticles have been employed for targeted regu -\nlation of immunosuppressive Treg cells in cancer treat -\nment, aiming to enhance immunotherapy potential. For \nexample, PLGA nanoparticles with antigen-capturing \ncapabilities have been developed for this purpose. These \nnanoparticles primarily elevate the CD 8+ T cell count, \nconsequently increasing the ratio of cytotoxic T cells to \nTreg cells [ 299]. By augmenting this ratio, the negative \nimpact of Treg cells on immune responses can be allevi -\nated.", "mimetype": "text/plain", "start_char_idx": 1922, "end_char_idx": 2920, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "01513411-0fc4-4312-8653-0fe7f1e8018a": {"__data__": {"id_": "01513411-0fc4-4312-8653-0fe7f1e8018a", "embedding": null, "metadata": {"page_label": "14", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "fe46a362-7871-46bc-9d56-2a7f3396288f", "node_type": "4", "metadata": {"page_label": "14", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "b477fd3599d562a0c6ca53231fad6462252a9ec456e59983da177d6d7d3b75ae", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dd8fd21e-6aa6-41fb-a71e-c19ceeaea478", "node_type": "1", "metadata": {"page_label": "14", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "e9e517404a881ce9961097929af51bb7321fca693b6065a904d1a10020f4f5e0", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "By augmenting this ratio, the negative \nimpact of Treg cells on immune responses can be allevi -\nated. For enhanced cargo delivery, layer-by-layer nano -\nstructures, composed of GITR/PLGA and modified with \nNanoparticle Cancer type/Cell \nline\nSize (nm)/Zeta \npotential (mV)\nOutcome Refer-\nence\nPhosphatidyl-\nserine-modified \nnanoparticles\nMelanoma/B16F10 \ncells\n230\u00a0nm/at a range \nof 20\u201330 mV\nExternalization of nanostructures occurs when they are exposed to the TME with upregulation of MMP2\nIncreasing depletion of tumular-associated macrophages in TME\n [272]\nHyaluronic acid-\nfunctionalized \nnanoparticles\nNon-small cell \nlung cancer\n92\u00a0nm/-12 mV Targeted delivery of miR-125b and increasing its transfection more than 6 times to induce M1 polarization and enhance iNOS levels  [273]\nTrimethyl chito-\nsan nanoparticles\nBreast cancer/4T1 \ncells\n120\u2013160\u00a0nm/20 \nmV\nFunctionalization with mannose and glycocholic acid\nDelivery of SIRP\u03b1-siRNA and MUC1 pDNA\nOral delivery of cargo\npMUC1 increases macrophage phagocytosis ability and M1 polarization\nIncreasing immunity by the SIRP\u03b1-siRNA\n [274]\nTable 1 (continued)", "mimetype": "text/plain", "start_char_idx": 2818, "end_char_idx": 3929, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "1abc359c-d314-4daa-b74c-c5084a96d351": {"__data__": {"id_": "1abc359c-d314-4daa-b74c-c5084a96d351", "embedding": null, "metadata": {"page_label": "15", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "8876b368-19a7-4502-aaa9-fc8a556abbfa", "node_type": "4", "metadata": {"page_label": "15", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "269a2b60f4f20e8b9a92f7107145273c0138c93b1341fec5213a3c2cac202b7e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1749a00f-65af-4822-b802-56040b98f1ef", "node_type": "1", "metadata": {}, "hash": "6e8ca4a62f62dcb1257578e9adec615bb66dcad778b1bd13406c34dc9a05de6a", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Page 15 of 48\nLu et al. Journal of Hematology & Oncology            (2024) 17:16 \nPLG and PLH that are responsive to the TME pH, have \nbeen designed to deliver IR780 dye. Subsequent irradia -\ntion with a 808\u00a0nm laser promotes the maturation of den -\ndritic cells, thereby increasing the activity of CD 8+ and \nCD 4+ T cells in cancer immunotherapy. Notably, these \nnanoparticles exhibit a suppressive effect on Treg cell \nfunction, contributing positively to immune reactions \n[300].\nSeveral widely used chemotherapeutic drugs, includ -\ning doxorubicin, face limitations such as low tumor site \naccumulation and the development of drug resistance. \nProdrug nanocarriers based on doxorubicin and indoxi -\nmod have been developed to suppress the IDO pathway. \nThese prodrug nanocarriers induce immunogenic cell \ndeath, enhance the infiltration of cytotoxic T cells (CD 8+ \nT cells), and suppress Treg cells, MDSCs, and TAMs in \nthe TME, thereby effectively promoting T cell/Treg cell \nratio for cancer immunotherapy [ 301].\nCo-delivery strategies have been used to improve can -\ncer immunotherapy. Metformin, a compound utilized for \ncancer immunotherapy, has shown promise in re-educat -\ning the TME and enhancing macrophage phagocytosis \nactivity. Co-assembled prodrug nanoparticles, designed \nwith hyaluronic acid-cisplatin/polystyrene-polymetfor -\nmin, effectively co-deliver metformin and cisplatin. With \na size of 166.5\u00a0nm and a zeta potential of -17.4 mV, these \nnanoparticles exhibit high potential in cancer immuno -\ntherapy. They induce apoptosis through PARP upregula -\ntion, enhance cisplatin sensitivity by suppressing ERCC1, \nand modulate AMPK\u03b1/mTOR pathways to increase \nCD 8+ and CD 4+ T cells, and reduce Treg cell numbers \n[302].\nUnmodified nanoparticles exhibit poor specific target -\ning of Treg cells.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1821, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "1749a00f-65af-4822-b802-56040b98f1ef": {"__data__": {"id_": "1749a00f-65af-4822-b802-56040b98f1ef", "embedding": null, "metadata": {"page_label": "15", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "8876b368-19a7-4502-aaa9-fc8a556abbfa", "node_type": "4", "metadata": {"page_label": "15", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "269a2b60f4f20e8b9a92f7107145273c0138c93b1341fec5213a3c2cac202b7e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1abc359c-d314-4daa-b74c-c5084a96d351", "node_type": "1", "metadata": {"page_label": "15", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "64ec574ead6ec60e0dbc80af657fc02bc22229f747fe12b5323acdf2e29005b0", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Unmodified nanoparticles exhibit poor specific target -\ning of Treg cells. This prompted the use of nanocarrier \nfunctionalization. Hybrid nanocarriers functionalized \nwith tLyp1 peptide have been developed to suppress \nSTAT3 and STAT5, reducing Treg cell numbers and \nincreasing the infiltration of CD 8+ T cells in the TME \n[303]. The functionalized nanoparticles contribute \nto tumor suppression by increasing the infiltration of \nFig. 3 The impact of nanoparticles on macrophages, showcasing their potential to re-educate and impede cancer progression. These nanoparticles \neffectively target key mechanisms associated with the M2 polarization of tumor-associated macrophages. They inhibit CD44/SIRP\u03b1, CS1R, and MAPK, \nprompting the M1 polarization of macrophages. Additionally, nanocarriers activate the TLR4/MyD88 axis, contributing to increased M1 polarization of \nthe tumor-associated macrophages. The nanoparticles further induce ferroptosis and photodynamic therapy, disrupting the polarization of these macro-\nphages into the M2 phenotype (Created by Biorender.com)", "mimetype": "text/plain", "start_char_idx": 1747, "end_char_idx": 2823, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "89fb493e-7f25-44f8-b315-b5d93164ad83": {"__data__": {"id_": "89fb493e-7f25-44f8-b315-b5d93164ad83", "embedding": null, "metadata": {"page_label": "16", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "1ae36d76-8e88-46f5-bd67-67be78e26f04", "node_type": "4", "metadata": {"page_label": "16", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "461315d5ff01dd1863099f4b9f9e8a43b932adbab04987a15277df2ac398bc17", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "71de077d-89cd-499a-b2ac-63926f9c45b7", "node_type": "1", "metadata": {}, "hash": "c154b1193e228fc636a5bcdb32e78023466a2eb1770f72b7cd58a265f2ae9af9", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Page 16 of 48\nLu et al. Journal of Hematology & Oncology            (2024) 17:16 \ndendritic cells, CD 8+ T, and natural killer cells, while \nreducing Treg and MDSC cells [ 304]. Furthermore, poly -\nmerosomes have been shown to stimulate the STING \naxis and enhance the infiltration and proliferation of T \ncells in cancer immunotherapy [ 57]. Table\u00a02 summarizes \nthe application of nanoparticles for the regulation of T \ncells in cancer therapy. Figure\u00a0 4 demonstrates the role of \nnanoparticles in the regulation of CAFs, T cells, and Treg \ncells.\nNanoparticles regulating hypoxia\nIn each tumor, the levels of oxygen are different [ 318]. \nThe oxygen insufficiency in tumor tissue generally ranges \nfrom more or less anoxic state (almost no oxygen) to \n60\u00a0mm Hg (8% oxygen). In spite of this, the tumor cells \ndemonstrate a specific condition known as hypoxia in \nwhich oxygen levels fluctuate from anoxia to 7.5\u00a0mm Hg \n(about 1% oxygen) [ 319]. Hypoxia can be considered a \nreliable biomarker, since it promotes the progression of \ntumor cells and can cause therapy resistance [ 320]. Along \nwith tumorigenesis, the hypoxia in cancer enhances, and \nit shows some coordination with angiogenesis, prolifera -\ntion, and metastasis. Hypoxia is able to enhance the lev -\nels of CCL22, CCL28 and increases the accumulation of \nMDSCs and Tregs to mediate immunosuppressive TME \n[321\u2013323]. Furthermore, hypoxia has been shown to be \na factor involved in immune resistance [ 324]. Metformin \nis able to improve cancer immunotherapy by impairing \nthe function of hypoxia in impairing CD 8+ T cells [ 325]. \nExercise has been shown as a mechanism for apoptosis \ninduction and decreasing the proliferation of cancer cells.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1712, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "71de077d-89cd-499a-b2ac-63926f9c45b7": {"__data__": {"id_": "71de077d-89cd-499a-b2ac-63926f9c45b7", "embedding": null, "metadata": {"page_label": "16", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "1ae36d76-8e88-46f5-bd67-67be78e26f04", "node_type": "4", "metadata": {"page_label": "16", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "461315d5ff01dd1863099f4b9f9e8a43b932adbab04987a15277df2ac398bc17", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "89fb493e-7f25-44f8-b315-b5d93164ad83", "node_type": "1", "metadata": {"page_label": "16", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "bc67ee14783f3970c9295bb9d6be499dabe01bd90bdc5a35439adac160093ace", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "20f8b5ba-e7b0-4a72-92d0-be6915b88963", "node_type": "1", "metadata": {}, "hash": "b33edac89882823f12d0d9c5e5fe98dc30abd6a9551b0f9da639d48eb646a8b4", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Exercise has been shown as a mechanism for apoptosis \ninduction and decreasing the proliferation of cancer cells. \nMoreover, exercise can ameliorate hypoxia, and enhance \nthe function of T cells and reduces levels of Treg cells \nin cancer immunotherapy [ 326]. Hypoxia has been also \nshown as a mechanism in increasing M2 polarization of \nmacrophages and secretion of factors with immunosup -\npressive function, including VEGF and TGF-\u03b2. Moreover, \nhypoxia has been suggested to cause therapy resistance, \nespecially during photodynamic therapy and radiation in \nwhich oxygen molecules are required for cancer suppres -\nsion [ 180, 327, 328].\nTherefore, the function of hypoxia in cancer immuno -\ntherapy is of importance [ 329]. Hypoxia can be exploited \nby the nanoparticles for improving their specificity and \nrecently, the hypoxia-responsive nanostructures have \nbeen designed for cancer immunotherapy [ 330\u2013332]. \nHowever, most of the attention has been paid to the \nregulation of hypoxia in cancer immunotherapy. The \nbiodegradable NIR-II pseudo conjugate polymeric nano -\nstructures can regulate hypoxia in cancer immunother -\napy. These nanostructures can deliver regorafenib and \nrespond to 808\u00a0nm laser irradiation to release drugs for \nthe reduction of cancer hypoxia through vascular nor -\nmalization, allowing for oxygen entrance into tumors \nto increase ROS generation, mediating immunogenic \ncell death (ICD) for cancer immunotherapy. Moreover, \nthese nanoparticles reprogram macrophages from M2 to \nM1 [ 269]. In another effort, albumin-based nanostruc -\ntures have been developed for the co-delivery of IR780, \nNLG919, and hypoxia-activated prodrug tirapazamine \n(TPZ) in synergistic tumor suppression. Exposure to \nnanoparticles to NIR irradiation mediates the generation \nof 1O2 to trigger the release of ROS-responsive linker for \nTPZ release, causing chemotherapy through enhancing \ntumor hypoxia.", "mimetype": "text/plain", "start_char_idx": 1599, "end_char_idx": 3518, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "20f8b5ba-e7b0-4a72-92d0-be6915b88963": {"__data__": {"id_": "20f8b5ba-e7b0-4a72-92d0-be6915b88963", "embedding": null, "metadata": {"page_label": "16", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "1ae36d76-8e88-46f5-bd67-67be78e26f04", "node_type": "4", "metadata": {"page_label": "16", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "461315d5ff01dd1863099f4b9f9e8a43b932adbab04987a15277df2ac398bc17", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "71de077d-89cd-499a-b2ac-63926f9c45b7", "node_type": "1", "metadata": {"page_label": "16", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "62303148e37d6df5b230306892d366376167e9c019625c05b81c57e58475c917", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "11831bc9-8348-437c-9f5a-9a28f430d9bb", "node_type": "1", "metadata": {}, "hash": "d7f5c443e3eae67b2a108391480646a6e1b7beaafbbc102d707e140e0154dd2c", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Exposure to \nnanoparticles to NIR irradiation mediates the generation \nof 1O2 to trigger the release of ROS-responsive linker for \nTPZ release, causing chemotherapy through enhancing \ntumor hypoxia. Moreover, these nanostructures stimu -\nlate ICD to enhance the activity of cytotoxicity of T lym -\nphocytes [ 333]. Doping the nanoparticles with Mn 2+ can \nalleviate hypoxia and increase cGAS sensitivity, inducing \nthe cGAS/STING pathway, causing macrophage re-edu -\ncation, and increasing the maturation of dendritic cells \n[334]. In a number of cases, the hypoxia is boosted in the \nTME to promote the release of drugs from nanoparticles \nfor cancer immunotherapy [ 335]. Furthermore, mac -\nrophage-mimetic microalgae and liposomes have been \nconjugated to suppress autophagy and reduce hypoxia in \ncancer immunotherapy [ 336]. Regarding autophagy regu -\nlation, it should be highlighted that autophagy has a dual \nfunction in cancer and can exert carcinogenic and anti-\ncarcinogenic functions, complicating its regulation in \ncancer therapy [ 337, 338]. According to these studies, the \nregulation of hypoxia by nanoparticles can pave the new \ngate for cancer immunotherapy [ 339\u2013342].\nNanoparticles targeting myeloid-derived suppressor cells\nThe infiltration of MDSCs is against anti-cancer immu -\nnity since it impairs T-cell proliferation and enhances the \ndifferentiation of Treg cells [ 343]. MDSCs are consid -\neredimmature myeloid cells with a heterogeneous nature \nproviding, an immunosuppressive TME [ 172]. Over -\nall, MDSCs utilize three distinct mechanisms to cause \nimmunosuppression. In the first method, the arginase \n1 and iNOS undergo upregulation in MDSCs, and they \ncan deplete L -arginine which is vital for the proliferation \nof T cells and CD3 \u03b6-chain formation of TCR.", "mimetype": "text/plain", "start_char_idx": 3320, "end_char_idx": 5114, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "11831bc9-8348-437c-9f5a-9a28f430d9bb": {"__data__": {"id_": "11831bc9-8348-437c-9f5a-9a28f430d9bb", "embedding": null, "metadata": {"page_label": "16", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "1ae36d76-8e88-46f5-bd67-67be78e26f04", "node_type": "4", "metadata": {"page_label": "16", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "461315d5ff01dd1863099f4b9f9e8a43b932adbab04987a15277df2ac398bc17", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "20f8b5ba-e7b0-4a72-92d0-be6915b88963", "node_type": "1", "metadata": {"page_label": "16", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "261043c250d37372c93bd05074456f023a57cc16883c5ce37ae41e1203d79669", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "However, \nenhancement in arginase 1 activity and iNOS can sup -\npress the proliferation and function of T cells [ 344\u2013347]. \nIn the second method, the MDSCs can enhance the gen -\neration of ROS and RNS to mediate dysfunction in T \ncells [ 348\u2013350]. The ROS and peroxynitrite derived from \nMDSCs can cause post-transcriptional alterations in \nTCR and CD8 to interfere with the function of periph -\neral CD 8+ T cells and cause antigen-specific tolerance in \nthese cells through impairing binding affinity to phos -\nphorylated MHC molecules [ 348]. In the third and final \nway, MDSCs are able to enhance Treg cell differentiation \nto disrupt anti-cancer immunity [ 172, 351]. Upon that, \nTreg cells secrete a number of inhibitory cytokines such \nas IL-10, IL-35, and TGF-\u03b2 to interfere with the proper", "mimetype": "text/plain", "start_char_idx": 5115, "end_char_idx": 5914, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "e90a1229-f665-4ee0-9258-eb4ae09e61bd": {"__data__": {"id_": "e90a1229-f665-4ee0-9258-eb4ae09e61bd", "embedding": null, "metadata": {"page_label": "17", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "acbced89-6a78-470f-a420-ae6270eaaa32", "node_type": "4", "metadata": {"page_label": "17", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "f3e3b6c81601aaa9d8ee5d8f821d45bd59d3a3071c0c25ac0f20351b00fd7964", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3aac689d-6dc1-4c71-9127-34492b7a5f23", "node_type": "1", "metadata": {}, "hash": "73981070d2b3aa29540d32f7483929060cd4bbeebf74cab2a76faeb3b614bdc3", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Page 17 of 48\nLu et al. Journal of Hematology & Oncology            (2024) 17:16 \nNanoparticle Cancer type/Cell line Size (nm)/Zeta potential \n(mV)\nHighlights Refer -\nence\nPolymeric \nnanoparticles\nLung cancer/LLC cells 75.9\u00a0\u00b1\u00a00.98\u00a0nm/32.5\u00a0\u00b1\u00a01.5 \nmv\nROS-responsive nanocarriers for the co-delivery of FGL1- and PD-L1-siRNA\nDevelopment of nanoparticles from poly-l-lysine-thioketal and modified cis-aconitate to facilitate endosomal escape\nFunctionalization of nanoparticles with iRGD peptide\nEnhancing infiltration of CD4+ and CD8+ T cells in cancer immunotherapy\n [305]\nChiral \nnanoparticles\nLymphoma/EG7.OVA \ncells\n- Stimulation of NK and CD8+ T cells  [306]\nBiomimetic \nnanoparticles\nColon cancer/CT26 \ncells\n- The phospholipid nanoparticles (PL1) can provide targeted delivery of mRNA (CD137 or OX40) in the stimulation of T \ncells\n [307]\nCisplatin \nnanoparticles\nLung cancer/LLC 14.4 \u00b1 3.3\u00a0nm/-12.8 mV Enhancing CD8+ T cell priming through elevating antigen presentation and providing T cell crosstalk  [308]\nLipid \nnanoparticles\nColon cancer/MC38 \ncells\n- Stimulation of CD8+ T cells and reprogramming TME to disrupt the proliferation of cancer cells  [309]\nEndogenous \nantigen-carrying \nnanoparticles\nBreast cancer/4T1 cells \u221215 \u00b1 3.3 mV Increasing proliferation of CD4+ and CD8+ T cells and promoting the ratio of cytotoxic T cells compared to Treg cells  [310]\nCationic polymer-\nic nanostructures\nMelanoma/B16F10 \ncells\n163.9 \u00b1 0.61\u00a0nm, \n523.9 \u00b1 15\u00a0nm and \n1278.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1470, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "3aac689d-6dc1-4c71-9127-34492b7a5f23": {"__data__": {"id_": "3aac689d-6dc1-4c71-9127-34492b7a5f23", "embedding": null, "metadata": {"page_label": "17", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "acbced89-6a78-470f-a420-ae6270eaaa32", "node_type": "4", "metadata": {"page_label": "17", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "f3e3b6c81601aaa9d8ee5d8f821d45bd59d3a3071c0c25ac0f20351b00fd7964", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e90a1229-f665-4ee0-9258-eb4ae09e61bd", "node_type": "1", "metadata": {"page_label": "17", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "34303af768738b8861711918315cb3ea2f5bcfe5fa62d07b7d47a4bef4499646", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "9 \u00b1 0.61\u00a0nm, \n523.9 \u00b1 15\u00a0nm and \n1278.3 \u00b1 27\u00a0nm/less than \n60 mV\nDevelopment of nanocarriers based on polyadmidoamine dendrimers and poly(d,l-lactic-co-glycolic acid)\nDevelopment of cancer vaccine\nEnhancing the number of T cells in the peripheral blood\n [311]\nPlatelet Breast cancer/4T1 cells \u221238.0 \u00b1 0.4 mV Co-delivery of anti-PD-L1 antibodies and iron oxide nanoparticles as photothermal agents in cancer therapy\nStimulation of necrosis through phototherapy\nStimulation of innate immune responses\nPromoting infiltration of CD4+ and CD8+ T cells\n [312]\nBacterial mem-\nbrane-coated \nnanoparticles\nMelanoma/B78 cells 207\u00a0nm/-11 mV Comprised of PC7A/CpG core with immune system induction ability\nThe presence of bacterial membrane and imide groups can increase antigen retrieval\nCapturing neoantigens and their presentation to dendritic cells\nStimulation of T cell responses\n [313]\nPhoto-respon-\nsive prodrug \nnanoparticles\nColon cancer/CT26 \ncells\n88.1\u2013119.2\u00a0nm Delivery of VPF as photosensitizer, FRRG and doxorubicin\nStimulation of immunogenic cell death\nERP effect\nMaturation of dendritic cells for cross-presenting of antigens to T cells\n [314]\nK3ZrF7:Yb/Er \nupconversion \nnanocarriers\nBreast cancer/4T1 cells 20\u00a0nm Increasing ROS levels\nCapase-1 upregulation\nGasdermin D cleavage\nIL-1\u03b2 maturity\nCytolysis induction\nIncreasing dendritic cell maturation and promoting number of effector-memory T cells\n [315]\nProdrug \nnanoparticles\nColon cancer/CT26 \ncells\n70\u00a0nm/-17 mV Targeted delivery of camptothecin and assembling with PEGylated lipids\nIncreasing half-life and blood circulation\nEnhancing infiltration of CD8+ T cells\n [316]\nTable 2 Nanoparticle-mediated T cell regulation in cancer therapy", "mimetype": "text/plain", "start_char_idx": 1432, "end_char_idx": 3129, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "f1029f33-4d0e-4ebb-8ae1-06c4958fa132": {"__data__": {"id_": "f1029f33-4d0e-4ebb-8ae1-06c4958fa132", "embedding": null, "metadata": {"page_label": "18", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "72bf1cf0-9d16-40d5-8ee5-808edcfdad08", "node_type": "4", "metadata": {"page_label": "18", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "585f69b9e2b11ec1909ca94c1f03766f2955aba243eba325e7b051589dbec6be", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b4849b4e-1c07-4af1-a991-748356e851cb", "node_type": "1", "metadata": {}, "hash": "59c1ced178a04748b4bf2ed62b8cb172c1f7c0be11f191ea269855c2b186af32", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Page 18 of 48\nLu et al. Journal of Hematology & Oncology            (2024) 17:16 \nfunction of the immune system [ 352, 353]. Therefore, tar -\ngeting MDSCs is critically vital for anti-cancer immunity. \nThe intravenous administration of DNA thioaptamer-\nfunctionalized liposomes can cause specific targeting of \nTME, particularly MDSCs. Moreover, such liposomes \nprovided targeted delivery of doxorubicin in breast can -\ncer animal models to enhance infiltration of CD 8+ T cells \nand diminish MDSCs [ 354]. Notably, there are different \nkinds of immune response-related molecules in TME, \nincluding IL-1\u03b2 [ 355, 356], IL-6 [ 357], prostaglandin E2 \n[358], VEGF [ 359], and IFN-\u03b3 [ 351] that disrupt the dif -\nferentiation procedure to increase the accumulation \nof immature myeloid cells [ 360]. As a result, one of the \npromising strategies can be targeting MDSCs for mediat -\ning their differentiation into other kinds of immune cells. \nIn line with this, the lipid-coated biodegradable hollow \nmesoporous silica nanostructures have been introduced \nto regulate MDSC differentiation. Such nanostructures \nare able to co-deliver IL-2 and all-trans retinoic acid to \ntrigger the MDSC differentiation into mature dendritic \ncells, macrophages and granulocytes. These nanoparti -\ncles showed significant capacity in enhancing the number \nof mature dendritic cells and decreasing MDSCs. Fur -\nthermore, these nanoparticles stimulated CD 4+ and CD 8+ \nT cells and increased the secretion of IL-12 and TNF-\u03b1 as \nanti-tumor cytokines [ 361].\nNanoparticles for delivery of cargo into antigen-presenting \ncells and lymph nodes\nOne of the prominent problems in cancer eradication \nusing immunotherapy is the lack of effective and proper \ndelivery into APCs and lymph nodes. The nanoparticles \nhave opened a new gate for the delivery of immuno -\ntherapeutics into APCs and lymph nodes [ 362].", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1882, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "b4849b4e-1c07-4af1-a991-748356e851cb": {"__data__": {"id_": "b4849b4e-1c07-4af1-a991-748356e851cb", "embedding": null, "metadata": {"page_label": "18", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "72bf1cf0-9d16-40d5-8ee5-808edcfdad08", "node_type": "4", "metadata": {"page_label": "18", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "585f69b9e2b11ec1909ca94c1f03766f2955aba243eba325e7b051589dbec6be", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f1029f33-4d0e-4ebb-8ae1-06c4958fa132", "node_type": "1", "metadata": {"page_label": "18", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "0905fd19bc11470a9be27b5f7d33235d6a61deef5e91b98eb714683e36c23162", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "The nanoparticles \nhave opened a new gate for the delivery of immuno -\ntherapeutics into APCs and lymph nodes [ 362]. Note -\nworthy, a number of nanostructures based on their \ndesign, demonstrate the immunostimulatory impact, \nand even in lack of delivery of cargo, they can stimulate \nT and B cell responses [ 363, 364]. The tumor antigens \nhave been conjugated into nanostructures, and upon \ninjection into OVA-expressing melanoma, thymoma, or \nlymphoma-bearing mice, they caused significant anti-\ncancer immunity [ 365, 366]. Furthermore, such model \nantigens conjugated into nanostructures triggered T \ncell and antibody responses against lymphoma or colon \ntumors to impair cancer growth and enhance the sur -\nvival of animal models [ 366\u2013368]. The particle size has \nbeen considered an important factor in this case, as small \nvirus-size particles ( \u2264 40\u00a0nm) can reach the lymph nodes \nand demonstrate high cellular uptake by dendritic cells. \nThen, the peptide presentation from coated antigen by \ndendritic cell-related MHC class I molecules occurs and \nthe stimulation of CD 8+ T cells is observed [ 369, 370]. \nThe endocytosis of such nanostructures by dendritic cells \ncan stimulate the danger-sensing pathway in dendritic \nNanoparticle Cancer type/Cell line Size (nm)/Zeta potential \n(mV)\nHighlights Refer-\nence\nLipid-coated cal-\ncium phosphate \nnanoparticles\nMelanoma/B16F10 \ncells\n30\u00a0nm/-20 mV Apoptosis induction\nAcceleration of immunosuppression\nPolarization of macrophages into M1 phenotype\nIncreasing CD8+ T cells\n [317]\nTable 2 (continued)", "mimetype": "text/plain", "start_char_idx": 1765, "end_char_idx": 3323, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "4b3d62ad-9e2a-4e3e-8dee-201c2e444af6": {"__data__": {"id_": "4b3d62ad-9e2a-4e3e-8dee-201c2e444af6", "embedding": null, "metadata": {"page_label": "19", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "3de89589-f389-4a0a-b91d-726e5db42433", "node_type": "4", "metadata": {"page_label": "19", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "737398ffe9758ea072082a80eee34108f4223ccd7bcfe3e8e8aca37f29f42859", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "277ee5cc-b685-479f-9049-5db40dcc5d72", "node_type": "1", "metadata": {}, "hash": "a34f95bebc023902b9021f0a59dced3041a48789ecd55fe84c9a8d9e944bb8b8", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Page 19 of 48\nLu et al. Journal of Hematology & Oncology            (2024) 17:16 \ncells and mature them for immunogenic APCs [ 371]. \nThe tumor antigen should reach the tumor-draining \nlymph nodes to be absorbed by professional APC cells \nsuch as dendritic cells, and then, their presentation to T \ncells occurs. The tumor-specific T cells have been found \nin lymph nodes. However, the dendritic cells in tumor-\ndraining lymph nodes demonstrate an immature/inactive \nform that compromises their ability to induce anti-tumor \nT cell responses [ 372\u2013379]. The nanoparticle-bound \ncytosine-phosphate-guanine (CpG) oligonucleotides \n(an adjuvant) have been shown to accumulate in tumor-\ndraining lymph nodes in melanoma to induce dendritic \ncells [ 380].\nNanoparticles targeting tumor cells\nA high number of nanostructure-based methods need \ntumor infiltration by nanoparticles [ 381]. The clinical \nimplication of EPR [ 382, 383] is still under question and \na controversial debate, and there is a discussion in which \nonly a small proportion of administered nanostructures \ncan reach the tumor tissues, lacking clinical importance \nand therapeutic value in the clinical setting [ 384]. There -\nfore, significant efforts have been made to improve the \nability of nanoparticles to reach tumor tissues and opti -\nmize the nanostructures in a way to control biologi -\ncal interactions due to the complicated nature of TME \nresulting from irregular vascular distribution, high tumor \ninterstitial fluid pressure, low blood flow, dense EZN \nand high number of stroma cells. Therefore, the strate -\ngies should be directed towards enhancing the entry of \nnanostructures into tumor tissue that can be obtained \nthrough improving tumor perfusion, elevating tumor \nvasculature permeability, and mediating ECM remodel -\ning. As an example, the nanostructures applied for ECM \ndegradation or restoring tumor vasculature into normal \ncondition [ 385] can mediate TME priming to provide \ndesirable immune reactions, reversing immunosuppres -\nsive TME and enhancing anti-cancer immunity [ 386].", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2077, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "277ee5cc-b685-479f-9049-5db40dcc5d72": {"__data__": {"id_": "277ee5cc-b685-479f-9049-5db40dcc5d72", "embedding": null, "metadata": {"page_label": "19", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "3de89589-f389-4a0a-b91d-726e5db42433", "node_type": "4", "metadata": {"page_label": "19", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "737398ffe9758ea072082a80eee34108f4223ccd7bcfe3e8e8aca37f29f42859", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4b3d62ad-9e2a-4e3e-8dee-201c2e444af6", "node_type": "1", "metadata": {"page_label": "19", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "fae23e00c59d21680a0e40ddf1b9e834f2deb9f75b142651b448748092de656b", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "In cases where tumors are accessible, the intratumoral \nadministration of nanoparticles is preferred into systemic \nFig. 4 Nanoparticles orchestrating immune cells and cancer-associated fibroblasts (CAFs). Nanoparticles elevate antigen presentation via MHC-I and \nMHC-II, stimulating CD 4+ and CD 8+ T cells, thereby facilitating cancer immunotherapy. The nanostructures amplify Dectin-2 and TLR-4 levels, fostering \nTH17 responses for effective cancer immunotherapy. Additionally, they boost dendritic cell maturation and, through the delivery of anti-miR-21, induce \npolarization of macrophages into the M1 phenotype. The nanoparticles\u2019 downregulation of osteopontin in CAFs disrupts cancer progression. Moreover, \nthese nanoparticles suppress Treg cells, preventing immunosuppression (Created by Biorender.com)", "mimetype": "text/plain", "start_char_idx": 2079, "end_char_idx": 2892, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "e5c76e65-8f47-44a9-aa9d-07b66c0d49ea": {"__data__": {"id_": "e5c76e65-8f47-44a9-aa9d-07b66c0d49ea", "embedding": null, "metadata": {"page_label": "20", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "50beb819-1b07-416c-a3ad-ef33c77c122c", "node_type": "4", "metadata": {"page_label": "20", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "dd4bf6afdf011adff1e4c7a27a3eb7811b7cff5b5f8f8caf69f83e6a00969f39", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "94d1d91f-f86d-4b92-9ac8-800e764e1d85", "node_type": "1", "metadata": {}, "hash": "1e3e75ebc7a9f86391f6a19ac08718e388a280300b8c56ebfdb321978a98c775", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Page 20 of 48\nLu et al. Journal of Hematology & Oncology            (2024) 17:16 \ninjection to enhance accumulation at the tumor region. \nThe proper accumulation of nanoparticles in TME and \nthe release of therapeutic cargo can enhance tumor sup -\npression, while it reduces the adverse impacts. A number \nof clinical studies have suggested the intratumoral injec -\ntion of immunotherapeutic compounds [ 387, 388] which \nhas also been confirmed in pre-clinical studies upon \nintratumoral injection of immune checkpoint inhibitors \n[389]. The nanoparticles optimized to bind into ECM or \ncancer cells can enhance the accumulation of these struc -\ntures in the tumor region [ 390] and provide a new insight \ninto the effective delivery of therapeutics into tumor cells \nor TME.\nNanoparticles in immunogenic cell death: a \nrational way in cancer immunotherapy\nIn recent years, ICD has been considered a promis -\ning strategy in cancer therapy [ 391]. The stressed and \ndying cells release damage-associated molecular pat -\nterns (DAMPs) to mediate innate anti-cancer immune \nresponse and increase T lymphocyte-induced tumor \nimmunity [ 392]. The ICD is capable of mediating T cell-\ninduced anti-cancer immune responses against tumor \nantigens [ 393]. In recent years, the stimulation of ICD by \nnanoparticles has been suggested as a promising strategy \nin cancer immunotherapy. The PLGA nanostructures \nhave been loaded with potassium chloride nanoparticles \nand then, functionalized with the cancer cell membrane \nto release K + and CI \u2212 ions upon lysosomal degradation. \nThen, these ions cause cancer cell death by mediating a \nhypertonic state in which cells secrete adenosine triphos -\nphate (ATP) and high mobility group box 1 (HMGB-1) \nfor stimulation of ICD [ 394]. The \u03b2-D-Glucose-reduced \nsilver nanostructures can release calreticulin and increase \nthe release of HSP70, HSP90, HMGGB1, and ATP [ 395]. \nThese factors are prerequisites for the induction of ICD.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1967, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "94d1d91f-f86d-4b92-9ac8-800e764e1d85": {"__data__": {"id_": "94d1d91f-f86d-4b92-9ac8-800e764e1d85", "embedding": null, "metadata": {"page_label": "20", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "50beb819-1b07-416c-a3ad-ef33c77c122c", "node_type": "4", "metadata": {"page_label": "20", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "dd4bf6afdf011adff1e4c7a27a3eb7811b7cff5b5f8f8caf69f83e6a00969f39", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e5c76e65-8f47-44a9-aa9d-07b66c0d49ea", "node_type": "1", "metadata": {"page_label": "20", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "05608cea0b6d0454adb73159c6d0cb6eaba5b321f2def183561c07a558f1b9a0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6285c43c-f238-4daf-b1c7-dd9cfa053881", "node_type": "1", "metadata": {}, "hash": "beac442435063debf788b2d1c44775b74d17ae40b41954015ba7e270112ca689", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "These factors are prerequisites for the induction of ICD. \nIn a novel strategy, the chitosan-coated PLGA nanopar -\nticles have been loaded with HPV16 E7 44 \u2212 62 peptides and \nthen, their functionalization with ICD tumor cell mem -\nbrane has been performed to enhance the maturation \nof dendritic cells for cancer immunotherapy [ 396]. Fur -\nthermore, the Fe 3O4 nanostructures have been modified \nwith living bacteria and cancer cell membranes to cause \nferroptosis and ICD for enhancing anti-cancer immune \nresponses [ 397]. Therefore, the increasing evidence high -\nlight the application of nanostructures for the stimula -\ntion of ICD in cancer immunotherapy [ 304, 398\u2013403]. \nIn an effort, albumin nanostructures have been devel -\noped in which IR780, as photosensitizer was loaded in \ncore and cGAS-STING agonists/H2S producer-ZnS was \nloaded in shell to mediate photodynamic and photother -\nmal therapy. These nanostructures mediated pyroptosis \nthrough the caspase-3/GSDME axis in mediating den -\ndritic cell maturation. Then, T cells are activated and \nimprove the potential PD-L1 blockade in cancer immu -\nnotherapy [ 404]. For stimulation of ICD, various kinds of \nnanoparticles including polymeric nanostructures [ 405, \n406], liposome-modified polysopamine structures [ 407], \ncRGD-functionalized TPGS nanoparticles [ 408], iron \n(II)-cytosine-phosphate-guanine nanoparticles [ 297] and \niron oxide nanostructures [ 409] have been introduced to \nenhance cancer immunotherapy. Therefore, nanoparti -\ncle-mediated ICD can cause stimulation of dendritic cells \nto activate T cells in lymph nodes for increasing cancer \nimmunotherapy.\nCell membrane-coated biomimetic nanostructures\nCancer cell membrane-functionalized nanoparticles\nBiomimetic nanoparticles are characterized by struc -\ntures whose surfaces are modified or coated with mem -\nbranes from other cells.", "mimetype": "text/plain", "start_char_idx": 1910, "end_char_idx": 3783, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "6285c43c-f238-4daf-b1c7-dd9cfa053881": {"__data__": {"id_": "6285c43c-f238-4daf-b1c7-dd9cfa053881", "embedding": null, "metadata": {"page_label": "20", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "50beb819-1b07-416c-a3ad-ef33c77c122c", "node_type": "4", "metadata": {"page_label": "20", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "dd4bf6afdf011adff1e4c7a27a3eb7811b7cff5b5f8f8caf69f83e6a00969f39", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "94d1d91f-f86d-4b92-9ac8-800e764e1d85", "node_type": "1", "metadata": {"page_label": "20", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "c486aa737122014df9950e86d1b653c828ca04dacfa5404237627d9d12ec0c57", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "58186b1e-0a5c-4b20-a17a-131d1704cb7d", "node_type": "1", "metadata": {}, "hash": "11ee3aebbfddb3f529ecc1d3ab9d6247f38baba173cfba2268831c53a7fb709a", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Cell membrane-coated biomimetic nanostructures\nCancer cell membrane-functionalized nanoparticles\nBiomimetic nanoparticles are characterized by struc -\ntures whose surfaces are modified or coated with mem -\nbranes from other cells. The development of biomimetic \nnanoparticles aims to enhance stealth properties, pre -\nventing their identification by the reticuloendothelial \nsystem. Biomimetic nanoparticles exhibit good biocom -\npatibility, making them widely applicable in cancer treat -\nment. Recent studies have explored the potential of \nbiomimetic nanoparticles in cancer therapy, demonstrat -\ning their versatility when modified with aptamers [ 410], \nfacilitating chemotherapy through co-delivery of chemo -\ntherapy drugs and natural products [ 411], and showcas -\ning high penetration and targeting features [ 412]. They \nhave also been utilized for bioimaging and immunother -\napy [ 413, 414], evading the mononuclear phagocyte sys -\ntem [ 415] and improving blood circulation time [ 416].\nThe application of biomimetic nanoparticles in cancer \nimmunotherapy has shown promising results in tumor \nsuppression. In some cases, chemotherapy using bio -\nmimetic nanoparticles can activate the immune system. \nFor instance, cancer cell membrane-functionalized phos -\nphorus dendrimer-copper(II) complexes (1G3-Cu) and \ntoyocamycin (Toy)-loaded polymeric nanocarriers with a \nsize of 210\u00a0nm can be cleaved in the TME to release cargo \nand reduce glutathione levels. By causing mitochondrial \ndysfunction and endoplasmic reticulum stress, these \nnanocarriers trigger apoptosis and immunogenic cell \ndeath. They accelerate the maturation of dendritic cells \nand increase T lymphocyte infiltration. With the applica -\ntion of PD-L1 antibodies, the nanoparticles can enhance \nchemotherapy, impair relapse, and prevent the invasion \nof cancer [ 417].\nBiomimetic nanoparticles also serve as effective car -\nriers for delivering siRNA. Recognizing PD-L1 as an \nimmune evasion factor, its downregulation by siRNA \ncan expedite cancer immunotherapy and prevent T cell \nexhaustion [ 418].", "mimetype": "text/plain", "start_char_idx": 3553, "end_char_idx": 5635, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "58186b1e-0a5c-4b20-a17a-131d1704cb7d": {"__data__": {"id_": "58186b1e-0a5c-4b20-a17a-131d1704cb7d", "embedding": null, "metadata": {"page_label": "20", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "50beb819-1b07-416c-a3ad-ef33c77c122c", "node_type": "4", "metadata": {"page_label": "20", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "dd4bf6afdf011adff1e4c7a27a3eb7811b7cff5b5f8f8caf69f83e6a00969f39", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6285c43c-f238-4daf-b1c7-dd9cfa053881", "node_type": "1", "metadata": {"page_label": "20", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "e15ef47a28dbfbbb35830b70d612e3fd06e789a34b854e43965dd717f30ffa98", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Recognizing PD-L1 as an \nimmune evasion factor, its downregulation by siRNA \ncan expedite cancer immunotherapy and prevent T cell \nexhaustion [ 418]. These nanoparticles exhibit the capa -\nbility to effectively suppress cancer progression in vivo, \nmaking them promising candidates for the development \nof cancer vaccines [ 419].", "mimetype": "text/plain", "start_char_idx": 5486, "end_char_idx": 5815, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "b2b0f19d-434b-43e3-a65a-377732015e79": {"__data__": {"id_": "b2b0f19d-434b-43e3-a65a-377732015e79", "embedding": null, "metadata": {"page_label": "21", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "dae59523-8e69-483b-8677-6182b6742476", "node_type": "4", "metadata": {"page_label": "21", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "66fbe2c92beb40b14c8b2ad4fe94b0b6523de35bbb5835bca5bfaa8fd3f25f09", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bf28ea60-28f6-4dbb-9630-b8f27f74e46f", "node_type": "1", "metadata": {}, "hash": "f211ff3087c48fd4f9539eedcc9f2b4d6b4c72a4b438d39b7cb3ec607e0a97b2", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Page 21 of 48\nLu et al. Journal of Hematology & Oncology            (2024) 17:16 \nThe field of cancer therapy has undergone a revolu -\ntionary transformation with the application of nanogels \nas drug carriers [ 420, 421]. Nanogels exhibit favorable \nphysicochemical features. They are potential carriers for \ndelivering both hydrophobic and hydrophilic drugs [ 422], \nrecombinant proteins [ 423], and genetic materials [ 424].\nNanogel-induced immunotherapy has proven effec -\ntive in impeding cancer progression. Polymeric \nnanogels, developed from PDEA-co-HP-\u03b2-cyclodextrin-\nco-Pluronic F127 and a charge-reversible polymer named \ndimethylmaleic anhydride-modified polyethyleneimine, \nundergo degradation in the TME. These nanogels, func -\ntionalized with cancer cell membranes, co-deliver pacli -\ntaxel and IL-2, inducing the maturation of dendritic cells \nand enhancing the infiltration of effector cells [ 425].\nStimuli-responsive biomimetic nanocarriers have \nbeen engineered to optimize cancer immunotherapy. \nPolydopamine-CaCO 3 nanocarriers, functionalized with \ncancer cell membranes and featuring pH-responsive \ncharacteristics, enable phototherapy and bioimaging. \nExposure to the TME triggers the degradation of nano -\ncarriers, releasing CO 2 bubbles that promote photo -\ntherapy-mediated immunotherapy. Combining this with \ncheckpoint inhibitors further enhances tumor immuno -\ntherapy [ 426].\nIn the realm of biomimetic nanovaccines, studies have \nprimarily focused on delivering therapeutics or stimu -\nlators to dendritic cells. However, the presence of the \nendocytosis system and endosomal degradation can hin -\nder the effectiveness of these nanovaccines. To address \nthis issue, biomimetic nanoplatforms have been devel -\noped to accelerate the internalization of nanoparticles in \ndendritic cells.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1819, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "bf28ea60-28f6-4dbb-9630-b8f27f74e46f": {"__data__": {"id_": "bf28ea60-28f6-4dbb-9630-b8f27f74e46f", "embedding": null, "metadata": {"page_label": "21", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "dae59523-8e69-483b-8677-6182b6742476", "node_type": "4", "metadata": {"page_label": "21", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "66fbe2c92beb40b14c8b2ad4fe94b0b6523de35bbb5835bca5bfaa8fd3f25f09", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b2b0f19d-434b-43e3-a65a-377732015e79", "node_type": "1", "metadata": {"page_label": "21", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "6e0c1824b1bced2dcffa04371b544ea3d3de4a2334225fad89b93e5d27b1d75c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "21edad98-906a-4fc5-a307-7a5efe781042", "node_type": "1", "metadata": {}, "hash": "a61eb70201af26a1616f2792b0074dfbffc8722e4120c2fc123993d659762141", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "To address \nthis issue, biomimetic nanoplatforms have been devel -\noped to accelerate the internalization of nanoparticles in \ndendritic cells. Utilizing ROS-responsive nanoparticu -\nlate cores fused with peptides and cell membranes, these \nnanovaccines induce micropinocytosis, facilitating direct \ncytosolic delivery of Stimulator of Interferon Genes \n(STING) agonists. This enhances dendritic cell matura -\ntion and T cell priming through STING upregulation in \ncancer immunotherapy [ 427].\nThe stimulation of immunogenic cell death and the \npromotion of dendritic cell maturation and T cell infil -\ntration represents the primary strategy utilized by biomi -\nmetic nanocarriers in cancer immunotherapy. Regulation \nof metabolites is crucial for achieving better immuno -\ntherapy responses and immunogenic cell death. Zinc \nions-bonded ZIF-8 frameworks with CuS nanodots, \nfunctionalized with cancer cell membranes, have been \nintroduced to amplify photothermal-mediated immu -\nnotherapy through Zn 2+ metabolic modulation. These \nframeworks induce immunogenic cell death, enhance \ndendritic cell maturation, and increase T cell infiltration \n[428]. Although less explored compared to macrophage- \nand cancer-derived membranes, the membranes of red \nblood cells may also be utilized for the development of \nbiomimetic nanocarriers [ 429, 430].\nOne of the main reasons for the modification of \nnanoparticles with the cancer cell membrane is to pro -\nvide an antigen resource [ 431, 432]. The PLGA structures \nhave been functionalized with the membrane of mela -\nnoma cells and then, monophosphoryl lipid A (MPLA) as \nan adjuvant was embedded into nanoparticles to stimu -\nlate the maturation of dendritic cells for enhancing anti -\ngen-specific T cell response [ 433]. Since the expression \nof MHC-I can be found in all cells, such as tumor cells, \nthe cancer cell membrane-functionalized nanostructures \ncan be considered novel APC to induce T cells, even in \nthe absence of professional APCs.", "mimetype": "text/plain", "start_char_idx": 1676, "end_char_idx": 3672, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "21edad98-906a-4fc5-a307-7a5efe781042": {"__data__": {"id_": "21edad98-906a-4fc5-a307-7a5efe781042", "embedding": null, "metadata": {"page_label": "21", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "dae59523-8e69-483b-8677-6182b6742476", "node_type": "4", "metadata": {"page_label": "21", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "66fbe2c92beb40b14c8b2ad4fe94b0b6523de35bbb5835bca5bfaa8fd3f25f09", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bf28ea60-28f6-4dbb-9630-b8f27f74e46f", "node_type": "1", "metadata": {"page_label": "21", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "bebacb7b132967b42adc78e9867bc9722500ea7162348b2e99e9b1e42ca3dc9c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c248cdc2-9ca8-45ca-bc7b-4cb489283a5d", "node_type": "1", "metadata": {}, "hash": "798a836d9bc3c77ad446872d558eafd1c37d34fb7025c8639700b3c16294d565", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "The CD80-expressing \ncancer cells were utilized to derive cell membranes for \ncoating nanoparticles. These nanostructures can directly \ninduce antigen-specific T cells through the interac -\ntion of CD28 with cognate T cell receptors, suppressing \ntumorigenesis in prophylactic and therapeutic tumor \nmodels [ 288]. Furthermore, the cancer cell-membrane \nfunctionalized nanoparticles could be considered as vac -\ncines. Despite significant efforts to highlight the potential \nof cancer cell membrane-functionalized nanoparticles \nin cancer immunotherapy, there are several limitations \nto be considered for future studies. Recent studies have \nhighlighted the potential of ferroptosis in cancer immu -\nnotherapy [ 434\u2013436]. More effort regarding the applica -\ntion of biomimetic nanoplatforms in the regulation of \nferroptosis and related pathways should be performed to \nfacilitate cancer immunotherapy. Moreover, autophagy is \nanother factor in the regulation of cancer immunother -\napy [ 437\u2013440]. The biomimetic nanoparticles should be \ndesigned in a rational way to modulate autophagy for the \nregulation of T cells and other components of immune \nsystems as well as reprogramming macrophages for effec -\ntive cancer immunotherapy.\nRed blood cell-functionalized nanoparticles\nRed blood cells (RBCs) have obtained much attention for \nthe purpose of drug delivery due to a number of char -\nacteristics, including biocompatibility, biodegradabil -\nity, long lifespan, and desirable encapsulation capacity \n[441]. The OVA-encapsulated RBCs are able to stimu -\nlate CD 4+ and CD 8+ T cells after intravenous injection in \nmice [ 442]. There is also a promising approach in which \nRBC membrane is utilized to coat the nanostructures for \nthe development of vaccines with long circulation abil -\nity [ 443]. In an attempt, RBC membrane-functionalized \nPLGA nanoparticles were designed to deliver both anti -\ngen hgp10025 \u2212 33 and adjuvant MPLA.", "mimetype": "text/plain", "start_char_idx": 3673, "end_char_idx": 5614, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "c248cdc2-9ca8-45ca-bc7b-4cb489283a5d": {"__data__": {"id_": "c248cdc2-9ca8-45ca-bc7b-4cb489283a5d", "embedding": null, "metadata": {"page_label": "21", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "dae59523-8e69-483b-8677-6182b6742476", "node_type": "4", "metadata": {"page_label": "21", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "66fbe2c92beb40b14c8b2ad4fe94b0b6523de35bbb5835bca5bfaa8fd3f25f09", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "21edad98-906a-4fc5-a307-7a5efe781042", "node_type": "1", "metadata": {"page_label": "21", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "c6990b5f57c803acc209085cd75b80a380d21ed115a47cb7a1290d53569b285e", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "In an attempt, RBC membrane-functionalized \nPLGA nanoparticles were designed to deliver both anti -\ngen hgp10025 \u2212 33 and adjuvant MPLA. In order to selec -\ntively target the dendritic cells, mannose was included in \nthe RBC membrane, and these structures demonstrated \nhigh potential in suppression of melanoma [ 444]. How -\never, the studies are limited, and more experiments", "mimetype": "text/plain", "start_char_idx": 5478, "end_char_idx": 5855, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "ec94d3fe-330a-45e1-a133-0db27dd522dc": {"__data__": {"id_": "ec94d3fe-330a-45e1-a133-0db27dd522dc", "embedding": null, "metadata": {"page_label": "22", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "66d5f9dd-87a8-4e3b-9d0f-3f00f07bed8b", "node_type": "4", "metadata": {"page_label": "22", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "0342b705ae17d3abb1598c853f4fe617c98215aa80c61e00c1a8f1133b8baeb5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c5dfe4c0-aa8a-4cc6-bbb8-05a44a77be5d", "node_type": "1", "metadata": {}, "hash": "823c08c0774e107de9965d4527caa10259b5b01d5ed6238ca131ab9f356a2f7c", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Page 22 of 48\nLu et al. Journal of Hematology & Oncology            (2024) 17:16 \nregarding the application of other kinds of nanostruc -\ntures, such as metal and carbon nanomaterials, and their \nmodification with RBC membrane should be performed \nto improve the potential in cancer therapy.\nPlatelet-functionalized nanoparticles\nPlatelets are released by megakaryocytes, and they can \ncontrol homeostasis, tumor invasion, and overall physi -\nological and pathological events. Since the platelets have \nshown expression of self-recognized proteins, includ -\ning CD47, they are beneficial for reducing clearance and \nstimulation of the complement system to enhance the \nblood circulation time of nanostructures [ 445, 446]. The \nplatelet membrane-functionalized nanoparticles have \nbeen exploited to deliver R848 as a TLR7/8 agonist in \nenhancing accumulation at the tumor region and pro -\nmoting the interaction with TME components. More -\nover, even at low doses (18\u00a0\u00b5g vaccine per mouse), they \ncould suppress tumors in 87.5% of mice [ 447]. More -\nover, there is the possibility of embedding metformin \nand IR780 as photosensitizers in platelet membranes \nto stimulate ICD and improve the potential in cancer \nimmunotherapy through suppressing MDSCs and Treg \ncells [ 448]. However, the potential of these nanocarriers \nin the regulation of TAMs and CAFs for cancer immuno -\ntherapy should be highlighted.\nMacrophage membrane-functionalized nanoparticles\nThe advantage of pH-sensitive biomimetic nanoparticles \nlies in their ability to induce cancer immunotherapy in a \nmore specific manner due to targeted decomposition in \nthe TME. Immunotherapy with the use of biomimetic \nnanocarriers may be enhanced through phototherapy. \nPhoto-responsive nanocarriers, through the accel -\neration of ROS generation, mediate immunotherapy. \nMacrophage membrane-based vesicles, functioning \nas nanoparticles, deliver drugs and photosensitizers \n(TAPP) to induce pyroptosis. These biomimetic vesicles, \nreleasing copper ions, mediate ROS-induced pyropto -\nsis.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2050, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "c5dfe4c0-aa8a-4cc6-bbb8-05a44a77be5d": {"__data__": {"id_": "c5dfe4c0-aa8a-4cc6-bbb8-05a44a77be5d", "embedding": null, "metadata": {"page_label": "22", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "66d5f9dd-87a8-4e3b-9d0f-3f00f07bed8b", "node_type": "4", "metadata": {"page_label": "22", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "0342b705ae17d3abb1598c853f4fe617c98215aa80c61e00c1a8f1133b8baeb5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ec94d3fe-330a-45e1-a133-0db27dd522dc", "node_type": "1", "metadata": {"page_label": "22", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "68c3e1d44e2b1439b201ccd26a7186f8f8b9428e61dfee7f928dd479440b6af9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3e092391-3ecf-4e7b-b155-116d5202646c", "node_type": "1", "metadata": {}, "hash": "bc7c4c0ee00a1c28ed024e5a462d1a7a87011feb8d3b57c0e52620f83e3af694", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "These biomimetic vesicles, \nreleasing copper ions, mediate ROS-induced pyropto -\nsis. Utilized as nanoparticles, they increase ROS levels, \ninducing pyroptosis through the upregulation of caspase-\n3-induced gasdermin E, resulting in pyroptosis-induced \nimmunotherapy [ 449].\nThe macrophage membrane-functionalized nano -\nstructures have shown high potential in specific tumor \ntargeting [ 450]. The macrophage membrane-coated \nnanoparticles have been utilized for the delivery of \nsaikopsaponin D, and the surface has been hybridized \nby adding T7 peptide to provide macrophage-homing \ncapacity for nanostructures and target the tumor cells \nupregulating transferrin receptor. These nanoparticles \nspecifically accumulate at the tumor site and can escape \nphagocytosis by the reticuloendothelial system [ 451]. The \nfunctionalization of MOF-derived mesoporous carbon \nnanostructures with macrophage membranes has been \nperformed to increase their escape from phagocytosis \nand improve the potential in cancer therapy [ 452]. In \naddition to high specificity in tumor targeting, the mac -\nrophage membrane-functionalized nanoparticles dem -\nonstrate high biocompatibility that, along with their \nanti-cancer activity, are promising candidates for tumor \neradication [ 251, 453]. Therefore, increasing evidences \nhighlight the application of macrophage membrane-func -\ntionalized nanoparticles in cancer therapy [ 454\u2013459]. In \norder to better highlight their potential, it is suggested \nto develop biomimetic nanoparticles functionalized with \ncancer and macrophage membranes to improve potential \nin cancer immunotherapy.\nThe biomimetic nanoplatforms are also interesting for \nthe regulation of specific mechanisms such as hypoxia \nand lipid metabolism in TME. Biomimetic nanoparticles \nmay be designed to present tumor antigens and co-stimu -\nlatory molecules simultaneously for cancer immunother -\napy [460]. The most effective strategy thus far is centered \naround the development of biomimetic nanoparticles \nwith pathogen-like features.", "mimetype": "text/plain", "start_char_idx": 1965, "end_char_idx": 4006, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "3e092391-3ecf-4e7b-b155-116d5202646c": {"__data__": {"id_": "3e092391-3ecf-4e7b-b155-116d5202646c", "embedding": null, "metadata": {"page_label": "22", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "66d5f9dd-87a8-4e3b-9d0f-3f00f07bed8b", "node_type": "4", "metadata": {"page_label": "22", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "0342b705ae17d3abb1598c853f4fe617c98215aa80c61e00c1a8f1133b8baeb5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c5dfe4c0-aa8a-4cc6-bbb8-05a44a77be5d", "node_type": "1", "metadata": {"page_label": "22", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "eb4690ee5450dde5817dc6a1702d7436389dc947282df7f725f0a8cd08379891", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "The most effective strategy thus far is centered \naround the development of biomimetic nanoparticles \nwith pathogen-like features. These biomimetic nanopar -\nticles can elicit significant and long-term immune \nresponses in cancer therapy. One of the key reasons for \nthe application of biomimetic nanoparticles is their abil -\nity to enhance the blood circulation time of cargo. Cho -\nlesterol reduction in the membrane used for nanoparticle \nfunctionalization improves blood circulation time and its \neffectiveness in inducing cancer immunotherapy [ 461]. \nBecause of rapid cancer cell proliferation, the hypoxic \nand nutrient-deficient conditions within the TME hin -\nder the proper functioning of immune cells. The devel -\nopment of a biomimetic platform to increase glucose \nand glutamine levels required by T cells can reprogram \nthe TME, and accelerate cancer immunotherapy [ 462]. \nTable\u00a03; Fig.\u00a05 summarize the application of biomimetic \nnanoparticles in cancer immunotherapy.\nExosomes as emerging nanostructures for cancer \nimmunotherapy\nExosomes, ranging in diameter from 30 to 150\u00a0 nm, are \nextracellular vesicles secreted by eukaryotic cells [ 470]. \nThey play a crucial role in intercellular communication \nby carrying lipids, proteins, and nucleic acids. After their \nsecretion into the extracellular matrix, exosomes can be \nfound in various biological fluids such as amniotic fluid, \nsaliva, urine, and breast milk, among others [ 471, 472].\nIn recent years, there has been a significant increase in \nthe application of exosomes in the field of cancer therapy, \nwith a heightened focus on the diverse cargo they can \ntransport. Exosomes exhibit the ability to target various \ncell types within the body and serve as reliable biomark -\ners for cancer. Advancements in bioengineering tech -\nniques have enabled the effective delivery of cargo using", "mimetype": "text/plain", "start_char_idx": 3876, "end_char_idx": 5738, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "04219a09-6d7a-4e24-ad68-f8595be57223": {"__data__": {"id_": "04219a09-6d7a-4e24-ad68-f8595be57223", "embedding": null, "metadata": {"page_label": "23", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "9f005ea6-598c-43fd-8d3d-391cb5fb6563", "node_type": "4", "metadata": {"page_label": "23", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "ea1374df0d36c0050c998878cfc5a725f6c78b8bc8020cde36e2b5a0ffc18f3f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7c5956e3-39d4-4fa1-bb96-dacf24c7946b", "node_type": "1", "metadata": {}, "hash": "50cf70e7faecfc09b389296e6cd8626a74f5f5c2d8e7a0693ea5f5cdd14d6750", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Page 23 of 48\nLu et al. Journal of Hematology & Oncology            (2024) 17:16 \nTable 3  Application of biomimetic nanostructures for enhancement of cancer immunotherapy\nVehicle Cancer type/\nCell line\nSize (nm)/zeta \npotential (mV)\nHighlights Ref-\ner-\nence\nBiomimetic \nnanovesicles\nBreast \ncancer/4T1 \ncells\n500\u00a0nm Loading 5-aminolevulinate hydrochloride (HAL) and 3-methyladenine (3MA) into cancer cell-derived microparticles\nIncreasing biosynthesis of PpIX in mitochondria, causing ROS generation after irradiation and increasing mitochondrial dysfunction\nSuppression of mitophagy\nPD-L1 downregulation to mediate immunogenic cell death\n \n[463]\nHybrid \nnanoparticles\nBreast \ncancer/4T1 \ncells\n180\u00a0nm/\u221218.93\u00a0mV \nand \u2212 26.4\u00a0mV\nDevelopment of hybrid nanoparticles from GTe and modification with cancer cell membrane and bacterial outer membrane\nGTe functions as a radiosensitizer and the membranes can increase anti-cancer immune responses\nIncreasing ROS generation\nStimulation of immunogenic cell death\n \n[464]\nBiomimetic \nnanovaccine\n- - Functionalization of nanoparticles with cancer cell membrane\nCo-delivery of CpG and propranolol\nHigh accumulation in lymph nodes and enough drug release\nIncreasing dendritic cell maturation and antigen presentation\nEnhancing CD8+ T cell priming and\nPromoting infiltration of B and NK cells\nInhibiting the immunosuppressive TME\n \n[465]\nBiomimetic PLGA \nnanoparticles\n147.8\u00a0nm/-1.8 mV Delivery of 2-bromo-palmitate by PLGA nanoparticles to increase its potential in breast cancer therapy\nFunctionalization of nanoparticles with cancer cell membrane\nDownregulation of PD-1/PD-L1\n \n[466]\nPorous silicon@Au \nnanocarriers\nBreast \ncancer/4T1 \ncells\nUp to 243.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1692, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "7c5956e3-39d4-4fa1-bb96-dacf24c7946b": {"__data__": {"id_": "7c5956e3-39d4-4fa1-bb96-dacf24c7946b", "embedding": null, "metadata": {"page_label": "23", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "9f005ea6-598c-43fd-8d3d-391cb5fb6563", "node_type": "4", "metadata": {"page_label": "23", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "ea1374df0d36c0050c998878cfc5a725f6c78b8bc8020cde36e2b5a0ffc18f3f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "04219a09-6d7a-4e24-ad68-f8595be57223", "node_type": "1", "metadata": {"page_label": "23", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "4b1c6705d9cf174e1aa127cb5b2ac3e43559ffa34d77af0ce8a25aa112d8c87b", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "30\u00a0nm Functionalization of nanocomposites with cancer cell membrane\nStimulation of anti-cancer immune responses and relieving immunosuppressive microenvironment\nSuppressing the proliferation and invasion of cancers\n \n[467]\nAIEgens Breast \ncancer/4T1 \ncells\n113.2\u00a0nm/-12.8 mV Modification with dendritic cell-derived membrane\nAccumulation in lipid droplets of cancer cells\nThe presence of cell membrane allows to accelerate hitchhiking of AIEdots into T cells and stimulates them in cancer immunotherapy\n \n[468]\nFePSe3 nanosheets Colon cancer/\nCT26 cells\n+ 28.5, + 24.0, + 37.8, \nand + 0.2\u00a0mV\nModification of nanoparticles with cancer cell membrane\nLoading anti-PD-1 peptide in the nanoparticles\nPhototherapy-induced immune responses and tumor ablation\nSuppression of PD-1/PD-L1 axis to stimulate T cells\n \n[469]", "mimetype": "text/plain", "start_char_idx": 1692, "end_char_idx": 2503, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "c57ca3ae-d1f8-476a-bad9-783c79203fe3": {"__data__": {"id_": "c57ca3ae-d1f8-476a-bad9-783c79203fe3", "embedding": null, "metadata": {"page_label": "24", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "8a5922cc-57db-492a-a06c-5af9acfc185f", "node_type": "4", "metadata": {"page_label": "24", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "94df22d14e46d785af8e6057dca3d203d75d10ec252250e896c3c2f1b1bc5b14", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e51efee7-2d05-4d05-a528-e1cc0f517da6", "node_type": "1", "metadata": {}, "hash": "c8900b2d97e4f16e66616a6322c779dddd00221b78206089085cdd8bf453668e", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Page 24 of 48\nLu et al. Journal of Hematology & Oncology            (2024) 17:16 \nexosomes in cancer treatment. The following subsections \ndelve into the exploration of the potential of endogenous \nexosomes that are naturally secreted by cells in the body, \nas well as bioengineered exosomes created in the labora -\ntory for the treatment of cancer.\nEndogenous exosomes\nThe primary source of exosome secretion includes nor -\nmal cells, stromal cells, cancer cells, and immune cells. \nExosomes secreted by breast cancer cells, for example, \nplay a role in inducing immunotherapy by reprogram -\nming macrophage polarization. These exosomes carry \nPEDF, promoting M1 macrophage polarization by \nincreasing CD80, IRF5, MCP1, and IL-1\u03b2 levels, while \nreducing CD206, Arg, TGM2, and TGF-\u03b2 levels [ 473].\nDespite the immunotherapeutic potential of exosomes, \nthere are endogenously-secreted exosomes that enhance \nM2 macrophages, thereby contributing to cancer pro -\ngression. Inflammation, a risk factor for cancer, can initi -\nate cancer development, and the regulatory functions of \nmacrophages in inflammation can alter the pathogenesis \nof cancer. Myeloid-derived suppressor cells (MDSCs) in \nthe TME secrete exosomes, transferring miR-93-5p to \nsuppress the STAT3 axis. Enrichment of miR-93-5p in \nthese exosomes, induced by IL-6, leads to MDSC dif -\nferentiation into M2 macrophages, facilitating colitis-\ninduced cancer development [ 474].\nWhen macrophages polarize into the M2 phenotype, \nthey release exosomes enriched with apolipoprotein E \nthat reduces MHC-I expression, resulting in decreased \nimmunogenicity and induced immune resistance [ 475]. \nDetecting exosomes with immunosuppressive/inductive \nfunctions involves recognizing their surface biomark -\ners. Exosomes positive for PD-L1 are implicated in sup -\npressing immune reactions during cancer progression.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1871, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "e51efee7-2d05-4d05-a528-e1cc0f517da6": {"__data__": {"id_": "e51efee7-2d05-4d05-a528-e1cc0f517da6", "embedding": null, "metadata": {"page_label": "24", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "8a5922cc-57db-492a-a06c-5af9acfc185f", "node_type": "4", "metadata": {"page_label": "24", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "94df22d14e46d785af8e6057dca3d203d75d10ec252250e896c3c2f1b1bc5b14", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c57ca3ae-d1f8-476a-bad9-783c79203fe3", "node_type": "1", "metadata": {"page_label": "24", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "080a54588b40e3e80861362d1b4e8338219aa117b9ad3bf7c5f2dec906e61208", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Detecting exosomes with immunosuppressive/inductive \nfunctions involves recognizing their surface biomark -\ners. Exosomes positive for PD-L1 are implicated in sup -\npressing immune reactions during cancer progression. \nPD-L1 + exosomes stimulate CD 8+ T cell exhaustion, \nenhancing tumorigenesis during cancer metastasis [ 476]. \nThe secretion of PD-L1 + exosomes involves intricate \nmolecular pathways, where HMGB1 upregulates RIC -\nTOR mRNA levels through miR-200 family downregu -\nlation, particularly miR-429. This HMGB1 and RICTOR \ncrosstalk increases PD-L1 generation, promoting the \nFig. 5 Biomimetic nanoparticles may be developed by the extraction of membranes from red blood cells, cancer cells, TAMs and CAFs. These modifica-\ntions improve the potential of nanoparticles in cancer immunotherapy. Biomimetic nanoparticles may be utilized for drug and gene delivery by improv-\ning stealth properties. They demonstrate prolonged blood circulation and can induce maturation of dendritic cells, increase infiltration of CD4+ and CD8+ \nT cells, and cause immunogenic cell death. (Created by Biorender.com)", "mimetype": "text/plain", "start_char_idx": 1654, "end_char_idx": 2764, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "5b8c7436-beb5-4d80-8974-897c750fd3a2": {"__data__": {"id_": "5b8c7436-beb5-4d80-8974-897c750fd3a2", "embedding": null, "metadata": {"page_label": "25", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "78b95546-d2da-4e4c-9867-d8be86dd08fc", "node_type": "4", "metadata": {"page_label": "25", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "0a5c0905a9839bde7f31b7da6acd3d512a12283c62adf4275ff7e44f9728142f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "53568206-b006-4547-a6cc-ea40852d3af5", "node_type": "1", "metadata": {}, "hash": "0921b228562d90cb35e0c294ae8ede0eb5b22844a702be278e77162d0532d263", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Page 25 of 48\nLu et al. Journal of Hematology & Oncology            (2024) 17:16 \nactivity of PD-L1 + exosomes in cancer immunotherapy \n[477].\nAlthough PD-L1 + exosomes have carcinogenic func -\ntions, other exosomes can suppress PD-L1 expression. \nConsidering the ability of exosomes to induce cancer \nimmunotherapy, they may be utilized as potential vac -\ncines in the future. Cancer-derived exosomes exhibit \nsuperior capabilities in dendritic cell maturation and \nMHC cross-presentation, compared to cytotoxic T \nlymphocytes. Furthermore, exosomes can reduce Treg \ncell numbers in cancer immunotherapy by suppress -\ning PD-L1 expression [ 478]. This insight suggests that \nbioengineered exosomes, specifically designed to target \ndendritic cells, may serve as effective vaccines in can -\ncer therapy. Although the discussion on bioengineered \nexosomes is reserved for the next section, it is notewor -\nthy that cells can be engineered to secrete exosomes for \ncancer immunotherapy. For example, the nuclei of can -\ncer cells introduced to M1 macrophages can lead to the \nsecretion of chimeric exosomes, selectively accumulating \nin lymph nodes and priming T cells to stimulate immune \nreactions against cancer cells [ 479]. Therefore, exosomes \nare potential regulators of the immune system in cancer \n[480]. Exploring the regulation of exosome secretion and \nbiogenesis from cells opens new avenues for controlling \ncancer immunotherapy.\nBioengineered exosomes\nExosomes are used in cancer therapy because they are \nnaturally present in the body, making it less likely for \nthem to be identified as foreign and cleared. Their high \nbiocompatibility allows effective cargo delivery and test -\ning in clinical trials. Dying cancer cell-derived exosomes, \nmodified with MART-1 peptide and CCL22-siRNA, \ninduce T cell-mediated responses and suppress Treg \nexpansion [ 481]. Bioengineered exosomes can produce \npersistent immunity against cancer cells, and this paves \nthe way for the development of bio-based vaccines.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2017, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "53568206-b006-4547-a6cc-ea40852d3af5": {"__data__": {"id_": "53568206-b006-4547-a6cc-ea40852d3af5", "embedding": null, "metadata": {"page_label": "25", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "78b95546-d2da-4e4c-9867-d8be86dd08fc", "node_type": "4", "metadata": {"page_label": "25", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "0a5c0905a9839bde7f31b7da6acd3d512a12283c62adf4275ff7e44f9728142f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5b8c7436-beb5-4d80-8974-897c750fd3a2", "node_type": "1", "metadata": {"page_label": "25", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "d3402a37af8a733a7f8649334f7b3482613d0895e938cb90942ae65147da55f8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0e5ebb3c-e5c2-471d-9f90-092864a5f866", "node_type": "1", "metadata": {}, "hash": "52fce576458c5e0b6cda6160efa6acab9a0e00ae20c75a5041df30c9d8e0e410", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Bioengineered exosomes can produce \npersistent immunity against cancer cells, and this paves \nthe way for the development of bio-based vaccines. Bio -\nengineered exosomes, painted with HMGB1, stimulate \ndendritic cells, enhance immunogenicity, and induce \nlong-term immunity against cancer. These exosomes \naccumulate in lymphoid tissues and enhance T cell func -\ntion, inducing long-term immunity and suppressing \ncancer progression [ 482]. Another approach involves \nfunctionalizing exosomes via CpG DNA to stimulate \ndendritic cells and enhance antigen presentation, show -\ncasing their co-delivery ability in synergistic cancer \nimmunotherapy [ 483, 484].\nFusogenic exosomes have been synthesized to address \ncancer cells escaping the immune system due to self-\nrecognition. These exosomes introduce viral antigens, \nstimulate dendritic cells, and present antigens to T lym -\nphocytes for CD 8+ T cell cross-priming [ 485]. Exosomes \nfrom bone marrow-mesenchymal stem cells, loaded with \ngalectin-9 siRNA and oxaliplatin, induce immunogenic \ncell death, recruit T lymphocytes, reduce Treg cells, \nand promote M1 polarization of macrophages, contrib -\nuting to cancer immunotherapy [ 486]. Engineered M1 \nmacrophage-derived exosomes, targeting TAMs with \nIL4RPep-1, NF-\u03baB p50 siRNA, and miR-511-3p, induce \ncancer immunotherapy by reprogramming macrophages \nand restricting cancer proliferation [ 487]. Considered as \nbiocompatible carriers, exosomes may be used to mod -\nify other nanoparticles. Combining exosomes and lipo -\nsomes enhances gene delivery, suppresses CD47 signal, \nand increases CD 8+ T cell potential. This strategy has the \npotential for clinical applications in cancer immunother -\napy [488]. Table\u00a04 is a summary of the use of exosomes in \ncancer immunotherapy.\nStimuli-responsive nanostructures for cancer \nimmunotherapy\npH-sensitive nanostructures\nSmart nanoparticles responsive to TME stimuli may be \nused to generate targeted delivery systems.", "mimetype": "text/plain", "start_char_idx": 1873, "end_char_idx": 3844, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "0e5ebb3c-e5c2-471d-9f90-092864a5f866": {"__data__": {"id_": "0e5ebb3c-e5c2-471d-9f90-092864a5f866", "embedding": null, "metadata": {"page_label": "25", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "78b95546-d2da-4e4c-9867-d8be86dd08fc", "node_type": "4", "metadata": {"page_label": "25", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "0a5c0905a9839bde7f31b7da6acd3d512a12283c62adf4275ff7e44f9728142f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "53568206-b006-4547-a6cc-ea40852d3af5", "node_type": "1", "metadata": {"page_label": "25", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "cbddb71a1208a4ffb8dedb177668266feb582c17cca7e68c1f6f9d36fe26a5d8", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Stimuli-responsive nanostructures for cancer \nimmunotherapy\npH-sensitive nanostructures\nSmart nanoparticles responsive to TME stimuli may be \nused to generate targeted delivery systems. Their multi -\nfunctionality stems from changing structures in response \nto TME stimuli, facilitating cargo release at the tumor \nsite. The TME, because of its acidic pH, is distinctive \nfrom normal cells, making pH-sensitive nanoparticles \nideal for cancer immunotherapy. Nanoparticles have \nbeen synthesized using a PLA-b-PEG core and a cytosine \n(C)-rich i-motif DNA surface to produce the so-called \nnanovaccines. They are used to deliver cyclic dinucleo -\ntides such as cyclic dimeric guanosine monophosphate \n(CDG) to endosomes, accelerating anti-tumor immunity \nand preventing TME immunosuppression. In TME\u2019s mild \nacidic pH, a conformational switch releases cargo, while \nphysiological pH minimally increases CDG release. These \npH-sensitive nanoparticles protect CDG from enzymatic \ndegradation, releasing the cargo into the cytoplasm, and \nstimulating polarization of macrophages into the M1 \nphenotype [ 504].\nA groundbreaking achievement in cancer immuno -\ntherapy involves the creation of prodrug nanoparticles \nfor cargo delivery. These nanoparticles release cargo \nin response to the pH of the TME. An innovative self-\ncascaded unimolecular prodrug was designed, com -\nprising an acidic pH-activatable doxorubicin, and an \naggregation-induced emission luminogen (AIEgen) pho -\ntosensitizer linked to a caspase-3-responsive peptide. \nThis engineered prodrug exhibits dual functionality- it \ncan actively release doxorubicin in the acidic TME and \ninitiate apoptosis-related caspase-3 activation. Further -\nmore, the activated caspase-3 can induce the release \nand in-situ aggregation of photosensitizers. This process \nenhances dendritic cell maturation, increases CD 8+ T cell \nnumbers, and prevents metastasis to lung tissue [ 505].", "mimetype": "text/plain", "start_char_idx": 3659, "end_char_idx": 5592, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "5557fe64-448f-407a-8a25-29bfb54cc617": {"__data__": {"id_": "5557fe64-448f-407a-8a25-29bfb54cc617", "embedding": null, "metadata": {"page_label": "26", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "f2742f62-db69-4fbf-b8a2-21103d882643", "node_type": "4", "metadata": {"page_label": "26", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "4d7d656753c18f3b7b5c27aa1d9b06b991f99cf67f5654ec46c2a8e806f20900", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "05383286-0878-419d-9409-525ab75fe178", "node_type": "1", "metadata": {}, "hash": "70b61d4867ca124132265fdd5ef5e382fdd30f18c12dbb87ac955d9cf2807257", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Page 26 of 48\nLu et al. Journal of Hematology & Oncology            (2024) 17:16 \nTable 4  Application of exosomes in cancer immunotherapy\nExosome \nsource\nCargo Cancer type Cell line Remark Refer-\nence\nDendritic cell Neoantigens Melanoma B16F10 cells Delivery of cargo to the lymph nodes and stimulation of T- and B-cell immune responses\nHigh biocompatibility\nImproving survival of animal model\nSuppressing proliferation and delayed tumor relapse\n [489]\nGlioblastoma LncRNA Glioblastoma Human \nglioma cell line \nLN229, mouse \nglioma cell line \nGL261, human \nmicroglial cell \nline HMC3, and \nmouse microg-\nlial cell line BV-2\nStimulation of microglia to generate and secrete complement C5 in chemotherapy resistance development  [490]\nM1 \nmacrophage\nHOTTIP Head and neck \ncancer\nHep-2 cells TLR5/NF-\u03baB overexpression to impair progression of head and neck cancer  [491]\nCD45RO- CD8+ \nT cell\n- Endometrial \ncancer\nIshikawa, RL95-2 \nand KLE cells\nThe exosomes suppress estrogen-induced endometrial cancer progression through miR-765 release  [492]\nM1 \nmacrophage\nSN38\nMnO2\nBreast cancer 4T1 cells Cancer-targeting ability and prolonging blood circulation\nStimulating M1 polarization of macrophages\nIncreasing recruitment of NK cells\n [493]\n\u03b3\u03b4-T cells - Nasopharyngeal \ncancer\nNP69,", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1278, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "05383286-0878-419d-9409-525ab75fe178": {"__data__": {"id_": "05383286-0878-419d-9409-525ab75fe178", "embedding": null, "metadata": {"page_label": "26", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "f2742f62-db69-4fbf-b8a2-21103d882643", "node_type": "4", "metadata": {"page_label": "26", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "4d7d656753c18f3b7b5c27aa1d9b06b991f99cf67f5654ec46c2a8e806f20900", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5557fe64-448f-407a-8a25-29bfb54cc617", "node_type": "1", "metadata": {"page_label": "26", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "75d0959f7cbf71dc24c20c0e2dbad9c91cdeaa0a636670bcc5640657a37722ce", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f9e95eaa-0245-4b93-a38f-208efc1cae17", "node_type": "1", "metadata": {}, "hash": "2b2de4978e3f01643373d44cecfb885941a4e98a249c74750757f753b72cbd58", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "HK-1 and \nNPC43 cells\nElimination and killing tumor cells\nStimulation of FasL and DR5/TRAIL axis\nSuppressing cancer growth\nIncreasing survival of animal model\nApoptosis induction\nIncreasing migration of T cells to the tumor site through CCR5 upregulation\n [494]\n- - Breast cancer 4T1 cells The smart and bioengineered exosomes with CD62L and OX40L can induce T cells and suppress Treg cell function  [495]\nDendritic cells - Melanoma B16-OVA cells Functionalization of exosomes with anti-CD3 and anti-EGFR to bind to T cells  [496]\niPSCs and \ndendritic cells \nexosomes\nDoxorubicin Gastric cancer MFC cell line Delivery of chemotherapy drug\nTumor-targeting ability\nRecruitment of immune cells to the TME\n [497]\nCancer cells Paclitaxel Breast cancer 4T1 cells Development of liposome-exosome conjugate with high biocompatibility to increase the number of CD8+ T cells  [498]\nCancer cells - Breast cancer 4T1 cells A combination of oxygenated water and cancer-secreted exosomes induce anti-tumor responses and suppress angio-\ngenesis and invasion\n [499]\nCancer cells - Pancreatic \ncancer\nPANC-1 cells Exosomes reduce the levels of HLA-DR on the surface of CD14 + monocytes to cause immunosuppression through regu-\nlation of STAT3,", "mimetype": "text/plain", "start_char_idx": 1279, "end_char_idx": 2505, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "f9e95eaa-0245-4b93-a38f-208efc1cae17": {"__data__": {"id_": "f9e95eaa-0245-4b93-a38f-208efc1cae17", "embedding": null, "metadata": {"page_label": "26", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "f2742f62-db69-4fbf-b8a2-21103d882643", "node_type": "4", "metadata": {"page_label": "26", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "4d7d656753c18f3b7b5c27aa1d9b06b991f99cf67f5654ec46c2a8e806f20900", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "05383286-0878-419d-9409-525ab75fe178", "node_type": "1", "metadata": {"page_label": "26", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "8891c9ca40c36708289fe8275fa074672c733f6c74dec083a27ce9063a8612a1", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "stimulation of arginase expression and ROS\n [500]\nM1 \nmacrophages\nDocetaxel Breast cancer 4T1 cells The docetaxel-loaded exosomes stimulate cancer immunotherapy through M1 polarization of macrophages  [501]\nDendritic cells siRNA Melanoma B16-F10 cells BRAF siRNA delivery by exosomes to induce T lymphocytes  [502]\nHEK 293T cell Chlorin e6 \n(Ce6) and im-\nmune adjuvant \nR848\nProstate cancer RM-1 cells The exosomes preferentially accumulate in the tumor site and induce dendritic cell maturation\nIncreasing levels of CD80 and CD86 as biomarkers of dendritic cells\nInducing M1 polarization of macrophages\n [503]", "mimetype": "text/plain", "start_char_idx": 2506, "end_char_idx": 3116, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "753b4e40-06ba-4159-81a0-d2013e02d22f": {"__data__": {"id_": "753b4e40-06ba-4159-81a0-d2013e02d22f", "embedding": null, "metadata": {"page_label": "27", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "601fe89c-ec16-42ba-b5a9-caddb108acd6", "node_type": "4", "metadata": {"page_label": "27", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "ffa5066623d53c5146dda5bd217e7049211665e2104d40ac27d27c69cc1b83d8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3d844ea4-0529-4216-a60f-9dfb8df21046", "node_type": "1", "metadata": {}, "hash": "19ae560731cd3b2cbe4efce334953554c3e742a9cd954e31cd62c545bd3227ed", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Page 27 of 48\nLu et al. Journal of Hematology & Oncology            (2024) 17:16 \nMounting evidence supports the combination of che -\nmotherapy and immunotherapy using pH-sensitive \nnanoparticles for cancer suppression. For example, \npoly(L-histidine) (PHIS) has been used to encapsulate \nR848, forming pH-sensitive PHIS/R848 nanocores. Con -\njugating doxorubicin to hyaluronic acid creates prodrug \nnanoparticles that coat PHIS/R848. These nanocarriers \nundergo a switch from hydrophobic to hydrophilic in \nresponse to pH change, releasing R848 to modulate the \nimmune system. At pH 5.5, the hydrazone bond cleaves, \nreleasing doxorubicin. The latter is internalized into \ntumor cells via endocytosis. This activates the immune \nsystem and suppresses cancer proliferation [ 506].\nMetal-based nanoparticles can also be designed to \ndecompose in response to TME pH. A human serum \nalbumin-coated zeolite imidazolate framework-8 has \nbeen developed for the delivery of a photosensitizer \n(HPZ), for selective recognition of the TME [ 507]. This \nframework enables rapid elevation of zinc ion concentra -\ntions while ensuring controlled release of the encapsu -\nlated photosensitizer. Under physiological pH (7.4), HPZ \nexhibits a size of approximately 170\u00a0nm, decreasing sig -\nnificantly to less than 10\u00a0nm in acidic conditions (pH 6.5). \nThe acid-induced decomposition of HPZ prompts a swift \nincrease in zinc ion concentration, exerting potent cyto -\ntoxic effects against colorectal, breast, and pancreatic \ncancers. Intravenous administration of HPZ in a CT26 \ntumor-bearing mouse model results in the expansion of \nT helper and cytotoxic T cells, and reduction in the Treg \ncell population. These changes lead to a significant inhi -\nbition of tumor growth.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1760, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "3d844ea4-0529-4216-a60f-9dfb8df21046": {"__data__": {"id_": "3d844ea4-0529-4216-a60f-9dfb8df21046", "embedding": null, "metadata": {"page_label": "27", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "601fe89c-ec16-42ba-b5a9-caddb108acd6", "node_type": "4", "metadata": {"page_label": "27", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "ffa5066623d53c5146dda5bd217e7049211665e2104d40ac27d27c69cc1b83d8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "753b4e40-06ba-4159-81a0-d2013e02d22f", "node_type": "1", "metadata": {"page_label": "27", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "992ac5a53c9b0bbba8ddef6d1e5428623f713338e2337aec1619fb241b6c1776", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8d3abd06-59fb-45fa-a74f-8135137ee775", "node_type": "1", "metadata": {}, "hash": "94ced0d4bbddaf7981a335c4296140c8cf0714d2782fb2f5b8ca00fa12f7792c", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "These changes lead to a significant inhi -\nbition of tumor growth.\nWhile the primary focus of this section is to assess \nthe role of nanoparticles in cancer immunotherapy, it is \nworth mentioning that microneedle arrays, composed of \ntiny needles, can also be used for sustained cargo deliv -\nery. pH-sensitive nanoparticles can be incorporated into \nmicroneedles, facilitating sustained release for hyperac -\ntivating the immune system and creating nanovaccines \n[508]. Hydrogels are also available for sustained cargo \ndelivery. For example, nanoparticles can be embedded \nin pH-sensitive hydrogels for delivering doxorubicin \nand JQ1 (a small molecular inhibitor) to induce immu -\nnogenic cell death [ 509]. Of note, pH-sensitive biomi -\nmetic nanocarriers, crafted from PLGA and coated with \nmembranes from macrophages and cancer cells, can \ndeliver FGL1-siRNA and metformin for cancer immuno -\ntherapy. These biomimetic nanoparticles enhance cargo \nendosomal escape, with metformin suppressing PD-L1 \nthrough AMPK upregulation, and siRNA reducing FGL1 \nexpression to boost anti-cancer immunity through T cell \ninduction [ 510]. Given the impact of TME pH on tumori -\ngenesis, pH regulators have been developed. Calcium \ncarbonate nanostructures neutralize TME pH by con -\nsuming lactate, promoting M1 macrophage polarization, \nimmune cell infiltration, dendritic cell stimulation, and T \ncell recruitment for cancer immunotherapy [ 511]. Table\u00a05 \nsummarizes the application of pH-sensitive nanoparticles \nin cancer immunotherapy.\nRedox-sensitive nanoparticles\nRedox-sensitive nanoparticles are carriers that release \ncargo in response to redox imbalances in the TME. The \ndevelopment of these nanoparticles involves introducing \nredox-sensitive bonds, such as disulfide bonds. They have \nfound application in cancer immunotherapy, capable of \nstimulating various immune cells.\nMultifunctional nanocarriers with redox-sensitive fea -\ntures, comprising toll-like receptor agonists, catalase, and \nPD-L1-siRNA, have been designed for cancer therapy.", "mimetype": "text/plain", "start_char_idx": 1694, "end_char_idx": 3745, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "8d3abd06-59fb-45fa-a74f-8135137ee775": {"__data__": {"id_": "8d3abd06-59fb-45fa-a74f-8135137ee775", "embedding": null, "metadata": {"page_label": "27", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "601fe89c-ec16-42ba-b5a9-caddb108acd6", "node_type": "4", "metadata": {"page_label": "27", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "ffa5066623d53c5146dda5bd217e7049211665e2104d40ac27d27c69cc1b83d8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3d844ea4-0529-4216-a60f-9dfb8df21046", "node_type": "1", "metadata": {"page_label": "27", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "f23c7c084b22d97123538a3f105a86baf4aad36c099044e8dcf19dd98beb74d5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5484a62d-001c-45a6-be9f-5384e7967524", "node_type": "1", "metadata": {}, "hash": "9dc079191e18a0c4c18de38dcad23aac6da227d39c011adfb250e071ba33d442", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Multifunctional nanocarriers with redox-sensitive fea -\ntures, comprising toll-like receptor agonists, catalase, and \nPD-L1-siRNA, have been designed for cancer therapy. \nThese nanoparticles induce M1 polarization of macro -\nphages, increase ROS production, downregulate PD-L1 \nexpression, and enhance CD 8+ T cell functions by sup -\npressing Treg cells [ 525].\nClinical application of immunotherapy hinges on using \nbiocompatible and long-term safe nanostructures like \nmicelles. Micelles containing doxorubicin and R848, a \nTLR7/8 agonist, were experimentally used as nanovac -\ncines. Elevated glutathione levels in the TME trigger \nmicelle decomposition, releasing cargo and inducing \nimmunogenic cell death, dendritic cell stimulation, and \naccelerated immune responses. Additionally, redox-\nresponsive polymers and an A2AR antagonist within \nmicelles suppress adenosinergic signaling to activate NK \nand CD 8+ T cells in cancer immunotherapy [ 526].\nCationic polymer dots, known for their small particle \nsize, imaging capabilities, and drug delivery potential, \nhave seen extensive use in biomedicine. PEI600-modified \nredox-sensitive hyperbranched poly(amido amine) nano -\nstructures, partially carbonized with polymer dots, were \nused for carrying ovalbumin. These structures enhance \nsplenocyte proliferation, elevate cytokine levels (includ -\ning IL-12 and IFN-\u03b3), promote dendritic cell maturation, \nand increase CD 4+ and CD 8+ T cell counts, as well as T \nlymphocytes. Ovalbumin release from these structures is \nredox-responsive [ 527].\nGiven that both pH and redox serve as endogenous \nstimuli, new nanocarriers have been developed that \nexhibit dual responsiveness. pH- and redox-sensitive \nmicelles containing ovalbumin, modified with PLH-PEG, \nare used as cancer vaccines.", "mimetype": "text/plain", "start_char_idx": 3576, "end_char_idx": 5366, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "5484a62d-001c-45a6-be9f-5384e7967524": {"__data__": {"id_": "5484a62d-001c-45a6-be9f-5384e7967524", "embedding": null, "metadata": {"page_label": "27", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "601fe89c-ec16-42ba-b5a9-caddb108acd6", "node_type": "4", "metadata": {"page_label": "27", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "ffa5066623d53c5146dda5bd217e7049211665e2104d40ac27d27c69cc1b83d8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8d3abd06-59fb-45fa-a74f-8135137ee775", "node_type": "1", "metadata": {"page_label": "27", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "3bc64c60be48e2fddaebdee3999df0f355b583446923258c2184ed912ab9134b", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "pH- and redox-sensitive \nmicelles containing ovalbumin, modified with PLH-PEG, \nare used as cancer vaccines. These micellar nanostruc -\ntures enable cytosolic delivery of ovalbumin through \nredox release, proton influx, micelle disassembly, and \nultimately, a proton sponge effect and lysosome break. \nThese micelles enhance MHC-I rates, antigen presenta -\ntion, lymph node accumulation, and improve immune \nreactions [ 528].", "mimetype": "text/plain", "start_char_idx": 5258, "end_char_idx": 5683, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "48101311-136a-4e6f-8111-e2259ca6061e": {"__data__": {"id_": "48101311-136a-4e6f-8111-e2259ca6061e", "embedding": null, "metadata": {"page_label": "28", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "81eae37b-ccf3-4aa5-8e22-b1c75bf034bc", "node_type": "4", "metadata": {"page_label": "28", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "7ce3a680a94dc72de7ffb68f73f31f392c0afffc798cb2f998c80a62bbcaa276", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e18002bb-73a2-4836-8959-69ebb283c763", "node_type": "1", "metadata": {}, "hash": "e6d90d5a74f63d3a5d6b0f86ab2f1b7680681187c98b65d9c19558aad9c49fd2", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Page 28 of 48\nLu et al. Journal of Hematology & Oncology            (2024) 17:16 \nPhoto-responsive nanoparticles and phototherapy\nLight serves as an exogenous stimulus in nanoparticle \ndevelopment, where laser irradiation induces bond cleav-\nage to release the loaded cargo. This forms the basis of \nphotodynamic therapy (PDT) and photothermal ther -\napy (PTT) for cancer ablation. In PDT, ROS production \ninduces cell death, while PTT causes cell death through \nhyperthermia. Combining phototherapy with immuno -\ntherapy can enhance cancer suppression. Two methods \nare utilized, including a combination of phototherapy \nand immunotherapy or stimulation of phototherapy-\nmediated immunotherapy. Both methods offer a high \nlikelihood of tumor suppression, improving the fight \nagainst cancer. PLGA nanoparticles loaded with R837, \ndocetaxel, and PB agents are used for immunotherapy \nand PTT. These nanoparticles are modified with cancer \ncell membranes for enhanced effectiveness. R837 stimu -\nlates dendritic cell maturation, and docetaxel increases \nM1 polarization of macrophages, impairing the immuno-\nsuppressive TME. This leads to increased infiltration of \ncytotoxic T lymphocytes in the TME for effective cancer \nimmunotherapy [529].\nSimilar to doxorubicin, which induces immunogenic \ncell death, docetaxel has shown potential in cancer \nimmunotherapy by regulating TAM polarization. CuS \nnanoparticles with NH 2 functional groups, function -\nalized with folic acid and conjugated to PEI-PpIX for \nenhanced solubility, deliver docetaxel and CpG, inducing \nPTT and immunotherapy. These nanoparticles exhibit \nexcellent photothermal conversion ability upon exposure \nto 650 and 808\u00a0nm laser irradiation and induce M1 polar-\nization of macrophages through the function of docetaxel \nin cancer immunotherapy [530].\nBeyond combining immunotherapy and PTT, it is pos -\nsible to induce immune reactions resulting from PTT. \nTumor cell killing and antigen release can accelerate \nimmune reactions.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1998, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "e18002bb-73a2-4836-8959-69ebb283c763": {"__data__": {"id_": "e18002bb-73a2-4836-8959-69ebb283c763", "embedding": null, "metadata": {"page_label": "28", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "81eae37b-ccf3-4aa5-8e22-b1c75bf034bc", "node_type": "4", "metadata": {"page_label": "28", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "7ce3a680a94dc72de7ffb68f73f31f392c0afffc798cb2f998c80a62bbcaa276", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "48101311-136a-4e6f-8111-e2259ca6061e", "node_type": "1", "metadata": {"page_label": "28", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "54b4971fbfeb10d2f0674374b54d988c1ae55d72abfc1929db76a38edaed75ab", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "36c133f6-a883-4cc4-aa21-95dd939027a8", "node_type": "1", "metadata": {}, "hash": "d92056fd6cb94aec233718c410dbaaa8cfb8e6a404e659961df1b89b98df5987", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Beyond combining immunotherapy and PTT, it is pos -\nsible to induce immune reactions resulting from PTT. \nTumor cell killing and antigen release can accelerate \nimmune reactions. A peptide-photosensitizer conjugate, \ndeveloped from anti-PD-L1 peptide, cleavable by MMP-\n2, and purpurin 18 as a photosensitizer, accumulates in \nthe tumor site. MMP-2 enzyme degradation releases \nthe peptide, causing antigen release. Irradiation induces \ndendritic cell maturation, migrating into lymph nodes, \nincreasing T cell infiltration, suppressing metastasis to \nlung tissue, and eliciting anti-tumor immune responses \n[531].\nPhoto-responsive structures can also function as vac -\ncines. Chelation of Fe 3+ ions with ovalbumin leads to \nbiomineralization into nanovaccines, embedding IR820 \nas a photosensitizer through electrostatic incorpora -\ntion. The presence of iron induces ferroptosis, mediat -\ning immunogenic cell death. Immunogenic cell death \nstimulates neoantigens and DAMPs, synergizing with \novalbumin in cancer immunotherapy. Near-infrared irra-\ndiation induces PTT, enhancing immunotherapy. These \nnanostructures enhance T cell infiltration, inhibit the \nprimary tumor, and show promising impacts in combina-\ntion with checkpoint inhibitors [532].\nThe combination of PDT and immunotherapy has \nshown promising results in cancer immunotherapy. \nAlthough PDT and PTT have different mechanisms \nof action, both can be combined with immunotherapy \nto expedite the immunotherapeutic process by expos -\ning antigens or inducing cell death to stimulate immune \nresponses. Photodynamic therapy is preferred over PTT \ndue to potential hyperthermia effects on normal tissues. \nHowever, when tumor-targeted nanoparticles are devel -\noped, they can precisely execute PDT in the tumor site, \neffectively killing cancer cells. Various nanoenzymes with \ncancer cell accumulation can be developed to induce \nPDT and enhance cancer immunotherapy.", "mimetype": "text/plain", "start_char_idx": 1820, "end_char_idx": 3755, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "36c133f6-a883-4cc4-aa21-95dd939027a8": {"__data__": {"id_": "36c133f6-a883-4cc4-aa21-95dd939027a8", "embedding": null, "metadata": {"page_label": "28", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "81eae37b-ccf3-4aa5-8e22-b1c75bf034bc", "node_type": "4", "metadata": {"page_label": "28", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "7ce3a680a94dc72de7ffb68f73f31f392c0afffc798cb2f998c80a62bbcaa276", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e18002bb-73a2-4836-8959-69ebb283c763", "node_type": "1", "metadata": {"page_label": "28", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "83d00c5cec069d4cda166c9467545bf132d22babe54ded6e11bef7fb30dcdf3a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "04fc74ef-0aab-4e7c-9503-6ed3095cce93", "node_type": "1", "metadata": {}, "hash": "dea2a69b58b47da262a04bc86a2d3168df3cdba4784f1680715a74da0e9afc5f", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Various nanoenzymes with \ncancer cell accumulation can be developed to induce \nPDT and enhance cancer immunotherapy.\nA nanoparticle core was created by connecting pacli -\ntaxel drugs through a disulfide bond (PTX-SS-PTX), \nwith P18 as a photosensitizer connected to MPEG-\nCPPA-b-P(M4). In response to glutathione, the disul -\nfide bond degrades, and laser irradiation in response to \nROS increases singlet oxygen generation, releasing high \nmobility group box 1 (HMGB1) due to GSDME activa -\ntion. HMGB1 releases and pyroptosis induction leads \nto dendritic cell maturation, educating na\u00efve T cells in \nlymph nodes, expanding T cells, and developing memory \nT cells for cancer immunotherapy [533].\nFor PDT stimulation, the photosensitizer is loaded into \nnanoparticles. Recent studies have shown the potential of \nherbal medicine in cancer treatment. Mesoporous silica \nnanoparticles modified with PEG can carry both chlorin \ne6 and astragaloside III, stimulating NK cells and sup -\npressing cancer cell growth. These nanoparticles accumu-\nlate in the tumor site, increasing immune cell infiltration, \npromoting the activity and cytotoxicity of CD 8+ T cells \nand NK cells, and impairing tumorigenesis [534].\nLiposomes are also potential nanocarriers in cancer \nimmunotherapy. Liposomes carrying IPI-549 as a PI3K\u03b3 \ninhibitor and chlorin e6 as a photosensitizer induce \nROS generation after irradiation, facilitating immuno -\ngenic cell death and improving the potential of T lym -\nphocytes in eliminating cancer cells. IPI-549 delivery by \nnanoparticles can decrease arginase-1 (Arg-1) and ROS \nlevels, increasing apoptosis in MDSCs, and preventing \ntheir suppressive function on T cells. In addition, these \nnanoparticles decrease the infiltration of M2-polarized \nmacrophages and mature dendritic cells in cancer immu-\nnotherapy [535].", "mimetype": "text/plain", "start_char_idx": 3639, "end_char_idx": 5477, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "04fc74ef-0aab-4e7c-9503-6ed3095cce93": {"__data__": {"id_": "04fc74ef-0aab-4e7c-9503-6ed3095cce93", "embedding": null, "metadata": {"page_label": "28", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "81eae37b-ccf3-4aa5-8e22-b1c75bf034bc", "node_type": "4", "metadata": {"page_label": "28", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "7ce3a680a94dc72de7ffb68f73f31f392c0afffc798cb2f998c80a62bbcaa276", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "36c133f6-a883-4cc4-aa21-95dd939027a8", "node_type": "1", "metadata": {"page_label": "28", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "a7109596166e02d59c4ba9e657c721de92c17b282d60d2a568a436fa24f19353", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "In addition, these \nnanoparticles decrease the infiltration of M2-polarized \nmacrophages and mature dendritic cells in cancer immu-\nnotherapy [535].\nIn both nanoparticle-mediated PDT and PTT, the \nmost prominent mechanism is the stimulation of immu -\nnogenic cell death to accelerate cancer immunother -\napy. Increasing evidence highlights the application of \nnanoparticle-mediated phototherapy and immunother -\napy in cancer suppression [536\u2013540]. Table\u00a06 summarizes", "mimetype": "text/plain", "start_char_idx": 5329, "end_char_idx": 5796, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "f7d7e415-2ce9-43b4-b88a-64c1c54e396c": {"__data__": {"id_": "f7d7e415-2ce9-43b4-b88a-64c1c54e396c", "embedding": null, "metadata": {"page_label": "29", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "4cc40bdd-3b88-451b-8008-e1a3b76a5612", "node_type": "4", "metadata": {"page_label": "29", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "18dc294bdc6e5885997a62a0b0e64c381aab2ce69e95bea976973fb6d9d596a5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fa5dfc01-2216-49b1-b848-545766f156ec", "node_type": "1", "metadata": {}, "hash": "b98fa881cb239963c0bb93c7ae59914dc82f1d3160df88f85bfce51e12ce5ae9", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Page 29 of 48\nLu et al. Journal of Hematology & Oncology            (2024) 17:16 \nNanoparticle Cancer type/\ncell line\nSize (nm)/zeta \npotential (mV)\nHighlights Refer -\nence\nPEG/PEI/CAD \nnanoparticles\nBreast \ncancer/4T1 cells\nAt a range of \n100\u2013250\u00a0nm/at a \nrange of 10\u201320 mV\nDelivery of doxorubicin and its release in a pH-sensitive manner\nImmunogenic cell death induction\nThe acidity of the endosome induces cleavage of cis-aconityl\nRecruitment of dendritic cells\n [512]\nHollow silica \nnanostructures\nBreast \ncancer/4T1 cells\n100\u00a0nm/+11 mV Increased retention in response to low pH level of TME\nTargeting mitochondria and increasing ROS levels\nStimulation of photodynamic therapy\nCombination with checkpoint inhibitors mediates anti-tumor immunity\n [513]\nDextran-mod-\nified BLZ-945 \nnanocarriers\nBreast \ncancer/4T1 cells\n11.35, 112.4, and \n\u223c135.6\u00a0nm\nPresence of a borate ester bond as a pH-sensitive bond\nImmunogenic cell death induction\nDendritic cell maturation, TAM depletion and T cell infiltration\n [514]\nManganese \nnanoparticles\nMelanoma/B16-\nOVA cells\n130\u00a0nm Mn2 + and 2-methylimidazole (2-MI) have been used to encapsulate ovalbumin with pH-sensitive features and the ability of dendritic \ncell maturation in cancer immunotherapy\n [515]\nMesopo-\nrous silica \nnanostructures\n- 146\u00a0nm pH-sensitive feature and delivery of R848\nUptake of nanoparticles by antigen-presenting cells\nStimulation of dendritic cells and boosting T cell-mediated immune responses\n [516]\nPeptide-\nfunctionalized \nnanobubbles\nBreast \ncancer/4T1 cells\n173.8\u00a0nm/-1.53 mV Functionalization of nanobubbles with anti-PD-L1 peptide\nLoading Ce6,", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1618, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "fa5dfc01-2216-49b1-b848-545766f156ec": {"__data__": {"id_": "fa5dfc01-2216-49b1-b848-545766f156ec", "embedding": null, "metadata": {"page_label": "29", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "4cc40bdd-3b88-451b-8008-e1a3b76a5612", "node_type": "4", "metadata": {"page_label": "29", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "18dc294bdc6e5885997a62a0b0e64c381aab2ce69e95bea976973fb6d9d596a5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f7d7e415-2ce9-43b4-b88a-64c1c54e396c", "node_type": "1", "metadata": {"page_label": "29", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "76bf7b40969232466b52834f2b06f2de2230153983fbba56e4ddbe9084c434fa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7c67e125-f50c-49de-af00-ef22d3c673c2", "node_type": "1", "metadata": {}, "hash": "6e5a62597d3be821b25b5b54684c9b68d05d2fa1523bfe380cd99d74dfe9f55d", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "8\u00a0nm/-1.53 mV Functionalization of nanobubbles with anti-PD-L1 peptide\nLoading Ce6, metformin and perfluorohexane in nanobubbles\nAccumulation of nanoparticles in acidic pH causes detachment of PEG ligands and then, exposure of peptide to suppress PD-L1\nHypoxia relief by metformin and increasing potential of Ce6 in cancer therapy\nIncreasing anti-tumor immunity and prevention of immunosuppression\n [517]\nPolymer-lipid \ncomplexes\nLymphoma/E.\nG7-OVA cells\n- The polymer-lipid-embedded liposomes release ovalbumin in response to pH and stimulate anti-cancer immunity by releasing oval-\nbumin in the cytoplasm of dendritic cells\n [518]\nPolymer-modi-\nfied liposomes\nLymphoma/E.\nG7-OVA cells\n100\u00a0nm/\u221215.7\u00a0mV \nand 1.3\u00a0mV at pH 7.4 \nand pH 5.5\npH-responsive feature and cationic lipid inclusion\nDelivery of ovalbumin\nIncreasing cytokine generation\nAntigen presentation through MHC-I and MHC-II\n [519]\nLiposome Lymphoma/E.\nG7-OVA cells\n136, 108 and \n115\u00a0nm/-0.87, -11 \nand \u2212 6.1 mV\nModification of liposomes with polymer\nDestabilization of liposomes in pH 6\nUptake of liposomes by dendritic cells\nDelivery of ovalbumin to cytosol\nTumor growth suppression\n [520]\nPolymer-modi-\nfied liposomes\nLymphoma/E.", "mimetype": "text/plain", "start_char_idx": 1535, "end_char_idx": 2729, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "7c67e125-f50c-49de-af00-ef22d3c673c2": {"__data__": {"id_": "7c67e125-f50c-49de-af00-ef22d3c673c2", "embedding": null, "metadata": {"page_label": "29", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "4cc40bdd-3b88-451b-8008-e1a3b76a5612", "node_type": "4", "metadata": {"page_label": "29", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "18dc294bdc6e5885997a62a0b0e64c381aab2ce69e95bea976973fb6d9d596a5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fa5dfc01-2216-49b1-b848-545766f156ec", "node_type": "1", "metadata": {"page_label": "29", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "3661409b3d09c94666fc7c730b56a0d679e0a66e85d8892790a19d1b996c9bcc", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "G7-OVA cells\n97, 100, 88, 110, 108 \nand 109\u00a0nm/-18, \n-19, -11, -63, -65 and \n\u2212 60 mV\nInclusion of cationic lipid and CpG-DNA\nInducing dendritic cells to secrete cytokines\nStimulation of antigen-specific immune responses\npH-sensitive feature\n [521]\nBiomimetic \nnanoparticles\nBreast \ncancer/4T1 cells\n102.86\u00a0nm Coating manganese nanoparticles with hybrid membranes\nMembrane is developed from mesenchymal stem cell membrane and pH-sensitive liposomes\nTargeted delivery of BPTES\nInducing STNG pathway and M1 polarization of macrophages\nRelief of immunosuppression TME\n [522]\nTable 5 pH-sensitive nanoparticles in cancer immunotherapy", "mimetype": "text/plain", "start_char_idx": 2730, "end_char_idx": 3359, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "9d481ff0-ce6d-43c3-9aed-f74d54089cda": {"__data__": {"id_": "9d481ff0-ce6d-43c3-9aed-f74d54089cda", "embedding": null, "metadata": {"page_label": "30", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "7fddc816-947f-43c5-a2ce-f7e189b6c1ff", "node_type": "4", "metadata": {"page_label": "30", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "5f690dd758d5e0d1dd74135e1a4b9e96d8eacdaf029ba8b3d64ddf2728bdc656", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "72bc67fb-f715-421d-98d9-0f2d20a1b7bc", "node_type": "1", "metadata": {}, "hash": "c8762ab4c75f6db3adc7e6c5c82ac2edbc5e07e7469abd8e4dc884d2c005491a", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Page 30 of 48\nLu et al. Journal of Hematology & Oncology            (2024) 17:16 \nthe nanoparticles causing PDT and PTT, and their com -\nbination and relationship with immunotherapy. Figure\u00a0 6 \nshows the application of stimuli-responsive nanocarriers \nin cancer immunotherapy. Since the pre-clinical stud -\nies demonstrate the function of nanoparticles for can -\ncer immunotherapy and tumor suppression, the clinical \napplication of nanostructures in cancer immunotherapy \nhas been performed to evaluate their potential [ 541]. \nTable\u00a07 and table 8\u00a0summarize the clinical application of \nnanoparticles in cancer immunotherapy.\nAn overview of various classes of nanoparticles in \ncancer immunotherapy\nPolymeric nanoparticles\nPolymeric nanoparticles are among the most commonly \napplied structures in cancer immunotherapy owing to \ntheir biocompatibility, biodegradability, chemical stabil -\nity, water solubility, and high drug loading [ 564, 565]. The \nPLGA, PGA, PLG, PEG, PEI and chitosan nanoparticles \nhave been widely used in cancer immunotherapy [ 566]. \nMoreover, such nanostructures have shown potential as \nimmunostimulatory adjuvants in cancer immunotherapy \n[567\u2013569]. Loading TLR7/8 agonists in PLGA nanostruc -\ntures enhanced levels of CD40, CD80, and CD86 through \nstimulation of bone marrow-derived dendritic cells and \nsubcutaneous administration of such nanoparticles stim -\nulated dendritic cells and CD 8+ T cells [ 570].\nLipid nanoparticles\nLiposomes are among the promising nanocarriers for \ndrugs, genes and vaccines [ 571].", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1546, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "72bc67fb-f715-421d-98d9-0f2d20a1b7bc": {"__data__": {"id_": "72bc67fb-f715-421d-98d9-0f2d20a1b7bc", "embedding": null, "metadata": {"page_label": "30", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "7fddc816-947f-43c5-a2ce-f7e189b6c1ff", "node_type": "4", "metadata": {"page_label": "30", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "5f690dd758d5e0d1dd74135e1a4b9e96d8eacdaf029ba8b3d64ddf2728bdc656", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9d481ff0-ce6d-43c3-9aed-f74d54089cda", "node_type": "1", "metadata": {"page_label": "30", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "3da4cd381b5008a7557ff9bcb1af8132ef4fe03d2b5b878dc04ae04d73650418", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2a4f1451-4f6d-4612-b059-37c9dbb77ea1", "node_type": "1", "metadata": {}, "hash": "1d35988ef5210a20ec7af9083600d91206c5f8c0262f79551cc1b33253e5b529", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Lipid nanoparticles\nLiposomes are among the promising nanocarriers for \ndrugs, genes and vaccines [ 571]. Until now, multiple \nkinds of liposomal nanostructures including 1,2-dioleoyl-\n3-trimethylammonium-propane (DOTAP), 3\u03b2- (N- [N\u2019 , \nN\u2019-dimethyl aminoethane] - carbamoyl) cholesterol \n(DC-Chol), and dimethyl diocta decylammonium (DDA) \n[572, 573] have been significantly applied for the antigen \nexposure to APCs and providing vaccine adjuvants to \nincrease antigen-specific immune reactions [ 574, 575]. \nThe dextran-functionalized liposomes with pH-sensitiv -\nity activity have shown high uptake by dendritic cells and \nthey can provide cytosol delivery of ovalbumin to accel -\nerate antigen-specific immune reactions and impair can -\ncer progression [ 576]. Furthermore, loading CpG-ODNs \nas TLR9 agonist and 3,5-didodecyloxybenzamidine as \nan adjuvant into liposomes can enhance dendritic cell-\nmediated cytokine production to enhance antigen-spe -\ncific immunity [ 521]. Micelles are among another kind of \nlipid nanoparticles that can function as delivery systems \nfor antigen/adjuvant to improve potential of vaccines. \nThe polymeric hybrid micelles have been utilized for the \ndelivery of CpG-ODN and Trp2 to create a nanovac -\ncine for targeting lymph nodes and enhancing the accu -\nmulation of cargo in dendritic cells, triggering CD 8+ T \nNanoparticle Cancer type/\ncell line\nSize (nm)/zeta \npotential (mV)\nHighlights Refer-\nence\nPolysaccharide-\nbased polymers\nLymphoma/E.", "mimetype": "text/plain", "start_char_idx": 1441, "end_char_idx": 2927, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "2a4f1451-4f6d-4612-b059-37c9dbb77ea1": {"__data__": {"id_": "2a4f1451-4f6d-4612-b059-37c9dbb77ea1", "embedding": null, "metadata": {"page_label": "30", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "7fddc816-947f-43c5-a2ce-f7e189b6c1ff", "node_type": "4", "metadata": {"page_label": "30", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "5f690dd758d5e0d1dd74135e1a4b9e96d8eacdaf029ba8b3d64ddf2728bdc656", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "72bc67fb-f715-421d-98d9-0f2d20a1b7bc", "node_type": "1", "metadata": {"page_label": "30", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "9769f14898d01df5db69b50d5dab270d165684a717e115244f023d78fa7a0fd6", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "G7-OVA cells\n157\u00a0nm/-50 mV Stimulation of dendritic cells\nCytoplasmic delivery of antigen\nTh1 cytokine production by dendritic cells\n [523]\nLiposomes Melanoma/B16-\nOVA cells\n401, 754, 636 and \n674\u00a0nm\npH-sensitive liposomes deliver STING and TLR9 agonist\nIncreasing Th1 immune responses in tumor suppression\n [524]\nTable 5 (continued)", "mimetype": "text/plain", "start_char_idx": 2928, "end_char_idx": 3261, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "c135bfab-49cc-4f57-b4b7-d22b49ab66e2": {"__data__": {"id_": "c135bfab-49cc-4f57-b4b7-d22b49ab66e2", "embedding": null, "metadata": {"page_label": "31", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "9c603077-5325-4529-94b5-c53e270b5935", "node_type": "4", "metadata": {"page_label": "31", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "3ed1e08b47e09e889822dce44a9376e0b3cbe4257a852d765e3dc3332ab3c9f7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4dc56958-af0d-41bb-a8a5-f8a5d250a676", "node_type": "1", "metadata": {}, "hash": "d2386fae3fcd8c6cccff22e4b7bfed9dc4d796a376d5f0fe120961fb2663e6d7", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Page 31 of 48\nLu et al. Journal of Hematology & Oncology            (2024) 17:16 \ncell-mediated immune responses and enhancing cancer \nsuppression (melanoma) [ 577].\nCarbon nanoparticles\nCarbon nanotubes (CNTs) have been shown to medi -\nate immunostimulatory impacts in vitro and in vivo. The \noxidized multiwalled carbon nanotubes (MWCNT) have \nshown the ability for the delivery of cancer-testis antigen, \nknown as NY-ESO-1 and CpG-ODNs. These structures \nshowed uptake by dendritic cells and mediated power -\nful CD 4+ and CD 8+ T cell-driven immune reactions to \nimpair melanoma progression [ 578]. Furthermore, the \nco-delivery of ovalbumin and CpG-ODN, as well as anti-\nCD40 Ig as immunoadjuvants by MWCNTs has shown \npotential in accelerating T cell responses and suppressing \nmelanoma progression [ 579].,\nMetal nanoparticles\nGold nanostructures are promising factors in cancer \nimmunotherapy owing to their characteristics, including \nbiocompatibility, adjustable surface chemistry, and ease \nof controlling size and shape [ 580]. The gold nanostruc -\ntures have shown potential in inducing differentiation of \nmacrophages into dendritic-like cells to enhance T cell \nproliferation and promote cytokine release [ 581]. Fur -\nthermore, the gold nanostructures have shown incred -\nible potential to act as adjuvants for enhancing antibody \ngeneration [ 582]. The potential of gold nanoparticles in \ncancer therapy via TME modulation has been revealed \n[583, 584]. The surface of hollow gold nanostructures has \nbeen functionalized with CpG-ODNs to enhance their \ncellular uptake and enhance function in the induction of \nimmune responses, including enhancing TNF-\u03b1 secre -\ntion [ 585]. The silica nanoparticles have also been applied \nwidely in biomedicine for imaging [ 586], specific target -\ning of cancer [ 587], and delivery of drugs and genes [ 588].", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1863, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "4dc56958-af0d-41bb-a8a5-f8a5d250a676": {"__data__": {"id_": "4dc56958-af0d-41bb-a8a5-f8a5d250a676", "embedding": null, "metadata": {"page_label": "31", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "9c603077-5325-4529-94b5-c53e270b5935", "node_type": "4", "metadata": {"page_label": "31", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "3ed1e08b47e09e889822dce44a9376e0b3cbe4257a852d765e3dc3332ab3c9f7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c135bfab-49cc-4f57-b4b7-d22b49ab66e2", "node_type": "1", "metadata": {"page_label": "31", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "8847b30c3c9bf6c6944abc6d98cfe457c3c46a47bd79bf9ffeb4742f4da187be", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3b567437-e044-42c0-87aa-7f16a6392b25", "node_type": "1", "metadata": {}, "hash": "3ea50de79bc44bb635598274e232b0390d610fa64917f5661f2f2b8a004d48e7", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "The silica nanoparticles have also been applied \nwidely in biomedicine for imaging [ 586], specific target -\ning of cancer [ 587], and delivery of drugs and genes [ 588]. \nThe mesoporous silica nanoparticles have been applied \nfor antigen delivery and acted as vaccines to induce \nhumoral- and cell-driven immune reactions while having \nhigh biocompatibility and lacking toxicity [ 589]. The hol -\nlow mesoporous silica nanoparticles have been shown to \nbe biodegradable and are capable of TME remodeling in \ncancer immunotherapy [ 361]. According to these studies, \nvarious categories of nanostructures demonstrate prom -\nising characteristics in cancer immunotherapy, and all \nof them have shown potential in TME remodeling. The \nnext step for the clinical application of these nanocarriers \ndepends on their biocompatibility and long-term safety \nthat lipid nanoparticles are at the front line.\nConclusion and challenges\nCancer immunotherapy and the development of vaccines \nhave ushered in a new era in cancer treatment, instilling \nhope in patients and significantly enhancing prognosis \nand survival rates. However, challenges persist in the \nutilization of adjuvants and immunomodulatory agents. \nThis prompted the exploration of novel solutions, par -\nticularly through the application of nanoparticles. The \nintricate interactions within the TME play a pivotal role \nin influencing cancer cell responses to immunother -\napy. In this context, nanoparticles designed for targeted \ndelivery of immunomodulatory compounds and TME \nremodeling have emerged as promising tools in cancer \nimmunotherapy.\nNanoparticles address the current challenges in cancer \nimmunotherapy by demonstrating the capability to regu -\nlate TME components, altering the trajectory of tumor \ncell progression, and mitigating the immunosuppres -\nsive milieu in cancer. Nanostructures designed for TME \nremodeling can increase the infiltration of cytotoxic T \ncells, stimulate dendritic cells, induce M1 macrophage \npolarization, and inhibit MDSCs. Furthermore, nanopar -\nticles serve as effective carriers for delivering adjuvants \nand other immunomodulatory compounds, such as \ndrugs or genes, in cancer immunotherapy.", "mimetype": "text/plain", "start_char_idx": 1693, "end_char_idx": 3891, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "3b567437-e044-42c0-87aa-7f16a6392b25": {"__data__": {"id_": "3b567437-e044-42c0-87aa-7f16a6392b25", "embedding": null, "metadata": {"page_label": "31", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "9c603077-5325-4529-94b5-c53e270b5935", "node_type": "4", "metadata": {"page_label": "31", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "3ed1e08b47e09e889822dce44a9376e0b3cbe4257a852d765e3dc3332ab3c9f7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4dc56958-af0d-41bb-a8a5-f8a5d250a676", "node_type": "1", "metadata": {"page_label": "31", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "f35cabf8dd2017abfbc18cd48eebd1bff51f2512c0e390c22e6f397f15b35a1a", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Furthermore, nanopar -\nticles serve as effective carriers for delivering adjuvants \nand other immunomodulatory compounds, such as \ndrugs or genes, in cancer immunotherapy.\nA significant breakthrough in nanoparticle develop -\nment for cancer immunotherapy lies in the creation \nof biomimetic nanocarriers, incorporating functional -\nized membranes derived from red blood cells, tumor-\nassociated macrophages, cancer-associated fibroblasts, \nand tumor cells. In addition, the utilization of exo -\nsomes, whether naturally secreted by cells or bioengi -\nneered in the laboratory, holds promise in regulating the \nimmune system in cancer therapy. Nanoparticles exhibit \nthe capacity to diminish the number of Treg cells and \nMDSCs, preventing immunosuppression. Moreover, \nnanoparticle-induced immunogenic cell death promotes \nthe activation of dendritic cells, facilitating their migra -\ntion into lymph nodes to stimulate T cells for cancer \nimmunotherapy.\nStimuli-responsive nanocarriers, particularly pH- and \nredox-sensitive nanoparticles, enhance the potential of \ncancer immunotherapy. Photo-responsive nanoparticles, \nthrough photothermal and photodynamic therapy, con -\ntribute to the augmentation of cancer immunotherapy \nby inducing immunogenic cell death, regulating dendritic \ncells and T cells, and promoting M1 polarization of mac -\nrophages. This multifaceted approach highlights the ver -\nsatility and promise of nanoparticles in advancing cancer \nimmunotherapy.\nThe clinical application of nanoparticles involves sev -\neral crucial considerations [ 590]. Once we comprehend \nthe potential of nanoparticles in cancer immunotherapy, \ntranslation of these technologies, advancements, and \nfindings to the clinical setting becomes imperative. Clini -\ncal trials involving immunotherapy for cancer patients \nare already underway. In the context of solid tumors and \ntheir clinical treatment, leveraging nanoparticle-induced", "mimetype": "text/plain", "start_char_idx": 3720, "end_char_idx": 5652, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "90ab7808-2842-4144-bc86-2d14dbcc2a88": {"__data__": {"id_": "90ab7808-2842-4144-bc86-2d14dbcc2a88", "embedding": null, "metadata": {"page_label": "32", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "bd29e430-dd99-46a4-b025-8ccd04ffc7fb", "node_type": "4", "metadata": {"page_label": "32", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "48fbe4fc90f4a7cd0b6c3d7e673a479780fb073077d59e083c638b3caa4854d4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "26410019-c612-4421-822c-b8965ea68c03", "node_type": "1", "metadata": {}, "hash": "b62d1d6cf207b941abe2465c3bbdc099a4faa34fcde30a236f3cba8bbbcef381", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Page 32 of 48\nLu et al. Journal of Hematology & Oncology            (2024) 17:16 \nNanoparticle Cancer type/\nCell line\nSize (nm)/zeta po -\ntential (mV)\nOutcome Ref -\ner-\nence\nNano-PROTACs Breast \ncancer/4T1 \ncells\n40 and 80\u00a0nm/ The nanoparticles have been comprised of PpIX as photosensitizer and SHP2-targeting PROTAC peptide (aPRO)\nThe stimulation of aPRO occurs as a response to upregulation of caspase-3\nTargeted degradation of SHP2 through ubiquitin-proteasome system\nSHP2 depletion suppresses immunosuppressive pathways, including CD47/SIRP\u03b1 and PD-1/PD-L1, to improve anti-cancer functions of \nmacrophages and T cells\n \n[542]\nMRC \nnanoparticles\nBreast \ncancer/4T1 \ncells\n38.69 \u00b1 0.20 Co-delivery of RGX-104 as an immune agonist and chlorin e6\nStimulation of ApoE by RGX-104 to impair the function of MDSCs and accelerate pyroptosis\nChlorin e6-induced PDT to facilitate oxidative damage and enhance immunogenicity\n \n[543]\nRu(II)-modified \nTiO2 nanocarriers\n4NQO-Oral \ncancer\n40\u00a0nm/\u00a0\u22127.41\u00a0\u00b1\u00a01.22 \nand + 27.65\u00a0\u00b1\u00a02.46\u00a0mV\nLoading HIF-1\u03b1-siRNA in nanoparticles\nStimulation of PDT and inducing lysosomal damage\nDownregulation of HIF-1\u03b1 and enhancing killing of oral cancer\nStimulation of CD4+ and CD8+ T cells\n \n[544]\nPDA-FA \nnanoparticles\nColon cancer/\nCT26 cells\n130\u00a0nm/-14.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1275, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "26410019-c612-4421-822c-b8965ea68c03": {"__data__": {"id_": "26410019-c612-4421-822c-b8965ea68c03", "embedding": null, "metadata": {"page_label": "32", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "bd29e430-dd99-46a4-b025-8ccd04ffc7fb", "node_type": "4", "metadata": {"page_label": "32", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "48fbe4fc90f4a7cd0b6c3d7e673a479780fb073077d59e083c638b3caa4854d4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "90ab7808-2842-4144-bc86-2d14dbcc2a88", "node_type": "1", "metadata": {"page_label": "32", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "ff2124cfad054eb7bc2c21331a492b57618804fccaf11cd8343e0243d8d21cb8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0cb3da40-c65c-4a91-beb4-6b33a56bc286", "node_type": "1", "metadata": {}, "hash": "cb461d9c91e7468daf060024d2f00b9868acabd73d1189731178176cb51ec76c", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "29 mV Delivery of CpG as immunomodulatory to induce dendritic cell maturation and increase T cell activity\nSuppressing Treg cells and MDSCs\nPTT induction\n \n[545]\nCopper sulphide \nnanoplatforms\nMelanoma/\nB16F10\u00a0cells\n28\u00a0nm/30.5 mV Delivery of Cas9 ribonucleoprotein to target PTPN2\nDownregulation of PTPN2 to increase infiltration of CD8+ T cells\nIncreasing levels of IFN-\u03b3 and TNF-\u03b1\nImproving immune-sensitivity\n \n[546]\nPolymer \nnanoadjuvants\nBreast \ncancer/4T1 \ncells\n40\u00a0nm/-31 mV Doping with TLR agonist as an immunomodulatory adjuvant\nPresence of lipid shell response to temperature\nThe PTT potential in response to NIR-II\nImmunogenic cell death induction and release of TLR agonist\nUpregulation of TLR7/TLR8 and stimulation of immunogenic cell death enhance dendritic cell maturation and amplification of anti-\ncancer immune responses\n \n[547]\nNanoenzymes Breast \ncancer/4T1 \ncells\n100\u00a0nm Cu-doped MoOx (CMO) nanozyme comprises the core that is coated with cancer cell membrane\nIncreasing the tumor accumulation and nanozymes causes oxidative damage through increasing ROS generation\nPTT causes immunogenic cell death to activate the immune system\n \n[548]\nGold nanorod Colon cancer/\nCT26 cells\n66.48 \u00b1 1.41, \n76.73 \u00b1 4.6, 93.72 \u00b1 2.7, \nand 116.8 \u00b1 6.5\u00a0nm/26 \nmV\nThe 808\u00a0nm laser irradiation causes PTT\nStimulation of immune cells in the lymph nodes\n \n[549]\nAIE Breast \ncancer/4T1 \ncells\n110.3\u00a0nm/+10.68 mV Modification with cancer cell membrane\nStimulation of immunogenic cell death\nIncreasing ROS generation through PDT\n \n[550]\nPolymer \nnanoagonist\nBreast \ncancer/4T1 \ncells\n42 and 50\u00a0nm/-19.", "mimetype": "text/plain", "start_char_idx": 1275, "end_char_idx": 2871, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "0cb3da40-c65c-4a91-beb4-6b33a56bc286": {"__data__": {"id_": "0cb3da40-c65c-4a91-beb4-6b33a56bc286", "embedding": null, "metadata": {"page_label": "32", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "bd29e430-dd99-46a4-b025-8ccd04ffc7fb", "node_type": "4", "metadata": {"page_label": "32", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "48fbe4fc90f4a7cd0b6c3d7e673a479780fb073077d59e083c638b3caa4854d4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "26410019-c612-4421-822c-b8965ea68c03", "node_type": "1", "metadata": {"page_label": "32", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "b22223cf0b4f34122a37bbc177bce6c4ca6cf0b3d42e2cf0392770d2c160b712", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "9 \nmV\nStimulation of PTT\nIncreasing immunotherapy and induction of immunogenic cell death\n \n[551]\nAntigen-captur-\ning nanoparticles\nBreast \ncancer/4T1 \ncells\n41.1\u00a0nm Stimulation of phototherapy under NIR irradiation\nIncreasing antigen uptake and presentation\nSuppressing cancer progression\n \n[552]\nTable 6 Nanoparticle-mediated PDT and PTT and their relationship with cancer immunotherapy", "mimetype": "text/plain", "start_char_idx": 2871, "end_char_idx": 3259, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "ef2b8976-6944-4d88-9904-3e4a378ea616": {"__data__": {"id_": "ef2b8976-6944-4d88-9904-3e4a378ea616", "embedding": null, "metadata": {"page_label": "33", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "bccae22b-16b6-481b-b0cc-d625db6ca65f", "node_type": "4", "metadata": {"page_label": "33", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "069985f69eec88a61beb7f04cd038ff6a807845d201e6d2423b00e1cb94c01e8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "63c9d658-6c01-4ab5-a86f-65ee121f4116", "node_type": "1", "metadata": {}, "hash": "83a8098458bf8aba9c4d99a7c421aec731c8f7c20feecb3553b2b3ad92b5cfa2", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Page 33 of 48\nLu et al. Journal of Hematology & Oncology            (2024) 17:16 \nphototherapy is recommended to enhance immune \nresponses and stimulate dendritic cells along with their \nmaturation.\nLast, but not least, it is essential to assess the biocom -\npatibility of nanoparticle-induced immune responses \nto prevent systemic immune reactions against normal \ncells. Evaluation of delivering immunomodulatory agents \nalongside chemotherapy drugs should be conducted \nto determine the synergistic impact on cancer therapy. \nHowever, careful consideration must be given to whether \nthe associated side effects are tolerable for patients. \nTherefore, assessing the biocompatibility and toxicity \nprofile of nanoparticles stands out as a critical aspect of \ntheir clinical application.\nCurrently, a high number of studies have focused on \nthe clinical utilization of nanostructures for boosting \nimmunotherapy [ 591]. One of the most prominent draw -\nbacks is that currently developed nanoplatforms are in \nphase I or II. The present review provided the possible \ninteraction and function of nanoparticles with TME \ncomponents and immune cells to induce cancer immu -\nnotherapy that can be used in clinics. In most cases, ani -\nmal models have been utilized to evaluate the potential \nof nanoparticles in cancer immunotherapy, making it \nhard to translate to humans. The selection of humanized \nanimal models can improve the chance of translation \ninto the clinic. Moreover, the appropriate nanoparticles \nshould be chosen for cancer immunotherapy. In this \nway, it is suggested to use FDA-approved agents such as \npolymers or lipid nanoparticles to accelerate the pace of \nclinical translation and immune regulation. The biosafety, \ntolerability, and reproducibility of nanocarriers should \nalso be considered for clinical application.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1837, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "63c9d658-6c01-4ab5-a86f-65ee121f4116": {"__data__": {"id_": "63c9d658-6c01-4ab5-a86f-65ee121f4116", "embedding": null, "metadata": {"page_label": "33", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "bccae22b-16b6-481b-b0cc-d625db6ca65f", "node_type": "4", "metadata": {"page_label": "33", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "069985f69eec88a61beb7f04cd038ff6a807845d201e6d2423b00e1cb94c01e8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ef2b8976-6944-4d88-9904-3e4a378ea616", "node_type": "1", "metadata": {"page_label": "33", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "352494449290fe99efb10f34225bb16f6dcd5b1f968f5c7a8fd54223dbba218c", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "The biosafety, \ntolerability, and reproducibility of nanocarriers should \nalso be considered for clinical application. In recent \nyears, a high number of nanoparticles have been intro -\nduced into clinics for the treatment of cancers, including \nlipid-based nanoparticles (generic name: JVRS-100) for \nthe treatment of leukemia (NCT00860522), liposomes \nfor the treatment of lymphoma, melanoma, breast, ovar -\nian and prostate cancers (NCT03349450, NCT01052142, \nNCT01095848), PLGA nanoparticles for the treatment of \nmetastatic melanoma (NCT01753089) and colloidal gold \nstructures for the treatment of advanced solid tumors \n[592]. However, all of these nanoparticles have been eval -\nuated in phase I and II studies.\nTaking everything together, there are a number of \npoints that should be considered for the application of \nnanoparticles in cancer immunotherapy [ 593]. Cur -\nrently, cancer immunotherapy is mainly based on the \napplication of nano-scale delivery systems for con -\nventional immunotherapeutic compounds, including \nantibodies, recombinant proteins, and small molecular-\nbased immune agonist, adjuvant, or inhibitor. The ratio -\nnale for the application of nanoparticles is to improve \nthe pharmacokinetic profile of immunotherapeutic \nNanoparticle Cancer type/\nCell line\nSize (nm)/zeta po-\ntential (mV)\nOutcome Ref-\ner-\nence\nBlack phospho-\nrus quantum dot \nnanovesicles\nBreast \ncancer/4T1 \ncells\n120\u00a0nm/-23 mV Loading them into thermosensitive hydrogels\nNIR irradiation increases dendritic cell activation and then, they migrate into lymph nodes for the stimulation of CD8+ T cells\n \n[553]\nGold nanocages Colon cancer/\nCT26 cells\n52 \u00b1 3\u00a0nm/ -24 \u00b1 2 mV Delivery of anti-PD-L1 and galunisertib by nanocages\nStimulation of PTT to cause immunotherapy\n \n[554]\nTable 6 (continued)", "mimetype": "text/plain", "start_char_idx": 1719, "end_char_idx": 3514, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "7457ec7c-4b87-4765-8a06-aed1a45137ea": {"__data__": {"id_": "7457ec7c-4b87-4765-8a06-aed1a45137ea", "embedding": null, "metadata": {"page_label": "34", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "efc2184b-6b98-42fe-8c89-a4da99c9f400", "node_type": "4", "metadata": {"page_label": "34", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "001c0fcc2e02e741594c2d8a78447d92664ecc7bd4af2ae52b4b339a2f08ec81", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "657c8563-81ec-407d-8947-453f46e704fd", "node_type": "1", "metadata": {}, "hash": "05cf286bd6c025e725ccad7dfd38b89de314bd7683a1b931105344ce0a7830b0", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Page 34 of 48\nLu et al. Journal of Hematology & Oncology            (2024) 17:16 \nagents, diminish the side impacts, prevent the cytokine \nstorm by immune hyperactivation, and ameliorate defi -\nciency in immune responses. Moreover, nanoparticles \nare promising for reversing immunosuppression and \npreventing immune evasion. Although this is an inter -\ndisciplinary field combining biology and engineering, \na number of factors should be carefully investigated, \nincluding nanoparticle-mediated immunogenicity, bio -\ncompatibility and engineering aspects regarding thera -\npeutic compound loading in nanostructures. Moreover, \nseveral nanoparticles have anti-cancer activity, caus -\ning synergistic impact with immunotherapeutics. One \nof the most important features of nanoparticles is \ntheir ability for controlled release of therapeutics. The \nTable 7 The application of nanoparticle-based immunotherapy in clinical studies [541, 555\u2013557]\nNanoparticle Phase Remark Reference\nRNA-lipoplexes Phase I Increasing maturation of dendritic cells and increasing T cell \nresponse\n [558]\nmiR-34a-loaded liposomes Phase I Reduction in the expression of immune evasion genes  [559]\nmiR-4157-loaded lipids Phase I Stimulation of neoantigen-specific T cells and increasing anti-\ncancer immune responses\n [560]\nIron oxide nanostructures Not \napplicable\nIncreasing M1 polarization of macrophages from M2 phenotype  [256]\nPaclitaxel-loaded lipid core nanostructures Phase II Enhancing dendritic cell maturation  [561, 562]\nDoxorubicin-loaded anti-EGFR immunoliposomes Phase II Stimulation of immunogenic cell death\nSuppressing EGFR-induced growth signaling\nNCT02833766\nPlasmid DNA complex-loaded cationic liposomes Phase I Stimulation of the immune system NCT00860522\nCombination of anti-PD-1 and hafnium oxide \nnanostructures\nPhase I Increase in tumor cell death, promotion of immunogenic cell \ndeath, and induction of the immune system\nNCT03589339\n [563]\nFig. 6 Stimuli-responsive nanocarriers in cancer immunotherapy.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2006, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "657c8563-81ec-407d-8947-453f46e704fd": {"__data__": {"id_": "657c8563-81ec-407d-8947-453f46e704fd", "embedding": null, "metadata": {"page_label": "34", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "efc2184b-6b98-42fe-8c89-a4da99c9f400", "node_type": "4", "metadata": {"page_label": "34", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "001c0fcc2e02e741594c2d8a78447d92664ecc7bd4af2ae52b4b339a2f08ec81", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7457ec7c-4b87-4765-8a06-aed1a45137ea", "node_type": "1", "metadata": {"page_label": "34", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "3b2ee42fad79ac408e0c909cc4092d295b8459bf2170eeaa9fda0d75e37af8db", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "6 Stimuli-responsive nanocarriers in cancer immunotherapy. Nanoparticles that respond to pH, redox, or light can release cargo to induce apoptosis, \nDNA damage, and regulation of molecular pathways. Moreover, stimuli-responsive nanocarriers stimulate immunogenic cell death to increase dendritic \ncell maturation. They migrate into lymph nodes and increase activation of T cells", "mimetype": "text/plain", "start_char_idx": 1948, "end_char_idx": 2326, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "05507c24-4f7e-4222-93b5-9c446d1d4bf9": {"__data__": {"id_": "05507c24-4f7e-4222-93b5-9c446d1d4bf9", "embedding": null, "metadata": {"page_label": "35", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "0db58665-1e8e-4c84-9173-ccc828c87871", "node_type": "4", "metadata": {"page_label": "35", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "f8415537228069419c7d67bacd36d863f353c90124c33af68fbf5f582dc3c405", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2b466e86-38aa-4e84-9437-402517c2d27f", "node_type": "1", "metadata": {}, "hash": "905a596a7d4249b40a9ff8fd32735cc9e0afc33ae209f74d1d744eb8f8ec1057", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Page 35 of 48\nLu et al. Journal of Hematology & Oncology            (2024) 17:16 \nTable 8  The challenges regarding the application of nanoparticles in cancer immunotherapy\nNanoparticles Benefits Challenges\nPolymeric \nnanoparticles\n\u2022 Targeted delivery of cargo to improve the therapeutic index and reduce the systemic side effects\n\u2022 Prolonged release of drugs\n\u2022 Potential in the delivery of various cargoes including small molecule drugs, proteins, peptides, and \nnucleic acids\n\u2022 Increased stability of drugs and preventing degradation\n\u2022 Stimulation of the immune system\n\u2022 Biocompatibility and biodegradability\n\u2022 The development of nanoparticles with desirable size, charge, and targeting \ncapacity is challenging\n\u2022 Strict rules regarding clinical application\n\u2022 Unexpected interactions with the immune system\n\u2022 Challenges in the scale-up generation, storage and stability\nLipid \nnanoparticles\n\u2022 Efficient delivery of genetic tools including mRNA, siRNA, and DNA\n\u2022 Targeted delivery\n\u2022 Protection of cargo\n\u2022 Long-term biocompatibility and safety\n\u2022 Adjuvant impact that a number of lipid components can function as adjuvants and increase anti-\ncancer immune responses\n\u2022 Complex manufacturer production, especially the development of nanopar-\nticles for gene delivery\n\u2022 They require ultra-low temperatures to preserve their stability\n\u2022 Immunogenicity that can lead to inflammation and other side effects\n\u2022 Low loading capacity\nMetal \nnanoparticles\n\u2022 Targeted delivery of drugs and high loading and encapsulation efficiencies\n\u2022 Application for photothermal therapy, since a number of nanostructures such as gold nanocarriers \ncan absorb light and cause photothermal-mediated tumor ablation\n\u2022 Delivery of immunomodulatory agents for cancer immunotherapy\n\u2022 Synergistic therapy through a combination of drug delivery and photothermal therapy\n\u2022 Imaging and biosensing\n\u2022 The biodistribution of metal nanostructures is challenging along with their \nclearance from the body\n\u2022 The metal nanostructures possess high cytotoxicity and poor biocompatibility\n\u2022 The chance of inflammation and immune reactions\n\u2022 Stability and toxicity towards normal cells\nCarbon \nnanoparticles\n\u2022 High drug-loading potential for the delivery of drugs, proteins,", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2225, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "2b466e86-38aa-4e84-9437-402517c2d27f": {"__data__": {"id_": "2b466e86-38aa-4e84-9437-402517c2d27f", "embedding": null, "metadata": {"page_label": "35", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "0db58665-1e8e-4c84-9173-ccc828c87871", "node_type": "4", "metadata": {"page_label": "35", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "f8415537228069419c7d67bacd36d863f353c90124c33af68fbf5f582dc3c405", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "05507c24-4f7e-4222-93b5-9c446d1d4bf9", "node_type": "1", "metadata": {"page_label": "35", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "f010c26d57ebbc7ffd1eb727c40476ed88cdec9a3801d8283e6e37975798be30", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "proteins, and genetic tools\n\u2022 Application in photothermal and photodynamic therapy\n\u2022 Imaging and biosensing of cancer biomarkers\n\u2022 The toxicity and poor biocompatibility\n\u2022 The changes in the biodegradation of carbon nanoparticles, leading to their \nlong-term accumulation\n\u2022 Complexity in the generation of nanoparticles at a large scale and achieving the \ndesirable physicochemical properties including size, zeta potential and others\n\u2022 Heterogeneous biological functions among the various classes of carbon nano-\nmaterials including tubes, dots and sheets", "mimetype": "text/plain", "start_char_idx": 2216, "end_char_idx": 2772, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "6ba74a3e-edbe-4c2c-a315-ef59f232b4de": {"__data__": {"id_": "6ba74a3e-edbe-4c2c-a315-ef59f232b4de", "embedding": null, "metadata": {"page_label": "36", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "79fdffcd-9489-4262-a81d-bcbe43beca14", "node_type": "4", "metadata": {"page_label": "36", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "671d72bb27c43905ee430ec1637ac28628f248d5097b2f72c4ce206886fa0884", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0b67ba50-2d70-4698-87b9-91f46f5d6f81", "node_type": "1", "metadata": {}, "hash": "fd61df4a99562f2a0f168c4d32021fa78c07da6a727a48f474389cf568d9c618", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Page 36 of 48\nLu et al. Journal of Hematology & Oncology            (2024) 17:16 \nhyperactivation of immune systems using immune ago -\nnists or adjuvants can affect normal cells and tissues. \nTherefore, the delivery of therapeutics should be per -\nformed in a controlled manner and safe levels should be \ndelivered. Moreover, the rapid or burst release of immu -\nnotherapy compounds is not effective in providing long-\nterm anti-cancer immunity. A number of nanoparticles \nare promising for the controlled release of therapeutic \ncompounds, including PLGA nanostructures that, upon \ndegradation of the polymer, the release of the immuno -\ntherapeutic compound occurs [ 594, 595]. Biocompatibil -\nity has been another important factor in pre-clinical and \nclinical studies [ 596]. Along with controlling the toxicity \nof immunomodulatory factors, including recombinant \ncytokines [ 597\u2013599], the physicochemical characteris -\ntics of nanostructures including size, shape and thermal \nconversion ability, among others, should be adjusted in a \nmanner to reduce the side effects of nanoparticles [ 600, \n601]. In this way, the toxicity of nanoparticles in vitro \nand in vivo, hemocompatibility, effect on major organs \nincluding liver and kidney, and metabolic pathways \nshould be investigated [ 602]. The surface functionaliza -\ntion of nanoparticles is another important factor in can -\ncer immunotherapy. The surface functionalization can \naffect the intracellular uptake of nanostructures and even \ntheir processing [ 603]. Furthermore, since nanoparticles \nhave been applied for antigen capture, the surface charge, \nhydrophobicity and hydrophobicity can change the func -\ntion of nanostructures in cancer immunotherapy [ 299]. \nAnother factor is that the nanostructures can specifically \ntarget the lymphoid tissues or immune cells to enhance \nthe potential of drugs in cancer immunotherapy [ 604]. \nPolymeric nanoparticles have shown high potential in \nvascular escape, infiltration into tissues and lymphatics \nand targeting lymphocytes, while liposomes show high \nuptake by phagocytic cells, including macrophages [ 603].", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2127, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "0b67ba50-2d70-4698-87b9-91f46f5d6f81": {"__data__": {"id_": "0b67ba50-2d70-4698-87b9-91f46f5d6f81", "embedding": null, "metadata": {"page_label": "36", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "79fdffcd-9489-4262-a81d-bcbe43beca14", "node_type": "4", "metadata": {"page_label": "36", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "671d72bb27c43905ee430ec1637ac28628f248d5097b2f72c4ce206886fa0884", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6ba74a3e-edbe-4c2c-a315-ef59f232b4de", "node_type": "1", "metadata": {"page_label": "36", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "6af1c24a70ee3edc00b407bbeecac61b5e4bb6f119da301fb13040ad491dd48e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ad03e95f-e539-4b21-9ab6-680d3e6c7cd8", "node_type": "1", "metadata": {}, "hash": "f168fdd8cd96a5945d49214834a4c8f66961e7b994ba8d9e91a5f1da4e26b890", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Polymeric nanoparticles have shown high potential in \nvascular escape, infiltration into tissues and lymphatics \nand targeting lymphocytes, while liposomes show high \nuptake by phagocytic cells, including macrophages [ 603]. \nIn addition, these nanoparticles demonstrate high safety \nalong with capacity in cancer immunotherapy [ 605\u2013\n608]. Notably, the nanoparticles can be considered as \nimmune potentiates in which metal nanoparticles, virus-\nlike nanostructures and other categories can stimulate \nimmune responses through induction of B and T cells \n[603, 609] that is highly dependent on the size and sur -\nface charge of nanostructures [ 366, 610, 611]. However, \ncarbon nanostructures have shown immunosuppressive \nimpacts in some cases [ 612, 613]. Therefore, the intro -\nduction of nanoparticles for thr purpose of cancer immu -\nnotherapy is of importance.\nAbbreviations\nICIs  Immune Checkpoint Inhibitors\nTME  Tumor Microenvironment\nNFAT  Nuclear Factor of Activated T Cells\nTOX  Thymocyte Selection-Associated High Mobility \nGroup Box Protein\nNR4A  Nuclear Receptor Subfamily 4 Group A\nFDA  U.S. Food and Drug Administration\nCTLA4  Cytotoxic T-Lymphocyte Antigen 4\nPD-1  Programmed Cell Death Protein 1\nPD-L1  Programmed Death-Ligand 1\nTAMs  Tumor-Associated Macrophages\nTh1  Type 1 T Helper Cell\nIL-4, IL-10, IL-13  Interleukin-4, Interleukin-10, Interleukin-13\nM1  M1 Macrophages\nM2  M2 Macrophages\nTGF-\u03b2  Transforming Growth Factor-Beta\n\u03b1-SMA  Alpha-Smooth Muscle Actin\nNK cells  Natural Killer Cells\nIFN-\u03b3  Interferon-Gamma\nB cells  B Lymphocytes\nT cells  T Lymphocytes\nPD-1  Programmed Cell Death Protein 1\nTCM  Central Memory T Cells\nTEM  Effector Memory T Cells\nTRM  Resident Memory T Cells\nTSCM  Stem Cell Memory T", "mimetype": "text/plain", "start_char_idx": 1903, "end_char_idx": 3637, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "ad03e95f-e539-4b21-9ab6-680d3e6c7cd8": {"__data__": {"id_": "ad03e95f-e539-4b21-9ab6-680d3e6c7cd8", "embedding": null, "metadata": {"page_label": "36", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "79fdffcd-9489-4262-a81d-bcbe43beca14", "node_type": "4", "metadata": {"page_label": "36", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "671d72bb27c43905ee430ec1637ac28628f248d5097b2f72c4ce206886fa0884", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0b67ba50-2d70-4698-87b9-91f46f5d6f81", "node_type": "1", "metadata": {"page_label": "36", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "110f36aa10b52be67f9bfc274e9d063e0ae8fa289e37d51b8c64b4b1e77bcd39", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "70e70abb-f1dd-4c06-b76c-0fe67463b262", "node_type": "1", "metadata": {}, "hash": "d49710f479f8f12b815e34f312152862f045b0767318101c37c00db23111da8e", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "T Lymphocytes\nPD-1  Programmed Cell Death Protein 1\nTCM  Central Memory T Cells\nTEM  Effector Memory T Cells\nTRM  Resident Memory T Cells\nTSCM  Stem Cell Memory T Cells\nTE  Effector T Cells\nTh1  Type 1 T Helper Cell\nIFN-\u03b3  Interferon-Gamma\nTCM  Central Memory T Cells\nCEMIP  Cell Migration-Inducing Hyaluronidase 1\nUSP22  Ubiquitin-Specific Peptidase 22\nRNF31  Ring Finger Protein 31\nYAP  Yes-Associated Protein\nCDKN2A/B  Cyclin-Dependent Kinase Inhibitor 2\u00a0A/B\nSUSD6  Sushi Domain Containing 6\nTMEM127  Transmembrane Protein 127\nWWP2  WW Domain Containing E3 Ubiquitin Protein Ligase \n2\nmTORC1  Mechanistic Target of Rapamycin Complex 1\nCD248  Cluster of Differentiation 248\nOPN  Osteopontin\nSERPINE1  Serpin Family E Member 1\nRGS5  Regulator of G Protein Signaling 5\napCAFs  Antigen-Presenting Cancer-Associated Fibroblasts\nrCAFs  Restraining Cancer-Associated Fibroblasts\niCAFs  Inflammatory Cancer-Associated Fibroblasts\nPRDM1  PR Domain Zinc Finger Protein 1\nZnCDA  Zinc Chlorodipyridine Acetate\nSTING  Stimulator of Interferon Genes\nROS  Reactive Oxygen Species\nTLR4  Toll-Like Receptor 4\nMyD88  Myeloid Differentiation Primary Response 88\nFe3O4-SAS@PLT  Ferrimagnetic Mesoporous Silica Nanoparticles \nLoaded with Sulfasalazine and Functionalized with \nPlatelets\nCSF1  Colony Stimulating Factor 1\nCSF1-R  Colony Stimulating Factor 1 Receptor\nSIRP\u03b1  Signal Regulatory Protein Alpha\nMCSF  Macrophage Colony-Stimulating Factor\nMAPK  Mitogen-Activated Protein Kinase\nPEGylated liposomes", "mimetype": "text/plain", "start_char_idx": 3475, "end_char_idx": 4963, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "70e70abb-f1dd-4c06-b76c-0fe67463b262": {"__data__": {"id_": "70e70abb-f1dd-4c06-b76c-0fe67463b262", "embedding": null, "metadata": {"page_label": "36", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "79fdffcd-9489-4262-a81d-bcbe43beca14", "node_type": "4", "metadata": {"page_label": "36", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "671d72bb27c43905ee430ec1637ac28628f248d5097b2f72c4ce206886fa0884", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ad03e95f-e539-4b21-9ab6-680d3e6c7cd8", "node_type": "1", "metadata": {"page_label": "36", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "05c9cdef92c74b83f6212c216e865440d2911d5ce563cb3d330b71e8fa0dd207", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Colony Stimulating Factor 1 Receptor\nSIRP\u03b1  Signal Regulatory Protein Alpha\nMCSF  Macrophage Colony-Stimulating Factor\nMAPK  Mitogen-Activated Protein Kinase\nPEGylated liposomes  Polyethylene Glycol-coated Liposomes\nR848  Imiquimod analog\nCCL5-siRNA  Chemokine (C-C motif ) Ligand 5 Small Interfering \nRNA\nCe6  Chlorin e6\nPFC  Perfluorocarbon\nMIP-3\u03b2  Macrophage Inflammatory Protein-3\u03b2\nAu@PG  Gold Nanoparticles coated with Polyaniline-Glucose\nCaCO3  Calcium Carbonate\nDGL-ZA  Dendrigraft Poly-L-Lysines-Zoledronate\nMMP2  Matrix Metalloproteinase 2\ncGAS/STING  Cyclic GMP-AMP Synthase/Stimulator of Interferon \nGenes\nPLGA  Poly(lactic-co-glycolic acid)\nCTL  Cytotoxic T Lymphocyte\nMDSCs  Myeloid-Derived Suppressor Cells\nTreg cells  Regulatory T cells", "mimetype": "text/plain", "start_char_idx": 4786, "end_char_idx": 5537, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "48b6f1a3-a591-4faf-8416-1bf2db236587": {"__data__": {"id_": "48b6f1a3-a591-4faf-8416-1bf2db236587", "embedding": null, "metadata": {"page_label": "37", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "8be2043a-23a5-499e-9c2e-0a960733f1e0", "node_type": "4", "metadata": {"page_label": "37", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "4d9fddb435b7948c31d9eb352085fecc7fb642964d5e97172daff6acd3113653", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2fdf36ba-8f1f-4efa-9ce4-691e81026b8d", "node_type": "1", "metadata": {}, "hash": "28e24f7c833a043a29092e4a37a90959b331ef62a7f4ce7794538323fd784725", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Page 37 of 48\nLu et al. Journal of Hematology & Oncology            (2024) 17:16 \nPARP  Poly(ADP-ribose) Polymerase\nAMPK\u03b1/mTOR  AMP-Activated Protein Kinase Alpha/Mammalian \nTarget of Rapamycin\nGITR  Glucocorticoid-Induced Tumor Necrosis Factor \nReceptor\nPLG  Poly(lactide-co-glycolide)\nPLH  Poly-L-Histidine\nIDO  Indoleamine 2,3-dioxygenase\nSTAT3  Signal Transducer and Activator of Transcription 3\nSTAT5  Signal Transducer and Activator of Transcription 5\nmPEG2k-DSPE  Methoxy Polyethylene Glycol \n2000-Distearoylphosphatidylethanolamine\niRGD  Internalizing RGD peptide\nIR-780  Near-Infrared Fluorescent Dye\nFGL1  Fibrinogen-Like Protein 1\nmPEG2k  Methoxy Polyethylene Glycol 2000\nERCC1  Excision Repair Cross-Complementation Group 1\nc-Myc  MYC Proto-Oncogene, BHLH Transcription Factor\nOX40  Tumor Necrosis Factor Receptor Superfamily, \nMember 4 (TNFRSF4)\nCpG  Cytosine-phosphate-Guanine\nPL1  Phospholipid Nanoparticles 1\nGITR  Glucocorticoid-Induced Tumor Necrosis Factor \nReceptor\nPLG  Poly(lactide-co-glycolide)\nPLH  Poly-L-Histidine\nIDO  Indoleamine 2,", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1059, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "2fdf36ba-8f1f-4efa-9ce4-691e81026b8d": {"__data__": {"id_": "2fdf36ba-8f1f-4efa-9ce4-691e81026b8d", "embedding": null, "metadata": {"page_label": "37", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "8be2043a-23a5-499e-9c2e-0a960733f1e0", "node_type": "4", "metadata": {"page_label": "37", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "4d9fddb435b7948c31d9eb352085fecc7fb642964d5e97172daff6acd3113653", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "48b6f1a3-a591-4faf-8416-1bf2db236587", "node_type": "1", "metadata": {"page_label": "37", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "e510ba9d9022591cd80f51beed0ecd7b2ffba81a8e3fa062dfd8a3bad7c79da5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b76cb0d6-8d86-4adf-920a-7c02794732cc", "node_type": "1", "metadata": {}, "hash": "c0cff16558e7677ec063eb5e137926fa884c56eefe0e9e412fd0a195df23c2be", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "3-dioxygenase\nmPEG2k-DSPE  Methoxy Polyethylene Glycol \n2000-Distearoylphosphatidylethanolamine\nmPEG2k  Methoxy Polyethylene Glycol 2000\nERCC1  Excision Repair Cross-Complementation Group 1\nCpG  Cytosine-phosphate-Guanine\nPL1  Phospholipid Nanoparticles 1\nAIEdots  Aggregation-Induced Emission dots\nHMGB1  High Mobility Group Box 1\nMART-1  Melan-A\nCCL22  C-C motif chemokine ligand 22\nLncRNA  Long Non-Coding RNA\nAcknowledgements\nWe would like to express our gratitude to Dr. Rupangi Verma from the \nMedical and Scientific Communication, Research Support Unit at the National \nUniversity Health System, Singapore for her meticulous review and editing of \nour manuscript for English language accuracy.\nAuthor contributions\nQ.L, D.K, S.L and M.A wrote the first draft of paper (Writing original draft). A.R.A, \nI.C, Y.T, X.N, Y.W, P .T and L.W critically revised and supervised the paper. G.S, \nV.T, F.T, Z.Y and P .H developed the idea and concept and revised the paper \n(Writing-review-editing).\nFunding\nThis work was supported by National Natural Science Foundation of China\u2019s \nGeneral Program (82072640), Outstanding Youth Project of Heilongjiang \nNatural Science Foundation (YQ2021H023), Special Key Projects of Guiding \nTechnological Innovation in Shaanxi Province(2021QFY01-03) and Major \nclinical research project of Tangdu Hospital(2021LCYJ008).\u00a0This work was also \nsupported by Singapore Ministry of Education Tier 1 grant to Dr. Gautam Sethi.\nData availability\nNo datasets were generated or analysed during the current study.\nDeclarations\nEthics approval and consent to participate\nNot applicable.\nConsent for publication\nNot applicable.\nCompeting interests\nThe authors declare no competing interests.\nAuthor details\n1Department of Thoracic Surgery, Tangdu Hospital, Air Force Medical \nUniversity, 569 Xinsi Road,", "mimetype": "text/plain", "start_char_idx": 1059, "end_char_idx": 2881, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "b76cb0d6-8d86-4adf-920a-7c02794732cc": {"__data__": {"id_": "b76cb0d6-8d86-4adf-920a-7c02794732cc", "embedding": null, "metadata": {"page_label": "37", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "8be2043a-23a5-499e-9c2e-0a960733f1e0", "node_type": "4", "metadata": {"page_label": "37", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "4d9fddb435b7948c31d9eb352085fecc7fb642964d5e97172daff6acd3113653", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2fdf36ba-8f1f-4efa-9ce4-691e81026b8d", "node_type": "1", "metadata": {"page_label": "37", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "967c0e7badec431ec650d7c4e1d802f70f0d54684697881f9741536e5d619885", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6fbd3de0-94a0-4975-8ba1-c0f1f307ccdc", "node_type": "1", "metadata": {}, "hash": "dbee354311462d764683a26fe08b05ec19da606372b63f5710503009550b8c72", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Consent for publication\nNot applicable.\nCompeting interests\nThe authors declare no competing interests.\nAuthor details\n1Department of Thoracic Surgery, Tangdu Hospital, Air Force Medical \nUniversity, 569 Xinsi Road, Xi\u2019an 710038, China\n2Department of Rehabilitation Medicine, Chongqing Public Health \nMedical Center, Chongqing, China\n3Department of Colorectal Surgery, Harbin Medical University Cancer \nHospital, Harbin, China\n4Department of General Surgery, Institute of Precision Diagnosis and \nTreatment of Digestive System Tumors, Carson International Cancer \nCenter, Shenzhen University General Hospital, Shenzhen University, \nShenzhen 518055, Guangdong, China\n5Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, \nFudan University, Shanghai 200032, China\n6Department of Radiation Oncology, Shandong Cancer Hospital and \nInstitute, Shandong First Medical University, Shandong Academy of \nMedical Sciences, Jinan 250000, Shandong, China\n7Xsphera Biosciences, Translational Medicine Group, 6 Tide Street, Boston, \nMA 02210, USA\n8Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard \nMedical School, Boston, MA 02115, USA\n9Blood Cell Development and Function Program, Fox Chase Cancer \nCenter, Philadelphia, PA, USA\n10School of Public Health, Benedictine University, Lisle, USA\n11Department of Urologic Sciences and Vancouver Prostate Centre, \nUniversity of British Columbia, Vancouver, BC V6H3Z6, Canada\n12Cumming School of Medicine, Arnie Charbonneau Cancer Research \nInstitute, University of Calgary, Calgary, AB T2N 4Z6, Canada\n13Department of Medical Sciences, University of Calgary, Calgary,  \nAB T2N 4Z6, Canada\n14Present address:  NUS Center for Cancer Research (N2CR), Yong Loo Lin \nSchool of Medicine, National University of Singapore, Singapore  \n117599, Singapore\n15Present address: Department of Pharmacology, Yong Loo Lin School of \nMedicine, National University of Singapore, 16 Medical Drive,  \nSingapore 117600,", "mimetype": "text/plain", "start_char_idx": 2666, "end_char_idx": 4628, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "6fbd3de0-94a0-4975-8ba1-c0f1f307ccdc": {"__data__": {"id_": "6fbd3de0-94a0-4975-8ba1-c0f1f307ccdc", "embedding": null, "metadata": {"page_label": "37", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "8be2043a-23a5-499e-9c2e-0a960733f1e0", "node_type": "4", "metadata": {"page_label": "37", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "4d9fddb435b7948c31d9eb352085fecc7fb642964d5e97172daff6acd3113653", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b76cb0d6-8d86-4adf-920a-7c02794732cc", "node_type": "1", "metadata": {"page_label": "37", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "dee768530354040a97d27ecc7a5b6af8b5a650af724ce8233fdcdc6f5b390812", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f98e02de-48bd-46ac-b133-872bd562085d", "node_type": "1", "metadata": {}, "hash": "fdbc57fa836f90194c1e334e8e795b7c391f43da723781f35c27ea3e675fb12a", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "National University of Singapore, Singapore  \n117599, Singapore\n15Present address: Department of Pharmacology, Yong Loo Lin School of \nMedicine, National University of Singapore, 16 Medical Drive,  \nSingapore 117600, Singapore\n16Laboratory of NF-\u03baB Signalling, Institute of Molecular and Cell Biology \n(IMCB), Agency for Science, Technology and Research (A*STAR), 61 \nBiopolis Drive, Proteos, 138673 Singapore, Republic of Singapore\n17The Graduate School, Augusta University, 30912 Augusta, GA, USA\n18Department of Oncology Surgery, Harbin Medical University Cancer \nHospital, Harbin, China\n19Key Laboratory of Tumor Immunology in Heilongjiang, Harbin, China\nReceived: 30 December 2023 / Accepted: 15 March 2024\nReferences\n1. Liu Y, et al. Emerging phagocytosis checkpoints in cancer immunotherapy. \nSignal Transduct Target Ther. 2023;8(1):104.\n2. Kennedy LB, Salama AKS. A review of cancer immunotherapy toxicity. CA \nCancer J Clin. 2020;70(2):86\u2013104.\n3. Mahoney KM, Rennert PD, Freeman GJ. Combination cancer immuno-\ntherapy and new immunomodulatory targets. Nat Rev Drug Discov. \n2015;14(8):561\u201384.\n4. Webster RM. The immune checkpoint inhibitors: where are we now? Nat Rev \nDrug Discov. 2014;13(12):883\u20134.\n5. Zhang Q, et al. Immune and Clinical features of CD96 expression in Glioma by \nin silico analysis. Front Bioeng Biotechnol. 2020;8:592.\n6. Galipeau J, Sens\u00e9b\u00e9 L. Mesenchymal stromal cells: Clinical challenges and \nTherapeutic opportunities. Cell Stem Cell. 2018;22(6):824\u201333.\n7. Liotta F, et al.", "mimetype": "text/plain", "start_char_idx": 4412, "end_char_idx": 5919, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "f98e02de-48bd-46ac-b133-872bd562085d": {"__data__": {"id_": "f98e02de-48bd-46ac-b133-872bd562085d", "embedding": null, "metadata": {"page_label": "37", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "8be2043a-23a5-499e-9c2e-0a960733f1e0", "node_type": "4", "metadata": {"page_label": "37", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "4d9fddb435b7948c31d9eb352085fecc7fb642964d5e97172daff6acd3113653", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6fbd3de0-94a0-4975-8ba1-c0f1f307ccdc", "node_type": "1", "metadata": {"page_label": "37", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "a17e736f748c99f7ecf3a49106e1196e046bc94271aaf60c3a279a40362f7e13", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Cell Stem Cell. 2018;22(6):824\u201333.\n7. Liotta F, et al. Toll-like receptors 3 and 4 are expressed by human bone \nmarrow-derived mesenchymal stem cells and can inhibit their T-cell modula -\ntory activity by impairing notch signaling. Stem Cells. 2008;26(1):279\u201389.\n8. Majeti R, et al. CD47 is an adverse prognostic factor and therapeutic \nantibody target on human acute myeloid leukemia stem cells. Cell. \n2009;138(2):286\u201399.", "mimetype": "text/plain", "start_char_idx": 5865, "end_char_idx": 6288, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "c4394a4e-dfde-49c2-8adb-8d5c3d1068f7": {"__data__": {"id_": "c4394a4e-dfde-49c2-8adb-8d5c3d1068f7", "embedding": null, "metadata": {"page_label": "38", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "37c094c9-4ded-4b8f-a3d5-bd6187acc8d7", "node_type": "4", "metadata": {"page_label": "38", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "e1983c848ea071c4f590e6ce03c395f8322c693241ef518e469b9738546100b3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e098b971-7ab2-4049-b0d8-dbcd0fb24a2b", "node_type": "1", "metadata": {}, "hash": "af4ea9f04317ac5d5e584e4bac65ecf8d693bba2d55150aa445dd264decec4ed", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Page 38 of 48\nLu et al. Journal of Hematology & Oncology            (2024) 17:16 \n9. Barkal AA, et al. CD24 signalling through macrophage Siglec-10 is a target for \ncancer immunotherapy. Nature. 2019;572(7769):392\u20136.\n10. Gordon SR, et al. PD-1 expression by tumour-associated macrophages inhib-\nits phagocytosis and tumour immunity. Nature. 2017;545(7655):495\u20139.\n11. Barkal AA, et al. Engagement of MHC class I by the inhibitory receptor LILRB1 \nsuppresses macrophages and is a target of cancer immunotherapy. Nat \nImmunol. 2018;19(1):76\u201384.\n12. Lin H, et al. Stanniocalcin 1 is a phagocytosis checkpoint driving tumor \nimmune resistance. Cancer Cell. 2021;39(4):480\u2013e4936.\n13. Theruvath J, et al. Anti-GD2 synergizes with CD47 blockade to mediate tumor \neradication. Nat Med. 2022;28(2):333\u201344.\n14. Gardner A, de Mingo \u00c1, Pulido, Ruffell B. Dendritic cells and their role in \nImmunotherapy. Front Immunol. 2020;11:924.\n15. Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity \ncycle. Immunity. 2013;39(1):1\u201310.\n16. Nakayama M. Antigen Presentation by MHC-Dressed cells. Front Immunol. \n2014;5:672.\n17. Lin A, Lor\u00e9 K. Granulocytes: New members of the Antigen-presenting cell \nfamily. Front Immunol. 2017;8:1781.\n18. Broz ML, et al. Dissecting the tumor myeloid compartment reveals rare \nactivating antigen-presenting cells critical for T cell immunity.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1366, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "e098b971-7ab2-4049-b0d8-dbcd0fb24a2b": {"__data__": {"id_": "e098b971-7ab2-4049-b0d8-dbcd0fb24a2b", "embedding": null, "metadata": {"page_label": "38", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "37c094c9-4ded-4b8f-a3d5-bd6187acc8d7", "node_type": "4", "metadata": {"page_label": "38", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "e1983c848ea071c4f590e6ce03c395f8322c693241ef518e469b9738546100b3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c4394a4e-dfde-49c2-8adb-8d5c3d1068f7", "node_type": "1", "metadata": {"page_label": "38", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "f6d0b726346441d6c95f8b99c75252bc350f02011ffd0b8d8022f25fd5b7c3a3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a546d785-06ff-40e9-8ca1-3f81a268015c", "node_type": "1", "metadata": {}, "hash": "ee1d4b29dd5e815b0170e56c1c3329cdda535e86b88e6c76d52d14dfbdfc527f", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Front Immunol. 2017;8:1781.\n18. Broz ML, et al. Dissecting the tumor myeloid compartment reveals rare \nactivating antigen-presenting cells critical for T cell immunity. Cancer Cell. \n2014;26(5):638\u201352.\n19. DeNardo DG, Ruffell B. Macrophages as regulators of tumour immunity and \nimmunotherapy. Nat Rev Immunol. 2019;19(6):369\u201382.\n20. Ruffell B, Coussens LM. Macrophages and therapeutic resistance in cancer. \nCancer Cell. 2015;27(4):462\u201372.\n21. S\u00e1nchez-Paulete AR, et al. Cancer Immunotherapy with Immunomodulatory \nAnti-CD137 and Anti-PD-1 monoclonal antibodies requires BATF3-Depen-\ndent dendritic cells. Cancer Discov. 2016;6(1):71\u20139.\n22. Hildner K, et al. Batf3 deficiency reveals a critical role for CD8alpha + dendritic \ncells in cytotoxic T cell immunity. Science. 2008;322(5904):1097\u2013100.\n23. Roberts EW, et al. Critical role for CD103(+)/CD141(+) dendritic cells bearing \nCCR7 for Tumor Antigen Trafficking and priming of T cell immunity in Mela -\nnoma. Cancer Cell. 2016;30(2):324\u201336.\n24. Salmon H, et al. Expansion and activation of CD103(+) dendritic cell progeni-\ntors at the Tumor Site enhances tumor responses to therapeutic PD-L1 and \nBRAF inhibition. Immunity. 2016;44(4):924\u201338.\n25. de Pulido M. TIM-3 regulates CD103(+) dendritic cell function and response \nto chemotherapy in breast Cancer. Cancer Cell. 2018;33(1):60\u201374.e6.\n26. Garris CS, et al.", "mimetype": "text/plain", "start_char_idx": 1198, "end_char_idx": 2564, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "a546d785-06ff-40e9-8ca1-3f81a268015c": {"__data__": {"id_": "a546d785-06ff-40e9-8ca1-3f81a268015c", "embedding": null, "metadata": {"page_label": "38", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "37c094c9-4ded-4b8f-a3d5-bd6187acc8d7", "node_type": "4", "metadata": {"page_label": "38", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "e1983c848ea071c4f590e6ce03c395f8322c693241ef518e469b9738546100b3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e098b971-7ab2-4049-b0d8-dbcd0fb24a2b", "node_type": "1", "metadata": {"page_label": "38", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "9c05d6383193e93da4a4d58efb10e6a79adbda7913fdad16c88a2c90d5c36d1d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "35d12205-0bf0-4367-9963-f5a456bb95e0", "node_type": "1", "metadata": {}, "hash": "944d732bbf931f492a5555b2d2f21af8b41f92b1f1d37c7ec30fe4f3a46f039b", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Cancer Cell. 2018;33(1):60\u201374.e6.\n26. Garris CS, et al. Successful Anti-PD-1 Cancer Immunotherapy requires T \ncell-dendritic cell crosstalk involving the cytokines IFN-\u03b3 and IL-12. Immunity. \n2018;49(6):1148\u2013e11617.\n27. Spranger S, et al. Tumor-residing Batf3 dendritic cells are required \nfor effector T cell trafficking and adoptive T cell therapy. Cancer Cell. \n2017;31(5):711\u2013e7234.\n28. Chow MT, et al. Intratumoral Activity of the CXCR3 chemokine sys -\ntem is required for the efficacy of Anti-PD-1 therapy. Immunity. \n2019;50(6):1498\u2013e15125.\n29. Xia Y, et al. Engineering macrophages for Cancer Immunotherapy and Drug \nDelivery. Adv Mater. 2020;32(40):e2002054.\n30. Gao J, Liang Y, Wang L. Shap Polarization Tumor-Associated Macrophages \nCancer Immunotherapy Front Immunol. 2022;13:888713.\n31. Kumari N, Choi SH. Tumor-associated macrophages in cancer: recent \nadvancements in cancer nanoimmunotherapies. J Exp Clin Cancer Res. \n2022;41(1):68.\n32. Li L, Ma SR, Yu ZL. Targeting the lipid metabolic reprogramming of tumor-\nassociated macrophages: a novel insight into cancer immunotherapy. Cell \nOncol (Dordr); 2023.\n33. Pei L, et al. Roles of cancer-associated fibroblasts (CAFs) in anti- PD-1/PD-L1 \nimmunotherapy for solid cancers. Mol Cancer. 2023;22(1):29.\n34. Zhang H, et al. Define cancer-associated fibroblasts (CAFs) in the tumor \nmicroenvironment: new opportunities in cancer immunotherapy and \nadvances in clinical trials.", "mimetype": "text/plain", "start_char_idx": 2509, "end_char_idx": 3947, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "35d12205-0bf0-4367-9963-f5a456bb95e0": {"__data__": {"id_": "35d12205-0bf0-4367-9963-f5a456bb95e0", "embedding": null, "metadata": {"page_label": "38", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "37c094c9-4ded-4b8f-a3d5-bd6187acc8d7", "node_type": "4", "metadata": {"page_label": "38", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "e1983c848ea071c4f590e6ce03c395f8322c693241ef518e469b9738546100b3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a546d785-06ff-40e9-8ca1-3f81a268015c", "node_type": "1", "metadata": {"page_label": "38", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "07f85976cb2d446c8825c478cad937026aabac351d12942d5d12008b9c812c45", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "75b217c5-cccc-4a3d-a4f4-4641c8bae85c", "node_type": "1", "metadata": {}, "hash": "126bfafe1f0f0fc67a3e9b43d7679f4cdfb8be68c73990b4e9ad3760205e3064", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "34. Zhang H, et al. Define cancer-associated fibroblasts (CAFs) in the tumor \nmicroenvironment: new opportunities in cancer immunotherapy and \nadvances in clinical trials. Mol Cancer. 2023;22(1):159.\n35. Raskov H, et al. Cancer-Associated fibroblasts and Tumor-Associated macro-\nphages in Cancer and Cancer Immunotherapy. Front Oncol. 2021;11:668731.\n36. Thiery J. Modulation of the antitumor immune response by cancer-associ -\nated fibroblasts: mechanisms and targeting strategies to hamper their immu-\nnosuppressive functions. Explor Target Antitumor Ther. 2022;3(5):598\u2013629.\n37. Wang Q, et al. Role of tumor microenvironment in cancer progression and \ntherapeutic strategy. Cancer Med. 2023;12(10):11149\u201365.\n38. Han S et al. Tumor Microenvironment Regulation and Cancer Targeting \nTherapy based on nanoparticles. J Funct Biomater, 2023. 14(3).\n39. Li Z, Yin P . Tumor microenvironment diversity and plasticity in cancer multi-\ndrug resistance. Biochim Biophys Acta Rev Cancer. 2023;1878(6):188997.\n40. Yang R, et al. Tumor microenvironment responsive metal nanoparticles in \ncancer immunotherapy. Front Immunol. 2023;14:1237361.\n41. Zhang Z, et al. Involvement of inflammasomes in tumor microenvironment \nand tumor therapies. J Hematol Oncol. 2023;16(1):24.\n42. Jin HR, et al. Lipid metabolic reprogramming in tumor microenvironment: \nfrom mechanisms to therapeutics. J Hematol Oncol. 2023;16(1):103.\n43. Arner EN, Rathmell JC. Metabolic programming and immune suppression in \nthe tumor microenvironment. Cancer Cell. 2023;41(3):421\u201333.", "mimetype": "text/plain", "start_char_idx": 3776, "end_char_idx": 5315, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "75b217c5-cccc-4a3d-a4f4-4641c8bae85c": {"__data__": {"id_": "75b217c5-cccc-4a3d-a4f4-4641c8bae85c", "embedding": null, "metadata": {"page_label": "38", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "37c094c9-4ded-4b8f-a3d5-bd6187acc8d7", "node_type": "4", "metadata": {"page_label": "38", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "e1983c848ea071c4f590e6ce03c395f8322c693241ef518e469b9738546100b3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "35d12205-0bf0-4367-9963-f5a456bb95e0", "node_type": "1", "metadata": {"page_label": "38", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "e75da743c3bf35c3e246929c811e4d8ac5cc7113b416af17bf26c0e0d7870a00", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e2752690-4c04-4c72-94a1-d31306fc2ea1", "node_type": "1", "metadata": {}, "hash": "30d866982510619909b3f4c358ba5af365f5fc03708d06821c1b7e1e31aaf458", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "43. Arner EN, Rathmell JC. Metabolic programming and immune suppression in \nthe tumor microenvironment. Cancer Cell. 2023;41(3):421\u201333.\n44. Lin MJ, et al. Cancer vaccines: the next immunotherapy frontier. Nat Cancer. \n2022;3(8):911\u201326.\n45. Beck JD, et al. mRNA therapeutics in cancer immunotherapy. Mol Cancer. \n2021;20(1):69.\n46. Siminiak N, et al. Immunotherapy in Ovarian Cancer. Arch Immunol Ther Exp \n(Warsz). 2022;70(1):19.\n47. Mauricio D, et al. Immunotherapy in Cervical Cancer. Curr Oncol Rep. \n2021;23(6):61.\n48. Bockorny B, Grossman JE, Hidalgo M. Facts and hopes in Immunotherapy of \nPancreatic Cancer. Clin Cancer Res. 2022;28(21):4606\u201317.\n49. Yang M, et al. The application of nanoparticles in cancer immunotherapy: \ntargeting tumor microenvironment. Bioact Mater. 2021;6(7):1973\u201387.\n50. Overchuk M, Zheng G. Overcoming obstacles in the tumor microenviron -\nment: recent advancements in nanoparticle delivery for cancer theranostics. \nBiomaterials. 2018;156:217\u201337.\n51. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in \ncancer chemotherapy: mechanism of tumoritropic accumulation of proteins \nand the antitumor agent smancs. Cancer Res. 1986;46(12 Pt 1):6387\u201392.\n52. Prabhakar U, et al. Challenges and key considerations of the enhanced per-\nmeability and retention effect for nanomedicine drug delivery in oncology. \nCancer Res. 2013;73(8):2412\u20137.\n53.", "mimetype": "text/plain", "start_char_idx": 5180, "end_char_idx": 6568, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "e2752690-4c04-4c72-94a1-d31306fc2ea1": {"__data__": {"id_": "e2752690-4c04-4c72-94a1-d31306fc2ea1", "embedding": null, "metadata": {"page_label": "38", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "37c094c9-4ded-4b8f-a3d5-bd6187acc8d7", "node_type": "4", "metadata": {"page_label": "38", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "e1983c848ea071c4f590e6ce03c395f8322c693241ef518e469b9738546100b3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "75b217c5-cccc-4a3d-a4f4-4641c8bae85c", "node_type": "1", "metadata": {"page_label": "38", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "e70f0d219a25fb448c585eee78310a80483ed75458e14d2b5454514cf6b24be9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "73f33687-ad78-4678-b4ee-e1fbee3c09cc", "node_type": "1", "metadata": {}, "hash": "8dcf41e2f662c93621d71368d53d8a7a329c585d9d8a02a34394697efdffb358", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Challenges and key considerations of the enhanced per-\nmeability and retention effect for nanomedicine drug delivery in oncology. \nCancer Res. 2013;73(8):2412\u20137.\n53. Yang S, Gao H. Nanoparticles for modulating tumor microenvironment to \nimprove drug delivery and tumor therapy. Pharmacol Res. 2017;126:97\u2013108.\n54. Chen Q, et al. Remodeling the Tumor Microenvironment with Emerging \nNanotherapeutics. Trends Pharmacol Sci. 2018;39(1):59\u201374.\n55. Li M, et al. Nanoparticles designed to regulate tumor microenvironment for \ncancer therapy. Life Sci. 2018;201:37\u201344.\n56. Guo B, et al. Cuproptosis Induced by ROS responsive nanoparticles with \nElesclomol and Copper Combined with \u03b1PD-L1 for enhanced Cancer Immu -\nnotherapy. Adv Mater. 2023;35(22):e2212267.\n57. Wang-Bishop L, et al. STING-activating nanoparticles normalize the vascular-\nimmune interface to potentiate cancer immunotherapy. Sci Immunol. \n2023;8(83):eadd1153.\n58. Ding B, et al. ZIF-8 nanoparticles evoke pyroptosis for high-efficiency Cancer \nImmunotherapy. Angew Chem Int Ed Engl. 2023;62(10):e202215307.\n59. Liu J et al. Ultrathin clay nanoparticles-mediated mutual reinforcement of \nferroptosis and Cancer immunotherapy. Adv Mater, 2023: p. e2309562.\n60. Huang A, et al. Engineered apoptosis-bioinspired nanoparticles initiate \nImmune Cascade for Cancer Immunotherapy of Malignant ascites. ACS Appl \nMater Interfaces. 2023;15(8):10371\u201382.\n61. Liu D et al. Tumor Microenvironment-Responsive nanoparticles amplifying \nSTING Signaling Pathway for Cancer Immunotherapy.", "mimetype": "text/plain", "start_char_idx": 6403, "end_char_idx": 7933, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "73f33687-ad78-4678-b4ee-e1fbee3c09cc": {"__data__": {"id_": "73f33687-ad78-4678-b4ee-e1fbee3c09cc", "embedding": null, "metadata": {"page_label": "38", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "37c094c9-4ded-4b8f-a3d5-bd6187acc8d7", "node_type": "4", "metadata": {"page_label": "38", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "e1983c848ea071c4f590e6ce03c395f8322c693241ef518e469b9738546100b3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e2752690-4c04-4c72-94a1-d31306fc2ea1", "node_type": "1", "metadata": {"page_label": "38", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "1b382f578ec402c7ea374b37a44368ab4929369631c0bb450fefac3dd011147b", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "2023;15(8):10371\u201382.\n61. Liu D et al. Tumor Microenvironment-Responsive nanoparticles amplifying \nSTING Signaling Pathway for Cancer Immunotherapy. Adv Mater, 2023: p. \ne2304845.\n62. Sun Y, et al. Sialic acid-targeted cyclodextrin-based nanoparticles deliver \nCSF-1R siRNA and reprogram tumour-associated macrophages for immuno-\ntherapy of prostate cancer. Eur J Pharm Sci. 2023;185:106427.\n63. Liu C, et al. Microfluidic sonication to assemble Exosome membrane-\ncoated nanoparticles for Immune evasion-mediated targeting. Nano Lett. \n2019;19(11):7836\u201344.\n64. Li M et al. Signaling pathways in macrophages: molecular mechanisms and \ntherapeutic targets MedComm (2020), 2023;4(5):e349.\n65. Ginhoux F, Guilliams M. Tissue-Resident Macrophage Ontogeny and Homeo-\nstasis. Immunity. 2016;44(3):439\u201349.\n66. Epelman S, Lavine KJ, Randolph GJ. Origin and functions of tissue macro-\nphages. Immunity. 2014;41(1):21\u201335.\n67. Italiani P , Boraschi D. From monocytes to M1/M2 macrophages: phenotypical \nvs. functional differentiation. Front Immunol. 2014;5:514.\n68. Schulz C, et al. A lineage of myeloid cells independent of myb and hemato -\npoietic stem cells. Science. 2012;336(6077):86\u201390.\n69. Sieweke MH, Allen JE. Beyond stem cells: self-renewal of differentiated mac -\nrophages. Science. 2013;342(6161):1242974.", "mimetype": "text/plain", "start_char_idx": 7786, "end_char_idx": 9090, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "0147068f-2e07-42cc-802a-617be82b8f48": {"__data__": {"id_": "0147068f-2e07-42cc-802a-617be82b8f48", "embedding": null, "metadata": {"page_label": "39", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "761bb3fe-8847-42e7-9d73-5d3d8abc6b6b", "node_type": "4", "metadata": {"page_label": "39", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "fcb9630e17309080bbf6f53ac9708a63fdbf44ddd52f692584301f007e447f79", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "80824659-5661-44e0-ac9d-9ab644235cd6", "node_type": "1", "metadata": {}, "hash": "faa80aa0ca5efb09db57de793f56a5a9299e16d9e37d66860a1b46f8dbfe95b5", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Page 39 of 48\nLu et al. Journal of Hematology & Oncology            (2024) 17:16 \n70. Zhan C et al. Antitumor therapy for breast cancer: focus on tumor-associated \nmacrophages and nanosized drug delivery systems. Cancer Med, 2023.\n71. Wang N, et al. Research trends in pharmacological modulation of tumor-\nassociated macrophages. Clin Transl Med. 2021;11(1):e288.\n72. Vitale I, et al. Macrophages and metabolism in the Tumor Microenvironment. \nCell Metab. 2019;30(1):36\u201350.\n73. Wang J, et al. Crosstalk between cancer and immune cells: role of tumor-\nassociated macrophages in the tumor microenvironment. Cancer Med. \n2019;8(10):4709\u201321.\n74. Wu T, Dai Y. Tumor microenvironment and therapeutic response. Cancer Lett. \n2017;387:61\u20138.\n75. Munir MT et al. Tumor-Associated macrophages as multifaceted regulators of \nbreast tumor growth. Int J Mol Sci, 2021. 22(12).\n76. Qiu SQ, et al. Tumor-associated macrophages in breast cancer: innocent \nbystander or important player? Cancer Treat Rev. 2018;70:178\u201389.\n77. Wang C, et al. Macrophage balance fraction determines the degree of immu -\nnosuppression and metastatic ability of breast cancer. Int Immunopharma-\ncol. 2021;97:107682.\n78. Steenbrugge J, et al. Anti-inflammatory signaling by mammary tumor cells \nmediates prometastatic macrophage polarization in an innovative intra-\nductal mouse model for triple-negative breast cancer. J Exp Clin Cancer Res. \n2018;37(1):191.\n79. Shu Y, Cheng P .", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1440, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "80824659-5661-44e0-ac9d-9ab644235cd6": {"__data__": {"id_": "80824659-5661-44e0-ac9d-9ab644235cd6", "embedding": null, "metadata": {"page_label": "39", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "761bb3fe-8847-42e7-9d73-5d3d8abc6b6b", "node_type": "4", "metadata": {"page_label": "39", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "fcb9630e17309080bbf6f53ac9708a63fdbf44ddd52f692584301f007e447f79", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0147068f-2e07-42cc-802a-617be82b8f48", "node_type": "1", "metadata": {"page_label": "39", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "d9c33ebcd4269342744bcf2051654d21da7ff9ce6191f3b6b892750aa349285f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e1887e6f-82a2-432b-9db6-ecb4139d36f7", "node_type": "1", "metadata": {}, "hash": "c51d7c373daa0c8544fea67222d4cd30706de6234bf55545122b94074067d4b8", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "J Exp Clin Cancer Res. \n2018;37(1):191.\n79. Shu Y, Cheng P . Targeting tumor-associated macrophages for cancer \nimmunotherapy Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, \n2020;1874(2):188434.\n80. Nascimento C, et al. Reprogramming of tumor-associated macrophages by \npolyaniline-coated iron oxide nanoparticles applied to treatment of breast \ncancer. Int J Pharm. 2023;636:122866.\n81. Shang Y, et al. Bioengineered Nanospores selectively blocking LC3-Associated \nphagocytosis in Tumor-Associated macrophages Potentiate Antitumor \nImmunity. ACS Nano. 2023;17(11):10872\u201387.\n82. Liu Y, et al. Multifunctional nanoparticles inhibit tumor and tumor-associated \nmacrophages for triple-negative breast cancer therapy. J Colloid Interface Sci. \n2024;657:598\u2013610.\n83. Liang DS, et al. Targeted delivery of pexidartinib to tumor-associated \nmacrophages via legumain-sensitive dual-coating nanoparticles for cancer \nimmunotherapy. Colloids Surf B Biointerfaces. 2023;226:113283.\n84. Sun H, et al. The role of cancer-associated fibroblasts in tumorigenesis of \ngastric cancer. Cell Death Dis. 2022;13(10):874.\n85. Gu J, et al. The role of PKM2 nuclear translocation in the constant activation \nof the NF-\u03baB signaling pathway in cancer-associated fibroblasts. Cell Death \nDis. 2021;12(4):291.\n86. Bu L, et al. Biological heterogeneity and versatility of cancer-associated fibro-\nblasts in the tumor microenvironment. Oncogene. 2019;38(25):4887\u2013901.\n87. Kalluri R. The biology and function of fibroblasts in cancer. Nat Rev Cancer.", "mimetype": "text/plain", "start_char_idx": 1380, "end_char_idx": 2910, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "e1887e6f-82a2-432b-9db6-ecb4139d36f7": {"__data__": {"id_": "e1887e6f-82a2-432b-9db6-ecb4139d36f7", "embedding": null, "metadata": {"page_label": "39", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "761bb3fe-8847-42e7-9d73-5d3d8abc6b6b", "node_type": "4", "metadata": {"page_label": "39", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "fcb9630e17309080bbf6f53ac9708a63fdbf44ddd52f692584301f007e447f79", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "80824659-5661-44e0-ac9d-9ab644235cd6", "node_type": "1", "metadata": {"page_label": "39", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "e3691286a78025a47572bb670a41ad632b507bfa3ae964fbb14077a7583a3b99", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dcd49bc2-c5d4-47a2-b545-5c6be08dcdfa", "node_type": "1", "metadata": {}, "hash": "30ec390160aefe98ebddfd2821f361313a5a6771129c8bf0426e77d112d12a0a", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Oncogene. 2019;38(25):4887\u2013901.\n87. Kalluri R. The biology and function of fibroblasts in cancer. Nat Rev Cancer. \n2016;16(9):582\u201398.\n88. Kobayashi H, et al. Cancer-associated fibroblasts in gastrointestinal cancer. \nNat Rev Gastroenterol Hepatol. 2019;16(5):282\u201395.\n89. Zhang T, et al. Cancer-associated fibroblasts in pancreatic ductal adenocarci-\nnoma. Cell Death Dis. 2022;13(10):897.\n90. \u00d6hlund D, et al. Distinct populations of inflammatory fibroblasts and myofi-\nbroblasts in pancreatic cancer. J Exp Med. 2017;214(3):579\u201396.\n91. Biffi G, et al. IL1-Induced JAK/STAT signaling is antagonized by TGF\u03b2 to shape \nCAF heterogeneity in pancreatic ductal adenocarcinoma. Cancer Discov. \n2019;9(2):282\u2013301.\n92. Elyada E, et al. Cross-species single-cell analysis of pancreatic ductal adeno-\ncarcinoma reveals Antigen-Presenting Cancer-Associated fibroblasts. Cancer \nDiscov. 2019;9(8):1102\u201323.\n93. Fang Z, et al. Signaling pathways in cancer-associated fibroblasts: recent \nadvances and future perspectives. Cancer Commun. 2023;43(1):3\u201341.\n94. Ai W, et al. Modulation of cancer-associated fibroblasts by nanodeliv-\nery system to enhance efficacy of tumor therapy. Nanomed (Lond). \n2023;18(15):1025\u201339.\n95. Geng S, et al. Safe engineering of cancer-associated fibroblasts enhances \ncheckpoint blockade immunotherapy. J Control Release. 2023;356:272\u201387.\n96. Jian C et al.", "mimetype": "text/plain", "start_char_idx": 2797, "end_char_idx": 4166, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "dcd49bc2-c5d4-47a2-b545-5c6be08dcdfa": {"__data__": {"id_": "dcd49bc2-c5d4-47a2-b545-5c6be08dcdfa", "embedding": null, "metadata": {"page_label": "39", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "761bb3fe-8847-42e7-9d73-5d3d8abc6b6b", "node_type": "4", "metadata": {"page_label": "39", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "fcb9630e17309080bbf6f53ac9708a63fdbf44ddd52f692584301f007e447f79", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e1887e6f-82a2-432b-9db6-ecb4139d36f7", "node_type": "1", "metadata": {"page_label": "39", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "07beb4ce2cc63da76a5240b8285e721f7b53a912e04a557b97f2474aaa60f304", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "81023747-298d-49e4-8db2-1a9cee50ba56", "node_type": "1", "metadata": {}, "hash": "c950abc1e93ad84998b7bc04d1621bc0a8ab22cdbf2530a0d4cbe4f633f69691", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Geng S, et al. Safe engineering of cancer-associated fibroblasts enhances \ncheckpoint blockade immunotherapy. J Control Release. 2023;356:272\u201387.\n96. Jian C et al. Biomimetic Nanoplatform for Dual-Targeted Clearance of \nActivated and Senescent Cancer-Associated Fibroblasts to Improve Radiation \nResistance in Breast Cancer Small, 2024: p. e2309279.\n97. Hu M, et al. Salvianolic acid B-loaded polydopamine-modified hollow \nmesoporous organic silica nanoparticles for treatment of breast cancer \nmetastasis via suppressing cancer-associated fibroblasts. Eur J Pharm Sci. \n2024;192:106641.\n98. Hinshaw DC, Shevde LA. The Tumor Microenvironment innately modulates \nCancer Progression. Cancer Res. 2019;79(18):4557\u201366.\n99. Wang J, et al. The clinical significance of tumor-infiltrating neutrophils and \nneutrophil-to-CD8 + lymphocyte ratio in patients with resectable esophageal \nsquamous cell carcinoma. J Transl Med. 2014;12:7.\n100. Deniset JF, Kubes P . Recent Adv Underst Neutrophils F1000Res. 2016;5:2912.\n101. Uribe-Querol E, Rosales C. Neutrophils in Cancer: two sides of the same Coin. \nJ Immunol Res. 2015;2015:983698.\n102. Cools-Lartigue J, et al. Neutrophil extracellular traps in cancer progression. \nCell Mol Life Sci. 2014;71(21):4179\u201394.\n103. Jin W, et al. Tumor-infiltrating NETs predict postsurgical survival in patients \nwith pancreatic ductal adenocarcinoma. Ann Surg Oncol. 2019;26(2):635\u201343.\n104. Fridlender ZG, Albelda SM. Tumor-associated neutrophils: friend or foe?", "mimetype": "text/plain", "start_char_idx": 4003, "end_char_idx": 5488, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "81023747-298d-49e4-8db2-1a9cee50ba56": {"__data__": {"id_": "81023747-298d-49e4-8db2-1a9cee50ba56", "embedding": null, "metadata": {"page_label": "39", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "761bb3fe-8847-42e7-9d73-5d3d8abc6b6b", "node_type": "4", "metadata": {"page_label": "39", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "fcb9630e17309080bbf6f53ac9708a63fdbf44ddd52f692584301f007e447f79", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dcd49bc2-c5d4-47a2-b545-5c6be08dcdfa", "node_type": "1", "metadata": {"page_label": "39", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "4baf25836af0902a2cd3e8702a4e356effe67cc0ccfdeecd8d53ffd4f3b2825a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a9fe4749-a380-4572-9785-5af8f66781c1", "node_type": "1", "metadata": {}, "hash": "f331052b568c2bfc7e09ec5954175fa23e518309ba8b2c4d7f9e5f12bac421cd", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Ann Surg Oncol. 2019;26(2):635\u201343.\n104. Fridlender ZG, Albelda SM. Tumor-associated neutrophils: friend or foe? \nCarcinogenesis. 2012;33(5):949\u201355.\n105. Demers M, et al. Priming of neutrophils toward NETosis promotes tumor \ngrowth. Oncoimmunology. 2016;5(5):e1134073.\n106. He M, et al. Peritumoral stromal neutrophils are essential for c-Met-elicited \nmetastasis in human hepatocellular carcinoma. Oncoimmunology. \n2016;5(10):e1219828.\n107. Schauer C, et al. Aggregated neutrophil extracellular traps limit inflammation \nby degrading cytokines and chemokines. Nat Med. 2014;20(5):511\u20137.\n108. Ralph SJ, Reynolds MJ. Intratumoral pro-oxidants promote cancer immuno-\ntherapy by recruiting and reprogramming neutrophils to eliminate tumors. \nCancer Immunol Immunother. 2023;72(3):527\u201342.\n109. Benguigui M et al. Interferon-stimulated neutrophils as a predictor of immu -\nnotherapy response. Cancer Cell, 2024.\n110. Huntington ND, Cursons J, Rautela J. The cancer\u2013natural killer cell immunity \ncycle. Nat Rev Cancer. 2020;20(8):437\u201354.\n111. Huntington ND, Vosshenrich CA, Di Santo JP . Developmental pathways that \ngenerate natural-killer-cell diversity in mice and humans. Nat Rev Immunol. \n2007;7(9):703\u201314.\n112. Pfefferle A, et al. Intra-lineage plasticity and functional reprogramming main-\ntain natural killer cell repertoire diversity. Cell Rep. 2019;29(8):2284\u2013e22944.\n113. Freud AG, Caligiuri MA. Human natural killer cell development.", "mimetype": "text/plain", "start_char_idx": 5377, "end_char_idx": 6815, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "a9fe4749-a380-4572-9785-5af8f66781c1": {"__data__": {"id_": "a9fe4749-a380-4572-9785-5af8f66781c1", "embedding": null, "metadata": {"page_label": "39", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "761bb3fe-8847-42e7-9d73-5d3d8abc6b6b", "node_type": "4", "metadata": {"page_label": "39", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "fcb9630e17309080bbf6f53ac9708a63fdbf44ddd52f692584301f007e447f79", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "81023747-298d-49e4-8db2-1a9cee50ba56", "node_type": "1", "metadata": {"page_label": "39", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "44b6e4ad7a5482a051c9009425256eea527b0d7410c5b28f35730ff1da310d0f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1ae18566-0bb6-471b-bd78-d48005cd3f8a", "node_type": "1", "metadata": {}, "hash": "e9d2f7b7fc7a0b94fc66d85fa79d33d4a6fdae6036395720766d87bb09958dc7", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Cell Rep. 2019;29(8):2284\u2013e22944.\n113. Freud AG, Caligiuri MA. Human natural killer cell development. Immunol Rev. \n2006;214:56\u201372.\n114. Gil M, Kim KE. Interleukin-18 is a prognostic biomarker correlated with \nCD8 + T cell and natural killer cell infiltration in skin cutaneous melanoma \nJournal of clinical medicine, 2019;8(11):1993.\n115. Cursons J, et al. A gene signature Predicting Natural Killer Cell Infiltra-\ntion and Improved Survival in Melanoma patients. Cancer Immunol Res. \n2019;7(7):1162\u201374.\n116. Lee H, et al. Integrated molecular and immunophenotypic analysis of NK \ncells in anti-PD-1 treated metastatic melanoma patients. Oncoimmunology. \n2019;8(2):e1537581.\n117. Li B et al. Natural killer cell and stroma abundance are independently prog-\nnostic and predict gastric cancer chemotherapy benefit. JCI Insight, 2020. \n5(9).\n118. Ran GH, et al. Natural killer cell homing and trafficking in tissues and tumors: \nfrom biology to application. Signal Transduct Target Therapy. 2022;7(1):205.\n119. Scoville SD, Freud AG, Caligiuri MA. Model Hum Nat Killer Cell Dev Era Innate \nLymphoid Cells Front Immunol. 2017;8:360.\n120. Stokic-Trtica V, Diefenbach A, Klose CSN. NK Cell Dev Times Innate Lymphoid \nCell Divers Front Immunol. 2020;11:813.\n121. Vivier E, et al. Innate lymphoid cells: 10 years on. Cell. 2018;174(5):1054\u201366.\n122. Freud AG, et al. The Broad Spectrum of Human Natural Killer Cell Diversity. \nImmunity. 2017;47(5):820\u201333.\n123.", "mimetype": "text/plain", "start_char_idx": 6714, "end_char_idx": 8166, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "1ae18566-0bb6-471b-bd78-d48005cd3f8a": {"__data__": {"id_": "1ae18566-0bb6-471b-bd78-d48005cd3f8a", "embedding": null, "metadata": {"page_label": "39", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "761bb3fe-8847-42e7-9d73-5d3d8abc6b6b", "node_type": "4", "metadata": {"page_label": "39", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "fcb9630e17309080bbf6f53ac9708a63fdbf44ddd52f692584301f007e447f79", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a9fe4749-a380-4572-9785-5af8f66781c1", "node_type": "1", "metadata": {"page_label": "39", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "9f0e0eb60146ab102ea3b7b808cba4b94403ca378c70621367867c4fe5194c93", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "122. Freud AG, et al. The Broad Spectrum of Human Natural Killer Cell Diversity. \nImmunity. 2017;47(5):820\u201333.\n123. Bj\u00f6rkstr\u00f6m NK, Ljunggren HG, Micha\u00eblsson J. Emerging insights into natural \nkiller cells in human peripheral tissues. Nat Rev Immunol. 2016;16(5):310\u201320.\n124. Yu J, Freud AG, Caligiuri MA. Location and cellular stages of natural killer cell \ndevelopment. Trends Immunol. 2013;34(12):573\u201382.\n125. Vivier E, et al. Functions of natural killer cells. Nat Immunol. 2008;9(5):503\u201310.\n126. Fang F, Xiao W, Tian Z. NK cell-based immunotherapy for cancer. Semin \nImmunol. 2017;31:37\u201354.\n127. Hammer Q, R\u00fcckert T, Romagnani C. Natural killer cell specificity for viral \ninfections. Nat Immunol. 2018;19(8):800\u20138.\n128. Bj\u00f6rkstr\u00f6m NK, Strunz B, Ljunggren HG. Natural killer cells in antiviral immu-\nnity. Nat Rev Immunol. 2022;22(2):112\u201323.\n129. Li Y, et al. Natural killer cells: friend or foe in metabolic diseases? Front Immu-\nnol. 2021;12:614429.\n130. Shimasaki N, Jain A, Campana D. NK cells for cancer immunotherapy. Nat Rev \nDrug Discov. 2020;19(3):200\u201318.", "mimetype": "text/plain", "start_char_idx": 8051, "end_char_idx": 9119, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "d9047c34-a108-4353-92e4-3197817657a7": {"__data__": {"id_": "d9047c34-a108-4353-92e4-3197817657a7", "embedding": null, "metadata": {"page_label": "40", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "56ff51f7-ccb5-4c78-8d0a-99145acf70e4", "node_type": "4", "metadata": {"page_label": "40", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "624d55bf5486df7a263ab86d8a4536843acf45dd1dfa2b3212fbbe0964913d69", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "397999f0-6ea0-4738-b94c-fb53b29788c0", "node_type": "1", "metadata": {}, "hash": "18613bba0ec311d056962823456c9d752ac3b0e5ff0bbb7b3faa3a8e3cd09c2d", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Page 40 of 48\nLu et al. Journal of Hematology & Oncology            (2024) 17:16 \n131. Maskalenko NA, Zhigarev D, Campbell KS. Harnessing natural killer cells \nfor cancer immunotherapy: dispatching the first responders. Nat Rev Drug \nDiscov. 2022;21(8):559\u201377.\n132. Pockley AG, Vaupel P , Multhoff G. NK cell-based therapeutics for lung cancer. \nExpert Opin Biol Ther. 2020;20(1):23\u201333.\n133. Muntasell A, et al. NK Cell infiltrates and HLA Class I expression in primary \nHER2(+) breast Cancer Predict and Uncouple Pathological Response and \nDisease-free survival. Clin Cancer Res. 2019;25(5):1535\u201345.\n134. Liu P , Chen L, Zhang H. Natural killer cells in Liver Disease and Hepatocel-\nlular Carcinoma and the NK cell-based immunotherapy. J Immunol Res. \n2018;2018:p1206737.\n135. Ali TH, et al. Enrichment of CD56(dim)KIR + CD57 + highly cytotoxic NK cells \nin tumour-infiltrated lymph nodes of melanoma patients. Nat Commun. \n2014;5:5639.\n136. Terr\u00e9n I et al. NK Cell-based immunotherapy in renal cell carcinoma. Cancers \n(Basel), 2020. 12(2).\n137. Lim SA, et al. Lipid metabolism in T cell signaling and function. Nat Chem \nBiol. 2022;18(5):470\u201381.\n138. Ando M, et al. Memory T cell, exhaustion, and tumor immunity. Immunologi-\ncal Med. 2020;43(1):1\u20139.\n139. Franco F, et al. Metabolic and epigenetic regulation of T-cell exhaustion. Nat \nMetabolism. 2020;2(10):1001\u201312.\n140. Douka S, et al.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1390, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "397999f0-6ea0-4738-b94c-fb53b29788c0": {"__data__": {"id_": "397999f0-6ea0-4738-b94c-fb53b29788c0", "embedding": null, "metadata": {"page_label": "40", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "56ff51f7-ccb5-4c78-8d0a-99145acf70e4", "node_type": "4", "metadata": {"page_label": "40", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "624d55bf5486df7a263ab86d8a4536843acf45dd1dfa2b3212fbbe0964913d69", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d9047c34-a108-4353-92e4-3197817657a7", "node_type": "1", "metadata": {"page_label": "40", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "2ce71430464b21260b47f663c6dbe26e2476983544271c2d44f65f2066c0d682", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2e11b28c-687d-4fd4-a9e9-6475b6df4cb3", "node_type": "1", "metadata": {}, "hash": "d49fc7fa3fbd3cff81c6155419df897f9dd0cc886991ff38380de936f9739436", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Metabolic and epigenetic regulation of T-cell exhaustion. Nat \nMetabolism. 2020;2(10):1001\u201312.\n140. Douka S, et al. Lipid nanoparticle-mediated messenger RNA delivery for ex \nvivo engineering of natural killer cells. J Control Release. 2023;361:455\u201369.\n141. Shamalov K, et al. Noninvasive Tracking of Natural Killer cells using gold \nnanoparticles. ACS Omega. 2021;6(43):28507\u201314.\n142. Kim KS, et al. Cationic nanoparticle-mediated activation of natural killer \ncells for Effective Cancer Immunotherapy. ACS Appl Mater Interfaces. \n2020;12(51):56731\u201340.\n143. Sun X, et al. Acid-switchable nanoparticles induce self-adaptive aggregation \nfor enhancing antitumor immunity of natural killer cells. Acta Pharm Sin B. \n2023;13(7):3093\u2013105.\n144. Liu GW, et al. Lipid nanoparticles for nucleic acid delivery to endothelial cells. \nPharm Res. 2023;40(1):3\u201325.\n145. F\u00e9l\u00e9tou M. Integrated Systems Physiology: from molecule to function to \nDisease, in The endothelium: part 1: multiple functions of the endothelial \ncells\u2014focus on endothelium-derived Vasoactive mediators. 2011, Morgan & \nClaypool Life Sciences copyright \u00a9 2011 by Morgan & Claypool Life Sciences \nPublishers.: San Rafael (CA).\n146. Stoltz JF, et al. Introduction to endothelial cell biology. Clin Hemorheol Micro -\ncirc. 2007;37(1\u20132):5\u20138.\n147. Martin FA, Murphy RP , Cummins PM. Thrombomodulin and the vascular \nendothelium: insights into functional, regulatory, and therapeutic aspects. \nAm J Physiol Heart Circ Physiol. 2013;304(12):H1585\u201397.\n148. Maroney SA, Mast AE.", "mimetype": "text/plain", "start_char_idx": 1275, "end_char_idx": 2802, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "2e11b28c-687d-4fd4-a9e9-6475b6df4cb3": {"__data__": {"id_": "2e11b28c-687d-4fd4-a9e9-6475b6df4cb3", "embedding": null, "metadata": {"page_label": "40", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "56ff51f7-ccb5-4c78-8d0a-99145acf70e4", "node_type": "4", "metadata": {"page_label": "40", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "624d55bf5486df7a263ab86d8a4536843acf45dd1dfa2b3212fbbe0964913d69", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "397999f0-6ea0-4738-b94c-fb53b29788c0", "node_type": "1", "metadata": {"page_label": "40", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "f52b173d32018218c33937e1ec37ec1430bea82c1acc57ca40d4249736a3b134", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8495d7c4-7983-453b-b9db-9d79906e58d4", "node_type": "1", "metadata": {}, "hash": "1b3e8d4df26cf500399bf5da82861e6fb0b449ac072b3e7006d04f1df85d7b66", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Am J Physiol Heart Circ Physiol. 2013;304(12):H1585\u201397.\n148. Maroney SA, Mast AE. Expression of tissue factor pathway inhibitor by endo-\nthelial cells and platelets. Transfus Apher Sci. 2008;38(1):9\u201314.\n149. Mohan Rao LV, Esmon CT, Pendurthi UR. Endothelial cell protein C receptor: a \nmultiliganded and multifunctional receptor. Blood. 2014;124(10):1553\u201362.\n150. Bremnes RM, et al. The role of tumor stroma in cancer progression and prog -\nnosis: emphasis on carcinoma-associated fibroblasts and non-small cell lung \ncancer. J Thorac Oncol. 2011;6(1):209\u201317.\n151. Pietras K, Ostman A. Hallmarks of cancer: interactions with the tumor stroma. \nExp Cell Res. 2010;316(8):1324\u201331.\n152. McAllister SS, Weinberg RA. The tumour-induced systemic environment \nas a critical regulator of cancer progression and metastasis. Nat Cell Biol. \n2014;16(8):717\u201327.\n153. Dillek\u00e5s H, Rogers MS, Straume O. Are 90% of deaths from cancer caused by \nmetastases? Cancer Med. 2019;8(12):5574\u20136.\n154. Khorana AA, et al. Thromboembolism is a leading cause of death in \ncancer patients receiving outpatient chemotherapy. J Thromb Haemost. \n2007;5(3):632\u20134.\n155. Tisdale MJ. Cachexia in cancer patients. Nat Rev Cancer. 2002;2(11):862\u201371.\n156. Preuss SF, Grieshober D, Augustin HG. Systemic Reprogramming Endothelial \ncell Signal Metastasis cachexia Physiol. 2023;38(4):189\u2013202.\n157. Eilken HM, et al.", "mimetype": "text/plain", "start_char_idx": 2721, "end_char_idx": 4096, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "8495d7c4-7983-453b-b9db-9d79906e58d4": {"__data__": {"id_": "8495d7c4-7983-453b-b9db-9d79906e58d4", "embedding": null, "metadata": {"page_label": "40", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "56ff51f7-ccb5-4c78-8d0a-99145acf70e4", "node_type": "4", "metadata": {"page_label": "40", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "624d55bf5486df7a263ab86d8a4536843acf45dd1dfa2b3212fbbe0964913d69", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2e11b28c-687d-4fd4-a9e9-6475b6df4cb3", "node_type": "1", "metadata": {"page_label": "40", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "af4e3be3562e09087c3ce47753a4ca199343522f58b16c0b7d4f74b21fc61fc4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "95de215d-2279-497c-9530-71d9e56a065b", "node_type": "1", "metadata": {}, "hash": "93dc2732c36fbe9f5e6a3e9e85c788752153d15bb8741d1769843c837df5d95a", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Systemic Reprogramming Endothelial \ncell Signal Metastasis cachexia Physiol. 2023;38(4):189\u2013202.\n157. Eilken HM, et al. Pericytes regulate VEGF-induced endothelial sprouting \nthrough VEGFR1. Nat Commun. 2017;8(1):1574.\n158. Rouget C. Memoire sur les development, la structure et la proprietes physi -\nologiques des capillaires sanguines et lymphatiques. Arch Physiol, 1873: p. \n603\u201363.\n159. Zimmermann KW. Der Feinere Bau Der Blutcapillaren. Z f\u00fcr Anatomie und \nEntwicklungsgeschichte. 1923;68:29\u2013109.\n160. Schrimpf C, et al. The role of pericyte detachment in vascular rarefaction. J \nVasc Res. 2014;51(4):247\u201358.\n161. Hirschi KK, D\u2019Amore PA. Pericytes in the microvasculature. Cardiovascular Res. \n1996;32(4):687\u201398.\n162. D\u00edaz-Flores L, et al. Microvascular pericytes, a review of their morphological \nand functional characteristics. Histology and histopathology; 1991.\n163. Birbrair A, et al. How plastic are pericytes? Stem Cells Dev. \n2017;26(14):1013\u20139.\n164. Birbrair A, et al. Pericytes at the intersection between tissue regeneration and \npathology. Clin Sci. 2015;128(2):81\u201393.\n165. Picoli CC et al. Pericytes cross-talks within the tumor microenvironment Bio -\nchimica et Biophysica Acta (BBA)-Reviews on Cancer, 2021;1876(2):188608.\n166. Jiang Z et al. Pericytes in the tumor microenvironment. Cancer Lett, 2023: p. \n216074.\n167.", "mimetype": "text/plain", "start_char_idx": 3977, "end_char_idx": 5317, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "95de215d-2279-497c-9530-71d9e56a065b": {"__data__": {"id_": "95de215d-2279-497c-9530-71d9e56a065b", "embedding": null, "metadata": {"page_label": "40", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "56ff51f7-ccb5-4c78-8d0a-99145acf70e4", "node_type": "4", "metadata": {"page_label": "40", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "624d55bf5486df7a263ab86d8a4536843acf45dd1dfa2b3212fbbe0964913d69", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8495d7c4-7983-453b-b9db-9d79906e58d4", "node_type": "1", "metadata": {"page_label": "40", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "95263dacf892dc2a64cdfb4fbc1f47b83f4590231d9712538d7001c450fe5a60", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "78a7702b-6022-4923-9d6f-00efdb029153", "node_type": "1", "metadata": {}, "hash": "accacd64d9ca4591f7bef7370f193f0c5812d969ca36ba974e3592626d23f5f7", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "166. Jiang Z et al. Pericytes in the tumor microenvironment. Cancer Lett, 2023: p. \n216074.\n167. Chen Z, Xu XH, Hu J. Role of pericytes in angiogenesis: focus on cancer \nangiogenesis and anti-angiogenic therapy. Neoplasma. 2016;63(2):173\u201382.\n168. Hong CL, et al. CD248 regulates wnt signaling in Pericytes to Promote Angio -\ngenesis and Tumor Growth in Lung Cancer. Cancer Res. 2022;82(20):3734\u201350.\n169. Meng YM, et al. Hexokinase 2-driven glycolysis in pericytes activates their \ncontractility leading to tumor blood vessel abnormalities. Nat Commun. \n2021;12(1):6011.\n170. Dasgupta S, et al. RGS5-TGF\u03b2-Smad2/3 axis switches pro- to anti-apoptotic \nsignaling in tumor-residing pericytes, assisting tumor growth. Cell Death \nDiffer. 2021;28(11):3052\u201376.\n171. Pillay J, et al. Immune suppression by neutrophils and granulocytic myeloid-\nderived suppressor cells: similarities and differences. Cell Mol Life Sci. \n2013;70(20):3813\u201327.\n172. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of \nthe immune system. Nat Rev Immunol. 2009;9(3):162\u201374.\n173. Rodriguez PC, et al. Arginase I-producing myeloid-derived suppressor cells in \nrenal cell carcinoma are a subpopulation of activated granulocytes. Cancer \nRes. 2009;69(4):1553\u201360.\n174. Youn JI, et al. Characterization of the nature of granulocytic myeloid-derived \nsuppressor cells in tumor-bearing mice. J Leukoc Biol. 2012;91(1):167\u201381.\n175.", "mimetype": "text/plain", "start_char_idx": 5221, "end_char_idx": 6639, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "78a7702b-6022-4923-9d6f-00efdb029153": {"__data__": {"id_": "78a7702b-6022-4923-9d6f-00efdb029153", "embedding": null, "metadata": {"page_label": "40", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "56ff51f7-ccb5-4c78-8d0a-99145acf70e4", "node_type": "4", "metadata": {"page_label": "40", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "624d55bf5486df7a263ab86d8a4536843acf45dd1dfa2b3212fbbe0964913d69", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "95de215d-2279-497c-9530-71d9e56a065b", "node_type": "1", "metadata": {"page_label": "40", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "14d586c9da925c0ac83175c0e9063a29d05a9277e676849adc5a474c2b789c72", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "abaaf669-00c0-4ba9-80f2-3fe711e31f81", "node_type": "1", "metadata": {}, "hash": "140f80340ac99dc3593099e91d1b9d28191085ce6d1e9116c1616098cfdd14b2", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Characterization of the nature of granulocytic myeloid-derived \nsuppressor cells in tumor-bearing mice. J Leukoc Biol. 2012;91(1):167\u201381.\n175. Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of \nmyeloid cells by tumours. Nat Rev Immunol. 2012;12(4):253\u201368.\n176. Bronte V, et al. Recommendations for myeloid-derived suppressor cell \nnomenclature and characterization standards. Nat Commun. 2016;7:12150.\n177. Kumar V, et al. The nature of myeloid-derived suppressor cells in the Tumor \nMicroenvironment. Trends Immunol. 2016;37(3):208\u201320.\n178. Condamine T, et al. Regulation of tumor metastasis by myeloid-derived sup-\npressor cells. Annu Rev Med. 2015;66:97\u2013110.\n179. Condamine T et al. Lectin-type oxidized LDL receptor-1 distinguishes popula -\ntion of human polymorphonuclear myeloid-derived suppressor cells in \ncancer patients. Sci Immunol, 2016. 1(2).\n180. Corzo CA, et al. HIF-1\u03b1 regulates function and differentiation of myeloid-\nderived suppressor cells in the tumor microenvironment. J Exp Med. \n2010;207(11):2439\u201353.\n181. Hossain F, et al. Inhibition of fatty acid oxidation modulates immunosup-\npressive functions of myeloid-derived suppressor cells and enhances Cancer \ntherapies. Cancer Immunol Res. 2015;3(11):1236\u201347.\n182. Zhou J, et al. Hepatoma-intrinsic CCRK inhibition diminishes myeloid-derived \nsuppressor cell immunosuppression and enhances immune-checkpoint \nblockade efficacy. Gut. 2018;67(5):931\u201344.\n183. Wu C, et al.", "mimetype": "text/plain", "start_char_idx": 6497, "end_char_idx": 7961, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "abaaf669-00c0-4ba9-80f2-3fe711e31f81": {"__data__": {"id_": "abaaf669-00c0-4ba9-80f2-3fe711e31f81", "embedding": null, "metadata": {"page_label": "40", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "56ff51f7-ccb5-4c78-8d0a-99145acf70e4", "node_type": "4", "metadata": {"page_label": "40", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "624d55bf5486df7a263ab86d8a4536843acf45dd1dfa2b3212fbbe0964913d69", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "78a7702b-6022-4923-9d6f-00efdb029153", "node_type": "1", "metadata": {"page_label": "40", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "7628f24ededa81dd6575b62489802edb4d8810eccc1f3445c1e3e10fd2614dbb", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Gut. 2018;67(5):931\u201344.\n183. Wu C, et al. Repolarization of myeloid derived suppressor cells via magnetic \nnanoparticles to promote radiotherapy for glioma treatment. Nanomedicine. \n2019;16:126\u201337.\n184. Ding M, et al. Augmenting immunogenic cell death and alleviating myeloid-\nderived suppressor cells by Sono-Activatable Semiconducting Polymer \nNanopartners for Immunotherapy. Adv Mater. 2023;35(33):e2302508.\n185. Zuo H, et al. Circumventing myeloid-derived suppressor cell-mediated \nimmunosuppression using an oxygen-generated and -economized nano -\nplatform. ACS Appl Mater Interfaces. 2020;12(50):55723\u201336.\n186. Habanjar O et al. Crosstalk of inflammatory cytokines within the breast Tumor \nMicroenvironment. Int J Mol Sci, 2023. 24(4).\n187. Zhang JM, An J. Cytokines, inflammation, and pain. Int Anesthesiol Clin. \n2007;45(2):27\u201337.\n188. Raman D, Sobolik-Delmaire T, Richmond A. Chemokines in health and \ndisease. Exp Cell Res. 2011;317(5):575\u201389.\n189. Bachelerie F, et al. International Union of Basic and Clinical Pharmacology. \n[corrected]. LXXXIX. Update on the extended family of chemokine receptors", "mimetype": "text/plain", "start_char_idx": 7920, "end_char_idx": 9030, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "a1a0c823-2afa-4689-ba11-37b67038c740": {"__data__": {"id_": "a1a0c823-2afa-4689-ba11-37b67038c740", "embedding": null, "metadata": {"page_label": "41", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "5f99e93f-2d79-41b7-bf31-24037874c191", "node_type": "4", "metadata": {"page_label": "41", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "e56dd24961bdfacfcb20b6906eae1520e7cfab3d425b1d0938cf058b02ee1b28", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6f4a5510-bf53-47cc-9d18-bc9077062075", "node_type": "1", "metadata": {}, "hash": "7f00fea7550188e0f2afc70f3f3d08fde23687ed6127d9c6774e2ebe82b7d297", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Page 41 of 48\nLu et al. Journal of Hematology & Oncology            (2024) 17:16 \nand introducing a new nomenclature for atypical chemokine receptors. \nPharmacol Rev. 2014;66(1):1\u201379.\n190. M\u00e9lik-Parsadaniantz S, Rost\u00e8ne W. Chemokines and neuromodulation. J \nNeuroimmunol. 2008;198(1\u20132):62\u20138.\n191. Zlotnik A, Yoshie O. The chemokine superfamily revisited. Immunity. \n2012;36(5):705\u201316.\n192. Kaneko N, et al. The role of interleukin-1 in general pathology. Inflamm \nRegen. 2019;39:12.\n193. Akdis M et al. Interleukins, from 1 to 37, and interferon-\u03b3: receptors, functions, \nand roles in diseases J Allergy Clin Immunol, 2011;127(3):701 \u2013 21.e1-70.\n194. Shin E, Koo JS. The role of Adipokines and bone marrow adipocytes in breast \nCancer bone metastasis. Int J Mol Sci, 2020. 21(14).\n195. Bl\u00fcher M, Mantzoros CS. From leptin to other adipokines in health and \ndisease: facts and expectations at the beginning of the 21st century. Metabo -\nlism. 2015;64(1):131\u201345.\n196. Mancuso P . The role of adipokines in chronic inflammation. Immunotargets \nTher. 2016;5:47\u201356.\n197. Barchetta I, et al. Sick fat: the good and the bad of old and new cir -\nculating markers of adipose tissue inflammation. J Endocrinol Invest. \n2019;42(11):1257\u201372.\n198. Nehme R et al. Targeting adiponectin in breast Cancer.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1289, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "6f4a5510-bf53-47cc-9d18-bc9077062075": {"__data__": {"id_": "6f4a5510-bf53-47cc-9d18-bc9077062075", "embedding": null, "metadata": {"page_label": "41", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "5f99e93f-2d79-41b7-bf31-24037874c191", "node_type": "4", "metadata": {"page_label": "41", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "e56dd24961bdfacfcb20b6906eae1520e7cfab3d425b1d0938cf058b02ee1b28", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a1a0c823-2afa-4689-ba11-37b67038c740", "node_type": "1", "metadata": {"page_label": "41", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "f88fc929ccdbab53a24f72d9d5dc1292b857ed53fc6b53b36e511e79ad15db08", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ba9642e2-6f66-4c7d-a141-be0059d06144", "node_type": "1", "metadata": {}, "hash": "655a0fe30988a204a53a9264ee208a384fb32492f08ac457d61e7753f99b7cca", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "J Endocrinol Invest. \n2019;42(11):1257\u201372.\n198. Nehme R et al. Targeting adiponectin in breast Cancer. Biomedicines, 2022. \n10(11).\n199. Artac M, Altundag K. Leptin and breast cancer: an overview. Med Oncol. \n2012;29(3):1510\u20134.\n200. Ferrer I, et al. Transforming growth factor-alpha (TGF-alpha) and epidermal \ngrowth factor-receptor (EGF-R) immunoreactivity in normal and pathologic \nbrain. Prog Neurobiol. 1996;49(2):99\u2013123.\n201. MaruYama T, Chen W, Shibata H. TGF-\u03b2 Cancer Immunotherapy Biol Pharm \nBull. 2022;45(2):155\u201361.\n202. Isaacs A, Lindenmann J. Virus interference. I. The interferon. Proc R Soc Lond B \nBiol Sci. 1957;147(927):258\u201367.\n203. Schroder K, et al. Interferon-gamma: an overview of signals, mechanisms and \nfunctions. J Leukoc Biol. 2004;75(2):163\u201389.\n204. Peng S, et al. Tumor-microenvironment-responsive nanomedicine for \nenhanced Cancer Immunotherapy. Adv Sci (Weinh). 2022;9(1):e2103836.\n205. Mu J, et al. Development of endogenous enzyme-responsive nanomaterials \nfor theranostics. Chem Soc Rev. 2018;47(15):5554\u201373.\n206. Hu J, Zhang G, Liu S. Enzyme-responsive polymeric assemblies, nanoparticles \nand hydrogels. Chem Soc Rev. 2012;41(18):5933\u201349.\n207. Shahriari M, et al. Enzyme responsive drug delivery systems in cancer treat -\nment. J Control Release. 2019;308:172\u201389.\n208. Qiu N, et al.", "mimetype": "text/plain", "start_char_idx": 1187, "end_char_idx": 2504, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "ba9642e2-6f66-4c7d-a141-be0059d06144": {"__data__": {"id_": "ba9642e2-6f66-4c7d-a141-be0059d06144", "embedding": null, "metadata": {"page_label": "41", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "5f99e93f-2d79-41b7-bf31-24037874c191", "node_type": "4", "metadata": {"page_label": "41", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "e56dd24961bdfacfcb20b6906eae1520e7cfab3d425b1d0938cf058b02ee1b28", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6f4a5510-bf53-47cc-9d18-bc9077062075", "node_type": "1", "metadata": {"page_label": "41", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "8590f1e3800e4746dcefd7c5afc39940774cc998b56fb75985a543de50474e1b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "77c83dc5-f3a4-4f2d-a215-0ab4fef80d41", "node_type": "1", "metadata": {}, "hash": "534a1412ffd6c7bbf0e8b63f614f97d44537bc27f249801ad85cfc8fb9efc996", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Shahriari M, et al. Enzyme responsive drug delivery systems in cancer treat -\nment. J Control Release. 2019;308:172\u201389.\n208. Qiu N, et al. Esterase-activated charge-reversal polymer for fibroblast-exempt \nCancer Gene Therapy. Adv Mater. 2016;28(48):10613\u201322.\n209. Luo Z, Dai Y, Gao H. Development and application of hyaluronic acid in tumor \ntargeting drug delivery. Acta Pharm Sin B. 2019;9(6):1099\u2013112.\n210. Li H, et al. The relationship between MMP-2 and MMP-9 expression levels \nwith breast cancer incidence and prognosis. Oncol Lett. 2017;14(5):5865\u201370.\n211. Pham HT, Block NL, Lokeshwar VB. Tumor-derived hyaluronidase: a diagnostic \nurine marker for high-grade bladder cancer. Cancer Res. 1997;57(4):778\u201383.\n212. Moreira AM et al. The Extracellular Matrix: an accomplice in gastric Cancer \nDevelopment and Progression. Cells, 2020. 9(2).\n213. Liu Y, et al. Tumor microenvironment-mediated immune tolerance in devel-\nopment and treatment of gastric cancer. Front Immunol. 2022;13:1016817.\n214. Mohan V, Das A, Sagi I. Emerging roles of ECM remodeling processes in \ncancer. Semin Cancer Biol. 2020;62:192\u2013200.\n215. Sung JY, Cheong JH. The Matrisome is Associated with metabolic reprogram-\ning in stem-like phenotypes of gastric Cancer. Cancers (Basel), 2022. 14(6).\n216. Moreira AM, et al. Proteomic identification of a gastric tumor ECM signature \nAssociated with Cancer Progression. Front Mol Biosci. 2022;9:818552.\n217. Jang M, et al.", "mimetype": "text/plain", "start_char_idx": 2366, "end_char_idx": 3808, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "77c83dc5-f3a4-4f2d-a215-0ab4fef80d41": {"__data__": {"id_": "77c83dc5-f3a4-4f2d-a215-0ab4fef80d41", "embedding": null, "metadata": {"page_label": "41", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "5f99e93f-2d79-41b7-bf31-24037874c191", "node_type": "4", "metadata": {"page_label": "41", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "e56dd24961bdfacfcb20b6906eae1520e7cfab3d425b1d0938cf058b02ee1b28", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ba9642e2-6f66-4c7d-a141-be0059d06144", "node_type": "1", "metadata": {"page_label": "41", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "99c0e3a1397022a87124ee8cf76aea288dcf5545af57baba851a7460d0ea261a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0953e172-4ccb-4096-bbe4-c987beb20c4a", "node_type": "1", "metadata": {}, "hash": "6b88bb8a4ea92b7bb30b73bb68221c16f1337a042630b6bbd492f6bfc47cb185", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Proteomic identification of a gastric tumor ECM signature \nAssociated with Cancer Progression. Front Mol Biosci. 2022;9:818552.\n217. Jang M, et al. Increased extracellular matrix density disrupts E-cadherin/\u03b2-\ncatenin complex in gastric cancer cells. Biomater Sci. 2018;6(10):2704\u201313.\n218. Acerbi I, et al. Human breast cancer invasion and aggression correlates \nwith ECM stiffening and immune cell infiltration. Integr Biol (Camb). \n2015;7(10):1120\u201334.\n219. Kuczek DE, et al. Collagen density regulates the activity of tumor-infiltrating T \ncells. J Immunother Cancer. 2019;7(1):68.\n220. Patel A, Sant S. Hypoxic tumor microenvironment: opportunities to develop \ntargeted therapies. Biotechnol Adv. 2016;34(5):803\u201312.\n221. Nelson DA, et al. Hypoxia and defective apoptosis drive genomic instability \nand tumorigenesis. Genes Dev. 2004;18(17):2095\u2013107.\n222. Harris AL. Hypoxia\u2014a key regulatory factor in tumour growth. Nat Rev \nCancer. 2002;2(1):38\u201347.\n223. Saito G, Swanson JA, Lee K-D. Drug delivery strategy utilizing conjugation via \nreversible disulfide linkages: role and site of cellular reducing activities. Adv \nDrug Deliv Rev. 2003;55(2):199\u2013215.\n224. Wilson WR, Hay MP . Targeting hypoxia in cancer therapy. Nat Rev Cancer. \n2011;11(6):393\u2013410.\n225. Naughton D. Drug targeting to hypoxic tissue using self-inactivating biore-\nductive delivery systems. Adv Drug Deliv Rev. 2001;53(2):229\u201333.\n226. V\u00e1zquez-Garc\u00eda I, et al. Ovarian cancer mutational processes drive site-\nspecific immune evasion. Nature.", "mimetype": "text/plain", "start_char_idx": 3661, "end_char_idx": 5173, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "0953e172-4ccb-4096-bbe4-c987beb20c4a": {"__data__": {"id_": "0953e172-4ccb-4096-bbe4-c987beb20c4a", "embedding": null, "metadata": {"page_label": "41", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "5f99e93f-2d79-41b7-bf31-24037874c191", "node_type": "4", "metadata": {"page_label": "41", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "e56dd24961bdfacfcb20b6906eae1520e7cfab3d425b1d0938cf058b02ee1b28", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "77c83dc5-f3a4-4f2d-a215-0ab4fef80d41", "node_type": "1", "metadata": {"page_label": "41", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "0a081dde9f4ac31e34b79bb32f8cd5a0449ea259021aba73ba2ab36f144e954b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0fc5b0e6-01f4-40b4-8c7a-5e8904f0b753", "node_type": "1", "metadata": {}, "hash": "44c60848af241f90635ae415487fcaadbaf7f395b9af3def99217e92b77160db", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "2001;53(2):229\u201333.\n226. V\u00e1zquez-Garc\u00eda I, et al. Ovarian cancer mutational processes drive site-\nspecific immune evasion. Nature. 2022;612(7941):778\u201386.\n227. Li Q, et al. PRDM1/BLIMP1 induces cancer immune evasion by modulating \nthe USP22-SPI1-PD-L1 axis in hepatocellular carcinoma cells. Nat Commun. \n2022;13(1):7677.\n228. Yang H, et al. RNF31 represses cell progression and immune evasion via YAP/\nPD-L1 suppression in triple negative breast Cancer. J Exp Clin Cancer Res. \n2022;41(1):364.\n229. Choi SY, et al. Cancer-generated lactic acid: a regulatory, immunosuppressive \nmetabolite? J Pathol. 2013;230(4):350\u20135.\n230. Wang JX et al. Lactic acid and an acidic Tumor Microenvironment suppress \nAnticancer Immunity. Int J Mol Sci, 2020. 21(21).\n231. Chen X, et al. A membrane-associated MHC-I inhibitory axis for cancer \nimmune evasion. Cell. 2023;186(18):3903\u2013e392021.\n232. Zhang B et al. Tumor CEMIP drives immune evasion of colorectal cancer via \nMHC-I internalization and degradation. J Immunother Cancer, 2023. 11(1).\n233. Quah HS, et al. Single cell analysis in head and neck cancer reveals potential \nimmune evasion mechanisms during early metastasis. Nat Commun. \n2023;14(1):1680.\n234. Bergholz JS, et al. PI3K\u03b2 controls immune evasion in PTEN-deficient breast \ntumours. Nature. 2023;617(7959):139\u201346.\n235. Barriga FM, et al.", "mimetype": "text/plain", "start_char_idx": 5044, "end_char_idx": 6379, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "0fc5b0e6-01f4-40b4-8c7a-5e8904f0b753": {"__data__": {"id_": "0fc5b0e6-01f4-40b4-8c7a-5e8904f0b753", "embedding": null, "metadata": {"page_label": "41", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "5f99e93f-2d79-41b7-bf31-24037874c191", "node_type": "4", "metadata": {"page_label": "41", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "e56dd24961bdfacfcb20b6906eae1520e7cfab3d425b1d0938cf058b02ee1b28", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0953e172-4ccb-4096-bbe4-c987beb20c4a", "node_type": "1", "metadata": {"page_label": "41", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "265e90f68083adb9db42033d00f7caeec697a04a3bdf60b99985a180a5c7af21", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ff753d51-5234-4293-9c13-cd83a41377ea", "node_type": "1", "metadata": {}, "hash": "86c9ef778310a7cd87c5c78586676566c68219c419c806f3fad0fdaac77a5b54", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "PI3K\u03b2 controls immune evasion in PTEN-deficient breast \ntumours. Nature. 2023;617(7959):139\u201346.\n235. Barriga FM, et al. MACHETE identifies interferon-encompassing chromo-\nsome 9p21.3 deletions as mediators of immune evasion and metastasis. Nat \nCancer. 2022;3(11):1367\u201385.\n236. Liu HJ, et al. mTORC1 upregulates B7-H3/CD276 to inhibit antitumor T cells \nand drive tumor immune evasion. Nat Commun. 2023;14(1):1214.\n237. Lidstr\u00f6m T, et al. Extracellular galectin 4 drives Immune Evasion and \npromotes T-cell apoptosis in pancreatic Cancer. Cancer Immunol Res. \n2023;11(1):72\u201392.\n238. Vinay DS, et al. Immune evasion in cancer: mechanistic basis and therapeutic \nstrategies. Sem Cancer Biol. 2015;35:S185\u201398.\n239. Polyak K, et al. Breast tumor heterogeneity: causes and consequences. Breast \nCancer Res. 2009;11:1\u20131.\n240. Miller FR. Intratumor immunologic heterogeneity. Cancer Metastasis Rev. \n1982;1:319\u201334.\n241. Nicolson GL. Generation of phenotypic diversity and progression in meta -\nstatic tumor cells. Cancer Metastasis Rev. 1984;3:25\u201342.\n242. Merlo LM, et al. Cancer as an evolutionary and ecological process. Nat Rev \nCancer. 2006;6(12):924\u201335.\n243. Sceneay J, et al. Primary tumor hypoxia recruits CD11b+/Ly6Cmed/\nLy6G + immune suppressor cells and compromises NK cell cytotoxicity in the \npremetastatic niche. Cancer Res. 2012;72(16):3906\u201311.\n244.", "mimetype": "text/plain", "start_char_idx": 6260, "end_char_idx": 7616, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "ff753d51-5234-4293-9c13-cd83a41377ea": {"__data__": {"id_": "ff753d51-5234-4293-9c13-cd83a41377ea", "embedding": null, "metadata": {"page_label": "41", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "5f99e93f-2d79-41b7-bf31-24037874c191", "node_type": "4", "metadata": {"page_label": "41", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "e56dd24961bdfacfcb20b6906eae1520e7cfab3d425b1d0938cf058b02ee1b28", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0fc5b0e6-01f4-40b4-8c7a-5e8904f0b753", "node_type": "1", "metadata": {"page_label": "41", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "f94d640d910ff38bdeee72c61b81a7e43b8b8158bcd7a110462526462bae607b", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Cancer Res. 2012;72(16):3906\u201311.\n244. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to \ninflammation. N Engl J Med. 1999;340(6):448\u201354.\n245. Dunn GP , Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu \nRev Immunol. 2004;22:329\u201360.\n246. Lauritzsen GF, et al. Clonal deletion of thymocytes as a tumor escape mecha-\nnism. Int J Cancer. 1998;78(2):216\u201322.\n247. Hegde PS, Chen DS. Top 10 challenges in cancer immunotherapy. Immunity. \n2020;52(1):17\u201335.\n248. Rao L, et al. Activating macrophage-mediated Cancer Immunotherapy by \ngenetically edited nanoparticles. Adv Mater. 2020;32(47):e2004853.\n249. Yang K, et al. Zinc cyclic di-AMP nanoparticles target and suppress tumours \nvia endothelial STING activation and tumour-associated macrophage rein-\nvigoration. Nat Nanotechnol. 2022;17(12):1322\u201331.\n250. Cao M, et al. Ginseng-derived nanoparticles alter macrophage polarization to \ninhibit melanoma growth. J Immunother Cancer. 2019;7(1):326.\n251. Zhang Y, et al. Macrophage-membrane-coated nanoparticles for Tumor-\ntargeted chemotherapy. Nano Lett. 2018;18(3):1908\u201315.\n252. Jiang Q, et al. Platelet membrane-camouflaged magnetic nanoparticles for \nferroptosis-enhanced Cancer Immunotherapy. Small. 2020;16(22):e2001704.\n253. Melamed JR, et al. Ionizable lipid nanoparticles deliver mRNA to pancreatic \u03b2 \ncells via macrophage-mediated gene transfer. Sci Adv. 2023;9(4):eade1444.", "mimetype": "text/plain", "start_char_idx": 7579, "end_char_idx": 8991, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "1ac810cb-ebf1-4b5c-8944-5ad981734de0": {"__data__": {"id_": "1ac810cb-ebf1-4b5c-8944-5ad981734de0", "embedding": null, "metadata": {"page_label": "42", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a932a3d2-886d-4a41-b4eb-c9e7304ef568", "node_type": "4", "metadata": {"page_label": "42", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "89e87dc62e093c4e34f1cc38a09334b8838587d01779ae8fab84549c458bd4cc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ff116434-58e2-4e06-a625-9bede3b4144f", "node_type": "1", "metadata": {}, "hash": "91ef2b6a5caaa9046029602ae13e61e6af00048899fe4d767be983ba21cfed41", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Page 42 of 48\nLu et al. Journal of Hematology & Oncology            (2024) 17:16 \n254. Chen C, et al. Tumor-Associated-Macrophage-membrane-coated \nnanoparticles for improved photodynamic immunotherapy. Nano Lett. \n2021;21(13):5522\u201331.\n255. Ramesh A, et al. CSF1R- and SHP2-Inhibitor-loaded nanoparticles enhance \ncytotoxic activity and phagocytosis in Tumor-Associated macrophages. Adv \nMater. 2019;31(51):e1904364.\n256. Zanganeh S, et al. Iron oxide nanoparticles inhibit tumour growth by \ninducing pro-inflammatory macrophage polarization in tumour tissues. Nat \nNanotechnol. 2016;11(11):986\u201394.\n257. Chim LK, et al. Tumor-associated macrophages induce inflammation and \ndrug resistance in a mechanically tunable engineered model of osteosar -\ncoma. Biomaterials. 2023;296:122076.\n258. Rohila D, et al. Syk Inhibition reprograms Tumor-Associated macrophages \nand overcomes Gemcitabine-Induced Immunosuppression in Pancreatic \nDuctal Adenocarcinoma. Cancer Res. 2023;83(16):2675\u201389.\n259. Xie R, et al. Furin-instructed aggregated gold nanoparticles for re-educating \ntumor associated macrophages and overcoming breast cancer chemoresis -\ntance. Biomaterials. 2021;275:120891.\n260. Shen W, et al. Metabolic homeostasis-regulated nanoparticles for \nantibody-independent Cancer Radio-Immunotherapy. Adv Mater. \n2022;34(51):e2207343.\n261. Sun M, et al.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1349, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "ff116434-58e2-4e06-a625-9bede3b4144f": {"__data__": {"id_": "ff116434-58e2-4e06-a625-9bede3b4144f", "embedding": null, "metadata": {"page_label": "42", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a932a3d2-886d-4a41-b4eb-c9e7304ef568", "node_type": "4", "metadata": {"page_label": "42", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "89e87dc62e093c4e34f1cc38a09334b8838587d01779ae8fab84549c458bd4cc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1ac810cb-ebf1-4b5c-8944-5ad981734de0", "node_type": "1", "metadata": {"page_label": "42", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "b525aab8715f6d2bc13a7a7a2ace522920f7f2966bee86d27ae8882a21d63b0e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bd8ec913-fbb1-4b25-bcf0-71401808fcf5", "node_type": "1", "metadata": {}, "hash": "d1252cbd5bcb9e96343f46989a3890b793f428e96220552a1c866ab219591a21", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Metabolic homeostasis-regulated nanoparticles for \nantibody-independent Cancer Radio-Immunotherapy. Adv Mater. \n2022;34(51):e2207343.\n261. Sun M, et al. Fibroblast activation Protein-\u03b1 responsive peptide assembling \nProdrug nanoparticles for Remodeling the Immunosuppressive Microenvi -\nronment and Boosting Cancer Immunotherapy. Small. 2022;18(9):e2106296.\n262. Gao C, et al. Injectable Immunotherapeutic Hydrogel containing RNA-Loaded \nlipid nanoparticles reshapes Tumor Microenvironment for Pancreatic Cancer \nTherapy. Nano Lett. 2022;22(22):8801\u20139.\n263. Yoon J, et al. Macrophage-reprogramming upconverting nanoparticles for \nenhanced TAM-mediated antitumor therapy of hypoxic breast cancer. J \nControl Release. 2023;360:482\u201395.\n264. Rong L, et al. Iron chelated melanin-like nanoparticles for tumor-\nassociated macrophage repolarization and cancer therapy. Biomaterials. \n2019;225:119515.\n265. Ramesh A, et al. Dual inhibition of CSF1R and MAPK pathways using supra-\nmolecular nanoparticles enhances macrophage immunotherapy. Biomateri-\nals. 2020;227:119559.\n266. He Y, et al. Targeted MIP-3\u03b2 plasmid nanoparticles induce dendritic cell matu-\nration and inhibit M2 macrophage polarisation to suppress cancer growth. \nBiomaterials. 2020;249:120046.\n267. Su WP , et al. Polyaniline-based glyco-condensation on au nanoparticles \nenhances Immunotherapy in Lung Cancer. ACS Appl Mater Interfaces. \n2022;14(21):24144\u201359.\n268. Yang S, et al. CaCO(3)-Encapsulated au nanoparticles modulate macrophages \ntoward M1-like phenotype. ACS Appl Bio Mater. 2021;4(4):3214\u201323.\n269.", "mimetype": "text/plain", "start_char_idx": 1197, "end_char_idx": 2766, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "bd8ec913-fbb1-4b25-bcf0-71401808fcf5": {"__data__": {"id_": "bd8ec913-fbb1-4b25-bcf0-71401808fcf5", "embedding": null, "metadata": {"page_label": "42", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a932a3d2-886d-4a41-b4eb-c9e7304ef568", "node_type": "4", "metadata": {"page_label": "42", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "89e87dc62e093c4e34f1cc38a09334b8838587d01779ae8fab84549c458bd4cc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ff116434-58e2-4e06-a625-9bede3b4144f", "node_type": "1", "metadata": {"page_label": "42", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "0b9f3faf6af30456aa19c54124f98bf467095474b04481f77d970417e01409a3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f1a3766a-94e9-4ac2-955f-83dc8081fa4a", "node_type": "1", "metadata": {}, "hash": "c173807f9c5c0e88093e2b8fda1d85189e59287e2c7d666b910acb0512b9844c", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CaCO(3)-Encapsulated au nanoparticles modulate macrophages \ntoward M1-like phenotype. ACS Appl Bio Mater. 2021;4(4):3214\u201323.\n269. Wan J, et al. Biodegradable NIR-II Pseudo Conjugate Polymeric nanopar-\nticles amplify photodynamic immunotherapy via alleviation of Tumor \nHypoxia and Tumor-Associated Macrophage Reprogramming. Adv Mater. \n2023;35(31):e2209799.\n270. Li L, et al. Functional Gadofullerene nanoparticles trigger Robust Cancer \nImmunotherapy based on rebuilding an immunosuppressive Tumor Micro -\nenvironment. Nano Lett. 2020;20(6):4487\u201396.\n271. Guo Q, et al. Dandelion-Like Tailorable nanoparticles for Tumor Microenviron-\nment Modulation. Adv Sci (Weinh). 2019;6(21):1901430.\n272. Liu Y, et al. Targeting Tumor-Associated macrophages by MMP2-Sensitive \napoptotic body-mimicking nanoparticles. ACS Appl Mater Interfaces. \n2020;12(47):52402\u201314.\n273. Parayath NN, Parikh A, Amiji MM. Repolarization of Tumor-Associated \nmacrophages in a genetically Engineered Nonsmall Cell Lung Cancer Model \nby Intraperitoneal Administration of Hyaluronic Acid-based nanoparticles \nencapsulating MicroRNA-125b. Nano Lett. 2018;18(6):3571\u20139.\n274. Xu L, et al. Engineering the Intestinal Lymphatic Transport of oral nanopar-\nticles to Educate macrophages for Cancer Combined Immunotherapy. ACS \nNano. 2023;17(12):11817\u201337.\n275. Zhang Y, et al. Gold nanoparticles inhibit activation of cancer-associated \nfibroblasts by disrupting communication from tumor and microenvironmen -\ntal cells. Bioact Mater. 2021;6(2):326\u201332.\n276. Kov\u00e1cs D, et al.", "mimetype": "text/plain", "start_char_idx": 2637, "end_char_idx": 4170, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "f1a3766a-94e9-4ac2-955f-83dc8081fa4a": {"__data__": {"id_": "f1a3766a-94e9-4ac2-955f-83dc8081fa4a", "embedding": null, "metadata": {"page_label": "42", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a932a3d2-886d-4a41-b4eb-c9e7304ef568", "node_type": "4", "metadata": {"page_label": "42", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "89e87dc62e093c4e34f1cc38a09334b8838587d01779ae8fab84549c458bd4cc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bd8ec913-fbb1-4b25-bcf0-71401808fcf5", "node_type": "1", "metadata": {"page_label": "42", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "76c4857ee6f49230c2d484b3a74c527300cccc4894b9c54b1496f205636fcc08", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fa21fca5-b7a5-4ece-8e39-be8a13c92af4", "node_type": "1", "metadata": {}, "hash": "f300ce29bba8f4d582f98003a9b0ec5137d1565056fb3d9843cc207e26844319", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Bioact Mater. 2021;6(2):326\u201332.\n276. Kov\u00e1cs D, et al. Core-shell nanoparticles suppress metastasis and modify the \ntumour-supportive activity of cancer-associated fibroblasts. J Nanobiotech-\nnol. 2020;18(1):18.\n277. Lopez S, et al. Magneto-mechanical destruction of cancer-associated fibro-\nblasts using ultra-small iron oxide nanoparticles and low frequency rotating \nmagnetic fields. Nanoscale Adv. 2022;4(2):421\u201336.\n278. Li L, et al. Photosensitizer-encapsulated ferritins mediate photodynamic \ntherapy against Cancer-Associated fibroblasts and improve Tumor Accumula-\ntion of nanoparticles. Mol Pharm. 2018;15(8):3595\u20139.\n279. Jin J, et al. Human Cancer Cell membrane-coated biomimetic nanoparticles \nreduce fibroblast-mediated Invasion and Metastasis and induce T-Cells. ACS \nAppl Mater Interfaces. 2019;11(8):7850\u201361.\n280. Zhou S et al. FAP-Targeted photodynamic therapy mediated by Ferritin \nnanoparticles elicits an Immune response against Cancer cells and Cancer \nAssociated fibroblasts. Adv Funct Mater, 2021. 31(7).\n281. Yu Q, et al. Targeting cancer-associated fibroblasts by dual-responsive \nlipid-albumin nanoparticles to enhance drug perfusion for pancreatic tumor \ntherapy. J Control Release. 2020;321:564\u201375.\n282. Liu JQ, et al. Intratumoral delivery of IL-12 and IL-27 mRNA using lipid \nnanoparticles for cancer immunotherapy. J Control Release. 2022;345:306\u201313.\n283. Huang KW, et al. Highly efficient and tumor-selective nanoparticles for dual-\ntargeted immunogene therapy against cancer. Sci Adv. 2020;6(3):eaax5032.\n284. Xiong J, et al.", "mimetype": "text/plain", "start_char_idx": 4117, "end_char_idx": 5673, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "fa21fca5-b7a5-4ece-8e39-be8a13c92af4": {"__data__": {"id_": "fa21fca5-b7a5-4ece-8e39-be8a13c92af4", "embedding": null, "metadata": {"page_label": "42", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a932a3d2-886d-4a41-b4eb-c9e7304ef568", "node_type": "4", "metadata": {"page_label": "42", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "89e87dc62e093c4e34f1cc38a09334b8838587d01779ae8fab84549c458bd4cc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f1a3766a-94e9-4ac2-955f-83dc8081fa4a", "node_type": "1", "metadata": {"page_label": "42", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "e9228c669c26999c9ae4478597613fb2a24b5fb4fc04ddba1a71cb5c784028b3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "85522ba5-68e3-49e1-853d-bc7b7fc4b540", "node_type": "1", "metadata": {}, "hash": "d3e48e87faed38036d2c428d3204704db0d1e1059f71efca8281e3b31bf0474e", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Highly efficient and tumor-selective nanoparticles for dual-\ntargeted immunogene therapy against cancer. Sci Adv. 2020;6(3):eaax5032.\n284. Xiong J, et al. Cancer-Erythrocyte Hybrid membrane-camouflaged magnetic \nnanoparticles with enhanced photothermal-immunotherapy for ovarian \nCancer. ACS Nano. 2021;15(12):19756\u201370.\n285. Patel SK, et al. Hydroxycholesterol substitution in ionizable lipid nanoparticles \nfor mRNA delivery to T cells. J Control Release. 2022;347:521\u201332.\n286. Billingsley MM, et al. Orthogonal Design of experiments for optimization \nof lipid nanoparticles for mRNA Engineering of CAR T cells. Nano Lett. \n2022;22(1):533\u201342.\n287. Lin YX et al. Reactivation of the tumor suppressor PTEN by mRNA nanopar -\nticles enhances antitumor immunity in preclinical models Sci Transl Med, \n2021. 13(599).\n288. Jiang Y, et al. Engineered cell-membrane-coated nanoparticles directly \nPresent Tumor antigens to promote anticancer immunity. Adv Mater. \n2020;32(30):e2001808.\n289. Li Z, et al. Immunogenic cell death augmented by Manganese Zinc Sulfide \nnanoparticles for metastatic Melanoma Immunotherapy. ACS Nano. \n2022;16(9):15471\u201383.\n290. Cao L, et al. Activating cGAS-STING pathway with ROS-responsive nanopar-\nticles delivering a hybrid prodrug for enhanced chemo-immunotherapy. \nBiomaterials. 2022;290:121856.\n291. Chen C, et al. Asynchronous blockade of PD-L1 and CD155 by polymeric \nnanoparticles inhibits triple-negative breast cancer progression and metasta-\nsis. Biomaterials. 2021;275:p120988.\n292. Tang S, et al.", "mimetype": "text/plain", "start_char_idx": 5519, "end_char_idx": 7048, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "85522ba5-68e3-49e1-853d-bc7b7fc4b540": {"__data__": {"id_": "85522ba5-68e3-49e1-853d-bc7b7fc4b540", "embedding": null, "metadata": {"page_label": "42", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a932a3d2-886d-4a41-b4eb-c9e7304ef568", "node_type": "4", "metadata": {"page_label": "42", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "89e87dc62e093c4e34f1cc38a09334b8838587d01779ae8fab84549c458bd4cc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fa21fca5-b7a5-4ece-8e39-be8a13c92af4", "node_type": "1", "metadata": {"page_label": "42", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "085ab75e5d2909d12d5e6121b86180c8712cb9662f8867d0acb2c53643affd8f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7abf6e28-78e8-4e28-a22a-18814cb9bf62", "node_type": "1", "metadata": {}, "hash": "3eb2ebd164e5e1f64d39344e60b41e1754ee784eb4f529fe223965abef16b088", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Biomaterials. 2021;275:p120988.\n292. Tang S, et al. MnO(2)-melittin nanoparticles serve as an effective anti-tumor \nimmunotherapy by enhancing systemic immune response. Biomaterials. \n2022;288:121706.\n293. Sun F, et al. Regulating glucose metabolism with Prodrug nanoparticles for \npromoting photoimmunotherapy of pancreatic Cancer. Adv Sci (Weinh). \n2021;8(4):2002746.\n294. Chou PY, et al. Glycosylation of OVA antigen-loaded PLGA nanopar-\nticles enhances DC-targeting for cancer vaccination. J Control Release. \n2022;351:970\u201388.\n295. Son S, et al. Induction of T-helper-17-cell-mediated anti-tumour immu-\nnity by pathogen-mimicking polymer nanoparticles. Nat Biomed Eng. \n2023;7(1):72\u201384.\n296. Kim KS, et al. Ovalbumin and poly(i:c) encapsulated dendritic cell-targeted \nnanoparticles for Immune activation in the small intestinal lymphatic system. \nAdv Healthc Mater. 2022;11(21):e2200909.\n297. Li S, et al. Pre-induced ICD membrane-coated carrier-free nanoparticles \nfor the personalized Lung Cancer Immunotherapy. Small Methods. \n2023;7(5):e2201569.\n298. Zhang Z, et al. Antitumor Activity of Anti-mir-21 delivered through lipid \nnanoparticles. Adv Healthc Mater. 2023;12(6):e2202412.\n299. Min Y, et al. Antigen-capturing nanoparticles improve the abscopal effect \nand cancer immunotherapy. Nat Nanotechnol. 2017;12(9):877\u201382.\n300. Ou W, et al. Combination of NIR therapy and regulatory T cell modulation \nusing layer-by-layer hybrid nanoparticles for effective cancer photoimmuno -\ntherapy. Theranostics. 2018;8(17):4574\u201390.\n301.", "mimetype": "text/plain", "start_char_idx": 6997, "end_char_idx": 8532, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "7abf6e28-78e8-4e28-a22a-18814cb9bf62": {"__data__": {"id_": "7abf6e28-78e8-4e28-a22a-18814cb9bf62", "embedding": null, "metadata": {"page_label": "42", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a932a3d2-886d-4a41-b4eb-c9e7304ef568", "node_type": "4", "metadata": {"page_label": "42", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "89e87dc62e093c4e34f1cc38a09334b8838587d01779ae8fab84549c458bd4cc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "85522ba5-68e3-49e1-853d-bc7b7fc4b540", "node_type": "1", "metadata": {"page_label": "42", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "c726ab03012335c644d60fb3b5fa32deb8bc6b66304beebb10666180cdd57cf5", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Combination of NIR therapy and regulatory T cell modulation \nusing layer-by-layer hybrid nanoparticles for effective cancer photoimmuno -\ntherapy. Theranostics. 2018;8(17):4574\u201390.\n301. Zang X, et al. Polymeric indoximod based prodrug nanoparticles with doxo -\nrubicin entrapment for inducing immunogenic cell death and improving the \nimmunotherapy of breast cancer. J Mater Chem B. 2022;10(12):2019\u201327.\n302. Yang T, et al. Dual polymeric prodrug co-assembled nanoparticles with \nprecise ratiometric co-delivery of cisplatin and metformin for lung cancer \nchemoimmunotherapy. Biomater Sci. 2020;8(20):5698\u2013714.", "mimetype": "text/plain", "start_char_idx": 8347, "end_char_idx": 8957, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "04007ba2-a955-474d-b2aa-7ee4dd6ae394": {"__data__": {"id_": "04007ba2-a955-474d-b2aa-7ee4dd6ae394", "embedding": null, "metadata": {"page_label": "43", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "fdaa53d7-c08b-4351-b327-0fea1e9db34b", "node_type": "4", "metadata": {"page_label": "43", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "1164cdf6ae64c85b648c0d345f1fc92b094d8d68077c2abb53f58d7570d64d5f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5e672d68-e79d-437e-899a-7eb42fcd09e1", "node_type": "1", "metadata": {}, "hash": "246085f444238e7c942996162f9c9eb5db7b1de1102b5a60d16f4736972eabd1", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Page 43 of 48\nLu et al. Journal of Hematology & Oncology            (2024) 17:16 \n303. Ou W, et al. Regulatory T cell-targeted hybrid nanoparticles combined with \nimmuno-checkpoint blockage for cancer immunotherapy. J Control Release. \n2018;281:84\u201396.\n304. He Y, et al. Remodeling tumor immunosuppression with molecularly \nimprinted nanoparticles to enhance immunogenic cell death for cancer \nimmunotherapy. J Control Release. 2023;362:44\u201357.\n305. Wan WJ, et al. Coadministration of iRGD peptide with ROS-sensitive nanopar-\nticles co-delivering siFGL1 and siPD-L1 enhanced tumor immunotherapy. \nActa Biomater. 2021;136:473\u201384.\n306. Wang W, et al. The development of Chiral nanoparticles to target NK cells and \nCD8(+) T cells for Cancer Immunotherapy. Adv Mater. 2022;34(16):e2109354.\n307. Wang B, et al. Liposomes co-loaded with ursolic acid and ginsenoside \nRg3 in the treatment of hepatocellular carcinoma. Acta Biochim Pol. \n2021;68(4):711\u20135.\n308. Yao H, et al. Cisplatin nanoparticles promote Intratumoral CD8(+) T cell \npriming via Antigen Presentation and T cell receptor crosstalk. Nano Lett. \n2022;22(8):3328\u201339.\n309. Munakata L, et al. Lipid nanoparticles of Type-A CpG D35 suppress tumor \ngrowth by changing tumor immune-microenvironment and activate CD8 T \ncells in mice. J Control Release. 2019;313:106\u201319.\n310. Chang HC, et al. Targeting and specific activation of Antigen-presenting \ncells by endogenous Antigen-Loaded nanoparticles elicits tumor-specific \nimmunity. Adv Sci (Weinh). 2020;7(1):1900069.\n311.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1522, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "5e672d68-e79d-437e-899a-7eb42fcd09e1": {"__data__": {"id_": "5e672d68-e79d-437e-899a-7eb42fcd09e1", "embedding": null, "metadata": {"page_label": "43", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "fdaa53d7-c08b-4351-b327-0fea1e9db34b", "node_type": "4", "metadata": {"page_label": "43", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "1164cdf6ae64c85b648c0d345f1fc92b094d8d68077c2abb53f58d7570d64d5f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "04007ba2-a955-474d-b2aa-7ee4dd6ae394", "node_type": "1", "metadata": {"page_label": "43", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "697b669326964064180ad3a8f0842d9e5b202da2f299a9409c8627d116c39d8d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "17ff836a-4198-418b-a03f-07a9995e5738", "node_type": "1", "metadata": {}, "hash": "0476ebe8ff135da83beb99230e4187e9b3adb8862af814ce6ada7af744fa64da", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Targeting and specific activation of Antigen-presenting \ncells by endogenous Antigen-Loaded nanoparticles elicits tumor-specific \nimmunity. Adv Sci (Weinh). 2020;7(1):1900069.\n311. Smith R, et al. Cationic nanoparticles enhance T cell tumor infiltration \nand antitumor immune responses to a melanoma vaccine. Sci Adv. \n2022;8(29):eabk3150.\n312. Gao Y, et al. Engineering platelets with PDL1 antibodies and Iron oxide \nnanoparticles for Postsurgical Cancer Immunotherapy. ACS Appl Bio Mater. \n2023;6(1):257\u201366.\n313. Patel RB, et al. Development of an in situ Cancer vaccine via Combinational \nRadiation and bacterial-membrane-coated nanoparticles. Adv Mater. \n2019;31(43):e1902626.\n314. Choi J, et al. Visible-light-triggered Prodrug nanoparticles combine che -\nmotherapy and photodynamic therapy to Potentiate Checkpoint Blockade \nCancer Immunotherapy. ACS Nano. 2021;15(7):12086\u201398.\n315. Ding B, et al. Biodegradable Upconversion nanoparticles induce pyroptosis \nfor Cancer Immunotherapy. Nano Lett. 2021;21(19):8281\u20139.\n316. Zhang L, et al. Glutathione-responsive nanoparticles of Camptothecin Pro-\ndrug for Cancer Therapy. Adv Sci (Weinh). 2023;10(3):e2205246.\n317. Zhang Y, et al. Gemcitabine nanoparticles promote antitumor immunity \nagainst melanoma. Biomaterials. 2019;189:48\u201359.\n318. Gowd V, et al. Advancement of cancer immunotherapy using nanoparticles-\nbased nanomedicine. Sem Cancer Biol. 2022;86:624\u201344.\n319. Casazza A, et al. Tumor stroma: a complexity dictated by the hypoxic tumor \nmicroenvironment. Oncogene. 2014;33(14):1743\u201354.", "mimetype": "text/plain", "start_char_idx": 1342, "end_char_idx": 2887, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "17ff836a-4198-418b-a03f-07a9995e5738": {"__data__": {"id_": "17ff836a-4198-418b-a03f-07a9995e5738", "embedding": null, "metadata": {"page_label": "43", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "fdaa53d7-c08b-4351-b327-0fea1e9db34b", "node_type": "4", "metadata": {"page_label": "43", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "1164cdf6ae64c85b648c0d345f1fc92b094d8d68077c2abb53f58d7570d64d5f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5e672d68-e79d-437e-899a-7eb42fcd09e1", "node_type": "1", "metadata": {"page_label": "43", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "51123ae5b9725e679fbe2b892568b85a1b0acf64486e927c1093aabd77c20fc3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8b83e115-7327-4950-ac95-470dec3a3065", "node_type": "1", "metadata": {}, "hash": "4fc36d85edad17548712a9e7f45f38315ffabc50b199186b863b93d6a4093ad4", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "319. Casazza A, et al. Tumor stroma: a complexity dictated by the hypoxic tumor \nmicroenvironment. Oncogene. 2014;33(14):1743\u201354.\n320. Yu JL, et al. Effect of p53 status on tumor response to antiangiogenic therapy. \nScience. 2002;295(5559):1526\u20138.\n321. Taylor CT, Colgan SP . Regulation of immunity and inflammation by hypoxia in \nimmunological niches. Nat Rev Immunol. 2017;17(12):774\u201385.\n322. Facciabene A, et al. Tumour hypoxia promotes tolerance and angiogenesis \nvia CCL28 and Treg cells. Nature. 2011;475(7355):226\u201330.\n323. Doedens AL, et al. Macrophage expression of hypoxia-inducible factor-1\u03b1 \nsuppresses T-cell function and promotes tumor progression. Cancer Res. \n2010;70(19):7465\u201375.\n324. Abou Khouzam R, et al. Hypoxia as a potential inducer of immune tolerance, \ntumor plasticity and a driver of tumor mutational burden: impact on cancer \nimmunotherapy. Semin Cancer Biol. 2023;97:104\u201323.\n325. Finisguerra V et al. Metformin improves cancer immunotherapy by directly \nrescuing tumor-infiltrating CD8 T lymphocytes from hypoxia-induced immu -\nnosuppression. J Immunother Cancer, 2023. 11(5).\n326. Yan H, et al. Exercise sensitizes PD-1/PD-L1 immunotherapy as a hypoxia \nmodulator in the tumor microenvironment of melanoma. Front Immunol. \n2023;14:1265914.\n327. Barsoum IB, et al. A mechanism of hypoxia-mediated escape from adaptive \nimmunity in cancer cells. Cancer Res. 2014;74(3):665\u201374.\n328. Silva VL.", "mimetype": "text/plain", "start_char_idx": 2758, "end_char_idx": 4176, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "8b83e115-7327-4950-ac95-470dec3a3065": {"__data__": {"id_": "8b83e115-7327-4950-ac95-470dec3a3065", "embedding": null, "metadata": {"page_label": "43", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "fdaa53d7-c08b-4351-b327-0fea1e9db34b", "node_type": "4", "metadata": {"page_label": "43", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "1164cdf6ae64c85b648c0d345f1fc92b094d8d68077c2abb53f58d7570d64d5f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "17ff836a-4198-418b-a03f-07a9995e5738", "node_type": "1", "metadata": {"page_label": "43", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "7281a4ecc482a9cf43178a7d73db45e0d969429c09ce0bbd1f5cdb8e5359d61b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b5982d9f-8de0-48e7-873c-4745b0a9b979", "node_type": "1", "metadata": {}, "hash": "b6601d156decd30ed194459497bee07e2bbef6b14009cb07eb6dee0739447f5b", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "A mechanism of hypoxia-mediated escape from adaptive \nimmunity in cancer cells. Cancer Res. 2014;74(3):665\u201374.\n328. Silva VL. Exploiting the cancer niche: tumor-associated macrophages and \nhypoxia as promising synergistic targets for nano-based therapy. J Controlled \nRelease. 2017;253:82\u201396.\n329. Jiang T et al. TAM-Hijacked Immunoreaction Rescued by Hypoxia-Pathway-\nIntervened Strategy for Enhanced Metastatic Cancer Immunotherapy Small, \n2023: p. e2305728.\n330. Qu S et al. Light-enhanced hypoxia-responsive gene editing for Hypoxia-\nresistant photodynamic and Immunotherapy. Adv Healthc Mater, 2023: p. \ne2302615.\n331. Sun T et al. Metal-Organic Framework-Mediated Synergistic Hypoxia-\nActivated Chemo-Immunotherapy Induced by High Intensity Focused \nUltrasound for Enhanced Cancer Theranostics Small, 2023: p. e2306338.\n332. Luo W et al. Strengthening the Combinational Immunotherapy from \nmodulating the Tumor Inflammatory Environment via Hypoxia-Responsive \nNanogels. Adv Healthc Mater, 2023: p. e2302865.\n333. Wang M, et al. Controllable hypoxia-activated chemotherapy as a dual \nenhancer for synergistic cancer photodynamic immunotherapy. Biomaterials. \n2023;301:122257.\n334. Luo G, et al. Multifunctional calcium-manganese Nanomodulator provides \nAntitumor Treatment and Improved Immunotherapy via Reprogramming of \nthe Tumor Microenvironment. ACS Nano. 2023;17(16):15449\u201365.\n335. Kang X, et al. A photo-triggered self-accelerated nanoplatform for multifunc-\ntional image-guided combination cancer immunotherapy. Nat Commun. \n2023;14(1):5216.\n336. Gao C, et al.", "mimetype": "text/plain", "start_char_idx": 4051, "end_char_idx": 5623, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "b5982d9f-8de0-48e7-873c-4745b0a9b979": {"__data__": {"id_": "b5982d9f-8de0-48e7-873c-4745b0a9b979", "embedding": null, "metadata": {"page_label": "43", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "fdaa53d7-c08b-4351-b327-0fea1e9db34b", "node_type": "4", "metadata": {"page_label": "43", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "1164cdf6ae64c85b648c0d345f1fc92b094d8d68077c2abb53f58d7570d64d5f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8b83e115-7327-4950-ac95-470dec3a3065", "node_type": "1", "metadata": {"page_label": "43", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "d46e1ad83db3e81d78d06d9b184181150f7d625dbbb690ef602be417d92e4a3e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "35783b00-240f-4ce6-b647-0336187bfd0d", "node_type": "1", "metadata": {}, "hash": "8ae98ae4598883fbf1303f5cc965282960f7bf4939d0dc98b7953a3e035fa2a3", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Nat Commun. \n2023;14(1):5216.\n336. Gao C, et al. Conjugation of macrophage-mimetic Microalgae and Liposome \nfor Antitumor Sonodynamic Immunotherapy via Hypoxia Alleviation and \nAutophagy Inhibition. ACS Nano. 2023;17(4):4034\u201349.\n337. Qin Y, et al. Autophagy and cancer drug resistance in dialogue: pre-clinical \nand clinical evidence. Cancer Lett. 2023;570:216307.\n338. Ashrafizadeh M, et al. A bioinformatics analysis, pre-clinical and clinical \nconception of autophagy in pancreatic cancer: complexity and simplicity in \ncrosstalk. Pharmacol Res. 2023;194:106822.\n339. Wang S, et al. Metabolic intervention Liposome boosted Lung Cancer \nRadio-Immunotherapy via Hypoxia Amelioration and PD-L1 Restraint. Adv Sci \n(Weinh). 2023;10(18):e2207608.\n340. Liu Y et al. An Injectable puerarin depot can potentiate chimeric antigen \nreceptor natural killer cell immunotherapy against targeted solid tumors by \nreversing tumor immunosuppression Small, 2024: p. e2307521.\n341. Jiang X, et al. Mitochondrial disruption Nanosystem simultaneously \ndepressed programmed death Ligand-1 and transforming growth Factor-\u03b2 \nto overcome photodynamic immunotherapy resistance. ACS Nano; 2024.\n342. Li M, et al. Sono-activatable semiconducting polymer nanoreshapers \nmultiply remodel tumor microenvironment for potent immunotherapy of \northotopic pancreatic cancer. Adv Sci (Weinh). 2023;10(35):e2305150.\n343. Jang H et al. Nanoparticles targeting innate immune cells in tumor microen -\nvironment. Int J Mol Sci, 2021. 22(18).\n344. Bronte V, Zanovello P .", "mimetype": "text/plain", "start_char_idx": 5575, "end_char_idx": 7108, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "35783b00-240f-4ce6-b647-0336187bfd0d": {"__data__": {"id_": "35783b00-240f-4ce6-b647-0336187bfd0d", "embedding": null, "metadata": {"page_label": "43", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "fdaa53d7-c08b-4351-b327-0fea1e9db34b", "node_type": "4", "metadata": {"page_label": "43", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "1164cdf6ae64c85b648c0d345f1fc92b094d8d68077c2abb53f58d7570d64d5f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b5982d9f-8de0-48e7-873c-4745b0a9b979", "node_type": "1", "metadata": {"page_label": "43", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "7d125ac51d1cb4b49bcd9e8605fab1041685f8a81e0cb07ead2a97d6d828c8a7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "efeb9872-ea92-4132-b8e0-21c1ddb6c497", "node_type": "1", "metadata": {}, "hash": "1545238d26bf9917322264caea7141b468c4963e0e05f0f4d3f89e8e7cde7f58", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Nanoparticles targeting innate immune cells in tumor microen -\nvironment. Int J Mol Sci, 2021. 22(18).\n344. Bronte V, Zanovello P . Regulation of immune responses by L-arginine \nmetabolism. Nat Rev Immunol. 2005;5(8):641\u201354.\n345. Rodriguez PC, et al. Arginase I in myeloid suppressor cells is induced by \nCOX-2 in lung carcinoma. J Exp Med. 2005;202(7):931\u20139.\n346. Rodr\u00edguez PC, Ochoa AC. Arginine regulation by myeloid derived suppressor \ncells and tolerance in cancer: mechanisms and therapeutic perspectives. \nImmunol Rev. 2008;222:180\u201391.\n347. Rodriguez PC, et al. Regulation of T cell receptor CD3zeta chain expression by \nL-arginine. J Biol Chem. 2002;277(24):21123\u20139.\n348. Nagaraj S, et al. Altered recognition of antigen is a mechanism of CD8 + T cell \ntolerance in cancer. Nat Med. 2007;13(7):828\u201335.\n349. Kusmartsev S, et al. Antigen-specific inhibition of CD8 + T cell response by \nimmature myeloid cells in cancer is mediated by reactive oxygen species. J \nImmunol. 2004;172(2):989\u201399.\n350. Kusmartsev S, Nagaraj S, Gabrilovich DI. Tumor-associated CD8 + T cell toler-\nance induced by bone marrow-derived immature myeloid cells. J Immunol. \n2005;175(7):4583\u201392.\n351. Huang B, et al. Gr-1 + CD115 + immature myeloid suppressor cells mediate \nthe development of tumor-induced T regulatory cells and T-cell anergy in \ntumor-bearing host. Cancer Res. 2006;66(2):1123\u201331.\n352. Sawant DV, et al.", "mimetype": "text/plain", "start_char_idx": 6977, "end_char_idx": 8378, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "efeb9872-ea92-4132-b8e0-21c1ddb6c497": {"__data__": {"id_": "efeb9872-ea92-4132-b8e0-21c1ddb6c497", "embedding": null, "metadata": {"page_label": "43", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "fdaa53d7-c08b-4351-b327-0fea1e9db34b", "node_type": "4", "metadata": {"page_label": "43", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "1164cdf6ae64c85b648c0d345f1fc92b094d8d68077c2abb53f58d7570d64d5f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "35783b00-240f-4ce6-b647-0336187bfd0d", "node_type": "1", "metadata": {"page_label": "43", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "3e4bf54727ea0cb1000de6dcd52960a8330e8e24e86f87ee781b719825e9956c", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Cancer Res. 2006;66(2):1123\u201331.\n352. Sawant DV, et al. Adaptive plasticity of IL-10(+) and IL-35(+) T(reg) cells coop-\neratively promotes tumor T cell exhaustion. Nat Immunol. 2019;20(6):724\u201335.\n353. Sullivan JA, et al. Treg-Cell-Derived IL-35-Coated Extracellular vesicles pro-\nmote infectious tolerance. Cell Rep. 2020;30(4):1039\u2013e10515.\n354. Liu H, et al. A novel DNA aptamer for dual targeting of Polymorpho-\nnuclear myeloid-derived suppressor cells and Tumor cells. Theranostics. \n2018;8(1):31\u201344.\n355. Song X, et al. CD11b+/Gr-1 + immature myeloid cells mediate suppression \nof T cells in mice bearing tumors of IL-1beta-secreting cells. J Immunol. \n2005;175(12):8200\u20138.\n356. Bunt SK, et al. Inflammation induces myeloid-derived suppressor cells that \nfacilitate tumor progression. J Immunol. 2006;176(1):284\u201390.", "mimetype": "text/plain", "start_char_idx": 8324, "end_char_idx": 9142, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "76064f35-8e07-4eb4-88fd-d4596e77ae08": {"__data__": {"id_": "76064f35-8e07-4eb4-88fd-d4596e77ae08", "embedding": null, "metadata": {"page_label": "44", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "017b08de-905a-4437-b0a2-d21b6c4cde5d", "node_type": "4", "metadata": {"page_label": "44", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "c1db0a076bd79315de61789242150dc1e7b7ec0514cd05fa7406b153c2cf3751", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8c4b1c7c-dcf9-474d-b66e-42763db1532e", "node_type": "1", "metadata": {}, "hash": "1a2ded2c0127304a7221ba5c036ab1136c818268f06ee63b3da4fe07d627fb67", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Page 44 of 48\nLu et al. Journal of Hematology & Oncology            (2024) 17:16 \n357. Jiang M, et al. Interleukin-6 trans-signaling pathway promotes immunosup-\npressive myeloid-derived suppressor cells via Suppression of Suppressor of \nCytokine Signaling 3 in breast Cancer. Front Immunol. 2017;8:1840.\n358. Sinha P , et al. Prostaglandin E2 promotes tumor progression by inducing \nmyeloid-derived suppressor cells. Cancer Res. 2007;67(9):4507\u201313.\n359. Gabrilovich DI, et al. Production of vascular endothelial growth factor by \nhuman tumors inhibits the functional maturation of dendritic cells. Nat Med. \n1996;2(10):1096\u2013103.\n360. Groth C, et al. Immunosuppression mediated by myeloid-derived suppressor \ncells (MDSCs) during tumour progression. Br J Cancer. 2019;120(1):16\u201325.\n361. Kong M, et al. Biodegradable Hollow Mesoporous silica nanoparticles for \nregulating Tumor Microenvironment and Enhancing Antitumor Efficiency. \nTheranostics. 2017;7(13):3276\u201392.\n362. Shao K, et al. Nanoparticle-based immunotherapy for cancer. ACS Nano. \n2015;9(1):16\u201330.\n363. Zolnik BS, et al. Minireview: nanoparticles and the immune system. Endocri -\nnology. 2010;151(2):458\u201365.\n364. Dwivedi PD, et al. Impact of nanoparticles on the immune system. J Biomed \nNanotechnol. 2011;7(1):193\u20134.\n365. Falo L Jr, et al. Targeting antigen into the phagocytic pathway in vivo induces \nprotective tumour immunity. Nat Med. 1995;1(7):649\u201353.\n366.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1422, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "8c4b1c7c-dcf9-474d-b66e-42763db1532e": {"__data__": {"id_": "8c4b1c7c-dcf9-474d-b66e-42763db1532e", "embedding": null, "metadata": {"page_label": "44", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "017b08de-905a-4437-b0a2-d21b6c4cde5d", "node_type": "4", "metadata": {"page_label": "44", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "c1db0a076bd79315de61789242150dc1e7b7ec0514cd05fa7406b153c2cf3751", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "76064f35-8e07-4eb4-88fd-d4596e77ae08", "node_type": "1", "metadata": {"page_label": "44", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "264c328cb4f07420d3906f187e6501e2817a1fbbfc85d9b68730dc31bdba045a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "26122383-65a0-4a19-97fc-26bd1a0c6e3c", "node_type": "1", "metadata": {}, "hash": "c83510024bdaeca9c702e4670fe8dfb00271bbb4bb0b2b02b3f35e4fd6489d19", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Falo L Jr, et al. Targeting antigen into the phagocytic pathway in vivo induces \nprotective tumour immunity. Nat Med. 1995;1(7):649\u201353.\n366. Fifis T, et al. Size-dependent immunogenicity: therapeutic and protective \nproperties of nano-vaccines against tumors. J Immunol. 2004;173(5):3148\u201354.\n367. Uto T, et al. Targeting of antigen to dendritic cells with poly (\u03b3-glutamic acid) \nnanoparticles induces antigen-specific humoral and cellular immunity. J \nImmunol. 2007;178(5):2979\u201386.\n368. Cho N-H, et al. A multifunctional core\u2013shell nanoparticle for dendritic cell-\nbased cancer immunotherapy. Nat Nanotechnol. 2011;6(10):675\u201382.\n369. Bourquin C, et al. Targeting CpG oligonucleotides to the lymph node \nby nanoparticles elicits efficient antitumoral immunity. J Immunol. \n2008;181(5):2990\u20138.\n370. Zwiorek K, et al. Delivery by cationic gelatin nanoparticles strongly increases \nthe immunostimulatory effects of CpG oligonucleotides. Pharm Res. \n2008;25:551\u201362.\n371. Romero P , et al. Ex vivo staining of metastatic lymph nodes by class I \nmajor histocompatibility complex tetramers reveals high numbers of \nantigen-experienced tumor-specific cytolytic T lymphocytes. J Exp Med. \n1998;188(9):1641\u201350.\n372. Cochran AJ, et al. Sentinel lymph nodes show profound downregulation of \nantigen-presenting cells of the paracortex: implications for tumor biology \nand treatment. Mod Pathol. 2001;14(6):604\u20138.\n373. Curiel TJ, et al. Blockade of B7-H1 improves myeloid dendritic cell\u2013mediated \nantitumor immunity. Nat Med.", "mimetype": "text/plain", "start_char_idx": 1282, "end_char_idx": 2793, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "26122383-65a0-4a19-97fc-26bd1a0c6e3c": {"__data__": {"id_": "26122383-65a0-4a19-97fc-26bd1a0c6e3c", "embedding": null, "metadata": {"page_label": "44", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "017b08de-905a-4437-b0a2-d21b6c4cde5d", "node_type": "4", "metadata": {"page_label": "44", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "c1db0a076bd79315de61789242150dc1e7b7ec0514cd05fa7406b153c2cf3751", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8c4b1c7c-dcf9-474d-b66e-42763db1532e", "node_type": "1", "metadata": {"page_label": "44", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "a2fd11be57732e8ad646d981bf6a01810606bf31bf96f4c3e092da954836a0c6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a49d974f-4423-4cb8-8de9-dc003050a48c", "node_type": "1", "metadata": {}, "hash": "a213f4d6cbef12cad126e4a00d16f6b266111ce7651c31db0753d5f87b8a9118", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "373. Curiel TJ, et al. Blockade of B7-H1 improves myeloid dendritic cell\u2013mediated \nantitumor immunity. Nat Med. 2003;9(5):562\u20137.\n374. Munn DH, et al. Expression of indoleamine 2, 3-dioxygenase by plas -\nmacytoid dendritic cells in tumor-draining lymph nodes. J Clin Investig. \n2004;114(2):280\u201390.\n375. Gabrilovich D. Mechanisms and functional significance of tumour-induced \ndendritic-cell defects. Nat Rev Immunol. 2004;4(12):941\u201352.\n376. Pinzon-Charry A, Maxwell T, L\u00f3pez JA. Dendritic cell dysfunction in cancer: a \nmechanism for immunosuppression. Immunol Cell Biol. 2005;83(5):451\u201361.\n377. Vicari AP , et al. Reversal of tumor-induced dendritic cell paralysis by CpG \nimmunostimulatory oligonucleotide and anti\u2013interleukin 10 receptor anti-\nbody. J Exp Med. 2002;196(4):541\u20139.\n378. van Mierlo GJ, et al. Activation of dendritic cells that cross-present tumor-\nderived antigen licenses CD8 + CTL to cause tumor eradication. J Immunol. \n2004;173(11):6753\u20139.\n379. Munn DH, Mellor AL. The tumor-draining lymph node as an immune\u2010privi-\nleged site. Immunol Rev. 2006;213(1):146\u201358.\n380. Jeanbart L, et al. Enhancing efficacy of anticancer vaccines by targeted deliv -\nery to tumor-draining lymph nodes. Cancer Immunol Res. 2014;2(5):436\u201347.\n381. Nam J, et al. Cancer nanomedicine for combination cancer immunotherapy. \nNat Reviews Mater. 2019;4(6):398\u2013414.\n382. Shi J, et al.", "mimetype": "text/plain", "start_char_idx": 2682, "end_char_idx": 4056, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "a49d974f-4423-4cb8-8de9-dc003050a48c": {"__data__": {"id_": "a49d974f-4423-4cb8-8de9-dc003050a48c", "embedding": null, "metadata": {"page_label": "44", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "017b08de-905a-4437-b0a2-d21b6c4cde5d", "node_type": "4", "metadata": {"page_label": "44", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "c1db0a076bd79315de61789242150dc1e7b7ec0514cd05fa7406b153c2cf3751", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "26122383-65a0-4a19-97fc-26bd1a0c6e3c", "node_type": "1", "metadata": {"page_label": "44", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "62193231c407b5ebf53b475e2a65530ed6d989ab6260b577a06541e040ac1198", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "19913503-6860-4554-b211-e3e6c41f5289", "node_type": "1", "metadata": {}, "hash": "0b734eb76d58f25a2bdb5a8da78c2b969b7f4d096f3d70800becfb8a0f76a57c", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "381. Nam J, et al. Cancer nanomedicine for combination cancer immunotherapy. \nNat Reviews Mater. 2019;4(6):398\u2013414.\n382. Shi J, et al. Cancer nanomedicine: progress, challenges and opportunities. Nat \nRev Cancer. 2017;17(1):20\u201337.\n383. Ojha T, et al. Pharmacological and physical vessel modulation strategies \nto improve EPR-mediated drug targeting to tumors. Adv Drug Deliv Rev. \n2017;119:44\u201360.\n384. Wilhelm S, et al. Analysis of nanoparticle delivery to tumours. Nat Reviews \nMater. 2016;1(5):1\u201312.\n385. Siegler EL, Kim YJ, Wang P . Nanomedicine targeting the tumor microenviron-\nment: therapeutic strategies to inhibit angiogenesis, remodel matrix, and \nmodulate immune responses. J Cell Immunotherapy. 2016;2(2):69\u201378.\n386. Shi K, Haynes M, Huang L. Nanovaccines for remodeling the suppressive \ntumor microenvironment: new horizons in cancer immunotherapy. Front \nChem Sci Eng. 2017;11:676\u201384.\n387. Marabelle A, et al. Intratumoral immunotherapy: using the tumor as the \nremedy. Ann Oncol. 2017;28:xii33\u201343.\n388. Aznar MA, et al. Intratumoral delivery of immunotherapy\u2014act locally, think \nglobally. J Immunol. 2017;198(1):31\u20139.\n389. Ishihara J, et al. Matrix-binding checkpoint immunotherapies enhance \nantitumor efficacy and reduce adverse events. Sci Transl Med. \n2017;9(415):eaan0401.\n390. Raav\u00e9 R, van Kuppevelt TH, Daamen WF. Chemotherapeutic drug delivery by \ntumoral extracellular matrix targeting. J Controlled Release. 2018;274:1\u20138.\n391. Yu S et al.", "mimetype": "text/plain", "start_char_idx": 3922, "end_char_idx": 5385, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "19913503-6860-4554-b211-e3e6c41f5289": {"__data__": {"id_": "19913503-6860-4554-b211-e3e6c41f5289", "embedding": null, "metadata": {"page_label": "44", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "017b08de-905a-4437-b0a2-d21b6c4cde5d", "node_type": "4", "metadata": {"page_label": "44", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "c1db0a076bd79315de61789242150dc1e7b7ec0514cd05fa7406b153c2cf3751", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a49d974f-4423-4cb8-8de9-dc003050a48c", "node_type": "1", "metadata": {"page_label": "44", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "fef45001deb34cb48b7bdad55e188fb5c230812100b741dff3da51a92fb20cbf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4c0ae015-b12c-4c2d-8dd7-aa96eaadc319", "node_type": "1", "metadata": {}, "hash": "aa7bf5e6bc63346dc5fe63026503ddaa6955746f73806f01c4220cdea153936b", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Chemotherapeutic drug delivery by \ntumoral extracellular matrix targeting. J Controlled Release. 2018;274:1\u20138.\n391. Yu S et al. Reinforcing the immunogenic cell death to enhance cancer immu -\nnotherapy efficacy Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, \n2023;1878(5):188946.\n392. Wu Q, et al. Autophagy induction by IGF1R inhibition with picropodophyllin \nand linsitinib. Autophagy. 2021;17(8):2046\u20137.\n393. Petroni G, et al. Immunomodulation by targeted anticancer agents. Cancer \nCell. 2021;39(3):310\u201345.\n394. Huang Z, et al. KCl nanoparticles as potential inducer of immunogenic cell \ndeath for Cancer Immunotherapy. ACS Appl Bio Mater. 2023;6(6):2404\u201314.\n395. F\u00e9lix-Pi\u00f1a P et al. Antitumoral and Immunogenic Capacity of \u03b2-D-Glucose-\nreduced silver nanoparticles in breast Cancer. Int J Mol Sci, 2023. 24(10).\n396. Liu Q, et al. Exploiting immunostimulatory mechanisms of immunogenic cell \ndeath to develop membrane-encapsulated nanoparticles as a potent tumor \nvaccine. J Nanobiotechnol. 2023;21(1):326.\n397. Xie B, et al. Supramolecularly Engineered Conjugate of Bacteria and cell \nmembrane-coated magnetic nanoparticles for enhanced ferroptosis and \nimmunotherapy of tumors. Adv Sci (Weinh). 2023;10(34):e2304407.\n398. Lu Y, et al. Self-driven bioactive hybrids co-deliver doxorubicin and indocya-\nnine green nanoparticles for chemo/photothermal therapy of breast cancer. \nBiomed Pharmacother. 2023;169:115846.\n399. Wang H et al.", "mimetype": "text/plain", "start_char_idx": 5258, "end_char_idx": 6707, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "4c0ae015-b12c-4c2d-8dd7-aa96eaadc319": {"__data__": {"id_": "4c0ae015-b12c-4c2d-8dd7-aa96eaadc319", "embedding": null, "metadata": {"page_label": "44", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "017b08de-905a-4437-b0a2-d21b6c4cde5d", "node_type": "4", "metadata": {"page_label": "44", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "c1db0a076bd79315de61789242150dc1e7b7ec0514cd05fa7406b153c2cf3751", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "19913503-6860-4554-b211-e3e6c41f5289", "node_type": "1", "metadata": {"page_label": "44", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "b3a358a2b3e1678190c225c66bc895b998545d2bca88cc31a96f72d2cad6753b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d575e133-9931-4aa0-b0b1-fd6674198764", "node_type": "1", "metadata": {}, "hash": "5a7cc175f97eca0fc3669cd610c5e43b7ad5d6503710fa03b37ede3feaeda6da", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Biomed Pharmacother. 2023;169:115846.\n399. Wang H et al. Near-Infrared Light-Driven Nanoparticles for Cancer Photoim-\nmunotherapy by Synergizing Immune Cell Death and Epigenetic Regulation \nSmall, 2023: p. e2309202.\n400. Wu Q et al. Photothermal ferrotherapy - induced immunogenic cell death via \niron-based ternary chalcogenide nanoparticles against triple-negative breast \ncancer Small, 2023: p. e2306766.\n401. Song S, et al. All-in-one glycol chitosan nanoparticles for co-delivery of \ndoxorubicin and anti-PD-L1 peptide in cancer immunotherapy. Bioact Mater. \n2023;28:358\u201375.\n402. Wang R, et al. Hydroxyapatite nanoparticles promote TLR4 agonist-mediated \nanti-tumor immunity through synergically enhanced macrophage polariza-\ntion. Acta Biomater. 2023;164:626\u201340.\n403. Wang Y, et al. Docetaxel-loaded pH/ROS dual-responsive nanoparticles with \nself-supplied ROS for inhibiting metastasis and enhancing immunotherapy of \nbreast cancer. J Nanobiotechnol. 2023;21(1):286.\n404. Yang J, et al. Self-assembled albumin nanoparticles induce pyroptosis for \nphotodynamic/photothermal/immuno synergistic therapies in triple-nega -\ntive breast cancer. Front Immunol. 2023;14:1173487.\n405. Xu X, et al. Guanidine-modified nanoparticles as robust BTZ delivery carriers \nand activators of immune responses. J Control Release. 2023;357:310\u20138.\n406. Chen W, et al. PEI-Based nanoparticles for Tumor Immunotherapy via in \nsitu Antigen-capture triggered by Photothermal Therapy. ACS Appl Mater \nInterfaces. 2023;15(48):55433\u201346.\n407. Li Y, et al.", "mimetype": "text/plain", "start_char_idx": 6651, "end_char_idx": 8183, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "d575e133-9931-4aa0-b0b1-fd6674198764": {"__data__": {"id_": "d575e133-9931-4aa0-b0b1-fd6674198764", "embedding": null, "metadata": {"page_label": "44", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "017b08de-905a-4437-b0a2-d21b6c4cde5d", "node_type": "4", "metadata": {"page_label": "44", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "c1db0a076bd79315de61789242150dc1e7b7ec0514cd05fa7406b153c2cf3751", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4c0ae015-b12c-4c2d-8dd7-aa96eaadc319", "node_type": "1", "metadata": {"page_label": "44", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "dc1c1f508558ca86210ed12e763bc83eeccbe22c3833866148ad5b5a72eb684a", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "ACS Appl Mater \nInterfaces. 2023;15(48):55433\u201346.\n407. Li Y, et al. Antigen-capturing dendritic-cell-targeting nanoparticles for \nenhanced Tumor Immunotherapy based on Photothermal-Therapy-Induced \nin situ vaccination. Adv Healthc Mater. 2023;12(22):e2202871.\n408. Zou C, et al. cRGD-modified nanoparticles of multi-bioactive agent conjugate \nwith pH-sensitive linkers and PD-L1 antagonist for integrative collaborative \ntreatment of breast cancer. Nanoscale Horiz. 2023;8(7):870\u201386.\n409. Chen S, et al. Tumor Acidic Microenvironment-Responsive Promodulator Iron \nOxide nanoparticles for Photothermal-enhanced Chemodynamic Immuno -\ntherapy of Cancer. ACS Biomater Sci Eng. 2023;9(2):773\u201383.\n410. Ma W, et al. Biomimetic nanoerythrosome-coated Aptamer-DNA Tetrahe-\ndron/Maytansine conjugates: pH-Responsive and targeted cytotoxicity for \nHER2-Positive breast Cancer. Adv Mater. 2022;34(46):e2109609.\n411. Zheng X, et al. Biomimetic co-assembled nanodrug of doxorubicin and \nberberine suppresses chemotherapy-exacerbated breast cancer metastasis. \nBiomaterials. 2021;271:120716.\n412. Liu XL, et al. Biomimetic liposomal nanoplatinum for targeted Cancer Che-\nmophototherapy. Adv Sci (Weinh). 2021;8(8):2003679.", "mimetype": "text/plain", "start_char_idx": 8116, "end_char_idx": 9323, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "0a23ccf6-773e-46bb-8c44-4914a99c1f15": {"__data__": {"id_": "0a23ccf6-773e-46bb-8c44-4914a99c1f15", "embedding": null, "metadata": {"page_label": "45", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "fde648af-5d4d-4dae-b4e2-a4d334b16383", "node_type": "4", "metadata": {"page_label": "45", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "bb842ef8925a3e021557e8e611cf5137c28568e0c57ad55083469e9a4d289489", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "36eb6093-0ec7-4855-99cc-331fb872b1c2", "node_type": "1", "metadata": {}, "hash": "a53ee0143b7eaf7b95b0815e0dfd32ca2790f6f4d8bf4acc095de17cb4438b63", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Page 45 of 48\nLu et al. Journal of Hematology & Oncology            (2024) 17:16 \n413. Zhao Y, et al. Biomimetic manganese-based theranostic nanoplatform for \ncancer multimodal imaging and twofold immunotherapy. Bioact Mater. \n2023;19:237\u201350.\n414. Zhao P , et al. Programming cell pyroptosis with biomimetic nanoparticles for \nsolid tumor immunotherapy. Biomaterials. 2020;254:120142.\n415. Ying K, et al. Macrophage membrane-biomimetic adhesive polycaprolactone \nnanocamptothecin for improving cancer-targeting efficiency and impairing \nmetastasis. Bioact Mater. 2023;20:449\u201362.\n416. Miao Y, et al. Cell membrane-camouflaged nanocarriers with Biomimetic \nDeformability of erythrocytes for Ultralong circulation and enhanced Cancer \nTherapy. ACS Nano. 2022;16(4):6527\u201340.\n417. Guo Y, et al. Chemotherapy mediated by Biomimetic Polymeric Nanopar-\nticles Potentiates Enhanced Tumor Immunotherapy via Amplification of \nEndoplasmic Reticulum Stress and mitochondrial dysfunction. Adv Mater. \n2022;34(47):e2206861.\n418. Wu P , et al. Engineered EGCG-Containing Biomimetic nanoassemblies as \neffective delivery platform for enhanced Cancer Therapy. Adv Sci (Weinh). \n2022;9(15):e2105894.\n419. Reuven EM, et al. Biomimetic Glyconanoparticle Vaccine for Cancer Immuno-\ntherapy. ACS Nano. 2019;13(3):2936\u201347.\n420. Molina M, et al. Stimuli-responsive nanogel composites and their application \nin nanomedicine. Chem Soc Rev. 2015;44(17):6161\u201386.\n421. Chuard N, et al.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1455, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "36eb6093-0ec7-4855-99cc-331fb872b1c2": {"__data__": {"id_": "36eb6093-0ec7-4855-99cc-331fb872b1c2", "embedding": null, "metadata": {"page_label": "45", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "fde648af-5d4d-4dae-b4e2-a4d334b16383", "node_type": "4", "metadata": {"page_label": "45", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "bb842ef8925a3e021557e8e611cf5137c28568e0c57ad55083469e9a4d289489", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0a23ccf6-773e-46bb-8c44-4914a99c1f15", "node_type": "1", "metadata": {"page_label": "45", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "46e2a915bb2d06907f889948b8aa07cd2329a3d673f2c197c17e5f177891befc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "544028d4-67cf-4db2-a126-2ee01e438abb", "node_type": "1", "metadata": {}, "hash": "78b55166e7ab6d831fe8fe0cbcc512b9b4ac9de8acf6dc44330239a265cb51dd", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Stimuli-responsive nanogel composites and their application \nin nanomedicine. Chem Soc Rev. 2015;44(17):6161\u201386.\n421. Chuard N, et al. Strain-promoted thiol-mediated Cellular Uptake of Giant \nsubstrates: liposomes and polymersomes. Angew Chem Int Ed Engl. \n2017;56(11):2947\u201350.\n422. Wang H, et al. A cooperative dimensional strategy for enhanced nucleus-\ntargeted delivery of anticancer drugs. Adv Funct Mater. 2017;27(24):1700339.\n423. Tang L, et al. Enhancing T cell therapy through TCR-signaling-responsive \nnanoparticle drug delivery. Nat Biotechnol. 2018;36(8):707\u201316.\n424. Sun CY, et al. Tumor acidity-sensitive polymeric vector for active targeted \nsiRNA delivery. J Am Chem Soc. 2015;137(48):15217\u201324.\n425. Shang L, et al. Enhancing cancer chemo-immunotherapy by biomimetic \nnanogel with tumor targeting capacity and rapid drug-releasing in tumor \nmicroenvironment. Acta Pharm Sin B. 2022;12(5):2550\u201367.\n426. Wan L, et al. Biomimetic, pH-Responsive nanoplatforms for Cancer \nMultimodal Imaging and Photothermal Immunotherapy. ACS Appl Mater \nInterfaces. 2023;15(1):1784\u201397.\n427. Yang C, et al. Biomimetic nanovaccines potentiating dendritic cell inter-\nnalization via CXCR4-Mediated macropinocytosis. Adv Healthc Mater. \n2023;12(5):e2202064.\n428. Wei X et al. Biomimetic nano-immunoactivator via ionic metabolic modula-\ntion for strengthened nir-ii photothermal immunotherapy small, 2023: p. \ne2304370.\n429. Wang Y, et al.", "mimetype": "text/plain", "start_char_idx": 1321, "end_char_idx": 2751, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "544028d4-67cf-4db2-a126-2ee01e438abb": {"__data__": {"id_": "544028d4-67cf-4db2-a126-2ee01e438abb", "embedding": null, "metadata": {"page_label": "45", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "fde648af-5d4d-4dae-b4e2-a4d334b16383", "node_type": "4", "metadata": {"page_label": "45", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "bb842ef8925a3e021557e8e611cf5137c28568e0c57ad55083469e9a4d289489", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "36eb6093-0ec7-4855-99cc-331fb872b1c2", "node_type": "1", "metadata": {"page_label": "45", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "a1190df0857893898cc4683ab493d059ee4905b3d2b861291922f20eb73c8e31", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f8b2839b-5060-48af-9ac5-854dd11470ed", "node_type": "1", "metadata": {}, "hash": "4ff30881eeba32a57c90a0897f90a8960ddf7aec56b2289eb46c0eacbe8ba382", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "429. Wang Y, et al. Engineering Endogenous Tumor-Associated macrophage-\ntargeted biomimetic Nano-RBC to Reprogram Tumor Immunosuppressive \nMicroenvironment for enhanced chemo-immunotherapy. Adv Mater. \n2021;33(39):e2103497.\n430. Zhao H, et al. Biomimetic Decoy inhibits Tumor Growth and Lung Metastasis \nby reversing the drawbacks of Sonodynamic Therapy. Adv Healthc Mater. \n2020;9(1):e1901335.\n431. Feng C, et al. Biomimetic and bioinspired nano-platforms for cancer vaccine \ndevelopment. Explor (Beijing). 2023;3(3):20210263.\n432. Fang RH, et al. Cell Membrane Coat Nanatechnol Adv Mater. \n2018;30(23):e1706759.\n433. Fang RH, et al. Cancer cell membrane-coated nanoparticles for anticancer \nvaccination and drug delivery. Nano Lett. 2014;14(4):2181\u20138.\n434. Zheng S, Guan XY. Ferroptosis: promising approach for cancer and cancer \nimmunotherapy. Cancer Lett. 2023;561:216152.\n435. Yin J, et al. Ferroptosis and Cancer immunotherapy. Curr Mol Med. \n2023;23(5):401\u20139.\n436. Xu H, et al. Ferroptosis in the tumor microenvironment: perspectives for \nimmunotherapy. Trends Mol Med. 2021;27(9):856\u201367.\n437. Gao W, et al. Autophagy, ferroptosis, pyroptosis, and necroptosis in tumor \nimmunotherapy. Signal Transduct Target Ther. 2022;7(1):196.\n438. Lei Y et al. Autophagy in cancer immunotherapy cells, 2022. 11(19).\n439. Pan H, et al.", "mimetype": "text/plain", "start_char_idx": 2732, "end_char_idx": 4060, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "f8b2839b-5060-48af-9ac5-854dd11470ed": {"__data__": {"id_": "f8b2839b-5060-48af-9ac5-854dd11470ed", "embedding": null, "metadata": {"page_label": "45", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "fde648af-5d4d-4dae-b4e2-a4d334b16383", "node_type": "4", "metadata": {"page_label": "45", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "bb842ef8925a3e021557e8e611cf5137c28568e0c57ad55083469e9a4d289489", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "544028d4-67cf-4db2-a126-2ee01e438abb", "node_type": "1", "metadata": {"page_label": "45", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "a20338851dc867974ad628ed2de5cf7b2b2c80b7fb8228d88eea64676f758287", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cb4ad102-0f04-415c-9c6b-be9c46edd8e6", "node_type": "1", "metadata": {}, "hash": "6de999e74f27aa199728a5143bf1e32ef304a27d9a3220e095324e69e1ce1ba1", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "2022;7(1):196.\n438. Lei Y et al. Autophagy in cancer immunotherapy cells, 2022. 11(19).\n439. Pan H, et al. Autophagy-associated immune responses and cancer immuno-\ntherapy. Oncotarget. 2016;7(16):21235\u201346.\n440. Jin Z, et al. Regulation of autophagy fires up the cold tumor microenviron -\nment to improve cancer immunotherapy. Front Immunol. 2022;13:1018903.\n441. Hamidi M, et al. Applications of carrier erythrocytes in delivery of biopharma-\nceuticals. J Control Release. 2007;118(2):145\u201360.\n442. Banz A, et al. In situ targeting of dendritic cells by antigen-loaded red \nblood cells: a novel approach to cancer immunotherapy. Vaccine. \n2010;28(17):2965\u201372.\n443. Hu CMJ, Fang RH, Zhang L. Erythrocyte-inspired delivery systems. Adv \nHealthc Mater. 2012;1(5):537\u201347.\n444. Guo Y, et al. Erythrocyte membrane-enveloped polymeric nanoparticles as \nNanovaccine for induction of Antitumor immunity against Melanoma. ACS \nNano. 2015;9(7):6918\u201333.\n445. Hu Q, et al. Anticancer Platelet-Mimicking Nanovehicles. Adv Mater. \n2015;27(44):7043\u201350.\n446. Hu CM, et al. Nanoparticle biointerfacing by platelet membrane cloaking. \nNature. 2015;526(7571):118\u201321.\n447. Bahmani B et al. Intratumoral immunotherapy using platelet-cloaked \nnanoparticles enhances antitumor immunity in solid tumors Nat Commun, \n2021;12(1):1999.\n448. Mai X, et al.", "mimetype": "text/plain", "start_char_idx": 3954, "end_char_idx": 5279, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "cb4ad102-0f04-415c-9c6b-be9c46edd8e6": {"__data__": {"id_": "cb4ad102-0f04-415c-9c6b-be9c46edd8e6", "embedding": null, "metadata": {"page_label": "45", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "fde648af-5d4d-4dae-b4e2-a4d334b16383", "node_type": "4", "metadata": {"page_label": "45", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "bb842ef8925a3e021557e8e611cf5137c28568e0c57ad55083469e9a4d289489", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f8b2839b-5060-48af-9ac5-854dd11470ed", "node_type": "1", "metadata": {"page_label": "45", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "7ebaa841e18f4339fcef023af8fd01ded1c7922784cf1e268d0bd0a6630108c1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "71a74f10-4890-41ea-84d8-8e9a62626825", "node_type": "1", "metadata": {}, "hash": "6b758a42cd41c6aeddc2c95bb6a1ebbdd36a056cc39ac11be5b75545459ad9c3", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Intratumoral immunotherapy using platelet-cloaked \nnanoparticles enhances antitumor immunity in solid tumors Nat Commun, \n2021;12(1):1999.\n448. Mai X, et al. Integration of immunogenic activation and immunosuppres-\nsive reversion using mitochondrial-respiration-inhibited platelet-mimicking \nnanoparticles. Biomaterials. 2020;232:119699.\n449. Wang Q et al. Biomimetic Nanophotosensitizer amplifies immunogenic \npyroptosis and triggers synergistic Cancer Therapy. Adv Healthc Mater, 2023: \np. e2301641.\n450. Gong P et al. Immunocyte membrane-coated nanoparticles for Cancer \nImmunotherapy. Cancers (Basel), 2020. 13(1).\n451. Sun K, et al. Saikosaponin D loaded macrophage membrane-biomimetic \nnanoparticles target angiogenic signaling for breast cancer therapy. Appl \nMater Today. 2020;18:100505.\n452. Chen LJ, et al. Macrophage membrane coated persistent luminescence \nnanoparticle@MOF-derived mesoporous carbon core-shell nanocomposites \nfor autofluorescence-free imaging-guided chemotherapy. J Mater Chem B. \n2020;8(35):8071\u201383.\n453. Cao H, et al. Liposomes coated with isolated macrophage membrane can \ntarget lung metastasis of breast Cancer. ACS Nano. 2016;10(8):7738\u201348.\n454. Meng QF, et al. Macrophage membrane-coated iron oxide nanopar-\nticles for enhanced photothermal tumor therapy. Nanotechnology. \n2018;29(13):134004.\n455. Zhao H, et al. C-C Chemokine Ligand 2 (CCL2) recruits macrophage-mem -\nbrane-camouflaged Hollow Bismuth Selenide nanoparticles to facilitate \nPhotothermal Sensitivity and inhibit lung metastasis of breast Cancer. ACS \nAppl Mater Interfaces.", "mimetype": "text/plain", "start_char_idx": 5122, "end_char_idx": 6697, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "71a74f10-4890-41ea-84d8-8e9a62626825": {"__data__": {"id_": "71a74f10-4890-41ea-84d8-8e9a62626825", "embedding": null, "metadata": {"page_label": "45", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "fde648af-5d4d-4dae-b4e2-a4d334b16383", "node_type": "4", "metadata": {"page_label": "45", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "bb842ef8925a3e021557e8e611cf5137c28568e0c57ad55083469e9a4d289489", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cb4ad102-0f04-415c-9c6b-be9c46edd8e6", "node_type": "1", "metadata": {"page_label": "45", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "deb554880a5ffcab8275891262526eee132d962844a7f1b8aa19fa09926722a1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ae5d7bb6-8723-48c4-867d-ff5bb7fd1a5c", "node_type": "1", "metadata": {}, "hash": "f13404f9c4ae77b480eaaef1bacbeb06e3c73bc33f3ee319cdde0fd2a4c1d025", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "ACS \nAppl Mater Interfaces. 2018;10(37):31124\u201335.\n456. Liang B, et al. Biomimetic theranostic strategy for anti-metastasis therapy of \nbreast cancer via the macrophage membrane camouflaged superparticles. \nMater Sci Eng C Mater Biol Appl. 2020;115:111097.\n457. Xuan M, et al. Macrophage cell membrane camouflaged mesopo -\nrous silica nanocapsules for in vivo Cancer therapy. Adv Healthc Mater. \n2015;4(11):1645\u201352.\n458. Rao L, et al. Effective cancer targeting and imaging using macrophage \nmembrane-camouflaged upconversion nanoparticles. J Biomed Mater Res A. \n2017;105(2):521\u201330.\n459. Cao X, et al. Paclitaxel-loaded macrophage membrane camouflaged Albumin \nnanoparticles for targeted Cancer Therapy. Int J Nanomed. 2020;15:1915\u201328.\n460. Ma J, et al. Copresentation of Tumor antigens and Costimulatory molecules \nvia Biomimetic nanoparticles for Effective Cancer Immunotherapy. Nano Lett. \n2020;20(6):4084\u201394.\n461. Li L, et al. Cholesterol removal improves performance of a model biomimetic \nsystem to co-deliver a photothermal agent and a STING agonist for cancer \nimmunotherapy. Nat Commun. 2023;14(1):5111.\n462. Xie W, et al. Biomimetic nanoplatform loading type I Aggregation-Induced \nEmission Photosensitizer and glutamine blockade to regulate nutri-\nent partitioning for enhancing Antitumor Immunotherapy. ACS Nano. \n2022;16(7):10742\u201353.\n463. Zuo L, et al. Biomimetic nanovesicle with Mitochondria-Synthesized Sono -\nsensitizer and Mitophagy Inhibition for Cancer Sono-Immunotherapy. Nano \nLett.", "mimetype": "text/plain", "start_char_idx": 6670, "end_char_idx": 8174, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "ae5d7bb6-8723-48c4-867d-ff5bb7fd1a5c": {"__data__": {"id_": "ae5d7bb6-8723-48c4-867d-ff5bb7fd1a5c", "embedding": null, "metadata": {"page_label": "45", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "fde648af-5d4d-4dae-b4e2-a4d334b16383", "node_type": "4", "metadata": {"page_label": "45", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "bb842ef8925a3e021557e8e611cf5137c28568e0c57ad55083469e9a4d289489", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "71a74f10-4890-41ea-84d8-8e9a62626825", "node_type": "1", "metadata": {"page_label": "45", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "50c729c5d2644512a6b8ab78805461592294fee11a6f4d002bb81078b5f7453b", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Zuo L, et al. Biomimetic nanovesicle with Mitochondria-Synthesized Sono -\nsensitizer and Mitophagy Inhibition for Cancer Sono-Immunotherapy. Nano \nLett. 2023;23(7):3005\u201313.\n464. Pan P , et al. A heterogenic membrane-based biomimetic hybrid nanoplat-\nform for combining radiotherapy and immunotherapy against breast cancer. \nBiomaterials. 2022;289:121810.\n465. Yang C, et al. Leveraging \u03b2-Adrenergic receptor signaling blockade for \nImproved Cancer Immunotherapy through Biomimetic Nanovaccine. Small. \n2023;19(14):e2207029.\n466. Wang X, et al. Intelligent Biomimetic Nanoplatform for systemic treatment \nof metastatic triple-negative breast Cancer via enhanced EGFR-Targeted \ntherapy and immunotherapy. ACS Appl Mater Interfaces; 2022.", "mimetype": "text/plain", "start_char_idx": 8022, "end_char_idx": 8757, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "4f55e565-fc97-4a01-9f08-f8d64da59106": {"__data__": {"id_": "4f55e565-fc97-4a01-9f08-f8d64da59106", "embedding": null, "metadata": {"page_label": "46", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "efdc7e73-93b5-4b14-8f55-54d4edd305b8", "node_type": "4", "metadata": {"page_label": "46", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "258e321a642865cd5b2b9e7527e45a884d2c4ae18eb26f85bb4441eaff335d7e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f422e3e6-fd9b-4b87-a07b-a49307b5a5c6", "node_type": "1", "metadata": {}, "hash": "94872b58bb75154dfb3b2dd744d35ff209b7197329012e41ce149eca026df6fc", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Page 46 of 48\nLu et al. Journal of Hematology & Oncology            (2024) 17:16 \n467. Li J, et al. Multifunctional biomimetic nanovaccines based on Photothermal \nand weak-immunostimulatory Nanoparticulate cores for the immunotherapy \nof solid tumors. Adv Mater. 2022;34(9):e2108012.\n468. Xu X, et al. A Biomimetic Aggregation-Induced Emission Photosensitizer \nwith Antigen-presenting and hitchhiking function for lipid droplet targeted \nphotodynamic immunotherapy. Adv Mater. 2021;33(33):e2102322.\n469. Fang X, et al. Biomimetic Anti-PD-1 peptide-loaded 2D FePSe(3) nanosheets \nfor efficient photothermal and enhanced Immune Therapy with Multimodal \nMR/PA/Thermal Imaging. Adv Sci (Weinh). 2021;8(2):2003041.\n470. Liu Z, et al. Exosomes in HBV infection. Clin Chim Acta. 2023;538:65\u20139.\n471. Zhang F, et al. Janus nanocarrier-based co-delivery of doxorubicin and \nberberine weakens chemotherapy-exacerbated hepatocellular carcinoma \nrecurrence. Acta Biomater. 2019;100:352\u201364.\n472. Chen G, et al. Exosomal PD-L1 contributes to immunosuppression and is \nassociated with anti-PD-1 response. Nature. 2018;560(7718):382\u20136.\n473. Moradi-Chaleshtori M, et al. Overexpression of pigment epithelium-derived \nfactor in breast cancer cell-derived exosomes induces M1 polarization in \nmacrophages. Immunol Lett. 2022;248:31\u20136.\n474. Wang Y et al. G-MDSC-derived exosomes mediate the differentiation of \nM-MDSC into M2 macrophages promoting colitis-to-cancer transition.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1456, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "f422e3e6-fd9b-4b87-a07b-a49307b5a5c6": {"__data__": {"id_": "f422e3e6-fd9b-4b87-a07b-a49307b5a5c6", "embedding": null, "metadata": {"page_label": "46", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "efdc7e73-93b5-4b14-8f55-54d4edd305b8", "node_type": "4", "metadata": {"page_label": "46", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "258e321a642865cd5b2b9e7527e45a884d2c4ae18eb26f85bb4441eaff335d7e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4f55e565-fc97-4a01-9f08-f8d64da59106", "node_type": "1", "metadata": {"page_label": "46", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "eedf2392e292384e86a3c0b6df18d963a1fe6289fc2876f770fbe5f0af5c26a3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "13141e2a-e8ab-4a32-b621-3155812403f9", "node_type": "1", "metadata": {}, "hash": "d3cf460a7912a46796c8c7df3435c94b2fe9ace03903f0fd702ce541d2ae74d4", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "474. Wang Y et al. G-MDSC-derived exosomes mediate the differentiation of \nM-MDSC into M2 macrophages promoting colitis-to-cancer transition. J \nImmunother Cancer, 2023. 11(6).\n475. Zheng N, et al. M2 macrophage-derived exosomes suppress tumor intrinsic \nimmunogenicity to confer immunotherapy resistance. Oncoimmunology. \n2023;12(1):2210959.\n476. Chen J, et al. PDL1-positive exosomes suppress antitumor immunity by \ninducing tumor-specific CD8(+) T cell exhaustion during metastasis. Cancer \nSci. 2021;112(9):3437\u201354.\n477. Wei Y, et al. An RNA-RNA crosstalk network involving HMGB1 and RICTOR \nfacilitates hepatocellular carcinoma tumorigenesis by promoting glutamine \nmetabolism and impedes immunotherapy by PD-L1 + exosomes activity. \nSignal Transduct Target Ther. 2021;6(1):421.\n478. Wang C, et al. Tumor Cell-associated exosomes robustly elicit anti-tumor \nImmune responses through modulating dendritic cell vaccines in Lung \nTumor. Int J Biol Sci. 2020;16(4):633\u201343.\n479. Wang S, et al. Macrophage-tumor chimeric exosomes accumulate in lymph \nnode and tumor to activate the immune response and the tumor microenvi -\nronment. Sci Transl Med. 2021;13(615):eabb6981.\n480. Lu Z, et al. Dendritic cell-derived exosomes elicit tumor regression in \nautochthonous hepatocellular carcinoma mouse models. J Hepatol. \n2017;67(4):739\u201348.\n481. Zhou W, et al. Exosomes derived from immunogenically dying tumor cells \nas a versatile tool for vaccination against pancreatic cancer. Biomaterials. \n2022;280:121306.\n482. Zuo B, et al.", "mimetype": "text/plain", "start_char_idx": 1315, "end_char_idx": 2838, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "13141e2a-e8ab-4a32-b621-3155812403f9": {"__data__": {"id_": "13141e2a-e8ab-4a32-b621-3155812403f9", "embedding": null, "metadata": {"page_label": "46", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "efdc7e73-93b5-4b14-8f55-54d4edd305b8", "node_type": "4", "metadata": {"page_label": "46", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "258e321a642865cd5b2b9e7527e45a884d2c4ae18eb26f85bb4441eaff335d7e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f422e3e6-fd9b-4b87-a07b-a49307b5a5c6", "node_type": "1", "metadata": {"page_label": "46", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "bb0afd97cb9c5e8449035f0f90b44925aeb12a02856567a440d636073d2a3fed", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "261b2be3-e88a-4660-a2e7-4ed93f0cfa86", "node_type": "1", "metadata": {}, "hash": "79b48b543b6460a062bc95e44d7eb267c655317f4b57e342c339a8129e2b9c26", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Exosomes derived from immunogenically dying tumor cells \nas a versatile tool for vaccination against pancreatic cancer. Biomaterials. \n2022;280:121306.\n482. Zuo B, et al. Alarmin-painted exosomes elicit persistent antitumor immunity \nin large established tumors in mice. Nat Commun. 2020;11(1):1790.\n483. Morishita M, et al. Exosome-based tumor antigens-adjuvant co-delivery \nutilizing genetically engineered tumor cell-derived exosomes with immunos -\ntimulatory CpG DNA. Biomaterials. 2016;111:55\u201365.\n484. Gehrmann U, et al. Synergistic induction of adaptive antitumor immunity by \ncodelivery of antigen with \u03b1-galactosylceramide on exosomes. Cancer Res. \n2013;73(13):3865\u201376.\n485. Kim GB et al. Xenogenization of tumor cells by fusogenic exosomes in tumor \nmicroenvironment ignites and propagates antitumor immunity. Sci Adv, \n2020. 6(27).\n486. Zhou W, et al. Pancreatic cancer-targeting exosomes for enhancing immu-\nnotherapy and reprogramming tumor microenvironment. Biomaterials. \n2021;268:120546.\n487. Gunassekaran GR, et al. M1 macrophage exosomes engineered to foster M1 \npolarization and target the IL-4 receptor inhibit tumor growth by reprogram-\nming tumor-associated macrophages into M1-like macrophages. Biomateri-\nals. 2021;278:121137.\n488. Cheng L, et al. Gene-engineered exosomes-thermosensitive liposomes \nhybrid nanovesicles by the blockade of CD47 signal for combined photother -\nmal therapy and cancer immunotherapy. Biomaterials. 2021;275:120964.\n489. Li J, et al. Dendritic cell derived exosomes loaded neoantigens for personal -\nized cancer immunotherapies. J Control Release.", "mimetype": "text/plain", "start_char_idx": 2668, "end_char_idx": 4267, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "261b2be3-e88a-4660-a2e7-4ed93f0cfa86": {"__data__": {"id_": "261b2be3-e88a-4660-a2e7-4ed93f0cfa86", "embedding": null, "metadata": {"page_label": "46", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "efdc7e73-93b5-4b14-8f55-54d4edd305b8", "node_type": "4", "metadata": {"page_label": "46", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "258e321a642865cd5b2b9e7527e45a884d2c4ae18eb26f85bb4441eaff335d7e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "13141e2a-e8ab-4a32-b621-3155812403f9", "node_type": "1", "metadata": {"page_label": "46", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "c30dd53d24ca0a0165d240426bb46ef14d416c217dea2f973323b5f626495793", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cf27b335-c15e-40c5-95ff-fa067d425e28", "node_type": "1", "metadata": {}, "hash": "fb376cd7946d616d5816a56b964df05021079665160d0d679b3754089ada3d36", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "2021;275:120964.\n489. Li J, et al. Dendritic cell derived exosomes loaded neoantigens for personal -\nized cancer immunotherapies. J Control Release. 2023;353:423\u201333.\n490. Xu J, et al. Enhanced penetrative siRNA delivery by a nanodiamond drug \ndelivery platform against hepatocellular carcinoma 3D models. Nanoscale. \n2021;13(38):16131\u201345.\n491. Jiang H, et al. M1 macrophage-derived exosomes and their key molecule \nlncRNA HOTTIP suppress head and neck squamous cell carcinoma progres -\nsion by upregulating the TLR5/NF-\u03baB pathway. Cell Death Dis. 2022;13(2):183.\n492. Zhou WJ, et al. CD45RO(-)CD8(+) T cell-derived exosomes restrict estrogen-\ndriven endometrial cancer development via the ER\u03b2/miR-765/PLP2/Notch \naxis. Theranostics. 2021;11(11):5330\u201345.\n493. Cheng L, et al. Multifunctional hybrid exosomes enhanced cancer \nchemo-immunotherapy by activating the STING pathway. Biomaterials. \n2023;301:122259.\n494. Wang X et al. Exosomes derived from \u03b3\u03b4-T cells synergize with radiotherapy \nand preserve antitumor activities against nasopharyngeal carcinoma in \nimmunosuppressive microenvironment. J Immunother Cancer, 2022. 10(2).\n495. Ji P , et al. Smart exosomes with lymph node homing and immune-amplifying \ncapacities for enhanced immunotherapy of metastatic breast cancer. Mol \nTher Nucleic Acids. 2021;26:987\u201396.\n496. Fan M, et al. A CAR T-inspiring platform based on antibody-engineered exo-\nsomes from antigen-feeding dendritic cells for precise solid tumor therapy. \nBiomaterials. 2022;282:121424.", "mimetype": "text/plain", "start_char_idx": 4119, "end_char_idx": 5625, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "cf27b335-c15e-40c5-95ff-fa067d425e28": {"__data__": {"id_": "cf27b335-c15e-40c5-95ff-fa067d425e28", "embedding": null, "metadata": {"page_label": "46", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "efdc7e73-93b5-4b14-8f55-54d4edd305b8", "node_type": "4", "metadata": {"page_label": "46", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "258e321a642865cd5b2b9e7527e45a884d2c4ae18eb26f85bb4441eaff335d7e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "261b2be3-e88a-4660-a2e7-4ed93f0cfa86", "node_type": "1", "metadata": {"page_label": "46", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "2edb3346af586577a5ee3ead4a59c7cb45d504b0a213ef72649e3f0522a8ebd3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6599f5e6-15b3-4400-9298-35e6184639fa", "node_type": "1", "metadata": {}, "hash": "867efe897e41cb586ab631f4d561f2efb2328f3446fe14c69a5974edfa7727b6", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "A CAR T-inspiring platform based on antibody-engineered exo-\nsomes from antigen-feeding dendritic cells for precise solid tumor therapy. \nBiomaterials. 2022;282:121424.\n497. Li Y, et al. A nanotherapeutic system for gastric cancer suppression by \nsynergistic chemotherapy and immunotherapy based on iPSCs and DCs \nexosomes. Cancer Immunol Immunother. 2023;72(6):1673\u201383.\n498. Huang H, et al. Synergistic strategy with hyperthermia therapy based immu-\nnotherapy and engineered exosomes-liposomes targeted chemotherapy \nprevents tumor recurrence and metastasis in advanced breast cancer. Bioeng \nTransl Med. 2022;7(2):e10284.\n499. Pakravan N, Abbasi A, Hassan ZM. Immunotherapy using oxygenated water \nand tumor-derived exosomes potentiates antitumor immune response and \nattenuates malignancy tendency in mice model of breast cancer oxid med \ncell longev, 2021;2021:5529484.\n500. Javeed N, et al. Immunosuppressive CD14(+)HLA-DR(lo/neg) monocytes \nare elevated in pancreatic cancer and primed by tumor-derived exosomes. \nOncoimmunology. 2017;6(1):e1252013.\n501. Zhao Y, et al. Docetaxel-loaded M1 macrophage-derived exosomes for a safe \nand efficient chemoimmunotherapy of breast cancer. J Nanobiotechnol. \n2022;20(1):359.\n502. Lin J, et al. Dendritic cell-derived exosomes Driven Drug Co-delivery \nBiomimetic Nanosystem for Effective Combination of Malignant Melanoma \nImmunotherapy and Gene Therapy. Drug Des Devel Ther. 2023;17:2087\u2013106.\n503. Wang D, et al. Sonodynamical reversion of immunosuppressive micro-\nenvironment in prostate cancer via engineered exosomes. Drug Deliv. \n2022;29(1):702\u201313.", "mimetype": "text/plain", "start_char_idx": 5457, "end_char_idx": 7056, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "6599f5e6-15b3-4400-9298-35e6184639fa": {"__data__": {"id_": "6599f5e6-15b3-4400-9298-35e6184639fa", "embedding": null, "metadata": {"page_label": "46", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "efdc7e73-93b5-4b14-8f55-54d4edd305b8", "node_type": "4", "metadata": {"page_label": "46", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "258e321a642865cd5b2b9e7527e45a884d2c4ae18eb26f85bb4441eaff335d7e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cf27b335-c15e-40c5-95ff-fa067d425e28", "node_type": "1", "metadata": {"page_label": "46", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "501b15c2cc2747087f6842afc2391c11e9f185f42f8350d844f6f681a488ce1f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "58b04eb3-8626-4be7-9353-20523afad44a", "node_type": "1", "metadata": {}, "hash": "44619c684c5b944aedcdd8cd84e576b29814d82ce404f86f688e8b9fd3204eda", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "503. Wang D, et al. Sonodynamical reversion of immunosuppressive micro-\nenvironment in prostate cancer via engineered exosomes. Drug Deliv. \n2022;29(1):702\u201313.\n504. Zhang Y et al. pH-Responsive STING-Activating DNA nanovaccines for Cancer \nImmunotherapy. Adv Ther (Weinh), 2020. 3(9).\n505. Yao D, et al. A self-cascaded unimolecular prodrug for pH-responsive chemo -\ntherapy and tumor-detained photodynamic-immunotherapy of triple-nega-\ntive breast cancer. Biomaterials. 2023;292:121920.\n506. Liu Y, et al. Dual pH-responsive multifunctional nanoparticles for targeted \ntreatment of breast cancer by combining immunotherapy and chemother -\napy. Acta Biomater. 2018;66:310\u201324.\n507. Lim B, Kim KS, Na K. pH-Responsive zinc Ion regulating Immunomodulatory \nnanoparticles for Effective Cancer Immunotherapy. Biomacromolecules. \n2023;24(9):4263\u201373.\n508. Duong HTT, et al. Smart vaccine delivery based on microneedle arrays \ndecorated with ultra-ph-responsive copolymers for cancer immunotherapy. \nBiomaterials. 2018;185:13\u201324.\n509. Gu J, et al. Injectable pH-responsive hydrogel for combinatorial chemoim -\nmunotherapy tailored to the tumor microenvironment. J Nanobiotechnol. \n2022;20(1):372.\n510. Gong C, et al. Regulating the immunosuppressive tumor microenvironment \nto enhance breast cancer immunotherapy using pH-responsive hybrid \nmembrane-coated nanoparticles. J Nanobiotechnol. 2021;19(1):58.\n511. Ding Y, et al. Construction of pH-Sensitive nanovaccines encapsulating \ntumor cell lysates and Immune adjuvants for breast Cancer therapy. Small. \n2023;19(37):e2301420.\n512.", "mimetype": "text/plain", "start_char_idx": 6897, "end_char_idx": 8472, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "58b04eb3-8626-4be7-9353-20523afad44a": {"__data__": {"id_": "58b04eb3-8626-4be7-9353-20523afad44a", "embedding": null, "metadata": {"page_label": "46", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "efdc7e73-93b5-4b14-8f55-54d4edd305b8", "node_type": "4", "metadata": {"page_label": "46", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "258e321a642865cd5b2b9e7527e45a884d2c4ae18eb26f85bb4441eaff335d7e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6599f5e6-15b3-4400-9298-35e6184639fa", "node_type": "1", "metadata": {"page_label": "46", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "49346d000427c0b3f1053d7f051ae4575aee0a453451364ced9856bf4a5d2c7b", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Construction of pH-Sensitive nanovaccines encapsulating \ntumor cell lysates and Immune adjuvants for breast Cancer therapy. Small. \n2023;19(37):e2301420.\n512. Jiang M, et al. Sequentially pH-Responsive drug-delivery Nanosystem for \nTumor Immunogenic Cell Death and cooperating with Immune checkpoint \nblockade for efficient Cancer Chemoimmunotherapy. ACS Appl Mater Inter -\nfaces. 2021;13(37):43963\u201374.\n513. Yang G, et al. Smart Nanoreactors for pH-Responsive Tumor Homing, \nMitochondria-Targeting, and enhanced photodynamic-immunotherapy of \nCancer. Nano Lett. 2018;18(4):2475\u201384.\n514. Sun X, et al. Binary regulation of the tumor microenvironment by a pH-\nresponsive reversible shielding nanoplatform for improved tumor chemo-\nimmunotherapy. Acta Biomater. 2022;138:505\u201317.", "mimetype": "text/plain", "start_char_idx": 8314, "end_char_idx": 9089, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "4834e53d-2136-45a5-bee3-e350c25bc308": {"__data__": {"id_": "4834e53d-2136-45a5-bee3-e350c25bc308", "embedding": null, "metadata": {"page_label": "47", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "ef7a8cb3-c404-4478-bfd6-d48cc93996ff", "node_type": "4", "metadata": {"page_label": "47", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "d18a07df6c5c3c397101ca7a308fb7ebf9a5894d2bda2a54f85b3f27541a1ca4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b0fa056b-b183-496b-8430-1f264752c904", "node_type": "1", "metadata": {}, "hash": "eca57d43a48985952a3dcbfce3f12e7cbc9e8a9c348c44c1f17937fb4e78b66e", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Page 47 of 48\nLu et al. Journal of Hematology & Oncology            (2024) 17:16 \n515. Lv X, et al. Multi-signaling pathway activation by pH responsive manganese \nparticles for enhanced vaccination. J Control Release. 2023;357:109\u201319.\n516. Wagner J, et al. Mesoporous silica nanoparticles as pH-Responsive carrier \nfor the Immune-Activating Drug Resiquimod enhance the local Immune \nresponse in mice. ACS Nano. 2021;15(3):4450\u201366.\n517. Zhao M, et al. Immune/Hypoxic Tumor Microenvironment Regulation-\nenhanced photodynamic treatment realized by pH-Responsive \nphase Transition-Targeting Nanobubbles. ACS Appl Mater Interfaces. \n2021;13(28):32763\u201379.\n518. Yuba E, et al. The application of pH-sensitive polymer-lipids to antigen deliv-\nery for cancer immunotherapy. Biomaterials. 2013;34(22):5711\u201321.\n519. Yoshizaki Y, et al. Potentiation of pH-sensitive polymer-modified liposomes \nwith cationic lipid inclusion as antigen delivery carriers for cancer immuno-\ntherapy. Biomaterials. 2014;35(28):8186\u201396.\n520. Yuba E, et al. A liposome-based antigen delivery system using pH-\nsensitive fusogenic polymers for cancer immunotherapy. Biomaterials. \n2013;34(12):3042\u201352.\n521. Yoshizaki Y, et al. pH-sensitive polymer-modified liposome-based immunity-\ninducing system: effects of inclusion of cationic lipid and CpG-DNA. Biomate -\nrials. 2017;141:272\u201383.\n522. Zhang J, et al. pH-sensitive tumor-tropism hybrid membrane-coated \nnanoparticles for reprogramming the tumor microenvironment and boost-\ning the antitumor immunity. Acta Biomater. 2023;166:470\u201384.\n523. Yuba E, et al.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1570, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "b0fa056b-b183-496b-8430-1f264752c904": {"__data__": {"id_": "b0fa056b-b183-496b-8430-1f264752c904", "embedding": null, "metadata": {"page_label": "47", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "ef7a8cb3-c404-4478-bfd6-d48cc93996ff", "node_type": "4", "metadata": {"page_label": "47", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "d18a07df6c5c3c397101ca7a308fb7ebf9a5894d2bda2a54f85b3f27541a1ca4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4834e53d-2136-45a5-bee3-e350c25bc308", "node_type": "1", "metadata": {"page_label": "47", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "decba4c4e37c3ba24df1bd17dbc62398795972f832405eec46e8b76729ec44c2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ad53ef8f-c34e-4a00-8735-654440ff0bcd", "node_type": "1", "metadata": {}, "hash": "75d12b832fbe25e28f6fd598abe8b7c90443e1def63f3dbac284771bb004932a", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Acta Biomater. 2023;166:470\u201384.\n523. Yuba E, et al. Bioactive polysaccharide-based pH-sensitive polymers for \ncytoplasmic delivery of antigen and activation of antigen-specific immunity. \nBiomaterials. 2017;120:32\u201345.\n524. Kocabas BB, et al. Dual-adjuvant effect of pH-sensitive liposomes loaded \nwith STING and TLR9 agonists regress tumor development by enhancing Th1 \nimmune response. J Control Release. 2020;328:587\u201395.\n525. Zhang W, et al. Multifunctional redox-responsive nanoplatform with Dual \nActivation of Macrophages and T Cells for Antitumor Immunotherapy. ACS \nNano. 2023;17(15):14424\u201341.\n526. Yan P , et al. A redox-responsive Nanovaccine combined with A2A \nreceptor antagonist for Cancer Immunotherapy. Adv Healthc Mater. \n2021;10(21):e2101222.\n527. Lv M, et al. Redox-responsive hyperbranched poly(amido amine) and poly -\nmer dots as a vaccine delivery system for cancer immunotherapy. J Mater \nChem B. 2017;5(48):9532\u201345.\n528. Jiang D, et al. Cascade Cytosol Delivery of Dual-Sensitive Micelle-tailored \nvaccine for Enhancing Cancer Immunotherapy. ACS Appl Mater Interfaces. \n2018;10(44):37797\u2013811.\n529. Chen Q, et al. Cancer cell membrane-coated nanoparticles for bimodal \nimaging-guided photothermal therapy and docetaxel-enhanced immuno -\ntherapy against cancer. J Nanobiotechnol. 2021;19(1):449.\n530. Chen L, et al. Tumor-targeted drug and CpG delivery system for Pho -\ntotherapy and Docetaxel-enhanced immunotherapy with polarization \ntoward M1-Type macrophages on Triple negative breast cancers. Adv Mater. \n2019;31(52):e1904997.\n531.", "mimetype": "text/plain", "start_char_idx": 1519, "end_char_idx": 3075, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "ad53ef8f-c34e-4a00-8735-654440ff0bcd": {"__data__": {"id_": "ad53ef8f-c34e-4a00-8735-654440ff0bcd", "embedding": null, "metadata": {"page_label": "47", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "ef7a8cb3-c404-4478-bfd6-d48cc93996ff", "node_type": "4", "metadata": {"page_label": "47", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "d18a07df6c5c3c397101ca7a308fb7ebf9a5894d2bda2a54f85b3f27541a1ca4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b0fa056b-b183-496b-8430-1f264752c904", "node_type": "1", "metadata": {"page_label": "47", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "94abac957383abdcdd4a139a591ee73a6e2e177e3773785ab867d092962a3c2a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "be6c3c81-dc82-429c-97a7-1b82b69f0e83", "node_type": "1", "metadata": {}, "hash": "5e4fab269b443bb5ae0e5204f024b0813084c3071d7fefb0e1fc5e6fa4d4b974", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Adv Mater. \n2019;31(52):e1904997.\n531. Sun Y, et al. An enzyme-responsive and transformable PD-L1 blocking \npeptide-photosensitizer conjugate enables efficient photothermal immuno -\ntherapy for breast cancer. Bioact Mater. 2023;22:47\u201359.\n532. Ma S, et al. Boosting cancer immunotherapy by biomineralized nanovac-\ncine with ferroptosis-inducing and photothermal properties. Biomater Sci. \n2023;11(2):518\u201332.\n533. Xiao Y, et al. Microenvironment-responsive prodrug-induced pyroptosis \nboosts cancer immunotherapy. Adv Sci (Weinh). 2021;8(24):e2101840.\n534. Wu X, et al. Nano-herb medicine and PDT induced synergistic immunother -\napy for colon cancer treatment. Biomaterials. 2021;269:120654.\n535. Ding D, et al. Multifunctional Nanodrug mediates synergistic photodynamic \ntherapy and MDSCs-Targeting immunotherapy of Colon cancer. Adv Sci \n(Weinh). 2021;8(14):e2100712.\n536. Zhou H, et al. A tumor-microenvironment-activatable Molecular Pro-ther-\nanostic Agent for Photodynamic and Immunotherapy of Cancer. Adv Mater. \n2023;35(30):e2211485.\n537. Yu Y, et al. Polymeric PD-L1 blockade nanoparticles for cancer photothermal-\nimmunotherapy. Biomaterials. 2022;280:121312.\n538. Liang X, et al. Photothermal cancer immunotherapy by erythrocyte \nmembrane-coated black phosphorus formulation. J Control Release. \n2019;296:150\u201361.\n539. Zhang R, et al. Chemodynamic/Photothermal synergistic Cancer immuno-\ntherapy based on yeast microcapsule-derived Au/Pt nanoparticles. ACS Appl \nMater Interfaces. 2023;15(20):24134\u201348.\n540.", "mimetype": "text/plain", "start_char_idx": 3037, "end_char_idx": 4552, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "be6c3c81-dc82-429c-97a7-1b82b69f0e83": {"__data__": {"id_": "be6c3c81-dc82-429c-97a7-1b82b69f0e83", "embedding": null, "metadata": {"page_label": "47", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "ef7a8cb3-c404-4478-bfd6-d48cc93996ff", "node_type": "4", "metadata": {"page_label": "47", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "d18a07df6c5c3c397101ca7a308fb7ebf9a5894d2bda2a54f85b3f27541a1ca4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ad53ef8f-c34e-4a00-8735-654440ff0bcd", "node_type": "1", "metadata": {"page_label": "47", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "22c0bb732ab40ea59d44f0400c7a43bb67e5018fc665ace20e17e0dcf0dec154", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "72b34996-2125-4abb-823e-d5865aed94db", "node_type": "1", "metadata": {}, "hash": "e54ae76345a1cfdb670029857d28264984ef23ec1324edc9490579b67ea3e7b6", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Chemodynamic/Photothermal synergistic Cancer immuno-\ntherapy based on yeast microcapsule-derived Au/Pt nanoparticles. ACS Appl \nMater Interfaces. 2023;15(20):24134\u201348.\n540. Wang M, et al. Synergistic interventional photothermal therapy and immu-\nnotherapy using an iron oxide nanoplatform for the treatment of pancreatic \ncancer. Acta Biomater. 2022;138:453\u201362.\n541. Debele TA, Yeh C-F, Su W-P . Cancer immunotherapy and application of \nnanoparticles in cancers immunotherapy as the delivery of immunothera -\npeutic agents and as the immunomodulators. Cancers. 2020;12(12):3773.\n542. Zhang C, et al. Checkpoint Nano-PROTACs for Activatable Cancer Photo-\nImmunotherapy. Adv Mater. 2023;35(6):e2208553.\n543. Qiu W, et al. Immunomodulatory-photodynamic nanostimulators for invok-\ning pyroptosis to augment Tumor Immunotherapy. Adv Healthc Mater. \n2022;11(21):e2201233.\n544. Zhou JY, et al. Ru(II)-modified TiO(2) nanoparticles for hypoxia-adaptive \nphoto-immunotherapy of oral squamous cell carcinoma. Biomaterials. \n2022;289:121757.\n545. Duan Y, et al. Immune Modulator and Low-Temperature PTT-Induced \nSynergistic Immunotherapy for Cancer Treatment. ACS Appl Bio Mater. \n2021;4(2):1524\u201335.\n546. Yan T, et al. Synergistic photothermal cancer immunotherapy by Cas9 \nribonucleoprotein-based copper sulfide nanotherapeutic platform targeting \nPTPN2. Biomaterials. 2021;279:121233.\n547. Li J, et al. Second Near-Infrared Photothermal Semiconducting poly-\nmer nanoadjuvant for enhanced Cancer Immunotherapy. Adv Mater.", "mimetype": "text/plain", "start_char_idx": 4380, "end_char_idx": 5891, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "72b34996-2125-4abb-823e-d5865aed94db": {"__data__": {"id_": "72b34996-2125-4abb-823e-d5865aed94db", "embedding": null, "metadata": {"page_label": "47", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "ef7a8cb3-c404-4478-bfd6-d48cc93996ff", "node_type": "4", "metadata": {"page_label": "47", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "d18a07df6c5c3c397101ca7a308fb7ebf9a5894d2bda2a54f85b3f27541a1ca4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "be6c3c81-dc82-429c-97a7-1b82b69f0e83", "node_type": "1", "metadata": {"page_label": "47", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "ddd1be0e470e8e4463bb353b4eaeccd5cc28e659aa711d0ebe7b9caf7f8f3335", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "31ba9be0-5c48-4471-9e98-73f85d7deebc", "node_type": "1", "metadata": {}, "hash": "58595a98f52c05ea07a4d5e25d78ed44df15032883f3ba1a0842867235fdb18d", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "2021;279:121233.\n547. Li J, et al. Second Near-Infrared Photothermal Semiconducting poly-\nmer nanoadjuvant for enhanced Cancer Immunotherapy. Adv Mater. \n2021;33(4):e2003458.\n548. Jana D et al. A defect-Engineered Nanozyme for targeted NIR-II Photothermal \nImmunotherapy of Cancer. Adv Mater, 2022: p. e2206401.\n549. Hwang J, et al. Escherichia coli Mimetic Gold nanorod-mediated photo- \nand immunotherapy for Treating Cancer and its metastasis. ACS Nano. \n2022;16(5):8472\u201383.\n550. Tang Y, et al. Pyroptosis-mediated synergistic photodynamic and photother-\nmal immunotherapy enabled by a tumor-membrane-targeted photosensi -\ntive dimer. Adv Mater. 2023;35(25):e2300232.\n551. Xu M, et al. Activatable Immunoprotease Nanorestimulator for Second \nNear-Infrared Photothermal Immunotherapy of Cancer. ACS Nano. \n2023;17(9):8183\u201394.\n552. Wang M, et al. NIR-Triggered Phototherapy and Immunotherapy via an \nAntigen-capturing nanoplatform for metastatic Cancer treatment. Adv Sci \n(Weinh). 2019;6(10):1802157.\n553. Ye X, et al. Surgical Tumor-Derived Personalized Photothermal Vaccine For-\nmulation for Cancer Immunotherapy. ACS Nano. 2019;13(3):2956\u201368.\n554. Wang S, et al. Photothermal therapy mediated by gold nanocages composed \nof anti-PDL1 and galunisertib for improved synergistic immunotherapy in \ncolorectal cancer. Acta Biomater. 2021;134:621\u201332.\n555. Mikelez-Alonso I, Aires A, Cortajarena AL. Cancer nano-immunotherapy \nfrom the injection to the target: the role of protein corona.", "mimetype": "text/plain", "start_char_idx": 5739, "end_char_idx": 7224, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "31ba9be0-5c48-4471-9e98-73f85d7deebc": {"__data__": {"id_": "31ba9be0-5c48-4471-9e98-73f85d7deebc", "embedding": null, "metadata": {"page_label": "47", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "ef7a8cb3-c404-4478-bfd6-d48cc93996ff", "node_type": "4", "metadata": {"page_label": "47", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "d18a07df6c5c3c397101ca7a308fb7ebf9a5894d2bda2a54f85b3f27541a1ca4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "72b34996-2125-4abb-823e-d5865aed94db", "node_type": "1", "metadata": {"page_label": "47", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "acb369a570e62e92bb56ff610996d7936b5c66b4a4ff59e3a2c534af9051cda6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7b656c36-d895-42d5-a60a-1bd576b871bb", "node_type": "1", "metadata": {}, "hash": "7dd6ab703009b9cbf25856e614aaf269b14d165ba3fce29d0b516f99af7c9696", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "2021;134:621\u201332.\n555. Mikelez-Alonso I, Aires A, Cortajarena AL. Cancer nano-immunotherapy \nfrom the injection to the target: the role of protein corona. Int J Mol Sci. \n2020;21(2):519.\n556. Yetisgin AA et al. Therapeutic nanoparticles and their targeted delivery appli-\ncations. Molecules, 2020. 25(9).\n557. Anselmo AC, Mitragotri S. Nanoparticles in the clinic: an update. Bioeng \nTransl Med. 2019;4(3):e10143.\n558. Kranz LM, et al. Systemic RNA delivery to dendritic cells exploits antiviral \ndefence for cancer immunotherapy. Nature. 2016;534(7607):396\u2013401.\n559. Beg MS, et al. Phase I study of MRX34, a liposomal miR-34a mimic, admin-\nistered twice weekly in patients with advanced solid tumors. Invest New \nDrugs. 2017;35(2):180\u20138.\n560. Burris III et al. H.A., A phase 1, open-label, multicenter study to assess the \nsafety, tolerability, and immunogenicity of mRNA-4157 alone in subjects with \nresected solid tumors and in combination with pembrolizumab in subjects \nwith unresectable solid tumors (Keynote-603). 2019, American Society of \nClinical Oncology.\n561. Pfannenstiel LW, et al. Paclitaxel enhances early dendritic cell maturation and \nfunction through TLR4 signaling in mice. Cell Immunol. 2010;263(1):79\u201387.\n562. Graziani SR, et al. Phase II study of paclitaxel associated with lipid core \nnanoparticles (LDE) as third-line treatment of patients with epithelial ovarian \ncarcinoma. Med Oncol. 2017;34:1\u20137.\n563. Shen C, et al.", "mimetype": "text/plain", "start_char_idx": 7071, "end_char_idx": 8514, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "7b656c36-d895-42d5-a60a-1bd576b871bb": {"__data__": {"id_": "7b656c36-d895-42d5-a60a-1bd576b871bb", "embedding": null, "metadata": {"page_label": "47", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "ef7a8cb3-c404-4478-bfd6-d48cc93996ff", "node_type": "4", "metadata": {"page_label": "47", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "d18a07df6c5c3c397101ca7a308fb7ebf9a5894d2bda2a54f85b3f27541a1ca4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "31ba9be0-5c48-4471-9e98-73f85d7deebc", "node_type": "1", "metadata": {"page_label": "47", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "e74007933ae893529e19f4183530fbc55c68bdf70d860b0a9fb8d52e284e7212", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Med Oncol. 2017;34:1\u20137.\n563. Shen C, et al. Phase I study of NBTXR3 activated by radiotherapy in patients \nwith advanced cancers treated with an anti-PD-1 therapy. American Society \nof Clinical Oncology; 2020.\n564. Li S, et al. Polymer nanoparticles as adjuvants in cancer immunotherapy. \nNano Res. 2018;11:5769\u201386.\n565. Thakur N, et al. Nanoparticles as smart carriers for enhanced Cancer Immuno-\ntherapy. Front Chem. 2020;8:597806.\n566. Zhao L, et al. Nanoparticle vaccines. Vaccine. 2014;32(3):327\u201337.", "mimetype": "text/plain", "start_char_idx": 8471, "end_char_idx": 8975, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "6bdff43a-0693-4707-8fb1-010e9a2cdcb2": {"__data__": {"id_": "6bdff43a-0693-4707-8fb1-010e9a2cdcb2", "embedding": null, "metadata": {"page_label": "48", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "27abbbdc-485a-4983-9ac7-0666588bd8f7", "node_type": "4", "metadata": {"page_label": "48", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "a8cad37288a5659c5ea38d1a8f459db0c54cc486efb61c8b0d8b4fedf05f2c29", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f5f29c4e-0f26-44e5-a81c-3d879b5c49d6", "node_type": "1", "metadata": {}, "hash": "cd6695e54f959ec0d8fb6c87a7648cd3b5b71ad7a95dcca79c42ab42f92da13d", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Page 48 of 48\nLu et al. Journal of Hematology & Oncology            (2024) 17:16 \n567. Chen P-G, et al. Chitosan nanoparticles based nanovaccines for cancer \nimmunotherapy. Pure Appl Chem. 2017;89(7):931\u20139.\n568. Shi GN, et al. Enhanced antitumor immunity by targeting dendritic cells \nwith tumor cell lysate-loaded chitosan nanoparticles vaccine. Biomaterials. \n2017;113:191\u2013202.\n569. Yang R, et al. Cancer Cell membrane-coated adjuvant nanoparticles with \nmannose modification for effective anticancer vaccination. ACS Nano. \n2018;12(6):5121\u20139.\n570. Kim H, et al. Polymeric nanoparticles encapsulating novel TLR7/8 agonists \nas immunostimulatory adjuvants for enhanced cancer immunotherapy. \nBiomaterials. 2018;164:38\u201353.\n571. Banerjee R. Liposomes: applications in medicine. J Biomater Appl. \n2001;16(1):3\u201321.\n572. Klinguer-Hamour C, et al. DDA adjuvant induces a mixed Th1/Th2 immune \nresponse when associated with BBG2Na, a respiratory syncytial virus poten-\ntial vaccine. Vaccine. 2002;20(21\u201322):2743\u201351.\n573. Christensen D, et al. Cationic liposomes as vaccine adjuvants. Expert Rev Vac-\ncines. 2011;10(4):513\u201321.\n574. Korsholm KS, et al. The adjuvant mechanism of cationic dimethyldioctadecyl-\nammonium liposomes. Immunology. 2007;121(2):216\u201326.\n575. Zamani P , et al. Nanoliposomes as the adjuvant delivery systems in cancer \nimmunotherapy. J Cell Physiol. 2018;233(7):5189\u201399.\n576.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1390, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "f5f29c4e-0f26-44e5-a81c-3d879b5c49d6": {"__data__": {"id_": "f5f29c4e-0f26-44e5-a81c-3d879b5c49d6", "embedding": null, "metadata": {"page_label": "48", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "27abbbdc-485a-4983-9ac7-0666588bd8f7", "node_type": "4", "metadata": {"page_label": "48", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "a8cad37288a5659c5ea38d1a8f459db0c54cc486efb61c8b0d8b4fedf05f2c29", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6bdff43a-0693-4707-8fb1-010e9a2cdcb2", "node_type": "1", "metadata": {"page_label": "48", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "8c9906e9dccc2034c8f86243c541a4864ca2afa98dfd7bb0168983928ebc1806", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2317ffc9-03ba-438a-9367-1968cac06888", "node_type": "1", "metadata": {}, "hash": "645a968aff2f3f3735c5350707b9959c27de2560570b4516fb87667599071937", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Zamani P , et al. Nanoliposomes as the adjuvant delivery systems in cancer \nimmunotherapy. J Cell Physiol. 2018;233(7):5189\u201399.\n576. Yuba E, et al. Dextran derivative-based pH-sensitive liposomes for cancer \nimmunotherapy. Biomaterials. 2014;35(9):3091\u2013101.\n577. Zeng Q, et al. Tailoring polymeric hybrid micelles with lymph node \ntargeting ability to improve the potency of cancer vaccines. Biomaterials. \n2017;122:105\u201313.\n578. de Faria PC, et al. Oxidized multiwalled carbon nanotubes as antigen delivery \nsystem to promote superior CD8(+) T cell response and protection against \ncancer. Nano Lett. 2014;14(9):5458\u201370.\n579. Hassan HA, et al. Dual stimulation of antigen presenting cells using carbon \nnanotube-based vaccine delivery system for cancer immunotherapy. Bioma -\nterials. 2016;104:310\u201322.\n580. Zhou Q, et al. Different-sized gold nanoparticle Activator/Antigen increases \ndendritic cells Accumulation in Liver-Draining Lymph Nodes and CD8 + T cell \nresponses. ACS Nano. 2016;10(2):2678\u201392.\n581. Fallarini S, et al. Factors affecting T cell responses induced by fully synthetic \nglyco-gold-nanoparticles. Nanoscale. 2013;5(1):390\u2013400.\n582. Dykman LA, et al. Gold nanoparticles as an adjuvant: influence of size, shape, \nand technique of combination with CpG on antibody production. Int Immu -\nnopharmacol. 2018;54:163\u20138.\n583. Melamed JR, et al. Using gold nanoparticles to disrupt the Tumor Microenvi -\nronment: an emerging therapeutic strategy. ACS Nano. 2016;10(12):10631\u20135.\n584. Saha S, et al.", "mimetype": "text/plain", "start_char_idx": 1258, "end_char_idx": 2766, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "2317ffc9-03ba-438a-9367-1968cac06888": {"__data__": {"id_": "2317ffc9-03ba-438a-9367-1968cac06888", "embedding": null, "metadata": {"page_label": "48", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "27abbbdc-485a-4983-9ac7-0666588bd8f7", "node_type": "4", "metadata": {"page_label": "48", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "a8cad37288a5659c5ea38d1a8f459db0c54cc486efb61c8b0d8b4fedf05f2c29", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f5f29c4e-0f26-44e5-a81c-3d879b5c49d6", "node_type": "1", "metadata": {"page_label": "48", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "3de5313fae54ce1224d35ec94806bc078a48db95e41b382e033b75d8f88fbed4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eefdf0d9-7940-427e-b6d9-95510bf42b21", "node_type": "1", "metadata": {}, "hash": "6155cd2d1b460aea57690f23515db54c40727b96ba2e991e60732faadfac9d87", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Using gold nanoparticles to disrupt the Tumor Microenvi -\nronment: an emerging therapeutic strategy. ACS Nano. 2016;10(12):10631\u20135.\n584. Saha S, et al. Gold nanoparticle reprograms pancreatic Tumor Microenviron-\nment and inhibits Tumor Growth. ACS Nano. 2016;10(12):10636\u201351.\n585. Luo J, et al. Self-assembled CpG oligodeoxynucleotides conjugated hollow \ngold nanospheres to enhance cancer-associated immunostimulation. Col-\nloids Surf B Biointerfaces. 2019;175:248\u201355.\n586. Ow H, et al. Bright and stable core-shell fluorescent silica nanoparticles. Nano \nLett. 2005;5(1):113\u20137.\n587. Benezra M, et al. Multimodal silica nanoparticles are effective cancer-targeted \nprobes in a model of human melanoma. J Clin Invest. 2011;121(7):2768\u201380.\n588. Chattopadhyay S, et al. Nanoparticle vaccines adopting virus-like features for \nenhanced Immune Potentiation. Nanotheranostics. 2017;1(3):244\u201360.\n589. Mahony D, et al. Mesoporous silica nanoparticles act as a self-adjuvant for \novalbumin model antigen in mice. Small. 2013;9(18):3138\u201346.\n590. Selvaraja VK, Gudipudi DK. Fundamentals to clinical application of nanopar-\nticles in cancer immunotherapy and radiotherapy. Ecancermedicalscience. \n2020;14:1095.\n591. Saeed M, et al. Engineering nanoparticles to reprogram the Tumor Immune \nMicroenvironment for Improved Cancer Immunotherapy. Theranostics. \n2019;9(26):7981\u20138000.\n592. Libutti SK, et al.", "mimetype": "text/plain", "start_char_idx": 2615, "end_char_idx": 4005, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "eefdf0d9-7940-427e-b6d9-95510bf42b21": {"__data__": {"id_": "eefdf0d9-7940-427e-b6d9-95510bf42b21", "embedding": null, "metadata": {"page_label": "48", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "27abbbdc-485a-4983-9ac7-0666588bd8f7", "node_type": "4", "metadata": {"page_label": "48", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "a8cad37288a5659c5ea38d1a8f459db0c54cc486efb61c8b0d8b4fedf05f2c29", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2317ffc9-03ba-438a-9367-1968cac06888", "node_type": "1", "metadata": {"page_label": "48", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "c7795af797ba08ec497b0a229609b6f55047e27581db857e5f3d7fe8fd2a559f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2bc5072d-d23f-47b4-b3cf-01a85ebe6aac", "node_type": "1", "metadata": {}, "hash": "4e0248b96541adcfecff2119014056c611c73283462652f553fba21ee0539144", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Theranostics. \n2019;9(26):7981\u20138000.\n592. Libutti SK, et al. Phase I and pharmacokinetic studies of CYT-6091, a \nnovel PEGylated colloidal gold-rhTNF nanomedicine. Clin Cancer Res. \n2010;16(24):6139\u201349.\n593. Wang S, Sun Z, Hou Y. Engineering nanoparticles toward the modulation of \nemerging cancer immunotherapy. Adv Healthc Mater. 2021;10(5):2000845.\n594. Chiang CL-L, Coukos G, Kandalaft LE. Whole tumor antigen vaccines: where \nare we? Vaccines. 2015;3(2):344\u201372.\n595. Prasad S, et al. Polymer nanoparticles containing tumor lysates as antigen \ndelivery vehicles for dendritic cell\u2013based antitumor immunotherapy. Nano -\nmed Nanotechnol Biol Med. 2011;7(1):1\u201310.\n596. Higashisaka K, et al. Nano-safety research: examining the associations among \nthe biological effects of nanoparticles and their physicochemical properties \nand kinetics. Biol Pharm Bull. 2017;40(3):243\u20138.\n597. Niu L, et al. Cytokine-mediated disruption of lymphocyte trafficking, hemo -\npoiesis, and induction of lymphopenia, anemia, and thrombocytopenia in \nanti-CD137-treated mice. J Immunol. 2007;178(7):4194\u2013213.\n598. Leonard JP , et al. Effects of single-dose interleukin-12 exposure on \ninterleukin-12-associated toxicity and interferon-gamma production. Blood. \n1997;90(7):2541\u20138.\n599. Di Giacomo AM, Biagioli M, Maio M. The emerging toxicity profiles \nof anti-CTLA-4 antibodies across clinical indications. Semin Oncol. \n2010;37(5):499\u2013507.\n600. Xia Q et al.", "mimetype": "text/plain", "start_char_idx": 3945, "end_char_idx": 5381, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "2bc5072d-d23f-47b4-b3cf-01a85ebe6aac": {"__data__": {"id_": "2bc5072d-d23f-47b4-b3cf-01a85ebe6aac", "embedding": null, "metadata": {"page_label": "48", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "27abbbdc-485a-4983-9ac7-0666588bd8f7", "node_type": "4", "metadata": {"page_label": "48", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "a8cad37288a5659c5ea38d1a8f459db0c54cc486efb61c8b0d8b4fedf05f2c29", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eefdf0d9-7940-427e-b6d9-95510bf42b21", "node_type": "1", "metadata": {"page_label": "48", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "8168870479fd46c55443fccfc28cf004cec43adcd7f69e623e4ca1a875fe05c4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d741d7e4-1e2f-4d12-9d21-699d0e754ec8", "node_type": "1", "metadata": {}, "hash": "7ea62b260c6ce442dfcd197c55f17577bd38fdc58da5f2bf4fc0e0cd8e8ddd3d", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Semin Oncol. \n2010;37(5):499\u2013507.\n600. Xia Q et al. Size-and cell type-dependent cellular uptake, cytotoxicity and in \nvivo distribution of gold nanoparticles. Int J Nanomed, 2019: p. 6957\u201370.\n601. Beki\u0107 M, et al. The effect of stabilisation agents on the immunomodulatory \nproperties of gold nanoparticles obtained by ultrasonic spray pyrolysis. \nMaterials. 2019;12(24):4121.\n602. Zhong Y, et al. In vivo molecular imaging for immunotherapy using \nultra-bright near-infrared-IIb rare-earth nanoparticles. Nat Biotechnol. \n2019;37(11):1322\u201331.\n603. Smith DM, Simon JK, Baker JR Jr. Applications of nanotechnology for immu-\nnology. Nat Rev Immunol. 2013;13(8):592\u2013605.\n604. Irvine DJ, Swartz MA, Szeto GL. Engineering synthetic vaccines using cues \nfrom natural immunity. Nat Mater. 2013;12(11):978\u201390.\n605. Kwong B, et al. Localized immunotherapy via liposome-anchored Anti-\nCD137 + IL-2 prevents lethal toxicity and elicits local and systemic antitumor \nimmunity. Cancer Res. 2013;73(5):1547\u201358.\n606. Kwong B, Liu H, Irvine DJ. Induction of potent anti-tumor responses while \neliminating systemic side effects via liposome-anchored combinatorial \nimmunotherapy. Biomaterials. 2011;32(22):5134\u201347.\n607. Liu H, et al. Structure-based programming of lymph-node targeting in \nmolecular vaccines. Nature. 2014;507(7493):519\u201322.\n608. Wu TY-H et al. Rational design of small molecules as vaccine adjuvants. Sci \nTransl Med, 2014. 6(263): p. 263ra160-263ra160.\n609.", "mimetype": "text/plain", "start_char_idx": 5330, "end_char_idx": 6788, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "d741d7e4-1e2f-4d12-9d21-699d0e754ec8": {"__data__": {"id_": "d741d7e4-1e2f-4d12-9d21-699d0e754ec8", "embedding": null, "metadata": {"page_label": "48", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "27abbbdc-485a-4983-9ac7-0666588bd8f7", "node_type": "4", "metadata": {"page_label": "48", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "a8cad37288a5659c5ea38d1a8f459db0c54cc486efb61c8b0d8b4fedf05f2c29", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2bc5072d-d23f-47b4-b3cf-01a85ebe6aac", "node_type": "1", "metadata": {"page_label": "48", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "8dd45dedefc1b6596200253c5726e4ff2c57cc42246ecd06576307b45d80d56c", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Rational design of small molecules as vaccine adjuvants. Sci \nTransl Med, 2014. 6(263): p. 263ra160-263ra160.\n609. Zolnik BS, et al. Nanoparticles and the immune system. Endocrinology. \n2010;151(2):458\u201365.\n610. Manolova V, et al. Nanoparticles target distinct dendritic cell populations \naccording to their size. Eur J Immunol. 2008;38(5):1404\u201313.\n611. Reddy ST, et al. Exploiting lymphatic transport and complement activation in \nnanoparticle vaccines. Nat Biotechnol. 2007;25(10):1159\u201364.\n612. Tkach AV, et al. Direct effects of carbon nanotubes on dendritic cells \ninduce immune suppression upon pulmonary exposure. ACS Nano. \n2011;5(7):5755\u201362.\n613. Ryan JJ, et al. Fullerene nanomaterials inhibit the allergic response. J Immu-\nnol. 2007;179(1):665\u201372.\nPublisher\u2019s Note\nSpringer Nature remains neutral with regard to jurisdictional claims in \npublished maps and institutional affiliations.", "mimetype": "text/plain", "start_char_idx": 6674, "end_char_idx": 7568, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "a42a0d5e-8326-4170-9c66-48a32c0ecf3c": {"__data__": {"id_": "a42a0d5e-8326-4170-9c66-48a32c0ecf3c", "embedding": null, "metadata": {"page_label": "1", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "793fdd24-7965-4ec3-b67b-002f28e312e3", "node_type": "4", "metadata": {"page_label": "1", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "b2486298939ec5ef3139be58b8d79c4a3364a20bb2aeb6a6c4d23676af0a7168", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "872fcdb6-1dd8-4ee6-91bf-0d5ef3ea0518", "node_type": "1", "metadata": {}, "hash": "22e4eee4a8a7057814ff5c87ac2368b202fd8c0e6d5199fab4599fa4bd5077ae", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "An Update on the Status of Vaccine\nDevelopment for SARS-CoV-2 Including\nVariants. Practical Considerations for\nCOVID-19 Special Populations\nBulent Kantarcioglu, MD1, Omer Iqbal, MD1, Joseph Lewis, BA1, Charles\nA. Carter, BS, PharmD, MBA2, Meharvan Singh, PhD3, Fabio Lievano, MD4,\nMark Ligocki, DDS5, Walter Jeske, PhD1, Cafer Adiguzel, MD6, Grigoris\nT. Gerotziafas, MD7, and Jawed Fareed, PhD1\nAbstract\nThe progress in the development of various vaccine platforms against SARS-CoV-2 have been rather remarkable owing to\nadvancement in molecular and biologic sciences. Most of the current vaccines and those in development focus on targeting\nthe viral spike proteins by generating antibodies of varying spectrum. These vaccines represent a variety of platforms including\nwhole virus vaccines, viral vector vaccines, nucleic acid vaccines representing RNA, DNA, and their hybrid forms.\nThe therapeutic ef\ufb01cacy of these vaccines varies owing to their pharmacodynamic individualities. COVID-19 variants are capable\nof inducing different pathologic responses and some of which may be resistant to antibodies generated by current vaccines. The\ncurrent clinical use of these vaccines has been through emergency use authorization until recently. Moreover, the ef\ufb01cacy and safety\nof these vaccines have been tested in substantial numbers of individuals but studies in special populations that better re\ufb02ect the\nglobal population are pending results. These specialized populations include young children, immunocompromised patients, preg-\nnant individuals, and other specialized groups. Combination approaches, molecularly modi\ufb01ed vaccination approaches, and vaccines\nconferring longer periods of immunity are being currently being investigated, as well as pharmacovigilance studies.\nThe continual transformation of SARS-CoV-2 and its variants are of concern along with the breakthrough infections. These con-\nsiderations pose new challenges for the development of vaccination platforms. For this purpose, booster doses, combination vaccine\napproaches, and other modalities are being discussed.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2085, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "872fcdb6-1dd8-4ee6-91bf-0d5ef3ea0518": {"__data__": {"id_": "872fcdb6-1dd8-4ee6-91bf-0d5ef3ea0518", "embedding": null, "metadata": {"page_label": "1", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "793fdd24-7965-4ec3-b67b-002f28e312e3", "node_type": "4", "metadata": {"page_label": "1", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "b2486298939ec5ef3139be58b8d79c4a3364a20bb2aeb6a6c4d23676af0a7168", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a42a0d5e-8326-4170-9c66-48a32c0ecf3c", "node_type": "1", "metadata": {"page_label": "1", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "1db4d37ed7b3be3f6634f08a71cbfc7ada3f0e176316afe6d796d9a3334afa52", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "74c8a6c7-0f05-4240-840f-3f4803bd4d90", "node_type": "1", "metadata": {}, "hash": "6d769cfb83ca9f08b48bee20cd691ce70e356637a0cc6d77381039a62d46188a", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "These con-\nsiderations pose new challenges for the development of vaccination platforms. For this purpose, booster doses, combination vaccine\napproaches, and other modalities are being discussed. This review provides an updated account of currently available vaccines and\nthose in advanced development with reference to their composition and mechanisms of action.\nA discussion on the use of vaccines in special populations including immunocompromised patients, pregnant women and other\nspecialized populations are also included.\nKeywords\nCOVID-19 vaccines, COVID-19 variants, children and adolescents, pregnancy and lactation, immunocomprimised patients\nDate received: 31 August 2021; revised: 25 September 2021;\naccepted: 13 October 2021.\nIntroduction\nSevere acute respiratory syndrome coronavirus-2 (SARS-\nCoV-2) has been detected in more than 206 million people\nand has caused more than 4.3 million deaths worldwide and\nthe coronavirus disease 2019 (COVID-19) pandemic has\nbecome a signi\ufb01cant global health problem.1 After its \ufb01rst\nappearance in late December of 2019, it was\ufb01rst reported as\n1 Cardiovascular Research Institute, Loyola University Chicago, Health Sciences\nDivision, Maywood, IL, USA\n2 Campbell University College of Pharmacy and Health Sciences, Campbell\nUniversity, Buies Creek, NC, USA\n3 Loyola University Chicago Stritch School of Medicine, Maywood, IL, USA\n4 AbbVie Inc., North Chicago, IL, USA\n5 Ligocki Dental Group, Oak Brook, IL, USA\n6 Bahcesehir University, Istanbul, Turkey\n7 Sorbonne Universit\u00e9, Assistance Publique-H\u00f4pitaux de Paris, Thrombosis\nCenter, Service D\u2019H\u00e9matologie Biologique H\u00f4pital Tenon, Paris, France\nCorresponding Author:\nBulent Kantarcioglu, Department of Pathology and Laboratory Medicine,\nCardiovascular Research Institute, Loyola University Chicago, Health Sciences\nDivision, Maywood, IL 60153, USA.", "mimetype": "text/plain", "start_char_idx": 1890, "end_char_idx": 3739, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "74c8a6c7-0f05-4240-840f-3f4803bd4d90": {"__data__": {"id_": "74c8a6c7-0f05-4240-840f-3f4803bd4d90", "embedding": null, "metadata": {"page_label": "1", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "793fdd24-7965-4ec3-b67b-002f28e312e3", "node_type": "4", "metadata": {"page_label": "1", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "b2486298939ec5ef3139be58b8d79c4a3364a20bb2aeb6a6c4d23676af0a7168", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "872fcdb6-1dd8-4ee6-91bf-0d5ef3ea0518", "node_type": "1", "metadata": {"page_label": "1", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "ed384623cd4c664288cec94f04c08b7e92cc536990dbeaf7a2f72af95a520e5e", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Email: bulentkantarcioglu@gmail.com\nCreative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons\nAttribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use,\nreproduction and distribution of the work without further permission provided the original work is attributed as speci\ufb01ed on the SAGE and Open Access\npage (https://us.sagepub.com/en-us/nam/open-access-at-sage).\nReview\nClinical and Applied\nThrombosis/Hemostasis\nVolume 28: 1-40\n\u00a9 The Author(s) 2022\nArticle reuse guidelines:\nsagepub.com/journals-permissions\nDOI: 10.1177/10760296211056648\njournals.sagepub.com/home/cat", "mimetype": "text/plain", "start_char_idx": 3740, "end_char_idx": 4425, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "dd82aaed-e0ef-4be2-8b62-e7c69f37e87d": {"__data__": {"id_": "dd82aaed-e0ef-4be2-8b62-e7c69f37e87d", "embedding": null, "metadata": {"page_label": "2", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a5cb8601-86b0-4a92-983b-21f73c7f3edb", "node_type": "4", "metadata": {"page_label": "2", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "cafff973f75d1e27ebbba0a4417e9f81bde61a2e042266f817ca7ac86ad2670d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "db4ad094-a2b3-4a9a-a2f5-79169853e8cc", "node_type": "1", "metadata": {}, "hash": "46ef07af03666629ad4e49ce4f9494b19c9be7cbcfd5436108236d0e599b9926", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "a new type of pneumonia of unknown etiology.2,3 However, the\nsituation is far more complex. Although the target organ for the\nvirus was initially thought to be the lungs, it has been recog-\nnized that binding to the endothelial lining, through\nangiotensin-converting-enzyme 2 (ACE 2) receptors expressed\non target cells, COVID-19 can affect almost all of the organ\nsystems.4\u20136 Most of the patients present with mild symptoms,\nhowever, a considerable subset of patients develop a more\nsevere condition, varying from pneumonia and acute respiratory\ndistress syndrome (ARDS) to multi-organ failure (MOF).7\u20139\nThe coagulation abnormalities and immunological syndromes\nthat occur during the course of the disease can cause life threat-\nening events, leading to signi\ufb01cant morbidity and mortality.10\u2013\n13 After more than a year of living with COVID-19, many fea-\ntures of the disease have been revealed, but there are still many\nunknowns such as lack of a curative treatment of the disease or\nthe importance of new emerging variants over the course of the\nCOVID-19 pandemic.14 While simple prevention measures\nsuch as using masks, physical distancing or hygiene can only\nslow down the pandemic, vaccines are the most powerful\ntools to \ufb01ght against COVID-19.15 Currently there are some\n19 clinically used vaccines which have been used to control\nCOVID-19 infections and over 100 in various phases of devel-\nopment. Thus, global vaccination will be of paramount impor-\ntance in the management of this pandemic.\nThe discovery of the vaccination is one of the greatest\nachievements of modern medicine. The eradication of smallpox\nis one of the best examples of how vaccination stopped a deadly\ndisease and saved millions of lives. The vaccinations against\ntetanus and rabies are similar examples. Many childhood infec-\ntions such as polio and measles also became preventable.\nMillions of lives have been saved by annual in\ufb02uenza vaccina-\ntions.16,17 Vaccines are complex biological products that need\nto be applied in large populations of healthy people.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2042, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "db4ad094-a2b3-4a9a-a2f5-79169853e8cc": {"__data__": {"id_": "db4ad094-a2b3-4a9a-a2f5-79169853e8cc", "embedding": null, "metadata": {"page_label": "2", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a5cb8601-86b0-4a92-983b-21f73c7f3edb", "node_type": "4", "metadata": {"page_label": "2", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "cafff973f75d1e27ebbba0a4417e9f81bde61a2e042266f817ca7ac86ad2670d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dd82aaed-e0ef-4be2-8b62-e7c69f37e87d", "node_type": "1", "metadata": {"page_label": "2", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "7cbb6578450f6ee6476fc7a5253e1e52269ca7aec5d8de30f16278792e193653", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "aa68ae17-9430-4503-b248-dbf996def1cc", "node_type": "1", "metadata": {}, "hash": "5aeb2cce576f202079697e9b422255adb0a42256a47445dd4252c697f9a930fe", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Millions of lives have been saved by annual in\ufb02uenza vaccina-\ntions.16,17 Vaccines are complex biological products that need\nto be applied in large populations of healthy people. Due to\nthis, the development of vaccines takes a long period of time.\nGenerally, development of any vaccine often takes 15 years\nor more from the initial design stage to the clinical studies.18\nVaccine clinical trials are often expensive and require recruit-\nment of large numbers of volunteers with different ethnicities,\nages, and health conditions. Long-term monitoring is also nec-\nessary to establish vaccine ef\ufb01cacy and to rule out or identify\nrare safety issues.\nThe development of the vaccines against COVID-19 started\nas soon as the virus genome was published in early January\n2020.19,20 Immense resources have been deployed to support\nvaccine development by thousands of researchers, using\nhighly sophisticated technology, and spending huge amounts\nof \ufb01nancial resources. Eventually, several different vaccines\nwere deployed by late December 2020, under emergency use\nauthorization, and mass vaccination campaigns have com-\nmenced all around the world. The fact that several COVID-19\nvaccine candidates entered into clinical trials in less than 6\nmonths and were approved for emergency use in less than 10\nmonths since the beginning of the COVID-19 pandemic, devel-\nopment of COVID-19 vaccines demonstrates a ground-\nbreaking speed in vaccine development history. Despite this\nhigh speed, safety standards for the development and approval\nprocess of these vaccines were consistent with those of previ-\nously developed vaccines, with rigorous review of their clinical\ndata by higher health authorities such as the World Health\nOrganization (WHO) or United States Center for Disease\nControl and Prevention (US-CDC). Beside the availability of\nvaccines, the control of this epidemic will require greater than\n80% vaccination of the global population. Additionally, uniform-\nity in the vaccination programs in various parts of the word is\nequally important. Most of the currently used vaccines have\nbeen approved in a fast-tracked emergency process and autho-\nrized for emergency use.", "mimetype": "text/plain", "start_char_idx": 1864, "end_char_idx": 4033, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "aa68ae17-9430-4503-b248-dbf996def1cc": {"__data__": {"id_": "aa68ae17-9430-4503-b248-dbf996def1cc", "embedding": null, "metadata": {"page_label": "2", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a5cb8601-86b0-4a92-983b-21f73c7f3edb", "node_type": "4", "metadata": {"page_label": "2", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "cafff973f75d1e27ebbba0a4417e9f81bde61a2e042266f817ca7ac86ad2670d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "db4ad094-a2b3-4a9a-a2f5-79169853e8cc", "node_type": "1", "metadata": {"page_label": "2", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "0934a43a7c177bba1412f5f5c3375a5cfe30823451b458f06b7d4df328aac6f5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5e14767c-7a3c-460f-8da4-7dee7e6f9d4c", "node_type": "1", "metadata": {}, "hash": "6fc0905b795a682a297085c1339837fd95de9851735ee18f531ffa3e3dc928b7", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Additionally, uniform-\nity in the vaccination programs in various parts of the word is\nequally important. Most of the currently used vaccines have\nbeen approved in a fast-tracked emergency process and autho-\nrized for emergency use. Only the P \ufb01zer vaccine has full\napproval as of August 24, 2021 by the US-FDA. Other widely\nused vaccines are likely to receive similar approvals from the\nUS-FDA and European Medicine Agency in the near future.\nCurrrently used vaccines provide immunity against\nSARS-CoV-2 by generating neutralizing antibodies through\nmolecularly de\ufb01ned mechanisms. All vaccines are capable of\ntriggering the endogenous generation of spike protein which\nin turn result in the formation of neutralizing antibodies and T\ncell responses to COVID-19. The generation of these neutraliz-\ning antibodies provide protection against viral infection by\nreadily complexing with the COVID-19 virus and arresting its\npropagation and subsequent pathophysiologic manifestation.\nThe spike proteins generated by different approaches result in\nthe formation of COVID-19 neutralizing antibodies with differ-\nential duration of fraction and antiviral spectrum.\nFigure 1 shows a comparison of whole virion COVID-19\nvaccines and viral vector vaccines. Whole virion vaccines are\nusually derived from chemically or molecularly modi \ufb01ed\nSARS-CoV-2. The viral vector vaccines are derived by recom-\nbination of genomic sequence encoding trimeric form of spike\nprotein. Figure 2 shows an illustration of the nucleic acid vac-\ncines with recombinant protein based vaccines. Nucleic acid\nvaccines are based on mRNA and DNA vaccines. mRNA vac-\ncines represent the genetic sequence of S protein. The DNA\nvaccines use the plasmids as vectors to transcript S protein.\nThe recombinant protein based vaccines employ prokaryotic\ncells to produce recombinant spike protein or viral particles.\nAdditional vaccines which are currently under development\nwill have broader targets beside the generation of spike\nprotein which include nucleocapsid protein and other viral\nantigens.", "mimetype": "text/plain", "start_char_idx": 3801, "end_char_idx": 5855, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "5e14767c-7a3c-460f-8da4-7dee7e6f9d4c": {"__data__": {"id_": "5e14767c-7a3c-460f-8da4-7dee7e6f9d4c", "embedding": null, "metadata": {"page_label": "2", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a5cb8601-86b0-4a92-983b-21f73c7f3edb", "node_type": "4", "metadata": {"page_label": "2", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "cafff973f75d1e27ebbba0a4417e9f81bde61a2e042266f817ca7ac86ad2670d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "aa68ae17-9430-4503-b248-dbf996def1cc", "node_type": "1", "metadata": {"page_label": "2", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "312d21568fb46063388f02f5d1dd7924342e664a274987a5553d5b85c02340f3", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Additional vaccines which are currently under development\nwill have broader targets beside the generation of spike\nprotein which include nucleocapsid protein and other viral\nantigens.\nIt is important to note that vaccination of at least 60-80% of\nthe world population is required to achieve herd immunity\nagainst COVID-19.21\u201323 According to WHO, more than 4\nbillion doses of COVID-19 vaccines have been administered\nglobally.24 However, vaccination rates are far less than would\nbe necessary to control the pandemic, especially in Africa and\nSoutheast Asian countries. Vaccination programs widely\ndiffer due to\ufb01nancial and logistics constraints throughout the\nworld with a direct impact on the prevalence of COVID-19\ninfections.25 Additionally, public acceptance of vaccines and\nvaccine hesitancy have become growing concerns for the\nsuccess of vaccination programs.26\u201329 The duration of protec-\ntion of COVID-19 vaccines or requirement of a booster dose\n2 Clinical and Applied Thrombosis/Hemostasis", "mimetype": "text/plain", "start_char_idx": 5672, "end_char_idx": 6671, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "e3eb41ec-c251-4ed7-b6dc-fb04d525dc73": {"__data__": {"id_": "e3eb41ec-c251-4ed7-b6dc-fb04d525dc73", "embedding": null, "metadata": {"page_label": "3", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "36ef91a0-45ad-4de5-b37f-0347da796824", "node_type": "4", "metadata": {"page_label": "3", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "cd8bbbb4f1375cae3c075d6791b113afbe634ce49838a95de38fe82c10a034b7", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "are also areas of uncertainty affecting vaccine hesitancy.\nEmergence of variant viruses and the ef\ufb01cacy of current vac-\ncines against them have also become important for the\nsuccess of vaccinations.30 With everything considered, the\n\ufb02ow of newer information is rapid, requiring periodic updates\nand objective assessments. For this reason, in this manuscript,\nwe tried to update and summarize the current status of\nCOVID-19 vaccinations in the light of current literature.\nVaccine Development for COVID-19\nMost of the vaccine candidates for COVID-19 were designed to\ninduce neutralizing antibodies against the viral spike (S) protein\nto prevent its binding to the human angiotensin 2 converting\nenzyme (ACE2) receptor which mediates entrance of the\nvirus into the human cells. The S protein is a fusion\nglycoprotein that is divided i nto two functionally distinct\nparts (S1 and S2). S1 is located on the virus surface and\ncontains the receptor-binding domain (RBD) that speci\ufb01-\ncally binds to the host cell receptor. The transmembrane\nS2 domain contains the fusion peptide, which mediates\nthe fusion of viral and cellular membranes. Besides the S\nprotein, SARS-CoV-2 has other structural proteins such\nas membrane (M), envelope (E) and nucleocapsid (N) pro-\nteins. Antibodies that target M and E proteins have failed to\nneutralize the COVID-19 infection. For this reason, these 2\nproteins are currently not considered as target antigen for\nCOVID-19 vaccines. On the other hand, N protein is also\nhighly immunogenic and can induce robust humoral and\ncellular immune responses.31\u201333\nFollowing the beginning of the COVID-19 pandemic, there\nhas been a worldwide race to develop vaccines against this\nFigure 1. A comparison of whole virion COVID-19 vaccines and viral vector vaccines. Whole virion vaccines are usually derived from\nchemically or molecularly modi\ufb01ed SARS-CoV-2 (Panel A). The viral vector vaccines are derived by recombination of genomic sequence\nencoding trimeric form of spike protein (Panel B)\nKantarcioglu et al. 3", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2028, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "d3d7351e-4e9b-4121-bea7-8309bb65e827": {"__data__": {"id_": "d3d7351e-4e9b-4121-bea7-8309bb65e827", "embedding": null, "metadata": {"page_label": "4", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "9fba4c60-5030-4e2d-a80a-dc88ba2d1be1", "node_type": "4", "metadata": {"page_label": "4", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "c640a6c675caea2faad2dda4e6a94a40ec9e5901f927866a1f604b329209b647", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f1a416bc-5cce-4cb0-99a3-7f9c8c3b29d6", "node_type": "1", "metadata": {}, "hash": "937855a1c1348c14d2813bf0b859c5c167222bbc15b21324da128a59531b2636", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "disease. By August 2021, a total of 296 COVID-19 vaccine\ncandidates have been developed, with 112 in clinical trials\nand 184 in preclinical studies.34 Many different vaccine tech-\nnology platforms have been used to develop a safe and effective\nvaccine, including conventional whole virus vaccines (live\nattenuated or inactivated vaccines), viral vector vaccines (non-\nreplicating and replicating), nucleic acid vaccines (DNA- and\nmRNA-based vaccines) and recombinant protein-based vac-\ncines [protein subunit vaccines, virus-like particles (VLP)].31\u201333\nVaccine Platforms and Currently Available\nVaccines\nWhole Virus Vaccines\nWhole virus vaccines are classi\ufb01ed as inactivated and live-\nattenuated vaccines. They are the oldest and most well-\nestablished types of vaccine, used in smallpox, BCG, and\nmeasles vaccines. The technology used in this platform is\ndecades old and is proven. Due to the presence of the whole\nvirus with a variety of viral surface antigens, these vaccines\ncause a diverse immunologic response. The manufacturing\nprocess of these vaccines requires handling live virus prepara-\ntions. For this reason, a high level of bio-safety installations\nis needed for their production.35\u201341\nLive-attenuated vaccines are produced by serial passage of\nthe pathogen virus in cell cultures for selection of a reduced rep-\nlication potential and thus reduced virulence. The virulence of\nthese viruses in live-attenuated vaccines is reduced, but they\ncan still replicate. These vaccines usually produce strong and\nlong-lasting humoral and cell-mediated immune responses by\nmimicking natural infection, but strict safety evaluation is\nrequired. Normally, live-attenuated viral vaccines do not\ncause disease, however they can be the source of infection\nwhen they are used in immunocompromised patients due to\nthe presence of live viruses in the vaccine. Inactivated vaccines\ncontain inactivated SARS-CoV-2 virus. They are usually inac-\ntivated by chemicals such as formaldehyde and beta-\npropiolactone, so that the antigenicity of the viral surface com-\nponents is retained.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2076, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "f1a416bc-5cce-4cb0-99a3-7f9c8c3b29d6": {"__data__": {"id_": "f1a416bc-5cce-4cb0-99a3-7f9c8c3b29d6", "embedding": null, "metadata": {"page_label": "4", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "9fba4c60-5030-4e2d-a80a-dc88ba2d1be1", "node_type": "4", "metadata": {"page_label": "4", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "c640a6c675caea2faad2dda4e6a94a40ec9e5901f927866a1f604b329209b647", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d3d7351e-4e9b-4121-bea7-8309bb65e827", "node_type": "1", "metadata": {"page_label": "4", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "5a1b582c1c5d4032d5595098e5bb413442ed8d198a9e640290d276bd879da608", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "They are usually inac-\ntivated by chemicals such as formaldehyde and beta-\npropiolactone, so that the antigenicity of the viral surface com-\nponents is retained. Because they cannot replicate, they cannot\ncause infections even in the immunocompromised individuals.\nThey are safer and more stable than live attenuated vaccines.\nThese vaccines generally require multiple doses or adjuvants\nto achieve immunity.35\u201341\nFigure 2. Illustration of the nucleic acid vaccines with recombinant protein based vaccines. Nucleic acid vaccines are based on mRNA and DNA\nvaccines. mRNA vaccines represent the genetic sequence of S protein (Panel A). The DNA vaccines use the plasmids as vectors to transcript S\nprotein. The recombinant protein based vaccines employ prokaryotic cells to produce recombinant spike protein or viral particles (Panel B).\n4 Clinical and Applied Thrombosis/Hemostasis", "mimetype": "text/plain", "start_char_idx": 1915, "end_char_idx": 2794, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "a4b9e899-3de5-405b-9d02-a1207b812d24": {"__data__": {"id_": "a4b9e899-3de5-405b-9d02-a1207b812d24", "embedding": null, "metadata": {"page_label": "5", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "66af6b35-4748-45dc-b047-5db47c7454a6", "node_type": "4", "metadata": {"page_label": "5", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "80b97cffae053ec2cf5e7cd0120774c52990f260cc57e8a4ee0d82dd1f279284", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "04e4edc3-8fa4-437f-9e3d-ccbf8812e7ff", "node_type": "1", "metadata": {}, "hash": "9e9356278b0295abee921b5857f49668a08be65891961d8a2d4935dc5b00338d", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Table 1. Current Whole Virion COVID-19 Vaccines in Clinical Trials\nVaccine Developer Country\nDoses &\nSchedule Route\nClinical\nEvaluation Status of Approval\nA) Inactivated Vaccines\nCoronaVac Sinovac Research and Development Co., Ltd China Day 0 +14 IM Phase 4 Approved\nBBIBP-CorV Sinopharm +China National Biotec Group Co+Beijing Institute of\nBiological Products\nChina Day 0 +21 IM Phase 4 Approved\nWIBP-CorV Sinopharm +China National Biotec Group Co+Wuhan Institute of\nBiological Products\nChina Day 0 +21 IM Phase 3 Approved\nCovaxin Bharat Biotech International Limited India Day 0 +14 IM Phase 3 Aproved\nMinhai or KCONVAC Shenzhen Kangtai Biological Products Co., Ltd China Day 0 +28 IM Phase 3 Approved\nName not provided\nyet.\nInstitute of Medical Biology+Chinese Academy of Medical Sciences\n(IMBCAMS)\nChina Day 0 +28 IM Phase 3 Approved\nCoviVac Russian Academy of Sciences Russia Day 0 +14 IM Phase 3 Approved\nQazCovid-in\u00ae Research Institute for Biological Safety Problems, Rep of Kazakhstan Khazakistan Day 0 +21 IM Phase 3 Approved\nCOVIran Shifa Pharmed Industrial Co Iran Day 0 +14 IM Phase 2/3 Approved\nVLA2001 Valneva, National Institute for Health Research, United Kingdom France \u2014\nUSA\nDay 0+21 IM Phase 3 Not approved yet.\nERUCOV-VAC Erciyes University, Turkey Turkey Day 0 +21 IM Phase 3 Not approved yet.\nName not provided\nyet.\nThe Government Pharmaceutical Organization (GPO); PATH;\nDynavax\nUSA Day 0 +28 IM Phase 1/2 Not approved yet.\nName not provided\nyet.\nKM Biologics Co., Ltd China Day 0 +28 IM Phase 1/2 Not approved yet.\nFAKHRAVAC\n(MIVAC)\nOrganization of Defensive Innovation and Research Iran Day 0 +14 +/\u2013\n21\nIM Phase 1 Not approved yet.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1657, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "04e4edc3-8fa4-437f-9e3d-ccbf8812e7ff": {"__data__": {"id_": "04e4edc3-8fa4-437f-9e3d-ccbf8812e7ff", "embedding": null, "metadata": {"page_label": "5", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "66af6b35-4748-45dc-b047-5db47c7454a6", "node_type": "4", "metadata": {"page_label": "5", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "80b97cffae053ec2cf5e7cd0120774c52990f260cc57e8a4ee0d82dd1f279284", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a4b9e899-3de5-405b-9d02-a1207b812d24", "node_type": "1", "metadata": {"page_label": "5", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "2bbf94a9edcbed038030b83318011a985eb256bb94a305a2b757186aa69f2dd1", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "FAKHRAVAC\n(MIVAC)\nOrganization of Defensive Innovation and Research Iran Day 0 +14 +/\u2013\n21\nIM Phase 1 Not approved yet.\nKo\u00e7ak-19 Kocak Farma, Turkey Turkey Day 0 +21 IM Phase 1 Not approved yet.\nName not provided\nyet.\nThe Scienti\ufb01c and Technological Research Council of Turkey\n(T\u00dcBITAK)\nTurkey Day 0 +21 IM Phase 1 Not approved yet.\nName not provided\nyet.\nLaboratorio Avi-Mex Mexico Day 0 +21 IM or\nIN\nPhase 1 Not approved yet.\nB) Live Attenuated\nVaccines\nCOVI-VAC Codagenix/Serum Institute of India India Day 0 or\nDay 0+28\nIN Phase 1 Not approved yet.\nMV-014-212 Meissa Vaccines, Inc. USA Day 0 IN Phase 1 Not approved yet.\n5", "mimetype": "text/plain", "start_char_idx": 1539, "end_char_idx": 2164, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "a672ec12-7596-482e-99d9-dedb5d5a6c8f": {"__data__": {"id_": "a672ec12-7596-482e-99d9-dedb5d5a6c8f", "embedding": null, "metadata": {"page_label": "6", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "1a5b021a-1251-462c-88b3-0441db498c9b", "node_type": "4", "metadata": {"page_label": "6", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "75e3602f512ad96e7ba1cd00c2b37c8f26f256089b7a01c4b6bf71806d9b91ba", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "67d15ed4-d9b4-434f-bcd6-65e6f0325a02", "node_type": "1", "metadata": {}, "hash": "eccc90f3d683e9a099bff6eccd2bef9290f35531c68dca82d1467a4efa0f8760", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "As depicted on Table 1, there are at least 19 whole virus\nCOVID-19 vaccines or vaccine candidates that are registered\nin clinical trials.34 While nine of these inactivated vaccines\nare approved for general or emergency use in several countries,\nthe development process of remaining vaccines are continuing\nin different stages of clinical trials.\nCoronavac is a propiolactone inactivated SARS-CoV-2\nvaccine. The inactivated virus was isolated from a patient in\nthe Jinyintan Hospital in Wuhan. (CN02 strain) The virus was\ncultivated in a quali\ufb01ed Vero cell line for propagation.31\u201333 In\nthe Phase 1 and 2 clinical trials, the vaccine-induced neutraliz-\ning antibodies in 100% of vaccine recipients.42,43 There were no\nsevere adverse reactions reported in any of the groups. Phase 3\nclinical trials started in July 2020. The interim results of Phase 3\nclinical trial in Turkey have been published showing an ef\ufb01cacy\nof 83.5%. Sinovac announced that the vaccine has an ef\ufb01cacy\nrate of 50.65% for all cases (83.70% for cases requiring\nmedical treatment, and 100.00% for hospitalized, severe, and\nfatal cases). There were no serious adverse events related to\nvaccination.44,45 China approved the vaccine for general use\nin February 2021. More recent reports have alluded to lower\nef\ufb01cacy of this vaccine.\nBBIBP-CorV and WIBP-CorVare propiolactone inactivated\nSARS-CoV-2 vaccines. The inactivated virus was isolated from\na patient in the Jinyintan Hospital in Wuhan. (HB02 and WIV04\nStrains). The vaccine viruses were cultivated in quali\ufb01ed Vero cell\nlines for propagation. In the Phase1 and 2 clinical trials, a robust\nhumoral immune response was observed in 100% of vaccine\nrecipients.46,47 All adverse reactions were mild or moderate in\nseverity. No serious adverse events were reported within 28\ndays post vaccination for all cohorts.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1832, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "67d15ed4-d9b4-434f-bcd6-65e6f0325a02": {"__data__": {"id_": "67d15ed4-d9b4-434f-bcd6-65e6f0325a02", "embedding": null, "metadata": {"page_label": "6", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "1a5b021a-1251-462c-88b3-0441db498c9b", "node_type": "4", "metadata": {"page_label": "6", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "75e3602f512ad96e7ba1cd00c2b37c8f26f256089b7a01c4b6bf71806d9b91ba", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a672ec12-7596-482e-99d9-dedb5d5a6c8f", "node_type": "1", "metadata": {"page_label": "6", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "d8aa629ff56736b5664b824c2496bb00a8d645d2243ab0c5aa2d1b0415a2d1e5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "240e5630-7082-4e0a-8116-f9b243f03da1", "node_type": "1", "metadata": {}, "hash": "90997fc5a25db783b03dfa975c168726d80ac09828287e036f5a01ed806901b0", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "No serious adverse events were reported within 28\ndays post vaccination for all cohorts. The Phase 3 clinical trials\nhave been launched with these results. The interim results of the\nPhase 3 clinical trial in the United Arab Emirates and Bahrain,\nhave been published showing an ef \ufb01cacy of 78.1% for\nBBIBP-CorV and 72.8% for WIBP-CorV.48 Sinopharm CNGB\nannounced that the vaccine has an ef\ufb01cacy rate of 79.34%.39\nChina approved the vaccine for general use in December 2020.\nBBV152 or Covaxin is a whole-virion inactivated\nSARSCoV- 2 vaccine designed by Bharat Biotech\nInternational Limited. It has been designed with 2 adjuvant\nforms, using aluminum (Algel) or an imidazoquinoline mole-\ncule, which is a toll-like receptor (TLR) 7/8 agonist absorbed\nto aluminum (Algel-IMDG). In the Phase 1 clinical trial, 375\nparticipants have been enrolled. BBV152-Covaxin elicited ef\ufb01-\ncient SARS-CoV-2 neutralizing antibody titers and T cell\nresponses.49 Local and systemic side effects were mild or mod-\nerate and were more frequent after the\ufb01rst dose. Only 1 serious\nadverse event (Viral Pneumonitis) has been reported, which\nwas not related to the vaccine. In the Phase 2 clinical trial,\n380 participants were enrolled.50 This study showed that\nBBV152-Covaxin has elicited high levels of neutralizing anti-\nbodies that remained elevated in all participants 3 months\nafter the second vaccination. No serious adverse events were\nreported in this study. Phase 3 clinical trials started in\nDecember 2020 with these results. The results of this trial have\nnot been published yet. The Indian Government granted\nemergency use authorization in January 2021.", "mimetype": "text/plain", "start_char_idx": 1744, "end_char_idx": 3384, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "240e5630-7082-4e0a-8116-f9b243f03da1": {"__data__": {"id_": "240e5630-7082-4e0a-8116-f9b243f03da1", "embedding": null, "metadata": {"page_label": "6", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "1a5b021a-1251-462c-88b3-0441db498c9b", "node_type": "4", "metadata": {"page_label": "6", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "75e3602f512ad96e7ba1cd00c2b37c8f26f256089b7a01c4b6bf71806d9b91ba", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "67d15ed4-d9b4-434f-bcd6-65e6f0325a02", "node_type": "1", "metadata": {"page_label": "6", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "ff11ea690ea7c4d7ee19fdcf288d183974d35510fcaa641bb0dcdf0d920978a9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b313e9a0-aabf-46b2-b9f6-7764a29932f5", "node_type": "1", "metadata": {}, "hash": "49899bd532b68f2ff88bcedf2bc9935e91e8dcceb8a648de090cd6d7792647e9", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Phase 3 clinical trials started in\nDecember 2020 with these results. The results of this trial have\nnot been published yet. The Indian Government granted\nemergency use authorization in January 2021. Bharat Biotech\nInternational Limited announced interim Phase 3 clinical trial\nresults of 25,800 participants that showed that\nBBV152-Covaxin demonstrated 81% ef \ufb01cacy and severe,\nserious and medically attended adverse events occurred in low\nlevels and were similar between vaccine and placebo groups.\nMinhai (KCONVAC), Institute of Medical Biology Chinese\nAcademy of Medical Sciences (IMBCAMS) COVID-19\nvaccine, QazCovid-in\u00ae and COVIran Barakat are inactivated\nvirus vaccines that are developed by China, Kazakhstan and\nIran respectively. China approved Minhai in May 2021 and\nIMBCAMS vaccine in June 2021 for emergency use.\nQazCovid-in\u00ae has been approved by Kazakhstan for emer-\ngency use in April 2021. Iran approved the COVIran Barakat\nfor emergency use in June 2021. Although these vaccines are\nregistered in WHO vaccine tracker and clinicaltrials.gov, the\nresults of these clinical trials for individual vaccines have not\nbeen published. CoviVac is another inactivated virus vaccine\nproduced by the Chumakov Centre at the Russian Academy\nof Sciences. There is no mention of it at clinicaltrials.gov, the\nUS Centers for Disease Control and Prevention, or the\nWHO\u2019s vaccine tracker for CoviVac, but Russia approved\nCoviVac for emergency use in February 2021.51\u201357\nViral Vector Vaccines\nViral vector vaccines are based on live recombinant virus\nvectors that are either replicating or non-replicating. The non-\nreplicating vector virus cannot replicate because the key\ngenes of the vector virus have been disabled. Although, many\ndifferent viral vectors are under investigation, non-replicating\nadenovirus (Ad) vectors are the most commonly employed\nviral vectors. Following the entry of the vector virus into the\nhost cells, the viral vector integrates its genomic code into the\nhost cell nucleus.", "mimetype": "text/plain", "start_char_idx": 3186, "end_char_idx": 5184, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "b313e9a0-aabf-46b2-b9f6-7764a29932f5": {"__data__": {"id_": "b313e9a0-aabf-46b2-b9f6-7764a29932f5", "embedding": null, "metadata": {"page_label": "6", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "1a5b021a-1251-462c-88b3-0441db498c9b", "node_type": "4", "metadata": {"page_label": "6", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "75e3602f512ad96e7ba1cd00c2b37c8f26f256089b7a01c4b6bf71806d9b91ba", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "240e5630-7082-4e0a-8116-f9b243f03da1", "node_type": "1", "metadata": {"page_label": "6", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "05fe2a68aec70511bc1d3b31ffdcae934fd65b5d40f57e2895f23bd4aeaba92d", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Following the entry of the vector virus into the\nhost cells, the viral vector integrates its genomic code into the\nhost cell nucleus. Upon integration, the S protein antigen is pro-\nduced by the host cell itself. These expressed antigens generate\nstrong humoral and cellular immune responses without the need\nof an adjuvant. Since viral vectors are common pathogens in\nnature, pre-existing immunity against the vector can reduce\nthe effectiveness of these vaccines. For this reason, the vector\nstrains that exhibit lower seroprevalence in humans (eg chim-\npanzee Ad, Ad5 and Ad26) are generally selected for vaccine\ndevelopment. In replicating vector virus vaccines, the vector\nvirus has been attenuated to lose its pathogenic capacity and\nmodi\ufb01ed to carry SARS-CoV-2 genes, but it remains able to\nreplicate in infected cells. Example of viruses that are used\nfor replicating vector virus vaccines are lentivirus (LV), in\ufb02u-\nenza virus (IFV), measles virus (MV), modi \ufb01ed vaccinia\nAnkara virus (MVA), vesicular stomatitis virus (VSV) and\nNewcastle disease virus (NDV). Due to the replicative potential\nof these vaccine viruses, they are highly immunogenic and gen-\nerate robust humoral and cellular-speci\ufb01c immunity. Their use\nin intranasal formulations may produce better IgA formation\nand prevention of asymptomatic carriage. Given that they\ncontain live viruses, there is a risk of disease in immunocom-\npromised individuals with their use. The production of viral\n6 Clinical and Applied Thrombosis/Hemostasis", "mimetype": "text/plain", "start_char_idx": 5051, "end_char_idx": 6563, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "cc5cd277-9217-4bbb-965c-e216757e512a": {"__data__": {"id_": "cc5cd277-9217-4bbb-965c-e216757e512a", "embedding": null, "metadata": {"page_label": "7", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "65906fe0-97af-478d-89e7-6eb93bae2203", "node_type": "4", "metadata": {"page_label": "7", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "cd85c6ed225bd9850177a1863ba8fa6178c1ba9f33cd51860e5efb8196247f9b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "097695a6-bd1f-4a70-9b89-136d149461bb", "node_type": "1", "metadata": {}, "hash": "b03500fcac2f0658b0fc9a90646c2ee00f0de5976d112bdf8a03b4f3a2a9b9d8", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Table 2. Current Viral Vector COVID-19 Vaccines in Clinical Trials\nVaccine Developer Country Schedule Route\nClinical\nEvaluation Status of Approval\nA) Non-Replicating Viral Vector Vaccines\nAZD1222 (ChAdOx1-S) AstraZeneca +University of Oxford United\nKingdom\nDay 0+28 IM Phase 4 Aproved\nConvidecia CanSino Biological Inc./Beijing Institute of\nBiotechnology\nChina Day 0 IM Phase 4 Aproved\nAd26.COV2.S Janssen Pharmaceutical USA Day 0 or Day 0 +56 IM Phase 4 Aproved\nSputnik V Gamaleya Research Institute ; Health Ministry of the\nRussian Federation\nRussia Day 0 +21 IM Phase 3 Aproved\nGRAd-COV2 ReiThera +Leukocare +Univercells Italy Day 0 IM Phase 2/3 Not approved yet.\nAZD2816 AstraZeneca +University of Oxford UK Day 0 +28 IM Phase 2/3 Not approved yet.\nDelNS1-2019-nCoV-RBD-OPT1 University of Hong Kong, Xiamen University and\nBeijing Wantai Biological Pharmacy\nChina Day 0 +28 IN Phase 2 Not approved yet.\nLV-SMENP-DC Shenzhen Geno-Immune Medical Institute China Day 0 SC & IV Phase 1/2 Not approved yet.\nHuman Adenovirus Type 5 ImmunityBio, Inc USA Day 0 +21 SC or Oral\nor SL\nPhase 1/2 Not approved yet.\nAdCLD-CoV19 Cellid Co., Ltd South Korea Day 0 IM Phase 1/2 Not approved yet.\nNDV-HXP-S Institute of Vaccines and Medical Biologicals, Vietnam Vietnam Day 0 +28 IM Phase 1/2 Not approved yet.\nMVA-SARS-2-ST German Center for Infection Research Germany Day 0 +28 IM Phase 1 Not approved yet.\nVXA-CoV2-1 Vaxart USA Day 0 +28 Oral Phase 1 Not approved yet.\nMVA-SARS-2-S University of Munich Germany Day 0 +28 IM Phase 1 Not approved yet.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1537, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "097695a6-bd1f-4a70-9b89-136d149461bb": {"__data__": {"id_": "097695a6-bd1f-4a70-9b89-136d149461bb", "embedding": null, "metadata": {"page_label": "7", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "65906fe0-97af-478d-89e7-6eb93bae2203", "node_type": "4", "metadata": {"page_label": "7", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "cd85c6ed225bd9850177a1863ba8fa6178c1ba9f33cd51860e5efb8196247f9b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cc5cd277-9217-4bbb-965c-e216757e512a", "node_type": "1", "metadata": {"page_label": "7", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "61480a96794a476279c599c351ccb49b5e8a6d2f859afacb207c366b78773a0a", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "VXA-CoV2-1 Vaxart USA Day 0 +28 Oral Phase 1 Not approved yet.\nMVA-SARS-2-S University of Munich Germany Day 0 +28 IM Phase 1 Not approved yet.\nCOH04S1 (MVA-SARS-2-S) City of Hope Medical Center +National Cancer\nInstitute\nUSA Day 0 +28 IM Phase 1 Not approved yet.\nBBV154 Bharat Biotech International Limited India Day 0 IN Phase 1 Not approved yet.\nChad-68 and SAM Gritstone Oncology USA Day 0 +14 +28 or Day 0+\n28 +56 or Day 0+ 112\nIM Phase 1 Not approved yet.\nSC-Ad6-1 Tetherex Pharmaceuticals Corporation USA Day 0 +/\u2013 21 IM Phase 1 Not approved yet.\nCVXGA1-001 CyanVac LLC USA Day 0 IN Phase 1 Not approved yet.B) Replicating Viral Vector VaccinesCovid-19/aAPC Shenzhen Geno-Immune Medical Institute China Day 0+14 +28 SC Phase 1 Not approved yet.\nrVSV-SARS-CoV-2-S Israel Institute for Biological Research Israel Day 0 IM Phase 1/2 Not approved yet.\nAV-COVID-19 Aivita Biomedical, Inc.\nNational Institute of Health Research andDevelopment, Ministry of Health Republic ofIndonesia\nIndonesia Day 0 IM Phase 1/2 Not approved yet.\n7", "mimetype": "text/plain", "start_char_idx": 1394, "end_char_idx": 2428, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "7e243e1a-a30e-42d8-907d-853e8632bbeb": {"__data__": {"id_": "7e243e1a-a30e-42d8-907d-853e8632bbeb", "embedding": null, "metadata": {"page_label": "8", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "bfaa9764-5597-4dd1-9ad9-b29835b17ea0", "node_type": "4", "metadata": {"page_label": "8", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "3a7943ae0ea19d6e4c9c835408528275942222c84a5e4152b19cd942643bb13b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "efe4bcbe-f8fc-4b43-b5a6-c74824608351", "node_type": "1", "metadata": {}, "hash": "265d438714aae44264b2f1b0b10702b44ada8c48c603a8c045a9505c72a17bf0", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "vector vaccines requires different cellular systems for high yield\npropagation. Great care must be taken to keep cell cultures free\nof any contaminating material during their production.35\u201341\nAs illustrated on Table 2, there are at least 22 viral vector\nCOVID-19 vaccines or vaccine candidates that are registered\nin clinical trials.34 While four of these inactivated vaccines\nare approved for general or emergency use in several countries,\nthe development process of the remaining vaccines is continu-\ning in different stages of clinical trials.\nNon-replicating viral vector vaccines. ChAdOx1-S, currently\nnamed as AZD1222, employs an Adenovirus derived from\nthe chimpanzee. The use of a chimpanzee vector minimizes\nthe possibility of interaction with preformed antibodies\nagainst adenoviruses. While the E1 deletion blocks the viral\nreplication, the E3 deletion enables incorporation of larger\ngenetic cargo into the viral vector. The added sequence\nencodes for the full-length S protein with a tissue plasminogen\nactivator signal sequence. The S protein sequence is\ncodon-optimized.31\u201333 In the Phase I clinical trial, the results\nshowed no severe side effects with ef\ufb01cient humoral and cellu-\nlar immune responses.58,59 On the basis of these results, they\nlaunched Phase 2-3 trials. In a recent interim analysis of\nPhase 2-3 trials, the outcomes of 11,636 from 23,848 enrolled\nparticipants have been published.60,61 Overall vaccine ef\ufb01cacy\nhas been reported as 70.4%. Interestingly, while the ef\ufb01cacy\nin participants who received two standard doses was 62.1%,\nthe ef\ufb01cacy in participants who received a low dose followed\nby a standard dose was 90.0%. In a 74,341 person/months of\nsafety follow-up, 175 severe adverse events have been observed\nin 168 participants, 84 events in the AZD1222 group and 91 in\nthe control group. However, only 3 events were initially consid-\nered to be vaccine related.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1901, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "efe4bcbe-f8fc-4b43-b5a6-c74824608351": {"__data__": {"id_": "efe4bcbe-f8fc-4b43-b5a6-c74824608351", "embedding": null, "metadata": {"page_label": "8", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "bfaa9764-5597-4dd1-9ad9-b29835b17ea0", "node_type": "4", "metadata": {"page_label": "8", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "3a7943ae0ea19d6e4c9c835408528275942222c84a5e4152b19cd942643bb13b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7e243e1a-a30e-42d8-907d-853e8632bbeb", "node_type": "1", "metadata": {"page_label": "8", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "665200ac75662bedfae8bff9a4442a041d0203f4295acf74f98db091e4ad2839", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9fb88f11-2b37-4938-8961-bb7e6b5fedad", "node_type": "1", "metadata": {}, "hash": "c89925448f8dd883ffe432b4b8a6e92bd2d3c146f40354bc069a345fd6ca4564", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "However, only 3 events were initially consid-\nered to be vaccine related. These events were: a case of transverse\nmyelitis in vaccine group that the independent neurological com-\nmittee considered the most likely diagnosis to be idiopathic, a\ncase of hemolytic anemia in the control group, and an individual\nwho recorded fever higher than 40 \u00b0C, but who recovered rapidly\nwithout an alternative diagnosis and was not admitted to hospital\nand remains masked to group allocation. There were four\nnon-COVID-19 deaths reported across the studies (three in the\ncontrol arm and one in the AZD1222 arm) that were all consid-\nered unrelated to the vaccine.\nConvidecia is another non-replicating adenoviral (Ad5)\nvector vaccine encoding for the full-length S protein. The\nvaccine gene was derived from the Wuhan-Hu-1 sequence for\nSARS-CoV2. Similar to the AZD1222 vaccine, the gene of\nthe vaccine contains E1 and E3 deletions with a tissue plasmin-\nogen activator signal sequence.31\u201333 In the Phase 1\ndose-escalation trial, 108 participants have reported high\nlevels of neutralizing antibody titers with speci \ufb01c T cell\nresponses. No serious adverse events have been reported.62 In\nthe Phase 2 trial, 508 participants were included. In this trial\nConvidecia induced signi \ufb01cant immune responses and no\nserious adverse events reported.63 The Phase 3 clinical trials\nhave been launched with these results. The results of this trial\nhave not been published yet. CanSino Biologics announced\nthat the vaccine has an ef\ufb01cacy rate of 65.28%. China approved\nthe vaccine for general use in February 2021.\nAd26.COV2.S is a recombinant non-replicating viral vector\nvaccine that uses adenovirus serotype 26 (Ad26). The vector\nencodes a full length and stabilized SARS-CoV-2 S protein.", "mimetype": "text/plain", "start_char_idx": 1828, "end_char_idx": 3591, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "9fb88f11-2b37-4938-8961-bb7e6b5fedad": {"__data__": {"id_": "9fb88f11-2b37-4938-8961-bb7e6b5fedad", "embedding": null, "metadata": {"page_label": "8", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "bfaa9764-5597-4dd1-9ad9-b29835b17ea0", "node_type": "4", "metadata": {"page_label": "8", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "3a7943ae0ea19d6e4c9c835408528275942222c84a5e4152b19cd942643bb13b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "efe4bcbe-f8fc-4b43-b5a6-c74824608351", "node_type": "1", "metadata": {"page_label": "8", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "ba12bb1be276078b5a1bc8f3ef8a81f3ccb7921cc1665214038018c82af8b155", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "056517c2-e40e-42cc-8543-a2b839f432cd", "node_type": "1", "metadata": {}, "hash": "8ad427f082039b9b018954b801649a29253316ef03e79f1c6d8f694e02725e57", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "The vector\nencodes a full length and stabilized SARS-CoV-2 S protein.\nThe vaccine gene was derived from the\ufb01rst clinical isolate of\nWuhan strain.31\u201333 The safety and ef\ufb01cacy have been studied\nin 805 participants in Phase 1 and 2 clinical trials.64 In these\ntrials, regardless of vaccine dose or age group, neutralizing anti-\nbody titers against the wild-type virus were detected in 90% or\nmore of all participants with accompanying T cell responses.\nThe results of Phase 3 clinical trials have been published.65\nIn January 2021, Johnson & Johnson announced that the ef\ufb01-\ncacy of their vaccine is 72% in the USA, 64% in South\nAfrica and 61% in Latin America. The local and systemic\nadverse events were mostly mild or moderate. Severe adverse\nevents have been reported in 83 of vaccine recipients (N=\n21,895) and 96 of placebo recipients (N=21,888). A numerical\nimbalance for venous thromboembolic events (11 in the vaccine\ngroup vs 3 in the placebo group) were observed. Deep venous\nthrombosis has been reported in 6 of the vaccine recipients\nand 2 of the placebo recipients. Pulmonary embolism has\nbeen reported in 4 of the vaccine recipients and 1 of the\nplacebo recipients. Transverse sinus thrombosis has been\nreported in 1 of the vaccine recipients and none of the\nplacebo recipients. Seizures have been reported in 4 of the\nvaccine recipients and 1 of the placebo recipients. Tinnitus\nhas been reported in 6 of the vaccine recipients and none of\nthe placebo recipients. For these imbalances, no causal relation-\nship can be determined. Three deaths were reported in the\nvaccine group and 16 in the placebo group, all of which were\nconsidered by the investigators to be unrelated to the trial inter-\nvention. No deaths related to COVID-19 were reported in the\nvaccine group, whereas 5 deaths related to COVID-19 were\nreported in the placebo group.", "mimetype": "text/plain", "start_char_idx": 3522, "end_char_idx": 5373, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "056517c2-e40e-42cc-8543-a2b839f432cd": {"__data__": {"id_": "056517c2-e40e-42cc-8543-a2b839f432cd", "embedding": null, "metadata": {"page_label": "8", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "bfaa9764-5597-4dd1-9ad9-b29835b17ea0", "node_type": "4", "metadata": {"page_label": "8", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "3a7943ae0ea19d6e4c9c835408528275942222c84a5e4152b19cd942643bb13b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9fb88f11-2b37-4938-8961-bb7e6b5fedad", "node_type": "1", "metadata": {"page_label": "8", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "029ef6c8b320663db657fef50c8f10d307ddb78e806d6255d529e344fac98425", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "No deaths related to COVID-19 were reported in the\nvaccine group, whereas 5 deaths related to COVID-19 were\nreported in the placebo group. Transverse sinus thrombosis\nwith cerebral hemorrhage and a case of Guillain\u2013Barr\u00e9 syn-\ndrome were each seen in 1 vaccine recipient. In the light of\nthese\ufb01ndings, the United States Food and Drug\nAdministration (FDA) issued an emergency use authorization\nin February 2021.\nSputnik V is an adenovirus-based vaccine combining two\nadenoviruses, rAd5 and rAd26 designed by the collaboration\nof the Gamaleya Research Institute with the Health Ministry\nof the Russian Federation.31\u201333 Both have been developed as\nfrozen and lyophilized formulations. In the Phase 1 clinical\ntrial, the vaccine showed high ef\ufb01cacy with a low side effect\npro\ufb01le. The most common side effects were pain at the injection\nsite, hyperthermia, headache, fatigue and muscle/joint pain.\nThese adverse events were mostly mild, and no serious\nadverse events reported.66 The Phase 3 clinical trial involved\n21,977 participants, showing a vaccine ef\ufb01cacy of 91.6%.67\nWhile most reported adverse events were grade 1, 45 of\n16,427 participants in the vaccine group and 23 of 5435 partic-\nipants in the placebo group had serious adverse events. None of\nthese were considered to be associated with vaccination by the\nindependent data monitoring committee. Four deaths were\n8 Clinical and Applied Thrombosis/Hemostasis", "mimetype": "text/plain", "start_char_idx": 5235, "end_char_idx": 6649, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "d791dd64-03cf-4a28-84b3-73a4bf6a98fc": {"__data__": {"id_": "d791dd64-03cf-4a28-84b3-73a4bf6a98fc", "embedding": null, "metadata": {"page_label": "9", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "b86e0623-b7c5-418e-af81-6f680a0cd825", "node_type": "4", "metadata": {"page_label": "9", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "cd9db9eaf0f622e0c68acf84c73f50cb1a8a5ffa38e944de586610d143706b9d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9682222d-863f-4319-b8a2-40c271a72810", "node_type": "1", "metadata": {}, "hash": "0ddc60b778c0cf02851fecf48352216fba8bd150a3b47c510bdf4fa50723179d", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "reported during the study period. Three participants (1 death is\ndue to thoracic vertebral fracture, 2 deaths are due to\nCOVID-19 infection) were in the vaccine group, 1 participant\n(due to hemorrhagic stroke) in the placebo group. None of\nthe deaths are considered to be vaccine related. Russia approved\nSputnik V in August 2020.\nGRAd-COV2 is a replication defective Simian Adenovirus\n(GRAd) vaccine candidate from Italy, that is derived from a\ngorilla, encoding full length profusion stabilized S protein for\nSARS-COV-2. It has a genome deleted of the entire E1 and\nE3 regions and the native E4 region replaced with the E4 orf6\nof human Ad5 (hAd5).68 The clinical trial results have not\nbeen published yet, but ReiThera Srl announced that its\nvaccine candidate is well tolerated and induced a clear\nimmune response in Phase 1 clinical trial. The Phase 2/3 clinical\ntrials are ongoing for this vaccine candidate.69\nAZD2816 is a viral vector vaccine that is developed by\nAstraZeneca company in the UK. It is designed using the\nsame adenoviral vector platform as AZD1222, with minor\ngenetic alterations to the spike protein based on the Beta\n(B.1.351, South African) variant. The vaccine candidate is cur-\nrently being evaluated in Phase 2/3 clinical trials.70\nDelNS1-2019-nCoV-RBD-OPT1 is a non-replicative viral\nvector vaccine candidate from China, that uses in\ufb02uenza virus\nas the vaccine platform. It is applied through an intranasal\nroute. The NS1 gene segment of the virus is knocked out so\nthat the virus can only multiply one round inside the cell at\nthe upper airway and will not disseminate inside the body. In\nthe empty space of the NS1 gene, the surface S protein receptor\nbinding domain (RBD) of COVID-19 applied which makes it a\nsafe mucosal vaccine platform.71\u201373 The clinical trial results\nhave not been published yet.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1832, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "9682222d-863f-4319-b8a2-40c271a72810": {"__data__": {"id_": "9682222d-863f-4319-b8a2-40c271a72810", "embedding": null, "metadata": {"page_label": "9", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "b86e0623-b7c5-418e-af81-6f680a0cd825", "node_type": "4", "metadata": {"page_label": "9", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "cd9db9eaf0f622e0c68acf84c73f50cb1a8a5ffa38e944de586610d143706b9d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d791dd64-03cf-4a28-84b3-73a4bf6a98fc", "node_type": "1", "metadata": {"page_label": "9", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "0d09a882dd4f8f26de250e4dc6dfec9a8afc3b346c404649a002aca627a7d9cd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "43d2c03e-3821-4049-ba1c-38429a38c5ec", "node_type": "1", "metadata": {}, "hash": "ae7729b76f8524c6548d14159dd0dfe0ceeb44e0bd65563d64547bcf71b7c701", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "The vaccine candidate is under\ninvestigation in Phase 2 clinical trials.74\nLV-SMENP-DC is developed by Shenzhen Geno Immune\nMedical Institute in China. It is made by modifying dendritic\ncells (DCs) with LV vectors expressing COVID-19 minigene\n(SMENP) and immune modulatory genes. The antigen-speci\ufb01c\ncytotoxic T lymphocytes (CTLs) will be activated by LV-DC\npresenting COVID-19 speci\ufb01c antigens. Currently, Phase 1/2\nclinical trials are ongoing for this vaccine candidate.75\nHuman Adenovirus Type 5 vaccine candidate (hAd5 S+N\nbivalent vaccine) is a second-generation viral-vector vaccine\nthat is developed by ImmunityBio, Inc in USA. It is targeting\nboth S and N SARS-CoV-2 proteins to generate B and T cell\nmemory to these antigens and, potentially, long-term immunity\nto the virus.76 The hAd5 vaccine platform was developed to\nelicit anti-SARS-CoV-2 immune responses even in\nAd-immune individuals, meaning subjects can receive the\nvaccine multiple times. The stimulation of anti-hAd5 immune\nresponses is attenuated with the second-generation platform in\ncomparison with the\ufb01rst-generation platforms due to additional\ngenetic deletions. Phase 1 studies of subcutaneous dosing in the\nUS have demonstrated no serious adverse events and potent\nT-cell responses after a single prime dose. In addition, a\nsingle prime subcutaneous vaccination with this vaccine candi-\ndate induced a 10-fold increase in T cell response\u2014 equivalent\nto T cell responses from patients previously infected with\nSARS-CoV-2. The Phase 1/2/3 trial is planned to study the ef\ufb01-\ncacy, safety, and immunogenicity of this vaccine as a booster in\nparticipants who have already received a S-only antibody-based\nvaccine.", "mimetype": "text/plain", "start_char_idx": 1833, "end_char_idx": 3519, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "43d2c03e-3821-4049-ba1c-38429a38c5ec": {"__data__": {"id_": "43d2c03e-3821-4049-ba1c-38429a38c5ec", "embedding": null, "metadata": {"page_label": "9", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "b86e0623-b7c5-418e-af81-6f680a0cd825", "node_type": "4", "metadata": {"page_label": "9", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "cd9db9eaf0f622e0c68acf84c73f50cb1a8a5ffa38e944de586610d143706b9d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9682222d-863f-4319-b8a2-40c271a72810", "node_type": "1", "metadata": {"page_label": "9", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "2d3e1251a70d21a461de7ac0d58001f226b4c984b0db51ed8ca868e13222010c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4e73f7a5-2a72-45ce-b5f6-0ff1bcf1d94d", "node_type": "1", "metadata": {}, "hash": "44e4993fa5d49d4982819e69cbe17bd73e0459184b5e8b801e0e81a84dbdb983", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "The Phase 1/2/3 trial is planned to study the ef\ufb01-\ncacy, safety, and immunogenicity of this vaccine as a booster in\nparticipants who have already received a S-only antibody-based\nvaccine. Finally, hAd5 vaccine candidate has been developed in\nfour formulations for different routes of administration: SC\ninjection, (sublingual) SL drops, intranasal spray, and a\nroom-temperature-stable oral capsule that could potentially\novercome the cold-chain distribution hurdles affecting many\ncurrent COVID-19 vaccines. The vaccine candidate is currently\nbeing evaluated in Phase 1/2 clinical trials.77\nAdCLD-CoV19 is a replication-defective human adenovirus\ntype 5/35 vector based vaccine developed by Cellid Co., Ltd in\nSouth Korea. The vaccine candidate is under investigation in\nPhase 1/2 clinical trials.78\nNDV-HXP-S (known as ButanVac in Brazil, COVIVAC in\nVietnam, HXP-GPOVac in Thailand, Patrial in Mexico)is a\nNDV vector expressing membrane-anchored pre-fusion-stabilized\ntrimeric S protein of SARS-CoV-2, with or without the adjuvant\nCpG 1018. CpG 1018 is a TLR 9 agonist adjuvant.79,80 Unlike\nthe vaccines that are already in use, NDV-HXP-S can be produced\nusing chicken eggs similar to\ufb02u vaccine production, making it\nsimpler to manufacture, especially for middle-and-low-income\ncountries. The vaccine candidate is under investigation in Phase\n1/2 clinical trials.81\nMVA-SARS-2-ST is developed by the German Center for\nInfection Research in Hamburg, is a vector vaccine candidate\nbased on MVA virus. The vector expresses a stabilized\nSARS-CoV-2 S protein. The results of the Phase I clinical\ntrial showed that the vaccines are safe and well tolerated\u2014\nhowever, the immune responses were below expectations. For\nthis reason, the Phase 2 trial planned for early 2021 was post-\nponed.", "mimetype": "text/plain", "start_char_idx": 3332, "end_char_idx": 5113, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "4e73f7a5-2a72-45ce-b5f6-0ff1bcf1d94d": {"__data__": {"id_": "4e73f7a5-2a72-45ce-b5f6-0ff1bcf1d94d", "embedding": null, "metadata": {"page_label": "9", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "b86e0623-b7c5-418e-af81-6f680a0cd825", "node_type": "4", "metadata": {"page_label": "9", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "cd9db9eaf0f622e0c68acf84c73f50cb1a8a5ffa38e944de586610d143706b9d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "43d2c03e-3821-4049-ba1c-38429a38c5ec", "node_type": "1", "metadata": {"page_label": "9", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "e0d37be6e3132b5465f40b9948427281e40e5ef17453f18c3b078bba522a0e7b", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "For\nthis reason, the Phase 2 trial planned for early 2021 was post-\nponed. With an optimized vaccine, the vaccine candidate is\nunder evaluation in Phase 1 trial.82\nVXA-CoV2-1 is an oral COVID-19 vaccine that is developed\nby Vaxart company in USA. It is formulated as tablets that are\nenteric coated for ef\ufb01cient delivery to the small bowel. The\nenteric coating protects the active ingredient from the stomach\u2019s\nacidic environment. While traditional injectable vaccines work\nby inducing a strong IgG response in the blood, oral vaccines\ninduce an IgA response in the GI and respiratory tracts with\nsome IgG responses in the blood as well. This is important in\nreducing viral shedding and preventing transmission. Vaxart\u2019s\nvaccine platform uses a non-replicating adenovirus type 5\n(Ad5) vector that delivers the antigen. The antigen in\nVXA-CoV2 is composed of the genes coding for both the\nSARS-CoV-2 S protein and the N protein. VXA-CoV2-1 is\none of the \ufb01rst COVID-19 vaccine candidates that contains\ngenes for both proteins. This is important because the mutations\nthat occur in S protein may decrease the ef\ufb01cacy of vaccines. The\nN protein is largely conserved between emerging strains of the\nSARS-CoV2 and may provide long-term immunity through vac-\ncinations. Vaxart also announced that they are working on a\nS-only vaccine which targets speci \ufb01cally variant strains.\nVXA-CoV2-1 also uses a TLR-3 agonist, as an adjuvant that\nactivates the innate immune system. The results of clinical\nKantarcioglu et al. 9", "mimetype": "text/plain", "start_char_idx": 5039, "end_char_idx": 6549, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "51838432-552c-41d1-9da9-8ecaffa95b4f": {"__data__": {"id_": "51838432-552c-41d1-9da9-8ecaffa95b4f", "embedding": null, "metadata": {"page_label": "10", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "211ae5a8-aeaf-4f78-a2a1-9bf5cde183b7", "node_type": "4", "metadata": {"page_label": "10", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "bc2246cee9fba476d00e8d2390350b3eacc036c10ff60ef2401eab07685a5171", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ce3a7b34-3ffd-4a7d-a7c0-86debf453268", "node_type": "1", "metadata": {}, "hash": "6231ea5e4d3cac4aa56e79f90315d9ce64727034c5098c0e83d3850554518606", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "studies have not been published yet, but Vaxart announced that\ntheir vaccine candidate was safe and effective.83,84 The vaccine\ncandidate is currently being evaluated in Phase 1 clinical trials.85\nMVA-SARS-2-S, is a vaccine candidate that uses a MVA\nvirus as a vector. It is developed by the University of Munich\nin Germany. MVA is a highly attenuated strain of vaccinia\nvirus originating from growth selection on chicken embryo\ntissue cultures, showing a characteristic replication defect in\nmammalian cells, and allows unimpaired production of heterol-\nogous proteins. MVA is a weakened poxvirus approved by the\nU.S. Food and Drug Administration for the prevention of small-\npox and monkeypox.86 The vaccine candidate is under investi-\ngation in Phase 1 clinical trials.87\nCOH04S1 (MVA-SARS-2-S) is based on a synthetic MVA\n(sMVA) platform. It is developed by the City of Hope\nMedical Center in California. The vaccine candidate contains\nthe SARS-CoV-2 S and N proteins inserted into the MVA plat-\nform. MVA can replicate DNA within cells, leading to the\nexpression of SARS-CoV-2 proteins in order to trigger host\nimmunity against the virus. The vaccine candidate is currently\nbeing evaluated in Phase 1 clinical trials.88\nBBV154 is an intranasal vaccine candidate that is developed\nby Bharat Biotech in India. It uses a non-replicating Ad5 vector\nplatform to present S protein antigen to the immune system.\nSimilar with other mucosal vaccines, it stimulates a broad\nimmune response including neutralizing IgG, mucosal IgA,\nand T cell responses.89 Currently, the vaccine candidate is\nunder investigation in Phase 1 clinical trials.90\nChimpanzee Adenovirus serotype 68 (ChAd) and self-\namplifying mRNA (SAM); Gritstone Oncology is working on\na different vaccine platform.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1772, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "ce3a7b34-3ffd-4a7d-a7c0-86debf453268": {"__data__": {"id_": "ce3a7b34-3ffd-4a7d-a7c0-86debf453268", "embedding": null, "metadata": {"page_label": "10", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "211ae5a8-aeaf-4f78-a2a1-9bf5cde183b7", "node_type": "4", "metadata": {"page_label": "10", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "bc2246cee9fba476d00e8d2390350b3eacc036c10ff60ef2401eab07685a5171", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "51838432-552c-41d1-9da9-8ecaffa95b4f", "node_type": "1", "metadata": {"page_label": "10", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "c59da4e47cee2b6aed4aa1fa0260abe55a44a3996e1e1016fb93d24f268af2a3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0fb8196a-1e04-4d67-a31d-59eddc796253", "node_type": "1", "metadata": {}, "hash": "fe5b0bfd3120deb93e642786bf9da6114684023ab2cd52efc00906d906318207", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "In this platform, Chimpanzee\nAdenovirus serotype 68 (ChAd) and SAM vectors are used,\nwhich express either S alone or S plus additional\nSARS-CoV-2 T cell epitopes. This vaccine candidate is under\ninvestigation in Phase 1 clinical trials.91\nSC-Ad6-1 is developed by Tetherex Pharmaceuticals\nCorporation in Oklahoma, USA. It is a novel single-cycle ade-\nnovirus vector (SC-Ad) expressing the SARS-CoV-2 S protein.\nThe SC-Ad6-1 vector undergoes replication in the initial cells\nthat it enters but lacks the genetic information to form infectious\nparticles. Therefore, SC-Ad6-1 utilizes the potency of a rep-\nlication competent adenovirus vector but does not have the\ncapacity to cause adenovirus infections in patients and/or\npersonnel through the formation of infectious particles. The\nvaccine candidate is currently being evaluated in Phase 1\nclinical trials.92\nCVXGA1-001 is developed by CyanVac LLC company in\nUSA. It is a viral vector vaccine that uses Parain\ufb02uenza Virus\nType 5 (PIV5) as the vector which encodes the SARS-CoV-2\nS protein. It is administered intra-nasally. The vaccine candi-\ndate is under investigation in Phase 1 clinical trials.93\nReplicating viral vector vaccines. Covid-19/aAPC vaccine is\ndeveloped by Shenzhen Geno-Immune Medical Institute in\nChina. The COVID-19/aAPC vaccine is prepared by applying\nLV modi\ufb01cation with immune modulatory genes and the viral\nmini-genes to the arti\ufb01cial antigen presenting cells (aAPCs).\nThe COVID-19/aAPCs are then inactivated for proliferation\nand safety is extensively tested. The vaccine candidate is\nunder investigation in Phase 1 clinical trials.94\nrVSV-SARS-CoV-2-S vaccine is developed by Israel Institute\nfor Biological Research in Ness Ziona.", "mimetype": "text/plain", "start_char_idx": 1773, "end_char_idx": 3481, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "0fb8196a-1e04-4d67-a31d-59eddc796253": {"__data__": {"id_": "0fb8196a-1e04-4d67-a31d-59eddc796253", "embedding": null, "metadata": {"page_label": "10", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "211ae5a8-aeaf-4f78-a2a1-9bf5cde183b7", "node_type": "4", "metadata": {"page_label": "10", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "bc2246cee9fba476d00e8d2390350b3eacc036c10ff60ef2401eab07685a5171", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ce3a7b34-3ffd-4a7d-a7c0-86debf453268", "node_type": "1", "metadata": {"page_label": "10", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "3bd2b00cbd5501c96828712246a0e5e1dbda2c799a5a8ca4e049064c867bc900", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8925c1bf-3e89-4ebf-8e63-5be315af0179", "node_type": "1", "metadata": {}, "hash": "aa7ebca4cbd7ff4b599846765cf258505a611e689052fb2d2c54d750fbcfbe5e", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "The vaccine candidate is\nunder investigation in Phase 1 clinical trials.94\nrVSV-SARS-CoV-2-S vaccine is developed by Israel Institute\nfor Biological Research in Ness Ziona. The replication compe-\ntent recombinant VSV-\u0394G-spike vaccine, in which the glyco-\nprotein of VSV is replaced by the S protein of\nSARS-CoV-2.95,96 The VSV can be easily propagated and\nreaches high titers and most of the general population is sero-\nnegative for VSV. Currently the vaccine candidate is under\ninvestigation in Phase 1/2 clinical trials.97\nAV-COVID-19, developed by Aivita Biomedical, Inc, is a\ndendritic cell (DC) vaccine. It is created by using AIVITA\u2019s\nautologous cell therapy platform. In this vaccine platform,\nautologous DCs are extracted and loaded with multiple recom-\nbinant SARS-CoV-2 S antigens to create a vaccine that is spe-\nci\ufb01c to each individual. These cells are re-administered to the\nindividual, with or without GM-CSF, to create fast immune pro-\ntection against the coronavirus. A kit containing all materials is\nprovided to local sites, which can carry out steps with minimal\nequipment, to de-centralize manufacturing even in a third party\nGLP setting. The vaccine candidate is under investigation in\nPhase 1/2 clinical trials.98\nNucleic Acid Vaccines\nSimilar to viral vector vaccines, nucleic acid vaccines introduce\ngenetic instructions (mRNA or DNA encoding the target\nantigen) to host cells for production of disease speci\ufb01c antigens.\nOnce these instructions have been taken by the host cell, the S\nprotein antigen is produced by the host cell itself. The produc-\ntion of these antigens by the host cells effectively elicits both\nantibody production and T-cell induction, which are important\nparameters of vaccine protection. The mRNA vaccine technol-\nogy consists of arti\ufb01cial synthesis of the mRNA sequence of the\nSARS-CoV-2 that encodes the S protein.", "mimetype": "text/plain", "start_char_idx": 3309, "end_char_idx": 5173, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "8925c1bf-3e89-4ebf-8e63-5be315af0179": {"__data__": {"id_": "8925c1bf-3e89-4ebf-8e63-5be315af0179", "embedding": null, "metadata": {"page_label": "10", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "211ae5a8-aeaf-4f78-a2a1-9bf5cde183b7", "node_type": "4", "metadata": {"page_label": "10", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "bc2246cee9fba476d00e8d2390350b3eacc036c10ff60ef2401eab07685a5171", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0fb8196a-1e04-4d67-a31d-59eddc796253", "node_type": "1", "metadata": {"page_label": "10", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "07c8c7e5b434358a8c7df5fb5cf6fe80041490fdbe75a4a21212acb99bca779c", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "The mRNA vaccine technol-\nogy consists of arti\ufb01cial synthesis of the mRNA sequence of the\nSARS-CoV-2 that encodes the S protein. Incorporation of lipid\nnanoparticles (LNP) into mRNA vaccines protects them from\nenzymatic degradation and ensures ef\ufb01cient cellular uptake.\nFollowing the cellular uptake, mRNA vaccines induce a\nprompt antigen expression, and the expressed antigens generate\nboth humoral and cellular immune responses. When it is com-\npared to other vaccine platforms, the production of mRNA vac-\ncines has less biosafety concerns, making them faster to\nproduce. However, they require ultra-cold conditions for long-\nterm storage.35\u201341\nDNA vaccines use plasmids for this purpose. They generally\ndepend on cloning the SARS-CoV-2 S gene into bacterial plas-\nmids that contain a strong mammalian promoter, such as CMV\nand/or SV40, followed by large plasmid production in a compe-\ntent bacterium. The advantages of plasmid DNA vaccines are\nthat they can target and stimulate both humoral and cellular\nimmune responses, they allow for\ufb02exible and simple large-\nscale production and formulation processes over short periods\nof time, and they offer\ufb02exibility for multivalency and room-\ntemperature storage of the\ufb01nal vaccine. However, because of\n10 Clinical and Applied Thrombosis/Hemostasis", "mimetype": "text/plain", "start_char_idx": 5045, "end_char_idx": 6340, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "be14fb39-8dd9-471d-baea-f11c7f5b05f8": {"__data__": {"id_": "be14fb39-8dd9-471d-baea-f11c7f5b05f8", "embedding": null, "metadata": {"page_label": "11", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "8ef58779-6977-4fb6-bb69-64d6dc4f6015", "node_type": "4", "metadata": {"page_label": "11", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "d30b3c6324f1b4be19f848734eac6714cba1b45ea687536a1b2c40ea8523290d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1dacee84-56c2-4829-a896-85985abb1444", "node_type": "1", "metadata": {}, "hash": "0bf12de36c8af1bd2b153c3f0cf34fdbcfcde65337a27c9c714e3d65cc7b5795", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Table 3. Current Nucleic Acid COVID-19 Vaccines in Clinical Trials\nVaccine Developer Country Schedule Route\nClinical\nEvaluation Status of Approval\nA) RNA Vaccines\nBNT162b2 P \ufb01zer/BioNTech +Fosun Pharma USA \u2014 Germany Day 0 +21 IM Phase 4 Aproved\nmRNA-1273 Moderna +National Institute of Allergy and Infectious\nDiseases\nUSA Day 0 +28 IM Phase 4 Aproved\nmRNA-1273.351. Moderna +National Institute of Allergy and Infectious\nDiseases\nUSA Day 0 or Day 0 +28 or\nDay 56\nIM Phase 4 Not approved yet.\nCVnCoV CureVac AG Germany Day 0 +28 IM Phase 3 Not approved yet.\nARCoV Academy of Military Science (AMS), Walvax\nBiotechnology and Suzhou Abogen Biosciences\nChina Day 0 +14 or\nDay 0+28\nIM Phase 3 Not approved yet.\nmRNA-1273.211. ModernaTX, Inc. USA Day 0 IM Phase 2/3 Not approved yet.\nARCT-021 Arcturus Therapeutics USA \u2014 Singapore ND IM Phase 2 Not approved yet.\nMRT5500 Sano \ufb01 Pasteur and Translate Bio France \u2014 USA Day 0 +21 IM Phase 2 Not approved yet.\nDS-5670a Daiichi Sankyo Co., Ltd Japan IM Phase 1/2 Not approved yet.\nEXG-5003. Elixirgen Therapeutics, Inc USA Day 0 ID Phase 1/2 Not approved yet.\nLNP-nCoVsaRNA Imperial College London United Kingdom ND IM Phase 1 Not approved yet.ChulaCov19 mRNA\nvaccine\nChulalongkorn University Thailand Day 0 +21 IM Phase 1 Not approved yet.\nPTX-COVID19-B Providence Therapeutics Canada Day 0 +28 IM Phase 1 Not approved yet.\nCoV2 SAM GlaxoSmithKline United Kingdom Day 0 +30 IM Phase 1 Not approved yet.\nHDT-301 SENAI CIMATEC Brasil Day 0 +28 IM Phase 1 Not approved yet.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1509, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "1dacee84-56c2-4829-a896-85985abb1444": {"__data__": {"id_": "1dacee84-56c2-4829-a896-85985abb1444", "embedding": null, "metadata": {"page_label": "11", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "8ef58779-6977-4fb6-bb69-64d6dc4f6015", "node_type": "4", "metadata": {"page_label": "11", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "d30b3c6324f1b4be19f848734eac6714cba1b45ea687536a1b2c40ea8523290d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "be14fb39-8dd9-471d-baea-f11c7f5b05f8", "node_type": "1", "metadata": {"page_label": "11", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "b145f5bdcefc84f39f1e679394411025556a494dc81ef22a42474bfc6f431ec9", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CoV2 SAM GlaxoSmithKline United Kingdom Day 0 +30 IM Phase 1 Not approved yet.\nHDT-301 SENAI CIMATEC Brasil Day 0 +28 IM Phase 1 Not approved yet.\nmRNA-1283 ModernaTX, Inc. USA Day 0 +28 IM Phase 1 Not approved yet.\nmRNA COVID-19\nvaccine\nShanghai East Hospital and Stemirna Therapeutics China TBD IM Phase 1 Not approved yet.\nLNP-nCOVsaRNA-02 MRC/UVRI and LSHTM Uganda Research Unit United Kingdom Day 0 +28 IM Phase 1 Not approved yet.\nB) DNA VaccinesZyCoV-D Zydus Cadila Israel Day 0 +28 +56 ID Phase 3 Not approved yet.\nAG0301-COVID19 AnGes +Takara Bio+Osaka University Japan Day 0 +14 IM Phase 2/3 Not approved yet.\nINO-4800 Inovio Pharmaceuticals +International Vaccine Institute+\nAdvaccine (Suzhou) Biopharmaceutical Co., Ltd\nUSA Day 0 +28 ID Phase 2/3 Not approved yet.\nGX-19N Genexine Consortium South Korea Day 0 +\n28 IM Phase 1/2 Not approved yet.\nGLS-5310 GeneOne Life Science, Inc. South Korea Day 0 +56 or\nDay 0+84\nID Phase 1/2 Not approved yet.\nAG0302-COVID19 AnGes, Inc Japan Day 0 +14 +28 IM Phase 1/2 Not approved yet.\nCOVID-eVax Takis +Rottapharm Biotech Italy Day 0 +28 IM or Phase 1/2 Not approved yet.\nCovigenix VAX-001 Entos Pharmaceuticals Inc. Canada Day 0 +14 IM Phase 1 Not approved yet.\nCORVax Providence Health & Services USA Day 0 +14 ID Phase 1 Not approved yet.\nbacTRL-Spike Symvivo Corporation Canada Day 0 Oral Phase 1 Not approved yet.\nCOVIGEN University of Sydney, Bionet Co., Ltd Technovalia Australia Day 0 +28 ID or IM Phase 1 Not approved yet.\n11", "mimetype": "text/plain", "start_char_idx": 1363, "end_char_idx": 2848, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "2d63a75e-0e47-4f72-920c-474e35d1c7d5": {"__data__": {"id_": "2d63a75e-0e47-4f72-920c-474e35d1c7d5", "embedding": null, "metadata": {"page_label": "12", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "b78963f2-1427-4e4b-bd11-712b03dd4aa9", "node_type": "4", "metadata": {"page_label": "12", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "c6786a2563e246676abb9cd6e9ea3378160a1ba3ee4588024886cf809dbd7973", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "75b8f2dd-5803-4d38-b795-8ea9c72c4978", "node_type": "1", "metadata": {}, "hash": "e1421811b76d0f56193fe01260c334591f10fc72f71f1d3306d9da142dcfe9ec", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "their low immunogenicity in humans, they require several doses\nfor optimum protection. Long-term risk of carcinogenesis is\nanother concern for DNA vaccines due to integration of\nplasmid DNA to the host cell.35\u201341\nAs shown on Table 3, there are at least 29 nucleic acid\nCOVID-19 vaccines or vaccine candidates that are registered\nin clinical trials.34 While two of these vaccines are approved\nfor general or emergency use in several countries, the develop-\nmental processes of remaining vaccines are continuing in differ-\nent stages of clinical trials.\nmRNA vaccines. BNT162b2 is a LNP formulated, nucleoside-\nmodi\ufb01ed messenger RNA (mRNA) vaccine, which encodes\nthe RBD of the S1 protein. The RBD is constructed on a\nT4-\ufb01britin derived fold on trimerization base, which helps to\nguide antigen folding into the native trimeric state. The\nN-methyl pseudo-uridine (m1\u03a8) nucleoside modi\ufb01cation pro-\ntects it from innate immunity. It is encapsulated with an LNP\nthat protects it from enzymatic degradation and ensures ef\ufb01cient\ncellular uptake.31\u201333 In the Phase 1 clinical trial, BNT162b2\nelicited high SARS-CoV-2 neutralizing antibody titers with\nrobust T cell responses. In addition, side effects were also\nacceptable, which were mainly composed of short-term local\n(ie, injection site) and systemic responses.99\nIn the Phase 3 clinical trial, a total of 43,448 participants\nwere enrolled: 21,720 receiving BNT162b2 and 21,728 receiv-\ning the placebo.100 A two-dose regimen of BNT162b2 con-\nferred 95% protection against COVID-19 in persons 16 years\nof age or older. Local reactions were common and included\npain, erythema and swelling at injection sites. Transient systemic\nreactions such as fever, fatigue, headache, and muscle and joint\npain were also noted.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1757, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "75b8f2dd-5803-4d38-b795-8ea9c72c4978": {"__data__": {"id_": "75b8f2dd-5803-4d38-b795-8ea9c72c4978", "embedding": null, "metadata": {"page_label": "12", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "b78963f2-1427-4e4b-bd11-712b03dd4aa9", "node_type": "4", "metadata": {"page_label": "12", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "c6786a2563e246676abb9cd6e9ea3378160a1ba3ee4588024886cf809dbd7973", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2d63a75e-0e47-4f72-920c-474e35d1c7d5", "node_type": "1", "metadata": {"page_label": "12", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "86b9d0c8e9f8a50f2bf0a9216344f637ac539f3cf89e325ef19340ebbd34aad2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4a633ea5-b255-408a-8925-b3ce3ec8bb8d", "node_type": "1", "metadata": {}, "hash": "fd66bcdb2b5162f37a32eb1ffe1d409d89fab5197da2c143eceac97dc4a234ae", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Local reactions were common and included\npain, erythema and swelling at injection sites. Transient systemic\nreactions such as fever, fatigue, headache, and muscle and joint\npain were also noted. The number of serious adverse events\nthat were reported were similar, showing 126 (0.6%) serious\nadverse events reported in the vaccine group and 111(0.5%)\nserious adverse events in the placebo group. Only four serious\nadverse events (shoulder injury related to vaccine administration,\nright axillary lymphadenopathy, paroxysmal ventricular arrhyth-\nmia, and right leg paresthesia) can be related with BNT162b2.\nDuring follow-up, two BNT162b2 recipients (one from arterio-\nsclerosis, one from cardiac arrest), and four placebo recipients\n(two from unknown causes, one from hemorrhagic stroke, and\none from myocardial infarction) have died. No deaths were con-\nsidered to be related to the vaccine or placebo.\nThe mRNA-1273 is another mRNA vaccine approved for\nuse. It is developed by Moderna Company in USA. It\nencodes the pre-fusion form of the S antigen that includes a\ntransmembrane anchor and an intact S1 \u2212S2 cleavage site.\nTwo proline substitutions in the vaccine mRNA keep the\nprotein stable in its perfusion conformation. It is also encapsu-\nlated with an LNP. In the Phase 1 dose escalation clinical trial,\nmRNA-1273 showed encouraging results in safety and\nimmunogenicity.101\nIn the Phase 3 trials, 30,420 volunteers were randomly\nassigned in a 1:1 ratio to receive either vaccine or placebo\n(15,210 participants in each group). The ef\ufb01cacy has been\nreported as 94.1% for the prevention of symptomatic\nSARS-CoV-2 infection and 100% for preventing severe\nCOVID-19 as compared with placebo. Although transient\nlocal and systemic reactions were higher in the vaccine recipi-\nents, the frequency of unsolicited adverse events, unsolicited\nsevere adverse events, and serious adverse events reported\nduring the study period were generally similar among partici-\npants in the two groups.", "mimetype": "text/plain", "start_char_idx": 1563, "end_char_idx": 3548, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "4a633ea5-b255-408a-8925-b3ce3ec8bb8d": {"__data__": {"id_": "4a633ea5-b255-408a-8925-b3ce3ec8bb8d", "embedding": null, "metadata": {"page_label": "12", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "b78963f2-1427-4e4b-bd11-712b03dd4aa9", "node_type": "4", "metadata": {"page_label": "12", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "c6786a2563e246676abb9cd6e9ea3378160a1ba3ee4588024886cf809dbd7973", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "75b8f2dd-5803-4d38-b795-8ea9c72c4978", "node_type": "1", "metadata": {"page_label": "12", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "274540b2dad9f6056f6911188ca214af6f0a075d3830e31f6e9680ebe2f13a68", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3da98959-7833-471c-8946-92563a61d93b", "node_type": "1", "metadata": {}, "hash": "65e246b06f260a7d8e15c7206708bd3290887063ff71f6155497e638f695b351", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Three deaths occurred in the placebo\ngroup: (one from intra-abdominal perforation, one from cardio-\npulmonary arrest, and one from severe systemic in\ufb02ammatory\nsyndrome in a participant with chronic lymphocytic leukemia\nand diffuse bullous rash) and two in the vaccine group (one\nfrom cardiopulmonary arrest and one by suicide).102\nThe mRNA-1273.351is another mRNA vaccine that is devel-\noped by Moderna company. It is an LNP-encapsulated\nmRNA-based vaccine that encodes for a full-length, prefusion\nstabilized S protein of the SARS-CoV-2 B.1.351 variant. The\nvaccine candidate is currently being evaluated in Phase 2 clin-\nical trials.103\nThe mRNA-1273.211is a multivalent booster vaccine candi-\ndate developed by Moderna company. The mRNA-1273.211,\nwhich combines mRNA-1273 and mRNA-1273.351 in a\nsingle vaccine. The vaccine candidate is currently being evalu-\nated in Phase 2/3 clinical trials.104\nmRNA-1283 is another vaccine candidate that is developed\nby Moderna company in Massachusetts, USA. It is designed\nas a refrigerator-stable mRNA vaccine to ease the distribution,\nhandling, and administration of vaccination programs, espe-\ncially in developing countries. The vaccine candidate is cur-\nrently being evaluated in Phase 1 clinical trials.105\nCVnCoV is an mRNA vaccine candidate developed by\nCureVacs in T\u00fcbingen, Germany. It is composed of mRNA\nnucleotides which expresses the full-length S protein and for-\nmulated with LNPs. CureVacs has announced that CVnCoV\nremains stable for at least three months when stored at a stand-\nard refrigerator temperature and for up to 24 hours as\nready-to-use vaccine when stored at room temperature. 106\nCureVacs announced the\ufb01nal data from the Phase 2b/3 clinical\ntrial showed an overall vaccine ef \ufb01cacy of 48% against\nCOVID-19 of any severity across all age groups and 15 var-\niants.", "mimetype": "text/plain", "start_char_idx": 3549, "end_char_idx": 5383, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "3da98959-7833-471c-8946-92563a61d93b": {"__data__": {"id_": "3da98959-7833-471c-8946-92563a61d93b", "embedding": null, "metadata": {"page_label": "12", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "b78963f2-1427-4e4b-bd11-712b03dd4aa9", "node_type": "4", "metadata": {"page_label": "12", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "c6786a2563e246676abb9cd6e9ea3378160a1ba3ee4588024886cf809dbd7973", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4a633ea5-b255-408a-8925-b3ce3ec8bb8d", "node_type": "1", "metadata": {"page_label": "12", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "ec113b19faeba4ab9d6b3532097033de8dfb9f562475c8ac8415bffa7bc014e0", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "The ef\ufb01cacy was 53% against disease of any severity,\n77% against moderate and severe disease and 100% against\nhospitalization or mortality. The vaccine candidate is currently\nunder investigation in Phase 3 clinical trials.107\nARCoV is a LNP-encapsulated mRNA vaccine candidate\nfrom China that encodes the RBD of SARS-CoV-2. In preclin-\nical studies with mice and primates, it has been shown that\nimmunization with ARCoV triggers potent T cell mediated\nimmune response and neutralizing antibodies against\nCOVID-19. It is manufactured as a liquid formulation and\ncan be stored at room temperature for at least 1 week.108\nARCoV is currently being evaluated in Phase 3 clinical\ntrials.109\nARCT-021 is a mRNA vaccine candidate developed by\nArcturus Therapeutics in California. It combines self-\ntranscribing and replicating mRNA (STARR \u2122) with\nLUNAR\u00ae lipid-mediated delivery technology, which is\n12 Clinical and Applied Thrombosis/Hemostasis", "mimetype": "text/plain", "start_char_idx": 5384, "end_char_idx": 6320, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "51eafc70-f43e-4298-8687-2409c97f3a2f": {"__data__": {"id_": "51eafc70-f43e-4298-8687-2409c97f3a2f", "embedding": null, "metadata": {"page_label": "13", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a2980ba1-b4f5-4bf3-acfc-46666d7c0419", "node_type": "4", "metadata": {"page_label": "13", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "bb6a729009f40b581cb316723c03cec6e353f75dd7a948aabe2fc1768a45a514", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "19b7979c-cf21-43bd-9623-1247c8e3bc50", "node_type": "1", "metadata": {}, "hash": "390878f28076255a813b52f98a766eceb9d047ae298354cabaa208d10eaf97ba", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "designed to enhance and extend antigen expression, enabling\nvaccination at lower doses. Arcturus Therapeutics announced\nthat their vaccine candidate requires up to a 40-fold smaller\ndose than other mRNA vaccines. Due to this, ARCT-021 is\nexpected to require less manufacturing capacity than other\nmRNA vaccines. Additionally, it is designed as a single shot,\nlyophilized, non-viral vector vaccine that may potentially\nprovide an extended variant coverage and can also be used\nfor periodic booster doses. The vaccine candidate is currently\nbeing evaluated in Phase 2 clinical trials.110\nMRT5500 is developed by Sano\ufb01 Pasteur company in Lyon,\nFrance and Translate Bio company in Massachusetts, USA. It is\nan mRNA vaccine candidate with 2P/GSAS, S protein modi\ufb01-\ncations of S protein. In MRT5500\u2019s preclinical design, this\nmodi\ufb01cation was selected among several mRNA constructs of\nS protein because it is more effective for immunogenicity and\nprotection from COVID-19.111 MRT5500 is currently being\nevaluated in Phase 2 clinical trials.112\nDS-5670a, is developed by Daiichi Sankyo Co., Ltd in\nJapan. It is an mRNA vaccine candidate that targets\nSARS-CoV-2 S protein. The vaccine candidate is currently\nunder investigation in Phase 1/2 clinical trials.113\nEXG-5003 is a temperature-sensitive self-replicating RNA\nvaccine expressing the RBD of the SARS-CoV-2 S protein. It\nis optimized for intradermal injection with potential\ndose-sparing and safety bene\ufb01ts. The vaccine candidate is cur-\nrently being evaluated in phase 1/2 clinical trials.114\nLNP-nCoVsaRNA is developed by Imperial College London\nin the UK. It is a puri\ufb01ed, synthetic mRNA vaccine candidate\nencoding the S glycoprotein of SARS-CoV-2 virus. The\nvaccine candidate is currently under investigation in Phase 1\nclinical trials.115\nChulaCov19 is an mRNA vaccine candidate that is devel-\noped by Chulalongkorn University in Thailand.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1891, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "19b7979c-cf21-43bd-9623-1247c8e3bc50": {"__data__": {"id_": "19b7979c-cf21-43bd-9623-1247c8e3bc50", "embedding": null, "metadata": {"page_label": "13", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a2980ba1-b4f5-4bf3-acfc-46666d7c0419", "node_type": "4", "metadata": {"page_label": "13", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "bb6a729009f40b581cb316723c03cec6e353f75dd7a948aabe2fc1768a45a514", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "51eafc70-f43e-4298-8687-2409c97f3a2f", "node_type": "1", "metadata": {"page_label": "13", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "371f3eda5ca203e24595aaf55fa9a7a71d4a6e42b9566eda72ebd12e7020f172", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7fee2ea4-22a8-4502-9efa-d14a97b0d633", "node_type": "1", "metadata": {}, "hash": "ef1b6258e2f7ac022b06a68419b8546ac4b18a49a33d77eee6ac7dd15ba01e88", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "The\nvaccine candidate is currently under investigation in Phase 1\nclinical trials.115\nChulaCov19 is an mRNA vaccine candidate that is devel-\noped by Chulalongkorn University in Thailand.\nChulalongkorn University announced that ChulaCov19 can\nbe stored in refrigerators for 3 months and at room temperature\nfor 2 weeks. The vaccine candidate is currently being evaluated\nin Phase 1 clinical trials.116\nPTX-COVID19-B, is an mRNA vaccine candidate that is\ndesigned by Providence Therapeutics in Canada. The vaccine\ncandidate encodes a full-length membrane-anchored S protein\ntaken from the Wuhan-Hu-1 isolate with a D614G mutation\nto match predominant SARS-CoV-2 variant strains in circula-\ntion. The vaccine candidate is currently under investigation in\nPhase 1 clinical trials.117\nCoV2 SAM is developed by GlaxoSmithKline company in\nthe UK. It is a self-amplifying mRNA (SAM) vaccine candidate\nthat targets the S protein of SARS-CoV2 virus. Similar to other\nmRNA vaccines, it is coated with an LNP. The vaccine candi-\ndate is currently being evaluated in Phase 1 clinical trials.118\nHDT-301 is a self-replicating mRNA vaccine candidate from\nBrazil, formulated with a novel Lipid-Inorganic Nanoparticle\n(LION\u2122) that encodes for a full-length S protein of the\nSARS-CoV-2 virus. As a self-replicating mRNA vaccine, it is\nconsidered to allow dose sparing and possibly a single dose\nvaccine in comparison with current mRNA platforms. The\nvaccine candidate is currently under investigation in Phase 1\nclinical trials.119\nCOVID-19 mRNAis a vaccine candidate that is developed by\nStemirna Therapeutics and Shanghai East Hospital in China. It\nis a mRNA vaccine that targets the S protein. The vaccine can-\ndidate is currently under investigation in Phase 1 clinical\ntrials.120\nLNP-nCOV saRNA-02 is a vaccine candidate that is devel-\noped by Imperial College London in the UK.", "mimetype": "text/plain", "start_char_idx": 1705, "end_char_idx": 3570, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "7fee2ea4-22a8-4502-9efa-d14a97b0d633": {"__data__": {"id_": "7fee2ea4-22a8-4502-9efa-d14a97b0d633", "embedding": null, "metadata": {"page_label": "13", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a2980ba1-b4f5-4bf3-acfc-46666d7c0419", "node_type": "4", "metadata": {"page_label": "13", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "bb6a729009f40b581cb316723c03cec6e353f75dd7a948aabe2fc1768a45a514", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "19b7979c-cf21-43bd-9623-1247c8e3bc50", "node_type": "1", "metadata": {"page_label": "13", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "3c62ae06e55009b624639ea30b1f9c505de6b083601c1478036017d7d85e5d32", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a56cc89d-18f9-485c-85c2-ef01d8974fea", "node_type": "1", "metadata": {}, "hash": "36838e3fab53390a0a8b9b9dcd4f11e9b778c4e40d2b3e38ff1138cde22a6fa6", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "The vaccine can-\ndidate is currently under investigation in Phase 1 clinical\ntrials.120\nLNP-nCOV saRNA-02 is a vaccine candidate that is devel-\noped by Imperial College London in the UK. It is a self-\namplifying RNA encapsulated in LNPs. The vaccine candidate\nis currently being evaluated in Phase 1 clinical trials.121\nDNA vaccines. ZyCoV-D is a DNA plasmid vector vaccine can-\ndidate from Israel, that encodes the S protein of SARS-CoV-2\nvirus. The vaccine is given as an intra-dermal injection using\na spring-powered jet injector. The vaccine candidate is currently\nbeing evaluated in Phase 3 clinical trials.122,123\nThe AG0301\u2014COVID-19 is developed by AnGes Inc. and\nOsaka University in Japan. It is a plasmid DNA vaccine candi-\ndate that targets S protein of COVID-19 virus. The vaccine can-\ndidate is currently under investigation in Phase 2/3 clinical\ntrials.124\nINO-4800 is developed by Inovio Pharmaceuticals in\nPennsylvania, USA. It is a nucleic-acid-based vaccine candi-\ndate that contains the plasmid pGX9501, which encodes for\nthe entire length of the S glycoprotein of SARS-CoV-2 virus.\nIt is stable at room temperature for more than a year and does\nnot require freezing for transport or storage. Inovio introduced\na proprietary hand-held smart device called CELLECTRA\u00ae,\nwhich uses a brief electrical pulse to open small pores in the\ncell reversibly to allow the plasmids to enter. This allows an\noptimal entry of plasmids with DNA into cells and provides a\nbetter immune response. The vaccine candidate is currently\nbeing evaluated in Phase 2/3 clinical trials.125\u2013127\nGX-19N is developed by the Korean biotech company\nGenexine. It is a DNA vaccine candidate that encodes both S\nand N proteins of SARS-CoV-2 virus.", "mimetype": "text/plain", "start_char_idx": 3384, "end_char_idx": 5113, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "a56cc89d-18f9-485c-85c2-ef01d8974fea": {"__data__": {"id_": "a56cc89d-18f9-485c-85c2-ef01d8974fea", "embedding": null, "metadata": {"page_label": "13", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a2980ba1-b4f5-4bf3-acfc-46666d7c0419", "node_type": "4", "metadata": {"page_label": "13", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "bb6a729009f40b581cb316723c03cec6e353f75dd7a948aabe2fc1768a45a514", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7fee2ea4-22a8-4502-9efa-d14a97b0d633", "node_type": "1", "metadata": {"page_label": "13", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "cee7a090c270811ff95ff3b537e1d39f82cda586fe42ebcf877797a817d6dcae", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "It is a DNA vaccine candidate that encodes both S\nand N proteins of SARS-CoV-2 virus. The vaccine candidate\nis currently being evaluated in Phase 1/2 clinical trials.128\nGLS-5310 is a DNA vaccine candidate encoding the S\nprotein and a second antigenic target of SARS-CoV-2. It is\ndeveloped by GeneOne Life Science, Inc. in South Korea.\nThe vaccine candidate is currently under investigation in\nPhase 1/2 clinical trials.129\nAG0302-COVID19 is another DNA vaccine candidate\ndeveloped by AnGes, Inc in Japan. It encodes the S protein\nof SARS-CoV-2. The vaccine candidate is currently being eval-\nuated in Phase 1/2 clinical trials.130\nCOVID-eVax, is a plasmid DNA vaccine candidate from\nItaly. It targets the RBD of S protein. It is administered as an\nintramuscular injection followed by a short, low voltage, elec-\ntrical pulse application. The procedure is called\nElectro-Gene-Transfer (EGT) which allows ef \ufb01cient DNA\ntransfer into the host cells. The vaccine candidate \u2019s EGT\nsystem is based on a special Cliniporator\u2122 technology which\nis already available for use in cancer patients in Europe. The\nKantarcioglu et al. 13", "mimetype": "text/plain", "start_char_idx": 5028, "end_char_idx": 6150, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "9b0234d0-94c3-4844-b52b-4f5046836b4c": {"__data__": {"id_": "9b0234d0-94c3-4844-b52b-4f5046836b4c", "embedding": null, "metadata": {"page_label": "14", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "4298f04d-6f99-48e7-bb95-9f26e912c4e1", "node_type": "4", "metadata": {"page_label": "14", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "3509c7ec1bd42f08a032285db00244e6ab4aa041194c03bcd3ff7294762e58a4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e7a6430e-652d-4768-acdb-141bd3422b5d", "node_type": "1", "metadata": {}, "hash": "4fcdf765091f5e0df5a4b98eb7dce5eae147e224caa687a461a4277a2346c208", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "vaccine candidate is currently under investigation in Phase 1/2\nclinical trials.131\nCovigenix VAX-001is developed by Entos Pharmaceuticals\nInc in Canada. It is a DNA vaccine candidate that uses a proteo-\nlipid vehicle (PLV) formulation. The vaccine candidate is cur-\nrently being evaluated in Phase 1 clinical trial.132\nCORVax is a S protein plasmid DNA vaccine candidate that\nis developed by Providence Health & Services in USA. It uses\nimmune stimulant plasmid IL-12 to promote a better immune\nresponse against the SARS-CoV-2 virus. CORVax is currently\nunder investigation in a Phase 1 clinical trial.133\nbacTRL-Spike is an oral DNA vaccine candidate that is\ndeveloped by Symvivo Corporation in Canada. It is composed\nof a bacterial medium with colony-forming-units of live\nBi\ufb01dobacterium longum which is engineered to deliver syn-\nthetic DNA encoding S protein by plasmids. Bacterially medi-\nated delivery of plasmid DNA bacTRL product produces,\nsecretes and delivers plasmid DNA to human cells. The\nvaccine candidate is currently being evaluated in Phase 1 clin-\nical trials.134\nCOVIGEN is a DNA vaccine candidate developed by\nTechnovalia company in Australia. The delivery of the\nvaccine is via a needle-free device which penetrates the skin\nwith a jet spray. The vaccine candidate is under investigation\nin Phase 1 clinical trial.135\nRecombinant Protein Based Vaccines\nSubunit vaccines are based on targeting viral protein subunits.\nBesides the S protein, SARS-CoV-2 has other structural pro-\nteins such as membrane (M), envelope (E) and N proteins.\nAntibodies that target M and E proteins have failed to neutralize\nthe COVID-19 infection. For this reason, these 2 proteins are\ncurrently not considered as target antigen for COVID-19 vac-\ncines. On the other hand, N protein is highly immunogenic\nand induces robust humoral and cellular immune responses.\nTo produce these recombinant protein vaccines, bacterial\nexpression systems represent the most commonly used techni-\nque.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1982, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "e7a6430e-652d-4768-acdb-141bd3422b5d": {"__data__": {"id_": "e7a6430e-652d-4768-acdb-141bd3422b5d", "embedding": null, "metadata": {"page_label": "14", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "4298f04d-6f99-48e7-bb95-9f26e912c4e1", "node_type": "4", "metadata": {"page_label": "14", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "3509c7ec1bd42f08a032285db00244e6ab4aa041194c03bcd3ff7294762e58a4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9b0234d0-94c3-4844-b52b-4f5046836b4c", "node_type": "1", "metadata": {"page_label": "14", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "7a605e0c6da1e1f4bb5993e23a2ec2b568e03a825e23521e781060a0414d8f2e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c2826f2a-699d-460e-9b8a-7be5b47a7856", "node_type": "1", "metadata": {}, "hash": "f071c8a3150d0a480ae1308709ac1e8981b344ebd2e6a251b84bc59d7ee56f66", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "On the other hand, N protein is highly immunogenic\nand induces robust humoral and cellular immune responses.\nTo produce these recombinant protein vaccines, bacterial\nexpression systems represent the most commonly used techni-\nque. These vaccines often require multiple doses and effective\nadjuvants to obtain a robust immune response. As live virus\nhandling is not required, the subunit vaccine manufacturing\nprocess is safer and simpler, although manufacturing these vac-\ncines can be dif\ufb01cult for mass vaccinations.35\u201341 To date, four\nsubunit vaccines are available for use. These are\nNVX-CoV2373, EpiVacCorona, Zi\ufb01Vax and FINLAY-FR-2\nvaccines.\nAs depicted on Table 4, there are at least 40 recombinant\nprotein based COVID-19 vaccines or vaccine candidates that are\nregistered in clinical trials.34 To date, four subunit vaccines are\napproved for general or emergency use in several countries.\nThese are NVX-CoV2373, EpiVacCorona, Zi \ufb01Vax and\nFINLAY-FR-2 vaccines. The developmental processes of remain-\ning vaccines are continuing in different stages of clinical trials.\nProtein subunit vaccines. NVX-CoV2373 is a recombinant\nSARS-CoV-2 (rSARS-CoV-2) nanoparticle vaccine\nconstructed from the full-length (including the transmembrane\ndomain) and wild-type SARS-CoV-2 S glycoprotein. The\nvaccine was designed with a special adjuvant called\nMatrix-M\u2122. Matrix-M \u2122, an adjuvant based on saponin\nextracted from the Quillaja saponaria Molina tree induces\nhigh and long-lasting levels of broadly reacting antibodies sup-\nported by a balanced TH1 andTH2 type of response. Although\nthe mode-of-action of Matrix-M adjuvant has not been eluci-\ndated in detail; the adjuvant promotes rapid and profound\neffects on cellular drainage to local lymph nodes creating a\nmilieu of activated cells including T cells, B cells, Natural\nKiller cells, neutrophils, monocytes and DCs.", "mimetype": "text/plain", "start_char_idx": 1752, "end_char_idx": 3614, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "c2826f2a-699d-460e-9b8a-7be5b47a7856": {"__data__": {"id_": "c2826f2a-699d-460e-9b8a-7be5b47a7856", "embedding": null, "metadata": {"page_label": "14", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "4298f04d-6f99-48e7-bb95-9f26e912c4e1", "node_type": "4", "metadata": {"page_label": "14", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "3509c7ec1bd42f08a032285db00244e6ab4aa041194c03bcd3ff7294762e58a4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e7a6430e-652d-4768-acdb-141bd3422b5d", "node_type": "1", "metadata": {"page_label": "14", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "b2e6d4832a6e824173fcfc9d8ffb57e8c0a7ab7892aba364ab02f004711a1eb5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fad729ef-da8c-4365-9be1-54dd34011692", "node_type": "1", "metadata": {}, "hash": "91620c738d2c8f239aba6a076ce895ec48b926c2108223c6f198557f294fcaf3", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "From the previ-\nous vaccine studies, it has shown a signi\ufb01cant dose-sparing\neffect and an acceptable safety pro\ufb01le.31\u201333 In the Phase 1-2\nclinical trial, participants were enrolled to receive the vaccine\nor placebo.136 At 35 days, NVX-CoV2373 elicited immune\nresponses that exceeded levels in COVID-19 convalescent\nserum. No serious adverse events were reported. After these\nresults, Phase 3 clinical trials have been launched in many dif-\nferent countries around the world. The results of these trials\nhave been published.137 Novavax announced interim Phase 3\nclinical trial results in the UK and South Africa in March\n2021. The results of these studies showed 100% ef\ufb01cacy in pre-\nventing severe disease. The overall ef\ufb01cacy was 96.4%. In both\nthe UK and South Africa trials, the vaccine was well-tolerated,\nwith low levels of severe, serious and medically attended\nadverse events at day 35, balanced between vaccine and\nplacebo groups. Novavax announced that their vaccine might\nget authorization by the US FDA in May 2021.\nEpiVacCorona is a subunit vaccine containing chemically\nsynthesized peptide immunogens corresponding to selected\nprotective epitopes of SARS-CoV-2 coronavirus S protein, con-\njugated to recombinant SARS-CoV-2 protein N, as a carrier,\nadjuvanted with aluminum hydroxide. 31\u201333 The Phase 1-2\ntrials were published in March 2021. In this study, the\ntwo-dose vaccination scheme induced the production of anti-\nbodies speci\ufb01c to the antigens that make up the vaccine in\n100% of the volunteers.138 No serious adverse events have\nbeen reported. Phase 3 clinical trials were registered in March\n2021 and have not been published yet.139 Russia approved\nEpiVacCorona in October 2020. Turkmenistan approved\nEpiVacCorona in January 2021.", "mimetype": "text/plain", "start_char_idx": 3615, "end_char_idx": 5367, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "fad729ef-da8c-4365-9be1-54dd34011692": {"__data__": {"id_": "fad729ef-da8c-4365-9be1-54dd34011692", "embedding": null, "metadata": {"page_label": "14", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "4298f04d-6f99-48e7-bb95-9f26e912c4e1", "node_type": "4", "metadata": {"page_label": "14", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "3509c7ec1bd42f08a032285db00244e6ab4aa041194c03bcd3ff7294762e58a4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c2826f2a-699d-460e-9b8a-7be5b47a7856", "node_type": "1", "metadata": {"page_label": "14", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "1ee78a8140efd6614fd89d719c6aa06a11a37354b03aa66e512cb6ea8240730a", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Turkmenistan approved\nEpiVacCorona in January 2021.\nZi\ufb01Vax also known as ZF2001 is a recombinant protein\nsubunit vaccine from China manufactured in the Chinese\nHamster Ovary (CHO) cell lines, encoding a dimeric form of\nthe receptor-binding domain of S protein. The vaccine was\njointly developed by the Institute of Microbiology, the\nChinese Academy of Sciences, and Anhui Zhifei Longcom\nBiopharmaceutical. In the Phase 1 and 2 clinical trials, the\nvaccine showed high ef\ufb01cacy with a low side effect\npro\ufb01le.140 China authorized the emergency use of the vaccine\non March 10, 2021. Currently the vaccine candidate is currently\nbeing evaluated in Phase 3 clinical trials.141\nFINLAY-FR-2 or Soberana 02is a COVID-19 vaccine pro-\nduced by the Finlay Institute, a Cuban epidemiological research\ninstitute. It is a conjugate vaccine. It consists of the RBD of the\n14 Clinical and Applied Thrombosis/Hemostasis", "mimetype": "text/plain", "start_char_idx": 5316, "end_char_idx": 6217, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "1c302e1c-5c91-408d-a4ba-01e6c5dccd7b": {"__data__": {"id_": "1c302e1c-5c91-408d-a4ba-01e6c5dccd7b", "embedding": null, "metadata": {"page_label": "15", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "807e3618-d7a6-4343-833b-06d85b548478", "node_type": "4", "metadata": {"page_label": "15", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "c65639a4c58475d9484698fc3b72e4ef4784db215f2dd29f1e3e71229a8b52cc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "32a72e73-22c3-4743-a5a4-38d376c66bb6", "node_type": "1", "metadata": {}, "hash": "73d12e2990129a60c249ce2a740566def851e8939e802efa2eee16ec4858183d", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Table 4. Current Recombinant Protein Based COVID-19 Vaccines in Clinical Trials\nVaccine Developer Country Schedule Route\nClinical\nEvaluation Status of Approval\nA) Protein Subunit Vaccines\nNVX-CoV2373 Novavax USA Day 0 +21 IM Phase 3 Approved\nEpiVacCorona Federal Budgetary Research Institution State Research Center\nof Virology and Biotechnology\u201cVector\u2019\nRussia Day 0 +21 IM Phase 3 Approved\nZi\ufb01vax (ZF2001) Anhui Zhifei Longcom Biopharmaceutical +Institute of\nMicrobiology, Chinese Academy of Sciences\nChina Day 0 +28 or Day 0\n+28 +56\nIM Phase 3 Approved\nFINLAY-FR-2 Instituto Finlay de Vacunas Cuba Day 0 +28 IM Phase 3 Approved\nVAT00002 Sano \ufb01 Pasteur +GSK France \u2014 UK Day 0 +21 IM Phase 3 Not approved yet.\nWest China Hospital\nCOVID-19 vaccine\nWest China Hospital+Sichuan University China Day 0 +28 IM Phase 3 Not approved yet.\nCIGB-66 Center for Genetic Engineering and Biotechnology (CIGB) Cuba Day 0 +14 +28 or\nDay 0+28 +56\nIM Phase 3 Not approved yet.\nNanocovax Nanogen Pharmaceutical Biotechnology Vietnam Day 0 +21 IM Phase 3 Not approved yet.\nSCB-2019 Clover Biopharmaceuticals Inc./GSK/Dynavax Australia \u2014 United\nKingdom\u2014 USA\nDay 0+21 IM Phase 2/3 Not approved yet.\nUB-612 Vaxxinity USA Day 0 +28 IM Phase 2/3 Not approved yet.\nCOVAX-19 Vaxine Pty Ltd/CinnaGen Co. Australia \u2014 Iran Day 0 +21 IM Phase 2 Not approved yet.\nMVC-COV1901 Medigen Vaccine Biologics +Dynavax +National Institute of\nAllergy and Infectious Diseases (NIAID)\nChina\u2014 USA Day 0 +28 IM Phase 2 Not approved yet.\nFINLAY-FR1 Instituto Finlay de Vacunas Cuba Day 0 +28 IM Phase 2 Not approved yet.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1574, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "32a72e73-22c3-4743-a5a4-38d376c66bb6": {"__data__": {"id_": "32a72e73-22c3-4743-a5a4-38d376c66bb6", "embedding": null, "metadata": {"page_label": "15", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "807e3618-d7a6-4343-833b-06d85b548478", "node_type": "4", "metadata": {"page_label": "15", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "c65639a4c58475d9484698fc3b72e4ef4784db215f2dd29f1e3e71229a8b52cc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1c302e1c-5c91-408d-a4ba-01e6c5dccd7b", "node_type": "1", "metadata": {"page_label": "15", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "c59db8391a61fdf58785e52bc760e6b40119fd16faa118b285b3d3f6cca4132f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "aab5d28e-1b5f-45f9-bbc1-5c3c1719de4b", "node_type": "1", "metadata": {}, "hash": "22133c189a1331504af62c3209b2f4a03328cc2338da9fb44e5d8398e04c9da2", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "FINLAY-FR1 Instituto Finlay de Vacunas Cuba Day 0 +28 IM Phase 2 Not approved yet.\nRazi Cov Pars Razi Vaccine and Serum Research Institute Iran Day 0 +21 +51 IM and\nIN\nPhase 2 Not approved yet.\nV-01 Guangdong Provincial Center for Disease Control and\nPrevention/Gaozhou Center for Disease Control andPrevention\nChina Day 0 +21 IM Phase 2 Not approved yet.\nSCB-2020S Clover Biopharmaceuticals AUS Pty Ltd Australia Day 0 +21 IM Phase 2 Not approved yet.\n202-CoV; SARS-CoV-2 Shanghai Zerun Biotechnology +Walvax Biotechnology +\nCEPI\nChina Day 0 +28 IM Phase 2 Not approved yet.\nKBP-COVID-19 Kentucky Bioprocessing Inc. USA Day 0 +21 IM Phase 1/2 Not approved yet.\nCIGB-669 Center for Genetic Engineering and Biotechnology (CIGB) Cuba Day 0 +14 +28 or\nDay 0+28 +56\nIN Phase 1/2 Not approved yet.\nBECOV2 Biological E. Limited Ind \u0131a Day 0 +28 IM Phase 1/2 Not approved yet.\nS-268019 Shionogi China Day 0 +21 IM Phase 1/2 Not approved yet.\nAKS-452 University Medical Center Groningen +Akston Biosciences\nInc.\nNetherlands\u2014 USA Day 0 +28 SC or\nIM\nPhase 1/2 Not approved yet.\nCOVAC-2 University of Saskatchewan Canada Day 0 +28 IM Phase 1/2 Not approved yet.\nGBP510 SK Bioscience Co., Ltd and CEPI South Korea Day 0 +28 IM Phase 1/2 Not approved yet.\nEuCorVac-19 POP Biotechnologies and EuBiologics Co., Ltd South Korea Day 0 +21 IM Phase 1/2 Not approved yet.\nCoVePit OSE Immunotherapeutics France Day 0 IM Phase 1/2 Not approved yet.QazCoVac-P Bagheiat-allah University of Medical Sciences Iran Day 0+21 IM Phase 1/2 Not approved yet.", "mimetype": "text/plain", "start_char_idx": 1492, "end_char_idx": 3020, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "aab5d28e-1b5f-45f9-bbc1-5c3c1719de4b": {"__data__": {"id_": "aab5d28e-1b5f-45f9-bbc1-5c3c1719de4b", "embedding": null, "metadata": {"page_label": "15", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "807e3618-d7a6-4343-833b-06d85b548478", "node_type": "4", "metadata": {"page_label": "15", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "c65639a4c58475d9484698fc3b72e4ef4784db215f2dd29f1e3e71229a8b52cc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "32a72e73-22c3-4743-a5a4-38d376c66bb6", "node_type": "1", "metadata": {"page_label": "15", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "74c0cc04f18218cbe386c5de6b3193810cf378e427b477f247c4ba456e786582", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "IMP CoVac-1 University Hospital T\u00fcbingen Germany Day 0 SC Phase 1 Not approved yet.\nAdimrSC-2f Adimmune Corporation Taiwan ND ND Phase 1 Not approved yet.\nThe University of Queensland Australia Day 0 +28 IM Phase 1 Not approved yet.\n(continued)\n15", "mimetype": "text/plain", "start_char_idx": 3021, "end_char_idx": 3268, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "497cb895-c115-479d-94e7-c0c5c6a406a0": {"__data__": {"id_": "497cb895-c115-479d-94e7-c0c5c6a406a0", "embedding": null, "metadata": {"page_label": "16", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "e041abad-2618-46dd-a041-1dbc2e08bfcd", "node_type": "4", "metadata": {"page_label": "16", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "a94dd787316e0ab5cda3fac8e31ba9cde57f5fdc1c96595b2ad8e9c77beff89b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b1324942-3a5b-4944-b531-a1c12e9eb11d", "node_type": "1", "metadata": {}, "hash": "8200d4f6b6f402abdd4af8db6ef69aa3b2ecd1f9540f88574072abf2289af386", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "SARS-CoV-2 S protein which is conjugated chemically to\ntetanus toxoid. Iran authorized the emergency use of the\nFINLAY-FR-2 in June 2021. 142 The vaccine candidate is\nunder investigation in Phase 3 clinical trials.143\nVAT00002 is a recombinant protein subunit vaccine candi-\ndate from France and the UK that is formulated in three\nforms. While two monovalent forms of the vaccine target\neither D614 or B.1.351 mutations, the bivalent form targets\nboth mutations. It is developed by Sano\ufb01 Pasteur and GSK\ncompanies. The vaccine candidate is currently being evaluated\nin Phase 3 clinical trials.144\nWest China Hospital COVID-19 vaccineis a vaccine candi-\ndate that is developed by West China Hospital and Sichuan\nUniversity in China. This vaccine is made by using baculovirus\nas a vector and expressing SARS-CoV-2 S-RBD in Sf9 cells,\nwhich is puri\ufb01ed by antigen isolation and added with aluminum\nhydroxide adjuvant. Insect cell line Sf9 has been shown as an\nef\ufb01cient protein expression system with eukaryotic protein\nfolding and modi\ufb01cations.145 The vaccine candidate is under\ninvestigation in Phase 3 clinical trials.146\nCIGB-66 is a recombinant protein-based vaccine from Cuba\nthat targets the RBD of SARS-CoV-2 virus. The vaccine candi-\ndate contains aluminum hydroxide as an adjuvant. The vaccine\ncandidate is currently being evaluated in Phase 3 clinical trials.147\nNanocovax is a subunit vaccine candidate that is developed\nand manufactured at Nanogen Pharmaceutical Biotechnology\nin Vietnam.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1496, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "b1324942-3a5b-4944-b531-a1c12e9eb11d": {"__data__": {"id_": "b1324942-3a5b-4944-b531-a1c12e9eb11d", "embedding": null, "metadata": {"page_label": "16", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "e041abad-2618-46dd-a041-1dbc2e08bfcd", "node_type": "4", "metadata": {"page_label": "16", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "a94dd787316e0ab5cda3fac8e31ba9cde57f5fdc1c96595b2ad8e9c77beff89b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "497cb895-c115-479d-94e7-c0c5c6a406a0", "node_type": "1", "metadata": {"page_label": "16", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "c045595def34e97409c6a1160dfb7a7c5c0700ce152a148304a516c6aa74382b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "16ef63c1-1b3c-4b5b-9ada-5bae87f0e448", "node_type": "1", "metadata": {}, "hash": "69413d7220b617aa1996aaca30322e658185ecbf408a791e3742252f6a8cf820", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "The vaccine\ncandidate is currently being evaluated in Phase 3 clinical trials.147\nNanocovax is a subunit vaccine candidate that is developed\nand manufactured at Nanogen Pharmaceutical Biotechnology\nin Vietnam. It contains the full-length pre-fusion stabilized\nrecombinant S glycoprotein of SARS-CoV-2 virus and alumi-\nnum hydroxide adjuvant.148 The vaccine candidate is under\ninvestigation in Phase 3 clinical trials.149\nSCB-2019 is a recombinant protein-based vaccine from\nAustralia, UK and USA which consists of a trimeric form of\nthe S protein (S-Trimer) formulated with either CpG 1018\nwith Alum adjuvant or AS03 preparations. CpG 1018 is a\nTLR9 agonist that increases vaccine ef\ufb01cacy. AS03 is an\noil-in-water emulsion adjuvant which is composed of\n\u03b1-tocopherol, squalene and polysorbate 80.150 The vaccine can-\ndidate is currently being evaluated in Phase 2/3 clinical trials.\nUB-612 is developed by Vaxxinity company in USA. It\ntargets the S protein of SARS-CoV-2. It can be stored at temper-\natures between 2 \u00b0C-8 \u00b0C. The vaccine candidate is under inves-\ntigation in Phase 2/3 clinical trials.151\nCOVAX-19 or Spikogen is developed by Vaxine Pty Ltd/\nCinnaGen Co from Australia and Iran. It is a monovalent recom-\nbinant protein subunit vaccine candidate that targets S protein of\nthe SARS-CoV-2 virus. Currently, this COVID-19 candidate\nvaccine is being evaluated in Phase 2 clinical trial.152,153\nMVC-COV1901 is another protein subunit vaccine candidate\nfrom China and USA.", "mimetype": "text/plain", "start_char_idx": 1287, "end_char_idx": 2769, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "16ef63c1-1b3c-4b5b-9ada-5bae87f0e448": {"__data__": {"id_": "16ef63c1-1b3c-4b5b-9ada-5bae87f0e448", "embedding": null, "metadata": {"page_label": "16", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "e041abad-2618-46dd-a041-1dbc2e08bfcd", "node_type": "4", "metadata": {"page_label": "16", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "a94dd787316e0ab5cda3fac8e31ba9cde57f5fdc1c96595b2ad8e9c77beff89b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b1324942-3a5b-4944-b531-a1c12e9eb11d", "node_type": "1", "metadata": {"page_label": "16", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "dbdb29ce90790c98078d31a2de2bd9160c6d60f450f3877f77d4d4a3a56fe624", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7398bddd-d207-4501-8a69-003df36c13d9", "node_type": "1", "metadata": {}, "hash": "8ca4751600ea2563be5d28f1dcd30dc6f9c83238ceaeb4cecc351dbe1c9342ea", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Currently, this COVID-19 candidate\nvaccine is being evaluated in Phase 2 clinical trial.152,153\nMVC-COV1901 is another protein subunit vaccine candidate\nfrom China and USA. It is based on a prefusion SARS-CoV-2 S\nimmunogen with CpG 1018 and aluminum hydroxide serving\nas adjuvants.154,155 The vaccine candidate is currently being\nevaluated in Phase 2 clinical trials.156\nFINLAY-FR1 is a COVID-19 vaccine produced by the\nFinlay Institute in Cuba. It is a vaccine candidate that targets\nthe RBD of S protein.157 This vaccine candidate is currently\nunder investigation in Phase 2 clinical trials.158\nTable 4. (continued)\nVaccine Developer Country Schedule Route\nClinical\nEvaluation Status of Approval\nSARS-CoV-2 Sclamp\nvaccine\nSK SARS-CoV-2\n(NBP2001)\nSK Bioscience Co., Ltd South Korea Day 0 +28 IM Phase 1 Not approved yet.\nName not provided yet. Walter Reed Army Institute of Research (WRAIR) USA Day 0 +28 +180 IM Phase 1 Not approved yet.\nReCOV Jiangsu Rec-Biotechnology China Day 0 +21 IM Phase 1 Not approved yet.\nCoV2-OGEN1 Research Institute for Biological Safety Problems Russia Day 0 +/- 14 Oral Phase 1 Not approved yet.\nBaiya SARS-CoV-2 VAX1 Baiya Phytopharm Co., Ltd Thailand Day 0 +21 IM Phase 1 Not approved yet.\nB) Virus like particle VaccinesCoVLP Medicago Inc. Canada Day 0 +21 IM Phase 2/3 Not approved yet.\nRBD SARS-CoV-2 HBsAg\nVLP vaccine\nSerum Institute of India+Accelagen Pty+SpyBiotech India Day 0 +28 IM Phase 1/2 Not approved yet.\nVBI-2902a VBI Vaccines Inc. Canada Day 0 +28 IM Phase 1/2 Not approved yet.", "mimetype": "text/plain", "start_char_idx": 2597, "end_char_idx": 4126, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "7398bddd-d207-4501-8a69-003df36c13d9": {"__data__": {"id_": "7398bddd-d207-4501-8a69-003df36c13d9", "embedding": null, "metadata": {"page_label": "16", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "e041abad-2618-46dd-a041-1dbc2e08bfcd", "node_type": "4", "metadata": {"page_label": "16", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "a94dd787316e0ab5cda3fac8e31ba9cde57f5fdc1c96595b2ad8e9c77beff89b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "16ef63c1-1b3c-4b5b-9ada-5bae87f0e448", "node_type": "1", "metadata": {"page_label": "16", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "edb7473b3f94d4c6cb8ede647571b802539f4a47584bed7f36ef53d8ab8b640c", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "VBI-2902a VBI Vaccines Inc. Canada Day 0 +28 IM Phase 1/2 Not approved yet.\nSARS-CoV-2 VLP Vaccine The Scienti\ufb01c and\nTechnological ResearchCouncil of Turkey\nTurkey Day 0 SC Phase 1 Not approved yet.\nABNCoV2 Radboud University Netherlands Day 0 +28 IM Phase 1 Not approved yet.\n16", "mimetype": "text/plain", "start_char_idx": 4051, "end_char_idx": 4330, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "f09d1838-a681-4c76-893c-e5f5e69551f6": {"__data__": {"id_": "f09d1838-a681-4c76-893c-e5f5e69551f6", "embedding": null, "metadata": {"page_label": "17", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "c0f03fd7-3c41-4ff5-a615-578abb7836cb", "node_type": "4", "metadata": {"page_label": "17", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "9a72d237982fbcfae28841c94c79ed38daf194c5b94e171523dfde59bf0acd8e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "355e5c34-3d5a-4abe-80bf-6d706a01d29d", "node_type": "1", "metadata": {}, "hash": "e8eeb0ed7800f6a5d6a233ab1d2fc907056b0738c0ca876d6836b5a565775f91", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Razi Cov Parsis developed under the leadership of Iran\u2019s\nHealth Ministry and Food and Drug Organization expertise. It\nis an injected-inhaled recombinant corona protein vaccine\nwhich is currently being evaluated in Phase 2 clinical trial.159\nV-01 is a recombinant protein vaccine from China that\ntargets RBD of S protein. However RBD is armed with an\ninterferon-\u03b1 at the N-terminus and dimerized by human IgG1\nFc at the C-terminus (named I-R-F) to target and activate\nDCs to migrate toward the local draining lymph nodes, thus\nenhancing antigen processing and presentation. 160 This\nvaccine candidate is currently under investigation in Phase 2\nclinical trials.161\nSCB-2020S is developed by Clover Biopharmaceuticals\nAUS Pty Ltd in China. It targets the SARS-CoV-2 trimeric\nS-protein from B.1.351 variant. The vaccine candidate is cur-\nrently being evaluated in phase 2 clinical trials.162\n202-CoV is developed by Shanghai Zerun Biotechnology\nCo. Ltd in China. It is a protein subunit vaccine targeting S\nprotein of SARS-CoV-2. The vaccine candidate is currently\nbeing evaluated in Phase 2 clinical trials.163\nKBP-COVID-19 is a plant-based subunit vaccine from USA\ncandidate that targets S protein. Kentucky BioProcessing Inc.\n(KBP) is primarily known for utilizing tobacco plants for the\nproduction of vaccines along with other biopharmaceutical\nproducts. KBP has utilized N. benthamiana as a bioreactor\nfor the production of the target S protein. The widely used agro-\nin\ufb01ltration technique is also employed by KBP to in\ufb01ltrate the\ntobacco leaves with the genetically modi\ufb01ed A. tumefaciensto\nenable the production of the target protein. This indirect gene\ntransfer technique increases the rate of transgene expression.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1720, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "355e5c34-3d5a-4abe-80bf-6d706a01d29d": {"__data__": {"id_": "355e5c34-3d5a-4abe-80bf-6d706a01d29d", "embedding": null, "metadata": {"page_label": "17", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "c0f03fd7-3c41-4ff5-a615-578abb7836cb", "node_type": "4", "metadata": {"page_label": "17", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "9a72d237982fbcfae28841c94c79ed38daf194c5b94e171523dfde59bf0acd8e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f09d1838-a681-4c76-893c-e5f5e69551f6", "node_type": "1", "metadata": {"page_label": "17", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "aebc8078a0e9986057590e39bbe25641d80a3aa8c0ce9e307d04a35983702e43", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "16dc24cd-81ef-4da7-a9bd-193de4d8e75c", "node_type": "1", "metadata": {}, "hash": "e5166bdabda6d56e9a7f94441f932507859cea2d601823c9eb6f5e6cd1bd0dd7", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "This indirect gene\ntransfer technique increases the rate of transgene expression.\nThe vaccine candidate is under investigation in Phase 1/2 clin-\nical trials.164\nCIGB-669 (Mambisa) is a conjugate subunit vaccine from\nCuba that uses the hepatitis B protein as an antigen. It will be\napplied nasally, with the ability to stimulate the immune\nresponse at the mucosal level, the\ufb01rst barrier against a patho-\ngen. The vaccine candidate is currently under investigation in\nPhase 1/2 clinical trials.165\nBECOV2 is developed by Indian company Biological E. The\nvaccine candidate has an antigen developed by the Texas\nChildren\u2019s Hospital Center for Vaccine Development and\nin-licensed from BCM Ventures, Baylor College of\nMedicine\u2019s integrated commercialisation team, and Dynavax\nTechnologies\u2019advanced adjuvant, CpG 1018. The vaccine can-\ndidate is currently under investigation in Phase 1/2 clinical\ntrials.166\nS-268019 is a recombinant protein vaccine candidate from\nChina that contains a puri\ufb01ed S antigen protein. The vaccine\ncandidate was developed by a special platform called\nBaculovirus Expression Vector System (BEVS) for production.\nThe vaccine candidate is currently under investigation in Phase\n1/2 clinical trials.167\nAKS-452 is a biologically engineered SARS-CoV-2-RBD-\nFc fusion protein vaccine candidate from Netherlands. In this\nvaccine candidate full RBD of SARS-CoV-2 is fused with Fc\nportion of an immunoglobulin molecule, providing better\npresentation of the S antigen to the immune system. The\nvaccine candidate is currently under investigation in Phase 1/\n2 clinical trials.168\nCOVAC-2 is developed by the University of Saskatchewan\nin Canada. The vaccine candidate contains a portion of the\nSARS-CoV-2 S protein, called S1. COVAC-2 contains a\nSWE adjuvant. This adjuvant belongs to a family of oil-based\nadjuvants that have been previously used in in\ufb02uenza vaccines.", "mimetype": "text/plain", "start_char_idx": 1639, "end_char_idx": 3520, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "16dc24cd-81ef-4da7-a9bd-193de4d8e75c": {"__data__": {"id_": "16dc24cd-81ef-4da7-a9bd-193de4d8e75c", "embedding": null, "metadata": {"page_label": "17", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "c0f03fd7-3c41-4ff5-a615-578abb7836cb", "node_type": "4", "metadata": {"page_label": "17", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "9a72d237982fbcfae28841c94c79ed38daf194c5b94e171523dfde59bf0acd8e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "355e5c34-3d5a-4abe-80bf-6d706a01d29d", "node_type": "1", "metadata": {"page_label": "17", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "11a4eba2b4327bf4b098dbdec5233034b2a7b8cae91deaa99eb5296971351831", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "499d12d2-bcd0-4a92-9a46-be68bc255779", "node_type": "1", "metadata": {}, "hash": "71fdb20b920651963ff0768b9dbec3c2e8a18d26e60dd4aa36a0184f755aa93d", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "COVAC-2 contains a\nSWE adjuvant. This adjuvant belongs to a family of oil-based\nadjuvants that have been previously used in in\ufb02uenza vaccines.\nThe vaccine candidate is currently under investigation in Phase\n1/2 clinical trials.169\nGBP510 is a recombinant protein vaccine candidate from\nSouth Korea, that targets RBD of S protein. The nanoparticle\ntechnology applied to this vaccine candidate provides signi\ufb01-\ncant dose-sparing effect. The vaccine candidate can be stored\nat refrigerator conditions.170 The vaccine candidate is currently\nunder investigation in Phase 1/2 clinical trials.171\nEuCorVac-19 is a recombinant protein vaccine from South\nKorea, that targets the S protein. The vaccine candidate is cur-\nrently under investigation in Phase 1/2 clinical trials.172\nCoVePit is another recombinant protein vaccine that is\ndeveloped by OSE Immunotherapeutics in France. The\nvaccine candidate incorporates 11 neoepitope targets chosen\nfollowing bioinformatic analysis of more than 167,000 different\nSARS-CoV-2 sequences collected globally. Selection and gen-\neration of this SARS-CoV-2 multi-target peptide vaccine (tar-\ngeting S, M, N, and several non-structural proteins), cover for\nalready observed up to 46,000 SARS-CoV-2 sequences with\nrecurrent mutations isolated worldwide and is ready to use for\nfuture virus evolution. The vaccine candidate is currently\nunder investigation in Phase 1/2 clinical trials.173\nQazCoVac-P is a recombinant protein vaccine from Iran,\nthat targets RBD and N-proteins of the SARS-CoV-2 coronavi-\nrus. The vaccine candidate is currently under investigation in\nPhase 1/2 clinical trials.174\nIMP CoVac-1 is a SARS-CoV-2-derived multi-peptide\nvaccine in combination with the TLR 1/2 ligand XS15 from\nGermany. The vaccine candidate is currently under investiga-\ntion in Phase 1 clinical trials.175\nAdimrSC-2f is developed by Adimmune Corporation in\nTaiwan.", "mimetype": "text/plain", "start_char_idx": 3378, "end_char_idx": 5266, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "499d12d2-bcd0-4a92-9a46-be68bc255779": {"__data__": {"id_": "499d12d2-bcd0-4a92-9a46-be68bc255779", "embedding": null, "metadata": {"page_label": "17", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "c0f03fd7-3c41-4ff5-a615-578abb7836cb", "node_type": "4", "metadata": {"page_label": "17", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "9a72d237982fbcfae28841c94c79ed38daf194c5b94e171523dfde59bf0acd8e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "16dc24cd-81ef-4da7-a9bd-193de4d8e75c", "node_type": "1", "metadata": {"page_label": "17", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "5bc1daedcef3e48b79dd3a20b464284b6f7af95370626490549499271a248a6f", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "The vaccine candidate is currently under investiga-\ntion in Phase 1 clinical trials.175\nAdimrSC-2f is developed by Adimmune Corporation in\nTaiwan. It is based on recombinant protein technology.\nAccording to the amino acid sequence of the S-protein\nSARS-CoV-2, a candidate vaccine fragment was designed\nand fused with the Fc fragment gene of human IgG1 antibody\nfor this vaccine. The vaccine candidate is currently under inves-\ntigation in Phase 1 clinical trials.176\nSARS-CoV-2 Sclamp vaccine is an adjuvanted protein\nsubunit vaccine from Australia, that comprises a recombinant\nSARS-CoV-2 S glycoprotein and squalene-oil-in-water adju-\nvant MF59. A molecular clamp is used to stabilize the S\nprotein in the authentic pre-fusion conformation that preserves\nneutralising epitopes present on the virion surface. This mimics\nthe response induced by natural infection and minimises the\ninduction of potentially confounding non-neutralising antibod-\nies. MF59 is a commercially approved adjuvant with a well-\nestablished safety record in children, adults, and older people\nand that elicits strong antibody responses, along with a balanced\nKantarcioglu et al. 17", "mimetype": "text/plain", "start_char_idx": 5120, "end_char_idx": 6276, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "c51fc633-364f-4aa8-a307-4266d6a20be4": {"__data__": {"id_": "c51fc633-364f-4aa8-a307-4266d6a20be4", "embedding": null, "metadata": {"page_label": "18", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "587dc3cd-fde2-4c71-9b40-2473b771f4ce", "node_type": "4", "metadata": {"page_label": "18", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "d0caab3a225473595dcee1775e2dcb361ac0c12192e28252cd2a3c74094cbef7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ae33e657-6d03-40de-81b3-86835125b63f", "node_type": "1", "metadata": {}, "hash": "215a90ac342c9af40dceabd84217af2bced06c55f721a4b8dd75148ed11bcdba", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "T-helper 1 (Th1) and T-helper 2 (Th2) cell response. The\nvaccine candidate is currently under investigation in Phase 1\nclinical trials.177\nSK SARS-CoV-2 (NBP2001) is a recombinant surface\nantigen protein subunit vaccine from South Korea, which is\nadjuvanted with aluminum. The vaccine candidate is currently\nunder investigation in Phase 1 clinical trials.178\nWalter Reed Army Institute of Research in USA developed\nanother recombinant protein vaccine. The researchers in\nWRAIR designed and characterized four categories of engi-\nneered nanoparticle immunogens that recapitulate the structural\nand antigenic properties of pre-fusion S, S1 and RBD.\nAdditionally, a liposomal formulation of QS21 (ALFQ) adju-\nvant has also been used in this vaccine candidate. The\nvaccine candidate is currently under investigation in Phase 1\nclinical trials.179\nReCOV is a recombinant protein vaccine candidate from\nChina, that is developed by Jiangsu Rec-Biotechnology. It is\na two-component vaccine that targets both S and RBD\nprotein of SARS-CoV-2. The vaccine candidate is manufac-\ntured in the Chinese Hamster Ovary (CHO) cell lines. The\nvaccine candidate is currently under investigation in Phase 1\nclinical trials.180\nCoV2-OGEN1 is a recombinant protein based vaccine candi-\ndate from Russia, that targets the S protein. The vaccine candi-\ndate incorporates a novel oral-delivery platform, allowing\nindividuals to obtain immune response orally without injection.\nIt is currently under investigation in Phase 1 clinical trials.181\nBaiya SARS-CoV-2 VAX1 is developed by Baiya\nPhytopharm Co., Ltd in Thailand. It is a RBD-Fc based\nprotein subunit vaccine. The vaccine candidate is currently\nbeing evaluated in Phase 1 clinical trials.182\nVirus like particle vaccines.CoVLP is a COVID-19 vaccine can-\ndidate developed by Medicago company in Canada and\nGlaxoSmithKline company in the UK.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1870, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "ae33e657-6d03-40de-81b3-86835125b63f": {"__data__": {"id_": "ae33e657-6d03-40de-81b3-86835125b63f", "embedding": null, "metadata": {"page_label": "18", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "587dc3cd-fde2-4c71-9b40-2473b771f4ce", "node_type": "4", "metadata": {"page_label": "18", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "d0caab3a225473595dcee1775e2dcb361ac0c12192e28252cd2a3c74094cbef7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c51fc633-364f-4aa8-a307-4266d6a20be4", "node_type": "1", "metadata": {"page_label": "18", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "853b538f6c28040f6066882963f7d1f16bfe36fb3d02b57726ca77edf85aa6cd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "821b7fc2-f9e1-451f-8ddc-a4252d3932cd", "node_type": "1", "metadata": {}, "hash": "0d7ae040cf07a9fc6712d2bf393a1649bbd3760ee4b1946e31611a2eb39acf4d", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "The virus-like particles\nare produced by creating a bacterium engineered with genes\nof the virus, then introducing the bacteria into Nicotiana ben-\nthamiana plants. The plants take up the bacteria virus-derived\ngeneric material, producing in its leaves the virus-like particles,\nwhich are then harvested and extracted. The method of using a\nplant like N. benthamiana has been called\u201cmolecular farming\u201d\nor a \u201cplant-based factory \u201d, having vaccine manufacturing\nadvantages of rapid, low-cost production of proteins, large scal-\nability for production, and safety of using plants for pharmaceu-\ntical production.183 The vaccine candidate is currently under\ninvestigation in Phase 2/3 clinical trials.184\nRBD SARS-CoV-2 HBsAg VLPis a vaccine candidate that is\ndeveloped by Serum Institute of India and SpyBiotech company\nin India. It is a virus-like particle vaccine candidate where the\nRBD antigen is conjugated to the hepatitis B surface antigen.\nVirus-like particles (VLPs) are protein-based vaccines that\nstimulate high immune responses because of their repetitive\nstructures. The vaccine candidate is currently under investiga-\ntion in Phase 1/2 clinical trials.185\nVBI-2902a is an enveloped virus-like particle (eVLP)\nvaccine candidate from Canada, that expresses the\nSARS-CoV-2 S protein and contains an aluminum phosphate\nadjuvant. The vaccine candidate is currently under investigation\nin Phase 1/2 clinical trials.186\nSARS-CoV-2 VLP is developed by The Scienti \ufb01c and\nTechnological Research Council of Turkey. It is a vaccine can-\ndidate that harbors M, N, E, and hexapro modi\ufb01ed S proteins of\nSARS-CoV-2 virus. The vaccine candidate is currently under\ninvestigation in Phase 1 clinical trials.187\nABNCoV2 is developed by Radboud University in\nNetherlands. It is a capsid virus-like particle (cVLP) vaccine\ncandidate. The vaccine is made in insect cells and is linked to\na nanoparticle. It uses an adjuvant called MF59.", "mimetype": "text/plain", "start_char_idx": 1871, "end_char_idx": 3796, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "821b7fc2-f9e1-451f-8ddc-a4252d3932cd": {"__data__": {"id_": "821b7fc2-f9e1-451f-8ddc-a4252d3932cd", "embedding": null, "metadata": {"page_label": "18", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "587dc3cd-fde2-4c71-9b40-2473b771f4ce", "node_type": "4", "metadata": {"page_label": "18", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "d0caab3a225473595dcee1775e2dcb361ac0c12192e28252cd2a3c74094cbef7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ae33e657-6d03-40de-81b3-86835125b63f", "node_type": "1", "metadata": {"page_label": "18", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "d94bba748ba0854fc5acf6622ae12c76a1599f8fb6ca5a2402d16165d76b9ed2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0ef7773c-ac18-4dbb-83d1-5c81e5cec00c", "node_type": "1", "metadata": {}, "hash": "f53567a5d1b8106f2a00d1a8f06567846cdfd877c18db8e940fde69c08abcbeb", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "It is a capsid virus-like particle (cVLP) vaccine\ncandidate. The vaccine is made in insect cells and is linked to\na nanoparticle. It uses an adjuvant called MF59. The vaccine\ncandidate is currently under investigation in Phase 1 clinical\ntrials.188\nCOVID-19 Variants and Vaccine Ef\ufb01cacy\nAll viruses mutate over time, and this includes SARS-CoV-2.\nSince the beginning of the COVID-19 pandemic, several muta-\ntions have risen in the viral genome of SARS-CoV-2, leading to\nmany new variants in different countries. In the analysis of an\ninternational database covering the infections between\nFebruary and May 2020, 5775 new variants have been\nreported.189 A consistent nomenclature has not been established\nfor SARS-CoV-2 variants. Three mainly used nomenclature\nsystems are GISAID (Global Initiative on Sharing Avian\nIn\ufb02uenza Database), Nextstrain Platform and PANGOLIN\n(Phylogenetic Assignment of Named Global Outbreak\nLineages) systems. Currently, eight global clades (S, O, L, V,\nG, GH, GR, and GV) have been identi\ufb01ed in GISAID; thirteen\nmajor clades (19A, 19B, 20A\u201320J and 21A) have been identi-\n\ufb01ed in Nextstrain Platform and six major lineages (A, B, B.1,\nB.1.1, B.1.177, B.1.1.7) have been identi\ufb01ed in PANGOLIN\nsystem.190\u2013193\nAn emerging variant that carries one or more of these muta-\ntions and becomes the responsible agent for the increasing pro-\nportion of the cases is considered as variant of interest (VOI).\nFurther expansion of VOIs, causing public health risks at\nnational or global levels, are considered as variants of concerns\n(VOCs).194,195 In fact, the surveillance of new SARS-CoV-2\nvariants is very important and is carried out by identi\ufb01cation\nof new viral sequences.", "mimetype": "text/plain", "start_char_idx": 3634, "end_char_idx": 5325, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "0ef7773c-ac18-4dbb-83d1-5c81e5cec00c": {"__data__": {"id_": "0ef7773c-ac18-4dbb-83d1-5c81e5cec00c", "embedding": null, "metadata": {"page_label": "18", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "587dc3cd-fde2-4c71-9b40-2473b771f4ce", "node_type": "4", "metadata": {"page_label": "18", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "d0caab3a225473595dcee1775e2dcb361ac0c12192e28252cd2a3c74094cbef7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "821b7fc2-f9e1-451f-8ddc-a4252d3932cd", "node_type": "1", "metadata": {"page_label": "18", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "547a1aad5edc3f31dc13600ec84c05fd3df1b1e7e5c6d7652bc9e8c79b402aed", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "However, genome sequencing capabil-\nities are limited in most parts of the world. More efforts are\nneeded for the necessary surveillance of these variants in an\ninternational level of attention. As national authorities, institu-\ntions and researchers continue to monitor SARS-CoV-2 muta-\ntions, the WHO has assigned simple, easy to say and\nremember labels for key variants of SARS-CoV-2 using\nletters of the Greek alphabet in May 2021. According to these\nlabels four VOCs (Alpha, Beta, Gamma and Delta) and four\nVOIs (Eta, Iota, Kappa and Lambda) have been designated\nfor emerging variants (Table 5).\nA major focus of current research is whether any of these\nmutations have any potential to signi\ufb01cantly alter important\n18 Clinical and Applied Thrombosis/Hemostasis", "mimetype": "text/plain", "start_char_idx": 5326, "end_char_idx": 6091, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "e9d9c288-6dbd-40b6-83bd-b380240aaad1": {"__data__": {"id_": "e9d9c288-6dbd-40b6-83bd-b380240aaad1", "embedding": null, "metadata": {"page_label": "19", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "98e95dbf-dafc-4247-b20b-a4d84fa6aa19", "node_type": "4", "metadata": {"page_label": "19", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "07574c2e33364620d2a42d064ceeb0d622a5385e2d48a322546f2df27598b57f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "44e061c9-c1cc-4064-9fbf-9fefb0e36448", "node_type": "1", "metadata": {}, "hash": "9012b1e6c1a0e24925a58c23bd7c85a8b2dcccc0b14b0b37a459e976b01ca35e", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "viral properties, such as the mode or rate of transmission, or the\nability to cause disease. However, the observation that a new\nmutation is increasing in prevalence or geographic range is\nnot suf\ufb01cient to prove its selective advantage because such\nincreases can also be generated by other causes such as non-\ncompliance to the preventive measures.196 Variant mutations\ncan occur in any part of the viral genome such as in structural\nprotein genes or non-structural protein coding regions. The\nmutations that occur in the S protein genes, particularly the\nRBD coding regions are of the greatest importance because\nthey are the main cause of SARS-CoV-2 variants with increased\ntransmission rates, increased disease severity-mortality rates\nand less susceptibility to monoclonal or polyclonal antibodies\nproduced in response to infection or vaccination. These muta-\ntions can also negatively impact diagnostics or drug therapies\nthat are used for COVID-19 disease.197 (Table 6)\nVaccine ef\ufb01cacy is the reduction of the risk or odds of\ndisease or infection among vaccinated persons. While new var-\niants continue to emerge, evaluation of the ef \ufb01cacy of\nCOVID-19 vaccines in different settings and populations has\nbecome more dif \ufb01cult.199,200 The necessity of additional\nvaccine doses for declining protection over time and decreased\nef\ufb01cacy for different variants of COVID-19 are unresolved\nissues for vaccine ef\ufb01cacy. Real world vaccine ef\ufb01cacy may\ndiffer from the results of randomized controlled trials because\nof the different target populations or different vaccine schedules\nthat are applied in different countries. While many vaccine ef\ufb01-\ncacy studies are continually published, the majority of these\ncame from three countries with early introduction of vaccina-\ntion campaigns: Israel, the UK and the USA. Additionally,\nmost of these reports on vaccine ef\ufb01cacy were carried out on\nonly two vaccines \u2014 BNT162b2 (P \ufb01zer) and AZD1222\n(AstraZeneca).", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1951, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "44e061c9-c1cc-4064-9fbf-9fefb0e36448": {"__data__": {"id_": "44e061c9-c1cc-4064-9fbf-9fefb0e36448", "embedding": null, "metadata": {"page_label": "19", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "98e95dbf-dafc-4247-b20b-a4d84fa6aa19", "node_type": "4", "metadata": {"page_label": "19", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "07574c2e33364620d2a42d064ceeb0d622a5385e2d48a322546f2df27598b57f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e9d9c288-6dbd-40b6-83bd-b380240aaad1", "node_type": "1", "metadata": {"page_label": "19", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "da60c6cac209464b777d716aa050c0f391368ed9fe8d8696d51c55e5d37b246e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d61e9618-b7c2-43ac-8c78-8c9e7c4d5b1a", "node_type": "1", "metadata": {}, "hash": "ac5c4a2c2f2c1ae2c0f385e11c3745f1002ae46338ecde1be2cd30106902311b", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Additionally,\nmost of these reports on vaccine ef\ufb01cacy were carried out on\nonly two vaccines \u2014 BNT162b2 (P \ufb01zer) and AZD1222\n(AstraZeneca). To improve vaccine ef \ufb01cacy studies, WHO\nhas produced best practice guidance on how to undertake\nvaccine ef\ufb01cacy studies.201\nIn general, symptomatic disease ef\ufb01cacy results of these\nstudies, for fully vaccinated individuals, have been similar to\nthe results of the randomized controlled studies of individual\nvaccines. Overall, vaccine ef\ufb01cacy against severe disease, hos-\npitalization and death is higher than ef\ufb01cacy against non-severe\ndisease, with the overall ef\ufb01cacy of above 80% for AZD1222,\nmRNA-1273, BNT162b2, and Coronavac vaccines. Although,\nthe vaccine ef\ufb01cacy against infection and asymptomatic infec-\ntion are slightly lower for AZD1222, mRNA-1273, and\nBNT162b2 vaccines, the vaccine ef\ufb01cacy rates for these out-\ncomes are almost uniformly >60%. Additionally, several\nstudies have shown that the transmission to household\nmembers is reduced by approximately 50% when the infected\nhousehold member was vaccinated with at least one dose as\ncompared to unvaccinated. Importantly, vaccine ef\ufb01cacy\nappears to be consistently higher for all outcomes after full vac-\ncination, de\ufb01ned as at least 7-14 days after the\ufb01nal dose.198\n(Table 7)\nThere is widespread concern that existing COVID-19 vac-\ncines may have reduced vaccine ef \ufb01cacy against the four\nVOCs designated by WHO. Neutralization studies have\nshown that there is a several-fold reduction in neutralization\nof the VOCs, speci\ufb01cally Beta, Gamma and Delta. However,\na reduction in neutralization does not directly correlate with\nreduced vaccine ef\ufb01cacy.", "mimetype": "text/plain", "start_char_idx": 1812, "end_char_idx": 3470, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "d61e9618-b7c2-43ac-8c78-8c9e7c4d5b1a": {"__data__": {"id_": "d61e9618-b7c2-43ac-8c78-8c9e7c4d5b1a", "embedding": null, "metadata": {"page_label": "19", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "98e95dbf-dafc-4247-b20b-a4d84fa6aa19", "node_type": "4", "metadata": {"page_label": "19", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "07574c2e33364620d2a42d064ceeb0d622a5385e2d48a322546f2df27598b57f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "44e061c9-c1cc-4064-9fbf-9fefb0e36448", "node_type": "1", "metadata": {"page_label": "19", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "b96c19cc2a0523a1e7fcce63234d905ec29847439b2cd8292052970bac3ee6a1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "754009c1-a993-4df4-9fd8-a3d2ef5a74be", "node_type": "1", "metadata": {}, "hash": "8a95b4979a779b118ff814766a6f9125bce74fd5906271b2694a06c70c388fb5", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "However,\na reduction in neutralization does not directly correlate with\nreduced vaccine ef\ufb01cacy. This can be explained by several\nreasons: 1) there is currently no known threshold of neutraliza-\ntion below which vaccines no longer protect; 2) some vaccines\nproduce higher neutralizing antibody concentrations so reduc-\ntions in neutralization will likely have a lesser effect on the ef\ufb01-\ncacy for these vaccines; 3) and other factors besides neutralizing\nantibody levels, such as cellular immunity, may maintain pro-\ntection. More vaccine ef\ufb01cacy studies of additional vaccines\nagainst the Delta variant and other VOCs are needed to better\nunderstand vaccine ef\ufb01cacy against VOCs.198\nCOVID-19 Vaccination in Pregnant or\nBreastfeeding Women\nAlthough, much progress has been achieved since the begin-\nning of the COVID-19 pandemic, the issue of vaccinations in\nspecial populations remains unclear. One of these populations\nis pregnant or breastfeeding women. Vaccination during preg-\nnancy and lactation is common to prevent maternal and infant\nmorbidity from other infectious diseases. Although live vacci-\nnations, such as measles, mumps, and rubella and varicella\nare contraindicated in pregnancy, in\ufb02uenza and Tdap vaccina-\ntions are speci \ufb01cally recommended to prevent infections\nduring pregnancy.202 All currently approved COVID-19 vac-\ncines are not live virus vaccines.", "mimetype": "text/plain", "start_char_idx": 3374, "end_char_idx": 4749, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "754009c1-a993-4df4-9fd8-a3d2ef5a74be": {"__data__": {"id_": "754009c1-a993-4df4-9fd8-a3d2ef5a74be", "embedding": null, "metadata": {"page_label": "19", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "98e95dbf-dafc-4247-b20b-a4d84fa6aa19", "node_type": "4", "metadata": {"page_label": "19", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "07574c2e33364620d2a42d064ceeb0d622a5385e2d48a322546f2df27598b57f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d61e9618-b7c2-43ac-8c78-8c9e7c4d5b1a", "node_type": "1", "metadata": {"page_label": "19", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "57ab57fe9f587e3d678347a3e4d0f17f37b876e5a3721a5b84ed161968bb6f74", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "According to available information in the literature, pregnant\nwomen do not appear to get infected by COVID-19 more fre-\nquently than the general population and when they are infected,\nmost experience mild to moderate disease.203,204 However,\napproximately 8\u2013 11% of pregnant women require hospital\nadmission for COVID-19 related morbidity, and between 2%\nand 4% of pregnant women require intensive care unit admis-\nsion during the course of the disease.205\u2013211 Risk factors for\nsevere COVID-19 in pregnant women include race/ethnicity,\nolder maternal age, pre-pregnancy obesity, asthma, cardiovas-\ncular disease, pre-gestational diabetes mellitus, chronic hyper-\ntension, chronic lung disease and healthcare personnel.212\u2013214\nPregnant women with COVID-19 may also have an increased\nrisk of preterm birth.215\u2013218 The risk for preterm delivery has\nranged from 10% to 25% in the literature with rates as high\nas 60% among women with critical illness. Additionally, the\nCenters for Disease Control and Prevention (CDC) has included\npregnancy as a risk factor that can lead to increased risk for\nsevere COVID-19.219\nIt is important to note that pregnant and lactating women\nwere not included in COVID-19 vaccine trials.220\u2013225 For this\nreason, the evidence for ef\ufb01cacy and safety of COVID-19 vac-\ncinations during pregnancy and lactation is scarce, which makes\nthe decision making more dif\ufb01cult. In this regard, most of the\ninformation comes from animal studies and the inadvertent vac-\ncination of pregnant women during clinical trials or observa-\ntional studies. The safety and ef\ufb01cacy of COVID-19 vaccines\nKantarcioglu et al. 19", "mimetype": "text/plain", "start_char_idx": 4750, "end_char_idx": 6377, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "7d6ee201-e1cc-47e7-8a71-a21e3f00cead": {"__data__": {"id_": "7d6ee201-e1cc-47e7-8a71-a21e3f00cead", "embedding": null, "metadata": {"page_label": "20", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "d9aebe03-7172-4603-a4b9-fc252f4f8120", "node_type": "4", "metadata": {"page_label": "20", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "90ffcc5b0dd24b6fbd20d160153f2ea3a7b59689e2ad777a6304789ef31d9628", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b64592f1-7a14-416a-9c34-7268c4b1f72b", "node_type": "1", "metadata": {}, "hash": "9e1807bfe2ff80b842d790a28105d507ea694c74fefc2002831bdaa40dd43c3c", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "have been tested in animal models, including mice, ferrets,\nsheep, and nonhuman primates. Developmental and reproduc-\ntive toxicology (DART) studies on the BNT162b2, mRNA\n1273, AdsCoV2S, AZD122, Coronavac and BBIBP-CorV vac-\ncines have not shown any harmful effects in pregnancy.226\u2013231\nInadvertent pregnancies in low number of recipients occurred in\nwomen having received a COVID-19 vaccine during\nBNT162b2, mRNA 1273, AdsCoV2S and AZD1222\nCOVID-19 vaccine trials, revealing no difference in miscar-\nriage rates between COVID-19 vaccinated and placebo-\nvaccinated women.232\u2013235 The results of observational studies\nhave shown that vaccinations in pregnant and lactating\nwomen generated robust humoral immunity with immunoge-\nnicity and reactogenicity similar to that observed in non-\npregnant women.236 Immune transfer of neutralizing antibodies\nfrom mother to neonates was observed via placenta and breast-\nmilk in these studies.237,238 However, the vast majority of these\nstudies were performed on mRNA vaccines and information on\nthe effect of inactivated, viral vector and subunit vaccines on\npregnancy or lactation is scant.239\u2013242 Furthermore, although\na causative relationship has not been fully established, a very\nrare syndrome, called vaccine induced thrombotic thrombocy-\ntopenia (VITT) has been described and only seems to occur\nafter adenovirus viral vector vaccines. 243 However, similar\nkinds of viral vector vaccines have been given to pregnant\nwomen in previous Ebola and Zika virus vaccination programs\nwithout adverse pregnancy-related outcomes.244\u2013246 Any inter-\nvention in pregnancy, including vaccinations, especially new\nones, requires special careful attention to ensure safety of the\npregnant women and their children. After several vaccines\nbecame available for use, a large amount of guidance was pub-\nlished by governmental public health agencies, drug regulatory\nagencies, and health care organizations regarding administra-\ntion of the COVID-19 vaccines in pregnant or lactating\nwomen.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2016, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "b64592f1-7a14-416a-9c34-7268c4b1f72b": {"__data__": {"id_": "b64592f1-7a14-416a-9c34-7268c4b1f72b", "embedding": null, "metadata": {"page_label": "20", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "d9aebe03-7172-4603-a4b9-fc252f4f8120", "node_type": "4", "metadata": {"page_label": "20", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "90ffcc5b0dd24b6fbd20d160153f2ea3a7b59689e2ad777a6304789ef31d9628", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7d6ee201-e1cc-47e7-8a71-a21e3f00cead", "node_type": "1", "metadata": {"page_label": "20", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "397b2edd67d3f1b583df1a48f8bea5af9ebba0bedded067b60ef1fe414aa7b69", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "813ca0b5-bbc1-41c6-b45b-fc6a86bc0f62", "node_type": "1", "metadata": {}, "hash": "088a71302541ce62f50dbedc0f395b88b12b18097f1b32e4430d7393672c850e", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "With the\ufb02ow of new information, these guidance doc-\numents have been substantially changed over time, between\nDecember 2020 until today.247\u2013253 Overall further decisions\non the use of COVID-19 vaccines in pregnancy and lactation\nperiod should include a risk\u2013bene\ufb01t analysis based on availabil-\nity of the vaccine, the best available data and the exposure risk\nin the epidemiological background. It is important to highlight\nthat the bene\ufb01ts of vaccinations in pregnant or breastfeeding\nwomen far outweigh the risks.\nCOVID-19 Vaccination in\nImmunocompromised Patients\nIt has been shown that patients with cancer are at signi\ufb01cantly\nincreased risk for COVID-19 infection. Additionally, when\ncancer patients are infected with COVID-19, they may have\nworse outcomes.254\u2013258 This is caused partly by the disease\nitself and also by the immunosuppression caused by different\ntreatment approaches such as chemotherapy, radiotherapy,\nand stem cell transplantation also make these patients more vul-\nnerable to COVID-19. Since the beginning of the COVID-19\npandemic, cancer patients have been classi\ufb01ed as high-risk\npatients for severe disease, excluding them from early vaccine\ntrials. Infectious Diseases Society of America (IDSA) and\nThe European Conference on Infections in Leukemia (ECIL)\nguidelines recommend vaccination with inactivated in\ufb02uenza,\nHepatitis B subunit and pneumococcus vaccinations in cancer\npatients.259\u2013261 In general, live-attenuated vaccines are not\nusually recommended in primary or acquired immunode\ufb01cient\nTable 5.", "mimetype": "text/plain", "start_char_idx": 2017, "end_char_idx": 3549, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "813ca0b5-bbc1-41c6-b45b-fc6a86bc0f62": {"__data__": {"id_": "813ca0b5-bbc1-41c6-b45b-fc6a86bc0f62", "embedding": null, "metadata": {"page_label": "20", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "d9aebe03-7172-4603-a4b9-fc252f4f8120", "node_type": "4", "metadata": {"page_label": "20", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "90ffcc5b0dd24b6fbd20d160153f2ea3a7b59689e2ad777a6304789ef31d9628", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b64592f1-7a14-416a-9c34-7268c4b1f72b", "node_type": "1", "metadata": {"page_label": "20", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "93f66cbd3367e4ca6ec181bf18b9a58dc271f6c7a2719f2008ec9567f9b43f2f", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "WHO de\ufb01ned VOCs and VOIsa\nWHO\nLabel\nPANGO\nLineages\nGISAID\nClade\nNextstrain\nClade\nAdditional\nMutations Earliest Documented Samples Date of Designation\nA) Variant of Concerns (VOCs)\nAlpha B.1.1.7 GRY 20I (V1) +S:484K\n+S:452R\nUnited Kingdom\u2014\nSep 2020\nDec 2020\nBeta B.1.351\nB.1.351.2\nB.1.351.3\nGH/501Y.V2 20H (V2) +S:L18F South Africa \u2014 May 2020 Dec 2020\nGamma P.1\nP.1.1\nP.1.2\nGR/501Y.V3 20J (V3) +S:681H Brazil \u2014 Nov 2020 Jan 2021\nDelta B.1.617.\nAY.1\nAY.2\nAY.3\nG/478K.V1 21A +S:417N India \u2014 Oct 2020 VOI: 4-Apr-2021\nVOC:\n11-May-2021\nB) Variant of Interests (VOI)\nEta B.1.525 G/484K.V3 21D +S:484K Multiple countries \u2013 Dec 2020 Mar 2021\nIota B.1.526 GH/\n253G.V1\n21F +S:484K United States of America\nNov-2020\nMar 2021\nKappa B.1.617.1 G/452R.V3 21B +S:484Q India,\nOct-2020\nApr 2021\nLambda C.37 GR/452Q.V1 21G +S:452Q Peru, Dec-2020 Jun 2021\naModi\ufb01ed from WHO Tracking SARS-CoV-2 variants.194\n20 Clinical and Applied Thrombosis/Hemostasis", "mimetype": "text/plain", "start_char_idx": 3550, "end_char_idx": 4481, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "d5099df0-2b78-417f-935c-5e9f174727f7": {"__data__": {"id_": "d5099df0-2b78-417f-935c-5e9f174727f7", "embedding": null, "metadata": {"page_label": "21", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "3b2cf5c8-27eb-4c9f-adb7-bfb585a20e39", "node_type": "4", "metadata": {"page_label": "21", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "ab128eeada50196a6cf0f2ba4f7a46cd8aff0a17fc5d673ade5ed532a4c2b52b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5a8afcab-3188-474d-90af-ebbc0375245d", "node_type": "1", "metadata": {}, "hash": "82841727c177be9c71ed75ba624a3195ed8f2c91de22123a5011441d2646e041", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "patients because of the risk of infection development by the live\npathogens present in the vaccine. All currently approved\nCOVID-19 vaccines are not live virus vaccines.\nCytotoxic chemotherapies interfere with DNA replication,\nsynthesis, and cell cycle progression. Lymphocytes are also sup-\npressed by these therapies.262 However, this suppression is not\ncomplete and immune responses can be achieved by vaccina-\ntions, although, the patients are on cytotoxic chemotherapy.263\u2013\n268 Titers can be helpful to assess the need for revaccination.\nHigher doses or boosters can be employed to enhance immuno-\ngenicity. Overall, with the exception of intensive chemotherapy\nperiods, patients undergoing chemotherapy are expected to gen-\nerate protective responses with COVID-19 vaccinations.\nTargeted therapies including the receptor tyrosine kinase\ninhibitors (TKIs) such as erlotinib, sunitinib, imatinib and ibru-\ntinib and monoclonal antibodies such as trastuzumab, do not\ndirectly cause immunosuppression but they may have inhibitory\neffects on APC function, T cell activation and B cell signaling.\nHowever, cancer patients that are receiving these therapies can\nstill produce enough immune response against vaccines.269\u2013274\nThus, it is reasonable to expect that the patients being treated\nwith targeted therapies will generate protective responses with\nCOVID-19 vaccination.\nImmune checkpoint inhibitors target immunological path-\nways such as programmed cell death protein 1 (PD-1) and cyto-\ntoxic T-lymphocyte-associated protein 4 (CTLA-4) that are\nup-regulated in tumor-reactive T cells.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1589, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "5a8afcab-3188-474d-90af-ebbc0375245d": {"__data__": {"id_": "5a8afcab-3188-474d-90af-ebbc0375245d", "embedding": null, "metadata": {"page_label": "21", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "3b2cf5c8-27eb-4c9f-adb7-bfb585a20e39", "node_type": "4", "metadata": {"page_label": "21", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "ab128eeada50196a6cf0f2ba4f7a46cd8aff0a17fc5d673ade5ed532a4c2b52b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d5099df0-2b78-417f-935c-5e9f174727f7", "node_type": "1", "metadata": {"page_label": "21", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "e37607ee2264dd5b87456400c9a96f7f9b2101eb70bb144e8f9560cd69d5ae01", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2810d43b-63e6-4a84-aa41-015fbc903e12", "node_type": "1", "metadata": {}, "hash": "db0b0657087fe6603fb5da86e662c612de73c00183e8407bd00d503e74992b19", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Checkpoint inhibitors\ncan cause immune-related adverse events (IRAEs), depending\non the speci\ufb01c therapy.275 There is a theoretical concern that\nvaccination could stimulate an over-reactive immune response\nand increase IRAEs in patients actively treated with immune\ncheckpoint inhibitors.276 However, larger studies with non-\nvaccinated comparison groups did not show higher frequencies\nof IRAEs with vaccinations.277,278\nPlasma-cell-depleting and lymph-depleting therapies, such\nas anti-CD20 and anti-CD38 monoclonal antibodies or\nCAR-T cells against CD19, reduce the number of peripheral\nB cells in patients. In practice, it is recommended that vaccines\nbe given at least 6 months after anti-B cell therapy due to\ndecreased ef\ufb01ciency.279\u2013286 However patients on anti-B cell\ntherapy are at especially high risk for severe disease and\ndeath from COVID-19 can be an exception for this because vac-\ncines are the most powerful tools in prevention of COVID-19\ninfections.\nRadiation therapy is commonly used for patients with malig-\nnancies as a curative or palliative treatment option. It is known\nthat radiation involving a large part of the body can have an\nimpact on the bone marrow, however it is rare for radiation to\nhave a signi \ufb01cant impact on the immune system. 287,288\nTherefore, most patients treated with radiation can generate pro-\ntective immune responses to COVID-19 vaccines.\nCOVID-19 prognosis is poor in patients receiving hemato-\npoietic stem cell transplantation (HSCT). In HSCT recipients\nwho develop COVID-19, the overall survival has been found\nto be 68% for recipients of allogeneic HSCT and 67% for recip-\nients of autologous HSCT. 289 In general, vaccines can be\nadministered 4-6 months after HSCT. Live-attenuated vaccines\nare not recommended and should be administered at least 24\nmonths after HSCT in patients who do not have graft versus\nhost disease (GVHD) and take no immunosuppressive drugs\nin the last three months.290\nOverall, most cancer treatments do not impair proper\nimmune response against vaccines.", "mimetype": "text/plain", "start_char_idx": 1590, "end_char_idx": 3625, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "2810d43b-63e6-4a84-aa41-015fbc903e12": {"__data__": {"id_": "2810d43b-63e6-4a84-aa41-015fbc903e12", "embedding": null, "metadata": {"page_label": "21", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "3b2cf5c8-27eb-4c9f-adb7-bfb585a20e39", "node_type": "4", "metadata": {"page_label": "21", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "ab128eeada50196a6cf0f2ba4f7a46cd8aff0a17fc5d673ade5ed532a4c2b52b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5a8afcab-3188-474d-90af-ebbc0375245d", "node_type": "1", "metadata": {"page_label": "21", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "dbdbbd5fde43c49e2e15a04be6c9da985e59f9b93722cbf78bad09de4335cb2d", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "However, the immune\nresponse may be weak in some cancer patients including\nthose who are on intensive immunosuppression or HSCT.\nMany oncology professional scienti\ufb01c societies including the\nAmerican Society of Clinical Oncology (ASCO), the\nEuropean Society for Medical Oncology (ESMO), Society for\nImmunotherapy of Cancer (SITC), and the American\nAssociation for Cancer Research (AACR) strongly recommend\nvaccinating patients with cancer.291\u2013294 It seems that vaccina-\ntion in all cancer patients is safe, effective, and recommended,\nTable 6. Summary Of WHO de\ufb01ned VOCs and Their Impact on Vaccinationsa\nWHO\nLabel Transmission Disease Severity Risk of Reinfection Impacts on Diagnosis\nAlpha Increased\ntransmission and\nsecondary attack\nrate.\nIncreased risk of\nhospitalization, possible\nincreased risk of severity\nand mortality.\nNeutralizing activity retained,\nrisk of reinfection remains\nsimilar.\nLimited impact\u2013 S gene target failure\n(SGTF); no impact on overall result\nfrom multiple target RT-PCR, No\nimpact on Ag RDTs observed.\nBeta Increased\ntransmission.\nNot con\ufb01rmed, possible\nincreased risk of in-hospital\nmortality.\nReduction in neutralizing activity\nreported; T cell response\nelicited by D614G virus\nremains effective.\nNo impact on RT-PCR or Ag RDTs\nobserved.\nGamma Increased\ntransmission.\nNot con\ufb01rmed, possible\nincreased risk of\nhospitalization.\nModerate reduction in\nneutralizing activity reported.\nNone reported to date.\nDelta Increased\ntransmission and\nsecondary attack\nrate.\nIncreased risk of\nhospitalization.\nReduction in neutralizing activity\nreported.\nNone reported to date\naModi\ufb01ed from WHO Weekly epidemiological update on COVID-19\u2013 6 July 2021.198\nKantarcioglu et al. 21", "mimetype": "text/plain", "start_char_idx": 3626, "end_char_idx": 5316, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "4eb70702-545b-4370-be43-87482225df7d": {"__data__": {"id_": "4eb70702-545b-4370-be43-87482225df7d", "embedding": null, "metadata": {"page_label": "22", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "69240135-82d6-4306-a1b8-5797f4d75cfd", "node_type": "4", "metadata": {"page_label": "22", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "b5872cff7a6e6a915f91abe24708d89b69ac50583165170848aaf0dd83025e79", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6069e7e2-0bb5-4312-91b7-42665316ee79", "node_type": "1", "metadata": {}, "hash": "d024f444ad38ad909ce860532efcc533ea3c97a666630e8b6a6e1f16837c73aa", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "except for those who are on anti-B cell therapies, for whom a 4\u2013\n6 months interval is needed after medication. It is important to\ncomplete the vaccination schedule and vaccination of house-\nhold members. All types of vaccines are safe and effective in\nthese patients, except live-attenuated vaccines.\nDue to the immunosuppression that is needed for preventing\ngraft rejection, the solid organ transplant (SOT) recipients are\nsusceptible to diverse infectious diseases including\nCOVID-19.295,296 SOT recipients are also at increased risk of\ndeveloping severe COVID-19 infections and higher mortality\nrates compared to the general population.297\u2013300 Furthermore,\ndue to the immunosuppressed status, these patients experience pro-\nlonged SARS-CoV-2 shedding, which has been linked to the\nemergence of viral mutants.301\u2013304 Although, prevention of\nCOVID-19 infections is critical in SOT recipients, they were\nexcluded from recent SARS- CoV-2 vaccine trials, so neither ef\ufb01-\ncacy, and durability, nor safety are known in this patient sub-\npopulation. In SOT recipients the immune response to vaccina-\ntions produce lower antibody titerscompared to the general popu-\nlations.305\u2013307 Although there have been some concerns, vaccines\nhave not been associated with graft rejection in SOT recipients.308\nIn general, live-attenuated virus vaccines are usually not rec-\nommended in SOT recipients due to the risk of disseminated\ninfection.309 The American Society of Transplantation (AST),\nthe International Society for Heart and Lung Transplantation\n(ISHLT) and the European Society for Organ Transplantation\nrecommend that all solid organ transplant recipients should be\nvaccinated against SARS-CoV-2, using locally approved vac-\ncines. All healthcare workers and household members who\ncare for these patients should also be vaccinated against\nCOVID-19 infection. Whenever possible, vaccinations are rec-\nommended prior to transplantation (ideally with completion of\nvaccine series a minimum of 2 weeks prior to transplant).", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2014, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "6069e7e2-0bb5-4312-91b7-42665316ee79": {"__data__": {"id_": "6069e7e2-0bb5-4312-91b7-42665316ee79", "embedding": null, "metadata": {"page_label": "22", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "69240135-82d6-4306-a1b8-5797f4d75cfd", "node_type": "4", "metadata": {"page_label": "22", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "b5872cff7a6e6a915f91abe24708d89b69ac50583165170848aaf0dd83025e79", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4eb70702-545b-4370-be43-87482225df7d", "node_type": "1", "metadata": {"page_label": "22", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "acff87db64e7fe32119975fba9c6a374258cd626144c85c9f87605f6aeeeccf5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "825a8cdf-50ca-4072-b42c-334eba3edc8c", "node_type": "1", "metadata": {}, "hash": "9e8fd07c0726308c0220029be99678c74cbb7eecb5b3e1c970e323938bf5727f", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Whenever possible, vaccinations are rec-\nommended prior to transplantation (ideally with completion of\nvaccine series a minimum of 2 weeks prior to transplant). The\nbest time for COVID-19 vaccine administration in the post-\ntransplantation period is probably a minimum of three months\nafter transplantation when immunosuppression is diminished,\nand other prophylactic medications are reduced. COVID-19\nvaccination should be avoided in acute cellular rejection\n(ACR) status until ACR episodes are resolved, and high dose\ncorticosteroid usage is not required anymore. Administration\nof an additional dose (third dose) of vaccine after completion\nof the vaccine series has been authorized by the EUA in the\nUS as of August 12, 2021.310\u2013312\nMultiple sclerosis (MS) is a chronic, in\ufb02ammatory, demye-\nlinating, and neurodegenerative disease affecting the central\nnervous system (CNS), often leads to irreversible disability.313\nThe MS has become a concerning issue in the COVID-19 pan-\ndemic. The use of lifelong disease modifying therapies (DMTs)\nin MS patients, cause immunosuppression and these patients\nbecome more susceptible to infections. 314\u2013316 Additionally,\nTable 7. Summary of Vaccine Ef\ufb01cacy against Variants of Concerna\nAlpha Beta Gamma Delta\nProtection retained against all\noutcomes\nProtection retained against severe\ndisease, possible reduced protection\nagainst symptomatic disease and\ninfection\nUnclear impact; very\nlimited evidence\nProtection retained against severe\ndisease, possible reduced protection\nagainst symptomatic disease and\ninfection\nA) Vaccine Ef\ufb01cacy against disease or infection (full vaccination)\nSevere Disease\n\u2194: mRNA-1273, BNT162b2\n\u2193: AZD1222\n\u2194: Ad26.COV2. S, BNT162b2 No evidence \u2194: AZD1222, BNT162b2\nSymptomatic disease\n\u2194: mRNA-1273, BNT162b2 \u2194\nto \u2193: AZ1222\n\u2193: NVX-CoV2373\n\u2194: Ad26.COV2.", "mimetype": "text/plain", "start_char_idx": 1854, "end_char_idx": 3672, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "825a8cdf-50ca-4072-b42c-334eba3edc8c": {"__data__": {"id_": "825a8cdf-50ca-4072-b42c-334eba3edc8c", "embedding": null, "metadata": {"page_label": "22", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "69240135-82d6-4306-a1b8-5797f4d75cfd", "node_type": "4", "metadata": {"page_label": "22", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "b5872cff7a6e6a915f91abe24708d89b69ac50583165170848aaf0dd83025e79", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6069e7e2-0bb5-4312-91b7-42665316ee79", "node_type": "1", "metadata": {"page_label": "22", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "501bfa608a84765f2860921d97a66775a5b9fbd476e785238ae02a06648e79cc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c1cd7434-5815-4c9e-a291-bb7aeebc40aa", "node_type": "1", "metadata": {}, "hash": "69e5dfb4628c3b8dec248221c0a2e831f4a0c5c9240add70c4f3f205003259b9", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "S\n\u2193\u2193\u2193: AZD1222, NVX-CoV2373\n\u2194 to \u2193: CoronaVac \u2194 to \u2193: BNT162b2\n\u2193: Covaxin\n\u2193\u2193: AZD1222\nInfection\n\u2194: BNT162b2\n\u2194 to \u2193: AZD1222\n\u2194: mRNA-1273\n\u2193: BNT162b2\nNo evidence \u2193: AZD1222, BNT162b2\nB) Neutralization (full vaccination).\n\u2194:Z i\ufb01vax, BBIBP-CorV,\nCovaxin, Sputnik V,\nNVX-CoV2373\n\u2194to \u2193: Ad26.COV2. S,\nmRNA-1273, BNT162b2,\nCoronaVac \u2193 to \u2193\u2193: AZD1222\n\u2194 to \u2193:Z i\ufb01vax, BBIBP-CorV\n\u2193: Covaxin\n\u2193 to \u2193\u2193: mRNA-1273, BNT162b2,\nCoronaVac\n\u2193to \u2193\u2193\u2193: Ad26.COV2. S\n\u2193\u2193: AZD1222, Sputnik V\n\u2193\u2193\u2193: NVX-CoV2373\n\u2194 to \u2193: BNT162b2,\nCoronaVac\n\u2193: AZD1222,\nAd26.COV2. S,\nmRNA-1273\n\u2194: Janssen-Ad.COV 2.5 (1)79\n\u0081 \u2193:Z i\ufb01vax, AZD1222, Covaxin,\nmRNA-1273, AZD1222\n\u2193 to \u2193\u2193: BNT162b2\n\u2193 to \u2193\u2193\u2193: CoronaVac\n\u2194: <10% reduction in vaccine ef\ufb01cacy, or vaccine ef\ufb01cacy >90% with no comparator, or that there was a <2-fold reduction in neutralization.\n\u2193: 10 to <20% reduction in vaccine ef\ufb01cacy, or 2 to <5-fold reduction in neutralization.\n\u2193\u2193: 20 to <30% reduction in vaccine ef\ufb01cacy, or 5 to <10-fold reduction in neutralization.", "mimetype": "text/plain", "start_char_idx": 3673, "end_char_idx": 4655, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "c1cd7434-5815-4c9e-a291-bb7aeebc40aa": {"__data__": {"id_": "c1cd7434-5815-4c9e-a291-bb7aeebc40aa", "embedding": null, "metadata": {"page_label": "22", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "69240135-82d6-4306-a1b8-5797f4d75cfd", "node_type": "4", "metadata": {"page_label": "22", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "b5872cff7a6e6a915f91abe24708d89b69ac50583165170848aaf0dd83025e79", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "825a8cdf-50ca-4072-b42c-334eba3edc8c", "node_type": "1", "metadata": {"page_label": "22", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "405fc4b41bb4933d7cc530fc08bcd16a56dc586642ea7ad66585b0bb0537d625", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "\u2193\u2193: 20 to <30% reduction in vaccine ef\ufb01cacy, or 5 to <10-fold reduction in neutralization.\n\u2193\u2193\u2193: \u226530% reduction in vaccine ef\ufb01cacy, or\u226510-fold reduction in neutralization.\nWhen more than one neutralization study is available, the interquartile range (25th and 75th percentiles) of fold-reductions across all studies forspeci\ufb01c vaccine/\nvariant was used.\naModi\ufb01ed from WHO Weekly epidemiological update on COVID-19\u2013 6 July 2021.198\n22 Clinical and Applied Thrombosis/Hemostasis", "mimetype": "text/plain", "start_char_idx": 4565, "end_char_idx": 5040, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "a2e90743-be84-43ba-9a7b-e15d17d8d14a": {"__data__": {"id_": "a2e90743-be84-43ba-9a7b-e15d17d8d14a", "embedding": null, "metadata": {"page_label": "23", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "cf63ca09-1733-45ca-8a29-5299aabac73e", "node_type": "4", "metadata": {"page_label": "23", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "ccbdc581f4a8307efab6b13319c9bfe02b0b8172cc599bf787e5c1537dee0a07", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2ebe2db7-9480-4df8-baaf-3a2c839bc5fd", "node_type": "1", "metadata": {}, "hash": "88984252f96b12ec0f34aec073b51cc4f531e6f82e163049fb8e8b879f07cf3a", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "even with mild infections, exacerbations of the MS (relapses or\nprogressions) can be observed. About 30\u201340% of MS patients\nexperience post-upper respiratory infection relapse, although\nthe mechanism is unknown.317\u2013321 This kind of disease\ufb02ares\nhave also been observed during the course of COVID-19\ndisease.322 The incidence of COVID-19 in people with MS\nranges from below 1% to 11%. COVID-19-related MS mortal-\nity has been reported to be approximately 1\u20134%.323 Several\nstudies have shown that some DMTs are associated with\nincreased risk of COVID-19. However, patients who are not\nreceiving DMTs have also been shown as a high risk for\nCOVID-19 infection in some studies.324,325 Moreover, discon-\ntinuing the routine therapeutic regimen for vaccination may\ncause progression and relapse, which needs to be taken into\nconsideration. For all of these, vaccinations against\nCOVID-19 in MS patients are very important, because vaccina-\ntions can be an effective way to prevent COVID-19.326\u2013328 It is\nimportant to highlight that there is no proven relationship\nbetween vaccination and relapse or progression in MS\npatients.329 But MS patients may not display the adequate\nimmune response because of the administration of DMTs. For\nthis reason, patients who are on DMTs, a post-vaccination\ncheckup may be necessary to make sure that the immunization\nhas occurred properly. If an adequate response is not seen, a\nbooster dose of vaccine may be administered. 327 Patients\nusing \u00df-interferons, teri \ufb02unomide, natalizumab, glatiramer\nacetate, or dimethyl fumarate probably have no issues regarding\nvaccine safety and ef\ufb01cacy. The vaccine could be administered at\nany given time. In patients using\ufb01ngolimod, alemtuzumab, ocre-\nlizumab, rituximab, or oral cladribine, there is a possibility of\ninsuf\ufb01cient response to the vaccine.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1819, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "2ebe2db7-9480-4df8-baaf-3a2c839bc5fd": {"__data__": {"id_": "2ebe2db7-9480-4df8-baaf-3a2c839bc5fd", "embedding": null, "metadata": {"page_label": "23", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "cf63ca09-1733-45ca-8a29-5299aabac73e", "node_type": "4", "metadata": {"page_label": "23", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "ccbdc581f4a8307efab6b13319c9bfe02b0b8172cc599bf787e5c1537dee0a07", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a2e90743-be84-43ba-9a7b-e15d17d8d14a", "node_type": "1", "metadata": {"page_label": "23", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "5d8bb19ec430a5576e0c82d62eb57e7a5088e5229afc951a8e85aa5ca0e02a23", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d0094173-0425-43c4-9e86-19a83eb1df01", "node_type": "1", "metadata": {}, "hash": "4b5fa0c7f53a983cc331134626b24cf09c7a9ad076f187d9093174ee3935d6ce", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "For instance, it was sug-\ngested to vaccinate patients starting B-cell-depleting therapies,\n4\u20136 weeks before their \ufb01rst dose. If the patient has started\ntherapy, the best vaccination time is 4\u20136 months after the last\ninfusion. In the case of alemtuzumab, if the medicine has been\nused in the last 12\u201324 months, a reduction in the vaccine ef\ufb01cacy\nmay happen. Thus, it is recommended to postpone the treatment\nuntil vaccination is completed. In patients on immunosuppressive\ntreatments, such as mitoxantrone, cyclophosphamide, azathio-\nprine, and methotrexate, vaccination is probably safe, but\nproper immunization might not occur. For high dose corticoste-\nroid therapy, the best time of vaccine administration is 4\u20136w e e k s\nfollowing the last corticosteroid treatment to achieve optimal\nimmunization. Vaccination is recommended in all MS patients\nwithout discontinuing their disease-modifying therapies, which\ncould increase the risk of relapse and progression. Right timing\nis of great importance to maximize the ef\ufb01cacy, especially in\npatients using high-dose corticosteroids and B cell-depleting\ntherapies such as rituximab and ocrelizumab.330\u2013333\nIn\ufb02ammatory bowel disease (IBD), comprising Crohn \u2019s\ndisease and ulcerative colitis, is a typical systemic immune\nmediated in \ufb02ammatory disease that presents with chronic\nin\ufb02ammation of the digestive tract, which is also associated\nwith the development of extraintestinal manifestations. The\nimpact of IBD on the risk of COVID-19 infection is controver-\nsial.", "mimetype": "text/plain", "start_char_idx": 1820, "end_char_idx": 3332, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "d0094173-0425-43c4-9e86-19a83eb1df01": {"__data__": {"id_": "d0094173-0425-43c4-9e86-19a83eb1df01", "embedding": null, "metadata": {"page_label": "23", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "cf63ca09-1733-45ca-8a29-5299aabac73e", "node_type": "4", "metadata": {"page_label": "23", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "ccbdc581f4a8307efab6b13319c9bfe02b0b8172cc599bf787e5c1537dee0a07", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2ebe2db7-9480-4df8-baaf-3a2c839bc5fd", "node_type": "1", "metadata": {"page_label": "23", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "89910e6a69228f69f5270cb3864486f23a871fa9c5e1dc16c5914bad2598acdb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "98cc149d-38ec-4a00-8450-0660f21c7f3c", "node_type": "1", "metadata": {}, "hash": "b7b445a761b20875aa798fdafd31b58b909cfb1804849e71e6c35e00123c66ea", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "The\nimpact of IBD on the risk of COVID-19 infection is controver-\nsial. Despite the above-mentioned information, there is no solid\nevidence indicating that IBD patients are at a higher risk of\nCOVID- 19 infection.334,335 However, as with other immune-\nmediated in\ufb02ammatory diseases, patients with IBD are treated\nwith immunosuppressive drugs, such as high-dose corticoste-\nroids (\u226520 mg prednisolone or equivalent), immunomodulators\n(thiopurines, methotrexate, and calcineurin inhibitors), anti-\ncytokine therapies (including anti-TNF and anti-IL-12p40\ndrugs), anti-integrin therapies (vedolizumab), and small-\nmolecule inhibitors of signaling (tofacitinib), which can leave\nthem susceptible to infections.336 Considering the importance\nof vaccinations in prevention of COVID- 19 infection, the\nsafety and ef\ufb01cacy of vaccines in IBD have been the subject\nof debate. Due to the exclusion of IBD patients from the\nphase 3 clinical trials for approved vaccines, the data regarding\nvaccinations is lacking for IBD. Based on previous experiences,\nit is possible to conclude that immunosuppressive treatments\ncan impair the vaccination ef\ufb01cacy. Live-attenuated\nCOVID-19 vaccines are not safe in patients receiving immune-\nmodifying treatments or those going to receive such therapies in\nthe next eight weeks. There is no relationship between vaccina-\ntion and the IBD disease onset,\ufb02ares, or exacerbation of IBD.\nThe patients that are treated with glucocorticoids and biologic\nagents may have impaired immune response to COVID-19 vac-\ncines. Vaccinations against COVID-19 are strongly recom-\nmended in patients with IBD. SARS-CoV-2 vaccination\nshould not be deferred because a patient with IBD is receiving\nimmune-modifying therapies. In patients with severe IBD\ufb02ares\nor those who need hospitalization, a delay in vaccination is pre-\nferred.", "mimetype": "text/plain", "start_char_idx": 3261, "end_char_idx": 5096, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "98cc149d-38ec-4a00-8450-0660f21c7f3c": {"__data__": {"id_": "98cc149d-38ec-4a00-8450-0660f21c7f3c", "embedding": null, "metadata": {"page_label": "23", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "cf63ca09-1733-45ca-8a29-5299aabac73e", "node_type": "4", "metadata": {"page_label": "23", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "ccbdc581f4a8307efab6b13319c9bfe02b0b8172cc599bf787e5c1537dee0a07", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d0094173-0425-43c4-9e86-19a83eb1df01", "node_type": "1", "metadata": {"page_label": "23", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "1c2e7252a0c79eb8d3527ff9b22ce804aac3fb256500a6fc02b2e2447faff856", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "In patients with severe IBD\ufb02ares\nor those who need hospitalization, a delay in vaccination is pre-\nferred. In patients receiving systemic corticosteroids, it is rec-\nommended to vaccinate IBD patients when the dose of\ncorticosteroids is at their lowest level.337,338\nPatients with rheumatic diseases that are treated with cortico-\nsteroids, immunomodulators and biologics are at an increased\nrisk of infection during COVID-19 pandemic due to their\nimmunocompromised status.339,340 Moreover, a higher risk of\nCOVID-19 morbidity and mortality might be possible due to\nthe comorbidities present in rheumatic disease patients.\nAlthough, data regarding clinical outcomes in COVID-19\npatients with an underlying rheumatic disease is very limited,\nthe use of moderate to high doses of corticosteroids increased\nthe chance of hospitalization. On the other hand, the use of\nTNF\u03b1 inhibitors reduced the hospitalization rates. The use of\nNSAIDs (non-steroidal anti-in\ufb02ammatory drugs), DMARDs\n(disease-modifying anti-rheumatic drugs), and JAK (Janus\nkinase) inhibitors did not change the rates of hospitalizations\nin COVID-19 infections.341 Similar with other special popula-\ntions, patients with rheumatic diseases were not included in\nCOVID-19 vaccine trials. Only in BNT162b2 vaccine trial,\n62 subjects (0.3%) with rheumatic disease included and\nreceived BNT162b2.98 Vaccination against COVID- 19 has\nbeen highly recommended by the American College of\nRheumatology (ACR), the European Alliance of Associations\nfor Rheumatology (EULAR) and the British Society of\nRheumatology (BSR) in patients with rheumatic disease.342\u2013344\nAnother important aspect is whether to continue or discon-\ntinue pharmacologic therapies in rheumatic disease patients\nKantarcioglu et al. 23", "mimetype": "text/plain", "start_char_idx": 4990, "end_char_idx": 6746, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "3dea4933-ce0e-46cc-9260-d1a1ff7cbbc7": {"__data__": {"id_": "3dea4933-ce0e-46cc-9260-d1a1ff7cbbc7", "embedding": null, "metadata": {"page_label": "24", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "ab208677-7742-45fd-ac0a-4cce1ba8ded8", "node_type": "4", "metadata": {"page_label": "24", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "8236c04858e7174c21051af10c309e722f6ed1625289082df1a9ba4353d01492", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9bf4c4f0-985f-4a25-85f0-683694b7c8f8", "node_type": "1", "metadata": {}, "hash": "a0c6f1d6ee7089d17f3d75f81a9e2c268da1fdc4ef88d8249a790ffa2651df19", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "with respect to SARS-CoV-2 vaccine administration. In this\nregard no modi\ufb01cations have been recommended for hydroxy-\nchloroquine, sulfasalazine; le\ufb02unomide, apremilast, azathioprine,\ncyclophosphamide (oral), intravenous immune globulin (IVIG),\nTNFi, IL-6R, IL-1R, IL-17, IL-12, IL-23, belimumab; oral calci-\nneurin inhibitors and glucocorticoids. Withholding of methotrex-\nate for 1-2 weeks after single-dose COVID-19 vaccination have\nbeen recommended for a better outcome. JAK inhibitors have\nbeen recommended to withhold for 1 week after each vaccine\ndose. Abatacept have been recommended to withhold 1 week\nprior to and 1 week after the\ufb01rst COVID-19 vaccine dose.\nAdministration of abatacept can be scheduled so that the\ufb01rst vac-\ncination will occur 4 weeks after abatacept infusion and postpone\nthe subsequent abatacept infusion by 1 week (a 5-week gap in\ntotal); no medication adjustments for the second vaccine dose.\nAdministration of cyclophosphamide (IV) have been recom-\nmended to be scheduled\u223c1 week after each vaccine dose,\nwhen feasible. For rituximab, vaccine series is recommended\nto initiate \u223c4 weeks prior to next scheduled rituximab cycle;\nand delay rituximab 2\u20134 weeks after\ufb01nal vaccine dose. Due to\nconsiderable B cell suppression alternative treatments recom-\nmended if available.342\u2013344\nCOVID-19 Vaccination in Children and\nAdolescents\nAs of 2020, the population under 20 years of age make up 33.3%\nof the world\u2019s population and 24.8% of the US population.345\nSimilar with other special populations children and adolescents,\nare excluded from vaccine trials. In children and adolescents the\ncourse of COVID-19 infections is mostly asymptomatic or mild.\nThe case fatality rate of COVID-19 infection is signi\ufb01cantly\nlower.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1741, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "9bf4c4f0-985f-4a25-85f0-683694b7c8f8": {"__data__": {"id_": "9bf4c4f0-985f-4a25-85f0-683694b7c8f8", "embedding": null, "metadata": {"page_label": "24", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "ab208677-7742-45fd-ac0a-4cce1ba8ded8", "node_type": "4", "metadata": {"page_label": "24", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "8236c04858e7174c21051af10c309e722f6ed1625289082df1a9ba4353d01492", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3dea4933-ce0e-46cc-9260-d1a1ff7cbbc7", "node_type": "1", "metadata": {"page_label": "24", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "031e61912ff7cb25e78279ef30489d1104ac08b98d7297ef927279e2182d30d4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c82ed998-695d-4f5f-856b-c9d8c48712e6", "node_type": "1", "metadata": {}, "hash": "5502e69726ba3b2d5b827c32540c0aae1cc67d36f087b207cd9de1dd115f18cc", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "In children and adolescents the\ncourse of COVID-19 infections is mostly asymptomatic or mild.\nThe case fatality rate of COVID-19 infection is signi\ufb01cantly\nlower. Although it is rare, severe courses of COVID-19 infec-\ntions are also observed in children and adolescents. 346,347\nSevere COVID-19 infections can be prevented by vaccinations\nin high-risk children and adolescents.348 Additionally, vaccines\nmay also prevent multisystem in\ufb02ammatory syndrome in chil-\ndren, which is associated with COVID-19. The indirect bene\ufb01t\nof vaccinations in children and adolescents is the formation of\nherd immunity. If only adults are vaccinated, COVID-19 out-\nbreaks may continue in the population of unvaccinated children\nand adolescents. Because infections may spread from children\nand adolescents to the adults, restrictions on school and limita-\ntions on social activities of pediatric population may continue.\nTherefore, vaccinating children and adolescents may be neces-\nsary to effectively prevent the spread of COVID-19 infections.\nThe results from phase 3 trials of multiple vaccines across dif-\nferent vaccine platforms have con\ufb01rmed that the vaccines are\neffective in preventing SARS-CoV-2 infection in adults. The\nmRNA vaccine BNT162b2 has shown 100% ef \ufb01cacy and\nrobust antibody responses in adolescents aged 12\u201315 years,\nleading to the FDA authorization for emergency use in adolescents\n12 through 15 years of age.349,350 Coronavac was well tolerated\nand safe and induced humoral responses in children and adoles-\ncents aged 3\u201317 years.351 Other vaccine companies have also\nbeen started to assess the safety and ef\ufb01cacy of various vaccines\namong the population aged 6 months to 17 years. It is important\nto note that, there are currently no data on the long-term effects\nof these new platform vaccines. Therefore, careful approach\nmust be taken in the decision for vaccinating children and adoles-\ncents. Therefore, it is absolutely necessary to obtain safety data\nprior to the decision of vaccinating children and adolescents.", "mimetype": "text/plain", "start_char_idx": 1580, "end_char_idx": 3608, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "c82ed998-695d-4f5f-856b-c9d8c48712e6": {"__data__": {"id_": "c82ed998-695d-4f5f-856b-c9d8c48712e6", "embedding": null, "metadata": {"page_label": "24", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "ab208677-7742-45fd-ac0a-4cce1ba8ded8", "node_type": "4", "metadata": {"page_label": "24", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "8236c04858e7174c21051af10c309e722f6ed1625289082df1a9ba4353d01492", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9bf4c4f0-985f-4a25-85f0-683694b7c8f8", "node_type": "1", "metadata": {"page_label": "24", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "05f838ae1ff0468311f6db41a5bc97729dee8bcc145085cd0f7e9163eb086822", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e6943aab-f624-4a93-8cd9-ba817d835cca", "node_type": "1", "metadata": {}, "hash": "d017e21c3d55815794f103f0425a227451d8eb92d4fe7cd063999e2ecdcae5f1", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Therefore, careful approach\nmust be taken in the decision for vaccinating children and adoles-\ncents. Therefore, it is absolutely necessary to obtain safety data\nprior to the decision of vaccinating children and adolescents.\nImportant Points Regarding COVID-19\nVaccinations\nBoth WHO and CDC recommend vaccination against\nCOVID-19 in older adults.352,353 Adults 65 and older who\nreceived COVID-19 vaccines showed a reduced risk of\nCOVID-19-related hospitalization. COVID-19 vaccines in\nolder adults reduce deaths, hospital visits, and number of\ncases. Vaccines are the safest and most powerful way to\nprotect them from COVID-19 infection. Particular concerns\nshould be counseled by respected scienti\ufb01c authorities.354\nThe administration of a third booster dose is motivated after\nthe emergence of the B.1.617.2 (delta) variant throughout the\nworld. COVID-19 vaccines that are currently in use seem to\nbe more than 90% effective against hospitalization and death\nfrom COVID-19. Although, some studies have found that\nvaccine-induced antibody levels wane after several months,\nthis is typical for all vaccines and not necessarily indicative of\nwaning protection against the coronavirus. A few trials have\ntested booster doses. Third doses of vaccines mRNA1273,\nBNT162b2, AZD1222 AND Coronavac prompted a spike in\nlevels of neutralizing antibodies, when administered several\nmonths after the second dose. What scientists do not know is\nwhether these decrease in vaccine-induced antibody levels\nre\ufb02ect a decline in protection against the virus. The drop in neu-\ntralizing antibody titers is not equal to waning cellular immunity.\nTo look more closely for evidence of waning protection,\nanalysis of health records may be a clue for evidence. In\nIsrael, health records of more than 1.3 million people who\nwere vaccinated between January and April 2021 analyzed,\nthey found that the risk for infection was 53% higher for\nearly vaccine recipients compared to those vaccinated later.", "mimetype": "text/plain", "start_char_idx": 3384, "end_char_idx": 5357, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "e6943aab-f624-4a93-8cd9-ba817d835cca": {"__data__": {"id_": "e6943aab-f624-4a93-8cd9-ba817d835cca", "embedding": null, "metadata": {"page_label": "24", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "ab208677-7742-45fd-ac0a-4cce1ba8ded8", "node_type": "4", "metadata": {"page_label": "24", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "8236c04858e7174c21051af10c309e722f6ed1625289082df1a9ba4353d01492", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c82ed998-695d-4f5f-856b-c9d8c48712e6", "node_type": "1", "metadata": {"page_label": "24", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "e275bc3321841df37d1c652c11a883af7772aa636668ccf0a956ef93ea0921de", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "At the end of July 2021, P\ufb01zer\u2013BioNTech, published data on\na preprint server showing that the vaccine ef\ufb01cacy against\nsymptomatic disease had dropped from 96% to 84% after 6\nmonths. However, vaccine ef\ufb01cacy against severe disease\nhave remained high at 97%. While some countries like\nGermany and Israel have announced their plans for booster-shot\nprograms, countries including the United Arab Emirates, China\nand Russia have started administering extra doses of vaccines.\nThe WHO has called for a moratorium on COVID-19 boosters\nuntil the end of September 2021, with the aim of ensuring that at\nleast 10% of people in all countries are vaccinated before extra\ndoses are handed out. Because, 58% of people in high-income\ncountries had received at least one vaccine dose; in low-income\ncountries this number stood at just 1.3%. Global vaccine avail-\nability is limited and will only become more limited if boosters\n24 Clinical and Applied Thrombosis/Hemostasis", "mimetype": "text/plain", "start_char_idx": 5358, "end_char_idx": 6315, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "c1c1556f-15af-4c1f-a048-8058fca21517": {"__data__": {"id_": "c1c1556f-15af-4c1f-a048-8058fca21517", "embedding": null, "metadata": {"page_label": "25", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "d8fa741f-944a-4fa7-923c-79699ba8d751", "node_type": "4", "metadata": {"page_label": "25", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "0783d52884e6631cf091f0f04e7dadf8e64e96a603487e8b5dcec0333b211310", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6cc8055e-1837-4af9-aaa6-6c4cb5d6ff6d", "node_type": "1", "metadata": {}, "hash": "5737483fdad02b5504587b881c56f8abb64b7d19ca57646965fd7c2c2360f3a7", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "are commonly used. However, If vaccines were not scarce,\nboosters would be less controversial. It is important to remem-\nber that: \u201cNo one is safe until everyone is safe\u201d which has\nbecome the mantra of the COVID-19 pandemic. Unmitigated\ntransmission means rampant viral replication, which in turn\nmeans in\ufb01nite opportunities for the emergence of new, more\ntransmissible variants that could escape natural or\nvaccine-induced immunity. On the other side, Israel announced\nplans to give people aged over 60 a third dose of the BNT162b2\nvaccine. The United Kingdom has drawn up the plans to offer\nvaccines to those over 50, as well as other high-risk groups,\nfrom September 2021. The CDC released a joint statement\nsaying that they have developed a plan to begin offering these\nbooster shots this fall subject to FDA conducting an indepen-\ndent evaluation and determination of the safety and effective-\nness of a third dose of available vaccines and CDC \u2019s\nAdvisory Committee on Immunization Practices (ACIP)\nissuing booster dose recommendations based on a thorough\nreview of the evidence.355\u2013357\nAnother important point about COVID-19 vaccines is\nmixing and matching approach in their administration.\nCurrently, most of the current vaccination regimens include a\nsecond homologous booster dose following a priming dose\nwith approximately a month interval. The idea of mixing vac-\ncines has come from the aim of increased protection, simplify-\ning immunization efforts for countries facing insuf\ufb01cient\nsupplies of the vaccines. This concept is not something new\nbut has been previously used for multiple illnesses including\nHIV, malaria, Ebola and in\ufb02uenza. \u201cHeterologous prime-boost\nvaccination\u201d involves delivery of the same or similar antigens\nof the disease-causing agent through two different vaccine\ntypes with the\ufb01rst dosage being used to prime the immune\nsystem while the subsequent dosage using different vaccine\ntypes to boost the immune response. This aims to increase the\nprotective ef\ufb01cacy and rationalize the usage of the available\nvaccines.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2051, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "6cc8055e-1837-4af9-aaa6-6c4cb5d6ff6d": {"__data__": {"id_": "6cc8055e-1837-4af9-aaa6-6c4cb5d6ff6d", "embedding": null, "metadata": {"page_label": "25", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "d8fa741f-944a-4fa7-923c-79699ba8d751", "node_type": "4", "metadata": {"page_label": "25", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "0783d52884e6631cf091f0f04e7dadf8e64e96a603487e8b5dcec0333b211310", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c1c1556f-15af-4c1f-a048-8058fca21517", "node_type": "1", "metadata": {"page_label": "25", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "9bb1b43d0eee50223ef9487b1ad954c9bfc54c1163718d8fc55349bcb0bc91ce", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bda5a8a4-5fcf-4428-8f1f-289fe07a9d5d", "node_type": "1", "metadata": {}, "hash": "f6d0d58f4a55e798ad27f80e066bfac781236987256202a3bdba3c28264efebc", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "This aims to increase the\nprotective ef\ufb01cacy and rationalize the usage of the available\nvaccines. Mixing two different vaccines can also elicit a\nstrong and long-lasting immune response as compared with\nthe single vaccine regimen. This idea has been simulated in\nanimal studies. 358 One potential risk involved in vaccine\nmixing may include increased side effects. However, the clini-\ncal evidence for COVID-19 mixing is scarce and is limited to\nsmall number of studies. During the abrupt reactions to the\nAZD1222 vaccine, which left certain populations who had\nreceived their\ufb01rst dose of AZD1222 vaccine, but not the\nsecond dose, some countries urged these recipients to proceed\nwith the second dose of AZD1222, while others, like Canada\nand several European countries, recommended a different\nvaccine for the second dose. However only a few of the poten-\ntial vaccine combinations have been tested in clinical trials.359\u2013\n361 In these studies, researchers have found that following one\ndose of the AZD1222 vaccine with a dose of the BNT162b2\nvaccine produces strong immune response, with an acceptable\nsafety pro\ufb01le.362\u2013366 Several studies are now ongoing to test\nthe combinations of BNT162b2, mRNA1273, AZD1222,\nNVX-CoV2373, Coronavac and Convidecia vaccines.367\u2013373\n(Table 8).\nFuture Considerations\nSAR-CoV-2 and related variants will continue to emerge for\nyears to come owing to the molecular adaptability and mutation\nduring replication. Such variants will have a wide spectrum of\npathogenic potential and will continually require optimized\napproaches to control their impact on public health. Until a\nlong-lasting vaccine is developed, periodic vaccination and\nbooster dosages will be required for specialized and compro-\nmised populations.\nCurrently, breakthrough infections with such variants as\nB.1.1.7 are occurring more frequently. Besides vaccination,\nother measures are recommended for the control of these mild\ninfections. The vaccine supply has steadily increased to meet\nthe demand and there is a need to provide vaccination globally.", "mimetype": "text/plain", "start_char_idx": 1954, "end_char_idx": 4006, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "bda5a8a4-5fcf-4428-8f1f-289fe07a9d5d": {"__data__": {"id_": "bda5a8a4-5fcf-4428-8f1f-289fe07a9d5d", "embedding": null, "metadata": {"page_label": "25", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "d8fa741f-944a-4fa7-923c-79699ba8d751", "node_type": "4", "metadata": {"page_label": "25", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "0783d52884e6631cf091f0f04e7dadf8e64e96a603487e8b5dcec0333b211310", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6cc8055e-1837-4af9-aaa6-6c4cb5d6ff6d", "node_type": "1", "metadata": {"page_label": "25", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "d95743a0a36260e0e00ac61634d94cff37fd5432a0fe4eb3345db76d81d6e284", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "00e8b91d-05b5-46d7-9734-735a8c8eb903", "node_type": "1", "metadata": {}, "hash": "b0c6b346367618ba7d2d4f184043a2e962d72692896807591fc925135da021c1", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Besides vaccination,\nother measures are recommended for the control of these mild\ninfections. The vaccine supply has steadily increased to meet\nthe demand and there is a need to provide vaccination globally.\nThere is a need for more controlled vaccinations in countries\nwhere the vaccination rates are low, and the insurgence of\nnew cases are high.\nThere is also growing concern regarding the vulnerability of the\nvaccine in the upcoming fall and winter seasons. This may result in\nan increase of the positivity rate in not only the non-vaccinated\npopulation but also in the vaccinated groups due to breakthrough\ninfection. Despite this, a largepercentage of people may not want\nto get the vaccine due to the wrongful information regarding the\nadverse outcomes in vaccines. Although various initiatives have\nbeen taken at different levels to promote vaccination due to the ill-\nfounded public reluctance, reaching vaccination coverage greater\nthan 80% is doubtful. Initial approaches such as non-vaccine anti-\nviral drugs will soon be introduced, however, the effectiveness of\nsuch an approach is questionable.\nCurrently available vaccines confer time dependent immu-\nnity as evident by the breakthrough infections in some of the\nvaccinated individuals, however de\ufb01nitive information on\nsuch breakthrough infection is not available at this time on spe-\nci\ufb01c vaccines. There is a need for multiple dosing vaccine to\nmaintain a desired level of immunity against this virus.\nThe complete elimination of SARS-CoV-2 infection may be\npossible in countries with high vaccination rates and appropri-\nate booster vaccine recommendations. However, such regional\ndiminishment in COVID-19 cases will be hindered secondary\nto international travel and pathogenicity of variants. Thus,\npotential travel restrictions and other embargo approaches\nmay require consideration.\nWhile the mortality rate of COVID-19 will be reduced with\nthe use of vaccination, it will remain higher than what is\nobserved with in\ufb02uenza. Moreover, the emergence of new var-\niants will continue to impact on current approaches to provide\nbroad-spectrum immunity. The variants forms are unpredictable\nand advanced approaches on molecular modelling may provide\nleads to developing a broad-spectrum vaccine with longer\nlasting effects. This will require continued pre-clinical and clin-\nical research.", "mimetype": "text/plain", "start_char_idx": 3799, "end_char_idx": 6156, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "00e8b91d-05b5-46d7-9734-735a8c8eb903": {"__data__": {"id_": "00e8b91d-05b5-46d7-9734-735a8c8eb903", "embedding": null, "metadata": {"page_label": "25", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "d8fa741f-944a-4fa7-923c-79699ba8d751", "node_type": "4", "metadata": {"page_label": "25", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "0783d52884e6631cf091f0f04e7dadf8e64e96a603487e8b5dcec0333b211310", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bda5a8a4-5fcf-4428-8f1f-289fe07a9d5d", "node_type": "1", "metadata": {"page_label": "25", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "cb4237593d825a1a83ef4b7c8ebd677d0b329d29b40e914d7698a90acf701ae7", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "The variants forms are unpredictable\nand advanced approaches on molecular modelling may provide\nleads to developing a broad-spectrum vaccine with longer\nlasting effects. This will require continued pre-clinical and clin-\nical research.\nOf great concern is the potential emergence of other corona-\nvirus pandemics with resistant viral pathologic pro\ufb01les that\nmay require focused or regional approaches for their\ncontrol. It is unlikely that coronavirus mediated infection\nKantarcioglu et al. 25", "mimetype": "text/plain", "start_char_idx": 5921, "end_char_idx": 6414, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "604deddb-80b6-4476-bbd3-c194ea0df1e9": {"__data__": {"id_": "604deddb-80b6-4476-bbd3-c194ea0df1e9", "embedding": null, "metadata": {"page_label": "26", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "45c8bb38-02a6-4db8-a11e-c0451354b3fd", "node_type": "4", "metadata": {"page_label": "26", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "98fde020e935bc77743c9bb17f90a7c1a802382c9ce509d77009ffd46f92c5bc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5f428a5f-5cc0-4367-96ae-a0980abe883f", "node_type": "1", "metadata": {}, "hash": "6951febfe264e8908b49f36c587e22b8854f8cdf49771085c07770bf56f7b723", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Table 8. Current Studies on COVID-19 Vaccine Combinations\nRef # Country Vaccine Combination Safety & Ef \ufb01cacy\nBorobia et al. (2021)362 Spain CombiVacs Study:\nStudy Group:\ufb01rst Dose AZD1222,\nsecond Dose BNT162b2\nControl Group: Received only\ufb01rst\ndose and not received any second\ndose.\nEf\ufb01cacy: BNT162b2 given as a second dose induced robust\nimmune responses.\nSafety: Acceptable and manageable reactogenicity\npro\ufb01le.\nGro\u00df et al. (2021)363 Germany Study Group:\n\ufb01rst dose: AZD1222\nsecond dose: BNT162b2\nNo control group.\nEf\ufb01cacy: BNT162b2 given as a second dose induced\npotent humoral and T cell immune responses. Variants\nof concern B.1.1.7, B.1.351 and B.1.617 are potently\nneutralized by sera of all participants.\nSafety: No serious adverse events have been observed.\nShaw et al. (2021), Liu et al.\n(2021)364,365\nUK ComCov1 Study\nStudy Group:\nArm 1:\ufb01rst Dose AZD1222, second\nDose BNT162b2\nArm 2:\ufb01rst Dose BNT162b2,\nsecond Dose AZD1222\nControl Group:\nArm 1:\ufb01rst Dose AZD1222, second\nDose AZD1222\nArm 2:\ufb01rst Dose BNT162b2,\nsecond Dose BNT162b2\nEf\ufb01cacy: AZD1222/BNT162b2 was non-inferior to\nAZD1222/AZD1222. The non-inferiority of the\nBNT162b2/AZD1222 against AZD1222/AZD1222\ncould not be shown.\nSafety: Both combination vaccine schedules induced\ngreater systemic reactogenicity following the second\ndose than\nthe vaccine schedules using the same vaccine. Most\ncommon symptom was fever.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1380, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "5f428a5f-5cc0-4367-96ae-a0980abe883f": {"__data__": {"id_": "5f428a5f-5cc0-4367-96ae-a0980abe883f", "embedding": null, "metadata": {"page_label": "26", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "45c8bb38-02a6-4db8-a11e-c0451354b3fd", "node_type": "4", "metadata": {"page_label": "26", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "98fde020e935bc77743c9bb17f90a7c1a802382c9ce509d77009ffd46f92c5bc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "604deddb-80b6-4476-bbd3-c194ea0df1e9", "node_type": "1", "metadata": {"page_label": "26", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "44a7f6c455c8885a94f35614de21b48f50405d454d2ec41d6d1b16d6fd848c11", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Safety: Both combination vaccine schedules induced\ngreater systemic reactogenicity following the second\ndose than\nthe vaccine schedules using the same vaccine. Most\ncommon symptom was fever. No serious adverse\nevents occurred related to vaccinations.\nHillus et al. (2021)366 Germany EICOV-COVIM Study\nStudy Group:\nArm 1:\ufb01rst Dose AZD1222, second\nDose BNT162b2\nArm 2:\ufb01rst Dose BNT162b2,\nsecond Dose BNT162b2\nSafety and Ef\ufb01cacy: AZD1222/BNT162b2 vaccine\nschedule is well tolerated and improved\nimmunogenicity compared with AZD1222/AZD1222\nvaccinations.\nUniversity of Oxford368 UK ComCov2 Study\nStudy Group:\nArm 1:\ufb01rst Dose AZD1222, second\nDose AZD1222\nArm 2:\ufb01rst Dose AZD1222, second\nDose mRNA1273\nArm 3:\ufb01rst Dose AZD1222, second\nDose NVXCoV2373\nControl Group:\nArm 1:\ufb01rst Dose BNT162b2,\nsecond Dose BNT162b2\nArm 2:\ufb01rst Dose BNT162b2,\nsecond Dose mRNA1273\nArm 3:\ufb01rst Dose BNT162b2,\nsecond Dose NVXCoV2373\nStudy is ongoing.\nCanadian Immunization\nResearch Network369\nCanada MOSAIC Study \u2014 Main Comparison\nGroups\n\ufb01rst Dose mRNA1273, second\nDose mRNA1273.\n\ufb01rst Dose mRNA1273, second\nDose BNT162b2\n\ufb01rst Dose BNT162b2, second Dose\nBNT162b2.\n\ufb01rst Dose BNT162b2, second Dose\nmRNA1273.\n\ufb01rst Dose AZD1222, second Dose\nmRNA1273.\n\ufb01rst Dose AZD1222, second Dose\nBNT162b2.\nStudy is ongoing.\n(continued)\n26 Clinical and Applied Thrombosis/Hemostasis", "mimetype": "text/plain", "start_char_idx": 1190, "end_char_idx": 2521, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "6d8f1af7-9c2e-4bb5-90f0-7142fb2ea6e7": {"__data__": {"id_": "6d8f1af7-9c2e-4bb5-90f0-7142fb2ea6e7", "embedding": null, "metadata": {"page_label": "27", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "ed0be872-0597-40be-a640-49c6a519b7af", "node_type": "4", "metadata": {"page_label": "27", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "b9d8f8ac50cfbd28a640f640a7d0289b291d49c0dfbcf03469f634d5443013d7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "562e797d-544e-4aeb-8b41-d5c1f1773239", "node_type": "1", "metadata": {}, "hash": "a9f1928aa52fb94f9a522ebcddb1f983f08357c8e4e9ebe67f5728827aeb5004", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "will be eradicated in the foreseeable time or may be phased\nout to viral mutation.\nContinual research including the information generated by\npharmacovigilance and drug safety programs will be of true\nimportance in the overall management of COVID-19 and\nrelated infections.\nFinally, it must be acknowledged that the supply, logistics,\nand monitoring of vaccine distribution and administration\ncannot be underestimated. These aspects of supply-chain man-\nagement require an unprecedented level of strategy and proper\ntactical execution that spans the globe. Only through\ncooperative actions across countries and regions of the world\nwith these considerations be met.\nConclusions\nIn the\ufb01ght against the COVID-19 pandemic, the vaccines have\nbeen our most effective weapon. Since the beginning of the\npandemic, the development and distribution of the vaccines\nhave been on an accelerated schedule like we have never seen\nbefore. In an incredibly short period of time, vaccines that are\nquite effective have been developed and delivered to hundreds\nTable 8.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1051, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "562e797d-544e-4aeb-8b41-d5c1f1773239": {"__data__": {"id_": "562e797d-544e-4aeb-8b41-d5c1f1773239", "embedding": null, "metadata": {"page_label": "27", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "ed0be872-0597-40be-a640-49c6a519b7af", "node_type": "4", "metadata": {"page_label": "27", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "b9d8f8ac50cfbd28a640f640a7d0289b291d49c0dfbcf03469f634d5443013d7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6d8f1af7-9c2e-4bb5-90f0-7142fb2ea6e7", "node_type": "1", "metadata": {"page_label": "27", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "c064f1ac780f3cc1545032f5404a21a3fc9cdeb351de032b985c39d6b76922f4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dba13983-679f-4202-a8ea-467308c322d5", "node_type": "1", "metadata": {}, "hash": "4d26460c435cd2897ee27eb258c588613daa9e01b082e21399c5149a8b9126e2", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "In an incredibly short period of time, vaccines that are\nquite effective have been developed and delivered to hundreds\nTable 8. (continued)\nRef # Country Vaccine Combination Safety & Ef \ufb01cacy\nNational Institute of Allergy\nand Infectious Diseases\n(NIAID)370\nUSA NIH Study \u2014 Main Comparison\nGroups\n\ufb01rst Dose Ad26.COV2-S, second\nDose mRNA-1273.211\n\ufb01rst Dose BNT162b2, second Dose\nmRNA-1273.211\n\ufb01rst Dose Ad26.COV.2.S, second\nDose mRNA-1273\n\ufb01rst Dose mRNA-1273, second\nDose mRNA-1273\n\ufb01rst Dose BNT162b2, second Dose\nmRNA-1273\n\ufb01rst Dose Ad26.COV2-S, second\nDose Ad26.COV2-S\n\ufb01rst Dose mRNA-1273, second\nDose Ad26.COV2.S\n\ufb01rst Dose BNT162b2, second Dose\nAd26.COV2.S\n\ufb01rst Dose Ad26.COV.2.S, second\nDose BNT162b2\n\ufb01rst Dose mRNA-1273, second\nDose BNT162b2\n\ufb01rst Dose BNT162b2, second Dose\nBNT162b2\nStudy is ongoing.\nJiangsu Province Centers for\nDisease Control and\nPrevention371\nChina Main Comparison Groups\n\ufb01rst Dose CoronaVac, second Dose\nConvidecia\n\ufb01rst Dose Convidecia, second Dose\nCoronaVac\nStudy is ongoing.\nAssistance Publique\u2014\nH\u00f4pitaux de Paris372\nFrance Main Comparison Groups\n\ufb01rst Dose BNT162b2, second Dose\nBNT162b2.\n\ufb01rst Dose BNT162b2, second Dose\nmRNA1273.\n\ufb01rst Dose mRNA1273, second\nDose mRNA1273.\n\ufb01rst Dose mRNA1273, second\nDose BNT162b2\nStudy is ongoing.", "mimetype": "text/plain", "start_char_idx": 924, "end_char_idx": 2182, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "dba13983-679f-4202-a8ea-467308c322d5": {"__data__": {"id_": "dba13983-679f-4202-a8ea-467308c322d5", "embedding": null, "metadata": {"page_label": "27", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "ed0be872-0597-40be-a640-49c6a519b7af", "node_type": "4", "metadata": {"page_label": "27", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "b9d8f8ac50cfbd28a640f640a7d0289b291d49c0dfbcf03469f634d5443013d7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "562e797d-544e-4aeb-8b41-d5c1f1773239", "node_type": "1", "metadata": {"page_label": "27", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "c5b30946d9e30dc996fbb819587c3172b08a0f94d644e385bdbcd25f6a9cbea8", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "\ufb01rst Dose mRNA1273, second\nDose mRNA1273.\n\ufb01rst Dose mRNA1273, second\nDose BNT162b2\nStudy is ongoing.\nMedical University\nInnsbruck373\nAustria Main Comparison Groups\n\ufb01rst Dose AZD1222, second Dose\nAZD1222\n\ufb01rst Dose BNT162b2, second Dose\nBNT162b2\n\ufb01rst Dose AZD1222, second Dose\nBNT162b2\nStudy is ongoing.\nKantarcioglu et al. 27", "mimetype": "text/plain", "start_char_idx": 2082, "end_char_idx": 2406, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "3f8cab12-a567-467a-81ea-435ca37ce7ef": {"__data__": {"id_": "3f8cab12-a567-467a-81ea-435ca37ce7ef", "embedding": null, "metadata": {"page_label": "28", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "234e85aa-e810-4fe5-9151-925d4e029b6a", "node_type": "4", "metadata": {"page_label": "28", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "12857ad022ab87278704bc128d8a9ee084a7c3beea80fdadda3caaed2cbe4700", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "76289406-e487-4837-82bc-71ef38a7dddf", "node_type": "1", "metadata": {}, "hash": "97f332128b522b805b268ca5f42687a868c0d72a1d7f55c5645ad6285cb7f251", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "of millions of people throughout the world. Today, the future\nstill holds some questions like the long-term effects of the vac-\ncines, how to vaccinate children or other currently unvaccinated\npopulations, or other virus variants that may develop. However,\nit has been incredibly uplifting to see the efforts and collabora-\ntion of the many researchers, physicians, corporations, institu-\ntions, and governments across the globe slow down the\nspread of a global pandemic and offer hope to eradicate it\nsomeday soon.\nAcknowledgements\nThe authors wish to acknowledge the support of the Cardiovascular\nResearch Institute at Loyola University, Chicago, Health Science\nDivision for the planning and completion of this manuscript. The\nauthors also acknowledge Dr Jin Shiomura from Nobelpharma\nTokyo, Japan, and Dr Nusrat Jabeen of the University of Karachi,\nKarachi, Pakistan, Dr Nicholas Kipshidze of New York\nCardiovascular Research Foundation, and Dr Amir Darki of Loyola\nUniversity Medical Center for their expert advise in the preparation\nof this manuscript. Special thanks to Dr Margaret Callahan, Provost,\nLoyola University Chicago and Dean Sam Marzo of Strictch School\nof Medicine for their continual encouragement and support for enhanc-\ning scienti\ufb01c research programs for the COVID-19 pandemic related\ninitiatives. We acknowledge the support from the Dr Eva Wojick chair-\nperson department of pathology and laboratory medicine and Dr Seth\nRobia director of cardiovascular research institute at Loyola University\nChicago in facilitating the completion of this manuscript. We are also\nthankful to Mrs. Erin Healey-Erickson for her skillful assistance in the\npreparation of this manuscript.\nDeclaration of Con\ufb02icting Interests\nThe author(s) declared no potential con\ufb02icts of interest with respect to\nthe research, authorship, and/or publication of this article.\nFunding\nThe author(s) received no\ufb01nancial support for the research, authorship\nand/or publication of this article.\nReferences\n1. World Health Organization (WHO).", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2025, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "76289406-e487-4837-82bc-71ef38a7dddf": {"__data__": {"id_": "76289406-e487-4837-82bc-71ef38a7dddf", "embedding": null, "metadata": {"page_label": "28", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "234e85aa-e810-4fe5-9151-925d4e029b6a", "node_type": "4", "metadata": {"page_label": "28", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "12857ad022ab87278704bc128d8a9ee084a7c3beea80fdadda3caaed2cbe4700", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3f8cab12-a567-467a-81ea-435ca37ce7ef", "node_type": "1", "metadata": {"page_label": "28", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "5ed94741b70a66b45f037b0273dc2e1b35ae68639c4fbda11309127a987ce933", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "704c03a7-6576-4ae2-9c96-cc765762fcf5", "node_type": "1", "metadata": {}, "hash": "b0b37676bfdb81add0f347e42fcc19b54125ba12a1dafec9792218a6c981cd1c", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Funding\nThe author(s) received no\ufb01nancial support for the research, authorship\nand/or publication of this article.\nReferences\n1. World Health Organization (WHO). Weekly epidemiological update\non COVID-19\u2013 17 August 2021 Edition 53 Retrieved from: https://\nwww.who.int/publications/m/item/weekly-epidemiological-update-\non-covid-19\u2014 17-august-2021.\n2. Wu F, Zhao S, Yu B, et al. A new coronavirus associated with\nhuman respiratory disease in China. Nature. 2020;579-\n(7798):265\u2013269.\n3. Zhu N, Zhang D, Wang W, et al. A novel coronavirus from\npatients with pneumonia in China, 2019. N Engl J Med .\n2020;382(8):727\u2013733.\n4. Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak asso-\nciated with a new coronavirus of probable bat origin.Nature.\n2020;579(7798):270\u2013273.\n5. Hu B, Guo H, Zhou P, et al. Characteristics of SARS-CoV-2 and\nCOVID-19. Nat Rev Microbiol. 2021;19(3):141\u2013154.\n6. V\u2019kovski P, Kratzel A, Steiner S, et al. Coronavirus biology and\nreplication: implications for SARS-CoV-2.Nat Rev Microbiol.\n2021;19(3):155\u2013170.\n7. Huang C, Wang Y, Li X, et al. Clinical features of patients\ninfected with 2019 novel coronavirus in Wuhan, China.\nLancet. 2020;395(10223):497\u2013506.\n8. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical\ncharacteristics of 99 cases of 2019 novel coronavirus pneumonia in\nWuhan, China: a descriptive study.Lancet. 2020;395(10223):507\u2013513.\n9. Wu Z, McGoogan JM.", "mimetype": "text/plain", "start_char_idx": 1864, "end_char_idx": 3259, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "704c03a7-6576-4ae2-9c96-cc765762fcf5": {"__data__": {"id_": "704c03a7-6576-4ae2-9c96-cc765762fcf5", "embedding": null, "metadata": {"page_label": "28", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "234e85aa-e810-4fe5-9151-925d4e029b6a", "node_type": "4", "metadata": {"page_label": "28", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "12857ad022ab87278704bc128d8a9ee084a7c3beea80fdadda3caaed2cbe4700", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "76289406-e487-4837-82bc-71ef38a7dddf", "node_type": "1", "metadata": {"page_label": "28", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "7598a392492b4e722abbefc2c2a6e3053e571c8a153282bb37e603c86a2bc477", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "12b48709-4a6d-4a50-88f1-1f47b1f0e595", "node_type": "1", "metadata": {}, "hash": "39f549e61b0e3162bb5d66509fa5e98bf9dc7a2a9282a1a6c6d9f52758dac5fb", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "2020;395(10223):507\u2013513.\n9. Wu Z, McGoogan JM. Characteristics of and important lessons From\nthe coronavirus disease 2019 (COVID-19) outbreak in China:\nsummary of a report of 72 314 cases From the Chinese center for\ndisease control and prevention.JAMA. 2020;323(13):1239\u20131242.\n10. Iba T, Levy JH, Connors JM, et al. The unique characteristics of\nCOVID-19 coagulopathy.Crit Care. 2020;24(1):360.\n11. Levy JH, Iba T, Olson LB, et al. COVID-19: thrombosis, throm-\nboin\ufb02ammation, and anticoagulation considerations.Int J Lab\nHematol. 2021;43(Suppl 1):29\u201335.\n12. Kipshidze N, Dangas G, White CJ, et al. Viral coagulopathy in\npatients With COVID-19: treatment and care. Clin Appl\nThromb Hemost. 2020;26:1076029620936776.\n13. Calabretta E, Moraleda JM, Iacobelli M, et al. COVID-\n19-induced endotheliitis: emerging evidence and possible thera-\npeutic strategies.Br J Haematol. 2021;193(1):43\u201351.\n14. Carvalho T, Krammer F, Iwasaki A. The \ufb01rst 12 months of\nCOVID-19: a timeline of immunological insights. Nat Rev\nImmunol. 2021;21(4):245\u2013256.\n15. Catching A, Capponi S, Yeh MT, et al. Examining the interplay\nbetween face mask usage, asymptomatic transmission, and social\ndistancing on the spread of COVID-19.Sci Rep. 2021;11(1):15998.\n16. Verdecia M, Kokai-Kun JF, Kibbey M, et al.", "mimetype": "text/plain", "start_char_idx": 3213, "end_char_idx": 4486, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "12b48709-4a6d-4a50-88f1-1f47b1f0e595": {"__data__": {"id_": "12b48709-4a6d-4a50-88f1-1f47b1f0e595", "embedding": null, "metadata": {"page_label": "28", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "234e85aa-e810-4fe5-9151-925d4e029b6a", "node_type": "4", "metadata": {"page_label": "28", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "12857ad022ab87278704bc128d8a9ee084a7c3beea80fdadda3caaed2cbe4700", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "704c03a7-6576-4ae2-9c96-cc765762fcf5", "node_type": "1", "metadata": {"page_label": "28", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "8df55248e5943d8590042222b1a3d35e813de9f3953e29eec02e1310336c6433", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0e02a1e4-b826-4366-bf96-7d6402142030", "node_type": "1", "metadata": {}, "hash": "4af804ca0d29f34d866107a7b2890838bc8b53bbb9fa10f5639247c7441dd7da", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "2021;11(1):15998.\n16. Verdecia M, Kokai-Kun JF, Kibbey M, et al. COVID-19 vaccine\nplatforms: delivering on a promise?Hum Vaccin Immunother.\n2021;17(9):2873\u20132893.\n17. Greenwood B. The contribution of vaccination to global health:\npast, present and future.Philos Trans R Soc Lond B Biol Sci.\n2014;369(1645):20130433.\n18. Li Y, Tenchov R, Smoot J, et al. A comprehensive review of the\nglobal efforts on COVID-19 vaccine development.ACS Cent Sci.\n2021;7(4):512\u2013533.\n19. Coronaviridae Study Group of the International Committee on\nTaxonomy of Viruses. The species severe acute respiratory\nsyndrome-related coronavirus: classifying 2019-nCoV and\nnaming it SARS-CoV-2.Nat Microbiol. 2020;5(4):536\u2013544.\n20. Dai L, Gao GF. Viral targets for vaccines against COVID-19.\nNat Rev Immunol. 2021;21(2):73\u201382.\n21. Billah MA, Miah MM, Khan MN. Reproductive number of coro-\nnavirus: a systematic review and meta-analysis based on global\nlevel evidence.PLoS One. 2020;15(11):e0242128.\n22. Anderson RM, Vegvari C, Truscott J, et al. Challenges in creat-\ning herd immunity to SARS-CoV-2 infection by mass vaccina-\ntion.Lancet. 2020;396(10263):1614\u20131616.\n23. Britton T, Ball F, Trapman P. A mathematical model reveals the\nin\ufb02uence of population heterogeneity on herd immunity to\nSARS-CoV-2. Science. 2020;369(6505):846\u2013849.\n24. World Health Organization. Coronavirus disease (COVID-19)\nSituation dashboard.", "mimetype": "text/plain", "start_char_idx": 4422, "end_char_idx": 5806, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "0e02a1e4-b826-4366-bf96-7d6402142030": {"__data__": {"id_": "0e02a1e4-b826-4366-bf96-7d6402142030", "embedding": null, "metadata": {"page_label": "28", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "234e85aa-e810-4fe5-9151-925d4e029b6a", "node_type": "4", "metadata": {"page_label": "28", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "12857ad022ab87278704bc128d8a9ee084a7c3beea80fdadda3caaed2cbe4700", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "12b48709-4a6d-4a50-88f1-1f47b1f0e595", "node_type": "1", "metadata": {"page_label": "28", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "6378863329e16f938e6c36c2dc846fab8ea14bb13b0286de8dcb4aa394d074ac", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Science. 2020;369(6505):846\u2013849.\n24. World Health Organization. Coronavirus disease (COVID-19)\nSituation dashboard. Retrieved from: https://covid19.who.int\n28 Clinical and Applied Thrombosis/Hemostasis", "mimetype": "text/plain", "start_char_idx": 5691, "end_char_idx": 5892, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "5b0a364e-a8fb-4562-af69-91614343d2fd": {"__data__": {"id_": "5b0a364e-a8fb-4562-af69-91614343d2fd", "embedding": null, "metadata": {"page_label": "29", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "9365d75b-df22-4bb1-87b1-c8becc020be8", "node_type": "4", "metadata": {"page_label": "29", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "e46d7068558276a44c2e6229759301840c7c40441f93d44289e27159fbffde5a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3c72cc7b-08c2-4a37-8fe4-9d6508dd1158", "node_type": "1", "metadata": {}, "hash": "e00b8c850150d2464f55747f2c363557437ff5268d6f97759e3598aa6abd69b2", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "25. Sabahelzain MM, Hartigan-Go K, Larson HJ. The politics of\nCOVID-19 vaccine con \ufb01dence. Curr Opin Immunol .\n2021;71:92\u201396.\n26. Sallam M. COVID-19 Vaccine hesitancy worldwide: a concise\nsystematic review of vaccine acceptance rates. Vaccines\n(Basel). 2021;9(2):160.\n27. Finney Rutten LJ, Zhu X, Leppin AL, et al. Evidence-Based\nstrategies for clinical organizations to address COVID-19\nvaccine hesitancy.Mayo Clin Proc. 2021;96(3):699\u2013707.\n28. Kreps S, Prasad S, Brownstein JS, et al. Factors associated with\nUS adults\u2019 likelihood of accepting COVID-19 vaccination.\nJAMA Netw Open. 2020;3(10):e2025594.\n29. Pogue K, Jensen JL, Stancil CK, et al. In\ufb02uences on attitudes\nregarding potential COVID-19 vaccination in the United\nStates. Vaccines (Basel). 2020;8(4):582.\n30. Yoo JH. What we do know and do not yet know about\nCOVID-19 vaccines as of the beginning of the year 2021.J\nKorean Med Sci. 2021;36(6):e54.\n31. Lee P, Kim CU, Seo SH, et al. Current status of COVID-19\nvaccine development: focusing on antigen design and clinical\ntrials on later stages.Immune Netw. 2021;21(1):e4.\n32. Sharma O, Sultan AA, Ding H, et al. A review of the progress\nand challenges of developing a vaccine for COVID-19.Front\nImmunol. 2020;11:585354.\n33. Chung YH, Beiss V, Fiering SN, et al. COVID-19 vaccine front-\nrunners and their nanotechnology design.ACS Nano. 2020;14-\n(10):12522\u201312537.\n34.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1377, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "3c72cc7b-08c2-4a37-8fe4-9d6508dd1158": {"__data__": {"id_": "3c72cc7b-08c2-4a37-8fe4-9d6508dd1158", "embedding": null, "metadata": {"page_label": "29", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "9365d75b-df22-4bb1-87b1-c8becc020be8", "node_type": "4", "metadata": {"page_label": "29", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "e46d7068558276a44c2e6229759301840c7c40441f93d44289e27159fbffde5a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5b0a364e-a8fb-4562-af69-91614343d2fd", "node_type": "1", "metadata": {"page_label": "29", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "6a1a9f8eeca05c30847c9d8d155f1cb7d4d6fd59bcd43b93ef2bf0e8dedf0927", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4e5ac5b4-e2ec-4289-8405-3923a4891d92", "node_type": "1", "metadata": {}, "hash": "88ce420e95959dfcb3cdaf83f016f490e9bde971cacfa036f8a928f71c393204", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "COVID-19 vaccine front-\nrunners and their nanotechnology design.ACS Nano. 2020;14-\n(10):12522\u201312537.\n34. World Health Organization. COVID-19 vaccine tracker and\nlandscape. 20 August 2021. Retrieved from: https://www.who.\nint/publications/m/item/draft-landscape-of-covid-19-candidate-\nvaccines.\n35. Frederiksen LSF, Zhang Y, Foged C, et al. The long road toward\nCOVID-19 herd immunity: vaccine platform technologies and\nmass immunization strategies.Front Immunol. 2020;11:1817.\n36. Carneiro DC, Sousa JD, Monteiro-Cunha JP. The COVID-19\nvaccine development: a pandemic paradigm. Virus Res .\n2021;301:198454.\n37. Hosseini SA, Zahedipour F, Mirzaei H, et al. Potential\nSARS-CoV-2 vaccines: concept, progress, and challenges.Int\nImmunopharmacol. 2021;97:107622.\n38. Nagy A, Alhatlani B. An overview of current COVID-19 vaccine\nplatforms. Comput Struct Biotechnol J. 2021;19:2508\u20132517.\n39. Patel SP, Patel GS, Suthar JV. Inside the story about the research\nand development of COVID-19 vaccines.Clin Exp Vaccine Res.\n2021;10(2):154\u2013170.\n40. Blumental S, Debr\u00e9 P. Challenges and issues of anti-SARS-CoV-2\nvaccines.Front Med (Lausanne). 2021;8:664179.\n41. Nakagami H. Development of COVID-19 vaccines utilizing\ngene therapy technology.Int Immunol. 2021;33(10):521\u2013527.\n42. Zhang Y, Zeng G, Pan H, et al.", "mimetype": "text/plain", "start_char_idx": 1273, "end_char_idx": 2568, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "4e5ac5b4-e2ec-4289-8405-3923a4891d92": {"__data__": {"id_": "4e5ac5b4-e2ec-4289-8405-3923a4891d92", "embedding": null, "metadata": {"page_label": "29", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "9365d75b-df22-4bb1-87b1-c8becc020be8", "node_type": "4", "metadata": {"page_label": "29", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "e46d7068558276a44c2e6229759301840c7c40441f93d44289e27159fbffde5a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3c72cc7b-08c2-4a37-8fe4-9d6508dd1158", "node_type": "1", "metadata": {"page_label": "29", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "3fb75bc002c5e83f7b622d7abc21ee363b57614a357c6baeb02dd83e513a82dc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "67c4f5b0-97fe-4f53-b74a-ae3bf41e473b", "node_type": "1", "metadata": {}, "hash": "be93477d5b1b9802c9e78adfb619dfe0c59d7450ad4031836a229797eeb5d2fc", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "2021;33(10):521\u2013527.\n42. Zhang Y, Zeng G, Pan H, et al. Safety, tolerability, and immuno-\ngenicity of an inactivated SARS-CoV-2 vaccine in healthy adults\naged 18\u201359 years: a randomised, double-blind, placebo-\ncontrolled, phase 1/2 clinical trial.Lancet Infect Dis. 2021;21-\n(2):181\u2013192.\n43. Wu Z, Hu Y, Xu M, et al. Safety, tolerability, and immunogenic-\nity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in\nhealthy adults aged 60 years and older: a randomised, double-\nblind, placebo-controlled, phase 1/2 clinical trial.Lancet Infect\nDis. 2021;21(6):803\u2013812.\n44. Tanriover MD, Dog\u0306 anay HL, Akova M, et al. Ef\ufb01cacy and safety of\nan inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac):\ninterim results of a double-blind, randomised, placebo-controlled,\nphase 3 trial in Turkey.Lancet. 2021;398(10296):213\u2013222.\n45. Jara A, Undurraga EA, Gonz\u00e1lez C, et al. Effectiveness of an\ninactivated SARS-CoV-2 vaccine in Chile. N Engl J Med .\n2021;385(10):875\u2013884.\n46. Xia S, Zhang Y, Wang Y, et al. Safety and immunogenicity of an\ninactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised,\ndouble-blind, placebo-controlled, phase 1/2 trial.Lancet Infect\nDis. 2021;21(1):39\u201351.\n47. Xia S, Duan K, Zhang Y, et al. Effect of an inactivated vaccine\nagainst SARS-CoV-2 on safety and immunogenicity outcomes:\ninterim analysis of 2 randomized clinical trials.JAMA. 2020;324-\n(10):951\u2013960.\n48.", "mimetype": "text/plain", "start_char_idx": 2513, "end_char_idx": 3894, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "67c4f5b0-97fe-4f53-b74a-ae3bf41e473b": {"__data__": {"id_": "67c4f5b0-97fe-4f53-b74a-ae3bf41e473b", "embedding": null, "metadata": {"page_label": "29", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "9365d75b-df22-4bb1-87b1-c8becc020be8", "node_type": "4", "metadata": {"page_label": "29", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "e46d7068558276a44c2e6229759301840c7c40441f93d44289e27159fbffde5a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4e5ac5b4-e2ec-4289-8405-3923a4891d92", "node_type": "1", "metadata": {"page_label": "29", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "4d83470fa2b4b40d185f3d69f673002ceefbb4fdcf36f463f9e6ce40e7c2a40c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "55bac4dc-dd5e-40d5-a516-1b17df1f4cb5", "node_type": "1", "metadata": {}, "hash": "c5d705fd76794cb8596c047b5f3b970a250015b21db3065ca3af3393358ad111", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Effect of an inactivated vaccine\nagainst SARS-CoV-2 on safety and immunogenicity outcomes:\ninterim analysis of 2 randomized clinical trials.JAMA. 2020;324-\n(10):951\u2013960.\n48. Al Kaabi N, Zhang Y, Xia S, et al. Effect of 2 inactivated\nSARS-CoV-2 vaccines on symptomatic COVID-19 infection in\nadults: a randomized clinical trial.JAMA. 2021;326(1):35\u201345.\n49. Ella R, Vadrevu KM, Jogdand H, et al. Safety and immunogenic-\nity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-\nblind, randomised, phase 1 trial. Lancet Infect Dis. 2021;21-\n(5):637\u2013646.\n50. Ella R, Reddy S, Jogdand H, et al. Safety and immunogenicity of\nan inactivated SARS-CoV-2 vaccine, BBV152: interim results\nfrom a double-blind, randomised, multicentre, phase 2 trial,\nand 3-month follow-up of a double-blind, randomised phase 1\ntrial.Lancet Infect Dis. 2021;21(7):950\u2013961.\n51. Pan HX, Liu JK, Huang BY, et al. Immunogenicity and safety of\na severe acute respiratory syndrome coronavirus 2 inactivated\nvaccine in healthy adults: randomized, double-blind, and\nplacebo-controlled phase 1 and phase 2 clinical trials.Chin\nMed J (Engl). 2021;134(11):1289\u20131298.\n52. Shenzhen Kangtai Biological Products Co., LTD. A study to\nevaluate the ef \ufb01cacy, safety and immunogenicity of\nSARS-CoV-2 vaccine (vero cells), inactivated in healthy adults\naged 18 years and older (COVID-19). Identi\ufb01cation Number:\nNCT04852705.", "mimetype": "text/plain", "start_char_idx": 3721, "end_char_idx": 5096, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "55bac4dc-dd5e-40d5-a516-1b17df1f4cb5": {"__data__": {"id_": "55bac4dc-dd5e-40d5-a516-1b17df1f4cb5", "embedding": null, "metadata": {"page_label": "29", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "9365d75b-df22-4bb1-87b1-c8becc020be8", "node_type": "4", "metadata": {"page_label": "29", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "e46d7068558276a44c2e6229759301840c7c40441f93d44289e27159fbffde5a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "67c4f5b0-97fe-4f53-b74a-ae3bf41e473b", "node_type": "1", "metadata": {"page_label": "29", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "e39422a390e51dad8ae702689c2df693597274e1b980c60f4c60a75a24d446f6", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Identi\ufb01cation Number:\nNCT04852705. Retrieved from: https://clinicaltrials.gov/ct2/\nshow/NCT04852705?term=vaccine&recrs=abdf&cond=COVID-\n19&phase=0123&sort=nwst&draw=2\n53. Pu J, Yu Q, Yin Z, et al. The safety and immunogenicity of an\ninactivated SARS-CoV-2 vaccine in Chinese adults aged 18\u2013\n59 years: a phase I randomized, double-blinded, controlled\ntrial.Vaccine. 2021;39(20):2746\u20132754.\n54. Che Y, Liu X, Pu Y, et al. Randomized, double-blinded and\nplacebo-controlled phase II trial of an inactivated SARS-CoV-2\nvaccine in healthy adults.Clin Infect Dis. 2020:ciaa1703.\n55. Research Institute for Biological Safety Problems.\nReactogenicity, safety and immunogenicity of QazCovid-in\u00ae\nCOVID-19 vaccine. Identi\ufb01cation Number: NCT04530357.\nRetrieved from: https://clinicaltrials.gov/ct2/show/\nNCT04530357?zterm=vaccine&cond=covid-19&draw=4\n56. Research Institute for Biological Safety Problems.\nImmunogenicity, ef \ufb01cacy and safety of QazCovid-in\u00ae\nKantarcioglu et al. 29", "mimetype": "text/plain", "start_char_idx": 5062, "end_char_idx": 6028, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "10d4d15f-2c73-4426-a50f-71ea7f5ea9fb": {"__data__": {"id_": "10d4d15f-2c73-4426-a50f-71ea7f5ea9fb", "embedding": null, "metadata": {"page_label": "30", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "ac87c0ae-85e3-4cf2-a730-61f926edf400", "node_type": "4", "metadata": {"page_label": "30", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "8251d8cf0bc6a7bf4a6c61ff6a6e636131331c6fe1d8602c872b3258f50b838d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2e6fc93b-c553-43a8-ad66-44e29001d417", "node_type": "1", "metadata": {}, "hash": "24a440dedf85de78747b55e7890b7802c3472109e02aa14691e27dc077cffd61", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "COVID-19 vaccine. Identi \ufb01cation Number: NCT04691908.\nRetrieved from: https://clinicaltrials.gov/ct2/show/NCT04691908\n57. Shifa Pharmed Industrial Co. A double-blind, randomized,\nplacebo-controlled phase II/III clinical trial to evaluate the\nsafety and ef\ufb01cacy of COVID-19 inactivated vaccine (shifa-\npharmed) in a population aged 18 to 75 years. Identi\ufb01cation\nNumber: IRCT20201202049567N3. Retrieved from: https://en.\nirct.ir/trial/54881\n58. Jordan R, Barrett JR, Belij-Rammerstorfer S, et al. Phase 1/2 trial\nof SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster\ndose induces multifunctional antibody responses.Nat Med.\n2021;27(2):279\u2013288.\n59. Folegatti PM, Ewer KJ, Aley PK, et al. Safety and immunogenic-\nity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a\npreliminary report of a phase 1/2, single-blind, randomised con-\ntrolled trial.Lancet. 2020;396(10249):467\u2013478.\n60. Ramasamy MN, Minassian AM, Ewer KJ, et al. Safety and\nimmunogenicity of ChAdOx1 nCoV-19 vaccine administered\nin a prime-boost regimen in young and old adults (COV002): a\nsingle-blind, randomised, controlled, phase 2/3 trial.Lancet.\n2021;396(10267):1979\u20131993.\n61. Voysey M, Costa-Clemens SA, Madhi SA, et al. Safety and ef\ufb01-\ncacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against\nSARS-CoV-2: an interim analysis of four randomised controlled\ntrials in Brazil, South Africa, and the UK.Lancet.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1371, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "2e6fc93b-c553-43a8-ad66-44e29001d417": {"__data__": {"id_": "2e6fc93b-c553-43a8-ad66-44e29001d417", "embedding": null, "metadata": {"page_label": "30", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "ac87c0ae-85e3-4cf2-a730-61f926edf400", "node_type": "4", "metadata": {"page_label": "30", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "8251d8cf0bc6a7bf4a6c61ff6a6e636131331c6fe1d8602c872b3258f50b838d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "10d4d15f-2c73-4426-a50f-71ea7f5ea9fb", "node_type": "1", "metadata": {"page_label": "30", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "eebdb52b0e75d03f5eefc85b0c16032590d5518fccf37489b3e8d39f4992e6bb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a11d218c-03c3-4287-9eee-1c3152479208", "node_type": "1", "metadata": {}, "hash": "6b32e655b22cf83da74b2b763bf9358b61f0e4e837a1bd163195aaee74b8d9ff", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "2021;397-\n(10269):99\u2013111.\n62. Zhu FC, Li YH, Guan XH, et al. Safety, tolerability, and immuno-\ngenicity of a recombinant adenovirus type-5 vectored COVID-19\nvaccine: a dose-escalation, open-label, non-randomised,\n\ufb01rst-in-human trial.Lancet. 2020;395(10240):1845\u20131854.\n63. Zhu FC, Guan XH, Li YH, et al. Immunogenicity and safety of a\nrecombinant adenovirus type-5-vectored COVID-19 vaccine in\nhealthy adults aged 18 years or older: a randomised, double-\nblind, placebo-controlled, phase 2 trial.Lancet. 2020;396-\n(10249):479\u2013488.\n64. Sadoff J, Le Gars M, Shukarev G, et al. Interim results of a phase\n1\u20132a trial of Ad26.COV2.S COVID-19 vaccine.N Engl J Med.\n2021;384(19):1824\u20131835.\n65. Sadoff J, Gray G, Vandebosch A, et al. Safety and ef\ufb01cacy of\nsingle-dose Ad26.COV2.S vaccine against COVID-19.N Engl\nJ Med. 2021;384(23):2187\u20132201.\n66. Logunov DY, Dolzhikova IV, Zubkova OV, et al. Safety and\nimmunogenicity of an rAd26 and rAd5 vector-based heterolo-\ngous prime-boost COVID-19 vaccine in two formulations: two\nopen, non-randomised phase 1/2 studies from russia.Lancet.\n2020;396(10255):887\u2013897.\n67. Logunov DY, Dolzhikova IV, Shcheblyakov DV, et al.", "mimetype": "text/plain", "start_char_idx": 1372, "end_char_idx": 2523, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "a11d218c-03c3-4287-9eee-1c3152479208": {"__data__": {"id_": "a11d218c-03c3-4287-9eee-1c3152479208", "embedding": null, "metadata": {"page_label": "30", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "ac87c0ae-85e3-4cf2-a730-61f926edf400", "node_type": "4", "metadata": {"page_label": "30", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "8251d8cf0bc6a7bf4a6c61ff6a6e636131331c6fe1d8602c872b3258f50b838d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2e6fc93b-c553-43a8-ad66-44e29001d417", "node_type": "1", "metadata": {"page_label": "30", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "3c959f2ed234efe9419bf5dcbef51dce92f775cfbcba573fc51b6b1cec1fdb75", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "38036193-c9c7-4342-8491-e9680c2b9ad1", "node_type": "1", "metadata": {}, "hash": "7afe1d22f430815520d94c1d586b12234ed464db2b058e27dbefd95d637c4ff3", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "2020;396(10255):887\u2013897.\n67. Logunov DY, Dolzhikova IV, Shcheblyakov DV, et al. Safety\nand ef\ufb01cacy of an rAd26 and rAd5 vector-based heterologous\nprime-boost COVID-19 vaccine: an interim analysis of a rando-\nmised controlled phase 3 trial in russia.Lancet. 2021;397-\n(10275):671\u2013681.\n68. Capone S, Raggioli A, Gentile M, et al. Immunogenicity of a new\ngorilla adenovirus vaccine candidate for COVID-19.Mol Ther.\n2021;29(8):2412\u20132423.\n69. ReiThera Srl. Study of GRAd-COV2 for the prevention of\nCOVID-19 in adults (COVITAR). Identi \ufb01cation Number:\nNCT04791423. Retrieved from: https://clinicaltrials.gov/ct2/\nshow/NCT04791423\n70. AstraZeneca. Phase II/III study of AZD2816, for the prevention\nof COVID-19 in adults (AZD2816). Identi \ufb01cation Number:\nNCT04973449. Retrieved from: https://clinicaltrials.gov/ct2/\nshow/NCT04973449\n71. M\u00f6ssler C, Groiss F, Wolzt M, et al. Phase I/II trial of a\nreplication-de\ufb01cient trivalent in\ufb02uenza virus vaccine lacking\nNS1. Vaccine. 2013;31(52):6194\u20136200.\n72. Wacheck V, Egorov A, Groiss F, et al. A novel type of in\ufb02uenza\nvaccine: safety and immunogenicity of replication-de \ufb01cient\nin\ufb02uenza virus created by deletion of the interferon antagonist\nNS1. J Infect Dis. 2010;201(3):354\u2013362.\n73. Wang P, Zheng M, Lau SY, et al.", "mimetype": "text/plain", "start_char_idx": 2444, "end_char_idx": 3697, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "38036193-c9c7-4342-8491-e9680c2b9ad1": {"__data__": {"id_": "38036193-c9c7-4342-8491-e9680c2b9ad1", "embedding": null, "metadata": {"page_label": "30", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "ac87c0ae-85e3-4cf2-a730-61f926edf400", "node_type": "4", "metadata": {"page_label": "30", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "8251d8cf0bc6a7bf4a6c61ff6a6e636131331c6fe1d8602c872b3258f50b838d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a11d218c-03c3-4287-9eee-1c3152479208", "node_type": "1", "metadata": {"page_label": "30", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "b36f121e2e8da8e05b671c92b348bccd19c4e8d525c83c8569d5fcaf6d976c33", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7411954a-86d9-4afa-8e46-22d0b9684ea9", "node_type": "1", "metadata": {}, "hash": "ff1fb07064cec9fba6377119c04fdbd4d9b844c9092ce7f8facb329a0c02f1d9", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "J Infect Dis. 2010;201(3):354\u2013362.\n73. Wang P, Zheng M, Lau SY, et al. Generation of DelNS1 in\ufb02u-\nenza viruses: a strategy for optimizing live attenuated in\ufb02uenza\nvaccines. mBio. 2019;10(5):e02180\u201319.\n74. Jiangsu Provincial Center For Disease Control and Prevention. A\nphase II clinical trial of in\ufb02uenza virus vector COVID-19 vaccine\nfor intranasal spray (DelNS1-2019-nCoV-RBD-OPT1).\nIdenti\ufb01cation Number: ChiCTR2000039715. Retrieved from:\nhttps://www.chictr.org.cn/showproj.aspx?proj=63754\n75. Shenzhen Geno-Immune Medical Institute. Immunity and safety\nof COVID-19 synthetic minigene vaccine. Identi \ufb01cation\nNumber: NCT04276896. Retrieved from: https://clinicaltrials.\ngov/ct2/show/NCT04276896\n76. Rice A, Verma M, Shin A, et al. Intranasal plus subcutaneous prime\nvaccination with a dual antigen COVID-19 vaccine elicits T-cell\nand antibody responses in mice.Sci Rep. 2021;11(1):14917.\n77. ImmunityBio, Inc. COVID-19 Supplemental vaccine boost to\nenhance T cell protection in those Who have already received\nEUA S-based vaccines. Identi\ufb01cation Number: NCT04843722.\nRetrieved from: https://clinicaltrials.gov/ct2/show/\nNCT04843722\n78. Cellid Co., Ltd. Safety and immunogenicity study of\nAdCLD-CoV19: a COVID-19 preventive vaccine in healthy vol-\nunteers. Identi\ufb01cation Number: NCT04666012. Retrieved from:\nhttps://clinicaltrials.gov/ct2/show/NCT04666012\n79. Sun W, Leist SR, McCroskery S, et al.", "mimetype": "text/plain", "start_char_idx": 3627, "end_char_idx": 5025, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "7411954a-86d9-4afa-8e46-22d0b9684ea9": {"__data__": {"id_": "7411954a-86d9-4afa-8e46-22d0b9684ea9", "embedding": null, "metadata": {"page_label": "30", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "ac87c0ae-85e3-4cf2-a730-61f926edf400", "node_type": "4", "metadata": {"page_label": "30", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "8251d8cf0bc6a7bf4a6c61ff6a6e636131331c6fe1d8602c872b3258f50b838d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "38036193-c9c7-4342-8491-e9680c2b9ad1", "node_type": "1", "metadata": {"page_label": "30", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "ec77fdd20d24c253d494254bdb791fffb3712090442b100adb267d9ccdb57730", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Retrieved from:\nhttps://clinicaltrials.gov/ct2/show/NCT04666012\n79. Sun W, Leist SR, McCroskery S, et al. Newcastle Disease virus\n(NDV) expressing the spike protein of SARS-CoV-2 as a live\nvirus vaccine candidate.EBioMedicine. 2020;62:103132.\n80. Sun W, McCroskery S, Liu WC, et al. A Newcastle disease virus\n(NDV) expressing a membrane-anchored spike as a cost-\neffective inactivated SARS-CoV-2 vaccine.Vaccines (Basel).\n2020;8(4):771.\n81. Institute of Vaccines and Medical Biologicals, Vietnam. A phase\n1/2 safety and immunogenicity trial of COVID-19 vaccine\nCOVIVAC. Identi\ufb01cation Number: NCT04830800. Retrieved\nfrom: https://clinicaltrials.gov/ct2/show/NCT04830800\n82. German Center for Infection Research. Safety, tolerability and\nimmunogenicity of the candidate vaccine MVA-SARS-2-ST\nagainst COVID-19 (MVA-SARS-2-ST). Identi\ufb01cation Number:\nNCT04895449. Retrieved from: https://www.clinicaltrials.gov/\nct2/show/NCT04895449?term=NCT04895449&draw=2&rank=1\n83. Tucker SN, Tingley DW, Scallan CD. Oral adenoviral-based\nvaccines: historical perspective and future opportunity.Expert\nRev Vaccines. 2008;7(1):25\u201331.\n30 Clinical and Applied Thrombosis/Hemostasis", "mimetype": "text/plain", "start_char_idx": 4920, "end_char_idx": 6079, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "a96347eb-b047-4b8b-9936-2264f2903860": {"__data__": {"id_": "a96347eb-b047-4b8b-9936-2264f2903860", "embedding": null, "metadata": {"page_label": "31", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "3d644fb7-3fee-4891-ad11-4a3c02452a32", "node_type": "4", "metadata": {"page_label": "31", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "c471eb3d0318d7c34a168bc45cd3ad5ee989627e415c6b3b6212777978375525", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ba1b3311-d8b5-4bb7-b815-180fa7982f00", "node_type": "1", "metadata": {}, "hash": "3aabb5eecd67daef82680657063a3d6fe5d24d688bf42da6fea548b509cb3428", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "84. Liebowitz D, Lindbloom JD, Brandl JR, et al. High titre neutral-\nising antibodies to in\ufb02uenza after oral tablet immunisation: a\nphase 1, randomised, placebo-controlled trial. Lancet Infect\nDis. 2015;15(9):1041\u20131048.\n85. Vaxart. Safety and immunogenicity trial of an oral SARS-CoV-2\nvaccine (VXA-CoV2-1) for prevention of COVID-19 in healthy\nadults. Identi\ufb01cation Number: NCT04563702. Retrieved from:\nhttps://clinicaltrials.gov/ct2/show/NCT04563702\n86. Tscherne A, Schwarz JH, Rohde C, et al. Immunogenicity and\nef\ufb01cacy of the COVID-19 candidate vector vaccine\nMVA-SARS-2-S in preclinical vaccination.Proc Natl Acad Sci\nUSA . 2021;118(28):e2026207118.\n87. Universit\u00e4tsklinikum Hamburg-Eppendorf. Safety, tolerability and\nimmunogenicity of the candidate vaccine MVA-SARS-2-S against\nCOVID-19. Identi\ufb01cation Number: NCT04569383. Retrieved\nfrom: https://clinicaltrials.gov/ct2/show/NCT04569383\n88. City of Hope Medical Center. A synthetic MVA-based\nSARS-CoV-2 vaccine, COH04S1, for the prevention of\nCOVID-19. Identi\ufb01cation Number: NCT04639466. Retrieved\nfrom: https://clinicaltrials.gov/ct2/show/NCT04639466\n89. Hassan AO, Kafai NM, Dmitrie v IP, et al. A single-dose\nintranasal ChAd vaccine protects upper and lower respira-\ntory tracts against SARS-CoV-2. Cell . 2020;183(1):169 \u2013\n184.e13.\n90. Bharat Biotech International Limited.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1334, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "ba1b3311-d8b5-4bb7-b815-180fa7982f00": {"__data__": {"id_": "ba1b3311-d8b5-4bb7-b815-180fa7982f00", "embedding": null, "metadata": {"page_label": "31", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "3d644fb7-3fee-4891-ad11-4a3c02452a32", "node_type": "4", "metadata": {"page_label": "31", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "c471eb3d0318d7c34a168bc45cd3ad5ee989627e415c6b3b6212777978375525", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a96347eb-b047-4b8b-9936-2264f2903860", "node_type": "1", "metadata": {"page_label": "31", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "1a81d71aab99e1538b0959aa6612b861c0d85fb26b726bb430eec8ecf01ec2e3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a2c40831-b334-4f94-9ef3-33b0ce88c725", "node_type": "1", "metadata": {}, "hash": "dade3e8dd27ccac93b21d6c73ca664c2d031e8063476e4bbb6ddd24e4c234358", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Cell . 2020;183(1):169 \u2013\n184.e13.\n90. Bharat Biotech International Limited. Safety and immunogenic-\nity of an intranasal SARS-CoV-2 vaccine (BBV154) for\nCOVID-19. Identi\ufb01cation Number: NCT04751682. Retrieved\nfrom: https://clinicaltrials.gov/ct2/show/NCT04751682\n91. National Institute of Allergy and Infectious Diseases (NIAID).\nChimpanzee adenovirus and self-amplifying mRNA prime-boost\nprophylactic vaccines against SARS-CoV-2 in healthy adults.\nIdenti\ufb01cation Number: NCT04776317. Retrieved from: https://\nclinicaltrials.gov/ct2/show/NCT04776317\n92. Tetherex Pharmaceuticals Corporation. A phase 1,\ufb01rst-In-human\nstudy of the investigational COVID-19 vaccine SC-Ad6-1 in\nhealthy volunteers. Identi\ufb01cation Number: NCT04839042.\nRetrieved from: https://clinicaltrials.gov/ct2/show/NCT04839042\n93. CyanVac LLC. Phase 1 study of intranasal PIV5-vectored\nCOVID-19 vaccine expressing SARS-CoV-2 spike protein in\nhealthy adults (CVXGA1-001). Identi \ufb01cation Number:\nNCT04954287. Retrieved from: https://clinicaltrials.gov/ct2/\nshow/NCT04954287\n94. Shenzhen Geno-Immune Medical Institute. Safety and immu-\nnity of COVID-19 aAPC vaccine. Identi \ufb01cation Number:\nNCT04299724. 2020. Retrieved from : https://clinicaltrials.\ngov/ct2/show/NCT04299724\n95. Dieterle ME, Haslwanter D, Bortz RH3rd, et al. A replication-\ncompetent vesicular stomatitis virus for studies of SARS-CoV-2\nspike-mediated cell entry and Its inhibition.Cell Host Microbe.\n2020;28(3):486\u2013496.e6.\n96.", "mimetype": "text/plain", "start_char_idx": 1259, "end_char_idx": 2714, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "a2c40831-b334-4f94-9ef3-33b0ce88c725": {"__data__": {"id_": "a2c40831-b334-4f94-9ef3-33b0ce88c725", "embedding": null, "metadata": {"page_label": "31", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "3d644fb7-3fee-4891-ad11-4a3c02452a32", "node_type": "4", "metadata": {"page_label": "31", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "c471eb3d0318d7c34a168bc45cd3ad5ee989627e415c6b3b6212777978375525", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ba1b3311-d8b5-4bb7-b815-180fa7982f00", "node_type": "1", "metadata": {"page_label": "31", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "8463cfcc4b83541f17c3f1e446ae302df18867d86b3d5aaa4cb4c78c72e369f2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5a77cd27-44d3-46b4-a875-5f3227d74f02", "node_type": "1", "metadata": {}, "hash": "98896697ab4d7ba43a0fc9cb6669001589ae4fde3107b1fa9da26bacea3cf27d", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "A replication-\ncompetent vesicular stomatitis virus for studies of SARS-CoV-2\nspike-mediated cell entry and Its inhibition.Cell Host Microbe.\n2020;28(3):486\u2013496.e6.\n96. Yahalom-Ronen Y, Tamir H, Melamed S, et al. A single dose of\nrecombinant VSV-\u0394G-spike vaccine provides protection against\nSARS-CoV-2 challenge.Nat Commun. 2020;11(1):6402.\n97. Israel Institute for Biological Research (IIBR). Evaluate the\nsafety, immunogenicity and potential ef \ufb01cacy of an\nrVSV-SARS-CoV-2-S vaccine. Identi \ufb01cation Number:\nNCT04608305. Retrieved from: https://clinicaltrials.gov/ct2/\nshow/NCT04608305\n98. Aivita Biomedical, Inc. Phase I-II trial of dendritic cell vaccine to\nprevent COVID-19 in adults. Identi \ufb01cation Number:\nNCT04386252. Retrieved from: https://clinicaltrials.gov/ct2/\nshow/NCT04386252\n99. Mulligan MJ, Lyke KE, Kitchin N, et al. Phase I/II study of\nCOVID-19 RNA vaccine BNT162b1 in adults. Nature.\n2020;586(7830):589\u2013593.\n100. Polack FP, Thomas SJ, Kitchin N, et al. Safety and ef\ufb01cacy of the\nBNT162b2 mRNA COVID-19 vaccine.N Engl J Med2020;383-\n(27):2603\u20132615.\n101. Jackson LA, Anderson EJ, Rouphael NG, et al. An mRNA\nvaccine against SARS-CoV-2\u2014 preliminary report. N Engl J\nMed. 2020;383(20):1920\u20131931.\n102. Baden LR, El Sahly HM, Essink B, et al. Ef\ufb01cacy and safety of\nthe mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med .", "mimetype": "text/plain", "start_char_idx": 2546, "end_char_idx": 3872, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "5a77cd27-44d3-46b4-a875-5f3227d74f02": {"__data__": {"id_": "5a77cd27-44d3-46b4-a875-5f3227d74f02", "embedding": null, "metadata": {"page_label": "31", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "3d644fb7-3fee-4891-ad11-4a3c02452a32", "node_type": "4", "metadata": {"page_label": "31", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "c471eb3d0318d7c34a168bc45cd3ad5ee989627e415c6b3b6212777978375525", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a2c40831-b334-4f94-9ef3-33b0ce88c725", "node_type": "1", "metadata": {"page_label": "31", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "8a48993eff42ee6d582fa3fddaccaad7e6f2c441e8192b5f59f26f4851f2851d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5686bf4d-0256-4464-8319-1b26b72344f7", "node_type": "1", "metadata": {}, "hash": "f3722b1f99bf54583ea19477ea8379882cc37669b919ca4fad60cc0c60e8fe15", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "102. Baden LR, El Sahly HM, Essink B, et al. Ef\ufb01cacy and safety of\nthe mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med .\n2021;384(5):403\u2013416.\n103. National Institute of Allergy and Infectious Diseases. Safety and\nimmunogenicity study of a SARS-CoV-2 (COVID-19) variant\nvaccine (mRNA-1273.351) in na\u00efve and previously vaccinated\nadults. Identi\ufb01cation Number: NCT04785144. Retrieved from:\nhttps://clinicaltrials.gov/ct2/show/NCT04785144\n104. ModernaTX, Inc. A study to evaluate the immunogenicity and\nsafety of mRNA-1273.211 vaccine for COVID-19 variants.\nIdenti\ufb01cation Number: NCT04927065. Retrieved from: https://\nclinicaltrials.gov/ct2/show/NCT04927065\n105. ModernaTX, Inc. A study to evaluate safety, reactogenicity, and\nimmunogenicity of mRNA-1283 and mRNA-1273 vaccines in\nhealthy adults between 18 years and 55 years of Age to\nprevent COVID-19. Identi\ufb01cation Number: NCT04813796.\nRetrieved from: https://clinicaltrials.gov/ct2/show/\nNCT04813796\n106. Kremsner PG, Mann P, Kroidl A, et al. Safety and immunogenic-\nity of an mRNA-lipid nanoparticle vaccine candidate against\nSARS-CoV-2 : a phase 1 randomized clinical trial.Wien Klin\nWochenschr. 2021;133(17\u201318):931\u2013941.\n107. CureVac AG. A study to evaluate the safety and immunogenicity\nof vaccine CVnCoV in healthy adults in Germany for\nCOVID-19. Identi\ufb01cation Number: NCT04674189. Retrieved\nfrom: https://clinicaltrials.gov/ct2/show/NCT04674189\n108.", "mimetype": "text/plain", "start_char_idx": 3757, "end_char_idx": 5156, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "5686bf4d-0256-4464-8319-1b26b72344f7": {"__data__": {"id_": "5686bf4d-0256-4464-8319-1b26b72344f7", "embedding": null, "metadata": {"page_label": "31", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "3d644fb7-3fee-4891-ad11-4a3c02452a32", "node_type": "4", "metadata": {"page_label": "31", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "c471eb3d0318d7c34a168bc45cd3ad5ee989627e415c6b3b6212777978375525", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5a77cd27-44d3-46b4-a875-5f3227d74f02", "node_type": "1", "metadata": {"page_label": "31", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "18dca0980096a53e1814ed5bdbb6eb77d4a5022f27672872979a0936eeebaf2b", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Identi\ufb01cation Number: NCT04674189. Retrieved\nfrom: https://clinicaltrials.gov/ct2/show/NCT04674189\n108. Zhang NN, Li XF, Deng YQ, et al. A thermostable mRNA\nvaccine against COVID-19.Cell. 2020;182(5):1271\u20131283.e16.\n109. Walvax Biotechnology Co., Ltd. A phase III clinical study of a\nSARS-CoV-2 messenger ribonucleic acid (mRNA) vaccine can-\ndidate against COVID-19 in population aged 18 years and above.\nIdenti\ufb01cation Number: NCT04847102. Retrieved from: https://\nclinicaltrials.gov/ct2/show/NCT04847102\n110. Arcturus Therapeutics, Inc. A trial evaluating the safety and\neffects of an RNA vaccine ARCT-021 in healthy adults.\nIdenti\ufb01cation Number: NCT04668339. Retrieved from: https://\nwww.clinicaltrials.gov/ct2/show/NCT04668339?term=\nvaccination&cond=covid&draw=1\n111. Kalnin KV, Plitnik T, Kishko M, et al. Immunogenicity and ef\ufb01-\ncacy of mRNA COVID-19 vaccine MRT5500 in preclinical\nanimal models.NPJ Vaccines. 2021;6(1):61.\nKantarcioglu et al. 31", "mimetype": "text/plain", "start_char_idx": 5053, "end_char_idx": 6003, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "48bd918a-35c7-4c06-9dc7-23cf1aaedbcf": {"__data__": {"id_": "48bd918a-35c7-4c06-9dc7-23cf1aaedbcf", "embedding": null, "metadata": {"page_label": "32", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "35f0cc85-d0d6-45e8-b14f-549678a8827a", "node_type": "4", "metadata": {"page_label": "32", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "47fc4f1b6292668804fe84643e32ef24c18ccf62cb82c2fa1e55901cd8b20711", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bf34aaee-81c0-402f-87c0-01e03e56d171", "node_type": "1", "metadata": {}, "hash": "0d00881cd13b91b066e0168d91202d5afed1234a496608c1f7eefc7a39dedfc4", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "112. Sano\ufb01 Pasteur, a Sano\ufb01 Company. Study of mRNA vaccine for-\nmulation against COVID-19 in healthy adults 18 years of Age\nand older (VAW00001). Identi\ufb01cation Number:\nNCT04798027. Retrieved from: https://clinicaltrials.gov/ct2/\nshow/NCT04798027\n113. Daiichi Sankyo Co., Ltd. Study of DS-5670a (COVID-19\nvaccine) in Japanese healthy adults and elderly subjects.\nIdenti\ufb01cation Number: NCT04821674. Retrieved from: https://\nclinicaltrials.gov/ct2/show/NCT04821674\n114. Elixirgen Therapeutics, Inc. Safety and immunogenicity of\nEXG-5003. Identi\ufb01cation Number: NCT04863131. Retrieved\nfrom: https://clinicaltrials.gov/ct2/show/NCT04863131\n115. Imperial College London. Clinical trial to assess the safety of a\ncoronavirus vaccine in healthy men and women. Identi\ufb01cation\nNumber: ISRCTN17072692. Retrieved from: https://www.\nisrctn.com/ISRCTN17072692\n116. Chulalongkorn University. Chulacov19 vaccine in healthy\nadults. Identi\ufb01cation Number: NCT04566276. Retrieved from:\nhttps://clinicaltrials.gov/ct2/show/NCT04566276\n117. Providence Therapeutics Holdings Inc.. A phase I,\n\ufb01rst-in-human, observer-blinded, randomized, placebo con-\ntrolled, ascending dose study to evaluate the safety, tolerability,\nand immunogenicity of PTX-COVID19-B vaccine in healthy\nseronegative adults aged 18 \u201364. Identi \ufb01cation Number:\nNCT04765436. Retrieved from: https://clinicaltrials.gov/ct2/\nshow/NCT04765436\n118. GlaxoSmithKline.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1403, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "bf34aaee-81c0-402f-87c0-01e03e56d171": {"__data__": {"id_": "bf34aaee-81c0-402f-87c0-01e03e56d171", "embedding": null, "metadata": {"page_label": "32", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "35f0cc85-d0d6-45e8-b14f-549678a8827a", "node_type": "4", "metadata": {"page_label": "32", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "47fc4f1b6292668804fe84643e32ef24c18ccf62cb82c2fa1e55901cd8b20711", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "48bd918a-35c7-4c06-9dc7-23cf1aaedbcf", "node_type": "1", "metadata": {"page_label": "32", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "9ea267c1d09a26936d09cb9f13963958fd39302362dbd1520ce20bfc6caf2d39", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0444363e-44b2-41ea-9752-86b51555eed7", "node_type": "1", "metadata": {}, "hash": "181ef9a8ddbb1772b5d9b4c1dcb8fe0c60d94021697cb952943f94e4db96646a", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Identi \ufb01cation Number:\nNCT04765436. Retrieved from: https://clinicaltrials.gov/ct2/\nshow/NCT04765436\n118. GlaxoSmithKline. A study of the safety of and immune response\nto varying doses of a vaccine against COVID-19 in healthy\nadults. Identi\ufb01cation Number: NCT04758962. Retrieved from:\nhttps://clinicaltrials.gov/ct2/show/NCT04758962\n119. SENAI CIMATEC. Study to assess safety, reactogenicity and\nimmunogenicity of the VACINA RNA MCTI CIMATEC HDT\nvaccine against COVID-19. Identi \ufb01cation Number:\nNCT04844268. Retrieved from: https://clinicaltrials.gov/ct2/\nshow/NCT04844268\n120. Stemirna Therapeutics Co., Ltd. Randomized, double-blind,\nplacebo-controlled phase I clinical trial to evaluate the safety\nand immunogenicity of mRNA COVID-19 vaccine in healthy\nsusceptible populations aged 18 years and older people.\nIdenti\ufb01cation Number: ChiCTR2100045984. Retrieved from:\nhttps://www.chictr.org.cn/showprojen.aspx?proj=126046\n121. MRC/UVRI and LSHTM Uganda Research Unit. Safety and\nimmunogenicity of LNP-nCOV saRNA-02 vaccine against\nSARS-CoV-2, the causative agent of COVID-19\n(COVAC-Uganda). Identi\ufb01cation Number: NCT04934111.\nRetrieved from: https://clinicaltrials.gov/ct2/show/NCT04934111\n122. Momin T, Kansagra K, Patel H, et al. Safety and immunogenicity of\na DNA SARS-CoV-2 vaccine (ZyCoV-D): results of an open-label,\nnon-randomized phase I part of phase I/II clinical study by intradermal\nroute in healthy subjects in India.EClinicalMedicine. 2021;38:101020.\n123. Cadila Healthcare Ltd.", "mimetype": "text/plain", "start_char_idx": 1281, "end_char_idx": 2773, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "0444363e-44b2-41ea-9752-86b51555eed7": {"__data__": {"id_": "0444363e-44b2-41ea-9752-86b51555eed7", "embedding": null, "metadata": {"page_label": "32", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "35f0cc85-d0d6-45e8-b14f-549678a8827a", "node_type": "4", "metadata": {"page_label": "32", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "47fc4f1b6292668804fe84643e32ef24c18ccf62cb82c2fa1e55901cd8b20711", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bf34aaee-81c0-402f-87c0-01e03e56d171", "node_type": "1", "metadata": {"page_label": "32", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "59656f0d2781bb557b279e5861661037528ca02356ad9195ec0a08662f8724e8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8f6e5557-84db-4f5b-bd14-dec247b4c19e", "node_type": "1", "metadata": {}, "hash": "1598dd612285a2a1506cb050bf270ca6e8615c3d321de5b2217443f9b43a9e60", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "2021;38:101020.\n123. Cadila Healthcare Ltd. A phase III, randomized, multi-centre,\ndouble blind, placebo controlled, study to evaluate ef\ufb01cacy,\nsafety and immunogenicity of novel Corona virus\u22122019-nCov\nvaccine candidate. Identi \ufb01cation Number: CTRI/2021/01/\n030416. Retrieved from: http://ctri.nic.in/Clinicaltrials/\nshowallp.php?mid1=51254&EncHid=&userName=ZyCoV-D\n124. AnGes, Inc. Phase II / III study of COVID-19 DNA vaccine\n(AG0302-COVID-19). Identi\ufb01cation Number: NCT04655625.\nRetrieved from: https://clinicaltrials.gov/ct2/show/NCT04655625\n125. Smith TRF, Patel A, Ramos S, et al. Immunogenicity of a DNA\nvaccine candidate for COVID-19. Nat Commun .\n2020;11(1):2601.\n126. Tebas P, Yang S, Boyer JD, et al. Safety and immunogenicity of\nINO-4800 DNA vaccine against SARS-CoV-2: a preliminary\nreport of an open-label, phase 1 clinical trial.EClinicalMedicine.\n2021;31:100689.\n127. Inovio Pharmaceuticals. Safety, immunogenicity, and ef\ufb01cacy of\nINO-4800 for COVID-19 in healthy seronegative adults at high risk\nof SARS-CoV-2 exposure. Identi\ufb01cation Number: NCT04642638.\nRetrieved from: https://clinicaltrials.gov/ct2/show/NCT04642638\n128. Genexine, Inc. Safety and immunogenicity study of GX-19, a\nCOVID-19 preventive DNA vaccine in healthy adults.\nIdenti\ufb01cation Number: NCT04445389. Retrieved from: https://\nclinicaltrials.gov/ct2/show/NCT04445389\n129. GeneOne Life Science, Inc.", "mimetype": "text/plain", "start_char_idx": 2730, "end_char_idx": 4112, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "8f6e5557-84db-4f5b-bd14-dec247b4c19e": {"__data__": {"id_": "8f6e5557-84db-4f5b-bd14-dec247b4c19e", "embedding": null, "metadata": {"page_label": "32", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "35f0cc85-d0d6-45e8-b14f-549678a8827a", "node_type": "4", "metadata": {"page_label": "32", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "47fc4f1b6292668804fe84643e32ef24c18ccf62cb82c2fa1e55901cd8b20711", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0444363e-44b2-41ea-9752-86b51555eed7", "node_type": "1", "metadata": {"page_label": "32", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "bb9553d4375bfaa73b4d3bdd2647b7ce491532ac741421eaf175d98b591ac9e0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5121ae10-e390-4da7-9d34-7d68066a37ca", "node_type": "1", "metadata": {}, "hash": "5a78c24c5041ddf0a7b0f08e4645720490280b22e3360b3d5301293089135c3f", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Identi\ufb01cation Number: NCT04445389. Retrieved from: https://\nclinicaltrials.gov/ct2/show/NCT04445389\n129. GeneOne Life Science, Inc. GLS-5310 Vaccine for the preven-\ntion of SARS-CoV-2 (COVID-19). Identi \ufb01cation Number:\nNCT04673149. Retrieved from: https://clinicaltrials.gov/ct2/\nshow/NCT04673149\n130. AnGes, Inc. Phase I/II study of COVID-19 DNA vaccine\n(AG0302-COVID19 high-dose). Identi \ufb01cation Number:\nNCT04993586. Retrieved from: https://clinicaltrials.gov/ct2/\nshow/NCT04993586\n131. Takis. Safety and immunogenicity of COVID-eVax, a candidate\nplasmid DNA vaccine for COVID-19, in healthy adult volun-\nteers. Identi\ufb01cation Number: NCT04788459. Retrieved from:\nhttps://clinicaltrials.gov/ct2/show/NCT04788459\n132. Entos Pharmaceuticals Inc. A clinical trial of a prophylactic\nplasmid DNA vaccine for COVID-19 [covigenix VAX-001] in\nadults. Identi\ufb01cation Number: NCT04591184. Retrieved from:\nhttps://clinicaltrials.gov/ct2/show/NCT04591184\n133. Providence Health & Services. CORVax12: SARS-CoV-2 spike\n(S) protein plasmid DNA vaccine trial for COVID-19\n(SARS-CoV-2) (CORVax12). Identi\ufb01cation Number:\nNCT04627675. Retrieved from: https://clinicaltrials.gov/ct2/\nshow/NCT04627675\n134. Symvivo Corporation. Evaluating the safety, tolerability and\nimmunogenicity of bacTRL-spike vaccine for prevention of\nCOVID-19. Identi\ufb01cation Number: NCT04334980.", "mimetype": "text/plain", "start_char_idx": 3981, "end_char_idx": 5329, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "5121ae10-e390-4da7-9d34-7d68066a37ca": {"__data__": {"id_": "5121ae10-e390-4da7-9d34-7d68066a37ca", "embedding": null, "metadata": {"page_label": "32", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "35f0cc85-d0d6-45e8-b14f-549678a8827a", "node_type": "4", "metadata": {"page_label": "32", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "47fc4f1b6292668804fe84643e32ef24c18ccf62cb82c2fa1e55901cd8b20711", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8f6e5557-84db-4f5b-bd14-dec247b4c19e", "node_type": "1", "metadata": {"page_label": "32", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "8bb5aa60f7a2578fd5ee261fb824a4c1117a988ecaf29d3e7f20f4a5dec65e2e", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Symvivo Corporation. Evaluating the safety, tolerability and\nimmunogenicity of bacTRL-spike vaccine for prevention of\nCOVID-19. Identi\ufb01cation Number: NCT04334980. Retrieved\nfrom: https://clinicaltrials.gov/ct2/show/NCT04334980\n135. University of Sydney. The safety and immunogenicity of a\nDNA-based vaccine (COVIGEN) in healthy volunteers\n(COVALIA). Identi\ufb01cation Number: NCT04742842. Retrieved\nfrom: https://clinicaltrials.gov/ct2/show/NCT04742842\n136. Keech C, Albert G, Cho I, et al. Phase 1\u20132 trial of a SARS-CoV-2\nrecombinant spike protein nanoparticle vaccine.N Engl J Med.\n2020;383(24):2320\u20132332.\n137. Heath PT, Galiza EP, Baxter DN, et al. Safety and ef\ufb01cacy of\nNVX-CoV2373 COVID-19 vaccine.N Engl J Med. 2021;385-\n(13):1172\u20131183.\n138. Ryzhikov AB, Ryzhikov EA, Bogryantseva MP, et al. A single\nblind, placebo-controlled randomized study of the safety, reacto-\ngenicity and immunogenicity of the\u201cEpiVacCorona\u201dvaccine for\n32 Clinical and Applied Thrombosis/Hemostasis", "mimetype": "text/plain", "start_char_idx": 5167, "end_char_idx": 6141, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "c0cecdb4-4a48-4a78-8301-d3672d43571c": {"__data__": {"id_": "c0cecdb4-4a48-4a78-8301-d3672d43571c", "embedding": null, "metadata": {"page_label": "33", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "9f50783a-89b7-4389-9e19-116448179aec", "node_type": "4", "metadata": {"page_label": "33", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "9f62200a82de3ce472e26fdc6c2d8ba78d6e627ccf23a22a9dbd5b32bc41ecc8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "16eafa85-a586-436c-8df5-132ecca5371d", "node_type": "1", "metadata": {}, "hash": "3107494854bf8706a7cc7916ffb923a8204a7286f7e79ebdaa9d66960a428652", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "the prevention of COVID-19, in volunteers aged 18\u201360 years\n(phase I\u2013II). Russian J Infect Immun. 11(2):283\u2013296.\n139. Federal Budgetary Research Institution State Research Center of\nVirology and Biotechnology\u201cVector\u201d(2021). Study of the toler-\nability, safety, immunogenicity and preventive ef\ufb01cacy of the\nEpiVacCorona vaccine for the prevention of COVID-19.\nIdenti\ufb01cation No: NCT04780035. Retrieved from: https://\nclinicaltrials.gov/ct2/show/NCT04780035\n140. Yang S, Li Y, Dai L, et al. Safety and immunogenicity of a\nrecombinant tandem-repeat dimeric RBD-based protein subunit\nvaccine (ZF2001) against COVID-19 in adults: two randomised,\ndouble-blind, placebo-controlled, phase 1 and 2 trials.Lancet\nInfect Dis. 2021;21(8):1107\u20131119.\n141. Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. A phase III\nclinical trial to determine the safety and ef\ufb01cacy of ZF2001 for\nprevention of COVID-19. Identi \ufb01cation No: NCT04646590.\nRetrieved from: https://clinicaltrials.gov/ct2/show/NCT04646590\n142. Gorry C. SOBERANA, Cuba \u2019s COVID-19 vaccine candi-\ndates: Dagmar Garc\u00eda-Rivera PhD. MEDICC Rev .\n2020;22(4):10 \u201315.\n143. Finlay Vaccine Institute (IFV). Phase II study, multicenter and\nadaptive for evaluating the immunogenicity, safety and reactoge-\nnicity of the anti-SARS prophylactic vaccine candidate\u2014 CoV\u2014\n2, FINLAY- FR-2 (COVID-19). Identi \ufb01cation No:\nRPCEC00000347. Retrieved from: https://rpcec.sld.cu/en/trials/\nRPCEC00000347-En\n144. Sano\ufb01 Pasteur, a Sano\ufb01 Company.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1465, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "16eafa85-a586-436c-8df5-132ecca5371d": {"__data__": {"id_": "16eafa85-a586-436c-8df5-132ecca5371d", "embedding": null, "metadata": {"page_label": "33", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "9f50783a-89b7-4389-9e19-116448179aec", "node_type": "4", "metadata": {"page_label": "33", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "9f62200a82de3ce472e26fdc6c2d8ba78d6e627ccf23a22a9dbd5b32bc41ecc8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c0cecdb4-4a48-4a78-8301-d3672d43571c", "node_type": "1", "metadata": {"page_label": "33", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "ad90488577ea32eadb6322bb37ee2084ea15d7b1b39dbd75dbd31746c278bead", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ace771a5-2f88-47d5-94a6-b20d6a50f760", "node_type": "1", "metadata": {}, "hash": "9d581b7c8a2d873882ae8caaa45ccc1ccd545acfdf68626070fc6bb2cac2645b", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Retrieved from: https://rpcec.sld.cu/en/trials/\nRPCEC00000347-En\n144. Sano\ufb01 Pasteur, a Sano\ufb01 Company. Study of recombinant protein\nvaccines With adjuvant as a primary series and as a booster dose\nagainst COVID-19 in adults 18 years of Age and older\n(VAT00002). Identi\ufb01cation No: NCT04762680. Retrieved\nfrom: https://clinicaltrials.gov/ct2/show/NCT04762680\n145. Meng FY, Gao F, Jia SY, et al. Safety and immunogenicity of a\nrecombinant COVID-19 vaccine (Sf9 cells) in healthy population\naged 18 years or older: two single-center, randomised, double-\nblind, placebo-controlled, phase 1 and phase 2 trials.Signal\nTransduct Target Ther. 2021;6(1):271.\n146. WestVac Biopharma Co., Ltd. A global phase III clinical trial of\nrecombinant COVID- 19 vaccine (Sf9 cells). Identi\ufb01cation No:\nNCT04904471. Retrieved from: https://clinicaltrials.gov/ct2/\nshow/NCT04904471\n147. Center for Genetic Engineering and Biotechnology (CIGB).\nPhase III, multicenter, randomized, double-blind, placebo-\ncontrolled clinical trial for the evaluation in adults of the ef\ufb01-\ncacy, safety and immunogenicity of the vaccine candidate\nCIGB-66 against SARS-CoV-2.JAMA Pediatr. (COVID-19).\nIdenti\ufb01cation No: RPCEC00000359. Retrieved from: https://\nrpcec.sld.cu/trials/RPCEC00000359-En\n148. Nguyen TP, Do Q, Phan LT, et al. Safety and immunogenicity of\nNanocovax, a SARS-CoV-2 recombinant spike protein vaccine.\nmedRxiv2021. 07.22.21260942; https://doi.org/10.1101/2021.", "mimetype": "text/plain", "start_char_idx": 1364, "end_char_idx": 2798, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "ace771a5-2f88-47d5-94a6-b20d6a50f760": {"__data__": {"id_": "ace771a5-2f88-47d5-94a6-b20d6a50f760", "embedding": null, "metadata": {"page_label": "33", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "9f50783a-89b7-4389-9e19-116448179aec", "node_type": "4", "metadata": {"page_label": "33", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "9f62200a82de3ce472e26fdc6c2d8ba78d6e627ccf23a22a9dbd5b32bc41ecc8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "16eafa85-a586-436c-8df5-132ecca5371d", "node_type": "1", "metadata": {"page_label": "33", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "102e9d890e10af4e43246429cc4bd498c065e85788f3430a7a3c90dccac03888", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9895a5c2-2c9d-4e27-8e53-22b6d44fd9fb", "node_type": "1", "metadata": {}, "hash": "8f696c2a22f9d34222ed42b175799dca22d7d32ae7646d89201649ede5a42593", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "medRxiv2021. 07.22.21260942; https://doi.org/10.1101/2021.\n07.22.21260942\n149. Nanogen Pharmaceutical Biotechnology Joint Stock Company.\nStudy to evaluate the safety, immunogenicity, and ef\ufb01cacy of\nnanocovax vaccine against COVID-19. Identi \ufb01cation No:\nNCT04922788. Retrieved from: https://clinicaltrials.gov/ct2/\nshow/NCT04922788\n150. Richmond P, Hatchuel L, Dong M, et al. Safety and immunoge-\nnicity of S-Trimer (SCB-2019), a protein subunit vaccine candi-\ndate for COVID-19 in healthy adults: a phase 1, randomised,\ndouble-blind, placebo-controlled trial.Lancet. 2021;397-\n(10275):682\u2013694.\n151. Clover Biopharmaceuticals AUS Pty Ltd. A controlled phase 2/3\nstudy of adjuvanted recombinant SARS-CoV-2 trimeric\nS-protein vaccine (SCB-2019) for the prevention of COVID-19\n(SCB-2019). Identi\ufb01cation No: NCT04672395. Retrieved\nfrom: https://clinicaltrials.gov/ct2/show/NCT04672395\n152. Chavda VP, Vora LK, Vihol DR. COVAX-19 \u00ae vaccine:\ncompletely blocks virus transmission to non-immune individu-\nals.Clin Complement Med Pharmacol. 2021;1(100004)\n153. Cinnagen. Phase II clinical trial of CinnaGen COVID-19 vaccine\n(SpikoGen). Identi\ufb01cation No: NCT04944368. Retrieved from:\nhttps://clinicaltrials.gov/ct2/show/NCT04944368\n154. Lien CE, Lin YJ, Chen C, et al. CpG-adjuvanted stable prefusion\nSARS-CoV-2 spike protein protected hamsters from\nSARS-CoV-2 challenge.Sci Rep.", "mimetype": "text/plain", "start_char_idx": 2740, "end_char_idx": 4108, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "9895a5c2-2c9d-4e27-8e53-22b6d44fd9fb": {"__data__": {"id_": "9895a5c2-2c9d-4e27-8e53-22b6d44fd9fb", "embedding": null, "metadata": {"page_label": "33", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "9f50783a-89b7-4389-9e19-116448179aec", "node_type": "4", "metadata": {"page_label": "33", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "9f62200a82de3ce472e26fdc6c2d8ba78d6e627ccf23a22a9dbd5b32bc41ecc8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ace771a5-2f88-47d5-94a6-b20d6a50f760", "node_type": "1", "metadata": {"page_label": "33", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "8d5b41f7665b0777ad4f4123c445bf7009a7a8ef770810baa8e4cd7c0478267f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4b3ea8f9-8ae0-42d9-812a-65ddf7cf34c7", "node_type": "1", "metadata": {}, "hash": "bc335213f49bc2393c72c2c7d4e61366f6d18b5a8a47e503ee5dc982de6c4244", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CpG-adjuvanted stable prefusion\nSARS-CoV-2 spike protein protected hamsters from\nSARS-CoV-2 challenge.Sci Rep. 2021;11(1):8761.\n155. Hsieh SM, Liu WD, Huang YS, et al. Safety and immunogenicity\nof a recombinant stabilized prefusion SARS-CoV-2 spike protein\nvaccine (MVC-COV1901) adjuvanted with CpG 1018 and alu-\nminum hydroxide in healthy adults: a phase 1, dose-escalation\nstudy. EClinicalMedicine. 2021;38:100989.\n156. Medigen Vaccine Biologics Corp. A study to evaluate\nMVC-COV1901 vaccine against COVID-19 in adult\n(COVID-19). Identi\ufb01cation No: NCT04695652. Retrieved\nfrom: https://clinicaltrials.gov/ct2/show/NCT04695652\n157. S\u00e1nchez-Ram\u00edrez B, Ochoa-Azze R, Climent-Ruiz Y, et al. A\nsingle dose of SARS-CoV-2 FINLAY-FR-1A dimeric-RBD\nrecombinant vaccine enhances neutralization response in\nCOVID-19 convalescents, with excellent safety pro\ufb01le. A pre-\nliminary report of an open-label phase 1 clinical trial.medRxiv\n2021.02.22.21252091. https://doi.org/10.1101/2021.02.22.21252091\n158. Finlay Vaccine Institute (FVI). A phase II, sequential, multicen-\nter, adaptive, parallel groups, randomized, placebo-controlled,\ndouble-blinded, to evaluate safety, reactogenicity and immuno-\ngenicity of the prophylactic vaccine candidate FINLAY-FR-1A\nanti SARS-CoV-2, in COVID-19 convalescents. (COVID-19).\nIdenti\ufb01cation No: RPCEC00000366.", "mimetype": "text/plain", "start_char_idx": 3998, "end_char_idx": 5331, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "4b3ea8f9-8ae0-42d9-812a-65ddf7cf34c7": {"__data__": {"id_": "4b3ea8f9-8ae0-42d9-812a-65ddf7cf34c7", "embedding": null, "metadata": {"page_label": "33", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "9f50783a-89b7-4389-9e19-116448179aec", "node_type": "4", "metadata": {"page_label": "33", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "9f62200a82de3ce472e26fdc6c2d8ba78d6e627ccf23a22a9dbd5b32bc41ecc8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9895a5c2-2c9d-4e27-8e53-22b6d44fd9fb", "node_type": "1", "metadata": {"page_label": "33", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "c70107a85deaf39d4a20962ffba0d766c3c5c81047c408110d4c8f4abf67c911", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "(COVID-19).\nIdenti\ufb01cation No: RPCEC00000366. Retrieved from: https://\nrpcec.sld.cu/trials/RPCEC00000366-En\n159. Phase II, Safety and Immunogenicity of RAZI SARS-CoV-2\nrecombinant Spike protein vaccine (RAZI Cov Pars) in adults\naged 18\u201370 years; a Randomised, double blind, parallel 2 arms\nclinical trial. Identi \ufb01cation No: IRCT20201214049709N2.\nRetrieved from: https://en.irct.ir/trial/55238\n160. Shu YJ, He JF, Pei RJ, et al. Immunogenicity and safety of a\nrecombinant fusion protein vaccine (V-01) against coronavirus\ndisease 2019 in healthy adults: a randomized, double-blind,\nplacebo-controlled, phase II trial.Chin Med J (Engl). 2021;134-\n(16):1967\u20131976.\n161. Guangdong Provincial Center for Disease Control and\nPrevention/ Gaozhou Municipal Center for Disease Control\nand Prevention. A randomized, double-blind, placebo-controlled\nphase II clinical trial to evaluate the immunogenicity and safety\nof recombinant SARS-CoV-2 fusion protein vaccine (V-01) in\nKantarcioglu et al. 33", "mimetype": "text/plain", "start_char_idx": 5287, "end_char_idx": 6272, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "83d8ea37-cc5b-461f-928b-e902185e304c": {"__data__": {"id_": "83d8ea37-cc5b-461f-928b-e902185e304c", "embedding": null, "metadata": {"page_label": "34", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "96d19885-c85b-4254-80c4-3c172b24dc5b", "node_type": "4", "metadata": {"page_label": "34", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "d13571f937a3a0bfbb833bd1789aa4d577e6af4bb753aa5079097cc290f8f32a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5225cc00-9503-44bd-a2c1-04a3c1cdb9dc", "node_type": "1", "metadata": {}, "hash": "d789a2daab54e898b0e960a022a3225b58f3b5818beb931a519d6518e1d2bc9f", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "healthy subjects. Identi \ufb01cation No: ChiCTR2100045107.\nRetrieved from: https://www.chictr.org.cn/showproj.aspx?proj=\n124702\n162. Clover Biopharmaceuticals AUS Pty Ltd. Immunogenicity and\nsafety of adjuvanted SCB-2020S vaccines in adults.\nIdenti\ufb01cation No: NCT04950751. Retrieved from: https://\nclinicaltrials.gov/ct2/show/NCT04950751\n163. Shanghai Zerun Biotechnology Co., Ltd. Phase II clinical trial of\nrecombinant SARS-CoV-2 spike protein vaccine (CHO cell).\nIdenti\ufb01cation No: NCT04990544. Retrieved from: https://\nclinicaltrials.gov/ct2/show/NCT04990544\n164. Kentucky BioProcessing, Inc. KBP-201 COVID-19 vaccine trial\nin healthy volunteers. Identi \ufb01cation No: NCT04473690.\nRetrieved from: https://clinicaltrials.gov/ct2/show/NCT04473690\n165. Center for Genetic Engineering and Biotechnology (CIGB).\nAdaptive phase I / II clinical trial, randomized, of parallel\ngroups, to evaluate the safety and immunogenicity in adults of\ntwo vaccine candidates, based on recombinant RBD subunits\nfor the prevention of COVID-19 in regimens that use the nasal\nroute of administration. (COVID-19). Identi\ufb01cation No:\nRPCEC00000345. Retrieved from: https://rpcec.sld.cu/en/trials/\nRPCEC00000345-En\n166. Biological E Limited. Biological E\u2019s novel COVID-19 vaccine of\nSARS-CoV-2 for protection against COVID-19 disease.\nIdenti\ufb01cation No: CTRI/2020/11/029032. Retrieved from: http://\nwww.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=48329\n167. Shionogi & Co., Ltd.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1451, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "5225cc00-9503-44bd-a2c1-04a3c1cdb9dc": {"__data__": {"id_": "5225cc00-9503-44bd-a2c1-04a3c1cdb9dc", "embedding": null, "metadata": {"page_label": "34", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "96d19885-c85b-4254-80c4-3c172b24dc5b", "node_type": "4", "metadata": {"page_label": "34", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "d13571f937a3a0bfbb833bd1789aa4d577e6af4bb753aa5079097cc290f8f32a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "83d8ea37-cc5b-461f-928b-e902185e304c", "node_type": "1", "metadata": {"page_label": "34", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "2506ffee92c7b30aa8bc4f6f6505f09f98f53b9262b3ab8fe8f16a1b48cd8dfc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4d614c56-7196-484d-a8c0-b0ab7f0367b2", "node_type": "1", "metadata": {}, "hash": "14a3b6ea30d092f465e4c74937f3090ed4d8fbfd56ea91fd3fe83db31baa8349", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Retrieved from: http://\nwww.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=48329\n167. Shionogi & Co., Ltd. A phase 1/2, randomized, double-blind,\nplacebo-controlled, parallel-group study of S-268019 in\nJapanese adult participants. Identi\ufb01cation No:\njRCT2051200092. Retrieved from: https://jrct.niph.go.jp/en-\nlatest-detail/jRCT2051200092\n168. University Medical Center Groningen. Anti-COVID19 AKS-452\n\u2014 ACT study (ACT). Identi \ufb01cation No: NCT04681092.\nRetrieved from: https://clinicaltrials.gov/ct2/show/\nNCT04681092\n169. University of Saskatchewan. A clinical trial of COVAC-2 in\nhealthy adults. Identi \ufb01cation No: NCT04702178. Retrieved\nfrom: https://clinicaltrials.gov/ct2/show/NCT04702178\n170. Arunachalam PS, Walls AC, Golden N, et al. Adjuvanting a\nsubunit COVID-19 vaccine to induce protective immunity.\nNature. 2021;594(7862):253\u2013258. Epub 2021 Apr 19.\n171. SK Bioscience Co., Ltd. Safety and immunogenicity study of\nSARS-CoV-2 nanoparticle vaccine (GBP510) adjuvanted With\naluminum hydroxide (COVID-19). Identi\ufb01cation No:\nNCT04742738. Retrieved from: https://clinicaltrials.gov/ct2/\nshow/NCT04742738\n172. EuBiologics Co., Ltd. Safety, tolerance and immunogenicity of\nEuCorVac-19 for the prevention of COVID-19 in healthy\nadults. Identi \ufb01cation No: NCT04783311. Retrieved from:\nhttps://clinicaltrials.gov/ct2/show/NCT04783311\n173. OSE Immunotherapeutics.", "mimetype": "text/plain", "start_char_idx": 1343, "end_char_idx": 2707, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "4d614c56-7196-484d-a8c0-b0ab7f0367b2": {"__data__": {"id_": "4d614c56-7196-484d-a8c0-b0ab7f0367b2", "embedding": null, "metadata": {"page_label": "34", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "96d19885-c85b-4254-80c4-3c172b24dc5b", "node_type": "4", "metadata": {"page_label": "34", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "d13571f937a3a0bfbb833bd1789aa4d577e6af4bb753aa5079097cc290f8f32a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5225cc00-9503-44bd-a2c1-04a3c1cdb9dc", "node_type": "1", "metadata": {"page_label": "34", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "330af8a279158809f6c4ad292798f7726ae76b78aefc3516827548711c3d87b8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "46aedb37-db5d-4362-babf-89be3e6f1435", "node_type": "1", "metadata": {}, "hash": "b9422b0ec280a300c1b9408a1b64cab3048210fd1635ec059fef5fa8da12d18c", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Identi \ufb01cation No: NCT04783311. Retrieved from:\nhttps://clinicaltrials.gov/ct2/show/NCT04783311\n173. OSE Immunotherapeutics. A randomized, open label, phase 1\nstudy to evaluate the safety, reactogenicity and immunogenicity\nof OSE-13E, a multiepitope-based vaccine candidate against\nCOVID-19, in healthy adults (COVEPIT-3). Identi\ufb01cation No:\nNCT04885361. Retrieved from: https://clinicaltrials.gov/ct2/\nshow/NCT04885361\n174. Research Institute for Biological Safety Problems. Reactogenicity,\nsafety and immunogenicity of QazCoVac-P COVID-19 vaccine.\nIdenti\ufb01cation No: NCT04930003. Retrieved from: https://\nclinicaltrials.gov/ct2/show/NCT04930003\n175. University Hospital Tuebingen. Safety and immunogenicity trial\nof multi-peptide vaccination to prevent COVID-19 infection in\nadults (pVAC). Identi \ufb01cation No: NCT04546841. Retrieved\nfrom: https://clinicaltrials.gov/ct2/show/NCT04546841\n176. Adimmune Corporation. A study to evaluate the safety and\nimmunogenicity of COVID-19 (AdimrSC-2f) vaccine.\nIdenti\ufb01cation No: NCT04522089. Retrieved from: https://\nclinicaltrials.gov/ct2/show/NCT04522089\n177. Chappell KJ, Mordant FL, Li Z, et al. Safety and immunogenic-\nity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for\nSARS-CoV-2: a randomised, double-blind, placebo-controlled,\nphase 1 trial.Lancet Infect Dis. 2021;21(10):1383\u20131394.\n178. SK Bioscience Co., Ltd. Safety and immunogenicity of a\nSARS-CoV-2 vaccine (NBP2001) in healthy adults\n(COVID-19).", "mimetype": "text/plain", "start_char_idx": 2583, "end_char_idx": 4040, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "46aedb37-db5d-4362-babf-89be3e6f1435": {"__data__": {"id_": "46aedb37-db5d-4362-babf-89be3e6f1435", "embedding": null, "metadata": {"page_label": "34", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "96d19885-c85b-4254-80c4-3c172b24dc5b", "node_type": "4", "metadata": {"page_label": "34", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "d13571f937a3a0bfbb833bd1789aa4d577e6af4bb753aa5079097cc290f8f32a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4d614c56-7196-484d-a8c0-b0ab7f0367b2", "node_type": "1", "metadata": {"page_label": "34", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "0bf206858bfd140dc564ba11bd246323ad31b5ea8ca2ee8fb0c2dfaaee947113", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a8d1690c-0990-43ac-b8fd-514d8dd018fc", "node_type": "1", "metadata": {}, "hash": "e8beab049946e8ceb3ed4c61de79ffd88715df447fc6973dda75881370481efe", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "178. SK Bioscience Co., Ltd. Safety and immunogenicity of a\nSARS-CoV-2 vaccine (NBP2001) in healthy adults\n(COVID-19). Identi\ufb01cation No: NCT04760743. Retrieved\nfrom: https://clinicaltrials.gov/ct2/show/NCT04760743\n179. U.S. Army Medical Research and Development Command.\nSARS-COV-2-Spike-Ferritin-Nanoparticle (SpFN) vaccine\nWith ALFQ adjuvant for prevention of COVID-19 in healthy\nadults. Identi \ufb01cation No: NCT04784767. Retrieved from:\nhttps://clinicaltrials.gov/ct2/show/NCT04784767\n180. Jiangsu Rec-Biotechnology Co., Ltd. Safety, reactogenicity and\nimmunogenicity study of ReCOV. Identi \ufb01cation No:\nNCT04818801. Retrieved from: https://clinicaltrials.gov/ct2/\nshow/NCT04818801\n181. Syneos Health. First-In-Human study Of orally adminis-\ntered CoV2-OGEN1 In healthy subjects. Identi \ufb01cation No:\nNCT04893512. 2021. Retrieved from: https://clinicaltrials.\ngov/ct2/show/NCT04893512\n182. Baiya Phytopharm Co., Ltd. A study to evaluate safety, tolerabil-\nity, and reactogenicity of an RBD-Fc-based vaccine to prevent\nCOVID-19. Identi\ufb01cation No: NCT04953078. 2021. Retrieved\nfrom: https://clinicaltrials.gov/ct2/show/NCT04953078\n183. Ward BJ, Gobeil P, S\u00e9guin A, et al. Phase 1 randomized trial of a\nplant-derived virus-like particle vaccine for COVID-19. Nat\nMed. 2021;27(6):1071\u20131078.\n184. Medicago. Study of a recombinant coronavirus-like particle\nCOVID-19 vaccine in adults.", "mimetype": "text/plain", "start_char_idx": 3922, "end_char_idx": 5298, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "a8d1690c-0990-43ac-b8fd-514d8dd018fc": {"__data__": {"id_": "a8d1690c-0990-43ac-b8fd-514d8dd018fc", "embedding": null, "metadata": {"page_label": "34", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "96d19885-c85b-4254-80c4-3c172b24dc5b", "node_type": "4", "metadata": {"page_label": "34", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "d13571f937a3a0bfbb833bd1789aa4d577e6af4bb753aa5079097cc290f8f32a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "46aedb37-db5d-4362-babf-89be3e6f1435", "node_type": "1", "metadata": {"page_label": "34", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "9dcd7c9d6ae5aa17e5447e8ff43e0aa5b2caf206fee8c47f22caac5e892099cc", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Nat\nMed. 2021;27(6):1071\u20131078.\n184. Medicago. Study of a recombinant coronavirus-like particle\nCOVID-19 vaccine in adults. Identi \ufb01cation No:\nNCT04636697. Retrieved from: https://clinicaltrials.gov/ct2/\nshow/NCT04636697\n185. Serum Institute of India Pvt Ltd. A phase 1/2 randomized,\nplacebo-controlled, multi-centre study to evaluate the safety\nand immunogenicity of COVID-19 vaccine in healthy adults.\nIdenti\ufb01cation No: ACTRN12620000817943. Retrieved from:\nhttps://anzctr.org.au/Trial/Registration/TrialReview.aspx?\nACTRN=12620000817943\n186. VBI Vaccines Inc. Safety, tolerability, and immunogenicity of\nthe COVID-19 vaccine candidate (VBI-2902a). Identi\ufb01cation\nNo: NCT04773665. Retrieved from: https://clinicaltrials.gov/\nct2/show/NCT04773665\n187. The Scienti\ufb01c and Technological Research Council of Turkey.\nStudy of a severe acute respiratory syndrome coronavirus-2\n34 Clinical and Applied Thrombosis/Hemostasis", "mimetype": "text/plain", "start_char_idx": 5176, "end_char_idx": 6090, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "016f89e3-237c-413d-8111-aa0f9a37ecd6": {"__data__": {"id_": "016f89e3-237c-413d-8111-aa0f9a37ecd6", "embedding": null, "metadata": {"page_label": "35", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "1f79b2e0-32a2-45a8-b114-db0d43b38822", "node_type": "4", "metadata": {"page_label": "35", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "118fb2b0a931f922dd85dd19b227151758d1aee9b4be64ba9299eedc40dde1d0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dbae4752-6df0-444c-bf7f-f728a713f3dd", "node_type": "1", "metadata": {}, "hash": "fdb26f91d9bceb6df11c515d2162e24f12750d1abdf2ad0b9082498e9b8f1242", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "(SARS-CoV-2) virus-like particle (VLP) vaccine (COVID-19).\nIdenti\ufb01cation No: NCT04962893. Retrieved from: https://\nclinicaltrials.gov/ct2/show/NCT04962893\n188. Radboud University. Safety and tolerability of COVID-19\nvaccine (ABNCoV2) (COUGH-1). Identi \ufb01cation No:\nNCT04839146. Retrieved from: https://clinicaltrials.gov/ct2/\nshow/NCT04839146\n189. Koyama T, Platt D, Parida L. Variant analysis of SARS-CoV-2\ngenomes. Bull World Health Organ. 2020;98(7):495\u2013504.\n190. Elbe S, Buckland-Merrett G. Data, disease and diplomacy:\nGISAID\u2019s innovative contribution to global health.Glob Chall.\n2017;1(1):33\u201346.\n191. Shu Y, McCauley J. GISAID: global initiative on sharing all\nin\ufb02uenza data \u2014 from vision to reality. Euro Surveill .\n2017;22(13):30494.\n192. Rambaut A, Holmes EC, O\u2019Toole \u00c1, et al. A dynamic nomencla-\nture proposal for SARS-CoV-2 lineages to assist genomic epide-\nmiology.Nat Microbiol. 2020;5(11):1403\u20131407.\n193. Had\ufb01eld J, Megill C, Bell SM, et al. Nextstrain: real-time track-\ning of pathogen evolution.Bioinformatics. 2018;34(23):4121\u2013\n4123.\n194. World Health Organization. Tracking SARS-CoV-2 variants.\nRetrieved from: https://www.who.int/en/activities/tracking-\nSARS-CoV-2-variants/\n195. Centers for Disease Control and Prevention. SARS-CoV-2\nvariant classi\ufb01cations and de\ufb01nitions.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1293, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "dbae4752-6df0-444c-bf7f-f728a713f3dd": {"__data__": {"id_": "dbae4752-6df0-444c-bf7f-f728a713f3dd", "embedding": null, "metadata": {"page_label": "35", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "1f79b2e0-32a2-45a8-b114-db0d43b38822", "node_type": "4", "metadata": {"page_label": "35", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "118fb2b0a931f922dd85dd19b227151758d1aee9b4be64ba9299eedc40dde1d0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "016f89e3-237c-413d-8111-aa0f9a37ecd6", "node_type": "1", "metadata": {"page_label": "35", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "9e5db9d80b710744812ad221102810db7333ae718549c45ab292d81d23403232", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6433faa6-dfdc-4130-ba33-1621c0c900eb", "node_type": "1", "metadata": {}, "hash": "6c7ae467bc29b9fc2c68fedd423ecb95657c81bda25dbcf11e659b7e17027084", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Centers for Disease Control and Prevention. SARS-CoV-2\nvariant classi\ufb01cations and de\ufb01nitions. Retrieved from: https://\nwww.cdc.gov/coronavirus/2019-ncov/variants/variant-info.html\n196. Lauring AS, Hodcroft EB. Genetic variants of SARS-CoV-2-what\nDo they mean?JAMA. 2021;325(6):529\u2013531.\n197. Singh J, Pandit P, McArthur AG, et al. Evolutionary trajectory of\nSARS-CoV-2 and emerging variants.Virol J. 2021;18(1):166.\n198. World Health Organization. Weekly epidemiological update on\nCOVID-19\u20136 July 2021. Edition 47. Retrieved from: https://\nwww.who.int/publications/m/item/weekly-epidemiological-\nupdate-on-covid-19\u2013\u20136-july-2021\n199. Hodgson SH, Mansatta K, Mallett G, et al. What de\ufb01nes an ef\ufb01-\ncacious COVID-19 vaccine? A review of the challenges assess-\ning the clinical ef\ufb01cacy of vaccines against SARS-CoV-2.Lancet\nInfect Dis. 2021;21(2):e26\u2013e35.\n200. Patel MK, Bergeri I, Bresee JS, et al. Evaluation of post-\nintroduction COVID-19 vaccine effectiveness: summary of\ninterim guidance of the world health organization.Vaccine.\n2021;39(30):4013\u20134024.\n201. World Health Organization. Evaluation of COVID-19 vaccine effec-\ntiveness. Retrieved from: https://www.who.int/publications/i/item/\nWHO-2019-nCoV-vaccine_effectiveness-measurement-2021.1\n202. Vojtek I, Dieussaert I, Doherty TM, et al. Maternal immuniza-\ntion: where are we now and how to move forward?Ann Med.\n2018;50(3):193\u2013208.\n203.", "mimetype": "text/plain", "start_char_idx": 1200, "end_char_idx": 2591, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "6433faa6-dfdc-4130-ba33-1621c0c900eb": {"__data__": {"id_": "6433faa6-dfdc-4130-ba33-1621c0c900eb", "embedding": null, "metadata": {"page_label": "35", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "1f79b2e0-32a2-45a8-b114-db0d43b38822", "node_type": "4", "metadata": {"page_label": "35", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "118fb2b0a931f922dd85dd19b227151758d1aee9b4be64ba9299eedc40dde1d0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dbae4752-6df0-444c-bf7f-f728a713f3dd", "node_type": "1", "metadata": {"page_label": "35", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "070e36a507bcf40443263d1cdff8d71339579b415e5900654369681abdd42335", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "67e4179a-c6ea-40a9-a364-5ffd6a5e9993", "node_type": "1", "metadata": {}, "hash": "0232370510718971e80dbc3298c9ddc1929709eb0be73fd1929bd14dee676a47", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Maternal immuniza-\ntion: where are we now and how to move forward?Ann Med.\n2018;50(3):193\u2013208.\n203. Royal College of Obstetricians and Gynaecologists. Coronavirus\n(COVID-19) infection and pregnancy. Retrieved from: https://\nwww.rcog.org.uk/en/guidelines-research-services/guidelines/\ncoronavirus-pregnancy/\n204. Juan J, Gil MM, Rong Z, et al. Effect of coronavirus disease 2019\n(COVID-19) on maternal, perinatal and neonatal outcome: sys-\ntematic review.Ultrasound Obstet Gynecol. 2020;56(1):15\u201327.\n205. Brillo E, Tosto V, Gerli S, et al. COVID-19 vaccination in preg-\nnancy and postpartum.J Matern Fetal Neonatal Med. 2021:1\u2013\n21.\n206. Dashraath P, Wong JLJ, Lim MXK, et al. Coronavirus disease\n2019 (COVID-19) pandemic and pregnancy. Am J Obstet\nGynecol. 2020;222(6):521\u2013531.\n207. Jering KS, Claggett BL, Cunningham JW, et al. Clinical charac-\nteristics and outcomes of hospitalized women giving birth With\nand without COVID-19.JAMA Intern Med. 2021;181(5):714\u2013\n717.\n208. DeBolt CA, Bianco A, Limaye MA, et al. Pregnant women with\nsevere or critical coronavirus disease 2019 have increased com-\nposite morbidity compared with nonpregnant matched controls.\nAm J Obstet Gynecol. 2021;224(5):510.e1\u2013510.e12.\n209. Zambrano LD, Ellington S, Strid P, et al. Update: characteristics\nof symptomatic women of reproductive age with laboratory-\ncon\ufb01rmed SARS-CoV-2 infection by pregnancy Status \u2013\nUnited States, January 22 \u2013October 3, 2020. MMWR Morb\nMortal Wkly Rep.", "mimetype": "text/plain", "start_char_idx": 2492, "end_char_idx": 3949, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "67e4179a-c6ea-40a9-a364-5ffd6a5e9993": {"__data__": {"id_": "67e4179a-c6ea-40a9-a364-5ffd6a5e9993", "embedding": null, "metadata": {"page_label": "35", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "1f79b2e0-32a2-45a8-b114-db0d43b38822", "node_type": "4", "metadata": {"page_label": "35", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "118fb2b0a931f922dd85dd19b227151758d1aee9b4be64ba9299eedc40dde1d0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6433faa6-dfdc-4130-ba33-1621c0c900eb", "node_type": "1", "metadata": {"page_label": "35", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "47f6c220b16769ab14b37d800515effbb37e171ea180919c5897b369ba4346b9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bfb44bbc-7d0e-4ca6-a2db-643981e5d3be", "node_type": "1", "metadata": {}, "hash": "a37f2565ebef289c72a967493763a4b12c665836f26b0aab0e45a9c5cdc7c5ac", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "MMWR Morb\nMortal Wkly Rep. 2020;69(44):1641\u20131647.\n210. Hantoushzadeh S, Shamshirsaz AA, Aleyasin A, et al. Maternal\ndeath due to COVID-19. Am J Obstet Gynecol . 2020;223-\n(1):109.e1\u2013109.e16.\n211. Pierce-Williams RAM, Burd J, Felder L, et al. Clinical course of\nsevere and critical coronavirus disease 2019 in hospitalized preg-\nnancies: a United States cohort study.Am J Obstet Gynecol\nMFM. 2020;2(3):100134.\n212. Knight M, Bunch K, Vousden N, et al. Characteristics and out-\ncomes of pregnant women admitted to hospital with con\ufb01rmed\nSARS-CoV-2 infection in UK: national population based\ncohort study.Br Med J. 2020;369:m2107.\n213. Martinez-Portilla RJ, Sotiriadis A, Chatzakis C, et al. Pregnant\nwomen with SARS-CoV-2 infection are at higher risk of death\nand pneumonia: propensity score matched analysis of a nation-\nwide prospective cohort (COV19Mx).Ultrasound Obstet\nGynecol. 2021;57(2):224\u2013231.\n214. Allotey J, Stallings E, Bonet M, et al. Clinical manifestations,\nrisk factors, and maternal and perinatal outcomes of coronavirus\ndisease 2019 in pregnancy: living systematic review and meta-\nanalysis.Br Med J. 2020;370:m3320.\n215. Adhikari EH, Spong CY. COVID-19 Vaccination in pregnant\nand lactating women.JAMA. 2021;325(11):1039\u20131040.\n216. WAPM (World Association of Perinatal Medicine) Working\nGroup on COVID-19. Maternal and perinatal outcomes of preg-\nnant women with SARS-CoV-2 infection.Ultrasound Obstet\nGynecol.", "mimetype": "text/plain", "start_char_idx": 3923, "end_char_idx": 5350, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "bfb44bbc-7d0e-4ca6-a2db-643981e5d3be": {"__data__": {"id_": "bfb44bbc-7d0e-4ca6-a2db-643981e5d3be", "embedding": null, "metadata": {"page_label": "35", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "1f79b2e0-32a2-45a8-b114-db0d43b38822", "node_type": "4", "metadata": {"page_label": "35", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "118fb2b0a931f922dd85dd19b227151758d1aee9b4be64ba9299eedc40dde1d0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "67e4179a-c6ea-40a9-a364-5ffd6a5e9993", "node_type": "1", "metadata": {"page_label": "35", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "6735900408ee0a21b6d72d095fa996fe00d1214ad67119126227c2ddea809586", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Maternal and perinatal outcomes of preg-\nnant women with SARS-CoV-2 infection.Ultrasound Obstet\nGynecol. 2021;57(2):232\u2013241.\n217. Woodworth KR, Olsen EO, Neelam V, et al. Birth and infant out-\ncomes following laboratory-con\ufb01rmed SARS-CoV-2 infection in\npregnancy \u2013 SET-NET, 16 jurisdictions, march 29\u2013October 14,\n2020. MMWR Morb Mortal Wkly Rep2020;69:1635\u20131640.\n218. Ko JY, DeSisto CL, Simeone RM, et al. Adverse pregnancy out-\ncomes, maternal complications, and severe illness Among US\ndelivery hospitalizations With and without a coronavirus\ndisease 2019 (COVID-19) diagnosis.Clin Infect Dis .\n2021;73(Suppl 1):S24\u2013S31.\n219. Centers for Disease Control and Prevention. Pregnant and\nrecently pregnant people At increased risk for severe illness\nKantarcioglu et al. 35", "mimetype": "text/plain", "start_char_idx": 5246, "end_char_idx": 6015, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "12cf5b7b-a7f0-4a11-8329-a5f3788912b5": {"__data__": {"id_": "12cf5b7b-a7f0-4a11-8329-a5f3788912b5", "embedding": null, "metadata": {"page_label": "36", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "ebe6da7b-2906-41d9-9edd-32ff3638114d", "node_type": "4", "metadata": {"page_label": "36", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "c2ab1426ff8243f3ce70ce115ed992e6b7e49b6599b2e4a193416b0b9eb7a500", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c122fe51-0a27-4b4e-9614-dcafea5fe866", "node_type": "1", "metadata": {}, "hash": "c711e1533deb035b1d6b7e530660f06ec6f004493ab75162c438b32b54c157db", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "from COVID-19. Retrieved from: https://www.cdc.gov/\ncoronavirus/2019-ncov/need-extra-precautions/pregnant-people.\nhtml\n220. Rasmussen SA, Jamieson DJ. Caring for women Who Are plan-\nning a pregnancy, pregnant, or postpartum during the COVID-19\npandemic.JAMA. 2020;324(2):190\u2013191.\n221. Bianchi DW, Kaeser L, Cernich AN. Involving pregnant individ-\nuals in clinical research on COVID-19 vaccines. JAMA.\n2021;325(11):1041\u20131042.\n222. Riley LE, Jamieson DJ. Inclusion of pregnant and lactating\npersons in COVID-19 vaccination efforts. Ann Intern Med.\n2021;174(5):701\u2013702.\n223. Beigi RH, Krubiner C, Jamieson DJ, et al. The need for inclusion\nof pregnant women in COVID-19 vaccine trials. Vaccine.\n2021;39(6):868\u2013870.\n224. Klein SL, Creisher PS, Burd I. COVID-19 vaccine testing in\npregnant females is necessary. J Clin Invest . 2021;131(5):\ne147553.\n225. Spong CY, Bianchi DW. Improving public health requires inclu-\nsion of underrepresented populations in research. JAMA.\n2018;319(4):337\u2013338.\n226. World Health Organization. WHO Recommendation BioNtech\nTozinameran \u2013 COVID-19 mRNA vaccine (nucleoside modi-\n\ufb01ed) \u2013 COMIRNATY\u00ae. Retrieved from: https://extranet.who.\nint/pqweb/vaccines/who-recommendation-covid-19-mrna-\nvaccine-nucleoside-modi\ufb01ed-comirnaty\n227. World Health Organization. WHO Recommendation Moderna\nCOVID-19 mRNA vaccine (nucleoside modi \ufb01ed).", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1353, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "c122fe51-0a27-4b4e-9614-dcafea5fe866": {"__data__": {"id_": "c122fe51-0a27-4b4e-9614-dcafea5fe866", "embedding": null, "metadata": {"page_label": "36", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "ebe6da7b-2906-41d9-9edd-32ff3638114d", "node_type": "4", "metadata": {"page_label": "36", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "c2ab1426ff8243f3ce70ce115ed992e6b7e49b6599b2e4a193416b0b9eb7a500", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "12cf5b7b-a7f0-4a11-8329-a5f3788912b5", "node_type": "1", "metadata": {"page_label": "36", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "da956242805e757b64cb904b7d9f5056b6d069c48e538b0d99b7ae4986097afa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0fc0d930-c092-440e-acd2-2e251160b7b7", "node_type": "1", "metadata": {}, "hash": "c85cf8008344de29a4e034144139d0884de4d6fe70102e0eaac38debcb06f2a0", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "World Health Organization. WHO Recommendation Moderna\nCOVID-19 mRNA vaccine (nucleoside modi \ufb01ed). Retrieved\nfrom: https://extranet.who.int/pqweb/vaccines/covid-19-mrna-\nvaccine-nucleoside-modi\ufb01ed\n228. World Health Organization. WHO Recommendation Janssen\u2013\nCilag international NV (Belgium) COVID-19 vaccine\n(Ad26.COV2-S [recombinant]). Retrieved from: https://\nextranet.who.int/pqweb/vaccines/who-recommendation-janssen-\ncilag-international-nv-belgium-covid-19-vaccine-ad26cov2-s\n229. World Health Organization (WHO). Interim recommendations for\nuse of the AZD1222 (ChAdOx1-S [recombinant]) vaccine against\nCOVID19 developed by Oxford University and AstraZeneca, 10\nFebruary 2021 [internet]. 2021 Feb 10 [cited Mar 28 2021].\nRetrieved from: https://apps.who.int/iris/handle/10665/339477\n230. World Health Organization. WHO Recommendation of Sinovac\nCOVID-19 vaccine (vero cell [inactivated]) \u2013 CoronaVac.\nRetrieved from: https://extranet.who.int/pqweb/vaccines/who-\nrecommendation-sinovac-covid-19-vaccine-vero-cell-\ninactivated-coronavac\n231. World Health Organization. WHO Recommendation COVID-19\nvaccine BIBP/sinopharm. Retrieved from: https://extranet.who.\nint/pqweb/vaccines/who-recommendation-covid-19-vaccine-bibp\n232. Garg I, Shekhar R, Sheikh AB, et al. COVID-19 Vaccine in preg-\nnant and lactating women: a review of existing evidence and\npractice guidelines.Infect Dis Rep. 2021;13(3):685\u2013699.\n233. Stafford IA, Parchem JG, Sibai BM.", "mimetype": "text/plain", "start_char_idx": 1255, "end_char_idx": 2699, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "0fc0d930-c092-440e-acd2-2e251160b7b7": {"__data__": {"id_": "0fc0d930-c092-440e-acd2-2e251160b7b7", "embedding": null, "metadata": {"page_label": "36", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "ebe6da7b-2906-41d9-9edd-32ff3638114d", "node_type": "4", "metadata": {"page_label": "36", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "c2ab1426ff8243f3ce70ce115ed992e6b7e49b6599b2e4a193416b0b9eb7a500", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c122fe51-0a27-4b4e-9614-dcafea5fe866", "node_type": "1", "metadata": {"page_label": "36", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "d3960e711104402e03dfd6563797274a729f8f3080269094ef930726a4713de0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e5ad5ebf-9544-44ed-922e-2be7cfd98801", "node_type": "1", "metadata": {}, "hash": "ed8dafdbfa4aada9de3d565b77dbd4c8187ececa8fe690f67f10981d22a4bf0a", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "2021;13(3):685\u2013699.\n233. Stafford IA, Parchem JG, Sibai BM. The coronavirus disease\n2019 vaccine in pregnancy: risks, bene\ufb01ts, and recommenda-\ntions. Am J Obstet Gynecol. 2021;224(5):484\u2013495.\n234. Cottin J, Benevent J, Khettar S, et al. COVID-19 vaccines and\npregnancy: what do we know?Therapie. 2021;76(4):373\u2013374.\n235. Wang EW, Parchem JG, Atmar RL, et al. SARS-CoV-2 vaccina-\ntion during pregnancy: a Complex decision.Open Forum Infect\nDis. 2021;8(5):ofab180.\n236. Collier AY, McMahan K, Yu J, et al. Immunogenicity of\nCOVID-19 mRNA vaccines in pregnant and lactating women.\nJAMA. 2021;325(23):2370\u20132380.\n237. Gray KJ, Bordt EA, Atyeo C, et al. Coronavirus disease 2019\nvaccine response in pregnant and lactating women: a cohort\nstudy.Am J Obstet Gynecol. 2021;225(3):303.e1\u2013303.e17.\n238. Perl SH, Uzan-Yulzari A, Klainer H, et al.\nSARS-CoV-2-Speci\ufb01c antibodies in breast milk after\nCOVID-19 vaccination of breastfeeding women. JAMA.\n2021;325(19):2013\u20132014.\n239. Blakeway H, Prasad S, Kalafat E, et al. COVID-19 vaccination\nduring pregnancy: coverage and safety.Am J Obstet Gynecol.\n2021:S0002-9378(21)00873-5.\n240. Chavan M, Qureshi H, Karnati S, et al. COVID-19 Vaccination\nin pregnancy: the bene\ufb01ts outweigh the risks.J Obstet Gynaecol\nCan.", "mimetype": "text/plain", "start_char_idx": 2640, "end_char_idx": 3886, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "e5ad5ebf-9544-44ed-922e-2be7cfd98801": {"__data__": {"id_": "e5ad5ebf-9544-44ed-922e-2be7cfd98801", "embedding": null, "metadata": {"page_label": "36", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "ebe6da7b-2906-41d9-9edd-32ff3638114d", "node_type": "4", "metadata": {"page_label": "36", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "c2ab1426ff8243f3ce70ce115ed992e6b7e49b6599b2e4a193416b0b9eb7a500", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0fc0d930-c092-440e-acd2-2e251160b7b7", "node_type": "1", "metadata": {"page_label": "36", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "bfe225844003ce57a549336c28abb8bdc1375971f976d5dc9fe7cd2d553a8fa2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5e4e087e-6fa0-4818-b58d-115409f2e83c", "node_type": "1", "metadata": {}, "hash": "2af27b59de4785887cf69388c7451c7e4954360f0c1382e843302b4256436397", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "240. Chavan M, Qureshi H, Karnati S, et al. COVID-19 Vaccination\nin pregnancy: the bene\ufb01ts outweigh the risks.J Obstet Gynaecol\nCan. 2021;43(7):814\u2013816.\n241. Principi N, Esposito S. Is the immunization of pregnant women\nagainst COVID-19 justi\ufb01ed? Vaccines (Basel). 2021;9(9):970.\n242. Shimabukuro TT, Kim SY, Myers TR, et al. Preliminary\ufb01ndings\nof mRNA COVID-19 vaccine safety in pregnant persons.N Engl\nJ Med. 2021;384(24):2273\u20132282.\n243. Kantarcioglu B, Iqbal O, Walenga JM, et al. An update on the\npathogenesis of COVID-19 and the reportedly rare thrombotic\nevents following vaccination.Clin Appl Thromb Hemost .\n2021;27:10760296211021498.\n244. Haddad LB, Jamieson DJ, Rasmussen SA. Pregnant women and\nthe ebola crisis.N Engl J Med. 2018;379(26):2492\u20132493.\n245. Legardy-Williams JK, Carter RJ, Goldstein ST, et al. Pregnancy\noutcomes among women receiving rVSV\u0394-ZEBOV-GP ebola\nvaccine during the Sierra Leone trial to introduce a vaccine\nagainst ebola.Emerg Infect Dis. 2020;26(3):541\u2013548.\n246. Schwartz DA. Clinical trials and administration of Zika\nvirus vaccine in pregnant women: lessons (that should\nhave been) learned from excluding immunization with the\nebola vaccine during pregnancy and lactation.Vaccines\n(Basel) . 2018;6(4):81.\n247. World Health Organization. Coronavirus disease (COVID-19):\npregnancy and childbirth. Retrieved from: https://www.who.int/\nnews-room/q-a-detail/coronavirus-disease-covid-19-pregnancy-\nand-childbirth\n248.", "mimetype": "text/plain", "start_char_idx": 3754, "end_char_idx": 5203, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "5e4e087e-6fa0-4818-b58d-115409f2e83c": {"__data__": {"id_": "5e4e087e-6fa0-4818-b58d-115409f2e83c", "embedding": null, "metadata": {"page_label": "36", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "ebe6da7b-2906-41d9-9edd-32ff3638114d", "node_type": "4", "metadata": {"page_label": "36", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "c2ab1426ff8243f3ce70ce115ed992e6b7e49b6599b2e4a193416b0b9eb7a500", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e5ad5ebf-9544-44ed-922e-2be7cfd98801", "node_type": "1", "metadata": {"page_label": "36", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "e3b55264305b777b9b6729b5103cbc2699e6e3adbbc5329413473a946fecc89a", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Retrieved from: https://www.who.int/\nnews-room/q-a-detail/coronavirus-disease-covid-19-pregnancy-\nand-childbirth\n248. Centers for Disease Control and Prevention. COVID-19\nVaccines while pregnant or breastfeeding. Retrieved from:\nhttps://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/\npregnancy.html\n249. The American College of Obstetricians and Gynecologists.\nVaccinating pregnant and lactating patients against COVID-19.\n2020. Retrieved from: https://www.acog.org/clinical/clinical-\nguidance/practice-advisory/articles/2020/12/covid-19-vaccination-\nconsiderations-for-obstetric-gynecolog ic-care?utm_source =\nredirect&utm_medium =web&utm_campaign =int\n250. Society for Maternal-Fetal Medicine (SMFM) Statement:\nSARS-Co-V-2 Vaccination in pregnancy. Retrieved from:\nhttps://www.smfm.org/publications/339-society-for-maternal-\n36 Clinical and Applied Thrombosis/Hemostasis", "mimetype": "text/plain", "start_char_idx": 5086, "end_char_idx": 5971, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "23699c03-7a89-419d-af4d-9010634a5051": {"__data__": {"id_": "23699c03-7a89-419d-af4d-9010634a5051", "embedding": null, "metadata": {"page_label": "37", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "5bab9eb1-2820-4291-945b-30ae3ce9e833", "node_type": "4", "metadata": {"page_label": "37", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "66f5b69e4d117e786e597ec474c5a80278700a743569f0e203adb6b14da68056", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a612f6e9-e19f-49ee-b14b-b35a8582366e", "node_type": "1", "metadata": {}, "hash": "f8cbfe2bdea0d586d81f317d64db4d9d1c2c07891669a5142ce7ebbbff068c1f", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "fetal-medicine-smfm-statement-sars-cov-2-vaccination-in-\npregnancy\n251. Academy of Breastfeeding Medicine. Considerations for\nCOVID-19 vaccination in lactation. ABM Statement. Retrieved\nfrom: https://abm.memberclicks.net/abm-statement-considerations-for-\ncovid-19-vaccination-in-lactation\n252. Royal College of Obstetricians and Gynaecologists. Updated\nadvice on COVID-19 vaccination in pregnancy and women\nwho are breastfeeding. Retrieved from: https://www.rcog.org.\nuk/en/news/updated-advice-on-covid-19-vaccination-in-pregnancy-\nand-women-who-are-breastfeeding/\n253. Public Health England. Guidance: COVID-19 vaccination: a\nguide for all women of childbearing age, pregnant or breastfeed-\ning. Retrieved from: https://www.gov.uk/government/\npublications/covid-19-vaccination-women-of-childbearing-age-\ncurrently-pregnant-planning-a-pregnancy-or-breastfeeding/\ncovid-19-vaccination-a-guide-for-women-of-childbearing-age-\npregnant-planning-a-pregnancy-or-breastfeeding\n254. Williamson EJ, Walker AJ, Bhaskaran K, et al. Factors associ-\nated with COVID-19-related death using OpenSAFELY.\nNature. 2020;584(7821):430\u2013436.\n255. Wang Q, Berger NA, Xu R. Analyses of risk, racial disparity, and\noutcomes Among US patients With cancer and COVID-19 infec-\ntion. JAMA Oncol. 2021;7(2):220\u2013227.\n256. Kuderer NM, Choueiri TK, Shah DP, et al. Clinical impact of\nCOVID-19 on patients with cancer (CCC19): a cohort study.\nLancet. 2020;395(10241):1907\u20131918.\n257. Rivera DR, Peters S, Panagiotou OA, et al.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1491, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "a612f6e9-e19f-49ee-b14b-b35a8582366e": {"__data__": {"id_": "a612f6e9-e19f-49ee-b14b-b35a8582366e", "embedding": null, "metadata": {"page_label": "37", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "5bab9eb1-2820-4291-945b-30ae3ce9e833", "node_type": "4", "metadata": {"page_label": "37", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "66f5b69e4d117e786e597ec474c5a80278700a743569f0e203adb6b14da68056", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "23699c03-7a89-419d-af4d-9010634a5051", "node_type": "1", "metadata": {"page_label": "37", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "89ee4e42be6cff4ec97034caac5896380d864810c8dab5d44daf58cafb2e4cc6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "69ba9788-6c92-4601-b1ae-59266085788d", "node_type": "1", "metadata": {}, "hash": "d13135a8892ca24196fae7825b27453b4bd07cf8961324d581d155f0f6de15f3", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Lancet. 2020;395(10241):1907\u20131918.\n257. Rivera DR, Peters S, Panagiotou OA, et al. Utilization of\nCOVID-19 treatments and clinical outcomes among patients\nwith cancer: a COVID-19 and cancer consortium (CCC19)\ncohort study.Cancer Discov. 2020;10(10):1514\u20131527.\n258. Garc\u00eda-Su\u00e1rez J, de la Cruz J, Cedillo \u00c1, et al. Impact of\nhematologic malignancy and type of cancer therapy on\nCOVID-19 severity and mortality: lessons from a large\npopulation-based registry study. J Hematol Oncol .\n2020;13(1):133.\n259. Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA Clinical\npractice guideline for vaccination of the immunocompromised\nhost.Clin Infect Dis. 2014;58(3):309\u2013318.\n260. Mikulska M, Cesaro S, de Lavallade H, et al. Vaccination of\npatients with haematological malignancies who did not have\ntransplantations: guidelines from the 2017 European conference\non infections in leukaemia (ECIL 7).Lancet Infect Dis .\n2019;19(6):e188\u2013e199.\n261. Cordonnier C, Einarsdottir S, Cesaro S, et al. Vaccination of hae-\nmopoietic stem cell transplant recipients: guidelines of the 2017\nEuropean conference on infections in leukaemia (ECIL 7).\nLancet Infect Dis. 2019;19(6):e200\u2013e212.\n262. M\u00e9n\u00e9trier-Caux C, Ray-Coquard I, Blay JY, et al. Lymphopenia\nin cancer patients and its effects on response to immunotherapy:\nan opportunity for combination with cytokines?J Immunother\nCancer. 2019;7(1):85.\n263. Goyal S, Pai SK, Kelkar R, et al.", "mimetype": "text/plain", "start_char_idx": 1409, "end_char_idx": 2823, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "69ba9788-6c92-4601-b1ae-59266085788d": {"__data__": {"id_": "69ba9788-6c92-4601-b1ae-59266085788d", "embedding": null, "metadata": {"page_label": "37", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "5bab9eb1-2820-4291-945b-30ae3ce9e833", "node_type": "4", "metadata": {"page_label": "37", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "66f5b69e4d117e786e597ec474c5a80278700a743569f0e203adb6b14da68056", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a612f6e9-e19f-49ee-b14b-b35a8582366e", "node_type": "1", "metadata": {"page_label": "37", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "7cf941ab8f1a6147fa054aed7e201819fa447a9881123f43a81a5f4abac52a53", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9d87171e-e6cb-48ad-807b-d91c54c3f3cf", "node_type": "1", "metadata": {}, "hash": "b6ef25e11a367785f2bb8c20c9e91e53b0193cdad86e00a09d6ffad5da17d475", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "2019;7(1):85.\n263. Goyal S, Pai SK, Kelkar R, et al. Hepatitis B vaccination in acute\nlymphoblastic leukemia.Leuk Res. 1998;22(2):193\u2013195.\n264. Ercan TE, Soycan LY, Apak H, et al. Antibody titers and immune\nresponse to diphtheria-tetanus-pertussis and measles-mumps-rubella\nvaccination in children treated for acute lymphoblastic leukemia.J\nPediatr Hematol Oncol. 2005;27(5):273\u2013277.\n265. Lo W, Whimbey E, Elting L, et al. Antibody response to a\ntwo-dose in\ufb02uenza vaccine regimen in adult lymphoma patients\non chemotherapy. Eur J Clin Microbiol Infect Dis. 1993;12-\n(10):778\u2013782.\n266. Mazza JJ, Yale SH, Arrowood JR, et al. Ef\ufb01cacy of the in\ufb02uenza\nvaccine in patients with malignant lymphoma.Clin Med Res.\n2005;3(4):214\u2013220.\n267. Nord\u00f8y T, Aaberge IS, Husebekk A, et al. Cancer patients under-\ngoing chemotherapy show adequate serological response to vac-\ncinations against in\ufb02uenza virus and Streptococcus pneumoniae.\nMed Oncol. 2002;19(2):71\u201378.\n268. Wumkes ML, van der Velden AM, Los M, et al. Serum antibody\nresponse to in\ufb02uenza virus vaccination during chemotherapy\ntreatment in adult patients with solid tumours.Vaccine. 2013;31-\n(52):6177\u20136184.\n269. Kersh AE, Ng S, Chang YM, et al. Targeted therapies: immuno-\nlogic effects and potential applications outside of cancer.J Clin\nPharmacol. 2018;58(1):7\u201324.\n270. de Lavallade H, Khoder A, Hart M, et al.", "mimetype": "text/plain", "start_char_idx": 2771, "end_char_idx": 4128, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "9d87171e-e6cb-48ad-807b-d91c54c3f3cf": {"__data__": {"id_": "9d87171e-e6cb-48ad-807b-d91c54c3f3cf", "embedding": null, "metadata": {"page_label": "37", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "5bab9eb1-2820-4291-945b-30ae3ce9e833", "node_type": "4", "metadata": {"page_label": "37", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "66f5b69e4d117e786e597ec474c5a80278700a743569f0e203adb6b14da68056", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "69ba9788-6c92-4601-b1ae-59266085788d", "node_type": "1", "metadata": {"page_label": "37", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "ab5641e12d02bc277dbd74b5f28e4cd3ad911ea2edcc0323f68e08aa41bd13b0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a60ce069-2d6d-4c1e-8ea7-6f600b86c23a", "node_type": "1", "metadata": {}, "hash": "67b79d4652f36c3738736a952e4913190551578eac06f3dcec7cde8a27a5202e", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "2018;58(1):7\u201324.\n270. de Lavallade H, Khoder A, Hart M, et al. Tyrosine kinase inhib-\nitors impair B-cell immune responses in CML through off-target\ninhibition of kinases important for cell signaling. Blood.\n2013;122(2):227\u2013238.\n271. Mulder SF, Jacobs JF, Olde Nordkamp MA, et al. Cancer\npatients treated with sunitinib or sorafenib have suf\ufb01cient anti-\nbody and cellular immune responses to warrant in\ufb02uenza vacci-\nnation. Clin Cancer Res. 2011;17(13):4541\u20134549.\n272. Joona TB, Digkas E, Wennstig AK, et al. In\ufb02uenza vaccination\nin breast cancer patients during subcutaneous trastuzumab in\nadjuvant setting.Breast Cancer Res Treat. 2020;184(1):45\u201352.\n273. Sun C, Gao J, Couzens L, et al. Seasonal in\ufb02uenza vaccination in\npatients With chronic lymphocytic leukemia treated With ibruti-\nnib.JAMA Oncol. 2016;2(12):1656\u20131657.\n274. Douglas AP, Trubiano JA, Barr I, et al. Ibrutinib may impair\nserological responses to in\ufb02uenza vaccination. Haematologica.\n2017;102(10):e397\u2013e399.\n275. Wang PF, Chen Y, Song SY, et al. Immune-Related adverse\nevents associated with anti-PD-1/PD-L1 treatment for malignan-\ncies: a meta-analysis.Front Pharmacol. 2017;8:730.\n276. L\u00e4ubli H, Balmelli C, Kaufmann L, et al. In\ufb02uenza vaccination\nof cancer patients during PD-1 blockade induces serological pro-\ntection but may raise the risk for immune-related adverse events.\nJ Immunother Cancer. 2018;6(1):40.\n277.", "mimetype": "text/plain", "start_char_idx": 4066, "end_char_idx": 5454, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "a60ce069-2d6d-4c1e-8ea7-6f600b86c23a": {"__data__": {"id_": "a60ce069-2d6d-4c1e-8ea7-6f600b86c23a", "embedding": null, "metadata": {"page_label": "37", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "5bab9eb1-2820-4291-945b-30ae3ce9e833", "node_type": "4", "metadata": {"page_label": "37", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "66f5b69e4d117e786e597ec474c5a80278700a743569f0e203adb6b14da68056", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9d87171e-e6cb-48ad-807b-d91c54c3f3cf", "node_type": "1", "metadata": {"page_label": "37", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "46db26d7803dd964559e7aa0d0f49714015ff39bc198f7e30f958c8cbb819da6", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "J Immunother Cancer. 2018;6(1):40.\n277. Gambichler T, Reuther J, Scheel CH, et al. On the use of immune\ncheckpoint inhibitors in patients with viral infections including\nCOVID-19.J Immunother Cancer. 2020;8(2):e001145.\n278. Keam B, Kang CK, Jun KI, et al. Immunogenicity of in\ufb02uenza\nvaccination in patients with cancer receiving immune checkpoint\ninhibitors.Clin Infect Dis. 2020;71(2):422\u2013425.\n279. Nazi I, Kelton JG, Larch\u00e9 M, et al. The effect of rituximab on\nvaccine responses in patients with immune thrombocytopenia.\nBlood. 2013;122(11):1946\u20131953. Epub 2013 Jul 12.\n280. Berglund A, Will\u00e9n L, Gr\u00f6deberg L, et al. The response to vac-\ncination against in\ufb02uenza A(H1N1) 2009, seasonal in\ufb02uenza and\nStreptococcus pneumoniae in adult outpatients with ongoing\nKantarcioglu et al. 37", "mimetype": "text/plain", "start_char_idx": 5415, "end_char_idx": 6198, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "586a93da-6cc5-467b-ab20-9bf860fd26c3": {"__data__": {"id_": "586a93da-6cc5-467b-ab20-9bf860fd26c3", "embedding": null, "metadata": {"page_label": "38", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "080f72b3-c692-44bf-8b6b-e35c0a8e24ff", "node_type": "4", "metadata": {"page_label": "38", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "9129f40347fb39dc4cc87aeaac8e2cc0f609adbc11e506d91506161dbfca0ef5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b9fd9aab-7702-4258-a5ed-d2082b8d6964", "node_type": "1", "metadata": {}, "hash": "e59776515bb050cd6038d4b90c8d34e179626a322243800ff31d2748b16a04a5", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "treatment for cancer with and without rituximab.Acta Oncol.\n2014;53(9):1212\u20131220.\n281. Bouaziz JD, Yanaba K, Venturi GM, et al. Therapeutic B cell\ndepletion impairs adaptive and autoreactive CD4+T cell activa-\ntion in mice.Proc Natl Acad Sci U S A. 2007;104(52):20878\u2013\n20883.\n282. Bhoj VG, Arhontoulis D, Wertheim G, et al. Persistence of long-\nlived plasma cells and humoral immunity in individuals respond-\ning to CD19-directed CAR T-cell therapy.Blood. 2016;128-\n(3):360\u2013370.\n283. Hill JA, Seo SK. How I prevent infections in patients receiving\nCD19-targeted chimeric antigen receptor T cells for B-cell malig-\nnancies.Blood. 2020;136(8):925\u2013935.\n284. Krejcik J, Casneuf T, Nijhof IS, et al. Daratumumab depletes\nCD38 +immune regulatory cells, promotes T-cell expansion,\nand skews T-cell repertoire in multiple myeloma. Blood.\n2016;128(3):384\u2013394.\n285. Frerichs KA, Bosman PWC, van Velzen JF, et al. Effect of dar-\natumumab on normal plasma cells, polyclonal immunoglobulin\nlevels, and vaccination responses in extensively pre-treated multiple\nmyeloma patients.Haematologica. 2020;105(6):e302\u2013e306.\n286. National Comprehensive Cancer Network (NCCN). COVID-19\nVaccination and cancer patients. Retrieved from: https://www.\nnccn.org/covid-19\n287. Hwang JK, Zhang T, Wang AZ, et al. COVID-19 vaccines for\npatients with cancer: bene\ufb01ts likely outweigh risks.J Hematol\nOncol. 2021;14(1):38.\n288.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1392, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "b9fd9aab-7702-4258-a5ed-d2082b8d6964": {"__data__": {"id_": "b9fd9aab-7702-4258-a5ed-d2082b8d6964", "embedding": null, "metadata": {"page_label": "38", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "080f72b3-c692-44bf-8b6b-e35c0a8e24ff", "node_type": "4", "metadata": {"page_label": "38", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "9129f40347fb39dc4cc87aeaac8e2cc0f609adbc11e506d91506161dbfca0ef5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "586a93da-6cc5-467b-ab20-9bf860fd26c3", "node_type": "1", "metadata": {"page_label": "38", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "a455d26c0899f0d957ad5c5d440414b1d5c873481cdf65aac8e77a81e4d13035", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f0dd57d1-1291-4488-bce6-38a30f81b82b", "node_type": "1", "metadata": {}, "hash": "e36c52fa540255ecdaee33bbb1e4f0b399388fa2fedd1a38d88f1c56d03d7e3a", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "COVID-19 vaccines for\npatients with cancer: bene\ufb01ts likely outweigh risks.J Hematol\nOncol. 2021;14(1):38.\n288. Scoccianti S, Delli Paoli C, Grilli Leonulli B, et al. Acute toler-\nance of Moderna mRNA-1273 vaccine against COVID-19 in\npatients with cancer treated with radiotherapy.Lancet Oncol.\n2021:S1470-2045(21)00427-7.\n289. Sharma A, Bhatt NS, St Martin A, et al. Clinical characteristics\nand outcomes of COVID-19 in haematopoietic stem-cell trans-\nplantation recipients: an observational cohort study.Lancet\nHaematol. 2021;8(3):e185\u2013e193.\n290. Ljungman P, Cordonnier C, Einsele H, et al. Vaccination of\nhematopoietic cell transplant recipients. Bone Marrow\nTransplant. 2009;44(8):521\u2013526.\n291. American Society of Clinical Oncology (ASCO). COVID-19\nVaccines & patients with cancer. Retrieved from: https://www.\nasco.org/asco-coronavirus-i nformation/covid-19-vaccines-\npatients-cancer\n292. European Society for Medical Oncology (ESMO). COVID-19 vac-\ncination in cancer patients: ESMO statements. Retrieved from:\nhttps://www.esmo.org/covid-19-and-cancer/covid-19-vaccination\n293. Society for Immunotherapy of Cancer (SITC). SITC Statement\non SARS-CoV-2 vaccination and cancer immunotherapy. Retrieved\nfrom: https://www.sitcancer.org/aboutsitc/press-releases/2020/\nsitc-statement-sars-cov-2-vaccination-cancer-immunotherapy\n294. American Association for Cancer Research (AACR). Letter to\npresident biden and leaders of state public health departments:\nprioritizing COVID-19 vaccinesfor patients with cancer and\nsurvivors of cancer.", "mimetype": "text/plain", "start_char_idx": 1282, "end_char_idx": 2815, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "f0dd57d1-1291-4488-bce6-38a30f81b82b": {"__data__": {"id_": "f0dd57d1-1291-4488-bce6-38a30f81b82b", "embedding": null, "metadata": {"page_label": "38", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "080f72b3-c692-44bf-8b6b-e35c0a8e24ff", "node_type": "4", "metadata": {"page_label": "38", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "9129f40347fb39dc4cc87aeaac8e2cc0f609adbc11e506d91506161dbfca0ef5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b9fd9aab-7702-4258-a5ed-d2082b8d6964", "node_type": "1", "metadata": {"page_label": "38", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "727bd1eb8e358d74f59b06adad703692caa647dc12c71dd6466380cc6c76aeac", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d1dd3c31-d761-4446-9874-c09a4a6180a9", "node_type": "1", "metadata": {}, "hash": "4ed6fdef7f8984baa0c21d2e3e82787032455c510f0c08178d084f618970a45e", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "American Association for Cancer Research (AACR). Letter to\npresident biden and leaders of state public health departments:\nprioritizing COVID-19 vaccinesfor patients with cancer and\nsurvivors of cancer. Retrieved from: https://www.aacr.org/\nprofessionals/policy-and-advocacy/aacr-and-the-biden-\nadministration/prioritizing-covid19-vaccines-for-cancer-\npatients/\n295. Fishman JA. Infection in solid-organ transplant recipients.\nN Engl J Med. 2007;357(25):2601\u20132614.\n296. Danziger-Isakov L, Blumberg EA, Manuel O, et al. Impact of\nCOVID-19 in solid organ transplant recipients. Am J\nTransplant. 2021;21(3):925\u2013937.\n297. Becchetti C, Zambelli MF, Pasulo L, et al. COVID-19 in an inter-\nnational European liver transplant recipient cohort. Gut.\n2020;69(10):1832\u20131840.\n298. Felldin M, S\u00f8fteland JM, Magnusson J, et al. Initial report From\na Swedish high-volume transplant center after the\ufb01rst wave of\nthe COVID-19 pandemic. Transplantation. 2021;105(1):108\u2013\n114.\n299. Husain SA, Dube G, Morris H, et al. Early outcomes of outpatient\nmanagement of kidney transplant recipients with coronavirus disease\n2019. Clin J Am Soc Nephrol. 2020;15(8):1174\u20131178.\n300. Kates OS, Haydel BM, Florman SS, et al. COVID-19 in solid\norgan transplant: a multi-center cohort study.Clin Infect Dis.\n2020:ciaa1097.\n301. Man Z, Jing Z, Huibo S, et al. Viral shedding prolongation in a\nkidney transplant patient with COVID-19 pneumonia. Am J\nTransplant. 2020;20(9):2626\u20132627.\n302. Decker A, Welzel M, Laubner K, et al.", "mimetype": "text/plain", "start_char_idx": 2613, "end_char_idx": 4102, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "d1dd3c31-d761-4446-9874-c09a4a6180a9": {"__data__": {"id_": "d1dd3c31-d761-4446-9874-c09a4a6180a9", "embedding": null, "metadata": {"page_label": "38", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "080f72b3-c692-44bf-8b6b-e35c0a8e24ff", "node_type": "4", "metadata": {"page_label": "38", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "9129f40347fb39dc4cc87aeaac8e2cc0f609adbc11e506d91506161dbfca0ef5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f0dd57d1-1291-4488-bce6-38a30f81b82b", "node_type": "1", "metadata": {"page_label": "38", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "15a6225041bcd9f46e5ce956b878775e5082e1b13b2f2f795de62bce83fa0bad", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "70e143c6-8c14-4800-9b1e-7b31067054df", "node_type": "1", "metadata": {}, "hash": "687a792f44b4f9b6e3ba84e62942c455c985a6505b1e11bb4650ede144499519", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Am J\nTransplant. 2020;20(9):2626\u20132627.\n302. Decker A, Welzel M, Laubner K, et al. Prolonged SARS-CoV-2\nshedding and mild course of COVID-19 in a patient after recent\nheart transplantation.Am J Transplant. 2020;20(11):3239\u20133245.\n303. Benotmane I, Gautier-Vargas G, Wendling MJ, et al. In-depth\nvirological assessment of kidney transplant recipients with\nCOVID-19.Am J Transplant. 2020;20(11):3162\u20133172.\n304. Johnson KM, Belfer JJ, Peterson GR, et al. Managing COVID-19\nin renal transplant recipients: a review of recent literature and\ncase supporting corticosteroid-sparing immunosuppression.\nPharmacotherapy. 2020;40(6):517\u2013524.\n305. Leung DH, Ton-That M, Economides JM, et al. High prevalence\nof hepatitis B nonimmunity in vaccinated pediatric liver trans-\nplant recipients.Am J Transplant. 2015;15(2):535\u2013540.\n306. Moal V, Motte A, Vacher-Coponat H, et al. Considerable\ndecrease in antibodies against hepatitis B surface antigen follow-\ning kidney transplantation.J Clin Virol. 2015;68:32\u201336.\n307. Miller-Handley H, Paulsen G, Hooper DK, et al. Durability of the\nhepatitis B vaccination in pediatric renal transplant recipients.\nClin Transplant. 2018;32(5):e13247.\n308. Mulley WR, Dendle C, Ling JEH, et al. Does vaccination in\nsolid-organ transplant recipients result in adverse immunologic\nsequelae? A systematic review and meta-analysis.J Heart\nLung Transplant. 2018;37(7):844\u2013852.\n309. Danziger-Isakov L, Kumar D; AST ID community of practice.", "mimetype": "text/plain", "start_char_idx": 4021, "end_char_idx": 5470, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "70e143c6-8c14-4800-9b1e-7b31067054df": {"__data__": {"id_": "70e143c6-8c14-4800-9b1e-7b31067054df", "embedding": null, "metadata": {"page_label": "38", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "080f72b3-c692-44bf-8b6b-e35c0a8e24ff", "node_type": "4", "metadata": {"page_label": "38", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "9129f40347fb39dc4cc87aeaac8e2cc0f609adbc11e506d91506161dbfca0ef5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d1dd3c31-d761-4446-9874-c09a4a6180a9", "node_type": "1", "metadata": {"page_label": "38", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "f1eb0e961e9d1f12f116d899c4a0d66995df50222ad7923fe4dfd87e812b85e7", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "A systematic review and meta-analysis.J Heart\nLung Transplant. 2018;37(7):844\u2013852.\n309. Danziger-Isakov L, Kumar D; AST ID community of practice.\nVaccination of solid organ transplant candidates and recipients:\nguidelines from the American society of transplantation infectious\ndiseases community of practice. Clin Transplant. 2019;33(9):\ne13563.\n310. The American Society of Transplantation. Joint statement on\nCOVID-19 vaccine. Retrieved from: https://www.myast.org/\naugust-statement-covid-19-vaccine\n311. The International Society for Heart and Lung Transplantation\n(ISHLT). Joint statement on COVID-19 vaccine. Retrieved\nfrom: https://ishlt.org/ishlt/media/documents/ISHLT-AST_SARS-\nCoV-2-Vaccination_8-13-21.pdf\n38 Clinical and Applied Thrombosis/Hemostasis", "mimetype": "text/plain", "start_char_idx": 5325, "end_char_idx": 6087, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "c24ed535-7f95-4b1b-8f59-cbee02fe50fd": {"__data__": {"id_": "c24ed535-7f95-4b1b-8f59-cbee02fe50fd", "embedding": null, "metadata": {"page_label": "39", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "75455cda-720f-4281-ad8d-c459a128196e", "node_type": "4", "metadata": {"page_label": "39", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "e15a74ddecd808fb0fb4c822003fe6631213d294d443a080b076ef7503e4d53e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "32741c93-6b65-4ea4-a5bf-c7187f27ff03", "node_type": "1", "metadata": {}, "hash": "e1c7bae62109146cb84a35d3e3242021c8494e5e55b119d2d97d762339d266a0", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "312. The European Society for Organ Transplantation. Joint statement\nabout vaccine ef\ufb01cacy in organ transplant recipients. Retrieved\nfrom: https://esot.org/joint-statement-about-vaccine-ef\ufb01cacy-in-\norgan-transplant-recipients-13-august-2021/\n313. McGinley MP, Goldschmidt CH, Rae-Grant AD. Diagnosis and\ntreatment of multiple sclerosis: a review.Jama. 2021;325:765\u2013779.\n314. Castelo-Branco A, Chiesa F, Conte S, et al. Infections in patients\nwith multiple sclerosis: a national cohort study in Sweden.Mult\nScler Relat Disord. 2020;45:102420.\n315. Persson R, Lee S, Ulcickas Yood M, et al. Infections in patients\ndiagnosed with multiple sclerosis: a multi-database study.Mult\nScler Relat Disord. 2020;41:101982.\n316. Nelson RE, Xie Y, DuVall SL, et al. Multiple sclerosis and risk\nof infection-related hospitalization and death in US veterans.Int\nJ MS Care. 2015;17(5):221\u2013230.\n317. Epstein DJ, Dunn J, Deresinski S. Infectious complications of\nmultiple sclerosis therapies: implications for screening, prophylaxis,\nand management.Open Forum Infect Dis. 2018;5(8):ofy174.\n318. Vollmer T. The natural history of relapses in multiple sclerosis.J\nNeurol Sci. 2007;256(Suppl 1):S5\u201313.\n319. Steelman AJ. Infection as an environmental trigger of multiple\nsclerosis disease exacerbation.Front Immunol. 2015;6:520.\n320. Oikonen M, Laaksonen M, Aalto V, et al. Temporal relationship\nbetween environmental in\ufb02uenza A and Epstein-Barr viral infec-\ntions and high multiple sclerosis relapse occurrence.Mult Scler.\n2011;17(6):672\u2013680.\n321.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1525, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "32741c93-6b65-4ea4-a5bf-c7187f27ff03": {"__data__": {"id_": "32741c93-6b65-4ea4-a5bf-c7187f27ff03", "embedding": null, "metadata": {"page_label": "39", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "75455cda-720f-4281-ad8d-c459a128196e", "node_type": "4", "metadata": {"page_label": "39", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "e15a74ddecd808fb0fb4c822003fe6631213d294d443a080b076ef7503e4d53e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c24ed535-7f95-4b1b-8f59-cbee02fe50fd", "node_type": "1", "metadata": {"page_label": "39", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "a727b80e84d1f5af270a304959b7370f2aa0fc8ce9ca32cd340dfb83df3cf1b3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "467104fb-f5db-4905-9bd1-e6f6ab56ae66", "node_type": "1", "metadata": {}, "hash": "791cff9f3e4bf281fe12601c0232386cbdbaa784d8f4a47b3cf9f47eba396a58", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Temporal relationship\nbetween environmental in\ufb02uenza A and Epstein-Barr viral infec-\ntions and high multiple sclerosis relapse occurrence.Mult Scler.\n2011;17(6):672\u2013680.\n321. Buljevac D, Flach HZ, Hop WC, et al. Prospective study on the\nrelationship between infections and multiple sclerosis exacerba-\ntions.Brain. 2002;125(Pt 5):952\u2013960.\n322. Sadeghmousavi S, Rezaei N. COVID-19 and multiple sclerosis:\npredisposition and precautions in treatment.SN Compr Clin Med.\n2020:1\u20136.\n323. Coyle PK, Gocke A, Vignos M, et al. Vaccine considerations for\nmultiple sclerosis in the COVID-19 Era. Adv Ther. 2021;38-\n(7):3550\u20133588.\n324. M\u00f6hn N, Konen FF, Pul R, et al. Experience in multiple sclerosis\npatients with COVID-19 and disease-modifying therapies: a\nreview of 873 published cases.J Clin Med. 2020;9(12):4067.\n325. Sormani MP, De Rossi N, Schiavetti I, et al. Ann Neurol.\n2021;89(4):780\u2013789.\n326. Diaz de la Fe A, Pel\u00e1ez Su\u00e1rez AA, Fuentes Campos M, et al.\nSARS-CoV-2 infection and risk management in multiple sclero-\nsis.Diseases. 2021;9(2):32.\n327. Nojszewska M, Kalinowska A, Adamczyk-Sowa M, et al.\nCOVID-19 mRNA vaccines (p\ufb01zer-BioNTech and moderna) in\npatients with multiple sclerosis: a statement by a working\ngroup convened by the section of multiple sclerosis and neuroim-\nmunology of the Polish neurological society.Neurol Neurochir\nPol. 2021;55(1):8\u201311.\n328. Mailand MT, Frederiksen JL. Vaccines and multiple sclerosis: a\nsystematic review.J Neurol.", "mimetype": "text/plain", "start_char_idx": 1351, "end_char_idx": 2807, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "467104fb-f5db-4905-9bd1-e6f6ab56ae66": {"__data__": {"id_": "467104fb-f5db-4905-9bd1-e6f6ab56ae66", "embedding": null, "metadata": {"page_label": "39", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "75455cda-720f-4281-ad8d-c459a128196e", "node_type": "4", "metadata": {"page_label": "39", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "e15a74ddecd808fb0fb4c822003fe6631213d294d443a080b076ef7503e4d53e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "32741c93-6b65-4ea4-a5bf-c7187f27ff03", "node_type": "1", "metadata": {"page_label": "39", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "9b5efffc6aa4b1e1c54ae7431fc95fe86b7cf55196b9e6b37b3b718eb2eae28a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6675e023-60b6-4e44-898e-5d59f4c4f31e", "node_type": "1", "metadata": {}, "hash": "0e8aa9903d9d13daf284c9895d348dc8a8b39e021299e000d4dafcac523877b7", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "2021;55(1):8\u201311.\n328. Mailand MT, Frederiksen JL. Vaccines and multiple sclerosis: a\nsystematic review.J Neurol. 2017;264(6):1035\u20131050.\n329. Zrzavy T, Kollaritsch H, Rommer PS, et al. Vaccination in mul-\ntiple sclerosis: friend or Foe?Front Immunol. 2019;10:1883.\n330. Woopen C, Schleu\u00dfner K, Akg\u00fcn K, et al. Approach to\nSARS-CoV-2 vaccination in patients With multiple sclerosis.\nFront Immunol. 2021;12:701752.\n331. Centonze D, Rocca MA, Gasperini C, et al. Disease-modifying\ntherapies and SARS-CoV-2 vaccination in multiple sclerosis:\nan expert consensus.J Neurol. 2021:1\u20138.\n332. Kelly H, Sokola B, Abboud H. Safety and ef\ufb01cacy of COVID-19\nvaccines in multiple sclerosis patients. J Neuroimmunol .\n2021;356:577599.\n333. Monschein T, Hartung HP, Zrzavy T, et al. Vaccination and mul-\ntiple sclerosis in the era of the COVID-19 pandemic.J Neurol\nNeurosurg Psychiatry. 2021:jnnp-2021-326839.\n334. Alexander JL, Moran GW, Gaya DR, et al. SARS-CoV-2 vacci-\nnation for patients with in\ufb02ammatory bowel disease: a British\nsociety of gastroenterology in\ufb02ammatory bowel disease section\nand IBD clinical research group position statement. Lancet\nGastroenterol Hepatol. 2021;6(3):218\u2013224.\n335. Taxonera C, Sagastagoitia I, Alba C, et al. 2019 Novel coronavi-\nrus disease (COVID-19) in patients with in\ufb02ammatory bowel\ndiseases. Aliment Pharmacol Ther.", "mimetype": "text/plain", "start_char_idx": 2695, "end_char_idx": 4035, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "6675e023-60b6-4e44-898e-5d59f4c4f31e": {"__data__": {"id_": "6675e023-60b6-4e44-898e-5d59f4c4f31e", "embedding": null, "metadata": {"page_label": "39", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "75455cda-720f-4281-ad8d-c459a128196e", "node_type": "4", "metadata": {"page_label": "39", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "e15a74ddecd808fb0fb4c822003fe6631213d294d443a080b076ef7503e4d53e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "467104fb-f5db-4905-9bd1-e6f6ab56ae66", "node_type": "1", "metadata": {"page_label": "39", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "6fb31fbe9c89134b77d12762b42804130a71e2079187b16b33019ec84e49d890", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9a7e5805-f608-4691-bd9c-b0714a308818", "node_type": "1", "metadata": {}, "hash": "3fc2c76f0fcf675544ad82763f5d781901d5d6e54fb061d8ffe861db5c33b02a", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "2019 Novel coronavi-\nrus disease (COVID-19) in patients with in\ufb02ammatory bowel\ndiseases. Aliment Pharmacol Ther. 2020;52(2):276\u2013283.\n336. Al-Ani AH, Prentice RE, Rentsch CA, et al. Review article: pre-\nvention, diagnosis and management of COVID-19 in the IBD\npatient.Aliment Pharmacol Ther. 2020;52(1):54\u201372.\n337. Kumar A, Quraishi MN, Segal JP, et al. COVID-19 vaccinations\nin patients with in \ufb02ammatory bowel disease. Lancet\nGastroenterol Hepatol. 2020;5(11):965\u2013966.\n338. Siegel CA, Melmed GY, McGovern DP, et al. SARS-CoV-2 vac-\ncination for patients with in\ufb02ammatory bowel diseases: recom-\nmendations from an international consensus meeting. Gut.\n2021;70(4):635\u2013640.\n339. Doran MF, Crowson CS, Pond GR, et al. Frequency of infection\nin patients with rheumatoid arthritis compared with controls: a\npopulation-based study.Arthritis Rheum . 2002;46(9):2287 \u2013\n2293.\n340. Kuo CF, Chou IJ, Rees F, et al. Temporal relationships between\nsystemic lupus erythematosus and comorbidities.Rheumatology\n(Oxford). 2019;58(5):840\u2013848.\n341. Gianfrancesco M, Hyrich KL, Al-Adely S, et al. Characteristics\nassociated with hospitalisation for COVID-19 in people with\nrheumatic disease: data from the COVID-19 global rheumatol-\nogy alliance physician-reported registry.Ann Rheum Dis .\n2020;79(7):859\u2013866.\n342. Curtis JR, Johnson SR, Anthony DD, et al. American College of\nrheumatology guidance for COVID-19 vaccination in patients\nWith rheumatic and musculoskeletal diseases: version 3.", "mimetype": "text/plain", "start_char_idx": 3923, "end_char_idx": 5394, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "9a7e5805-f608-4691-bd9c-b0714a308818": {"__data__": {"id_": "9a7e5805-f608-4691-bd9c-b0714a308818", "embedding": null, "metadata": {"page_label": "39", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "75455cda-720f-4281-ad8d-c459a128196e", "node_type": "4", "metadata": {"page_label": "39", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "e15a74ddecd808fb0fb4c822003fe6631213d294d443a080b076ef7503e4d53e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6675e023-60b6-4e44-898e-5d59f4c4f31e", "node_type": "1", "metadata": {"page_label": "39", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "ee300150d38ac2224102a8b32811e928d536680e984acc022f084259d7318755", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "342. Curtis JR, Johnson SR, Anthony DD, et al. American College of\nrheumatology guidance for COVID-19 vaccination in patients\nWith rheumatic and musculoskeletal diseases: version 3.\nArthritis Rheumatol. 2021.\n343. Furer V, Rondaan C, Heijstek MW, et al. 2019 Update of\nEULAR recommendations for vaccination in adult patients\nwith autoimmune in\ufb02ammatory rheumatic diseases. Ann\nRheum Dis. 2020;79(1):39\u201352.\n344. Arthritis and Musculoskeletal Alliance. Principles for\nCOVID-19 vaccination in musculoskeletal and rheumatology\nfor clinicians. March 10, 2021. Retrieved from: http://arma.uk.\nnet/covid-19-vaccination-and-msk/\n345. Kang HM, Choi EH, Kim YJ. Updates on the coronavirus\ndisease 2019 vaccine and consideration in children.Clin Exp\nPediatr. 2021;64(7):328\u2013338.\n346. The American Academy of Pediatrics. Children and COVID-19:\nstate-level data report. Retrieved from: https://www.aap.org/en/\nKantarcioglu et al. 39", "mimetype": "text/plain", "start_char_idx": 5213, "end_char_idx": 6132, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "09572bee-5327-49af-9760-3685b32ef464": {"__data__": {"id_": "09572bee-5327-49af-9760-3685b32ef464", "embedding": null, "metadata": {"page_label": "40", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "40a58b3d-7df0-4217-8a28-e348002a8d80", "node_type": "4", "metadata": {"page_label": "40", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "8c1948b64aa6166b93879104e23ec9a563a8aada3f348d865a82a821f8fc94da", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "552c93a8-2f38-47cc-b3aa-6c1eddf6297b", "node_type": "1", "metadata": {}, "hash": "6c0524cd8914e1468e0aa99ca807a5ef01f65938d8193ca06df7e29fbab12d77", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "pages/2019-novel-coronavirus-covid-19-infections/children-\nand-covid-19-state-level-data-report/\n347. Han MS, Choi EH, Chang SH, et al. Clinical characteristics and\nviral RNA detection in children with coronavirus disease 2019 in\nthe Republic of Korea.JAMA Pediatr2021;175:73\u201380.\n348. Revon-Riviere G, Ninove L, Min V, et al. The BNT162b2 mRNA\nCOVID-19 vaccine in adolescents and young adults with cancer: a\nmonocentric experience.Eur J Cancer. 2021;154:30\u201334.\n349. Frenck RWJr, Klein NP, Kitchin N, et al. Safety, immunogenic-\nity, and ef\ufb01cacy of the BNT162b2 COVID-19 vaccine in adoles-\ncents. N Engl J Med. 2021;385(3):239\u2013250.\n350. The United States Food and Drug Administration. (US FDA).\nCoronavirus (COVID-19) update: FDA authorizes\np\ufb01zer-BioNTech COVID-19 vaccine for emergency Use in ado-\nlescents in another important action in\ufb01ght against pandemic.\nRetrieved from: https://www.fda.gov/news-events/press-\nannouncements/coronavirus-covid-19-update-fda-authorizes-\np\ufb01zer-biontech-covid-19-vaccine-emergency-use\n351. Han B, Song Y, Li C, et al. Safety, tolerability, and immunoge-\nnicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in\nhealthy children and adolescents: a double-blind, randomised,\ncontrolled, phase 1/2 clinical trial.Lancet Infect Dis. 2021:\nS1473-3099(21)00319-4.\n352. Centers for Disease Control and Prevention. COVID-19\nRecommendations for older adults. Retrieved from: https://\nwww.cdc.gov/aging/covid19-guidance.html\n353. World Health Organization. The older people & COVID-19.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1511, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "552c93a8-2f38-47cc-b3aa-6c1eddf6297b": {"__data__": {"id_": "552c93a8-2f38-47cc-b3aa-6c1eddf6297b", "embedding": null, "metadata": {"page_label": "40", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "40a58b3d-7df0-4217-8a28-e348002a8d80", "node_type": "4", "metadata": {"page_label": "40", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "8c1948b64aa6166b93879104e23ec9a563a8aada3f348d865a82a821f8fc94da", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "09572bee-5327-49af-9760-3685b32ef464", "node_type": "1", "metadata": {"page_label": "40", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "a5c868194712c87ba68ee7077c3ca870b98a767420fa2000b684ade249c77546", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ca34776d-066a-4226-8723-2af30872f5e0", "node_type": "1", "metadata": {}, "hash": "e3b30367789337ccb085541ea1de4ddc3592a9e6d6dbe6379ee1bb3942b4ad87", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "COVID-19\nRecommendations for older adults. Retrieved from: https://\nwww.cdc.gov/aging/covid19-guidance.html\n353. World Health Organization. The older people & COVID-19.\nRetrieved from: https://www.who.int/teams/social-determinants-\nof-health/demographic-change-and-healthy-ageing/covid-19\n354. The American Geriatrics Society. AGS Coronavirus disease\n2019 (COVID-19) information Hub. Retrieved from: https://\nwww.americangeriatrics.org/covid19\n355. Callaway E. COVID Vaccine boosters: the most important ques-\ntions. Nature. 2021;596(7871):178\u2013180.\n356. The Lancet Infectious Diseases. COVID-19 vaccine equity and\nbooster doses.Lancet Infect Dis. 2021;21(9):1193.\n357. Centers for Disease Control and Prevention. Joint statement from\nHHS public health and medical experts on COVID-19 booster\nshots. Retrieved from: https://www.cdc.gov/media/releases/\n2021/s0818-covid-19-booster-shots.html\n358. Tan HX, Juno JA, Lee WS, et al. Immunogenicity of prime-boost\nprotein subunit vaccine strategies against SARS-CoV-2 in mice\nand macaques.Nat Commun. 2021;12(1):1403.\n359. Kunal S, Sakthivel P, Gupta N, et al. Mix and match COVID-19\nvaccines: potential bene\ufb01t and perspective from India.Postgrad\nMed J. 2021:postgradmedj-2021-140648.\n360. Vogel G. Mixing vaccines may boost immune responses.\nScience. 2021;372(6547):1138.\n361. Lewis D. Mix-and-match COVID vaccines: the case is growing,\nbut questions remain.Nature. 2021;595(7867):344\u2013345.\n362. Borobia AM, Carcas AJ, P\u00e9rez-Olmeda M, et al.", "mimetype": "text/plain", "start_char_idx": 1343, "end_char_idx": 2827, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "ca34776d-066a-4226-8723-2af30872f5e0": {"__data__": {"id_": "ca34776d-066a-4226-8723-2af30872f5e0", "embedding": null, "metadata": {"page_label": "40", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "40a58b3d-7df0-4217-8a28-e348002a8d80", "node_type": "4", "metadata": {"page_label": "40", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "8c1948b64aa6166b93879104e23ec9a563a8aada3f348d865a82a821f8fc94da", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "552c93a8-2f38-47cc-b3aa-6c1eddf6297b", "node_type": "1", "metadata": {"page_label": "40", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "d2989f087030fc6ae0ed6d56dce0b445118972cd09cbfd9ed6be3edeb2e4c170", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fe080274-f7b4-4e97-900d-5c50cc802205", "node_type": "1", "metadata": {}, "hash": "8b66bd4b8e8051d1fdd0d9ba930b4b65292c916c4d9ebacd85555ce901f64ff4", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "2021;595(7867):344\u2013345.\n362. Borobia AM, Carcas AJ, P\u00e9rez-Olmeda M, et al.\nImmunogenicity and reactogenicity of BNT162b2 booster in\nChAdOx1-S-primed participants (CombiVacS): a multicentre,\nopen-label, randomised, controlled, phase 2 trial. Lancet.\n2021;398(10295):121\u2013130.\n363. Gro\u00df R, Zanoni M, Seidel A, et al. Heterologous ChAdOx1\nnCoV-19 and BNT162b2 prime-boost vaccination elicits potent\nneutralizing antibody responses and T cell reactivity.medRxiv.\n2021.\n364. Shaw RH, Stuart A, Greenland M, et al. Heterologous prime-\nboost COVID-19 vaccination: initial reactogenicity data.\nLancet. 2021;397(10289):2043\u20132046.\n365. Liu X, Shaw RH, Stuart ASV, et al. Safety and immunogenicity\nof heterologous versus homologous prime-boost schedules with\nan adenoviral vectored and mRNA COVID-19 vaccine\n(Com-COV): a single-blind, randomised, non-inferiority trial.\nLancet. 2021;398(10303):856\u2013869.\n366. Hillus D, Schwarz T, Tober-Lau P, et al. Safety, reactogenicity,\nand immunogenicity of homologous and heterologous prime-\nboost immunisation with ChAdOx1 nCoV-19 and BNT162b2:\na prospective cohort study.Lancet Respir Med . 2021;9-\n(11):1255\u20131265.\n367. University of Oxford. Comparing coronavirus (COVID-19) vacc-\nine schedule combinations. Identi\ufb01cation No: ISRCTN69254139.\n2021. Retrieved from: https://www.isrctn.com/ISRCTN69254139\n368. University of Oxford. Comparing COVID-19 vaccine schedule\ncombinations \u2013 stage 2.", "mimetype": "text/plain", "start_char_idx": 2753, "end_char_idx": 4169, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "fe080274-f7b4-4e97-900d-5c50cc802205": {"__data__": {"id_": "fe080274-f7b4-4e97-900d-5c50cc802205", "embedding": null, "metadata": {"page_label": "40", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "40a58b3d-7df0-4217-8a28-e348002a8d80", "node_type": "4", "metadata": {"page_label": "40", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "8c1948b64aa6166b93879104e23ec9a563a8aada3f348d865a82a821f8fc94da", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ca34776d-066a-4226-8723-2af30872f5e0", "node_type": "1", "metadata": {"page_label": "40", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "dfe96898a228d0d139bed0030d88b6cf165ba85bc5287b391703e5724f3fca45", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "54509ef9-e00c-47c0-a106-6ec84e7fdfa4", "node_type": "1", "metadata": {}, "hash": "07b4750a86fccdf2d999f5753368e898cfe778ba13cb0cef7e1075a2d089287d", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "2021. Retrieved from: https://www.isrctn.com/ISRCTN69254139\n368. University of Oxford. Comparing COVID-19 vaccine schedule\ncombinations \u2013 stage 2. Identi\ufb01cation No: ISRCTN27841311.\nRetrieved from: https://www.isrctn.com/ISRCTN27841311\n369. Canadian Immunization Research Network. Mix and match of\nthe second COVID-19 vaccine dose for safety and immunogenic-\nity (MOSAIC). Identi\ufb01cation No: NCT04894435. Retrieved\nfrom: https://clinicaltrials.gov/ct2/show/NCT04894435\n370. National Institute of Allergy and Infectious Diseases (NIAID).\nDelayed heterologous SARS-CoV-2 vaccine dosing (boost) after\nreceipt of EUA vaccines. Identi \ufb01cation No: NCT04889209.\nRetrieved from: https://clinicaltrials.gov/ct2/show/NCT04889209\n371. Jiangsu Province Centers for Disease Control and Prevention.\nStudy on sequential immunization of inactivated SARS-CoV-2\nvaccine and recombinant SARS-CoV-2 vaccine (Ad5 vector).\nIdenti\ufb01cation No: NCT04892459. Retrieved from: https://\nclinicaltrials.gov/ct2/show/NCT04892459\n372. Assistance Publique \u2014 H\u00f4pitaux de Paris. Compare immu-\nnological ef \ufb01cacy of a vaccine regimen combining Two\nCovid19 mRNA vaccines (p \ufb01zer-BioNTech and moderna)\nWith that of a homologous vaccination of each Covid19\nmRNA vaccine (ARNCOMBI). Identi\ufb01cation No:\nNCT04900467. Retrieved from: https://clinicaltrials.gov/\nct2/show/NCT04900467\n373. Medical University Innsbruck.", "mimetype": "text/plain", "start_char_idx": 4023, "end_char_idx": 5393, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "54509ef9-e00c-47c0-a106-6ec84e7fdfa4": {"__data__": {"id_": "54509ef9-e00c-47c0-a106-6ec84e7fdfa4", "embedding": null, "metadata": {"page_label": "40", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "40a58b3d-7df0-4217-8a28-e348002a8d80", "node_type": "4", "metadata": {"page_label": "40", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "8c1948b64aa6166b93879104e23ec9a563a8aada3f348d865a82a821f8fc94da", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fe080274-f7b4-4e97-900d-5c50cc802205", "node_type": "1", "metadata": {"page_label": "40", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "d71222c2ed5fa3960970aadc379a3419e170fde9b504d13486ba0b68b6bf6e0e", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Identi\ufb01cation No:\nNCT04900467. Retrieved from: https://clinicaltrials.gov/\nct2/show/NCT04900467\n373. Medical University Innsbruck. Heterologous vaccination With\nan vaxzevria (ChAdOx1-S) prime and a comirnaty\n(BNT162b2) boost compared With homolog vaccination With\nvaxzervria (prime/boost) or comirnaty (prime/boost) (HeVacc).\nIdenti\ufb01cation No: NCT04907331. Retrieved from: https://\nclinicaltrials.gov/ct2/show/NCT04907331\n40 Clinical and Applied Thrombosis/Hemostasis", "mimetype": "text/plain", "start_char_idx": 5263, "end_char_idx": 5730, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "e1b1819e-6c38-4e5d-bb5f-7776fddf1899": {"__data__": {"id_": "e1b1819e-6c38-4e5d-bb5f-7776fddf1899", "embedding": null, "metadata": {"page_label": "1", "file_name": "diabetes.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\diabetes.pdf", "file_type": "application/pdf", "file_size": 367943, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "c5f7a6a3-9008-43b6-9d62-bd8d67c3fb4e", "node_type": "4", "metadata": {"page_label": "1", "file_name": "diabetes.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\diabetes.pdf", "file_type": "application/pdf", "file_size": 367943, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "e8781b60361953c0213c1d6027e9a2eaf08dd9740ea630ce1bcca2f6d86b8802", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eca16efd-d3d1-4110-81b8-0dd23cf8dd60", "node_type": "1", "metadata": {}, "hash": "244d63e2e33ec5d8848bc0a61571b79553c637fa0f967b6ac56154d75f5a6b67", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Management of Diabetes Insipidus following \nSurgery for Pituitary and Suprasellar Tumours\n*Mussa H. Almalki,1,2 Maswood M. Ahmad,1 Imad Brema,1 Mohammed Almehthel,1,3 Khaled M AlDahmani,4,5\nMoeber Mahzari,2,6 Salem A Beshyah7,8\nSultan Qaboos University Med J, August 2021, Vol. 21, Iss. 3, pp. 354\u2013364, Epub. 29 Aug 21\nSubmitted 2 Jun 20\nRevision Req. 22 Jul 20; Revision Recd. 14 Aug 20\nAccepted 9 Aug 20\n1Obesity, Endocrine and Metabolism Centre, King Fahad Medical City, Riyadh, Saudi Arabia; 2Faculty of Medicine, King Saud Bin Abdul Aziz University \nof Health Sciences, Riyadh, Saudi Arabia; 3Division of Endocrinology, University of British Columbia, Vancouver, Canada; 4Division of Endocrinology, \nTawam Hospital, Al Ain, United Arab Emirates; 5Department of Medicine, United Arab Emirates University, Al Ain, United Arab Emirates; 6Department of \nMedicine, Ministry of National Guard Health Affair, Riyadh, Saudi Arabia; 7Department of Medicine, Dubai Medical College, Dubai, United Arab Emirates; \n8Department of Endocrinology, Mediclinic Airport Road, Abu Dhabi, United Arab Emirates\n*Corresponding Author\u2019s e-mail: m2malki@yahoo.com\nP\nituitary adenomas are the third most  \ncommon intracranial neoplasm which accounts \nfor 10\u201315% of all diagnosed intracranial tumours \nand are frequently treated with transsphenoidal surgery \n(TSS), except prolactinomas.1 Neurosurgical operations \nfor pituitary and suprasellar tumours may result in \npostoperative complications due to the crucial \nanatomical location of these tumours.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1531, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "eca16efd-d3d1-4110-81b8-0dd23cf8dd60": {"__data__": {"id_": "eca16efd-d3d1-4110-81b8-0dd23cf8dd60", "embedding": null, "metadata": {"page_label": "1", "file_name": "diabetes.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\diabetes.pdf", "file_type": "application/pdf", "file_size": 367943, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "c5f7a6a3-9008-43b6-9d62-bd8d67c3fb4e", "node_type": "4", "metadata": {"page_label": "1", "file_name": "diabetes.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\diabetes.pdf", "file_type": "application/pdf", "file_size": 367943, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "e8781b60361953c0213c1d6027e9a2eaf08dd9740ea630ce1bcca2f6d86b8802", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e1b1819e-6c38-4e5d-bb5f-7776fddf1899", "node_type": "1", "metadata": {"page_label": "1", "file_name": "diabetes.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\diabetes.pdf", "file_type": "application/pdf", "file_size": 367943, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "2a661674257e1948ada5527ee50a56cf52f3578d92601426554cac130b780524", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c28979a0-a56d-455c-94f8-1eee57118566", "node_type": "1", "metadata": {}, "hash": "829be73f74c4de2489beb3ab67cbf66216d25ca8249755b1920a9cba09b69175", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "The resulting \npostoperative complications can manifest as anterior \nor posterior pituitary dysfunction, particularly sodium \ndisturbances, due to the changes in antidiuretic \nhormone (ADH) secretion, which remains one of \nthe most frequent postoperative reasons for hospital \nreadmission.2 The patterns of water and electrolyte \ndisorders after TSS can be divided into either polyuria \nor oliguria/hyponatremia, depending on the presence \nof either low or high levels of ADH, respectively.2 Some \ndisturbances of water and electrolytes may not reach \nthe level of clinically defined central diabetes insipidus \n(CDI) or syndrome of inappropriate antidiuretic \nhormone (SIADH). However, they may still require \nacute or chronic management and are generally divided \ninto six profiles of polyuria or hyponatremia as follows: \ntransient or sustained polyuria, immediate or delayed \nhyponatremia and biphasic or triphasic diabetes \ninsipidus (DI).2,3 CDI manifests as the excretion of large \namounts of dilute urine that frequently occurs in the \nacute phase following surgery for pituitary adenomas, \nsubarachnoid haemorrhage or traumatic brain injury. \nNonetheless, it occurs rarely in association with large \npituitary adenomas before surgical interventions. \nIts occurrence in this setting should question this \ndiagnosis and point towards other diagnoses such as \ncraniopharyngioma or granulomatous diseases.4\nSerum sodium and osmolality levels are generally \nmaintained within a very narrow range (within 1\u20132%) \ndespite marked variations in water and salt intake and \nthis is controlled by two mechanisms, namely arginine \nvasopressin (AVP) and thirst. The development of CDI \nafter TSS for pituitary adenoma is common, but it is \nusually transient. Most patients who have free access to \nfluids and have intact thirst mechanisms can maintain \nnormal serum sodium and normal fluid balance, as \nwell as avoid dehydration and hypernatremia that \nusually result from the development of a significant \nwater deficit.", "mimetype": "text/plain", "start_char_idx": 1532, "end_char_idx": 3547, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "c28979a0-a56d-455c-94f8-1eee57118566": {"__data__": {"id_": "c28979a0-a56d-455c-94f8-1eee57118566", "embedding": null, "metadata": {"page_label": "1", "file_name": "diabetes.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\diabetes.pdf", "file_type": "application/pdf", "file_size": 367943, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "c5f7a6a3-9008-43b6-9d62-bd8d67c3fb4e", "node_type": "4", "metadata": {"page_label": "1", "file_name": "diabetes.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\diabetes.pdf", "file_type": "application/pdf", "file_size": 367943, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "e8781b60361953c0213c1d6027e9a2eaf08dd9740ea630ce1bcca2f6d86b8802", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eca16efd-d3d1-4110-81b8-0dd23cf8dd60", "node_type": "1", "metadata": {"page_label": "1", "file_name": "diabetes.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\diabetes.pdf", "file_type": "application/pdf", "file_size": 367943, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "f7a12a8b1992abb4285179235760910a8d4fa7f455a4a4f88033c8c4ef40b7b0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "084760c7-1e6e-477f-8d56-866e153245be", "node_type": "1", "metadata": {}, "hash": "7e99b514bd6cd6a38bf3f9503516ef3f82eff63029a6708d62671ac17ed1d394", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Hence, it is exceptionally vital to freq- \nuently monitor the urine output, serum sodium \nand daily fluid balance in all neurosurgical patients \nfollowing TSS. When patients have impaired levels of \nconsciousness due to various factors, such as sedation, \nor if the thirst mechanism is impaired, for example \nin the rare subtype of adipsic DI, they can develop \nsignificant water deficit and severe hypernatremia.5,6\nThe measurement of copeptin as a surrogate \nmarker for AVP in the diagnostic workup of the \nthree main causes of polyuria (i.e. CDI, nephrogenic \nREVIEW\nThis work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.\nhttps://doi.org/10.18295/squmj.4.2021.010\nabstract: Central diabetes insipidus (CDI) is a common complication after pituitary surgery. However, it is most \nfrequently transient. It is defined by the excretion of an abnormally large volume of dilute urine with increasing \nserum osmolality. The reported incidence of CDI after pituitary surgery ranges from 0\u201390%. Large tumour size, \ngross total resection and intraoperative cerebrospinal fluid leak usually pose an increased risk of CDI as observed \nwith craniopharyngioma and Rathke\u2019s cleft cysts. CDI can be associated with high morbidity and mortality if not \npromptly recognised and treated on time. It is also essential to rule out other causes of postoperative polyuria to \navoid unnecessary pharmacotherapy and iatrogenic hyponatremia. Once the diagnosis of CDI is established, \nclose monitoring is required to evaluate the response to treatment and to determine whether the CDI is transient \nor permanent. This review outlines the evaluation and management of patients with CDI following pituitary and \nsuprasellar tumour surgery to help recognise the diagnosis, consider the differential diagnosis, initiate therapeutic \ninterventions and guide monitoring and long-term management.", "mimetype": "text/plain", "start_char_idx": 3548, "end_char_idx": 5458, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "084760c7-1e6e-477f-8d56-866e153245be": {"__data__": {"id_": "084760c7-1e6e-477f-8d56-866e153245be", "embedding": null, "metadata": {"page_label": "1", "file_name": "diabetes.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\diabetes.pdf", "file_type": "application/pdf", "file_size": 367943, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "c5f7a6a3-9008-43b6-9d62-bd8d67c3fb4e", "node_type": "4", "metadata": {"page_label": "1", "file_name": "diabetes.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\diabetes.pdf", "file_type": "application/pdf", "file_size": 367943, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "e8781b60361953c0213c1d6027e9a2eaf08dd9740ea630ce1bcca2f6d86b8802", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c28979a0-a56d-455c-94f8-1eee57118566", "node_type": "1", "metadata": {"page_label": "1", "file_name": "diabetes.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\diabetes.pdf", "file_type": "application/pdf", "file_size": 367943, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "c42a837e809da9791829cf8e98cbd36872024b00eba84bcf7f135f4e8334fb60", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "This review outlines the evaluation and management of patients with CDI following pituitary and \nsuprasellar tumour surgery to help recognise the diagnosis, consider the differential diagnosis, initiate therapeutic \ninterventions and guide monitoring and long-term management. \nKeywords: Central Diabetes Insipidus; Polydipsia; Polyuria; Pituitary Adenoma; Preoperative Risk Factor; Pituitary \nSurgery; Arginine Vasopressin; Desmopressin; Treatment.", "mimetype": "text/plain", "start_char_idx": 5182, "end_char_idx": 5631, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "55df77c4-2154-48a7-873d-7d2a379ab133": {"__data__": {"id_": "55df77c4-2154-48a7-873d-7d2a379ab133", "embedding": null, "metadata": {"page_label": "2", "file_name": "diabetes.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\diabetes.pdf", "file_type": "application/pdf", "file_size": 367943, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "b5ea9a47-6efd-4bbb-a59f-d20d7c568fc0", "node_type": "4", "metadata": {"page_label": "2", "file_name": "diabetes.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\diabetes.pdf", "file_type": "application/pdf", "file_size": 367943, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "1792c248c4eb71672b0e1826c20a669447f9e3bc7e9a8ffac4b12f504c34486d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "08590a5c-4710-49d6-9590-49040107a158", "node_type": "1", "metadata": {}, "hash": "36f6bc23c1196448a7098d042939793c32d3317dc8794643e05cf70a3bc36b86", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Mussa H. Almalki, Maswood M. Ahmad, Imad Brema, Mohammed Almehthel, Khaled M AlDahmani, \nMoeber Mahzari and Salem A Beshyah\nReview  | 355\nDI and primary polydipsia) has revolutionised the \nmanagement approach of the patients with these \nsuspected conditions, given its stable assays, high \ndiagnostic accuracy and high specificity. 7\u201310  Due to \na paucity of studies comparing different treatment \nand monitoring strategies for acute CDI following \ntranssphenoidal pituitary surgery, there is a general \nlack of clear guidelines based on grades of evidence \nfor acute DI following TSS management. Nonetheless, \nthere have been increasing adverse events, including \ndeath, which have been highlighted in recent years for \nthe patients with established CDI, mainly due to a lack \nof knowledge among health professionals dealing with \nthis condition. 11  Hence, there is a need to update the \nknowledge highlighting all the pitfalls that can lead to \nadverse patient outcomes.\nThe rationale for this review article is to present \nupdated information regarding the frequency, predictors  \nof occurrence, clinical presentation and diagnostic \nworkup, including the role of measurement of copeptin, \nwhich fills an important gap that exists regarding the \nlimitation of water deprivation test in differentiating \nbetween CDI and primary polydipsia. The therapeutic \ninterventions for CDI will also be reviewed, including \nthose used for treating the rare and serious subtype of \nadipsic DI, as well as the prognosis of CDI following TSS.\nepidemiology  \nCDI is a significant complication following pituitary \nsurgery which has been reported in the medical \nliterature. Transient diabetes insipidus (TDI) has been \nreported in 1.6\u201345.6% of the patients after pituitary \nsurgery with a transnasal microsurgical approach \nand in 2.5\u201326% of those who had surgery with the \ntransnasal endoscopic approach.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1893, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "08590a5c-4710-49d6-9590-49040107a158": {"__data__": {"id_": "08590a5c-4710-49d6-9590-49040107a158", "embedding": null, "metadata": {"page_label": "2", "file_name": "diabetes.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\diabetes.pdf", "file_type": "application/pdf", "file_size": 367943, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "b5ea9a47-6efd-4bbb-a59f-d20d7c568fc0", "node_type": "4", "metadata": {"page_label": "2", "file_name": "diabetes.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\diabetes.pdf", "file_type": "application/pdf", "file_size": 367943, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "1792c248c4eb71672b0e1826c20a669447f9e3bc7e9a8ffac4b12f504c34486d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "55df77c4-2154-48a7-873d-7d2a379ab133", "node_type": "1", "metadata": {"page_label": "2", "file_name": "diabetes.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\diabetes.pdf", "file_type": "application/pdf", "file_size": 367943, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "b07cfbc32b24222da96b6865a80ab12e6a56055c7333fc9c86e819212402a8c0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b9478731-1b40-46fc-b0d7-de120548439a", "node_type": "1", "metadata": {}, "hash": "8576c91192885eff1d4a8e05e7c7aab1d5973634692fe9824bd26db157f1b255", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "6,21  Permanent diabetes  \ninsipidus (PDI) is less common and has been reported in \n0\u201310% of patients following the microsurgical approach \nand in 0\u201312.5% of patients following the endoscopic \napproach. 12,13  The evidence is inconsistent regarding \nwhether endoscopic TSS is associated with a lower \nincidence of DI in comparison to microscopic TSS, with \nsome studies showing a lower incidence while others \ndo not. 13\u201315  One study investigated the DI following \ntranscranial pituitary surgery and found the incidence of \nTDI and PDI to be 21.1% and 12.2%, respectively. 16  CDI is \nmore common after craniopharyngioma surgery and has \nbeen reported in up to 90% of the patients. 17  Additionally, \nDI occurs in the acute phase of traumatic brain injury \n(TBI) in approximately 3% and 26% of cases and 15% of \ncases of subarachnoid haemorrhage (SAH). 18,19  CDI in \nthe vast majority of cases of TBI and SAH is transient. \nPersistent CDI in the setting of TBI and SAH is usually \na late manifestation of severely raised intracranial \npressure and, in this context, has a considerably grave \nprognosis. 18\u201320\npredictors  \nEarly detection of CDI can be meaningful to patient \ncare and outcomes following pituitary surgery. DI \nafter pituitary surgery is reported to be associated with \n3.9-fold increase in patients\u2019 mortality. 21  Therefore, \nrisk factors for CDI following pituitary surgery have \nbeen explored in several studies. The factors that may \npredict both transient and permanent DI include \ncraniopharyngioma, Rathke\u2019s cleft cysts, larger \ntumour size, low postoperative copeptin levels and \nintraoperative cerebrospinal fluid (CSF) leak.", "mimetype": "text/plain", "start_char_idx": 1894, "end_char_idx": 3546, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "b9478731-1b40-46fc-b0d7-de120548439a": {"__data__": {"id_": "b9478731-1b40-46fc-b0d7-de120548439a", "embedding": null, "metadata": {"page_label": "2", "file_name": "diabetes.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\diabetes.pdf", "file_type": "application/pdf", "file_size": 367943, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "b5ea9a47-6efd-4bbb-a59f-d20d7c568fc0", "node_type": "4", "metadata": {"page_label": "2", "file_name": "diabetes.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\diabetes.pdf", "file_type": "application/pdf", "file_size": 367943, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "1792c248c4eb71672b0e1826c20a669447f9e3bc7e9a8ffac4b12f504c34486d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "08590a5c-4710-49d6-9590-49040107a158", "node_type": "1", "metadata": {"page_label": "2", "file_name": "diabetes.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\diabetes.pdf", "file_type": "application/pdf", "file_size": 367943, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "aa0208191867c68a25354e921ec927b39088c59aebc0cacbabe2ebeead4ca882", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d85d410f-5469-4dc7-950e-55b38733ab8e", "node_type": "1", "metadata": {}, "hash": "c6d3578b49e18fc2dbd15126dac93654456705d8f71f472a9480ca22bb585f14", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Other \nfactors that have been shown to predict only TDI include \nACTH-producing adenoma, visual abnormalities on \npresentation, suprasellar tumour extension, gross total \nresection, postoperative CSF leak and first postoperative \nserum sodium of >145 mmol/L. In contrast, predictors \nof PDI only include younger age and reoperation, the \nformer likely due to large tumour mass, while the latter \ndue to possible injury to the neurohypophysis and/\nor stalk traction. 2,8,22\u201325  After the transcranial pituitary \nsurgery, the degree of deformation of the third ventricle \nand hypothalamus as assessed by preoperative magnetic \nresonance imaging and postoperative haemorrhage was \nassociated with both transient and permanent DI. 17\nPresentation and Diagnosis\nclinical  presentation\nCDI should be considered when a patient excretes \nlarge volumes of diluted urine after surgery, typically \nranging in 3.5\u201316.8 L per day,  in the presence of \nhigh or normal serum sodium and osmolality. 26  The \nonset of polyuria is usually abrupt and occurs within \nthe first 12\u201324 hours after surgery. 27  However, later \npresentation (two weeks to three months after surgery) \nhas been reported in patients with Rathke\u2019s cleft cyst. 28  \nThe pathophysiology of this is not well understood \nbut it has been suggested to be resulting from the \nrelease of cyst contents, causing inflammation to the \ninfundibulum. 29\nPolyuria is the hallmark of CDI. However, not \nall patients with polyuria after pituitary surgery \nhave CDI, as polyuria could result from the reactive \npostoperative diuresis in patients who received excess \namounts of intravenous fluids during surgery. It is also \nessential to rule out other common causes of polyuria \nsuch as hyperglycaemia and diuretics use before \nlabelling a patient with CDI.", "mimetype": "text/plain", "start_char_idx": 3547, "end_char_idx": 5344, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "d85d410f-5469-4dc7-950e-55b38733ab8e": {"__data__": {"id_": "d85d410f-5469-4dc7-950e-55b38733ab8e", "embedding": null, "metadata": {"page_label": "2", "file_name": "diabetes.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\diabetes.pdf", "file_type": "application/pdf", "file_size": 367943, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "b5ea9a47-6efd-4bbb-a59f-d20d7c568fc0", "node_type": "4", "metadata": {"page_label": "2", "file_name": "diabetes.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\diabetes.pdf", "file_type": "application/pdf", "file_size": 367943, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "1792c248c4eb71672b0e1826c20a669447f9e3bc7e9a8ffac4b12f504c34486d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b9478731-1b40-46fc-b0d7-de120548439a", "node_type": "1", "metadata": {"page_label": "2", "file_name": "diabetes.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\diabetes.pdf", "file_type": "application/pdf", "file_size": 367943, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "b2d53a4ba1f1290f31dc519c9e9c05828d72617fcb3f24cc6998076e968ccb08", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "It is also \nessential to rule out other common causes of polyuria \nsuch as hyperglycaemia and diuretics use before \nlabelling a patient with CDI. The classic triphasic water \ndysregulation is rare and occurs in approximately \n1.1\u20133.4% of postoperative patients where transient \nDI, a polyuric phase occurring due to the abrupt \ncessation of AVP release as a result of the temporary \nhypothalamic dysfunction, is followed by the second", "mimetype": "text/plain", "start_char_idx": 5199, "end_char_idx": 5633, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "35792614-9985-437c-a269-60be3cc60c4e": {"__data__": {"id_": "35792614-9985-437c-a269-60be3cc60c4e", "embedding": null, "metadata": {"page_label": "3", "file_name": "diabetes.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\diabetes.pdf", "file_type": "application/pdf", "file_size": 367943, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "dca39f39-0906-442f-a7e3-1281a5f2d30a", "node_type": "4", "metadata": {"page_label": "3", "file_name": "diabetes.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\diabetes.pdf", "file_type": "application/pdf", "file_size": 367943, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "95b92ea0e9a9908135da080e28e42529c4f3a8b751b3a365d9fef72dc6b1f461", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "51172858-d7ee-4a8b-aa02-f564c201792e", "node_type": "1", "metadata": {}, "hash": "be6d998779dbaea07d4115b67682dc387bc7ca5506310a1b7dc2996ad57690a7", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Management of Diabetes Insipidus following Surgery for Pituitary and Suprasellar Tumours\n356 | SQU Medical Journal, August 2021, Volume 21, Issue 3\nphase that resembles SIADH, which is caused by the \nsudden release of AVP from the degenerating pituitary. \nFinally, depletion of AVP stores leads to permanent \nCDI.30,31 The onset of polyuria is usually abrupt and \noccurs within the first 12\u201324 hours after surgery. \nThe initial transient phase of DI happens within 1\u20133 \ndays after surgery and typically lasts for 5\u20137 days. The \nsecond phase ensues 7\u20138 days postoperatively and can \nlast 2\u201314 days if there is no recovery of antidiuretic \nhormone (ADH)-secreting neurons. The third phase \noccurs when DI reappears as a result of depletion of \nADH stores.32\u201335\nPatients with DI typically complain of persistent \nexcessive thirst and drink to compensate for the water \nloss to maintain serum sodium within the normal \nrange. However, patients with limited access to water, \nimpaired consciousness level or impaired thirst sensation \nmay rapidly develop signs of dehydration on physical \nexamination in addition to hypernatremia (serum sodium \n>145 mmol/L) if free water loss is not replaced.36,37\ndiagnostic  workup\nThe diagnosis of CDI postoperatively begins with \nthe risk assessment using pre- and intra-operative \npredictive factors before the patient is transferred \nfrom the operation room. Excessive thirst and \npolyuria are the clinical features that typically trigger \nan evaluation for CDI.38 Hence, careful documentation \nof hourly fluid intake and urine output is essential for \nthe early identification of CDI. It is crucial to note \nthat polyuria may not always be due to DI; as seen \nin cases of mobilisation of intraoperative fluids and \nhyperglycaemia, it can also be due to a sharp drop of \ngrowth hormone level post acromegaly surgery and \nthe use of certain medications such as furosemide \nor SGLT2 inhibitors.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1927, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "51172858-d7ee-4a8b-aa02-f564c201792e": {"__data__": {"id_": "51172858-d7ee-4a8b-aa02-f564c201792e", "embedding": null, "metadata": {"page_label": "3", "file_name": "diabetes.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\diabetes.pdf", "file_type": "application/pdf", "file_size": 367943, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "dca39f39-0906-442f-a7e3-1281a5f2d30a", "node_type": "4", "metadata": {"page_label": "3", "file_name": "diabetes.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\diabetes.pdf", "file_type": "application/pdf", "file_size": 367943, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "95b92ea0e9a9908135da080e28e42529c4f3a8b751b3a365d9fef72dc6b1f461", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "35792614-9985-437c-a269-60be3cc60c4e", "node_type": "1", "metadata": {"page_label": "3", "file_name": "diabetes.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\diabetes.pdf", "file_type": "application/pdf", "file_size": 367943, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "8c6249484fe69a7ca8c89882d17a3acf9abed335f9bb17b631211307a00b6ef3", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "39 Therefore, documentation of \nhypotonic polyuria is essential in establishing the \ndiagnosis of DI. Seckel and Dunger criteria to diagnose \nCDI rely on the presence of hypotonic polyuria (urine \nosmolality <300 mOsmol/kg and urine output more \nthan 2 mL/kg/h) in addition to increased serum \nosmolality (>300 mOsmol/kg) after excluding other \ncauses of polyuria, such as glucosuria. 40 In adult \npatients in particular, urine output of more than \n250 mL per hour for two consecutive hours when \nsupplemented with the presence of normal or high \nserum sodium, normal or high serum osmolality \nwith a urine osmolality of less than 300 mOsmol/\nkg is highly suggestive of DI. 41 Urine specific gravity \nis easily assessed at the bedside and could provide a \nFigure 1: Post-pituitary-surgery evaluation (risk-based assessment).\nDI = diabetes insipidus; U = urine; S = serum; DDA VP = desmopressin; LOC = level of consciousness; PRN = as needed.\nDI Risk: Low = No risk factors; High = Any DI postoperative or intraoperative risk factors.", "mimetype": "text/plain", "start_char_idx": 1928, "end_char_idx": 2961, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "86e29728-680c-4951-817c-a38010f4fa7b": {"__data__": {"id_": "86e29728-680c-4951-817c-a38010f4fa7b", "embedding": null, "metadata": {"page_label": "4", "file_name": "diabetes.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\diabetes.pdf", "file_type": "application/pdf", "file_size": 367943, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "aac21c47-5379-4e51-86de-fe537032c27f", "node_type": "4", "metadata": {"page_label": "4", "file_name": "diabetes.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\diabetes.pdf", "file_type": "application/pdf", "file_size": 367943, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "81b634b9310f13e04584d40c8041a5f0a819595ec6bda9718d51cfc951330d42", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8155e70a-1c8c-4820-a5d5-cb600f880e2f", "node_type": "1", "metadata": {}, "hash": "a7f61dab1a51645665294bb177136f3d2dd72be4239a2112c735594b760cf673", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Mussa H. Almalki, Maswood M. Ahmad, Imad Brema, Mohammed Almehthel, Khaled M AlDahmani, \nMoeber Mahzari and Salem A Beshyah\nReview  | 357\nquicker evaluation of urine tonicity, with a value less \nthan 1.005 suggesting low urine osmolality. 42\nHowever, despite the availability of these tools, \nthe diagnosis of post-pituitary-surgery CDI could be \na challenge due to several factors. First, there is a lack \nof universal diagnostic criteria for DI and enormous \nvariability in the monitoring of patients following \npituitary surgery. Moreover, the current diagnostic \ncriteria may not apply to patients who are able to \nconsume water and self-manage CDI, especially if \nthe DI is partial. Furthermore, thin adults could have \nDI, but their urine output is <200 mL/h, which may \ndelay the diagnosis. For such patients, using weight-\nbased criteria to define polyuria (urine output of >2 \nmL/kg/h or >50 mL/kg/day) would be more accurate. \nAdditionally, the frequency of monitoring electrolytes \nis highly variable among physicians. 43  Therefore, \nfrequent assessment of electrolytes and osmolality \nin patients with a decreased level of consciousness \nor impaired thirst sensation is necessary for early \ndetection of CDI.\nThe difficulty in diagnosing CDI, particularly in \nthe immediate postoperative period, has led to the \nexploration of other ways to diagnose CDI. 44  Plasma \nAVP measurement has been explored; however, it \ncould be challenging as its half-life is short (16 minutes) \nand the AVP is usually unstable in collected plasma \nsamples and is affected by many factors leading to its \ninaccurate level. 45\u201347  Moreover, AVP measurement \nwith ELISA is not usually feasible due to the small size \nof AVP . 48  Furthermore, AVP measurement, usually \ndone by rapid acting insulin and requires a relatively \nlarge sample volume, is not available in a timely manner \nto diagnose DI as it requires a relatively long time \nand specialised labs to process it.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1963, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "8155e70a-1c8c-4820-a5d5-cb600f880e2f": {"__data__": {"id_": "8155e70a-1c8c-4820-a5d5-cb600f880e2f", "embedding": null, "metadata": {"page_label": "4", "file_name": "diabetes.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\diabetes.pdf", "file_type": "application/pdf", "file_size": 367943, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "aac21c47-5379-4e51-86de-fe537032c27f", "node_type": "4", "metadata": {"page_label": "4", "file_name": "diabetes.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\diabetes.pdf", "file_type": "application/pdf", "file_size": 367943, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "81b634b9310f13e04584d40c8041a5f0a819595ec6bda9718d51cfc951330d42", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "86e29728-680c-4951-817c-a38010f4fa7b", "node_type": "1", "metadata": {"page_label": "4", "file_name": "diabetes.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\diabetes.pdf", "file_type": "application/pdf", "file_size": 367943, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "e845d0878e668d75a67c1c6cae4e2514df19c53966ce91f667641f5d9549be52", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9eea549a-7051-4428-8d41-c1bbb8d3455b", "node_type": "1", "metadata": {}, "hash": "19938d5cf740ffbe17f6bf5037f2fd635126e5a01e41f8f1aa09c141d0506e75", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "For these reasons, \nAVP measurement is rarely useful in the diagnosis of \npostoperative DI.\nOn the other hand, copeptin is the C-terminal \npeptide of pro-vasopressin, co-secreted with AVP \nin an iso-osmolar manner, and reflects AVP level \naccurately. Unlike AVP , copeptin measurement is less \ncumbersome as it remains stable in collected plasma \nsamples for days and its measurement is associated \nwith less preanalytical errors. 49,50  It is highly accurate \nin identifying the aetiology of polyuria in the non-\nacute setting. 51  However, its utility in the post-\npituitary-surgery setting has been evaluated in only a \nfew studies. A multicentre study, 50 out of 205 patients \nwho developed CDI revealed that a copeptin level of \n<2.5 pmol/L is accurate in establishing the diagnosis \nof CDI with a specificity of 97% and positive predictive \nvalue of 81% when measured within 24 hours of \nsurgery. 52  In contrast, a value of >30 pmol/L almost \nexcluded the diagnosis with a negative predictive value \nTable 1: Biochemical parameters in patients with post-  \noperative diabetes insipidus\nParameter Description\nFluid balance Variable, usually negative (more output \nthan input)\nUrine output At least >2 mL/kg/h for two consecutive \nhours in addition to other parameters\nSerum \nosmolality\nNormal, if the patient has free access to \nwater, or high, >300 mOsmol/kg, if the \npatient has limited access to water\nSerum \nsodium\nNormal, if the patient has free access to \nwater, or high, >145 mmol/L, if the patient \nhas limited access to water\nUrine \nosmolality\nPersistently <300 mOsmol/L\nUrine specific \ngravity\nPersistently <1.005\nCopeptin <2.5 pmol/L \nTable 2: General management strategies for a patient \nwith diabetes insipidus\nImmediate postoperative period\n\u2022 Assessment of volume and hydration status;", "mimetype": "text/plain", "start_char_idx": 1964, "end_char_idx": 3769, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "9eea549a-7051-4428-8d41-c1bbb8d3455b": {"__data__": {"id_": "9eea549a-7051-4428-8d41-c1bbb8d3455b", "embedding": null, "metadata": {"page_label": "4", "file_name": "diabetes.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\diabetes.pdf", "file_type": "application/pdf", "file_size": 367943, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "aac21c47-5379-4e51-86de-fe537032c27f", "node_type": "4", "metadata": {"page_label": "4", "file_name": "diabetes.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\diabetes.pdf", "file_type": "application/pdf", "file_size": 367943, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "81b634b9310f13e04584d40c8041a5f0a819595ec6bda9718d51cfc951330d42", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8155e70a-1c8c-4820-a5d5-cb600f880e2f", "node_type": "1", "metadata": {"page_label": "4", "file_name": "diabetes.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\diabetes.pdf", "file_type": "application/pdf", "file_size": 367943, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "25421f617a97a0da885802e84c73a592cd1669bf6ab65fca52f4564127d357f6", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "005\nCopeptin <2.5 pmol/L \nTable 2: General management strategies for a patient \nwith diabetes insipidus\nImmediate postoperative period\n\u2022 Assessment of volume and hydration status; measurement \nof serum sodium\n\u2022 Close monitoring of serum sodium and urine output\n\u2022 Optimisation of fluid replacement \n\u2022 Consideration of desmopressin therapy in a patient with \nexcessive and inappropriately dilute urine output\n\u2022 Titration of desmopressin dose to keep 24-hour urine \noutput above the normal range (15\u201330 mL/kg/day)\nAfter hospital discharge\n\u2022 Limiting fluid intake to the amounts required to satisfy \nthirst\n\u2022 Performing electrolyte panel checks in any unwell patient \nafter hospital discharge; close postoperative follow-up \n\u2022 Monitoring for water intoxication and hyponatremia \n\u2022 Delaying a dose of desmopressin once or twice per week to \nallow an aquaresis to occur \n\u2022 Regular counselling of patient and their family about the \nprinciple of the treatment regime\nTable 3: Management of hypodipsia/adipsia with central\ndiabetes insipidus\n\u2022 Set a target (kg) at the weight the patient is known to be \neuvolemic and normonatremic\n\u2022 Fix 24-hour urine output at 1.5\u20132 L\n\u2022 Determine the obligate fluid intake (approximately 1.5 L)\n\u2022 Measure weight daily\n\u2022 Daily water intake = obligate volume + (target weight \u2013 \ndaily weight)\n\u2022 Check plasma sodium weekly \n\u2022 Educate patients and their family about the principle of the \ntreatment regime", "mimetype": "text/plain", "start_char_idx": 3590, "end_char_idx": 5018, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "414e5bfe-4872-42b5-9cd6-307662e6dc0b": {"__data__": {"id_": "414e5bfe-4872-42b5-9cd6-307662e6dc0b", "embedding": null, "metadata": {"page_label": "5", "file_name": "diabetes.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\diabetes.pdf", "file_type": "application/pdf", "file_size": 367943, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a844fd4c-b679-4cf6-b6f7-c4b6aa1923bb", "node_type": "4", "metadata": {"page_label": "5", "file_name": "diabetes.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\diabetes.pdf", "file_type": "application/pdf", "file_size": 367943, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "c1e5ea6ca7aab6104ebd4a95da300fa1136417bfdf231ed88c70fc49cff51b2d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "184b8647-d17e-466f-9ef2-7466476f8e0c", "node_type": "1", "metadata": {}, "hash": "1bd2757638fee3d3152c6486a6b79ebfda4637e9f852479ced2836937df183a9", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Management of Diabetes Insipidus following Surgery for Pituitary and Suprasellar Tumours\n358 | SQU Medical Journal, August 2021, Volume 21, Issue 3\n(NPV) of 95%. The performance of the test was better \nwhen performed <12 hours after surgery with lower \naccuracy beyond 24 hours. Similarly, the test proved \nsuperior in predicting persistent rather than transient \nDI (68% versus 32%). Another study of eight out of 58 \npatients with CDI with a standardised copeptin testing \ntime showed that a peak copeptin level of <12.8 pmol/l \nat 60 minutes post-extubation predicted CDI, while \npermanent CDI was excluded with 100% NPV in those \nwith a level of >4.2 pmol/L. 53 Interestingly, there was \nno significant difference in the copeptin level between \nthe two groups in the subsequent post-extubation \nassessments at 6\u201348 hours. \nCopeptin is a promising marker that will likely \nbe a routine diagnostic test in the evaluation of CDI \nin the future. However, presently, the limited number \nof studies about copeptin use, the uncertainty about \nthe optimal time of its measurement after surgery \nand the limited availability of the assay are factors \nlimiting its widespread use. Table 1 summarises the \nvarious parameters that are frequently needed to be \nevaluated in post-pituitary-surgery patients and the \nexpected changes in these parameters in patients with \npostoperative DI. A risk-based algorithm is proposed \non the frequency of laboratory investigation to identify \nDI in the postoperative period [Figure 1].\ntreatment\nAlthough ADH secretion impairment and the \ndisturbance of fluid balance often begin during the \nintraoperative period, CDI usually presents within \na few hours after surgery. It is imperative to rule \nout intraoperative fluid overload and glycosuria as \npotential causes of polyuria. It is also noteworthy that \npatients with acromegaly may experience increased \nurinary output following the resection of their \npituitary mass due to diuresis of excess fluid within \nthe soft tissues.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2010, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "184b8647-d17e-466f-9ef2-7466476f8e0c": {"__data__": {"id_": "184b8647-d17e-466f-9ef2-7466476f8e0c", "embedding": null, "metadata": {"page_label": "5", "file_name": "diabetes.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\diabetes.pdf", "file_type": "application/pdf", "file_size": 367943, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a844fd4c-b679-4cf6-b6f7-c4b6aa1923bb", "node_type": "4", "metadata": {"page_label": "5", "file_name": "diabetes.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\diabetes.pdf", "file_type": "application/pdf", "file_size": 367943, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "c1e5ea6ca7aab6104ebd4a95da300fa1136417bfdf231ed88c70fc49cff51b2d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "414e5bfe-4872-42b5-9cd6-307662e6dc0b", "node_type": "1", "metadata": {"page_label": "5", "file_name": "diabetes.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\diabetes.pdf", "file_type": "application/pdf", "file_size": 367943, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "07d376dd5cba6c60a549dd64f89c92e6dd794677a561c1c66e327e5129bed45e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "47907812-53e5-43ec-95dd-44fe1b6cfea0", "node_type": "1", "metadata": {}, "hash": "9ce77adffeeb306e91b8af88dad0c1d344344b286c1994bcf32cca6bbcbbd389", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "It is also noteworthy that \npatients with acromegaly may experience increased \nurinary output following the resection of their \npituitary mass due to diuresis of excess fluid within \nthe soft tissues. 54,55 Furthermore, approximately 50% \nand 80% of patients with transient DI recover within \nseven and 90 days of surgery, respectively. 56 As such, \npatients are advised to monitor for the cessation of \nthirst sensation and resolution of polyuria as potential \nsigns of DI recovery. Moreover, periodic monitoring \nof electrolytes can be useful to confirm DI recovery, as \nwater deprivation tests are not routinely recommended \nin this situation. 57 An additional advice is to delay \ndesmopressin (DDAVP) dose for a few hours to see if \nincreased thirst and polyuria persist.57\nPatients require continuous monitoring of fluid \nintake and urine output and frequent assessment \nof electrolyte. DDAVP should be used cautiously \nas required, especially during the first two weeks \npostoperatively to avoid hyponatremia due to over-\nreplacement.31 Treatment of postoperative CDI is \nmultifaceted and can be divided into acute or chronic \nphases, depending on the stage of the disease, to \nrestore osmotic equilibrium. Although specific \nguidelines related to the management of postoperative \nDI are unavailable, in the recent past, a disease state \nreview, followed by guidelines on hypopituitarism, \nwas published, offering some guidance to the \nclinical management. 42,58 The general strategies of \nmanagement of CDI are presented in Table 2. The \nacute phase management covers the first two phases \nof the triphasic water dysregulation phenomenon.\nAcute Management of Central \nDiabetes Insipidus\nfree  water  access\nThe management is straightforward, provided there \nis an intact thirst mechanism, i.e. the patient is not \nreceiving fluids for any reason and can drink water at will. \nWater balance can be achieved under such a situation \nas long as the patient can consume enough fluids.", "mimetype": "text/plain", "start_char_idx": 1810, "end_char_idx": 3796, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "47907812-53e5-43ec-95dd-44fe1b6cfea0": {"__data__": {"id_": "47907812-53e5-43ec-95dd-44fe1b6cfea0", "embedding": null, "metadata": {"page_label": "5", "file_name": "diabetes.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\diabetes.pdf", "file_type": "application/pdf", "file_size": 367943, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a844fd4c-b679-4cf6-b6f7-c4b6aa1923bb", "node_type": "4", "metadata": {"page_label": "5", "file_name": "diabetes.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\diabetes.pdf", "file_type": "application/pdf", "file_size": 367943, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "c1e5ea6ca7aab6104ebd4a95da300fa1136417bfdf231ed88c70fc49cff51b2d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "184b8647-d17e-466f-9ef2-7466476f8e0c", "node_type": "1", "metadata": {"page_label": "5", "file_name": "diabetes.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\diabetes.pdf", "file_type": "application/pdf", "file_size": 367943, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "c0e29bf747711f3d5aab24cdd956c32af67dc53a4fd62112a52ac03405b84cd7", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "the patient is not \nreceiving fluids for any reason and can drink water at will. \nWater balance can be achieved under such a situation \nas long as the patient can consume enough fluids. 59,60 \nPatients with a decreased level of consciousness and \nimpaired thirst mechanisms or those on intravenous \n(IV) fluids will require continuous adjustment of IV \nfluids and pharmacotherapy to maintain adequate \nhydration and sodium equilibrium. The appearance of \nhypernatremia and polyuria along with dehydration \nheralds the onset of CDI. It should be aggressively \nsought out during the immediate postoperative period \nas hypernatremia can cause brain shrinkage, leading to \nvascular rupture and intracranial bleeding, along with \nother complications.61\nThe serum sodium level can be normalised \nsafely at a correction rate of 1 mEq/L/h without any \nuntoward complications. 62,63 Hypotonic fluids should \nbe used when intravenous fluids are mandated. The \nleast amount of fluid possible should be used and \nrapid overcorrection must be avoided as it can lead to \ncerebral edema.63\nvasopressin\nVasopressin is available as an aqueous solution. Due \nto its short half-life of around 20 minutes, it should be \nadministered through IV infusion when acute control \nof antidiuresis is needed. 64 Infusion is usually started \nat a rate of 0.25\u20131.0 micro unit/kg/h and titrated every \nhalf hour after that to maintain the urine output rate \nat around 100 mL/h and/or urine specific gravity at \naround 1.010\u20131.020.\ndesmopressin\nDDAVP (1-deamino-8-D-arginine vasopressin) is a \nsynthetic analogue of vasopressin, having a prolonged", "mimetype": "text/plain", "start_char_idx": 3611, "end_char_idx": 5225, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "8fb71b35-2a1f-4ecc-a47b-c9b01968957f": {"__data__": {"id_": "8fb71b35-2a1f-4ecc-a47b-c9b01968957f", "embedding": null, "metadata": {"page_label": "6", "file_name": "diabetes.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\diabetes.pdf", "file_type": "application/pdf", "file_size": 367943, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "3539126f-3ec2-4806-9bd1-bd7333cf6313", "node_type": "4", "metadata": {"page_label": "6", "file_name": "diabetes.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\diabetes.pdf", "file_type": "application/pdf", "file_size": 367943, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "c5603c6f4fe985612d27b52ea7e9e6c31a379a1a5ac049726be20e0a67b089ae", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "92f1a912-88bb-4d1b-ae5f-7dacd9a0e1e8", "node_type": "1", "metadata": {}, "hash": "7f909b451a87de224f6fde4cce43b595cb2975bb0813601d11eb72eb5911159e", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Mussa H. Almalki, Maswood M. Ahmad, Imad Brema, Mohammed Almehthel, Khaled M AlDahmani, \nMoeber Mahzari and Salem A Beshyah\nReview  | 359\naction profile with minimal vasopressor activity. It can \nbe administered orally, intranasally, subcutaneously \nor intravenously. 65  Studies have shown a definite \nrelationship between the magnitude and duration of \nits therapeutic effect and its IV dosage. In patients \nwith CDI, 1 \u00b5g IV \u2018push\u2019 infusion can increase urine \nosmolality to a maximum of 700\u2013800 mOsmol/\nkg. 66,67  Further increase in dose, from 1 to 8 \u00b5g led to \nprolongation of the duration of action from around \n26 hours to 46 hours. The magnitude and duration \nof its therapeutic effects showed large interindividual \nvariability attributed to individual differences in renal \nconcentration abilities, as it persisted even when the \ndose was increased to more than 2 \u00b5g. 67\u201370\nFurther studies have shown that the antidiuretic \nefficacy depends on the total dose as well as the rate \nof increase in plasma DDAVP level. 71  The human \nkidney loses concentrating capacity in the absence \nof vasopressin. Therefore, once treatment is initiated, \nit requires at least eight hours of continued therapy \nfor full recovery. 72  According to several studies, the \nparenteral DDAVP can be administered safely to \nacutely ill patients with CDI. However, the needed dose \ndepends on the individual response, intactness of thirst \nmechanism and other factors determining fluid intake. \nIn patients with intact thirst mechanisms, a starting \ndose of 0.25\u20130.50 \u00b5g twice daily as an IV infusion over \ntwo hours is usually administered, which is adjusted \nfurther to normalise urine output and maintain sodium \nequilibrium. A smaller dose of 0.06\u20130.125 \u00b5g is usually \npreferred with further titration to the desired effects \nfor patients who are unable to drink at will or are on IV \nfluids.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1882, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "92f1a912-88bb-4d1b-ae5f-7dacd9a0e1e8": {"__data__": {"id_": "92f1a912-88bb-4d1b-ae5f-7dacd9a0e1e8", "embedding": null, "metadata": {"page_label": "6", "file_name": "diabetes.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\diabetes.pdf", "file_type": "application/pdf", "file_size": 367943, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "3539126f-3ec2-4806-9bd1-bd7333cf6313", "node_type": "4", "metadata": {"page_label": "6", "file_name": "diabetes.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\diabetes.pdf", "file_type": "application/pdf", "file_size": 367943, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "c5603c6f4fe985612d27b52ea7e9e6c31a379a1a5ac049726be20e0a67b089ae", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8fb71b35-2a1f-4ecc-a47b-c9b01968957f", "node_type": "1", "metadata": {"page_label": "6", "file_name": "diabetes.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\diabetes.pdf", "file_type": "application/pdf", "file_size": 367943, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "69bc20219cee29ab4f1ee2848f090d5244ea8bf100e1d23477328fa7b0982436", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b669ff45-46b9-4e4d-98d1-f8eaf5ded86e", "node_type": "1", "metadata": {}, "hash": "e14b9f720100da2e799ec670a5e5d0659cf2fbeaff0f18c4c4051e232dcc9f94", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "A smaller dose of 0.06\u20130.125 \u00b5g is usually \npreferred with further titration to the desired effects \nfor patients who are unable to drink at will or are on IV \nfluids. Although hyponatremia can be a manifestation \nof excessive DDAVP administration, the second phase \nof the triphasic water dysregulation phenomenon \nalso presents with hyponatremia. Both of these have \nthe same underlying mechanism and management \nprinciples that require withholding DDAVP along \nwith careful electrolyte and fluid balance monitoring.\nchronic  management  of  central  \ndiabetes  insipidus\nSince CDI rarely remits once established, it requires \ncontinuous, complete and around-the-clock manage- \nment of the polyuria and maintenance of sodium and \nwater equilibrium. Hypernatremia rarely goes unnoticed  \nas it is always associated with polyuria and dehydration. \nManagement principles of hypernatremia are same \nas mentioned above; however, in case the duration \nof hypernatremia cannot be ascertained, the serum \nsodium level should be corrected at a rate of 0.5 mEq/\nL/h, with no more than an 8\u201310 mEq/L decrease over \n24 hours, while keeping the target sodium level at 145 \nmEq/L. 61,63,73\nMinimising the risk of hyponatremia due to \nexcessive water retention is another critical challenge \nas it can be occasionally symptomatic and, rarely, life-\nthreatening. Excessive fluid consumption suppresses \nvasopressin secretion in normal subjects by non-\nosmotic mechanisms,  leading to diuresis and thus \npreventing over-hydration. 74,75  This \u2018escape\u2019 mechanism \nis not possible in patients with CDI as they are on \nexogenous long-acting desmopressin. Consequently, \ndilutional hyponatremia occurs. A longer-acting form \nof antidiuretic therapy and limiting fluid intake to the \namounts required to satisfy thirst are the possible ways \nto achieve this goal.", "mimetype": "text/plain", "start_char_idx": 1715, "end_char_idx": 3558, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "b669ff45-46b9-4e4d-98d1-f8eaf5ded86e": {"__data__": {"id_": "b669ff45-46b9-4e4d-98d1-f8eaf5ded86e", "embedding": null, "metadata": {"page_label": "6", "file_name": "diabetes.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\diabetes.pdf", "file_type": "application/pdf", "file_size": 367943, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "3539126f-3ec2-4806-9bd1-bd7333cf6313", "node_type": "4", "metadata": {"page_label": "6", "file_name": "diabetes.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\diabetes.pdf", "file_type": "application/pdf", "file_size": 367943, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "c5603c6f4fe985612d27b52ea7e9e6c31a379a1a5ac049726be20e0a67b089ae", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "92f1a912-88bb-4d1b-ae5f-7dacd9a0e1e8", "node_type": "1", "metadata": {"page_label": "6", "file_name": "diabetes.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\diabetes.pdf", "file_type": "application/pdf", "file_size": 367943, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "eec3f86ae8ac0b67c895c9d4d669859090237a0be252d96f7b902356439e2f82", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3963aa60-62f6-4aa0-bbf5-a376ac8c9630", "node_type": "1", "metadata": {}, "hash": "44192b3561d363b92fe60df6e9dd01385024817657b3859078cd1b820b058e0a", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "A longer-acting form \nof antidiuretic therapy and limiting fluid intake to the \namounts required to satisfy thirst are the possible ways \nto achieve this goal. Titration of antidiuretic dose to \nkeep 24 hours urine output within the normal range \n(15\u201330 mL/kg/day) is equally important. 76\ndesmopressin  \u2013 nasal  spray\nIntranasal DDAVP has an absorption ratio of around \n10\u201320% when compared to IV preparation in patients \nwith CDI. 77  Moreover, it has interindividual and \nintraindividual variability in the magnitude and \nduration of its antidiuretic effect. The variability is \nirrespective of age, severity of polyuria or body- \nweight, 78,79  leading to the duration of action ranging \nfrom 4\u201318 hours to 8\u201324 hours seen with 5\u201310 and \n20 \u00b5g, respectively. 69,80,81  The intranasal preparation \nis useful as it allows individualisation of treatment \nand dose titration by metered-dose spray (2.5\u201310 \n\u00b5g per spray). One must note that the absorption \nof nasal DDAVP may be decreased in the setting of \nnasal inflammation and rhinorrhoea, such as in upper \nrespiratory tract infections, and therefore patients \nmay need to use extra doses or shift to other routes if \npolyuria and dehydration are present.\ndesmopressin  oral  tablets\nDue to their large molecular size and susceptibility to \nenzymatic degradation coupled with short plasma half-\nlife, vasopressin and DDAVP were initially considered \nto be unsuitable for oral use. However, despite low oral \nbioavailability of around 16%, 82  a stable antidiuretic \neffect with a clear dose\u2013response relationship has \nbeen observed in clinical trials, 83  and preparation \nstrengths (0.1, 0.2 and 0.4 mg) are available for oral use.", "mimetype": "text/plain", "start_char_idx": 3399, "end_char_idx": 5085, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "3963aa60-62f6-4aa0-bbf5-a376ac8c9630": {"__data__": {"id_": "3963aa60-62f6-4aa0-bbf5-a376ac8c9630", "embedding": null, "metadata": {"page_label": "6", "file_name": "diabetes.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\diabetes.pdf", "file_type": "application/pdf", "file_size": 367943, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "3539126f-3ec2-4806-9bd1-bd7333cf6313", "node_type": "4", "metadata": {"page_label": "6", "file_name": "diabetes.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\diabetes.pdf", "file_type": "application/pdf", "file_size": 367943, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "c5603c6f4fe985612d27b52ea7e9e6c31a379a1a5ac049726be20e0a67b089ae", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b669ff45-46b9-4e4d-98d1-f8eaf5ded86e", "node_type": "1", "metadata": {"page_label": "6", "file_name": "diabetes.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\diabetes.pdf", "file_type": "application/pdf", "file_size": 367943, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "8d4e66dd58c5cb2b42627a317f92dc646766e0f63bb78df24c38dd240c85f3d1", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "DDAVP oral doses required for equivalent antidiuretic \nefficacy are around 10\u201320 times of the intranasal \ndoses; however, the ease of administration makes \noral formulations the preferred route of treatment for \nmost patients. Although individualisation of therapy \nand titration of the dose is needed, 0.1\u20130.2 mg every \neight hours is the usual maintenance dose, 80  while \nless frequent dosing, such as once or twice daily, is \ngenerally sufficient for infants and children. 84", "mimetype": "text/plain", "start_char_idx": 5087, "end_char_idx": 5566, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "5aa4316d-0ebb-4717-b46f-49bd3cd4ca55": {"__data__": {"id_": "5aa4316d-0ebb-4717-b46f-49bd3cd4ca55", "embedding": null, "metadata": {"page_label": "7", "file_name": "diabetes.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\diabetes.pdf", "file_type": "application/pdf", "file_size": 367943, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a1d7cf10-2bd5-4ce6-92e0-722bdf4869e1", "node_type": "4", "metadata": {"page_label": "7", "file_name": "diabetes.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\diabetes.pdf", "file_type": "application/pdf", "file_size": 367943, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "18f34fe1f3ca72007a5533a0742919d741d67ed1b48039bc3a94d039048aacc1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bca466cd-6cd6-4f38-b74a-de5195810b24", "node_type": "1", "metadata": {}, "hash": "d4c4b70cf0478e6391c91b337350d28fd266fe14e075c3544c4ca3efe69473b8", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Management of Diabetes Insipidus following Surgery for Pituitary and Suprasellar Tumours\n360 | SQU Medical Journal, August 2021, Volume 21, Issue 3\ndesmopressin  oral  formulations  \n\u2013 oral  melt\nSince 2005, DDAVP has been available as a sublingual \nlyophilizate (Melt) formulation containing 60, 120 and \n240 \u00b5g, having bioavailability of around 25%. 85 In a \nrecent study, DDAVP Melt has shown a similar level of \nantidiuretic control and was found to be as efficacious \nas intranasal DDAVP in both children and adults.86\nCentral Diabetes Insipidus in \nSpecific Populations\nneonatal  infants /children\nThe treatment of CDI in this group requires consideration \nof their diets which contain a proportionally larger \namount of water. Therefore, to prevent hyponatremia, \nurine volume must not be reduced too much and \ncareful dose titration with close input/output and \nplasma sodium monitoring are required. Continuous \nintravenous infusion of low dose DDAVP (0.1\u20130.2 \n\u00b5g s.c./i.m)  or arginine ADH (0.25\u20133 mU/kg/h) \nunder intensive monitoring is often used in the first \n24\u201348 hours postoperatively. 87,88 Once CDI is stable \nand permanent, regular DDAVP can be prescribed. \nA diluted rhinyl preparation of nasal spray in the \namount containing 1\u20135 \u00b5g of DDAVP once or twice \ndaily usually provides good control of CDI in infants.89 \nDDAVP can be administered subcutaneously in doses \nranging from 0.02 to 0.08 \u00b5g once or twice daily. 90 \nChildren and their parents need to be educated about \nthe features of water intoxication and the hazards of \nexcessive fluid intake.\npregnancy  and  lactation\nDDAVP , being resistant to placental leucine amino- \npeptidase, can be administered safely to pregnant \nwomen, both for gestational DI as well as to patients \nwith pre-existing CDI who become pregnant.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1801, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "bca466cd-6cd6-4f38-b74a-de5195810b24": {"__data__": {"id_": "bca466cd-6cd6-4f38-b74a-de5195810b24", "embedding": null, "metadata": {"page_label": "7", "file_name": "diabetes.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\diabetes.pdf", "file_type": "application/pdf", "file_size": 367943, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a1d7cf10-2bd5-4ce6-92e0-722bdf4869e1", "node_type": "4", "metadata": {"page_label": "7", "file_name": "diabetes.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\diabetes.pdf", "file_type": "application/pdf", "file_size": 367943, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "18f34fe1f3ca72007a5533a0742919d741d67ed1b48039bc3a94d039048aacc1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5aa4316d-0ebb-4717-b46f-49bd3cd4ca55", "node_type": "1", "metadata": {"page_label": "7", "file_name": "diabetes.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\diabetes.pdf", "file_type": "application/pdf", "file_size": 367943, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "2abfcda9e7275491575b8d6fa67d0b106574897f5b9fea9ea641809a3877247c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e1c61976-c09b-4a76-b40b-d2419f725813", "node_type": "1", "metadata": {}, "hash": "9e87cc245aa179dff3a27821a530f74f57d60e69445f1e90ade6351266c0a470", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "91,92 \nCompared to non-pregnant women, the doses needed \nare usually the same or slightly higher. Placental leucine \naminopeptidase usually disappears in 4\u20136 postpartum \nweeks when DDAVP can be discontinued in patients \nwith gestational DI. It should be kept in mind during \nthe monitoring of therapeutic effects that serum \nsodium level during pregnancy decreases typically by \napproximately 5 mmol/L compared to the nongravid \nstate. As DDAVP appears in an infinitesimal amount \nin breast milk, it can be continued during lactation.93\nelderly\nAs mentioned above, CDI requires lifelong manage- \nment and, even if the underlying cause is eliminated, \nCDI once established rarely remits. The treatment \nof CDI in the elderly does not differ much from that \nin young adults, though the former faces a higher \nrisk of developing hyponatremia, primarily when \nintranasal DDAVP is used.78 The aetiology is not clear \nat present. Abnormalities of osmoregulation of thirst \nand fluid intake, along with increased renal sensitivity \nto DDAVP , may be the possible explanation as this \npopulation is known to be affected by these factors.94\nhypodipsia /adipsia  with  central  \ndiabetes  insipidus\nAnterior hypothalamus injury leading to osmoreceptor \ndamage culminates in the absence or deficiency of \nthirst and results in the rare occurrence of adipsic \nDI. As a result, these patients have neither of the \nhomeostatic mechanisms required for water balance \nregulation. Consequently, their management becomes \ndifficult and they suffer from wide fluctuation in serum \nsodium levels. 95 In addition, during acute illnesses, \npatients can develop life-threatening hypernatremia, \nresulting in somnolence, seizures, hemiplegia, coma \nand acute renal failure and can experience thrombotic \nepisodes.", "mimetype": "text/plain", "start_char_idx": 1802, "end_char_idx": 3591, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "e1c61976-c09b-4a76-b40b-d2419f725813": {"__data__": {"id_": "e1c61976-c09b-4a76-b40b-d2419f725813", "embedding": null, "metadata": {"page_label": "7", "file_name": "diabetes.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\diabetes.pdf", "file_type": "application/pdf", "file_size": 367943, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a1d7cf10-2bd5-4ce6-92e0-722bdf4869e1", "node_type": "4", "metadata": {"page_label": "7", "file_name": "diabetes.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\diabetes.pdf", "file_type": "application/pdf", "file_size": 367943, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "18f34fe1f3ca72007a5533a0742919d741d67ed1b48039bc3a94d039048aacc1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bca466cd-6cd6-4f38-b74a-de5195810b24", "node_type": "1", "metadata": {"page_label": "7", "file_name": "diabetes.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\diabetes.pdf", "file_type": "application/pdf", "file_size": 367943, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "9670e98e830107de839a14ceb606e51294b87e2eb4dbe872e3b2af4957da0bc9", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Furthermore, other complications such as \nobesity and sleep apnoea, which is largely attributed \nto hypothalamic abnormalities, may be seen in assoc- \niation with adipsic DI; these conditions contribute to \nthe excess morbidity and mortality found in a patient \nwith adipsic DI. 96 It becomes necessary to prescribe \nfluid intake on a sliding scale based on daily weight and \nserum sodium level.97 DDAVP , alone or in combination \nwith hydrochlorothiazide, is a useful agent in this \nregard.\nAn alternative and more practical approach is to \nset a target weight (kg) at which the patient is known \nto be euvolemic and normonatremic and maintain \nfixed urine output at 1.5\u20132 L with a fixed amount of \nDDAVP . Furthermore, daily fluid intake can be titrated \nas obligate load (1.5 L in temperate climates) + (target \nweight \u2013 daily weight) to maintain volume status, \nsodium and osmolality within the defined range. 98 \nSuccessful treatment can be achieved through daily \nmeasurement of body weight and perhaps weekly serum \nsodium measurement along with careful monitoring \nand patient and family education. 98 Additionally, due \nto the high rates of venous thrombosis and thrombo- \nembolism in patients with adipsic DI, giving low- \nmolecular-weight heparin during periods of hyper- \nnatremia dehydration is recommended. Furthermore, \nscreening for sleep abnormalities is indicated. 99 The \nprinciples of management of adipsic DI are displayed \nin Table 3.", "mimetype": "text/plain", "start_char_idx": 3592, "end_char_idx": 5048, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "1d79b886-737a-483d-a26d-376cfc48458f": {"__data__": {"id_": "1d79b886-737a-483d-a26d-376cfc48458f", "embedding": null, "metadata": {"page_label": "8", "file_name": "diabetes.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\diabetes.pdf", "file_type": "application/pdf", "file_size": 367943, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a7f203c6-f1c6-4391-9a2f-93ecbac8d1dd", "node_type": "4", "metadata": {"page_label": "8", "file_name": "diabetes.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\diabetes.pdf", "file_type": "application/pdf", "file_size": 367943, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "650714bcd0126d9b0a50a2d63b2cae1d613f3497ec5a0eaeedfd2de114ca9d9f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a2a99af2-e4cc-432f-bce4-8edad3763e80", "node_type": "1", "metadata": {}, "hash": "c93cf70403d72d1c9f4a363a3717601687f1f5f3fd456099052c890213079ae4", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Mussa H. Almalki, Maswood M. Ahmad, Imad Brema, Mohammed Almehthel, Khaled M AlDahmani, \nMoeber Mahzari and Salem A Beshyah\nReview  | 361\nConclusion\nCDI is a frequent complication that occurs in patients \nwho undergo surgery for pituitary and suprasellar \ntumours and is the commonest leading cause for \nhospital readmission of these patients. Therefore, \nclinicians dealing with these patients need to perform \na thorough preoperative risk assessment in order to \nidentify known predictive factors for CDI, such as \nin patients with craniopharyngioma and with larger \ntumours, in order to have clear strategies in place \nfor early diagnosis and management. Moreover, \npostoperative evaluation should be performed in \nthe early and late postoperative periods in order to \nreduce the risk of complications and unnecessary \nreadmissions to the hospital. While the management \nof CDI which complicates surgery for pituitary and \nsuprasellar tumours is a commonly encountered topic, \nit nonetheless remains a challenging area for clinicians \nand requires high standards of medical knowledge in \ntandem with superior clinical experience and skills, \nespecially regarding the decision about when to start \ndesmopressin therapy and for how long, as well as \nplanning the long-term follow-up for those who \ndevelop permanent CDI.\nconflict  of  interest\nThe authors declare no conflicts of interest. \nfunding\nNo funding was received for this study.\nauthors \u2019 contribution\nMHA contributed to study design. All authors \ncontributed to the literature review and data collection. \nAll authors drafted the initial manuscript. MHA, \nMMA, and IB edited the manuscript. MA, KMD, MM \nand SAB made critical revision and approved final \nversion. All authors reviewed and approved the final \nversion of the manuscript.\nReferences\n1. Ezzat S, Asa SL, Couldwell WT, Barr CE, Dodge WE, Vance ML,  \net al. The prevalence of pituitary adenomas: A systematic review.  \nCancer 2004; 101:613\u201319.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1966, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "a2a99af2-e4cc-432f-bce4-8edad3763e80": {"__data__": {"id_": "a2a99af2-e4cc-432f-bce4-8edad3763e80", "embedding": null, "metadata": {"page_label": "8", "file_name": "diabetes.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\diabetes.pdf", "file_type": "application/pdf", "file_size": 367943, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a7f203c6-f1c6-4391-9a2f-93ecbac8d1dd", "node_type": "4", "metadata": {"page_label": "8", "file_name": "diabetes.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\diabetes.pdf", "file_type": "application/pdf", "file_size": 367943, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "650714bcd0126d9b0a50a2d63b2cae1d613f3497ec5a0eaeedfd2de114ca9d9f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1d79b886-737a-483d-a26d-376cfc48458f", "node_type": "1", "metadata": {"page_label": "8", "file_name": "diabetes.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\diabetes.pdf", "file_type": "application/pdf", "file_size": 367943, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "1703aca3a33c9e55853c97263fb174c7354b3d47db20f59f155cfd92928be071", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3eafa7ba-56f5-4451-8785-c328b29ec380", "node_type": "1", "metadata": {}, "hash": "a2451f2b4a401d117e7c1f2b4d74b5fc4ac75a883cc620265ed04b8519e27b6e", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "The prevalence of pituitary adenomas: A systematic review.  \nCancer 2004; 101:613\u201319. https://doi.org/10.1002/cncr.20412.\n2. Hensen J, Henig A, Fahlbusch R, Meyer M, Boehnert M, Buchfelder M. \nPrevalence, predictors and patterns of postoperative polyuria and  \nhyponatraemia in the immediate course after trans-sphenoidal \nsurgery for pituitary adenomas. Clin Endocrinol (Oxf ) 1999; \n50:431\u20139. https://doi.org/10.1046/j.1365-2265.1999.00666.x .\n3. Blair ET, Clemmer JS, Harkey HL, Hester RL, Pruett WA. \nPhysiologic mechanisms of water and electrolyte disturbances \nafter transsphenoidal pituitary surgery. World Neurosurg 2017; \n107:429\u201336. https://doi.org/10.1016/j.wneu.2017.07.175.\n4. Thompson CJ. Polyuric states in man. Baillieres Clin Endocrinol \nMetab 1989; 3:473\u201397. https://doi.org/10.1016/s0950-351x(89)80012-6.\n5. Smith D, McKenna K, Moore K, Tormey W, Finucane J, Phillips J,  \net al. Baroregulation of vasopressin release in adipsic diabetes \ninsipidus. J Clin Endocrinol Metab 2002; 87:4564\u20138. https://\ndoi.org/10.1210/jc.2002-020090.\n6. Sherlock M, Agha A, Crowley R, Smith D, Thompson CJ. Adipsic  \ndiabetes insipidus following pituitary surgery for a macropro- \nlactinoma. Pituitary 2006; 9:59\u201364. https://doi.org/10.1007/s11 \n102-006-8280-x .\n7.", "mimetype": "text/plain", "start_char_idx": 1881, "end_char_idx": 3146, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "3eafa7ba-56f5-4451-8785-c328b29ec380": {"__data__": {"id_": "3eafa7ba-56f5-4451-8785-c328b29ec380", "embedding": null, "metadata": {"page_label": "8", "file_name": "diabetes.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\diabetes.pdf", "file_type": "application/pdf", "file_size": 367943, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a7f203c6-f1c6-4391-9a2f-93ecbac8d1dd", "node_type": "4", "metadata": {"page_label": "8", "file_name": "diabetes.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\diabetes.pdf", "file_type": "application/pdf", "file_size": 367943, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "650714bcd0126d9b0a50a2d63b2cae1d613f3497ec5a0eaeedfd2de114ca9d9f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a2a99af2-e4cc-432f-bce4-8edad3763e80", "node_type": "1", "metadata": {"page_label": "8", "file_name": "diabetes.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\diabetes.pdf", "file_type": "application/pdf", "file_size": 367943, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "c31664829ae11e92184cb4ffe953f6134b8b9c3f36bee9da7423554ef80e8cfb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f3aa6e5d-e0e8-4ee0-bc61-708245188420", "node_type": "1", "metadata": {}, "hash": "68f1353987abdd2d55465d6614ee65379c9c6757e92b3d366b7c77b87bce760c", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Pituitary 2006; 9:59\u201364. https://doi.org/10.1007/s11 \n102-006-8280-x .\n7. Szinnai G, Morgenthaler NG, Berneis K, Struck J, Muller B, \nKeller U et al. Changes in plasma copeptin, the c-terminal \nportion of arginine vasopressin during water deprivation and \nexcess in healthy subjects. J Clin Endocrinol Metab 2007; \n92:3973\u20138. https://doi.org/10.1210/jc.2007-0232.\n8. Balanescu S, Kopp P , Gaskill MB, Morgenthaler NG, Schindler C, \nRutishauser J. Correlation of plasma copeptin and vasopressin \nconcentrations in hypo-, iso-, and hyperosmolar states. J Clin \nEndocrinol Metab 2011; 96:1046\u201352. https://doi.org/10.1210/\njc.2010-2499.\n9. Katan M, Morgenthaler NG, Dixit KC, Rutishauser J, Brabant G, \nMuller B, et al. Anterior and posterior pituitary function testing \nwith simultaneous insulin tolerance test and a novel copeptin assay. \nJ Clin Endocrinol Metab 2007; 92:2640\u20133. https://doi.org/10.1 \n210/jc.2006-2046.\n10. Winzeler B, Zweifel C, Nigro N, Arici B, Bally M, Schuetz P , \net al. Postoperative copeptin concentration predicts diabetes \ninsipidus after pituitary surgery. J Clin Endocrinol Metab 2015; \n100:2275\u201382. https://doi.org/10.1210/jc.2014-4527.\n11. Baldeweg SE, Ball S, Brooke A, Gleeson HK, Levy MJ, Prentice \nM, et al. Inpatient management of cranial diabetes insipidus.", "mimetype": "text/plain", "start_char_idx": 3073, "end_char_idx": 4365, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "f3aa6e5d-e0e8-4ee0-bc61-708245188420": {"__data__": {"id_": "f3aa6e5d-e0e8-4ee0-bc61-708245188420", "embedding": null, "metadata": {"page_label": "8", "file_name": "diabetes.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\diabetes.pdf", "file_type": "application/pdf", "file_size": 367943, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a7f203c6-f1c6-4391-9a2f-93ecbac8d1dd", "node_type": "4", "metadata": {"page_label": "8", "file_name": "diabetes.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\diabetes.pdf", "file_type": "application/pdf", "file_size": 367943, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "650714bcd0126d9b0a50a2d63b2cae1d613f3497ec5a0eaeedfd2de114ca9d9f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3eafa7ba-56f5-4451-8785-c328b29ec380", "node_type": "1", "metadata": {"page_label": "8", "file_name": "diabetes.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\diabetes.pdf", "file_type": "application/pdf", "file_size": 367943, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "c3a1c226c7a6ce94244915e85da4345b28140957541080ecdf67a404928ae13b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fe81ec9e-e6e6-4483-8856-a4e2850143c9", "node_type": "1", "metadata": {}, "hash": "b4f5b7eb54c62447523adc364dbe8c89341e40a9e8243ee286b4b4e086f69028", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "11. Baldeweg SE, Ball S, Brooke A, Gleeson HK, Levy MJ, Prentice \nM, et al. Inpatient management of cranial diabetes insipidus. \nEndocr Connect 2018; 7:G8\u201311. https://doi.org/10.1530/EC-\n18-0154.\n12. Sheehan JM, Sheehan JP , Douds GL, Page RB. DDAVP use \nin patients undergoing transsphenoidal surgery for pituitary \nadenomas. Acta Neurochir (Wien) 2006; 148:287\u201391. https://\ndoi.org/10.1007/s00701-005-0686-0.\n13. Goudakos JK, Markou KD, Georgalas C. Endoscopic versus \nmicroscopic trans-sphenoidal pituitary surgery: A systematic \nreview and metaanalysis. Clin Otolaryngol 2011; 36:212\u201320. \nhttps://doi.org/10.1111/j.1749-4486.2011.02331.x .\n14. Little AS, Kelly DF, White WL, Gardner PA, Fernandez-Miranda JC,  \nChicoine MR, et al. Results of a prospective multicenter contr- \nolled study comparing surgical outcomes of microscopic versus \nfully endoscopic transsphenoidal surgery for nonfunctioning \npituitary adenomas: The Transsphenoidal Extent of Resection \n(TRANSSPHER) study. J Neurosurg 2019; 132:1043\u201353. \nhttps://doi.org/10.3171/2018.11.JNS181238.\n15. Agam MS, Wedemeyer MA, Wrobel B, Weiss MH, Carmichael JD, \nZada G. Complications associated with microscopic and endo- \nscopic transsphenoidal pituitary surgery: Experience of 1153 \nconsecutive cases treated at a single tertiary care pituitary \ncenter. J Neurosurg 2018; 130:1576\u201383. https://doi.org/10.317 \n1/2017.12.JNS172318.\n16.", "mimetype": "text/plain", "start_char_idx": 4238, "end_char_idx": 5634, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "fe81ec9e-e6e6-4483-8856-a4e2850143c9": {"__data__": {"id_": "fe81ec9e-e6e6-4483-8856-a4e2850143c9", "embedding": null, "metadata": {"page_label": "8", "file_name": "diabetes.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\diabetes.pdf", "file_type": "application/pdf", "file_size": 367943, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a7f203c6-f1c6-4391-9a2f-93ecbac8d1dd", "node_type": "4", "metadata": {"page_label": "8", "file_name": "diabetes.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\diabetes.pdf", "file_type": "application/pdf", "file_size": 367943, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "650714bcd0126d9b0a50a2d63b2cae1d613f3497ec5a0eaeedfd2de114ca9d9f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f3aa6e5d-e0e8-4ee0-bc61-708245188420", "node_type": "1", "metadata": {"page_label": "8", "file_name": "diabetes.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\diabetes.pdf", "file_type": "application/pdf", "file_size": 367943, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "b1bfeaa7b5571a5f4f8ad25d7084be45bcf0a3d4de19298f185e033b10dfdaef", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "J Neurosurg 2018; 130:1576\u201383. https://doi.org/10.317 \n1/2017.12.JNS172318.\n16. Wang S, Li D, Ni M, Jia W, Zhang Q, He J, Jia G. Clinical \npredictors of diabetes insipidus after transcranial surgery for \npituitary adenoma. World Neurosurg 2017; 101:1\u201310. https://\ndoi.org/10.1016/j.wneu.2017.01.075.\n17. Smith D, Finucane F, Phillips J,  Baylis PH, Finucane J, Tormey W, \net al. Abnormal regulation of thirst and vasopressin secretion \nfollowing surgery for craniopharyngioma. Clin Endocrinol (Oxf ) \n2004; 61:273\u20139. https://doi.org/10.1111/j.1365-2265.2004.02086.x .\n18. Agha A, Rogers B, Mylotte D, Taleb F, Tormey W, Phillips J, et al. \nNeuroendocrine dysfunction in the acute phase of traumatic \nbrain injury. Clin Endocrinol (Oxf ).2004; 60:584\u201391. https://\ndoi.org/10.1111/j.1365-2265.2004.02023.x .\n19. Hannon MJ, Crowley RK, Behan LA, O\u2019Sullivan EP , O\u2019Brien MMC,  \nSherlock M, et al. Acute glucocorticoid deficiency and diabetes \ninsipidus are common after acute traumatic brain injury and \npredict mortality. J Clin Endocrinol Metab 2013; 98:3229\u201337. \nhttps://doi.org/10.1210/jc.2013-1555.", "mimetype": "text/plain", "start_char_idx": 5555, "end_char_idx": 6654, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "ab368f89-f8c5-409b-9013-c183c28d1418": {"__data__": {"id_": "ab368f89-f8c5-409b-9013-c183c28d1418", "embedding": null, "metadata": {"page_label": "9", "file_name": "diabetes.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\diabetes.pdf", "file_type": "application/pdf", "file_size": 367943, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "39481e14-6b63-4449-a5ee-4b06a012c44f", "node_type": "4", "metadata": {"page_label": "9", "file_name": "diabetes.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\diabetes.pdf", "file_type": "application/pdf", "file_size": 367943, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "90bed498b9bdb05c44f190186339d95412f6629f4e2aa67619be83c5cbd31f1e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0dce0402-7f17-4b1f-a472-d6a3d72da830", "node_type": "1", "metadata": {}, "hash": "479406fcd1be115f3ea6cdcc7ca90087ad11fa3670c710d620cd9245b622215c", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Management of Diabetes Insipidus following Surgery for Pituitary and Suprasellar Tumours\n362 | SQU Medical Journal, August 2021, Volume 21, Issue 3\n20. Qureshi AI, Suri MF, Sung GY, Straw R, Yahia AM, Saad M, et al. \nPrognostic significance of hypernatremia and hyponatremia \namong patients with aneurysmal subarachnoid hemorrhage. \nNeurosurgery 2002; 50:749\u201356. https://doi.org/10.1097/000061 \n23-200204000-00012.\n21. Barker FG 2nd; Klibanski A; Swearingen B. Transsphenoidal \nsurgery for pituitary tumours in the United States, 1996-2000: \nMortality, morbidity, and the effects of hospital and surgeon \nvolume. J Clin Endocrinol Metab 2003; 88:4709\u201319. https://\ndoi.org/10.1210/jc.2003-030461.\n22. Ajlan AM, Abdulqader SB, Achrol AS, Aljamaan Y, Feroze AH, \nKatznelson L, et al. Diabetes insipidus following endoscopic \ntranssphenoidal surgery for pituitary adenoma. J Neurol \nSurg B Skull Base 2018; 79:117\u201322. https://doi.org/10.1055/s-0 \n037-1604363.\n23. Sigounas D, Sharpless J, Cheng D, Johnson T, Senior B, Ewend M. \nPredictors and incidence of central diabetes insipidus after \nendoscopic pituitary surgery. Neurosurgery 2008; 62:71\u20138. \nhttps://doi.org/10.1227/01.NEU.0000311063.10745.D8.\n24. Nemergut EC, Zuo Z, Jane Jr JA, Laws Jr ER. Predictors of \ndiabetes insipidus after transsphenoidal surgery: A review \nof 881 patients.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1337, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "0dce0402-7f17-4b1f-a472-d6a3d72da830": {"__data__": {"id_": "0dce0402-7f17-4b1f-a472-d6a3d72da830", "embedding": null, "metadata": {"page_label": "9", "file_name": "diabetes.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\diabetes.pdf", "file_type": "application/pdf", "file_size": 367943, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "39481e14-6b63-4449-a5ee-4b06a012c44f", "node_type": "4", "metadata": {"page_label": "9", "file_name": "diabetes.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\diabetes.pdf", "file_type": "application/pdf", "file_size": 367943, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "90bed498b9bdb05c44f190186339d95412f6629f4e2aa67619be83c5cbd31f1e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ab368f89-f8c5-409b-9013-c183c28d1418", "node_type": "1", "metadata": {"page_label": "9", "file_name": "diabetes.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\diabetes.pdf", "file_type": "application/pdf", "file_size": 367943, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "3e8641d580338b3d995d4455d4fda8b16906a606e7584cc04fdb41f7afd62e82", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e4fc74fc-a671-4d39-8083-3f025e8aeb39", "node_type": "1", "metadata": {}, "hash": "db755cf01855eec3b4a71d8933b8f73bd456c4404172e983aef764db55fc0ef2", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "24. Nemergut EC, Zuo Z, Jane Jr JA, Laws Jr ER. Predictors of \ndiabetes insipidus after transsphenoidal surgery: A review \nof 881 patients. J Neurosurg 2005; 103:448\u201354. https://doi.\norg/10.3171/jns.2005.103.3.0448.\n25. Pratheesh R, Swallow DMA, Rajaratnam S, Jacob KS, Chacko G, \nJoseph M, et al. Incidence, predictors and early postoperative \ncourse of diabetes insipidus in paediatric craniopharygioma: \nA comparison with adults. Child\u2019s Nerv Syst 2013; 29:941\u20139.  \nhttps://doi.org/10.1007/s00381-013-2041-8.\n26. Kristof RA, Rother M, Neuloh G, Klingm\u00fcller D. Incidence, \nclinical manifestations, and course of water and electrolyte meta- \nbolism disturbances following transsphenoidal pituitary adenoma \nsurgery: A prospective observational study. J Neurosurg 2009; \n111:555\u201362. https://doi.org/10.3171/2008.9.JNS08191.\n27. Prete A, Corsello SM, Salvatori R. Current best practice in the \nmanagement of patients after pituitary surgery. Ther Adv Endo- \ncrinol Metab 2017; 8:33\u201348. https://doi.org/10.1177/204201881 \n6687240.\n28. Wedemeyer MA, Lin M, Fredrickson VL, Arakelyan A, Bradley D, \nDonoho DA, et al. Recurrent Rathke\u2019s cleft cysts: Incidence \nand surgical management in a tertiary pituitary center over \n2 decades. Oper Neurosurg (Hagerstown) 2018; 16:675\u201384. \nhttps://doi.org/10.1093/ons/opy258.\n29.", "mimetype": "text/plain", "start_char_idx": 1198, "end_char_idx": 2511, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "e4fc74fc-a671-4d39-8083-3f025e8aeb39": {"__data__": {"id_": "e4fc74fc-a671-4d39-8083-3f025e8aeb39", "embedding": null, "metadata": {"page_label": "9", "file_name": "diabetes.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\diabetes.pdf", "file_type": "application/pdf", "file_size": 367943, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "39481e14-6b63-4449-a5ee-4b06a012c44f", "node_type": "4", "metadata": {"page_label": "9", "file_name": "diabetes.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\diabetes.pdf", "file_type": "application/pdf", "file_size": 367943, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "90bed498b9bdb05c44f190186339d95412f6629f4e2aa67619be83c5cbd31f1e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0dce0402-7f17-4b1f-a472-d6a3d72da830", "node_type": "1", "metadata": {"page_label": "9", "file_name": "diabetes.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\diabetes.pdf", "file_type": "application/pdf", "file_size": 367943, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "3e17398d41710cd54b0782370fbce16432eac504485f13bc3596c25e858b06e5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ea34ce3d-650b-41d0-a490-b067537189c1", "node_type": "1", "metadata": {}, "hash": "a10dc204274853aa2af0c79e6f60bd374ecbe15bc1956d41353bdc0d4058e430", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Oper Neurosurg (Hagerstown) 2018; 16:675\u201384. \nhttps://doi.org/10.1093/ons/opy258.\n29. Hayashi Y, Aida Y, Sasagawa Y, Oishi M, Kita D, Tachibana O, \net al. Delayed occurrence of diabetes insipidus after transs- \nphenoidal surgery with radiologic evaluation of the pituitary \nstalk on magnetic resonance imaging. World Neurosurg 2018; \n110:e1072\u20137. https://doi.org/10.1016/j.wneu.2017.11.169.\n30. Schreckinger M, Walker B, Knepper J, Hornyak M, Hong D, \nKim Jung-Min, et al. Post-operative diabetes insipidus after \nendoscopic transsphenoidal surgery. Pituitary 2013; 16:445\u201351. \nhttps://doi.org/10.1007/s11102-012-0453-1.\n31. Yuen KCJ, Ajmal A, Correa R, Little AS. Sodium perturbations \nafter pituitary surgery. Neurosurg Clin N Am 2019; 30:515\u201324. \nhttps://doi.org/10.1016/j.nec.2019.05.011. \n32. Hoorn EJ, Zietse R. Water balance disorders after neurosurgery: \nThe triphasic response revisited. NDT Plus 2010; 3:42\u20134. \nhttps://doi.org/10.1093/ndtplus/sfp117.\n33. Loh JA, Verbalis JG. Diabetes insipidus as a complication after \npituitary surgery. Nat Clin Pract Endocrinol Metab 2007; \n3:489\u201394. https://doi.org/10.1038/ncpendmet0513.\n34. Seckl J, Dunger D. Postoperative diabetes insipidus. BMJ 1989; \n298:2\u20133. https://doi.org/10.1136/bmj.298.6665.2.", "mimetype": "text/plain", "start_char_idx": 2426, "end_char_idx": 3679, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "ea34ce3d-650b-41d0-a490-b067537189c1": {"__data__": {"id_": "ea34ce3d-650b-41d0-a490-b067537189c1", "embedding": null, "metadata": {"page_label": "9", "file_name": "diabetes.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\diabetes.pdf", "file_type": "application/pdf", "file_size": 367943, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "39481e14-6b63-4449-a5ee-4b06a012c44f", "node_type": "4", "metadata": {"page_label": "9", "file_name": "diabetes.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\diabetes.pdf", "file_type": "application/pdf", "file_size": 367943, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "90bed498b9bdb05c44f190186339d95412f6629f4e2aa67619be83c5cbd31f1e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e4fc74fc-a671-4d39-8083-3f025e8aeb39", "node_type": "1", "metadata": {"page_label": "9", "file_name": "diabetes.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\diabetes.pdf", "file_type": "application/pdf", "file_size": 367943, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "311eca1923d4e8884d1143c745fd47c080a84bec45bc20f5727087e62c878bfd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e6839b33-cc71-42a9-96b6-c2314e023cbe", "node_type": "1", "metadata": {}, "hash": "0635298adda205219ac40105aaa69a47183716d6a78f0892423139a14df3bd35", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "BMJ 1989; \n298:2\u20133. https://doi.org/10.1136/bmj.298.6665.2.\n35. Hans P , Stevenaert A, Albert A. Study of hypotonic polyuria after \ntrans-sphenoidal pituitary adenomectomy. Intensive Care Med \n1986; 12:95\u20139. https://doi.org/10.1007/BF00254519.\n36. Fenske W, Allolio B. Current state and future perspectives in the \ndiagnosis of diabetes insipidus: A clinical review. J Clin Endo- \ncrinol 2012; 97:3426\u201337. https://doi.org/10.1210/jc.2012-1981.\n37. Loh JA, Verbalis JG. Diabetes insipidus as a complication after \npituitary surgery. Nat Clin Pract Endocrinol Metab 2007; \n3:489\u201394. https://doi.org/10.1038/ncpendmet0513.\n38. Kiran Z, Sheikh A, Momin SN, Majeed I, Awan S, Rashid O, \net al. Sodium and water imbalance after sellar, suprasellar, and \nparasellar surgery. Endocr Pract 2017; 23:309\u201317. https://doi.\norg/10.4158/EP161616.OR.\n39. Gubbi S, Hannah-Shmouni F, Koch CA, Verbalis JG. Diagnostic \ntesting for diabetes insipidus. In: Feingold KR, Anawalt B, \nBoyce A, Chrousos G, de Herder WW, Dhatariya K, et al., Eds. \nEndotext. South Dartmouth: MDText.com, Inc., 2019. \n40. Seckel J, Dunger D. Postoperative diabetes insipidus. BMJ 1989; \n298:2. https://doi.org/10.1136/bmj.298.6665.2.\n41.", "mimetype": "text/plain", "start_char_idx": 3620, "end_char_idx": 4815, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "e6839b33-cc71-42a9-96b6-c2314e023cbe": {"__data__": {"id_": "e6839b33-cc71-42a9-96b6-c2314e023cbe", "embedding": null, "metadata": {"page_label": "9", "file_name": "diabetes.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\diabetes.pdf", "file_type": "application/pdf", "file_size": 367943, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "39481e14-6b63-4449-a5ee-4b06a012c44f", "node_type": "4", "metadata": {"page_label": "9", "file_name": "diabetes.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\diabetes.pdf", "file_type": "application/pdf", "file_size": 367943, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "90bed498b9bdb05c44f190186339d95412f6629f4e2aa67619be83c5cbd31f1e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ea34ce3d-650b-41d0-a490-b067537189c1", "node_type": "1", "metadata": {"page_label": "9", "file_name": "diabetes.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\diabetes.pdf", "file_type": "application/pdf", "file_size": 367943, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "3c804db6693d3bed26b876dc74665b00247c961aafd1a79b1584c61353977ff0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b6e2be3d-e2d6-4829-ad67-47a0c3d672cf", "node_type": "1", "metadata": {}, "hash": "fa79252128524be6573cbff269e0b68856979dfec12919ea0427243d09b10409", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "BMJ 1989; \n298:2. https://doi.org/10.1136/bmj.298.6665.2.\n41. Ausiello JC, Bruce JN, Freda PU. Postoperative assessment of \nthe patient after transsphenoidal pituitary surgery. Pituitary \n2008; 11:391-401. https://doi.org/10.1007/s11102-008-0086-6.\n42. Woodmansee WW, Carmichael J, Kelly D. American Assoc- \niation of Clinical Endocrinologists and American College of \nEndocrinology Disease State Clinical Review: Postoperative \nmanagement following pituitary surgery. Endocr Pract 2015; \n21:832\u20138. https://doi.org/10.4158/EP14541.DSCR.\n43. Musch W, Thimpont J, Vandervelde D, Verhaeverbeke I, Berghmans T, \nDecaux G. Combined fractional excretion of sodium and urea \nbetter predicts response to saline in hyponatremia than do \nusual clinical and biochemical parameters. Am J Med 1995; \n99:348\u201355. https://doi.org/10.1016/s0002-9343(99)80180-6.\n44. Christ-Crain M, Fenske W. Copeptin in the diagnosis of vaso- \npressin-dependent disorders of fluid homeostasis. Nat Rev \nEndocrinol 2016; 12:168. https://doi.org/10.1038/nrendo.2015.224.\n45. Czaczkes J, Kleeman C, Koenig M, Boston R. Physiologic \nstudies of antidiuretic hormone by its direct measurement in \nhuman plasma. J Clin Invest 1964; 43:1625\u201340. https://doi.\norg/10.1172/JCI105038.\n46. Ellis MJ, Livesey JH, Evans MJ. Hormone stability in human \nwhole blood. Clin Biochem 2003; 36:109\u201312. https://doi.", "mimetype": "text/plain", "start_char_idx": 4754, "end_char_idx": 6113, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "b6e2be3d-e2d6-4829-ad67-47a0c3d672cf": {"__data__": {"id_": "b6e2be3d-e2d6-4829-ad67-47a0c3d672cf", "embedding": null, "metadata": {"page_label": "9", "file_name": "diabetes.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\diabetes.pdf", "file_type": "application/pdf", "file_size": 367943, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "39481e14-6b63-4449-a5ee-4b06a012c44f", "node_type": "4", "metadata": {"page_label": "9", "file_name": "diabetes.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\diabetes.pdf", "file_type": "application/pdf", "file_size": 367943, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "90bed498b9bdb05c44f190186339d95412f6629f4e2aa67619be83c5cbd31f1e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e6839b33-cc71-42a9-96b6-c2314e023cbe", "node_type": "1", "metadata": {"page_label": "9", "file_name": "diabetes.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\diabetes.pdf", "file_type": "application/pdf", "file_size": 367943, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "e20b825bed5e668588c787a74ce99f555ffeea3745421fda326292839ad72fa8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0dd99e3b-76c5-4a19-95f3-981e59f654b6", "node_type": "1", "metadata": {}, "hash": "ace6b970a88df62a1c0906c3dee43f19f68bd7ed161d84cd41f58ccbb593f587", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "46. Ellis MJ, Livesey JH, Evans MJ. Hormone stability in human \nwhole blood. Clin Biochem 2003; 36:109\u201312. https://doi.\norg/10.1016/s0009-9120(02)00440-x.\n47. Timper K, Fenske W, K\u00fchn F, Frech N, Arici B, Rutishauser J, et al. \nDiagnostic accuracy of copeptin in the differential diagnosis of \nthe polyuria-polydipsia syndrome: A prospective multicenter \nstudy. J Clin Endocrinol Metab 2015; 100:2268\u201374. https://doi.\norg/10.1210/jc.2014-4507.\n48. Morgenthaler NG, Struck J, Alonso C, Bergmann A. Assay for \nthe measurement of copeptin, a stable peptide derived from the \nprecursor of vasopressinn. Clin Chem 2006; 52:112\u20139. https://\ndoi.org/10.1373/clinchem.2005.060038.\n49. Balanescu S, Kopp P , Gaskill MB, Morgenthaler NG, Schindler C, \nRutishauser J. Correlation of plasma copeptin and vasopressin \nconcentrations in hypo-, iso-, and hyperosmolar States. J Clin \nEndocrinol Metab 2011; 96:1046\u201352. https://doi.org/10.1210/\njc.2010-2499.\n50. Fenske W, Refardt J, Chifu I, Schnyder I, Winzeler B, Drummond J, \net al. A copeptin-based approach in the diagnosis of diabetes \ninsipidus. N Engl J Med 2018; 379:428\u201339. https://doi.org/10.10 \n56/NEJMoa1803760.\n51. Winzeler B, Zweifel C, Nigro N, Arici B, Bally M, Schuets P , \net al.", "mimetype": "text/plain", "start_char_idx": 5994, "end_char_idx": 7226, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "0dd99e3b-76c5-4a19-95f3-981e59f654b6": {"__data__": {"id_": "0dd99e3b-76c5-4a19-95f3-981e59f654b6", "embedding": null, "metadata": {"page_label": "9", "file_name": "diabetes.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\diabetes.pdf", "file_type": "application/pdf", "file_size": 367943, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "39481e14-6b63-4449-a5ee-4b06a012c44f", "node_type": "4", "metadata": {"page_label": "9", "file_name": "diabetes.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\diabetes.pdf", "file_type": "application/pdf", "file_size": 367943, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "90bed498b9bdb05c44f190186339d95412f6629f4e2aa67619be83c5cbd31f1e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b6e2be3d-e2d6-4829-ad67-47a0c3d672cf", "node_type": "1", "metadata": {"page_label": "9", "file_name": "diabetes.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\diabetes.pdf", "file_type": "application/pdf", "file_size": 367943, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "ce3eb571efb12a3eab1d2eb72d9db94c1aa27567b6680cdda714c1aae0c6b883", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "51. Winzeler B, Zweifel C, Nigro N, Arici B, Bally M, Schuets P , \net al. Postoperative copeptin concentration predicts diabetes \ninsipidus after pituitary surgery. J Clin Endocrinol Metab 2015; \n100:2275\u201382.  https://doi.org/10.1210/jc.2014-4527.\n52. Berton AM, Gatti F, Penner F, Varaldo E, Prencipe N, Rumbolo, \net al. Early copeptin determination allows prompt diagnosis of \npost-neurosurgical central diabetes insipidus. Neuroendocrin- \nology 2019; 110:525\u201334.  https://doi.org/10.1159/000503145.\n53. Eisenberg Y, Charles S, Dugas L, Agrawal N. Clinical practice \npatterns for postoperative water balance after pituitary surgery. \nEndocr Pract 2019; 25:943\u201350. https://doi.org/10.4158/EP-\n2019-0160.", "mimetype": "text/plain", "start_char_idx": 7153, "end_char_idx": 7857, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "4b6b46c6-3d6a-4af0-ad3f-7b9a69e689d9": {"__data__": {"id_": "4b6b46c6-3d6a-4af0-ad3f-7b9a69e689d9", "embedding": null, "metadata": {"page_label": "10", "file_name": "diabetes.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\diabetes.pdf", "file_type": "application/pdf", "file_size": 367943, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "7827c7e0-209d-4f3c-98cd-4e7e5502aaa8", "node_type": "4", "metadata": {"page_label": "10", "file_name": "diabetes.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\diabetes.pdf", "file_type": "application/pdf", "file_size": 367943, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "8649a668a9b7dd6413fc4b59deddce3eee5e59d569e0f992f2e45b4b7389363d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e4140117-03cc-4202-b9f9-fffa9720af1b", "node_type": "1", "metadata": {}, "hash": "7ac6d93065cb2dc5022948512c5983a9d42c223fbb81eb1e3a84b0a719841133", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Mussa H. Almalki, Maswood M. Ahmad, Imad Brema, Mohammed Almehthel, Khaled M AlDahmani, \nMoeber Mahzari and Salem A Beshyah\nReview  | 363\n54. Sheehan JM, Sheehan JP , Douds GL, Page RB. DDAVP use in \npatients undergoing transsphenoidal surgery for pituitary adenomas.  \nActa Neurochir 2006; 148:287\u201391. https://doi.org/10.1007/s00 \n701-005-0686-0.\n55. Adams JR, Blevins LS, Allen GS, Verity DK, Devin JK. Disorders \nof water metabolism following transsphenoidal pituitary surgery  \n a single institution\u2019s experience. Pituitary 2006; 9:93\u20139. https://\ndoi.org/10.1007/s11102-006-9276-2.\n56. Adams JR, Belvins Jr LS, Verity DK, Devin JK. Disorders of \nwater metabolism following transphenoidal pituitary surgery: \nA single institution\u2019s experience. Pituitary 2006; 9:93\u20139. https://\ndoi.org/10.1007/s11102-006-9276-2.\n57. Garrahy A, Moran C, Thompson CJ. Diagnosis and management \nof central diabetes insipidus in adults. Clin Endocrinol (Oxf ) \n2019; 90:23\u201330. https://doi.org/10.1111/cen.13866.\n58. Fleseriu M, Hashim IA, Karavitaki N, Melmed S, Murad MH, \nSalvatori R, et al. Hormonal replacement in hypopituitarism in \nadults: An endocrine society clinical practice guideline. J Clin \nEndocrinol Metab 2016; 101:3888\u2013921.  https://doi.org/10.121 \n0/jc.2016-2118.\n59.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1267, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "e4140117-03cc-4202-b9f9-fffa9720af1b": {"__data__": {"id_": "e4140117-03cc-4202-b9f9-fffa9720af1b", "embedding": null, "metadata": {"page_label": "10", "file_name": "diabetes.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\diabetes.pdf", "file_type": "application/pdf", "file_size": 367943, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "7827c7e0-209d-4f3c-98cd-4e7e5502aaa8", "node_type": "4", "metadata": {"page_label": "10", "file_name": "diabetes.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\diabetes.pdf", "file_type": "application/pdf", "file_size": 367943, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "8649a668a9b7dd6413fc4b59deddce3eee5e59d569e0f992f2e45b4b7389363d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4b6b46c6-3d6a-4af0-ad3f-7b9a69e689d9", "node_type": "1", "metadata": {"page_label": "10", "file_name": "diabetes.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\diabetes.pdf", "file_type": "application/pdf", "file_size": 367943, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "9dca6e0a860c328e717e5c09f005139a697e4085db7038f9e1f2a6db435491a2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d6489447-2c60-4546-82bb-5727e8008381", "node_type": "1", "metadata": {}, "hash": "1514974e798e37ff4fb023725c5de009ecfbd16628d34012bdb7d3c15e58589d", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "J Clin \nEndocrinol Metab 2016; 101:3888\u2013921.  https://doi.org/10.121 \n0/jc.2016-2118.\n59. Dumont AS, Nemergut EC, Jane Jr JA, Laws Jr ER. Postoperative \ncare following pituitary surgery. J Intensive Care Med 2005; \n20:127\u201340. https://doi.org/10.1177/0885066605275247.\n60. Makaryus AN, McFarlane SI. Diabetes insipidus: Diagnosis and \ntreatment of a complex disease. Cleve Clin J Med 2006; 73:65\u201371.  \nhttps://doi.org/10.3949/ccjm.73.1.65.\n61. Adrogu\u00e9 HJ, Madias NE. Hypernatremia. N Engl J Med 2000; \n342:1493\u20139. https://doi.org/10.1056/NEJM200005183422006.\n62. Pfennig CL, Slovis CM. Sodium disorders in the emergency \ndepartment: A review of hyponatremia and hypernatremia. \nEmerg Med Pract 2012; 14:1\u201326. PMID: 23114652.\n63. Reynolds RM, Padfield P , Seckl JR. Disorders of sodium balance. \nBMJ 2006; 332:702\u20135. https://doi.org/10.1136/bmj.332.7543.702.\n64. Chanson P , Jedynak CP , Dabrowski G, Rohan J, Bouchama A, \nRohan-Chabot P , et al. Ultralow doses of vasopressin in the \nmanagement of diabetes insipidus. Crit Care Med 1987; 15:44\u20136.  \nhttps://doi.org/10.1097/00003246-198701000-00010.\n65.", "mimetype": "text/plain", "start_char_idx": 1178, "end_char_idx": 2279, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "d6489447-2c60-4546-82bb-5727e8008381": {"__data__": {"id_": "d6489447-2c60-4546-82bb-5727e8008381", "embedding": null, "metadata": {"page_label": "10", "file_name": "diabetes.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\diabetes.pdf", "file_type": "application/pdf", "file_size": 367943, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "7827c7e0-209d-4f3c-98cd-4e7e5502aaa8", "node_type": "4", "metadata": {"page_label": "10", "file_name": "diabetes.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\diabetes.pdf", "file_type": "application/pdf", "file_size": 367943, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "8649a668a9b7dd6413fc4b59deddce3eee5e59d569e0f992f2e45b4b7389363d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e4140117-03cc-4202-b9f9-fffa9720af1b", "node_type": "1", "metadata": {"page_label": "10", "file_name": "diabetes.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\diabetes.pdf", "file_type": "application/pdf", "file_size": 367943, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "ab0ea8fe4addfca8f519cbf1af27307ea6fb22d9711ebc95502d19012ba4018a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "66532eb0-3541-4668-876a-8fd4e0346f49", "node_type": "1", "metadata": {}, "hash": "862d5f7478e0c8101892fb6dcc619f5ca87db12dbd0fc4db4c48d38b911d3b69", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Crit Care Med 1987; 15:44\u20136.  \nhttps://doi.org/10.1097/00003246-198701000-00010.\n65. Andersson KE, Arner B. Effects of DDAVP , a synthetic analogue \nof vasopressin, in patients with cranial diabetes insipidus. Acta \nMed Scand 1972; 192:21\u20137. https://doi.org/10.1111/j.0954-682 \n0.1972.tb04772.x .\n66. Rad\u00f3 JP , Marosi J, Szende L, Borb\u00e9ly L, Tak\u00f3 J, Fischer J. The \nantidiuretic action of 1-deamino-8-D-arginine vasopressin \n(DDAVP) in man. Int J Clin Pharmacol Biopharm 1976; \n13:199\u2013209.\n67.  Rad\u00f3 JP , Marosi J, Fischer J, Tak\u00f3 J, Kiss N. Relationship between \nthe dose of 1-deamino-8-D-arginine vasopressin (DDAVP) and \nantidiuretic response in man. Endokrinologie 1975; 66:184\u2013195.\n68. Rad\u00f3 JP , Marosi J, Borb\u00e9ly L, Tak\u00f3 J. Individual differences in the \nantidiuretic response induced by single doses of 1-deamino-8-D- \narginine-vasopressin (DDAVP) in patients with pituitary diabetes  \ninsipidus. Int J Clin Pharmacol Biopharm 1976; 14:259\u201365. \n69. Czak\u00f3 L, Mezei G, L\u00e1szl\u00f3 FA. Treatment of diabetes insipidus \nwith 1-deamino-8-D-arginine-vasopressin. Acta Med Acad Sci \nHung 1975; 32:75\u201384.\n70.", "mimetype": "text/plain", "start_char_idx": 2195, "end_char_idx": 3297, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "66532eb0-3541-4668-876a-8fd4e0346f49": {"__data__": {"id_": "66532eb0-3541-4668-876a-8fd4e0346f49", "embedding": null, "metadata": {"page_label": "10", "file_name": "diabetes.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\diabetes.pdf", "file_type": "application/pdf", "file_size": 367943, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "7827c7e0-209d-4f3c-98cd-4e7e5502aaa8", "node_type": "4", "metadata": {"page_label": "10", "file_name": "diabetes.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\diabetes.pdf", "file_type": "application/pdf", "file_size": 367943, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "8649a668a9b7dd6413fc4b59deddce3eee5e59d569e0f992f2e45b4b7389363d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d6489447-2c60-4546-82bb-5727e8008381", "node_type": "1", "metadata": {"page_label": "10", "file_name": "diabetes.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\diabetes.pdf", "file_type": "application/pdf", "file_size": 367943, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "6194935d3efd0a09f6399d45a65cea572c5cfb6d7660bf20ba60cc88048b6540", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "71c79a8f-8287-4e48-a5d6-1ad1dabdc29a", "node_type": "1", "metadata": {}, "hash": "bb444d7fcbb2412982e345512e521b83b1b1772dd0ab58b220a8f0aa4be6df20", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Treatment of diabetes insipidus \nwith 1-deamino-8-D-arginine-vasopressin. Acta Med Acad Sci \nHung 1975; 32:75\u201384.\n70. Rad\u00f3 JP , Marosi J, Fischer J.Shortened duration of action of \n1-deamino-8-D-arginine-vasopressinn (DDAVP) in patients \nwith diabetes insipidus requiring high doses of peroral \nantidiuretic drugs. J Clin Pharmacol 1976; 16:518\u201324. \n71. Juul KV, Bichet DG, Norgaard JP . Desmopressin duration of \nantidiuretic action in patients with central diabetes insipidus. \nEndocrine 2011; 40:67\u201374. https://doi.org/10.1007/s12020-\n011-9492-z .\n72. Zerbe RL, Robertson GL. A comparison of plasma vasopressin \nmeasurements with a standard indirect test in the differential \ndiagnosis of polyuria. N Engl J Med 1981; 305:1539\u201346. https://\ndoi.org/10.1056/NEJM198112243052601.\n73. Kahn A, Brachet E, Blum D. Controlled fall in natremia and \nrisk of seizures in hypertonic dehydration. Intensive Care Med \n1979; 5:27\u201331. https://doi.org/10.1007/BF01738999.\n74. Thompson CJ, Burd JM, Baylis PH. Acute suppression of plasma \nvasopressin and thirst after drinking in hypernatremic humans. \nAm J Physiol 1987; 252:R1138\u201342. https://doi.org/10.1152/\najpregu.1987.252.6.R1138.\n75. Seckl JR, Williams TD, Lightman SL. Oral hypertonic saline causes  \ntransient fall of vasopressin in humans. Am J Physiol 1986; \n251:R214\u201317.", "mimetype": "text/plain", "start_char_idx": 3180, "end_char_idx": 4498, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "71c79a8f-8287-4e48-a5d6-1ad1dabdc29a": {"__data__": {"id_": "71c79a8f-8287-4e48-a5d6-1ad1dabdc29a", "embedding": null, "metadata": {"page_label": "10", "file_name": "diabetes.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\diabetes.pdf", "file_type": "application/pdf", "file_size": 367943, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "7827c7e0-209d-4f3c-98cd-4e7e5502aaa8", "node_type": "4", "metadata": {"page_label": "10", "file_name": "diabetes.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\diabetes.pdf", "file_type": "application/pdf", "file_size": 367943, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "8649a668a9b7dd6413fc4b59deddce3eee5e59d569e0f992f2e45b4b7389363d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "66532eb0-3541-4668-876a-8fd4e0346f49", "node_type": "1", "metadata": {"page_label": "10", "file_name": "diabetes.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\diabetes.pdf", "file_type": "application/pdf", "file_size": 367943, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "4d6d0dfd85b22af7c5e40112e7bea5ad7873045ab2591d58086c057924f30369", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "953758ae-18d0-4aab-8c51-e0867a21c2b5", "node_type": "1", "metadata": {}, "hash": "922603c96a59ef1b54870b4351453c11774f0c362ffa902e66eced2c50a0c131", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Seckl JR, Williams TD, Lightman SL. Oral hypertonic saline causes  \ntransient fall of vasopressin in humans. Am J Physiol 1986; \n251:R214\u201317. https://doi.org/10.1152/ajpregu.1986.251.2.R214.\n76. Kovacs L, Rittig S, Robertson GL. Effect of sustained antidiuretic \ntreatment on plasma sodium concentration and body water \nhomeostasis in healthy humans on ad libitum fluid intake. Clin \nRes 1992; 40:165A.\n77. Andersson KE, Arner B. Effects of DDAVP , a synthetic analogue \nof vasopressin, in patients with cranial diabetes insipidus. Acta \nMed Scand 1972; 192:21\u20137. https://doi.org/10.1111/j.0954-68 \n20.1972.tb04772.x .\n78. Aronsen AS, Andersson KE, Bergstrand CG, Mulder JL. Treatment  \nof diabetes insipidus in children with DDAVP , a synthetic \nanalogue of vasopressinn. Acta P\u00e6diat Scand 1973; 62:133\u201340. \nhttps://doi.org/10.1111/j.1651-2227.1973.tb08080.x .\n79. Becker DJ, Foley TP Jr.1-Deamino-8-D-arginine-vasopressinn \nin the treatment of central diabetes insipidus in childhood. J \nPediatr 1978; 92:1011\u201315. https://doi.org/10.1016/s0022-3476 \n(78)80389-8.\n80. Robinson AG. DDAVP in the treatment of central diabetes \ninsipidus. N Engl J Med 1976; 294:507\u201311. https://doi.org/10.10 \n56/NEJM197603042941001.\n81. Ward MK, Fraser TR. DDAVP in treatment of vasopressin-\nsensitive diabetes insipidus.", "mimetype": "text/plain", "start_char_idx": 4357, "end_char_idx": 5660, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "953758ae-18d0-4aab-8c51-e0867a21c2b5": {"__data__": {"id_": "953758ae-18d0-4aab-8c51-e0867a21c2b5", "embedding": null, "metadata": {"page_label": "10", "file_name": "diabetes.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\diabetes.pdf", "file_type": "application/pdf", "file_size": 367943, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "7827c7e0-209d-4f3c-98cd-4e7e5502aaa8", "node_type": "4", "metadata": {"page_label": "10", "file_name": "diabetes.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\diabetes.pdf", "file_type": "application/pdf", "file_size": 367943, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "8649a668a9b7dd6413fc4b59deddce3eee5e59d569e0f992f2e45b4b7389363d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "71c79a8f-8287-4e48-a5d6-1ad1dabdc29a", "node_type": "1", "metadata": {"page_label": "10", "file_name": "diabetes.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\diabetes.pdf", "file_type": "application/pdf", "file_size": 367943, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "c42f7a34af17d21f3fd6204bde10462da7b1e2e9740ce75f5bf3e38ea6465f31", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "752fdde1-5c2f-48e1-a8fd-049456f462ce", "node_type": "1", "metadata": {}, "hash": "66156d30f89f11d5e11b4289afeb5053d2ff55d97d54713b3ab552bcd6501737", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "https://doi.org/10.10 \n56/NEJM197603042941001.\n81. Ward MK, Fraser TR. DDAVP in treatment of vasopressin-\nsensitive diabetes insipidus. Br Med J 1974; 3:86\u20139. https://doi.\norg/10.1136/bmj.3.5923.86.\n82. Fjellestad-Paulsen A, H\u00f6glund P , Lundin S, Paulsen O. Pharma- \ncokinetics of 1-deamino-8-D-argininevasopressinn after various \nroutes of administration in health volunteers. Clin Endocrinol \n(Oxf ) 1993; 38:177\u201382. https://doi.org/10.1111/j.1365-2265.1993.\ntb00990.x .\n83. Westgren U, Wittstr\u00f6m C, Harris AS. Oral desmopressin in \ncentral diabetes insipidus. Arch Dis Child 1986; 61:247\u201350. \nhttps://doi.org/10.1136/adc.61.3.247.\n84. Rivkees SA, Dunbar N, Wilson TA. The management of central \ndiabetes insipidus in infancy: Desmopressin, low renal salt load \nformula, thiazide diuretics. J Pediatr Endocrinol Metab 2007; \n20:459\u201369. https://doi.org/10.1515/jpem.2007.20.4.459.\n85. \u00d8sterberg O, Balchen T, Riis A, Senderovitz T. Pharmacokinetics \nof desmopressin in children and adults using a new oral \nlyophilisate. Arch Dis Child 2006; 91:A33.\n86. Arima H, Oiso Y, Juul KV, N\u00f8rgaard JP . Efficacy and safety of \ndesmopressin orally disintegrating tablet in patients with central \ndiabetes insipidus: Results of a multicenter open-label dose-\ntitration study.", "mimetype": "text/plain", "start_char_idx": 5525, "end_char_idx": 6790, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "752fdde1-5c2f-48e1-a8fd-049456f462ce": {"__data__": {"id_": "752fdde1-5c2f-48e1-a8fd-049456f462ce", "embedding": null, "metadata": {"page_label": "10", "file_name": "diabetes.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\diabetes.pdf", "file_type": "application/pdf", "file_size": 367943, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "7827c7e0-209d-4f3c-98cd-4e7e5502aaa8", "node_type": "4", "metadata": {"page_label": "10", "file_name": "diabetes.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\diabetes.pdf", "file_type": "application/pdf", "file_size": 367943, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "8649a668a9b7dd6413fc4b59deddce3eee5e59d569e0f992f2e45b4b7389363d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "953758ae-18d0-4aab-8c51-e0867a21c2b5", "node_type": "1", "metadata": {"page_label": "10", "file_name": "diabetes.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\diabetes.pdf", "file_type": "application/pdf", "file_size": 367943, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "656486cb6d50f3e914b4dd90c936173c8a07d95de39f733f16e1b964094b2adb", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Efficacy and safety of \ndesmopressin orally disintegrating tablet in patients with central \ndiabetes insipidus: Results of a multicenter open-label dose-\ntitration study. Endocr J 2013; 60:1085\u201394. https://doi.org/10.15  \n07/endocrj.ej13-0165.\n87. Lehrnbecher T, Muller-Scholden J, Danhauser-Leistner I, Sorensen N,  \nvon Stockhausen HB. Perioperative fluid and electrolyte \nmanagement in children undergoing surgery for craniopharyn- \ngioma: A 10-year experience in a single institution. Childs Nerv \nSyst 1998; 14:276\u20139. https://doi.org/10.1007/s003810050224.\n88. McDonald JA, Martha PM, Kerrigan J, Clarke WL, Rogol AD, \nBlizzard RM. Treatment of the young child with postoperative \ncentral diabetes insipidus. Am J Dis Child 1989; 143:201\u20134. \nhttps://doi.org/10.1001/archpedi.1989.02150140095027.\n89. Gutmark-Little I, Repaske DR, Backeljauw PF. Efficacy and \nsafety of intranasal desmopressin acetate administered orally \nfor the management of infants with neurogenic diabetes \ninsipidus (DI). Endocrine Rev 2010; 31:P3\u2013324.", "mimetype": "text/plain", "start_char_idx": 6620, "end_char_idx": 7649, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "6a838443-b8b5-4cb7-a153-0a1ec754f796": {"__data__": {"id_": "6a838443-b8b5-4cb7-a153-0a1ec754f796", "embedding": null, "metadata": {"page_label": "11", "file_name": "diabetes.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\diabetes.pdf", "file_type": "application/pdf", "file_size": 367943, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "33045505-2c07-40e6-82b9-5f3306e83032", "node_type": "4", "metadata": {"page_label": "11", "file_name": "diabetes.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\diabetes.pdf", "file_type": "application/pdf", "file_size": 367943, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "e2c64b51c1fa408bfecb14973be1a6492b70524e5018fb271c3620e9e77de9cd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5be15974-4aa0-4328-abdd-2ab743e97e0b", "node_type": "1", "metadata": {}, "hash": "d51ce9dc5f0a512833c9c4d238f39c042245fb80829e9eb91bd2c615e95618ef", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Management of Diabetes Insipidus following Surgery for Pituitary and Suprasellar Tumours\n364 | SQU Medical Journal, August 2021, Volume 21, Issue 3\n90. Blanco EJ, Lane AH, Aijaz N, Blumberg D, Wilson TA. Use of \nsubcutaneous DDAVP in infants with central diabetes insipidus. \nJ Pediatr Endocrinol Metab 2006; 19:919\u201325. https://doi.org/1 \n0.1515/jpem.2006.19.7.919.\n91. Durr JA, Hoggard JG, Hunt JM, Schrier RW. Diabetes insipidus \nin pregnancy associated with abnormally high circulating \nvasopressinase activity. N Engl J Med 1987; 316:1070\u20134. \nhttps://doi.org/10.1056/NEJM198704233161707.\n92. Barron WM. Water metabolism and vasopressin secretion during \npregnancy. Baillieres Clin Obstet Gynaecol 1987; 1:853\u201371. \nhttps://doi.org/10.1016/s0950-3552(87)80038-x.\n93. Burrow GN, Wassenaar W, Robertson GL, Sehl H. DDAVP \ntreatment of diabetes insipidus during pregnancy and the \npostpartumm period. Acta Endocrinol (Copenh) 1981; 97:23\u20135. \nhttps://doi.org/10.1530/acta.0.0970023.\n94. Czernichow P . Treatment of diabetes insipidus. In: Argente J, \nEd. Diabetes Insipidus. Madrid, Spain: Editorial Justim, 2010. \nPp. 107\u2013112.\n95. Cuesta M, Hannon MJ, Thompson CJ. Adipsic diabetes \ninsipidus in adult patients. Pituitary 2017; 20:372\u201380.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1237, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "5be15974-4aa0-4328-abdd-2ab743e97e0b": {"__data__": {"id_": "5be15974-4aa0-4328-abdd-2ab743e97e0b", "embedding": null, "metadata": {"page_label": "11", "file_name": "diabetes.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\diabetes.pdf", "file_type": "application/pdf", "file_size": 367943, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "33045505-2c07-40e6-82b9-5f3306e83032", "node_type": "4", "metadata": {"page_label": "11", "file_name": "diabetes.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\diabetes.pdf", "file_type": "application/pdf", "file_size": 367943, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "e2c64b51c1fa408bfecb14973be1a6492b70524e5018fb271c3620e9e77de9cd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6a838443-b8b5-4cb7-a153-0a1ec754f796", "node_type": "1", "metadata": {"page_label": "11", "file_name": "diabetes.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\diabetes.pdf", "file_type": "application/pdf", "file_size": 367943, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "105b91f1577b72d2619515bd1c9e11b59a7b5ac7d5cb370184109bb863033279", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "107\u2013112.\n95. Cuesta M, Hannon MJ, Thompson CJ. Adipsic diabetes \ninsipidus in adult patients. Pituitary 2017; 20:372\u201380. https://\ndoi.org/10.1007/s11102-016-0784-4. \n96. Miljic D, Miljic P , Doknic M, Pekic S, Stojanovic M, Petakov M, \net al. Adipsic diabetes insipidus and venous thromboembolism \n(VTE): Recommendations for addressing its hypercoagulability. \nHormones (Athens) 2014; 13:420\u20133. https://doi.org/10.14310/\nhorm.2002.1496.\n97. Green RP , Landt M. Home sodium monitoring in patients with \ndiabetes insipidus. J Pediatr 2002; 141:618\u201324. https://doi.\norg/10.1067/mpd.2002.128544.\n98. Ball SG, Vaidja B, Baylis PH. Hypothalamic adipsic syndrome: \nDiagnosis and management. Clin endocrinol (Oxf ) 1997; \n47:405\u20139. https://doi.org/10.1046/j.1365-2265.1997.2591079.x.\n99. Crowley RK, Woods C, Fleming M, Rogers B, Behan LA, \nO'Sullivan EP , et al. Somnolence in adult craniopharyngioma \npatients is a common, heterogeneous condition that is \npotentially treatable. Clin Endocrinol (Oxf ) 2011; 74:750\u20135. \nhttps://doi.org/10.1111/j.1365-2265.2011.03993.x.", "mimetype": "text/plain", "start_char_idx": 1117, "end_char_idx": 2179, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "7866a12d-ea8e-4bda-a978-6372894c2c1b": {"__data__": {"id_": "7866a12d-ea8e-4bda-a978-6372894c2c1b", "embedding": null, "metadata": {"page_label": "1", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "dd91fae4-be27-449b-a248-277d07df1d2b", "node_type": "4", "metadata": {"page_label": "1", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "2fde571f99712701b13aceb6c2fa2fbae066b2fce62a4e995aadc8f077a92a52", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "16b8c2c7-c3a3-42c7-b179-2a778bbef49e", "node_type": "1", "metadata": {}, "hash": "78bae3295910666395c4c08ca80bddc6d32ee375c544ea6fbd490ae989d3db86", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Treatment algorithm for pulmonary arterial hypertension\nKelly M. Chin1, Sean P. Gaine2, Christian Gerges 3, Zhi-Cheng Jing 4, Stephen C. Mathai 5,\nYuichi Tamura 6, Vallerie V. McLaughlin7,8 and Olivier Sitbon 9,10\n1Division of Pulmonary and Critical Care Medicine, UT Southwestern, Dallas, TX, USA.2Department of Respiratory Medicine, National\nPulmonary Hypertension Unit, Mater Misericordiae University Hospital, Dublin, Ireland.3Division of Cardiology, Department of Internal\nMedicine II, Vienna General Hospital, Medical University of Vienna, Vienna, Austria. 4Department of Cardiology, Guangdong\nCardiovascular Institute, Guangdong Provincial People\u2019s Hospital, Guangdong Academy of Medical Sciences, Southern Medical University,\nGuangzhou, China. 5Division of Pulmonary and Critical Care Medicine, Johns Hopkins University, Baltimore, MD, USA.6Pulmonary\nHypertension Center, International University of Health and Welfare Mita Hospital, Tokyo, Japan.7Division of Cardiovascular Medicine,\nUniversity of Michigan, Ann Arbor, MI, USA.8Frankel Cardiovascular Center, Ann Arbor, MI, USA.9Department of Respiratory Medicine,\nH\u00f4pital Bic\u00eatre (AP-HP), Le Kremlin-Bic\u00eatre, France.10Universit\u00e9 Paris-Saclay, Le Kremlin-Bic\u00eatre, France.\nCorresponding author: Vallerie V. McLaughlin (vmclaugh@med.umich.edu)\nShareable abstract (@ERSpublications)\nIn this document from the 7th World Symposium on Pulmonary Hypertension, an updated\ntreatment algorithm is outlined. Medications targeting four pathways are now available, and initial\ncombination therapy with early and frequent reassessment is recommended.https://bit.ly/46ctth4\nCite this article as:Chin KM, Gaine SP, Gerges C,et al. Treatment algorithm for pulmonary arterial\nhypertension. Eur Respir J2024; 64: 2401325 [DOI: 10.1183/13993003.01325-2024].", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1796, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "16b8c2c7-c3a3-42c7-b179-2a778bbef49e": {"__data__": {"id_": "16b8c2c7-c3a3-42c7-b179-2a778bbef49e", "embedding": null, "metadata": {"page_label": "1", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "dd91fae4-be27-449b-a248-277d07df1d2b", "node_type": "4", "metadata": {"page_label": "1", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "2fde571f99712701b13aceb6c2fa2fbae066b2fce62a4e995aadc8f077a92a52", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7866a12d-ea8e-4bda-a978-6372894c2c1b", "node_type": "1", "metadata": {"page_label": "1", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "d9689373c3da71f1a1d77a102763c0414971a4b08ba236e1a03e4db5b6e9d0eb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "80afa5aa-912c-4fd0-bb49-05fc5a3c142d", "node_type": "1", "metadata": {}, "hash": "4eab86d2f8337b09526ac2b81abe39191395292fba5b56eef7f1ac8d80c3992c", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Treatment algorithm for pulmonary arterial\nhypertension. Eur Respir J2024; 64: 2401325 [DOI: 10.1183/13993003.01325-2024].\nAbstract\nPulmonary arterial hypertension leads to significant impairment in haemodynamics, right heart function,\nexercise capacity, quality of life and survival. Current therapies have mechanisms of action involving\nsignallingvia one of four pathways: endothelin-1, nitric oxide, prostacyclin and bone morphogenetic\nprotein/activin signalling. Efficacy has generally been greater with therapeutic combinations and with\nparenteral therapy compared with monotherapy or nonparenteral therapies, and maximal medical therapy is\nnow four-drug therapy. Lung transplantation remains an option for selected patients with an inadequate\nresponse to therapies.\nIntroduction\nMedications approved to treat pulmonary arterial hypertension (PAH) lead to improvement in functional\nclass, exercise capacity, haemodynamics, right heart function and brain natriuretic peptide (BNP)/\nN-terminal pro-BNP (NT-proBNP) levels, among others [1\u2013 3]. These benefits have been seen in clinical\ntrials across a wide range of PAH severities and across multiple PAH subgroups.\nCompared with monotherapy, larger improvements are seen with combination therapy and thus most\npatients with PAH are candidates for oral or oral plus parenteral combination therapy from the time of\ndiagnosis, along with early reassessment and escalation in therapy when indicated (figure 1).\nTrials utilising a time-to-clinical-worsening composite as a primary or secondary end-point have\ndemonstrated that PAH therapies also improve longer-term outcomes. Results have been driven most\nstrongly by reductions in PAH clinical worsening and in PAH-related hospitalisations, but in meta-analyses\na modest reduction in all-cause mortality has also been reported [4]. Indeed, survival from the time of\ndiagnosis appears to be improving in observational studies as well, although the median survival time\nremains <10 years [5, 6]. There remains a need for improved utilisation of existing therapies, particularly\nparenteral prostacyclin pathway agents (PPAs), as well as the targeting of novel therapeutic pathways.", "mimetype": "text/plain", "start_char_idx": 1674, "end_char_idx": 3851, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "80afa5aa-912c-4fd0-bb49-05fc5a3c142d": {"__data__": {"id_": "80afa5aa-912c-4fd0-bb49-05fc5a3c142d", "embedding": null, "metadata": {"page_label": "1", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "dd91fae4-be27-449b-a248-277d07df1d2b", "node_type": "4", "metadata": {"page_label": "1", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "2fde571f99712701b13aceb6c2fa2fbae066b2fce62a4e995aadc8f077a92a52", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "16b8c2c7-c3a3-42c7-b179-2a778bbef49e", "node_type": "1", "metadata": {"page_label": "1", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "314dd22ca1aae75718c322d24aa5d39eabf8f590e88b147cac056b537371cf22", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "There remains a need for improved utilisation of existing therapies, particularly\nparenteral prostacyclin pathway agents (PPAs), as well as the targeting of novel therapeutic pathways.\nThe addition of sotatercept, an activin signalling inhibitor, to the treatment armamentarium has brought\nsignificant optimism, as it is the first treatment to act on a completely novel pathway in nearly two decades\n[7, 8], and four-pathway drug combination therapy is now an option (figure 2). Longer-term studies are\nstill underway and will be important in providing a better understanding of the overall benefits and safety\nprofile of this medication.\nCopyright \u00a9The authors 2024.\nThis version is distributed under\nthe terms of the Creative\nCommons Attribution\nNon-Commercial Licence 4.0.\nFor commercial reproduction\nrights and permissions contact\npermissions@ersnet.org\nThis article has an editorial\ncommentary:\nhttps://doi.org/10.1183/\n13993003.01222-2024\nReceived: 9 July 2024\nAccepted: 9 July 2024\nhttps://doi.org/10.1183/13993003.01325-2024 Eur Respir J 2024; 64: 2401325\nEUROPEAN RESPIRATORY JOURNAL\nTASK FORCE REPORT\nK.M. CHIN ET AL.", "mimetype": "text/plain", "start_char_idx": 3667, "end_char_idx": 4794, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "71f6c3d3-5174-4810-b031-f8452bf8f1d9": {"__data__": {"id_": "71f6c3d3-5174-4810-b031-f8452bf8f1d9", "embedding": null, "metadata": {"page_label": "2", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "e96eecb7-db70-42f3-9855-5a5d46be4548", "node_type": "4", "metadata": {"page_label": "2", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "0011b4023ea45d4ec782b7cabd1ed91f834431bde0e0e2663f4443525222d6c8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "13cc55f7-6d02-4e6a-adc1-876b28b1978f", "node_type": "1", "metadata": {}, "hash": "32882a7d2d01127dde35c919736fb3e64cb48bf0c342cc7f53bde53dddf6a8bb", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "In this expert consensus document from the World Symposium on Pulmonary Hypertension (WSPH), we\naim to:\n1) outline overall treatment recommendations for PAH (figure 1);\n2) provide recommendations for specific PAH subgroups;\n3) review clinical trials completed since the last WSPH in 2018 (table 1 [7\u2013 17]);\n4) review medication profiles (table 2), and discuss transitions from one medication to another;\n5) discuss knowledge gaps and proposals for future research.\nTreatment goals and risk stratification\nA wide range of prognostic measures have been identified in PAH, with functional class, 6-min walk\ndistance (6MWD), NT-proBNP, right ventricular imaging and haemodynamics among the strongest.\nPatients achieving a lower-risk status based on these measures have better outcomes than patients who fail\nto do so [37], and PAH treatment guidelines have traditionally utilised these severity measures as a means\nfor choosing PAH therapies, with a goal of achieving a low-risk status.\nWhile this approach has made sense based on both the order in which PAH therapies were discovered as\nwell as the inclusion criteria and trial design for most early studies where only patients of certain\nfunctional classes were included, achieving a low-risk status in the short-term has not been found to be a\nstrong surrogate for longer-term clinical worsening outcomes [38].\nIt is therefore likely that alternative strategies will be needed in the future, optimally determined\nempirically and through randomised studies to identify optimal treatment strategies.\nWhat future treatment algorithms may look like remains to be seen: will early or upfront initiation of three\nor even four medications be shown to be beneficial, leading to a strategy similar to guideline directed\nmedical therapy in heart failure [39]? Or will a targeted stepwise approach be recommended, perhaps with\nTherapy for group 1 PAH including IPAH, HPAH, DT-PAH and CTD-PAHa\nNot high riskc\nCombination ERA + PDE-5i\nIntermediate-low riske\nAdd activin-signalling \ninhibitor, oral or \ninhaled PPA\nCan consider switch \nPDE-5i to sGCS\nIntermediate-high riskf\nAdd i.v./s.c.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2123, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "13cc55f7-6d02-4e6a-adc1-876b28b1978f": {"__data__": {"id_": "13cc55f7-6d02-4e6a-adc1-876b28b1978f", "embedding": null, "metadata": {"page_label": "2", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "e96eecb7-db70-42f3-9855-5a5d46be4548", "node_type": "4", "metadata": {"page_label": "2", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "0011b4023ea45d4ec782b7cabd1ed91f834431bde0e0e2663f4443525222d6c8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "71f6c3d3-5174-4810-b031-f8452bf8f1d9", "node_type": "1", "metadata": {"page_label": "2", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "f65d11fd9f80e4b20b631bd8e6cea21afa14645f1575ef0d02e9d87d5f71b613", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "654a5b40-f7a2-4739-bfc9-7c34c1940a93", "node_type": "1", "metadata": {}, "hash": "9f0453b80059fe3ad2ea890cedf9a26cdcb4c9de9766706b825b5d74bf37c8c0", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "PPA or \nactivin-signalling \ninhibitor\nLow riskd\nContinue initial \ntherapy\nHighf\nAdd i.v./s.c. PPA \n(1st choice if not on) \nor activin-signalling \ninhibitor\nHigh riskc,f\nCombination i.v./s.c. PPA, ERA, PDE-5i\nInitial risk assessmentb\nFirst follow-up risk reassessment at 3\u20134 months \nAnd repeated frequentlyb\nTreatment algorithm key points\nPersistent intermediate-high or high\nMaximal Rx: 4-drug i.v./s.c. PPA, ERA, PDE-5i \nor sGCS, activin-signalling inhibitor \nLung transplant evaluation\na. The treatment algorithm is intended for patients with  \n confirmed group 1 PAH (phenotypically clear-cut,   \n including mPAP \u226525 mmHg and PVR >3 Wood Units  \n and no significant response on acute vasoreactivity  \n testing).  See text for treatment in PAH with complex  \n phenotypes.\nb.  Risk assessment should be performed at baseline,   \n within 3\u20134 months and periodically thereafter, and   \n using FC, 6MWD and natriuretic peptides as a part of  \n a validated risk calculator.  Haemodynamics, RV   \n imaging and other measures should be used to   \n supplement risk assessment.\nc.  Initial triple therapy with an  i.v./s.c. PPA is   \n recommended in high-risk patients and may be   \n considered in non-high risk with severe \n haemodynamics and/or poor RV function.\nd.  Most low-risk patients at follow-up should continue  \n initial therapy.\ne. Clinical trials with oral and inhaled treprostinil   \n included only patients on monotherapy, while   \n studies of selexipag and sotarcept included patients  \n on combination therapy. \nf.  Transplant referral  should be considered for select  \n high-risk patients at diagnosis, and for \n intermediate-high and high-risk patients at first or   \n subsequent follow-up.\nFIGURE 1 Treatment algorithm.", "mimetype": "text/plain", "start_char_idx": 2124, "end_char_idx": 3857, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "654a5b40-f7a2-4739-bfc9-7c34c1940a93": {"__data__": {"id_": "654a5b40-f7a2-4739-bfc9-7c34c1940a93", "embedding": null, "metadata": {"page_label": "2", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "e96eecb7-db70-42f3-9855-5a5d46be4548", "node_type": "4", "metadata": {"page_label": "2", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "0011b4023ea45d4ec782b7cabd1ed91f834431bde0e0e2663f4443525222d6c8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "13cc55f7-6d02-4e6a-adc1-876b28b1978f", "node_type": "1", "metadata": {"page_label": "2", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "dbccbb2524125e8b31f0738352d60524016aeb8c72493cbe181d2a22f7a4b420", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "f.  Transplant referral  should be considered for select  \n high-risk patients at diagnosis, and for \n intermediate-high and high-risk patients at first or   \n subsequent follow-up.\nFIGURE 1 Treatment algorithm. PAH: pulmonary arterial hypertension; IPAH: idiopathic PAH; HPAH: hereditary PAH; DT: drug and toxin; CTD:\nconnective tissue disease; ERA: endothelin-1 receptor antagonist; PDE-5i: phosphodiesterase-5 inhibitor;i.v.: intravenous; s.c.: subcutaneous; PPA:\nprostacyclin pathway agent; sGCS: soluble guanylyl cyclase stimulator; Rx: prescription; mPAP: mean pulmonary artery pressure; PVR: pulmonary\nvascular resistance; FC: functional class; 6MWD: 6-min walk distance; RV: right ventricle.\nhttps://doi.org/10.1183/13993003.01325-2024 2\nEUROPEAN RESPIRATORY JOURNAL 7TH WORLD SYMPOSIUM ON PULMONARY HYPERTENSION | K.M. CHIN ET AL.", "mimetype": "text/plain", "start_char_idx": 3646, "end_char_idx": 4485, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "de3de816-f2c3-4703-8b4e-f4550c230a41": {"__data__": {"id_": "de3de816-f2c3-4703-8b4e-f4550c230a41", "embedding": null, "metadata": {"page_label": "3", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "1182aac5-628f-4dfc-8301-7bcdceca52b4", "node_type": "4", "metadata": {"page_label": "3", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "0eae57b0a4c45206d1a733535c646499e6085bcf608363f965acd11d6cc5cf64", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5a140d87-0202-43ed-a33d-d451e6603d91", "node_type": "1", "metadata": {}, "hash": "6c8971f55c7962e3107a40f3c19f936cd75a95b1caa1273e56a7d5eca8f3703c", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "alternative goals such as normalisation or near-normalisation of mean pulmonary artery pressure (mPAP)\nand pulmonary vascular resistance (PVR)?\nAt the present time, we lack evidence to support either of these approaches. Indeed, initial triple oral\ntherapy was found not to be superior in the TRITON study, which evaluated combination therapy with\ntadalafil, macitentan, and selexipagversus tadalafil, macitentan and placebo [9]. Continued use of a\npredominantly risk-based treatment approach is therefore recommended, but with the anticipation that this\nwill likely change as additional studies are completed.\nDetails on risk stratification can be found in the WSPH task force article on PAH risk stratification\nand treatment goals [40]. In general, recommendations are for initial treatment based on stratification as\nhighversus not high risk, while beginning at first follow-up a \u201cfour-tier\u201d approach is recommended,\nstratifying patients into low risk, intermediate-low, intermediate-high and high risk based on risk\ncalculators. The most commonly utilised include those developed from the Registry to Evaluate Early and\nLong-term PAH Disease Management (REVEAL registry), including REVEAL 2.0 and REVEAL lite\n2.0 [41], and the European Society of Cardiology (ESC)/European Respiratory Society (ERS) calculator,\nstudied with slight variations across multiple cohorts [42\u2013 46]. Noninvasive prognostic measures included\nin all the commonly used risk calculators include functional class, 6MWD and BNP or NT-proBNP\nlevels. Patients with good results on all three measures have excellent 1-year outcomes and these\nresults can be utilised as a core component in decisions regarding PAH medical therapies. However,\noptimal risk reassessment for making treatment decisions requires other measures including serial cardiac\nimaging and haemodynamics, particularly when considering major treatment changes. These measures are\nimportant in order to more fully characterise overall disease status and because factors including age,\ncomorbidities, musculoskeletal disease and other factors beyond PAH severity can also affect the\nnoninvasive results.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2140, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "5a140d87-0202-43ed-a33d-d451e6603d91": {"__data__": {"id_": "5a140d87-0202-43ed-a33d-d451e6603d91", "embedding": null, "metadata": {"page_label": "3", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "1182aac5-628f-4dfc-8301-7bcdceca52b4", "node_type": "4", "metadata": {"page_label": "3", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "0eae57b0a4c45206d1a733535c646499e6085bcf608363f965acd11d6cc5cf64", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "de3de816-f2c3-4703-8b4e-f4550c230a41", "node_type": "1", "metadata": {"page_label": "3", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "0c16d158711333115cc693dab5bccd9c37970d0dda9edc790e5f4f1373aea0ba", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c5bcad1f-9701-4136-8f47-f3a809c7d7d2", "node_type": "1", "metadata": {}, "hash": "2f1e294df97e5e2d70c5f768bfdae45b65d4d99ba58b26daa4a685a9620deb85", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "These measures are\nimportant in order to more fully characterise overall disease status and because factors including age,\ncomorbidities, musculoskeletal disease and other factors beyond PAH severity can also affect the\nnoninvasive results.\nEndothelin\npathway\nNitric oxide\npathway\nProstacyclin\npathway\nActivin/BMP\npathway\nNO PGI2 ActivinEndothelin-1\nPromotes vasodilation and has\nantiproliferative effects\nSmooth \nmuscle cells\nEndothelial\ncells\nRebalances pro-/antiproliferative\nsignalling\n#\nERA\nPDE-5i\nPPAs Activin signalling\ninhibitors (scavenge)sGC\nstimulatorERA\nsGC\ncGMP GMP\nPDE-5ET-B\nreceptorET-A\nreceptor\nALK4/5/7 and \nActRIIA/B\nmultiple\ncAMP\nIP receptor BMPRII and\nALK1/2/3/6\nFIGURE 2 Pulmonary arterial hypertension (PAH) therapies work through four major pathways: endothelin-1 receptor antagonists (ERAs) block the\nendothelin (ET)-1 receptor. Phosphodiesterase-5 inhibitors (PDE-5i) and soluble guanylyl cyclase (sGC) stimulators increase signalling in the nitric\noxide (NO) and cyclic GMP (cGMP) pathway, resulting in increased cGMP levels, and prostacyclin (PGI2) and other prostacyclin pathway agents\n(PPAs) bind the prostacyclin receptor (IP receptor), promoting the production of cAMP, leading to vasodilation and inhibiting vascular cell growth.\nSotatercept, a novel biologic agent targeting the transforming growth factor-\u03b2 superfamily, acts as a ligand trap for activins and related growth\nfactors. This helps rebalance growth-promoting and growth-inhibiting signalling pathways, with multiple downstream effects. Signalling is showna s\nproceeding from endothelial cell to smooth muscle cell for simplicity, but is bidirectional.", "mimetype": "text/plain", "start_char_idx": 1900, "end_char_idx": 3547, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "c5bcad1f-9701-4136-8f47-f3a809c7d7d2": {"__data__": {"id_": "c5bcad1f-9701-4136-8f47-f3a809c7d7d2", "embedding": null, "metadata": {"page_label": "3", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "1182aac5-628f-4dfc-8301-7bcdceca52b4", "node_type": "4", "metadata": {"page_label": "3", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "0eae57b0a4c45206d1a733535c646499e6085bcf608363f965acd11d6cc5cf64", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5a140d87-0202-43ed-a33d-d451e6603d91", "node_type": "1", "metadata": {"page_label": "3", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "7ca700db2ac6b4d26487cea82a25170ea514a6ebcc2b73cdb06cb1aa45888292", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "This helps rebalance growth-promoting and growth-inhibiting signalling pathways, with multiple downstream effects. Signalling is showna s\nproceeding from endothelial cell to smooth muscle cell for simplicity, but is bidirectional. BMPR: bone morphogenetic protein receptor; ALK:\nanaplastic lymphocyte kinase; ActR: activin receptor.#: in addition, signalling mediators also originate from multiple other cell types, particularly\nfor activin.\nhttps://doi.org/10.1183/13993003.01325-2024 3\nEUROPEAN RESPIRATORY JOURNAL 7TH WORLD SYMPOSIUM ON PULMONARY HYPERTENSION | K.M. CHIN ET AL.", "mimetype": "text/plain", "start_char_idx": 3317, "end_char_idx": 3898, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "3846a556-2d32-4516-a106-3072212efb6c": {"__data__": {"id_": "3846a556-2d32-4516-a106-3072212efb6c", "embedding": null, "metadata": {"page_label": "4", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "1c377ee8-1469-4e10-b0b8-ba80ff296a3a", "node_type": "4", "metadata": {"page_label": "4", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "7ac508df555fe445bf10002ff518d4dbdb107418e4b327746880f7f06e9ed19c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d598ef87-fae1-4432-a1fe-21317eeb9186", "node_type": "1", "metadata": {}, "hash": "b7c62136c80276ab55c5defe2a93cf2570757234de8965dc636e3eff44008f1f", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Supportive measures\nSupportive measures recommended for PAH patients are summarised in table 3 [47\u2013 53]. Although no\nmajor new supportive care recommendations are made when compared to the most recent WSPH and ESC/\nERS PAH guidelines [47, 48], attention to these measures remains important. In particular, female patients\nof childbearing potential should be offered highly effective birth control, and recommendations against\npregnancy for most patients are maintained, due to unacceptably high maternal risk in PAH; see also\npregnancy recommendations in the WSPH article on PAH management in special conditions [54]. As\ngeneral healthcare measures, all PAH patients should receive vaccinations, with particular attention to\nrespiratory pathogens including influenza,Streptococcus pneumoniae and severe acute respiratory\nsyndrome coronavirus 2 [47], and vaccination against respiratory syncytial virus should be recommended\nTABLE 1 Key clinical trials with approved pulmonary arterial hypertension (PAH) medications since the 6th World Symposium on Pulmonary\nHypertension in 2018\nAetiology\nSubjects n\nGroups Weeks\nn\nPrimary\nend-point\nPrimary\nend-point results\n(95% CI)\nPositive\nprimary\nend-point\nOther end-points\nmet\nInitial combination therapy (all or majority)\nTRITON [9] PAH\n247\nMacitentan, tadalafil,\nselexipag versus\nmacitentan, tadalafil,\nplacebo\n26 PVR GMR: 0.96 (0.86 \u2013 1.07) No NA\nA DUE [10] PAH\n187\nMacitentan + tadalafil\nFDC versus macitentan\nor tadalafil#\n16 PVR GMR: macitentan +\ntadalafil versus\nmacitentan:\n0.71 (0.61\u2013 0.82)\nGMR: macitenan +\ntadalafil versus tadalafil:\n0.72 (0.64\u2013 0.8)\nYes NT-proBNP\nSequential combination therapy\nFREEDOM-EV [11] PAH\n690\nOral treprostinilversus\nplacebo\nNA TTCW HR: 0.74 (0.56 \u2013 0.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1730, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "d598ef87-fae1-4432-a1fe-21317eeb9186": {"__data__": {"id_": "d598ef87-fae1-4432-a1fe-21317eeb9186", "embedding": null, "metadata": {"page_label": "4", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "1c377ee8-1469-4e10-b0b8-ba80ff296a3a", "node_type": "4", "metadata": {"page_label": "4", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "7ac508df555fe445bf10002ff518d4dbdb107418e4b327746880f7f06e9ed19c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3846a556-2d32-4516-a106-3072212efb6c", "node_type": "1", "metadata": {"page_label": "4", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "fa1bb4f0988e2ecbcf8763f58c5e64b0d8ac0d6e3a41e3589fa9a3cf70c98345", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "27237d82-84ff-4a1b-b944-f5fafa775657", "node_type": "1", "metadata": {}, "hash": "ade92494093d56990f42cecbab01e24045a62f92fa03d1c602f96d2d631b3a5c", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "74 (0.56 \u2013 0.97) Yes FC, Borg\ndyspnoea score,\nNT-proBNP\nNovel therapies\nPULSAR [7, 12] PAH\n106\nSotatercept 0.3 mg,\n0.7 mg, placebo\n24 PVR LSM: 0.3 mg \u2212145.8\n(\u2212241.0\u2013 \u221250.6), 0.7 mg\n\u2212239.5 (\u2212329.3\u2013 \u2212149.7)\nYes 6MWD,\nNT-proBNP\nSTELLAR [8] PAH\n323\nSotatercept versus\nplacebo\n24 Walk HLE: 40.8 (27.5 \u2013 54.1) m Yes NT-proBNP, FC,\nTTCW, others\nSpecific subgroups\nPORTICO [13] PoPH\n85\nMacitentan versus\nplacebo\n12 PVR GMR: 0.65 (0.0.59 \u2013 0.72) Yes mPAP, cardiac\nindex\nMAESTRO [14] Eisenmenger\nsyndrome\n226\nMacitentan versus\nplacebo\n16 Walk \u22124.7 (\u221222.8\u2013 13.5) m No NA\nNew end-points\nREPLACE [15] PAH\n226\nOpen-label riociguat\nversus continued\nPDE-5i\n24 Clinical\nimprovement\nOR: 2.78 (1.53\u2013 5.06) Yes Clinical\nworsening events\nTRACE [16] PAH\n108\nSelexipag versus\nplacebo\n24 Actigraphy 3 primary end-points, no\ndifference (time, steps)\nNo NA\nAFFILIATE [17] PAH\n385\nSildenafil 5, 20, 80 mg\nthree times daily\nNA Mortality 5 mg\nversus 80 mg\n(noninferiority)\nMortality 80 mgversus\n5 mg: HR 0.51 (99.7% CI\n0.22\u2013 1.21)\nYes\u00b6 80 mg superior to\n5 mg for TTCW,", "mimetype": "text/plain", "start_char_idx": 1717, "end_char_idx": 2756, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "27237d82-84ff-4a1b-b944-f5fafa775657": {"__data__": {"id_": "27237d82-84ff-4a1b-b944-f5fafa775657", "embedding": null, "metadata": {"page_label": "4", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "1c377ee8-1469-4e10-b0b8-ba80ff296a3a", "node_type": "4", "metadata": {"page_label": "4", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "7ac508df555fe445bf10002ff518d4dbdb107418e4b327746880f7f06e9ed19c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d598ef87-fae1-4432-a1fe-21317eeb9186", "node_type": "1", "metadata": {"page_label": "4", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "d3e7171326ae83264cca327b344ffcfa0b1f3b5bdac5b7fc7e24e57e81670642", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "51 (99.7% CI\n0.22\u2013 1.21)\nYes\u00b6 80 mg superior to\n5 mg for TTCW,\n6MWD\nPVR: pulmonary vascular resistance; GMR: geometric mean ratio; NA: not applicable; FDC: fixed-dose combination (of macitentan and tadalafil);\nNT-proBNP: N-terminal pro-brain natriuretic peptide; TTCW: time to clinical worsening; HR: hazard ratio; FC: functional class; LSM: least-squares\nmean; 6MWD: 6-min walk distance, HLE: Hodges\u2013 Lehmann estimate; PoPH: portopulmonary hypertension; mPAP: mean pulmonary artery pressure;\nPDE-5i: phosphodiesterase-5 inhibitor. #: in A DUE, the macitentan + tadalafil comparison groups were 1) former treatment-na\u00efve or endothelin-1\nreceptor antagonist (ERA) patients, for the comparisonversus macitentan and 2) former treatment-na\u00efve or PDE-5i patients, for the comparison\nversus tadalafil. \u00b6: the AFFILIATE study met its primary end-point of noninferiority between sildenafil 80 mg three times daily and 5 mg three times\ndaily on mortality, based on prespecified noninferiority thresholds. However, the study was halted early because of the numeric imbalance in\nmortality (26.4%, 19.5% and 14.8% in the 5 mg, 20 mg and 80 mg groups, respectively).\nhttps://doi.org/10.1183/13993003.01325-2024 4\nEUROPEAN RESPIRATORY JOURNAL 7TH WORLD SYMPOSIUM ON PULMONARY HYPERTENSION | K.M. CHIN ET AL.", "mimetype": "text/plain", "start_char_idx": 2694, "end_char_idx": 3987, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "d5d4676e-b888-4b05-ba77-945f806a0550": {"__data__": {"id_": "d5d4676e-b888-4b05-ba77-945f806a0550", "embedding": null, "metadata": {"page_label": "5", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "791a0f49-b547-4d2a-9f91-edfdf60f37bb", "node_type": "4", "metadata": {"page_label": "5", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "2f087b04adce9e1a72454271e19b7b02e699740f6adca79e1fa45341a828218c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e023cf11-7e7a-43a2-8d7b-ec64206ea261", "node_type": "1", "metadata": {}, "hash": "ac391ae071165a2f05c595bf66ca5839692869c57cb5589e23173a9c1140f38c", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "in patients aged >60 years and can be considered in PAH in general [49]. Data from randomised controlled\nclinical trials (RCTs) on anticoagulation in PAH are lacking and available data derived from observational\nstudies and registries have demonstrated conflicting results regarding efficacy in idiopathic (IPAH),\nhereditary (HPAH) or drug- or toxin-induced (DT)-PAH [55\u2013 58]. Therefore, anticoagulation is not\ngenerally recommended but may be considered on an individual basis [47]. In contrast, registry data have\nmore consistently suggested an absence of benefit and probable harm with anticoagulation in CTD-PAH,\nTABLE 2 Medications for pulmonary arterial hypertension\nMedications Common adverse reactions Other important information\nOral medications\nPDE-5i [18\u2013 21] Sildenafil, tadalafil Headache\nFlushing\nDyspepsia\nEpistaxis\nRare loss of vision or hearing\nAvoid with nitrates, riociguat\nGuanylyl cyclase\nstimulators [22]\nRiociguat Headache\nDyspepsia\nDizziness\nHypotension\nAvoid in pregnancy#, avoid with\nnitrates, PDE-5i\nMonitor for hypotension; may\nrequire dose adjustment based on\nsystemic SBP\nEndothelin-1\nreceptor antagonists\n[21, 23\u2013 27]\nAmbrisentan,\nbosentan,\nmacitentan\nPeripheral oedema\nNasal congestion\nAnaemia\u00b6\nAvoid in pregnancy#, monitor\nhaemoglobin (all), liver function\n(monthly for bosentan, as clinically\nindicated for others)\nProstacyclin receptor\nagonists [28]\nSelexipag Prostanoid-type AEs + Data on selexipag in pregnancy are\nnot available\nProstanoids, p.o.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1483, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "e023cf11-7e7a-43a2-8d7b-ec64206ea261": {"__data__": {"id_": "e023cf11-7e7a-43a2-8d7b-ec64206ea261", "embedding": null, "metadata": {"page_label": "5", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "791a0f49-b547-4d2a-9f91-edfdf60f37bb", "node_type": "4", "metadata": {"page_label": "5", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "2f087b04adce9e1a72454271e19b7b02e699740f6adca79e1fa45341a828218c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d5d4676e-b888-4b05-ba77-945f806a0550", "node_type": "1", "metadata": {"page_label": "5", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "f9973cf4ac3efd956238281c906bc36a5cb19bad50e7c89a8909301a7c3356fa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "92648530-da59-40b6-82f1-4e7f40c3ff41", "node_type": "1", "metadata": {}, "hash": "ed9ce3856d2083b675359864967c0fbcedbbed52961dc2042a8ce5af6a549061", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "[11, 29\u2013 32]\nTreprostinil,\nberaprost\nProstanoid-type AEs+\nInhaled medications\nProstanoids, inhaled\n[33, 34]\nIloprost, treprostinil Cough\nProstanoid-type AEs+\nParenteral medications\nProstanoids, parenteral\n[35, 36]\nEpoprostenol\n(i.v.), treprostinil\n(i.v., s.c.)\nProstanoid-type AEs+ Sudden discontinuation of\nparenteral prostanoids can be\nlife-threatening\nActivin-signalling\ninhibitor [7, 8]\nSotatercept (s.c.) Headache\nDiarrhoea\nNosebleed\nBleeding events\nTelangiectasia\nAvoid in pregnancy#; potential risk\nof reduced future fertility based on\nanimal studies; monitor for\nthrombocytopenia and increased\nhaemoglobin for first five doses\nand periodically\nPDE-5i: phosphodiesterase-5 inhibitor; SBP: systolic blood pressure; AE: adverse events;i.v.: intravenous; s.c.:\nsubcutaneous. #: highly reliable contraception and monthly pregnancy testing required for all individuals of\nchildbearing potential due to risk of teratogenicity; \u00b6: while adverse reactions to endothelin-1 receptor\nantagonists tend to be class effects, there is some variability and switching within the same class can be\nconsidered; +: prostanoid-type AEs include flushing, headache, jaw pain, nausea/vomiting, diarrhoea.\nTABLE 3 Recommended supportive measures [47\u2013 49]\nSupervised exercise training\nPsychological support\nImmunisation against SARS-CoV-2, influenza,Streptococcus pneumoniaeand consider vaccination against RSV\nDiuretic treatment in patients with fluid retention\nContinuous LTOT when arterial blood oxygen pressure is consistently <8 kPa (60 mmHg)\nCorrection of iron status in patients with iron-deficiency anaemia\nAdvise against pregnancy\nClear contraceptive advice\nPre-transplant counselling\nSARS-CoV-2: severe acute respiratory syndrome coronavirus 2; RSV: respiratory syncytial virus; LTOT: long-term\noxygen therapy.", "mimetype": "text/plain", "start_char_idx": 1484, "end_char_idx": 3285, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "92648530-da59-40b6-82f1-4e7f40c3ff41": {"__data__": {"id_": "92648530-da59-40b6-82f1-4e7f40c3ff41", "embedding": null, "metadata": {"page_label": "5", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "791a0f49-b547-4d2a-9f91-edfdf60f37bb", "node_type": "4", "metadata": {"page_label": "5", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "2f087b04adce9e1a72454271e19b7b02e699740f6adca79e1fa45341a828218c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e023cf11-7e7a-43a2-8d7b-ec64206ea261", "node_type": "1", "metadata": {"page_label": "5", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "a2bdb74b9365227f8116d89fe4bb5412bf970be83d4ba3de6428650e283e229e", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "https://doi.org/10.1183/13993003.01325-2024 5\nEUROPEAN RESPIRATORY JOURNAL 7TH WORLD SYMPOSIUM ON PULMONARY HYPERTENSION | K.M. CHIN ET AL.", "mimetype": "text/plain", "start_char_idx": 3286, "end_char_idx": 3425, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "497852dc-ae34-4097-bd60-8f9def2d1b94": {"__data__": {"id_": "497852dc-ae34-4097-bd60-8f9def2d1b94", "embedding": null, "metadata": {"page_label": "6", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "10a724cc-bf62-43cb-92a1-a06be3357109", "node_type": "4", "metadata": {"page_label": "6", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "a9cccba29496e0881b90828155a3f9dd72e742423230030fc6e9c20f99302116", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4e01d8e4-5747-4590-9030-b053b1624161", "node_type": "1", "metadata": {}, "hash": "57ac2d9ec1182438ce151ddbdf3ecbb63be2738e7e3cacbaa2ce52c8f9930f53", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "and its routine use is not recommended [47]. Finally, pre-transplant counselling on issues such as weight\noptimisation, avoidance of tobacco and illicit drugs, and attention to treatment of comorbidities is\nrecommended, in order to ensure potential future barriers to transplant are addressed [59].\nVasoreactivity and calcium channel blockers\nIt is recommended that patients with IPAH, HPAH or DT-PAH undergo acute vasoreactivity testing during\nthe index right heart catheterisation in order to identify patients who should be treated with calcium channel\nblockers (CCBs). Acute vasoreactivity is defined by a decrease of the mPAP by\u2a7e10 mmHg to reach an\nabsolute mPAP <40 mmHg, without a decrease in cardiac output [47]. A recent multicentre study evaluating\nacute vasoresponders has found that patients meeting these haemodynamic criteria plus having a large\nimprovement in pulmonary arterial compliance were more likely to have a long-term response, but we do not\nrecommend a change in the acute vasoresponder criteria at this time. Significant heterogeneity in long-term\nresponse was also found in this study, emphasising the need for early comprehensive risk-reassessment at 3\u2013\n4 months [60]. CCBs should be initiated at a low doses followed by uptitration based on overall response\nincluding haemodynamic measures; to achieve an optimal response, high doses may be required. Treatment\ngoals include a low-risk profile on noninvasive testing and near normalisation in haemodynamics. Former\nCCB responders should be managed as per the standard (nonvasodilator) PAH algorithm; whether to\ndiscontinue CCBs is not well studied.\nPatients with PAH and mPAP 21\u2013 24 mmHg and/or PVR <3 Wood Units\nThe 6th WSPH recommended lowering the mPAP threshold for the diagnosis of PH from\u2a7e25 mmHg to\n>20 mmHg [61]. Subsequently, the ESC/ERS guidelines recommended lowering the threshold for\nabnormal from >3 Wood Units (WU) to >2 WU [47].", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1923, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "4e01d8e4-5747-4590-9030-b053b1624161": {"__data__": {"id_": "4e01d8e4-5747-4590-9030-b053b1624161", "embedding": null, "metadata": {"page_label": "6", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "10a724cc-bf62-43cb-92a1-a06be3357109", "node_type": "4", "metadata": {"page_label": "6", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "a9cccba29496e0881b90828155a3f9dd72e742423230030fc6e9c20f99302116", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "497852dc-ae34-4097-bd60-8f9def2d1b94", "node_type": "1", "metadata": {"page_label": "6", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "262ba6906e46c97862c4f58b3cd07e093eebf519cc4c71f6cb1e9fa37bb27230", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "59f7dca9-88f5-457f-8c8b-5a0e08c9f925", "node_type": "1", "metadata": {}, "hash": "20d62f4fe3c924d22568e47f6c881c7b20f3701abb7d0c387a6c275c070caff0", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Subsequently, the ESC/ERS guidelines recommended lowering the threshold for\nabnormal from >3 Wood Units (WU) to >2 WU [47]. Taken together, these modifications to the\nhaemodynamic definition of pulmonary hypertension (PH) will change the expected incidence and\nprevalence of PH, although the magnitude of this change has not been well characterised to date [62].\nImportantly, while the new definition of PH identifies a larger cohort of patients with pulmonary vascular\ndisease, current therapies for PAH were studied in populations fulfilling the old definition. As such, there\nare no approved therapies for patients with mPAP between 21 and 24 mmHg. There are few current studies\nexamining the impact of vasodilator therapy in patients with mildly elevated pressures (clinicaltrials.gov\nidentifier NCT04797286); most of the completed studies included patients with scleroderma and exercise\nPH and thus lack generalisability to PH patients with mildly elevated pressures [63\u2013 65]. A consensus is\ntherefore lacking on whether patients with mildly elevated pulmonary arterial pressures and PVR should be\nconsidered for initiation of PAH therapies. Clinical trial enrolment is recommended, if available, and all\npatients should be closely monitored for progression. If a decision to initiate therapy is made despite a lack\nof robust trial data, initial monotherapy is recommended over combination therapy.\nTreatment algorithm: initial treatment, patient selection and choice of therapy\nThe majority of patients included in PAH clinical trials have had IPAH, HPAH, DT-PAH or connective\ntissue disease (CTD)-associated PAH, and therefore the treatment algorithm presented is focused on these\npatients. This algorithm is also intended for patients with phenotypically clear-cut PAH, similar to the\nmajority of patients enrolled in PAH clinical trials, and for patients with a mPAP\u2a7e25 mmHg and PVR\n>3 WU; see also the section on comorbidities and phenotypes herein and in the WSPH article on\ndefinition, classification and diagnosis of pulmonary hypertension [66].\nInitial therapy following diagnosis should be based on an evaluation of risk status.", "mimetype": "text/plain", "start_char_idx": 1800, "end_char_idx": 3943, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "59f7dca9-88f5-457f-8c8b-5a0e08c9f925": {"__data__": {"id_": "59f7dca9-88f5-457f-8c8b-5a0e08c9f925", "embedding": null, "metadata": {"page_label": "6", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "10a724cc-bf62-43cb-92a1-a06be3357109", "node_type": "4", "metadata": {"page_label": "6", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "a9cccba29496e0881b90828155a3f9dd72e742423230030fc6e9c20f99302116", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4e01d8e4-5747-4590-9030-b053b1624161", "node_type": "1", "metadata": {"page_label": "6", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "10411a76a94c7b603fa483ccf1c4512a67585bcd2a312ec8a1c5802db28ffc50", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Initial therapy following diagnosis should be based on an evaluation of risk status. For patients not\nclassified as being at high risk at baseline, initial therapy with an endothelin-1 receptor antagonist (ERA)\nand phosphodiesterase-5 inhibitor (PDE-5i) combination is recommended [47]. Same-day initiation of both\nmedications is well tolerated and is a recommended option, but sequential initiation over a short period of\ntime (1\u2013 2 weeks) to assess tolerability is also acceptable. Use of tadalafil in combination with macitentan\nor ambrisentan is preferred, based on stronger evidence of efficacy for these combinations [9, 10, 21]\nversuscombinations containing bosentan or sildenafil [67]. When using sildenafil, initiation with 20 mg\norally three times daily is recommended, but uptitration to 80 mg can be considered if needed, though at a\ncost of a higher rate of adverse events [17, 18].\nPatients with severe PAH and classified as high risk at the time of diagnosis should receive a parenteral\nPPA in combination with an ERA and a PDE-5i [47]. Although parenteral therapies (intravenous\nepoprostenol, subcutaneous ori.v. treprostinil) were initially evaluated as monotherapy [35, 36, 68],\nwell-conducted observational studies have suggested significantly improved outcomes, including survival,\nfor initial triple combination therapy that includes a parenteral PPA in high-risk patients [5, 69].\nA discussion about lung transplant and potential referral should also be considered at diagnosis in\nhigh-risk patients, depending on patient, centre- and region-specific criteria; see also the WSPH article on\nhttps://doi.org/10.1183/13993003.01325-2024 6\nEUROPEAN RESPIRATORY JOURNAL 7TH WORLD SYMPOSIUM ON PULMONARY HYPERTENSION | K.M. CHIN ET AL.", "mimetype": "text/plain", "start_char_idx": 3859, "end_char_idx": 5610, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "824d7b93-602b-46fe-9b10-4bfc25b204d2": {"__data__": {"id_": "824d7b93-602b-46fe-9b10-4bfc25b204d2", "embedding": null, "metadata": {"page_label": "7", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a5baa07e-5af2-46c6-a9a2-1afb1352c612", "node_type": "4", "metadata": {"page_label": "7", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "f6ce2615a5c600725bafa23dd066a340d98446f496d9571e6c1508286f3bee08", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c2ccfc5a-0072-402e-ba0e-cffcf5cd1ea7", "node_type": "1", "metadata": {}, "hash": "7ba87b420f22e8edbba63968ac80beab7445206167bd6597f3b50286a4746424", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "transplantation and bridging and support technologies in pulmonary hypertension [70]. Patients classified\nas non-high risk, but having some high-risk features may also be considered for initial parenteral therapy,\nbased on observational data showing excellent and possibly superior long-term outcomes in some\nsubgroups of patients with this approach [5].\nInitial triple oral therapy with selexipag, a PDE-5i and an ERA is not recommended based on the TRITON\ntrial, which found no difference in PVR or other end-points at 26 weeks [9, 71]. Finally, while inhaled\ntherapies (inhaled treprostinil, inhaled iloprost) and oral riociguat may be considered as a component of\ninitial therapies, the overall evidence for this based on patient number, duration and types of studies is\nlower compared with initial ERA\u2013 PDE-5i combination therapy [21, 23].\nInitial reassessment for potential therapy escalation: early is preferred\nThe optimal timing of the first follow-up reassessment and potential treatment escalation has not been fully\nestablished, but 3\u2013 4 months appears to be a reasonable compromise allowing most prognostic measures to\nhave reached or neared a plateau [72]. There is some evidence that patients receiving add-on therapy\nearlier following their diagnosis may have a more robust responseversus those much later in the disease\nprocess, although this is more speculative [73]. The 3\u2013 4-month time point for reassessment applies only to\npatients who are stable or improving during this time; those with clear-cut deterioration should be\nconsidered for treatment escalation promptly. For patients initially receiving monotherapy, the addition of a\nsecond agent at this time (or earlier) should be considered for most patients, including in particular patients\nwho have not reached a low-risk status.\nLow risk at follow-up: is additional therapy indicated?\nMost patients currently classified as low risk still have significant symptoms and reduced exercise capacity.\nRisk of progression is also present; in a combined analysis of the AMBITION, GRIPHON and\nSERAPHIN trials, >20% of patients classified as low risk on multiparameter risk scores developed a\nclinical worsening event within 3 years of study entry [38].", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2221, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "c2ccfc5a-0072-402e-ba0e-cffcf5cd1ea7": {"__data__": {"id_": "c2ccfc5a-0072-402e-ba0e-cffcf5cd1ea7", "embedding": null, "metadata": {"page_label": "7", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a5baa07e-5af2-46c6-a9a2-1afb1352c612", "node_type": "4", "metadata": {"page_label": "7", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "f6ce2615a5c600725bafa23dd066a340d98446f496d9571e6c1508286f3bee08", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "824d7b93-602b-46fe-9b10-4bfc25b204d2", "node_type": "1", "metadata": {"page_label": "7", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "9803fa49f9850dd442dc7f86dfc59173b8d7a9b968a68c354f749b535fd2a7b7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1e538796-df0c-4506-8a6c-36039334b143", "node_type": "1", "metadata": {}, "hash": "de43a2afb092fae610d8099807c2f6bc110e71d8fbad660caf3e9b3c042e65be", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "These results suggest that simply achieving a\nlow-risk status based on current risk calculators alone is insufficient to ensure optimal symptom control or\nan adequate long-term clinical response in all patients.\nHowever, clinical trials have also found smaller short-term improvements in functional class and 6MWD\nin PAH patients with low-risk scores [74]. And while the relative risk reduction in clinical worsening in\nPAH RCTs appears similar in magnitude in lower-riskversus higher-risk patients, the absolute risk\nreduction in lower-risk patients is small [75]. Additional PAH therapy may also lead to additional\nside-effects and expense.\nIndividualised management may therefore be considered. Expanded goals of therapy have been proposed,\nincluding a PVR <5 WU [76], large declines in the PVR (e.g. >50\u2013 60%) [77\u2013 79], improvement in stroke\nvolume index or other haemodynamic measures [80] and achieving a normal or near-normal right heart\nsize and function on cardiac imaging [81]. However, longer-term studies are needed in order to better\ndetermine the extent to which these measures add value on top of an already low risk status.\nIntermediate-low risk at follow-up: treatment escalation\nPatients already on combination oral therapy who are at intermediate-low risk on a four-tiered risk scale\nshould be considered for add-on or transitions in therapy, including add-on therapy with sotatercept, with\nan oral PPA (selexipag, oral treprostinil), with an inhaled PPA, or with transition from an oral PDE-5\ninhibitor to riociguat. Table 4 summarises key trials performed with these medications among patients\nalready on one or more therapies. Studies of both sotatercept and selexipag included large numbers of\npatients on combination background therapy, providing a higher level of evidence for their use in this\nsetting, while studies of oral and inhaled treprostinil included only patients on monotherapy.\nDifferences in route of administration, types of background therapy, trial designs and safety profiles for\nthese medications make comparisons difficult, with the impressive and more robust improvement with\nsotatercept countered by larger and longer clinical trials focused on the prevention of clinical worsening\nfor the oral PPAs.", "mimetype": "text/plain", "start_char_idx": 2222, "end_char_idx": 4468, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "1e538796-df0c-4506-8a6c-36039334b143": {"__data__": {"id_": "1e538796-df0c-4506-8a6c-36039334b143", "embedding": null, "metadata": {"page_label": "7", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a5baa07e-5af2-46c6-a9a2-1afb1352c612", "node_type": "4", "metadata": {"page_label": "7", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "f6ce2615a5c600725bafa23dd066a340d98446f496d9571e6c1508286f3bee08", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c2ccfc5a-0072-402e-ba0e-cffcf5cd1ea7", "node_type": "1", "metadata": {"page_label": "7", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "0d427f62d2429056824f1f64ad8f75101bf57363b16aa032372cb6a67603bd25", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Specifically, in STELLAR (n=323), patients receiving sotatercept showed a placebo-corrected improvement\nin 6MWD of 41 m (p<0.001, primary end-point) at 24 weeks, along with improvementversus placebo in\nhealth-related quality of life, functional class, haemodynamics, echocardiography and NT-proBNP [82].\nIn addition, patients in the sotatercept arm had significantly fewer clinical worsening events over a median\nfollow-up of 33 weeks (hazard ratio 0.16, 95% CI 0.08\u2013 0.35) [8]. Generally consistent results were also\nhttps://doi.org/10.1183/13993003.01325-2024 7\nEUROPEAN RESPIRATORY JOURNAL 7TH WORLD SYMPOSIUM ON PULMONARY HYPERTENSION | K.M. CHIN ET AL.", "mimetype": "text/plain", "start_char_idx": 4469, "end_char_idx": 5126, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "41fde725-70c6-465a-a0e5-a02f9c112da8": {"__data__": {"id_": "41fde725-70c6-465a-a0e5-a02f9c112da8", "embedding": null, "metadata": {"page_label": "8", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "aecfdb3e-ff3d-4f2c-8cc1-48157ad3b135", "node_type": "4", "metadata": {"page_label": "8", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "60630ad1c88e0e0a6605b0671c6e427c29dd122d4e24123d3584d1f1f56bd693", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "13456ae3-8aa7-4e2a-9037-18fe7a5ebcda", "node_type": "1", "metadata": {}, "hash": "2b8d20d8efcf15eb0aec8d7c455a3880e47cc06180e3f68669fb4c410d630548", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "seen across multiple subgroups. All patients were on background PAH therapy including 4% on one, 35%\non two and 61% on three approved background PAH therapies. Additionally, 40% were receiving a\nparenteral PPA.\nBy contrast, studies targeting the prostacyclin pathway with oral agents, GRIPHON (selexipag) and\nFREEDOM-EV (oral treprostinil) were larger, longer-term studies (median follow-up >1 year) with\nevent-driven composite primary end-points. Both studies showed a significant reduction in worsening\nevents, with a 40% (p<0.001) reduction in GRIPHON and 26% (p=0.03) reduction in FREEDOM-EV\n[11, 28]. Change in 6MWD was more modest, with an improvement of 12 m (p=0.003) in GRIPHON and\n8 m (p=0.12) in FREEDOM-EV (both placebo-corrected). Patients in GRIPHON were treatment-na\u00efve\n(20%), on oral monotherapy (47%) or on oral combination therapy (33%), while patients in\nFREEDOM-EV were receiving background oral monotherapy with an ERA, soluble guanylate cyclase\nstimulator or PDE-5i.\nThe safety and adverse event profiles are similarly difficult to compare due to a lack of head-to-head data,\ndifferences in study design and duration, differences in sample sizes and significant differences in types\nand frequency of adverse events. For the sotatercept trials, adverse events leading to sotatercept\ndiscontinuation were uncommon (2% in STELLAR), but a number of adverse events including serious\nadverse events have been associated with sotatercept use. Bleeding events occurred in 22% of the\nsotatercept arm and 13% of the control arm in STELLAR, usually as minor mucosal bleeding (nosebleeds,\ngingival bleeding), but serious events have also been reported across the sotatercept studies including\ngastrointestinal bleeding, central nervous system bleeding and haemoptysis.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1778, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "13456ae3-8aa7-4e2a-9037-18fe7a5ebcda": {"__data__": {"id_": "13456ae3-8aa7-4e2a-9037-18fe7a5ebcda", "embedding": null, "metadata": {"page_label": "8", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "aecfdb3e-ff3d-4f2c-8cc1-48157ad3b135", "node_type": "4", "metadata": {"page_label": "8", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "60630ad1c88e0e0a6605b0671c6e427c29dd122d4e24123d3584d1f1f56bd693", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "41fde725-70c6-465a-a0e5-a02f9c112da8", "node_type": "1", "metadata": {"page_label": "8", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "37e7e982a401d37b5f1d242394a82e589e9e67f7cc4dc3d0464fd5833c036b29", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0138a9e3-a65c-4817-9a9e-e0cc78ce9191", "node_type": "1", "metadata": {}, "hash": "fb2542de85d38cdb6644752899a877e8d333c8d6cde2854c23a135c32d7b0f99", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Other adverse events of\npotential importance included the development or worsening of telangiectasias, increases in haemoglobin\nand decreases in platelets. In contrast, the most common PPA-associated adverse events seen in these\nstudies were those common to all prostacyclins and include headache, flushing, jaw pain, extremity pain,\nnausea and diarrhoea. These PPA associated adverse events tend to occur early on after medication\ninitiation and may improve over time or with dose reduction.\nOverall, these differences make it difficult to make any strong recommendations. In general, one might\nconsider sotatercept in those with greater symptom burden or greater impairment in exercise capacity,\ngiven the improvement in these measures seen in STELLAR. In contrast, one might consider selexipag or\noral treprostinil as a simpler approach initially in those at higher bleeding risk, such as with hereditary\nhaemorrhagic telangiectasia, or when aiming for a reduction in long-term clinical worsening events and/or\nin those who are more comfortable with the more established long-term safety profile.\nInhaled PPA (inhaled treprostinil or iloprost) [33, 34, 83] are also options as add-on therapy for patients at\nintermediate-low risk.", "mimetype": "text/plain", "start_char_idx": 1779, "end_char_idx": 3012, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "0138a9e3-a65c-4817-9a9e-e0cc78ce9191": {"__data__": {"id_": "0138a9e3-a65c-4817-9a9e-e0cc78ce9191", "embedding": null, "metadata": {"page_label": "8", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "aecfdb3e-ff3d-4f2c-8cc1-48157ad3b135", "node_type": "4", "metadata": {"page_label": "8", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "60630ad1c88e0e0a6605b0671c6e427c29dd122d4e24123d3584d1f1f56bd693", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "13456ae3-8aa7-4e2a-9037-18fe7a5ebcda", "node_type": "1", "metadata": {"page_label": "8", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "ce1d3e1329909ff3b36d9e804d57886da1fff7a7e9a9fde52808c1ead71875a0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bf796889-c1e7-4fd8-b0aa-517cd9178427", "node_type": "1", "metadata": {}, "hash": "bdc6b8a4061db80edd775c96197aaaaf47fcc92cc2ee49a66dbe34f7b3402516", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Inhaled PPA (inhaled treprostinil or iloprost) [33, 34, 83] are also options as add-on therapy for patients at\nintermediate-low risk. However, as a less convenient option due to route of delivery and the number of\nTABLE 4 Key randomised trials of prostacyclin pathway agents, riociguat and sotatercept in studies of patients on background endothelin-1\nantagonists and/or phosphodiesterase-5 inhibitors\nStudy [reference]\ndrug\nSubjects\nn\nBlinded Duration\nweeks\nBackground\nmedical\ntreatments %\nPrimary\nend-point\nPrimary\nend-point\nresults (95% CI)\nPositive\nprimary\nend-point\nOther key\npositive\nend-points\n012 3\nGRIPHON [28]\nselexipag\n1156 Yes \u223c71 20 47 33 0 TTCW HR 0.60\n(0.46\u2013 0.78)\nYes 6MWD,\nNT-proBNP\nSTELLAR [8]\nsotatercept\n323 Yes 24 0 4 35 61 6MWD HLE 40.8\n(27.5\u2013 54.1) m\nYes 6MWD, PVR,\nNT-proBNP, FC,\nTTCW, others\nTRIUMPH [33]\ninhaled\ntreprostinil\n235 Yes 12 0 100 0 0 6MWD HLE 20.0\n(8.0\u2013 32.8) m\nYes 6MWD,\nNT-proBNP, QoL\nFREEDOM-EV [11]\ntreprostinil p.o.", "mimetype": "text/plain", "start_char_idx": 2879, "end_char_idx": 3837, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "bf796889-c1e7-4fd8-b0aa-517cd9178427": {"__data__": {"id_": "bf796889-c1e7-4fd8-b0aa-517cd9178427", "embedding": null, "metadata": {"page_label": "8", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "aecfdb3e-ff3d-4f2c-8cc1-48157ad3b135", "node_type": "4", "metadata": {"page_label": "8", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "60630ad1c88e0e0a6605b0671c6e427c29dd122d4e24123d3584d1f1f56bd693", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0138a9e3-a65c-4817-9a9e-e0cc78ce9191", "node_type": "1", "metadata": {"page_label": "8", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "cc1c7c33579a8d68d49a0663c6a8312b4b752dcc3fdf3a9a6339aa4741d3b97d", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "690 Yes \u223c52 0 100 0 0 TTCW HR 0.74\n(0.56\u2013 0.97)\nYes NT-proBNP, FC\nREPLACE [15]\nriociguat\n226 No 24 0 29 71 0 Clinical\nimprovement\nOR 2.78\n(1.53\u2013 5.06)\nYes 6MWD, FC\nTTCW: time to clinical worsening; HR: hazard ratio; 6MWD: 6-min walk distance; NT-proBNP: N-terminal pro-brain natriuretic peptide; HLE: Hodges\u2013\nLehmann estimate; PVR: pulmonary vascular resistance; FC: functional class; QoL: quality of life.\nhttps://doi.org/10.1183/13993003.01325-2024 8\nEUROPEAN RESPIRATORY JOURNAL 7TH WORLD SYMPOSIUM ON PULMONARY HYPERTENSION | K.M. CHIN ET AL.", "mimetype": "text/plain", "start_char_idx": 3838, "end_char_idx": 4384, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "b5e6becb-1df3-442d-bfb2-9bb3b61fb783": {"__data__": {"id_": "b5e6becb-1df3-442d-bfb2-9bb3b61fb783", "embedding": null, "metadata": {"page_label": "9", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a4a8ac4a-99d7-4810-ba3b-e6894f3e75ae", "node_type": "4", "metadata": {"page_label": "9", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "26eed7792074b041557ab4c5656e445afcae93d592459fbe3b726d8585f64457", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "45133e3c-cd70-4d5d-a82c-afdbbe2385d7", "node_type": "1", "metadata": {}, "hash": "fa2e237bf758d71c55397b1bd32d69508b97cdd412fb64f1a12f1c170cbbef34", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "treatments required per day (four for treprostinil, between six and nine for iloprost), and as medications\nstudied either as monotherapy (iloprost) or added-on to monotherapy (inhaled treprostinil), these\nmedications are most often considered when issues with tolerability arise with other medications, or in\npatients felt to be at higher risk of adverse events with oral medications. Positives include a lower\nfrequency of prostacyclin-type side effectsversus other routes, and potentially fewer systemic effects in\ngeneral [84].\nSwitching from a PDE-5i to riociguat may also be considered, based on a positive randomised but\nunblinded study evaluating the likelihood of clinical improvement in patients previously treated with a\nPDE-5i who were randomised to either switch to riociguatversus continuing a PDE-5i [15, 85]. Clinical\nimprovement was defined as absence of clinical worsening and improvement in at least two of three of the\nfollowing: 6MWD, World Health Organization functional class and NT-proBNP. Although the study was\npositive, the lack of blinding as well as the use of an unvalidated outcome measure lowers the strength of\nthis recommendation.\nIntermediate-high and high risk at follow-up: maximal therapy and transplant\nPatients at intermediate-high risk at follow-up should receive a parenteral PPA or be considered for add-on\nsotatercept, while those at highest risk should receive a parenteral PPA, if not already receiving. Parenteral\nPPA have been studied as monotherapy [35, 36, 68], double combination [19] and triple combination\ntherapy (observational), including in patients with functional class IV symptoms and other signs of severe\ndisease [5, 79]. Maximal medical therapy is now four-drug therapy; this is based on the sotatercept RCTs\nwhere a majority of patients studied were receiving background triple therapy [7, 8].\nTiming of referral, evaluation and listing for transplant will depend on many factors including potential\nbarriers to transplant that may need to be addressed, local criteria for listing, local waitlist and prioritisation\nfactors.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2086, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "45133e3c-cd70-4d5d-a82c-afdbbe2385d7": {"__data__": {"id_": "45133e3c-cd70-4d5d-a82c-afdbbe2385d7", "embedding": null, "metadata": {"page_label": "9", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a4a8ac4a-99d7-4810-ba3b-e6894f3e75ae", "node_type": "4", "metadata": {"page_label": "9", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "26eed7792074b041557ab4c5656e445afcae93d592459fbe3b726d8585f64457", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b5e6becb-1df3-442d-bfb2-9bb3b61fb783", "node_type": "1", "metadata": {"page_label": "9", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "5588030383940387d1105eec01cdb3a3d90f3eedbf9e563f5cd5461a0d1ebcd2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0ae5e854-fb4a-49a9-a284-ac5dfb4d6509", "node_type": "1", "metadata": {}, "hash": "355ee50f3ea072dedec30a7608bc2fb249d9ef5cddbb5520d67c8db727d593a4", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Timing of referral, evaluation and listing for transplant will depend on many factors including potential\nbarriers to transplant that may need to be addressed, local criteria for listing, local waitlist and prioritisation\nfactors. Patients should be considered for referral for lung transplant evaluation with any of the following:\nprogressive disease or hospitalisation for PAH despite therapy, need for parenteral PPA, known or\nsuspected pulmonary veno-occlusive disease (PVOD)/pulmonary capillary haemangiomatosis (PCH) or the\ndevelopment of secondary liver or kidney dysfunction. Transplant evaluation is generally considered in\nhigh-risk patients at diagnosis, and is recommended in all follow-up patients with progression to or\npersistence of intermediate-high- or high-risk features [86]. Additional criteria which may also be\nconsidered for referral and listing are discussed in the WSPH article on transplantation and bridging and\nsupport technologies in PH [70].\nAmong those listed for transplant, further prioritisation (ranking on the priority list) can be difficult in\nPAH as traditional measures utilised for transplant prioritisation have not performed very well in PAH in\nthis setting, and PAH patients have higher rates of waitlist mortality compared with patients with\nparenchymal lung disease [87, 88]. Alternative strategies, such as moving acutely decompensated PAH\npatients who are failing to improve with initial intensive care treatments to the top of the waitlist, may\nreduce mortality [89]. Appeal for a higher lung allocation score may also be an option in regions where\nthis strategy is available [87].\nComorbidities and other patient populations at higher risk of adverse response to medications\nGiven the large variability in pathophysiology and phenotypes for patients with PH and comorbidities, a\nseparate\u201ccomorbidities\u201d arm has not been included in the PAH treatment algorithm. Instead, a very careful\napproach to these patients is recommended, as detailed later, in order to identify patients who have\ndefinite/phenotypically clear-cut PAH and may benefit from PAH therapies, including potentially upfront\ncombination therapy as per the treatment algorithm, as well as others who are unlikely to benefit and may\nbe harmed by PAH therapies.", "mimetype": "text/plain", "start_char_idx": 1856, "end_char_idx": 4129, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "0ae5e854-fb4a-49a9-a284-ac5dfb4d6509": {"__data__": {"id_": "0ae5e854-fb4a-49a9-a284-ac5dfb4d6509", "embedding": null, "metadata": {"page_label": "9", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a4a8ac4a-99d7-4810-ba3b-e6894f3e75ae", "node_type": "4", "metadata": {"page_label": "9", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "26eed7792074b041557ab4c5656e445afcae93d592459fbe3b726d8585f64457", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "45133e3c-cd70-4d5d-a82c-afdbbe2385d7", "node_type": "1", "metadata": {"page_label": "9", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "a322bf6dc78f4ed014d51c5503efe7cac9538b333b05bbab278e4a3b07730ce1", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "PAH patients with comorbidities are increasingly seen in clinical practice and have been found in several\nstudies to have a higher rate of adverse events with therapy [90] and possibly a less robust treatment\nresponse. Potential contributors include differences in PAH phenotype as well as the occurrence of occult\ngroup 2 PH, where patients meet typical haemodynamic criteria for pre-capillary PH at rest, but manifest\ngroup 2 haemodynamics with provocative manoeuvres such as exercise or fluid challenge, resulting in\nmisclassification.\nClinical, haemodynamic and imaging findings may raise concern for occult group 2 PH. This includes\ncatheterisation findings of a relatively higher pulmonary capillary wedge pressure (12\u2013 15 mmHg range)\nand relatively lower PVR (3\u2013 5 WU), echocardiographic findings of left atrial enlargement, grade 2 or\nhttps://doi.org/10.1183/13993003.01325-2024 9\nEUROPEAN RESPIRATORY JOURNAL 7TH WORLD SYMPOSIUM ON PULMONARY HYPERTENSION | K.M. CHIN ET AL.", "mimetype": "text/plain", "start_char_idx": 4130, "end_char_idx": 5112, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "6879715a-a8a2-421d-9290-66a7604a7e33": {"__data__": {"id_": "6879715a-a8a2-421d-9290-66a7604a7e33", "embedding": null, "metadata": {"page_label": "10", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a1d5c5e6-4e47-480d-8c2c-af946efb80fb", "node_type": "4", "metadata": {"page_label": "10", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "38fe7a7d648f777a6c86352ee3a2f3b2099e04c1a51393ff55f28441db356400", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "498e746c-cefd-44f5-add4-c03336001e00", "node_type": "1", "metadata": {}, "hash": "3a376d718388adb1c0bcabe0c2e77463a570099c04bf2e5159d08978cbfd6fc2", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "higher diastolic dysfunction, a reduced left ventricular ejection fraction or left-sided valve dysfunction, and\nmedical conditions associated with left heart disease, including hypertension, diabetes, obesity, sleep\napnoea, atrial fibrillation and coronary artery disease [91].\nWhile many patients with these features will have group 2 PH and should not receive PAH therapies at all,\na subset of patients may have PAH, but with a high comorbidity burden. In this setting, initiating therapy\nas monotherapy may be preferred in order to monitor for tolerability and response to therapy. Although\nhead-to-head data are lacking, the rate of adverse events and medication discontinuation rate may be higher\nfor the ERAsversus the PDE-5i in this setting, so starting therapy with a PDE-5i may be preferred [92].\nAnother subset of patients present with more clear-cut group 1 PAH, despite having one or more\ncomorbidities. This patient population is increasing in clinical trials, mirroring the prevalence of\ncomorbidities in the general population. For example, in GRIPHON, 51% of all patients had at least one\ncardiovascular comorbidity, including hypertension (33%), obesity (27%), diabetes (11%), and coronary\nartery disease (10%), while in AMBITION, 40% had hypertension, 10% diabetes and 4% coronary artery\ndisease [90]. Subgroup analyses can be difficult to interpret, but reductions in risk of clinical worsening in\nthe\u201ccomorbidities\u201d patients in these two studies were generally similar to the overall results [90, 93].\nThese findings demonstrate the potential benefits of PAH therapy in patients with comorbidities, including\nthe use of combination therapy in some patients with comorbidities who meet the rigorous inclusion\ncriteria typical of PAH clinical trials. However, caution is warranted, as treatment-associated adverse events\nwere more common and improvement in symptoms and walk distance end-points were more modest [90, 93].\nAnother common setting where concern for a non-group 1 diagnosis may occur is with significant\npre-capillary PH in combination with lung disease. PAH clinical trials have typically excluded those with\nmoderate or severe lung disease, but not mild lung disease.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2200, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "498e746c-cefd-44f5-add4-c03336001e00": {"__data__": {"id_": "498e746c-cefd-44f5-add4-c03336001e00", "embedding": null, "metadata": {"page_label": "10", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a1d5c5e6-4e47-480d-8c2c-af946efb80fb", "node_type": "4", "metadata": {"page_label": "10", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "38fe7a7d648f777a6c86352ee3a2f3b2099e04c1a51393ff55f28441db356400", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6879715a-a8a2-421d-9290-66a7604a7e33", "node_type": "1", "metadata": {"page_label": "10", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "15cf505edce2cb132fdfae8d3a8b364c237a2c176c21d5ec6c7123b2fbc32a04", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dc1b7aa9-d0c4-48e2-a54d-cf43695252bf", "node_type": "1", "metadata": {}, "hash": "ee4ebf08bad7b1af3475cad74b83a2a2315658cb97213ba4e83a955551206894", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "PAH clinical trials have typically excluded those with\nmoderate or severe lung disease, but not mild lung disease. Subgroup analyses focused on lung function\nand/or oxygen use from PAH clinical trials are lacking. Registry data suggests that patients with both a\nsmoking history and a diffusing capacity of the lung for carbon monoxide <45% may have a less robust\nimprovement in 6MWD and shorter average survival times after PAH therapy (and other unique\nphenotypic findings), but clinical trial outcomes focused on this subgroup are needed [94]. Criteria for\napproaching the diagnosis and treatment of group 3 PH as well as details on differentiating group 1 PAH\nversusgroup 3 PH are discussed separately in the WSPH article on PH associated with lung diseases [95].\nWhen PAH therapies are started in PAH patients with comorbidities, close follow-up is needed due to\nhigher adverse event rates. There is also the potential for an alternative and sometimes non-group 1 PH\ndiagnosis to be revealed only following therapy initiation. In this setting, PAH therapies should generally\nbe discontinued and treatment focused on the underlying condition.\nIn all the settings described, evaluation at an expert centre is recommended. While PAH therapies may be\nof benefit to a subset of patients with these more complicated phenotypes, harm or possible harm with\nPAH therapies has been seen across a wide range of pulmonary and cardiac conditions, including ERAs\nand riociguat in interstitial lung disease, ERAs in heart failure with preserved ejection fraction (HFPEF),\nPDE-5i in group 2 PH with a history of left-sided valve disease or HFPEF and PDE-5i in PH associated\nwith sickle cell anaemia [92, 96\u2013 105]. Management recommendations are described in the WSPH article\non PH associated with left heart disease [106].\nPAH subgroups\nCTD-PAH\nPatients with CTD-PAH comprise the second-largest PAH subgroup included in clinical trials of PAH\ntherapy, after IPAH, accounting for 30\u2013 40% of the study population [107, 108].", "mimetype": "text/plain", "start_char_idx": 2086, "end_char_idx": 4097, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "dc1b7aa9-d0c4-48e2-a54d-cf43695252bf": {"__data__": {"id_": "dc1b7aa9-d0c4-48e2-a54d-cf43695252bf", "embedding": null, "metadata": {"page_label": "10", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a1d5c5e6-4e47-480d-8c2c-af946efb80fb", "node_type": "4", "metadata": {"page_label": "10", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "38fe7a7d648f777a6c86352ee3a2f3b2099e04c1a51393ff55f28441db356400", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "498e746c-cefd-44f5-add4-c03336001e00", "node_type": "1", "metadata": {"page_label": "10", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "ffbe60f82845395e26e0d159db50a1d37644d0f762b76acace12995d59c51ef7", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "The majority of these\npatients have scleroderma-related PAH (SSc-PAH). Despite a lower disease prevalence in the general\npopulation than other CTDs such as rheumatoid arthritis or systemic lupus erythematosus, PAH is more\ncommonly seen in SSc, with 8\u2013 12% of patients developing this disease [109, 110]. Outcomes for patients\nwith CTD-PAH vary, with the worst outcomes noted for SSc-PAH compared to other CTDs [111]. In\ngeneral, survival in SSc-PAH is worse than IPAH, but has improved over the past decade, with median\nsurvival approaching 8 years in SSc-PAH [112]. Similarly, relative improvements in other outcomes, such\nas time to clinical worsening and 6MWD, have been observed, although the magnitude tends to be smaller\nthan that seen in IPAH populations [107]. Reasons for these differences may include limitations of the\noutcome measures for CTD-PAH patients where comorbidities contribute to time to clinical worsening and\nfunctional limitations and lower thresholds for clinically relevant changes as seen in the 6MWD [113].\nFurthermore, pulmonary venular involvement leading to a PVOD phenotype may be under-recognised in\nhttps://doi.org/10.1183/13993003.01325-2024 10\nEUROPEAN RESPIRATORY JOURNAL 7TH WORLD SYMPOSIUM ON PULMONARY HYPERTENSION | K.M. CHIN ET AL.", "mimetype": "text/plain", "start_char_idx": 4098, "end_char_idx": 5372, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "3b303a47-137a-41cd-be1a-f40037d3ff59": {"__data__": {"id_": "3b303a47-137a-41cd-be1a-f40037d3ff59", "embedding": null, "metadata": {"page_label": "11", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a1c087bc-2e51-4305-9201-5228bfb3c768", "node_type": "4", "metadata": {"page_label": "11", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "ab021d8d7d942d59ff5f147abaec3a6001951f9071a9e92bd6217285176a7f3a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "35d67d94-f935-473d-a051-e812556f9355", "node_type": "1", "metadata": {}, "hash": "9fd4c412250d467614c1e33d657e06e9f70269f4a7a644dd8f7846efde00f8bd", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "SSc-PAH and is associated with poor response to vasodilators and poorer outcomes overall [114, 115].\nDespite these potential modifiers of response to therapy, post hoc analysis of the AMBITION study\ndemonstrates similarly robust improvements in time to clinical worsening and 6MWD with initial PDE-5i\nand ERA therapy in CTD-PAH patients as IPAH patients [116]. As such, previous consensus\nrecommendations have supported application of the same general treatment algorithm for CTD-PAH as\nother forms of PAH.\nOne caveat to this treatment approach based on risk assessment is the limitation of risk assessment tools in\nCTD-PAH and specifically SSc-PAH populations, where model performance may not be as robust as in\nIPAH [117]. Given the differences in treatment response and outcomes in CTD-PAH compared to other\nforms of PAH, CTD-specific tools may be needed to better assess risk in this population, along with close\nattention to haemodynamics and right ventricular imaging.\nIn addition to differences in treatment response, CTD-PAH patients have a higher incidence of treatment-\nrelated adverse events compared to other PAH types, which may limit use of certain therapies in this\npopulation [107]. Caution should be exercised with initiation of medications that may increase bleeding\nrisk, such as sotatercept, in CTD patients who are predisposed to gastrointestinal bleeding due to vascular\nanomalies. In addition, digital contractures and impaired manual dexterity may impact the ability of some\nCTD-PAH patients to manage parenteral therapies, further limiting treatment options.\nCongenital heart disease associated PAH with unrepaired defects\nCongenital heart disease (CHD)-associated PAH includes four subtypes: Eisenmenger syndrome, PAH\nassociated with persistent systemic-to-pulmonary shunts, PAH with small/coincidental defects and\nPAH associated with repaired defects. Many clinical trials of PAH therapies included CHD patients with\nrepaired defects as long as >1 year since the time of repair, and these patients are typically treated similarly\nto those with IPAH.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2076, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "35d67d94-f935-473d-a051-e812556f9355": {"__data__": {"id_": "35d67d94-f935-473d-a051-e812556f9355", "embedding": null, "metadata": {"page_label": "11", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a1c087bc-2e51-4305-9201-5228bfb3c768", "node_type": "4", "metadata": {"page_label": "11", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "ab021d8d7d942d59ff5f147abaec3a6001951f9071a9e92bd6217285176a7f3a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3b303a47-137a-41cd-be1a-f40037d3ff59", "node_type": "1", "metadata": {"page_label": "11", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "e4d321bcb6b6d3624338d01d91906023b6b111c2e3c4c44bbadd253b7ceb328c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "71cd2865-07a0-45d1-bcaa-d3ad396dd52d", "node_type": "1", "metadata": {}, "hash": "1cbadaa1afd365370e2cf1f016be9a4b463e5cc8873c219dd716a060489529e3", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Many clinical trials of PAH therapies included CHD patients with\nrepaired defects as long as >1 year since the time of repair, and these patients are typically treated similarly\nto those with IPAH.\nIn contrast, patients in the first two groups, having significant and unrepaired congenital heart defects, have\nmore complicated pathophysiology and have been excluded from most PAH clinical trials. A\ncomprehensive evaluation including assessment for potential closure, medical therapeutic strategy,\ncomplication monitoring and psychological support is important, and should be performed by\nmultidisciplinary team in an experienced centre. Post-capillary PH must also be excluded prior to\nconsidering PAH therapies. Supportive therapies include assessment for iron deficiency, avoidance of\nroutine phlebotomy, use of antibiotic prophylaxis for the prevention of endocarditis (for cyanotic CHD or\nwith prosthetic material), and the use of air-filters withi.v. lines [118].\nCompared with other group 1 PAH subgroups, particularly IPAH and CTD-associated PAH, clinical trial\ndata on PAH therapies in patients with unrepaired CHD-PAH are limited. In the BREATHE-5 trial, greater\nfunctional and haemodynamic improvement was seen with bosentanversus placebo [119], while in the\nMAESTRO trial, macitentan failed to improve 6MWD versus placebo, but led to lower NT-proBNP\n(overall study) and improved haemodynamics (substudy) [14]. BREATHE-5 included only\nPAH-treatment-na\u00efve patients, while 27% of patients in MAESTRO were on a background PDE-5i.\nImprovement in exercise capacity, symptoms and survival in CHD-PAH has also been suggested with\nPAH therapies more generally, including double and triple combination therapy [120\u2013 127], but these data\nare largely observational. Larger and higher-quality studies in CHD-PAH are needed.\nInitiation of PAH therapies in a sequential and symptom-oriented fashion is generally recommended (initial\nmonotherapy, add-on therapy as needed) in both Eisenmenger syndrome and in PAH associated with\npersistent systemic-to-pulmonary shunts, especially in those patients with preserved exercise capacity.", "mimetype": "text/plain", "start_char_idx": 1879, "end_char_idx": 4007, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "71cd2865-07a0-45d1-bcaa-d3ad396dd52d": {"__data__": {"id_": "71cd2865-07a0-45d1-bcaa-d3ad396dd52d", "embedding": null, "metadata": {"page_label": "11", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a1c087bc-2e51-4305-9201-5228bfb3c768", "node_type": "4", "metadata": {"page_label": "11", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "ab021d8d7d942d59ff5f147abaec3a6001951f9071a9e92bd6217285176a7f3a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "35d67d94-f935-473d-a051-e812556f9355", "node_type": "1", "metadata": {"page_label": "11", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "aa73f612246335edc8f3039b874aca72fb58e5ffd94e14ee3c60f90b8d3fcd03", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "However, greater haemodynamic improvement has been reported with use of combination therapy, and in\nrecent years the use of combination therapy has become more common [127, 128]. For patients with\npersistent high-risk clinical features, lung or heart\u2013 lung transplantation should be considered [129, 130].\nFor patients in whom closure is not initially considered feasible, a number of reports have suggested that\nclosure might be considered after treatment with targeted drug therapy for PAH, if sufficient improvement\nis seen [131]. However, there is still no evidence for a long-term benefit from this approach, and caution is\nwarranted. Decisions on shunt closure should not be made on haemodynamic parameters alone, and a\nmultiparametric strategy should be followed. There is a need for future prospective studies, ideally with\nrandomisation, to ascertain the benefit and safety of this approach; see also the WSPH article on paediatric\nPH [132].\nhttps://doi.org/10.1183/13993003.01325-2024 11\nEUROPEAN RESPIRATORY JOURNAL 7TH WORLD SYMPOSIUM ON PULMONARY HYPERTENSION | K.M. CHIN ET AL.", "mimetype": "text/plain", "start_char_idx": 4008, "end_char_idx": 5099, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "20106827-6f98-4085-a815-ed964909bcad": {"__data__": {"id_": "20106827-6f98-4085-a815-ed964909bcad", "embedding": null, "metadata": {"page_label": "12", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "4cb35e6b-30fc-4519-9aa4-975b4b57c0c8", "node_type": "4", "metadata": {"page_label": "12", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "548fa27c914d4422e219d960004387faf9f9240e5498d95a12c70a8a7972337e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a772ff8e-9458-45c8-9d0b-f4f20c78032f", "node_type": "1", "metadata": {}, "hash": "55478c1c14c2522d16c49503bee8972b42d0495bc19ea5c488e69e8918586870", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Drug- and toxin-associated PAH\nA number of medications are associated with the development of PAH, covered in greater detail in the\nWSPH article on the definition, classification and diagnosis of pulmonary hypertension [66]. Outcomes\nappear to be heterogeneous. Partial or full reversal of PAH has been reported after discontinuation of some\nagents, including dasatinib [133] and interferon [134], and thus for patients exposed to these medications\nand presenting with lower-risk features, discontinuation of the causative medication followed by close\nobservation can be considered. If no improvement is seen over a period of 3\u2013 4 months, PAH therapy\nshould be started. Some medications, particularly chemotherapy agents, have also been associated with\nPVOD/PCH, and this should be considered in the appropriate setting [135]. For stimulant-associated PAH,\nthe most common form of drug/toxin-associated PAH in the current era, spontaneous remission is not\ntypical, and patients with DT-PAH associated with stimulants also appear to have worse outcomesversus\nIPAH [136, 137]. Treatment recommendations include initiation of PAH therapy following the treatment\nalgorithm (figure 1) and referral for treatment of substance use at the time of diagnosis.\nHIV-PAH\nPatients with PAH associated with HIV tend to be younger and are more likely to be male and to have\nmore severe haemodynamic abnormalitiesversus patients with IPAH/HPAH [138, 139]. HIV itself is a risk\nfactor for the development of PAH, although high rates of stimulant use and intravenous drug use, both\nrisks for PAH, are also seen [86]. Treatment response to PAH therapies appears similarversus IPAH,\nbased on open-label clinical studies [140] and observational data [138, 139, 141], and small numbers of\nHIV-PAH patients have been included in many of the large PAH RCTs [9, 21, 23, 24, 28]. Treatment with\nboth highly active antiretroviral therapy (HAART) and PAH therapies is therefore recommended.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1961, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "a772ff8e-9458-45c8-9d0b-f4f20c78032f": {"__data__": {"id_": "a772ff8e-9458-45c8-9d0b-f4f20c78032f", "embedding": null, "metadata": {"page_label": "12", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "4cb35e6b-30fc-4519-9aa4-975b4b57c0c8", "node_type": "4", "metadata": {"page_label": "12", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "548fa27c914d4422e219d960004387faf9f9240e5498d95a12c70a8a7972337e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "20106827-6f98-4085-a815-ed964909bcad", "node_type": "1", "metadata": {"page_label": "12", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "c3c0d6a64301e09a1b8c4b261f90605301e4af3f28ac0629f218020f89ea655e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "03549e66-b6ba-41ad-8126-3c1b244583ce", "node_type": "1", "metadata": {}, "hash": "4dbde26aac16e21ffd36e8599fb81c7533217895c4309273119b62169a533b97", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Treatment with\nboth highly active antiretroviral therapy (HAART) and PAH therapies is therefore recommended. This does\nrequire extra attention to potential medication interactions, particularly when protease inhibitors are being\nutilised as a component of HAART. Drug levels of both sildenafil and tadalafil, in particular, are increased\nsignificantly in this setting, and the manufacturers of both PDE-5i recommend against their use in PAH\nwith any strong cytochrome P450 3A inhibitors. However, given the fatal nature of untreated/inadequately\ntreated PAH, coadministration of protease inhibitors and reduced-dose PDE-5i has been described in the\nliterature in a small number of case reports [142], and might be considered if no other options exist.\nPortopulmonary hypertension\nPortopulmonary hypertension (PoPH) is the occurrence of PAH in the setting of portal hypertension\n(hepatic venous pressure gradient >5 mmHg or indirect signs of portal hypertension). While most PoPH\npatients also have cirrhosis, PoPH can occur without cirrhosis and across all Child\u2013 Pugh classes [143].\nThe prevalence of PoPH in patients with cirrhosis or portal hypertension is not insignificant, accounting\nfor\u223c5\u2013 15% of all patients with PAH in the United States of America, France and Japan [144\u2013 147].\nConversely, the prevalence of PAH in patients with portal hypertension is reported to be between 2% and\n6% [147\u2013 149].\nThe management of PoPH is unique. Prior to initiating treatment, it is important to distinguish true PoPH\nfrom other forms of PH that can occur in liver disease, including PH due to volume overload and/or high\ncardiac output states. Patients with PoPH will generally meet group 1 PAH haemodynamic criteria\nincluding a pulmonary artery wedge pressure\u2a7d15 mmHg, but some degree of volume excess and high\ncardiac output may also be present and can complicate diagnosis. Optimising both volume state and\ntreating the underlying liver disease are both important components of therapy.", "mimetype": "text/plain", "start_char_idx": 1853, "end_char_idx": 3838, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "03549e66-b6ba-41ad-8126-3c1b244583ce": {"__data__": {"id_": "03549e66-b6ba-41ad-8126-3c1b244583ce", "embedding": null, "metadata": {"page_label": "12", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "4cb35e6b-30fc-4519-9aa4-975b4b57c0c8", "node_type": "4", "metadata": {"page_label": "12", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "548fa27c914d4422e219d960004387faf9f9240e5498d95a12c70a8a7972337e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a772ff8e-9458-45c8-9d0b-f4f20c78032f", "node_type": "1", "metadata": {"page_label": "12", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "57803a338fd6196f733987e63626cf5c4be4cbcf44941446d994978b6777d11e", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Optimising both volume state and\ntreating the underlying liver disease are both important components of therapy.\nRegarding PAH pharmacotherapy, the PORTICO study, utilising macitentan, is the only RCT with a\nplacebo-controlled, double-blind design specifically targeting PoPH. This study compared PVR after\n12 weeks of macitentan 10 mgversus placebo, finding a 35% reduction in PVR with macitentan [13].\nOther smaller studies, mostly open-label case series, have shown improvementversus baseline for PoPH\nwith other PAH therapies including greater improvement in haemodynamics with the use of two- and\nthree-drug combination therapy [150\u2013 152]. Overall numbers of patients are low, particularly for Child\u2013\nPugh grade C disease. For those with more advanced liver disease, caution is recommended due to the\nhigher potential for impaired drug metabolism.\nA subset of patients with PoPH may be candidates for liver transplantation, and in observational studies,\npatients undergoing PAH medical therapy followed by liver transplantation have better survival rates\nversusPAH medical therapy alone [151, 153]. Haemodynamic targets prior to consideration of listing, as\nsuggested by the International Liver Transplantation Society, include a mPAP <35 mmHg and a PVR\n<5 WU, or a mPAP 35\u2013 45 mmHg with a PVR <3 WU [152, 154]. These values are slightly more lenient\nthan those utilised in earlier years. Pressures higher than this are generally considered an absolute\ncontraindication to liver transplantation. Following liver transplant, PAH usually no longer progresses and\nhttps://doi.org/10.1183/13993003.01325-2024 12\nEUROPEAN RESPIRATORY JOURNAL 7TH WORLD SYMPOSIUM ON PULMONARY HYPERTENSION | K.M. CHIN ET AL.", "mimetype": "text/plain", "start_char_idx": 3726, "end_char_idx": 5432, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "cacc2a75-4d8e-476e-9aa9-c80c0716b262": {"__data__": {"id_": "cacc2a75-4d8e-476e-9aa9-c80c0716b262", "embedding": null, "metadata": {"page_label": "13", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "4c17322b-c2e5-40ca-8710-f8857fb2cb81", "node_type": "4", "metadata": {"page_label": "13", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "3e3d645441dd65cda2ac999304c366c66d8e4d145f46fb2819bd8040bf8a2790", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a6620ad9-62c5-4854-a84e-e25dd8aa4d54", "node_type": "1", "metadata": {}, "hash": "7d06446abf1c7b68a4206f669223e0f3d0834d6e8dcb5da296139933dff82ce3", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "some PAH patients have tolerated de-escalation or discontinuation of PAH therapies, but this is not\nuniversal [155].\nSchistosomiasis\nSchistosomiasis-associated PAH (Sch-PAH) is one of the most common causes of PAH worldwide\n[156, 157]. While Sch-PAH typically occurs in the setting of severe hepatosplenic schistosomiasis, the\noverall pathophysiology, prognosis and treatment response appear distinct from PoPH, albeit incompletely\nstudied [156, 158]. Treatment with PAH therapies is associated with improvement in survival, with most\nreports describing treatment with PDE-5i or ERA monotherapy or combination therapy [159, 160].\nTreatment of the underlying parasitic infection is also considered in all or some patients, although a\nhaemodynamic benefit has not been established [159].\nPVOD/PCH\nPVOD/PCH represents a rare variant of PAH, distinguished by remodelling of the pulmonary venules and\ncapillaries. Although PVOD/PCH and PAH share a similar clinical presentation with features of severe\npre-capillary PH, it is important to differentiate these two conditions, as PVOD/PCH carries a worse\nprognosis and life-threatening pulmonary oedema may occur following the initiation of PAH therapy\n[47, 161\u2013 165]. To date, there is a lack of established evidence-based medical therapy for PVOD/PCH,\nmaking lung transplantation the preferred definitive treatment for eligible patients. It is strongly\nrecommended that patients receive early referral to specialised centres upon diagnosis [72, 166].\nThe safety and efficacy of PAH-targeted drugs in the context of PVOD remain uncertain. Consequently,\ntheir use should be approached with great caution and limited to PH expert centres experienced in\nmanaging this complex condition.\nA recent systematic review evaluating the safety and efficacy of PAH-targeted treatments in PVOD/PCH\nidentified 14 single case reports, no RCTs and four case series involving between eight and 16 patients.\nThese reports included patients treated with CCBs, ERAs, PDE-5i and low-dose parenteral epoprostenol,\nmostly as monotherapy [167].", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2064, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "a6620ad9-62c5-4854-a84e-e25dd8aa4d54": {"__data__": {"id_": "a6620ad9-62c5-4854-a84e-e25dd8aa4d54", "embedding": null, "metadata": {"page_label": "13", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "4c17322b-c2e5-40ca-8710-f8857fb2cb81", "node_type": "4", "metadata": {"page_label": "13", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "3e3d645441dd65cda2ac999304c366c66d8e4d145f46fb2819bd8040bf8a2790", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cacc2a75-4d8e-476e-9aa9-c80c0716b262", "node_type": "1", "metadata": {"page_label": "13", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "ec7e92f6bb5fef67ac751961b03ce7d9a40b96589e91fe58344d80f38362bb90", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "05e4ef80-5524-42bd-9ab4-1057b69cf6fe", "node_type": "1", "metadata": {}, "hash": "53a41fc4005c657d321f55f74af31105af295e4a436f0f30e69e1e3450af8f21", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "These reports included patients treated with CCBs, ERAs, PDE-5i and low-dose parenteral epoprostenol,\nmostly as monotherapy [167]. While moderate clinical and haemodynamic improvement was reported in\nsome individual cases, sustained long-term effects are generally lacking [166].\nLimited-resource settings\nUnfortunately, access to PH medications may be limited in some areas, whether due to a lack of resources\nin general or due to inequitable distribution of resources/healthcare coverage, as is even seen in some\nwealthier countries. Generally, symptomatic management with diuretics and general and supportive\nmeasures are universally available options. Unfortunately, the cost and national availability of PH\nmedication makes use impossible for many, and monotherapy a default approach in others. Parenteral\ntherapies are generally not available where resources are limited. On a positive note, the approval of\ngeneric medications for some types of PAH therapies is welcomed. Advocacy programmes by the broader\nPH community for access to cheaper and effective generics as well as education on approaches to PH\nwhere resources are limited are recommended. Atrial septostomy has shown significant benefit in PAH,\nmost notably where access to medications is limited, but, unfortunately, familiarity with the procedure is\nuncommon globally [168].\nHaemodynamic effects of PAH therapies\nMedications other than sotatercept have both acute and chronic vasodilatory effects [169, 170]. Acutely,\nthe decline in mPAP and PVR in response to PAH medications is often modest, presumably due to the\nextensive vascular remodelling that is often present in PAH. Greater haemodynamic improvement is\nobserved long-term [171], and combination therapy leads to greater haemodynamic improvementversus\nmonotherapy, particularly when given as upfront therapy. The largest overall declines in PVR have been\nreported for upfront triple combination therapy that includes a parenteral PPA [3].\nSignificant improvement in right atrial pressure (RAP), mPAP, PVR, cardiac index and mixed venous\noxygen saturation (SvO2), among others, have been reported in clinical trials and observational studies\n[3, 172].", "mimetype": "text/plain", "start_char_idx": 1934, "end_char_idx": 4114, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "05e4ef80-5524-42bd-9ab4-1057b69cf6fe": {"__data__": {"id_": "05e4ef80-5524-42bd-9ab4-1057b69cf6fe", "embedding": null, "metadata": {"page_label": "13", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "4c17322b-c2e5-40ca-8710-f8857fb2cb81", "node_type": "4", "metadata": {"page_label": "13", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "3e3d645441dd65cda2ac999304c366c66d8e4d145f46fb2819bd8040bf8a2790", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a6620ad9-62c5-4854-a84e-e25dd8aa4d54", "node_type": "1", "metadata": {"page_label": "13", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "37702d3c733d48ed3e6c341f7038878de5a1e666e943829510b5912a2c9afa4f", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "As nonselective vasodilators, PAH therapies also lead to modest declines in systemic vascular\nresistance [173]. Clinically significant decreases in systemic blood pressure are uncommon, but can be\nseen when PAH therapies are used in combination, or with use of riociguat, which appears to have more\npotent systemic effects [22].\nIn contrast, sotatercept also leads to long-term improvements in pulmonary haemodynamics, but it lacks\nacute vasodilatory effects in the pulmonary or systemic circulation, suggesting that long-term improvements\nhttps://doi.org/10.1183/13993003.01325-2024 13\nEUROPEAN RESPIRATORY JOURNAL 7TH WORLD SYMPOSIUM ON PULMONARY HYPERTENSION | K.M. CHIN ET AL.", "mimetype": "text/plain", "start_char_idx": 4115, "end_char_idx": 4795, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "68799a17-b209-44e9-8512-8d4f40cec8a2": {"__data__": {"id_": "68799a17-b209-44e9-8512-8d4f40cec8a2", "embedding": null, "metadata": {"page_label": "14", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "e5c7d5c0-71be-4ad5-9125-36dfd5ae13e4", "node_type": "4", "metadata": {"page_label": "14", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "688dd1275fd26f2d21a2ff51796c4adafaf3e627e2b664c9d95601e358979664", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ad70c1d4-03e3-4afc-908b-e674f2c2bcda", "node_type": "1", "metadata": {}, "hash": "95be16c6c6f4eaaa3bdb7afc8abae31d4ce8d40a5727fd817e1e1e9a3aef2e12", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "in haemodynamics occur through other mechanisms. Significant improvements in RAP, mPAP, PVR and\nSvO2, but not cardiac index, have been seen in sotatercept clinical trials [7, 12].\nThe reasons for the lack of improvement in cardiac index are unclear, but sotatercept also leads to increases\nin haemoglobin and systemic vascular resistance, both of which would theoretically reduce the tendency\nfor cardiac output to increase, and have been hypothesised to contribute to this finding. In addition, all\npatients in the sotatercept studies were on background PAH medications, and many had a cardiac index in\nthe normal range at baseline. Conversely, even when looking at the subgroup of patients in the sotatercept\nstudies with a low cardiac index, a statistically significant increase in cardiac index was not seen, although\na small (nonsignificant) numeric increase was reported [82]. What this means from a clinical standpoint is\nnot yet completely clear, as sotatercept leads to a robust reduction in PVR, improvements in right\nventricular function on imaging, a lower NT-proBNP and clinically meaningful improvement in quality of\nlife and exercise capacity.\nStill, in patients presenting seriously ill and with a low cardiac index, the far greater experience with\nparenteral PPA in this setting suggests that these medications remain first-line. Rapid and pronounced\nimprovement has been documented, including an early mortality benefit in the sickest patients [35].\nMedication administration and adverse effects\nMore detailed information on the dosing and management of PAH therapies can be reviewed in prior\nWSPH publications and PH treatment guidelines [47, 48]. Medications and common adverse effects by\npharmaceutical class are shown in table 2 [7, 8, 11, 18\u2013 27, 29\u2013 31, 33\u2013 36].\nWhile most adverse events can be managed with supportive therapy and/or dose adjustment, when\napplicable, a few require special consideration. Volume overload is common in PAH as a part of the\ndisease process, but can also develop in response to PAH therapies, particularly with the ERAs.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2075, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "ad70c1d4-03e3-4afc-908b-e674f2c2bcda": {"__data__": {"id_": "ad70c1d4-03e3-4afc-908b-e674f2c2bcda", "embedding": null, "metadata": {"page_label": "14", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "e5c7d5c0-71be-4ad5-9125-36dfd5ae13e4", "node_type": "4", "metadata": {"page_label": "14", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "688dd1275fd26f2d21a2ff51796c4adafaf3e627e2b664c9d95601e358979664", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "68799a17-b209-44e9-8512-8d4f40cec8a2", "node_type": "1", "metadata": {"page_label": "14", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "7310abaead31b7a524e96e3873fce481a8507839cd281682d6ba8e36a6bc920a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7d4f5ed1-ed0b-4932-b2bf-cd6cd364d03e", "node_type": "1", "metadata": {}, "hash": "b4e2da8266e2502acae22114160055b35712f7dd1c0a3e83b289e87e5bcf33f4", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Volume overload is common in PAH as a part of the\ndisease process, but can also develop in response to PAH therapies, particularly with the ERAs.\nManagement involves frequent follow-up, adjusting diuretics, and occasionally discontinuation and\ntransition to other medications. This effect tends to be magnified in patients with group 2 risk factors, and\nsevere fluid retention with ERAs should prompt review of the overall PH diagnosis.\nNew or worsened hypoxia related to PAH therapy is not common based on clinical trial data, despite\nthe potential for increased ventilation/perfusion mismatch with PAH medications seen in experimental\nstudies [174].\nIn those developing more severe hypoxia, echocardiography with bubble study and high-resolution\ncomputed tomography should be considered, and if no other causes are identified, previously unrecognised\nPVOD/PCH, although rare, should be considered. Typical findings suggestive of PVOD/PCH include the\ndevelopment of new hypoxia in combination with increased septal lines and/or ground-glass opacities on\nimaging following the introduction of PAH therapies, as well as mediastinal adenopathy.\nFor sotatercept, the most recently approved PAH therapy, treatment is initiated at 0.3 mg\u00b7kg\u22121, and then\nincreased to 0.7 mg\u00b7kg\u22121 for subsequent doses administered every 3 weeks. Downtitration to 0.3 mg\u00b7kg\u22121\ncan be considered when required for adverse events (particularly for elevated haemoglobin) or tolerability.\nMonitoring is recommended for increased haemoglobin, reduced platelets and the development of new\ntelangiectasias, and an increased risk of bleeding events has been seen in trials. In addition, sotatercept\ncarries a risk of fetal harm, and may have the potential to reduce future fertility and males and females,\nbased on animal studies [175].", "mimetype": "text/plain", "start_char_idx": 1930, "end_char_idx": 3732, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "7d4f5ed1-ed0b-4932-b2bf-cd6cd364d03e": {"__data__": {"id_": "7d4f5ed1-ed0b-4932-b2bf-cd6cd364d03e", "embedding": null, "metadata": {"page_label": "14", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "e5c7d5c0-71be-4ad5-9125-36dfd5ae13e4", "node_type": "4", "metadata": {"page_label": "14", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "688dd1275fd26f2d21a2ff51796c4adafaf3e627e2b664c9d95601e358979664", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ad70c1d4-03e3-4afc-908b-e674f2c2bcda", "node_type": "1", "metadata": {"page_label": "14", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "f67bc226b5358393415c17a0058d71b4c925d50975474743084679d923acb1e4", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "In addition, sotatercept\ncarries a risk of fetal harm, and may have the potential to reduce future fertility and males and females,\nbased on animal studies [175].\nParenteral PPAs and transitions between parenteral and nonparenteral PPAs\nParenteral PPAs are initiated at 1\u2013 2 ng\u00b7kg\u22121\u00b7min\u22121 for both epoprostenol and treprostinil, followed by\nuptitration over weeks to months, typically to an initial dose of 15\u2013 20 ng\u00b7kg\u22121\u00b7min\u22121 for epoprostenol [35,\n173, 176, 177] and \u2a7e40 ng\u00b7kg\u22121\u00b7min\u22121 for treprostinil [178, 179]. Additional uptitration may be\nconsidered if needed, but there is considerable variability across centres [178]. Higher targets are also\nadvocated by some centres, mainly in Japan [180, 181]. Haemodynamic reassessment prior to additional\ndose escalation is recommended in order to avoid excessive side-effects as well as the potential for\noverdose and high cardiac output state [173, 182, 183].\nTransitions between epoprostenol and treprostinil and/or changes in route of delivery between\nsubcutaneous and intravenous administration may be required due to delivery-route complications (site\npain, line infections) or other reasons. Transitions should be performed with close monitoring. There is no\nestablished dose conversion formula, but in general, higher doses of treprostinil relative to epoprostenol are\nhttps://doi.org/10.1183/13993003.01325-2024 14\nEUROPEAN RESPIRATORY JOURNAL 7TH WORLD SYMPOSIUM ON PULMONARY HYPERTENSION | K.M. CHIN ET AL.", "mimetype": "text/plain", "start_char_idx": 3570, "end_char_idx": 5035, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "e99027de-fc48-419e-8e16-9e8d1474b75d": {"__data__": {"id_": "e99027de-fc48-419e-8e16-9e8d1474b75d", "embedding": null, "metadata": {"page_label": "15", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "8e7c1b08-1d21-4307-abcc-1e340fabac0a", "node_type": "4", "metadata": {"page_label": "15", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "49857bef9c6f01cb1249f98daabce8617e9937d7df979ee3d8a7081e06fbb40c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1d4e135d-dfbf-4eda-9b58-35279bb92cad", "node_type": "1", "metadata": {}, "hash": "350ed3cfafc7a4b812c1a9386b7f3ddc4e1272f8f0fb7e81b312f7dc3094b790", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "utilised [184]. Acutely, modest under-dosing is preferred to over-dosing, such that many studies have\nutilised a relatively lower initial short-term transition target followed by a higher (outpatient) target based\non tolerability and clinical response [185\u2013 191].\nTransitions from parenteral PPAs to oral or inhaled PPA are also considered in some patients, often at\npatient request and usually in patients with a good response to current therapy (PVR <5 WU, normal\ncardiac index, low-risk findings). With the increasing armamentarium of PAH therapies, requests for this\ntype of transition may increase in the coming years. However, while short-term case series describe mostly\npositive outcomes, these data are very limited with some patients worsening during or after the transition,\nand with a poor response to reinitiation of the parenteral PPA in some cases [192, 193].\nFor those choosing to proceed, downtitration of epoprostenol or treprostinil is typically completed over\nweeks to months. Many centres utilise catheterisation during downtitration while still on a very low dose\nof epoprostenol or treprostinil and/or at the time of discontinuation, and again 3\u2013 4 months following\ntransition [193 \u2013 195]. More rapid downtitration is also possible, particularly for transitions to oral\ntreprostinil [196], but requires particularly careful management. Initiation of the oral or inhaled PPA often\noccurs during the parenteral therapy downtitration, most often with overlap of the two medications for a\nshort time.\nShared decision-making\nBefore therapy is prescribed for a patient with PAH, a patient \u2013 clinician discussion should occur to\npromote shared decision-making. Topics discussed should include information on the underlying disease\nprocess(es), benefits of potential therapies, route of administration and administration burden, adverse\neffect profile, any medication interactions, comorbidities and patient preferences [197].\nIt is important during this process to ask the patient about their preferred level of participation in treatment\ndecision-making, as some prefer a much more active role, while others prefer to leave decisions almost\nentirely to their physicians [198].", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2193, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "1d4e135d-dfbf-4eda-9b58-35279bb92cad": {"__data__": {"id_": "1d4e135d-dfbf-4eda-9b58-35279bb92cad", "embedding": null, "metadata": {"page_label": "15", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "8e7c1b08-1d21-4307-abcc-1e340fabac0a", "node_type": "4", "metadata": {"page_label": "15", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "49857bef9c6f01cb1249f98daabce8617e9937d7df979ee3d8a7081e06fbb40c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e99027de-fc48-419e-8e16-9e8d1474b75d", "node_type": "1", "metadata": {"page_label": "15", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "e22b53361051ff3e8661e9c494188b5dc1598e7f871a313a66d880ec4c470629", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7d47a0da-dc5e-4a4b-a215-82096cf4fbda", "node_type": "1", "metadata": {}, "hash": "83d8796d7a9a83d2ba22f445370adf08eb278421113c5e2fadc9e964927803db", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "It is important during this process to ask the patient about their preferred level of participation in treatment\ndecision-making, as some prefer a much more active role, while others prefer to leave decisions almost\nentirely to their physicians [198]. Decision-making is aided by an understanding of the patient\u2019s most\nimportant treatment goals, whether improvement in prognosis, improvement in symptoms, avoidance of\nburdensome therapies, other goals, or all of the above.\nKnowledge gaps and future directions\n\u0081 In acute vasodilator responders with subsequent loss of response, it remains unknown whether CCBs\nshould be continued, dosage reduced or discontinued.\n\u0081 Studies on treatment response for patients with mPAP 21\u2013 24 mmHg and PVR 2\u2013 3 WU and for those\nwith exercise PH are needed, as there is a paucity of clinic trial information.\n\u0081 While combination therapy is more effective than monotherapy, additional studies on the timing and\nsequence of subsequent therapy escalation and optimal treatment goals are needed.\n\u0081 High-quality observational data may be of use to help to supplement clinical trial data, particularly for\nnewer therapies and to assess safety; registries should strive to enhance phenotyping, to include\npatients across different medications, and particular attention should be paid to transitions between\ntherapies including intravenous/subcutaneous PPA.\n\u0081 There remains concern that progressive subclinical deterioration in right ventricular function can occur\ndespite favourable early clinical measures. Finding reliable markers of progression and response to\nescalation in therapies remains an important focus of research.\n\u0081 Interventions to increase the acceptance and timing of initiation of parenteral prostacyclins are needed.\n\u0081 With older median age at diagnosis and improved survival for patients with established PAH, study of\nthe interaction between PAH therapies and new or previously diagnosed comorbid conditions is\nneeded.\n\u0081 Some subgroups of PAH remain particularly under-studied. In particular, this includes PoPH,\nunrepaired CHD, schistosomiasis-associated PAH and PVOD/PCH.\n\u0081 Optimal treatment in resource-limited areas remains under-studied, and worldwide access to PAH\ntherapies is a critical need.", "mimetype": "text/plain", "start_char_idx": 1942, "end_char_idx": 4188, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "7d47a0da-dc5e-4a4b-a215-82096cf4fbda": {"__data__": {"id_": "7d47a0da-dc5e-4a4b-a215-82096cf4fbda", "embedding": null, "metadata": {"page_label": "15", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "8e7c1b08-1d21-4307-abcc-1e340fabac0a", "node_type": "4", "metadata": {"page_label": "15", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "49857bef9c6f01cb1249f98daabce8617e9937d7df979ee3d8a7081e06fbb40c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1d4e135d-dfbf-4eda-9b58-35279bb92cad", "node_type": "1", "metadata": {"page_label": "15", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "c0134b78a9ed2861ce89e52e121db92ef9605c1d50b9e3b1d27a998e124bcc47", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "\u0081 Optimal treatment in resource-limited areas remains under-studied, and worldwide access to PAH\ntherapies is a critical need.\nConclusions\nOptimal treatment of PAH involves combination therapy for a majority of patients, including upfront\ncombination therapy with an ERA and PDE-5i for most newly diagnosed patients. Exceptions include\nIPAH/HPAH/DT-PAH with a positive vasodilator response who should receive a CCB initially. Maximal\nmedical therapy is now four-drug therapy. Reassessment and early escalation in therapy is recommended.\nhttps://doi.org/10.1183/13993003.01325-2024 15\nEUROPEAN RESPIRATORY JOURNAL 7TH WORLD SYMPOSIUM ON PULMONARY HYPERTENSION | K.M. CHIN ET AL.", "mimetype": "text/plain", "start_char_idx": 4062, "end_char_idx": 4739, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "996d1ae0-b8f2-4bff-bb53-0fb42c8cc539": {"__data__": {"id_": "996d1ae0-b8f2-4bff-bb53-0fb42c8cc539", "embedding": null, "metadata": {"page_label": "16", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "56b81214-cfed-44aa-aaec-bdb3ee5d19e3", "node_type": "4", "metadata": {"page_label": "16", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "510b557b9d5e7d6a1d30ff2d3bd781acb7a93c451aaba90d79ce2d8bffb62942", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "10a69b3c-1745-4bc7-8685-073f0c1a09d3", "node_type": "1", "metadata": {}, "hash": "1c626104f44056395c1c17c36b4ea8c18514ee22fc42538119ccf2dbed0285e4", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Conflict of interest: K.M. Chin reports grants and consultancy fees from Janssen, Merck, Gossamer Bio and United\nTherapeutics, support for attending meetings from Janssen, and is an associate editor forCirculation. S.P. Gaine\nreports grants from Janssen, Aerovent and Gossamer Bio, consultancy fees from Janssen, Merck, Gossamer Bio,\nUnited Therapeutics and Altavent, payment or honoraria for lectures, presentations, manuscript writing or\neducational events and support for attending meetings from Janssen, and participation on a data safety\nmonitoring board or advisory board with Janssen. C. Gerges reports grants from OrphaCare, payment or honoraria\nfor lectures, presentations, manuscript writing or educational events from AOPHealth, AstraZeneca, Janssen and\nFerrer, and support for attending meetings from AOPHealth, AstraZeneca, Cordis, Janssen and MSD. Z-C. Jing has\nno potential conflicts of interest to disclose. S.C. Mathai reports consultancy fees from Janssen, United\nTherapeutics, Merck and Acceleron, participation on a data safety monitoring board or advisory board with Bayer,\nand a leadership role on the Patient Centered Outcomes Research Institute Rare Disease Advisory Panel. Y. Tamura\nreports grants from Nippon Shinyaku Co. Ltd and Mochida, consultancy fees from MSD, and payment or honoraria\nfor lectures, presentations, manuscript writing or educational events from Nippon Shinyaku Co. Ltd and Janssen\nPharmaceuticals. V.V. McLaughlin reports grants from Aerovate, Gossamer-Bio, Janssen, Keros, Merck and Sonovie,\nand consultancy fees from 35Pharma, Aerami, Aerovate, Caremark, L.L.C., Corvista, Gossamer Bio, Janssen, Keros,\nMerck, Riovant and United Therapeutics.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1691, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "10a69b3c-1745-4bc7-8685-073f0c1a09d3": {"__data__": {"id_": "10a69b3c-1745-4bc7-8685-073f0c1a09d3", "embedding": null, "metadata": {"page_label": "16", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "56b81214-cfed-44aa-aaec-bdb3ee5d19e3", "node_type": "4", "metadata": {"page_label": "16", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "510b557b9d5e7d6a1d30ff2d3bd781acb7a93c451aaba90d79ce2d8bffb62942", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "996d1ae0-b8f2-4bff-bb53-0fb42c8cc539", "node_type": "1", "metadata": {"page_label": "16", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "a75425315653a8b048dd0733f20adf6aae240e4df076fe80314c3f08fd7c8a2a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2efb6bb5-ee70-4803-b291-673b3279d5d4", "node_type": "1", "metadata": {}, "hash": "ce6d55415410c3bc33d2c4803d4f1d73aa21f20c154bb0f612b8c5fec7fda6bc", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "O. Sitbon reports grants from Aerovate, AOP Orphan, Ferrer, Janssen and\nMSD, consultancy fees from Altavant/Enzyvant, AOP Orphan, Ferrer, Gossamer Bio, Janssen, Liquidia, MSD, Respira\nTherapeutics and Roivant Sciences, payment or honoraria for lectures, presentations, manuscript writing or\neducational events from Aerovate, AOP Orphan, Janssen, Ferrer and MSD, and participation on a data safety\nmonitoring board or advisory board with Altavant/Enzyvant, Gossamer Bio, Janssen and Respira Therapeutics.\nReferences\n1 Gabler NB, French B, Strom BL, et al. Validation of 6-minute walk distance as a surrogate end point in\npulmonary arterial hypertension trials.Circulation 2012; 126: 349\u2013 356.\n2 Savarese G, Paolillo S, Costanzo P,et al. Do changes of 6-minute walk distance predict clinical events in\npatients with pulmonary arterial hypertension? A meta-analysis of 22 randomized trials.J Am Coll Cardiol\n2012; 60: 1192\u2013 1201.\n3 Farmakis IT, Vrana E, Mouratoglou SA, et al. Haemodynamic effects of initial combination therapy in\npulmonary arterial hypertension: a systematic review and meta-analysis.ERJ Open Res2022; 8: 00313-2022.\n4 Tremblay E, Gosselin C, Mai V, et al. Assessment of clinical worsening end points as a surrogate for\nmortality in pulmonary arterial hypertension: a systematic review and meta-analysis of randomized\ncontrolled trials.Circulation 2022; 146: 597\u2013 612.\n5 Boucly A, Savale L, Ja\u00efs X,et al. Association between initial treatment strategy and long-term survival in\npulmonary arterial hypertension.Am J Respir Crit Care Med2021; 204: 842\u2013 854.\n6 Ramjug S, Hussain N, Hurdman J, et al.", "mimetype": "text/plain", "start_char_idx": 1692, "end_char_idx": 3304, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "2efb6bb5-ee70-4803-b291-673b3279d5d4": {"__data__": {"id_": "2efb6bb5-ee70-4803-b291-673b3279d5d4", "embedding": null, "metadata": {"page_label": "16", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "56b81214-cfed-44aa-aaec-bdb3ee5d19e3", "node_type": "4", "metadata": {"page_label": "16", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "510b557b9d5e7d6a1d30ff2d3bd781acb7a93c451aaba90d79ce2d8bffb62942", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "10a69b3c-1745-4bc7-8685-073f0c1a09d3", "node_type": "1", "metadata": {"page_label": "16", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "873621dc7cd526b212e327ef429903d7a54255460dd53886b58e820e5143699a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0a43f452-f539-4fe3-95b7-575d8dadbf30", "node_type": "1", "metadata": {}, "hash": "217164c35e453970a44c7e6135fba41634ff2e1880bb9a56fcdcaef67a7efb81", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "6 Ramjug S, Hussain N, Hurdman J, et al. Idiopathic and systemic sclerosis-associated pulmonary arterial\nhypertension: a comparison of demographic, hemodynamic, and MRI characteristics and outcomes.Chest\n2017; 152: 92\u2013 102.\n7 Humbert M, McLaughlin V, Gibbs JSR, et al. Sotatercept for the treatment of pulmonary arterial\nhypertension. N Engl J Med2021; 384: 1204\u2013 1215.\n8 Hoeper MM, Badesch DB, Ghofrani HA,et al. Phase 3 trial of sotatercept for treatment of pulmonary arterial\nhypertension. N Engl J Med2023; 388: 1478\u2013 1490.\n9 Chin KM, Sitbon O, Doelberg M, et al. Three- versus two-drug therapy for patients with newly diagnosed\npulmonary arterial hypertension.J Am Coll Cardiol2021; 78: 1393\u2013 1403.\n10 Gr\u00fcnig E, Jansa P, Fan F,et al. Randomized trial of macitentan/tadalafil single-tablet combination therapy\nfor pulmonary arterial hypertension.J Am Coll Cardiol2024; 83: 473\u2013 484.\n11 White RJ, Jerjes-Sanchez C, Bohns Meyer GM, et al. Combination therapy with oral treprostinil for\npulmonary arterial hypertension. A double-blind, placebo-controlled clinical trial.Am J Respir Crit Care Med\n2020; 201: 707\u2013 717.\n12 Humbert M, McLaughlin V, Gibbs JSR, et al. Sotatercept for the treatment of pulmonary arterial\nhypertension: PULSAR open-label extension.Eur Respir J2023; 61: 2201347.\n13 Sitbon O, Bosch J, Cottreel E, et al. Macitentan for the treatment of portopulmonary hypertension\n(PORTICO): a multicentre, randomised, double-blind, placebo-controlled, phase 4 trial.Lancet Respir Med\n2019; 7: 594\u2013 604.", "mimetype": "text/plain", "start_char_idx": 3264, "end_char_idx": 4776, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "0a43f452-f539-4fe3-95b7-575d8dadbf30": {"__data__": {"id_": "0a43f452-f539-4fe3-95b7-575d8dadbf30", "embedding": null, "metadata": {"page_label": "16", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "56b81214-cfed-44aa-aaec-bdb3ee5d19e3", "node_type": "4", "metadata": {"page_label": "16", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "510b557b9d5e7d6a1d30ff2d3bd781acb7a93c451aaba90d79ce2d8bffb62942", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2efb6bb5-ee70-4803-b291-673b3279d5d4", "node_type": "1", "metadata": {"page_label": "16", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "536a57f138f63eceb6c57baa7bfcb30092dfd8b34cb3cc0a7d0a731200b5c475", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "14 Gatzoulis MA, Landzberg M, Beghetti M, et al. Evaluation of macitentan in patients with Eisenmenger\nsyndrome. Circulation 2019; 139: 51\u2013 63.\n15 Hoeper MM, Al-Hiti H, Benza RL, et al. Switching to riociguat versus maintenance therapy with\nphosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre,\nopen-label, randomised controlled trial.Lancet Respir Med2021; 9: 573\u2013 584.\n16 Howard LS, Rosenkranz S, Frantz RP,et al.Assessing daily life physical activity by actigraphy in pulmonary arterial\nhypertension: insights from the randomized controlled study with selexipag (TRACE).Chest 2023; 163: 407\u2013 418.\nhttps://doi.org/10.1183/13993003.01325-2024 16\nEUROPEAN RESPIRATORY JOURNAL 7TH WORLD SYMPOSIUM ON PULMONARY HYPERTENSION | K.M. CHIN ET AL.", "mimetype": "text/plain", "start_char_idx": 4777, "end_char_idx": 5569, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "6f3216fa-99e0-4495-b69d-bb8eb06b0efb": {"__data__": {"id_": "6f3216fa-99e0-4495-b69d-bb8eb06b0efb", "embedding": null, "metadata": {"page_label": "17", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "6656a408-9072-424b-a574-b2d5d7ae23fa", "node_type": "4", "metadata": {"page_label": "17", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "9aefe0faf15a2a411375b857b6d5244fd15fbccb371424924a00134b9447b35f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "363349bf-8bdf-471c-ad57-ccd1f0a3933a", "node_type": "1", "metadata": {}, "hash": "ada8caf56849550062d920600fb2c9a0f459c7ce0c95cd123e093a051dec50ca", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "17 Hoeper MM, Ewert R, Jansa P,et al. Randomized, multicenter study to assess the effects of different doses\nof sildenafil on mortality in adults with pulmonary arterial hypertension.Circulation 2024; 149: 1949\u2013 1959.\n18 Gali\u00e8 N, Ghofrani HA, Torbicki A,et al. Sildenafil citrate therapy for pulmonary arterial hypertension.N Engl\nJ Med2005; 353: 2148\u2013 2157.\n19 Simonneau G, Rubin LJ, Gali\u00e8 N,et al. Addition of sildenafil to long-term intravenous epoprostenol therapy\nin patients with pulmonary arterial hypertension: a randomized trial.Ann Intern Med2008; 149: 521\u2013 530.\n20 Gali\u00e8 N, Brundage BH, Ghofrani HA,et al. Tadalafil therapy for pulmonary arterial hypertension.Circulation\n2009; 119: 2894\u2013 2903.\n21 Gali\u00e8 N, Barber\u00e0 JA, Frost AE, et al . Initial use of ambrisentan plus tadalafil in pulmonary arterial\nhypertension. N Engl J Med2015; 373: 834\u2013 844.\n22 Ghofrani HA, Gali\u00e8 N, Grimminger F,et al. Riociguat for the treatment of pulmonary arterial hypertension.\nN Engl J Med2013; 369: 330\u2013 340.\n23 Pulido T, Adzerikho I, Channick RN, et al. Macitentan and morbidity and mortality in pulmonary arterial\nhypertension. N Engl J Med2013; 369: 809\u2013 818.\n24 Gali\u00e8 N, Olschewski H, Oudiz RJ,et al. Ambrisentan for the treatment of pulmonary arterial hypertension:\nresults of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind,\nplacebo-controlled, multicenter, efficacy (ARIES) study 1 and 2.Circulation 2008; 117: 3010\u2013 3019.\n25 Channick RN, Simonneau G, Sitbon O,et al.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1495, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "363349bf-8bdf-471c-ad57-ccd1f0a3933a": {"__data__": {"id_": "363349bf-8bdf-471c-ad57-ccd1f0a3933a", "embedding": null, "metadata": {"page_label": "17", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "6656a408-9072-424b-a574-b2d5d7ae23fa", "node_type": "4", "metadata": {"page_label": "17", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "9aefe0faf15a2a411375b857b6d5244fd15fbccb371424924a00134b9447b35f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6f3216fa-99e0-4495-b69d-bb8eb06b0efb", "node_type": "1", "metadata": {"page_label": "17", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "3db85ff490fc944fc2eef7ceed25e270b160112496ffa97e142229bf93b91f8b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a26b4899-0d39-4ddb-adf0-9bed04d7565f", "node_type": "1", "metadata": {}, "hash": "103ce00eb21e7fdfd563075fca1433bdf5990095db86b2245ae7a3e2f18f0ac1", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "25 Channick RN, Simonneau G, Sitbon O,et al. Effects of the dual endothelin-receptor antagonist bosentan in\npatients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001; 358:\n1119\u2013 1123.\n26 Rubin LJ, Badesch DB, Barst RJ,et al. Bosentan therapy for pulmonary arterial hypertension.N Engl J Med\n2002; 346: 896\u2013 903.\n27 Gali\u00e8 N, Badesch D, Oudiz R, et al. Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll\nCardiol 2005; 46: 529\u2013 535.\n28 Sitbon O, Channick R, Chin KM,et al. Selexipag for the treatment of pulmonary arterial hypertension.N Engl\nJ Med2015; 373: 2522\u2013 2533.\n29 Jing ZC, Parikh K, Pulido T,et al. Efficacy and safety of oral treprostinil monotherapy for the treatment of\npulmonary arterial hypertension: a randomized, controlled trial.Circulation 2013; 127: 624\u2013 633.\n30 Barst RJ, McGoon M, McLaughlin V,et al. Beraprost therapy for pulmonary arterial hypertension.J Am Coll\nCardiol 2003; 41: 2119\u2013 2125.\n31 Tapson VF, Jing ZC, Xu KF,et al. Oral treprostinil for the treatment of pulmonary arterial hypertension in\npatients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor\ntherapy (the FREEDOM-C2 study): a randomized controlled trial.Chest 2013; 144: 952\u2013 958.\n32 Tapson VF, Torres F, Kermeen F,et al. Oral treprostinil for the treatment of pulmonary arterial hypertension\nin patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor\ntherapy (the FREEDOM-C study): a randomized controlled trial.Chest 2012; 142: 1383\u2013 1390.", "mimetype": "text/plain", "start_char_idx": 1451, "end_char_idx": 3011, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "a26b4899-0d39-4ddb-adf0-9bed04d7565f": {"__data__": {"id_": "a26b4899-0d39-4ddb-adf0-9bed04d7565f", "embedding": null, "metadata": {"page_label": "17", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "6656a408-9072-424b-a574-b2d5d7ae23fa", "node_type": "4", "metadata": {"page_label": "17", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "9aefe0faf15a2a411375b857b6d5244fd15fbccb371424924a00134b9447b35f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "363349bf-8bdf-471c-ad57-ccd1f0a3933a", "node_type": "1", "metadata": {"page_label": "17", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "b07b6bc85b8c8fa53f14d7aa8b36c2731c64d8564a93015ce54cf53f1477afb5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f8f188ae-091e-477f-b425-0ce420677492", "node_type": "1", "metadata": {}, "hash": "603100d8f41f46734816484f27293aebba193a107ff79d8ce9a568e33151939f", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "33 McLaughlin VV, Benza RL, Rubin LJ, et al. Addition of inhaled treprostinil to oral therapy for pulmonary\narterial hypertension: a randomized controlled clinical trial.J Am Coll Cardiol2010; 55: 1915\u2013 1922.\n34 Olschewski H, Simonneau G, Gali\u00e8 N,et al. Inhaled iloprost for severe pulmonary hypertension.N Engl J\nMed 2002; 347: 322\u2013 329.\n35 Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin)\nwith conventional therapy for primary pulmonary hypertension.N Engl J Med1996; 334: 296\u2013 301.\n36 Simonneau G, Barst RJ, Galie N, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin\nanalogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled\ntrial.Am J Respir Crit Care Med2002; 165: 800\u2013 804.\n37 Sitbon O, Nikkho S, Benza R,et al. Novel composite clinical endpoints and risk scores used in clinical trials\nin pulmonary arterial hypertension.Pulm Circ2020; 10: 2045894020962960.\n38 Blette BS, Moutchia J, Al-Naamani N, et al. Is low-risk status a surrogate outcome in pulmonary arterial\nhypertension? An analysis of three randomised trials.Lancet Respir Med2023; 11: 873\u2013 882.\n39 Sharma A, Verma S, Bhatt DL,et al. Optimizing foundational therapies in patients with HFrEF: how do we\ntranslate these findings into clinical care?JACC Basic Transl Sci2022; 7: 504\u2013 517.\n40 Dardi F, Boucly A, Benza R,et al. Risk stratification and treatment goals in pulmonary arterial hypertension.\nEur Respir J2024; 64: 2401323.\n41 Benza RL, Kanwar MK, Raina A,et al.", "mimetype": "text/plain", "start_char_idx": 3012, "end_char_idx": 4572, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "f8f188ae-091e-477f-b425-0ce420677492": {"__data__": {"id_": "f8f188ae-091e-477f-b425-0ce420677492", "embedding": null, "metadata": {"page_label": "17", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "6656a408-9072-424b-a574-b2d5d7ae23fa", "node_type": "4", "metadata": {"page_label": "17", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "9aefe0faf15a2a411375b857b6d5244fd15fbccb371424924a00134b9447b35f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a26b4899-0d39-4ddb-adf0-9bed04d7565f", "node_type": "1", "metadata": {"page_label": "17", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "282f95770c36d6f933e33ff608d693e73b83a9810b7cb8031cda0fa12f30b801", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Risk stratification and treatment goals in pulmonary arterial hypertension.\nEur Respir J2024; 64: 2401323.\n41 Benza RL, Kanwar MK, Raina A,et al. Development and validation of an abridged version of the REVEAL 2.0\nrisk score calculator, REVEAL Lite 2, for use in patients with pulmonary arterial hypertension.Chest 2021;\n159: 337\u2013 346.\n42 Hoeper MM, Kramer T, Pan Z,et al. Mortality in pulmonary arterial hypertension: prediction by the 2015\nEuropean pulmonary hypertension guidelines risk stratification model.Eur Respir J2017; 50: 1700740.\n43 Boucly A, Weatherald J, Savale L, et al. Risk assessment, prognosis and guideline implementation in\npulmonary arterial hypertension.Eur Respir J2017; 50: 1700889.\nhttps://doi.org/10.1183/13993003.01325-2024 17\nEUROPEAN RESPIRATORY JOURNAL 7TH WORLD SYMPOSIUM ON PULMONARY HYPERTENSION | K.M. CHIN ET AL.", "mimetype": "text/plain", "start_char_idx": 4427, "end_char_idx": 5275, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "89cab3be-0e04-44ce-abe3-405a57c41158": {"__data__": {"id_": "89cab3be-0e04-44ce-abe3-405a57c41158", "embedding": null, "metadata": {"page_label": "18", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "96bbad54-f8ad-4af4-9292-0bc5be3d8462", "node_type": "4", "metadata": {"page_label": "18", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "630495b358d33b476c863eadbd6b1c15f0aa4791400f72b6bc0cc175d89087c0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f70ec346-0b6e-48c5-99ba-99e9db14c076", "node_type": "1", "metadata": {}, "hash": "1e079eaa18f89d4a53885f711a50e16177dde1fe0cd1e1918d87fc137c2c4408", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "44 Kylhammar D, Kjellstr\u00f6m B, Hjalmarsson C, et al. A comprehensive risk stratification at early follow-up\ndetermines prognosis in pulmonary arterial hypertension.Eur Heart J2018; 39: 4175\u2013 4181.\n45 McLaughlin VV, Gaine SP, Howard LS,et al. Treatment goals of pulmonary hypertension.J Am Coll Cardiol\n2013; 62: Suppl. 25, D73\u2013 D81.\n46 Gali\u00e8 N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS guidelines for the diagnosis and treatment of\npulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension\nof the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by:\nAssociation for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and\nLung Transplantation (ISHLT).Eur Respir J2015; 46: 903\u2013 975.\n47 Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC/ERS guidelines for the diagnosis and treatment of\npulmonary hypertension.Eur Respir J2023; 61: 2200879.\n48 Gali\u00e8 N, Channick RN, Frantz RP, et al. Risk stratification and medical therapy of pulmonary arterial\nhypertension. Eur Respir J2019; 53: 1801889.\n49 Addo M, Cornely O, Denkinger M, et al. RSV vaccination strategies for high-risk patients 2023: a\ncollaborative position paper by leading German medical societies and organizations. Infection 2024; 52:\n285\u2013 288.\n50 Gr\u00fcnig E, MacKenzie A, Peacock AJ,et al. Standardized exercise training is feasible, safe, and effective in\npulmonary arterial and chronic thromboembolic pulmonary hypertension: results from a large European\nmulticentre randomized controlled trial.Eur Heart J2021; 42: 2284\u2013 2295.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1607, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "f70ec346-0b6e-48c5-99ba-99e9db14c076": {"__data__": {"id_": "f70ec346-0b6e-48c5-99ba-99e9db14c076", "embedding": null, "metadata": {"page_label": "18", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "96bbad54-f8ad-4af4-9292-0bc5be3d8462", "node_type": "4", "metadata": {"page_label": "18", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "630495b358d33b476c863eadbd6b1c15f0aa4791400f72b6bc0cc175d89087c0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "89cab3be-0e04-44ce-abe3-405a57c41158", "node_type": "1", "metadata": {"page_label": "18", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "5960bc0c750834228725b855b641e0ff270db6f8f49012b3852ea55c07316630", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f55c21cd-439f-4bf5-9d28-65625c6b6150", "node_type": "1", "metadata": {}, "hash": "c7d8899885e1c861ec15872899625b2a49dbcb59a4aa85abb477d8c76a75505d", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "51 Kramer T, Wissm\u00fcller M, Natsina K, et al. Ferric carboxymaltose in patients with pulmonary arterial\nhypertension and iron deficiency: a long-term study.J Cachexia Sarcopenia Muscle2021; 12: 1501\u2013 1512.\n52 Weiss BM, Zemp L, Seifert B, et al. Outcome of pulmonary vascular disease in pregnancy: a systematic\noverview from 1978 through 1996.J Am Coll Cardiol1998; 31: 1650\u2013 1657.\n53 B\u00e9dard E, Dimopoulos K, Gatzoulis MA. Has there been any progress made on pregnancy outcomes among\nwomen with pulmonary arterial hypertension?Eur Heart J2009; 30: 256\u2013 265.\n54 Preston IR, Howard LS, Langleben D,et al. Management of pulmonary hypertension in special conditions.\nEur Respir J2024; 64: 2401180.\n55 Olsson KM, Delcroix M, Ghofrani HA,et al. Anticoagulation and survival in pulmonary arterial hypertension:\nresults from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension\n(COMPERA). Circulation 2014; 129: 57\u2013 65.\n56 Preston IR, Roberts KE, Miller DP,et al. Effect of warfarin treatment on survival of patients with pulmonary\narterial hypertension (PAH) in the Registry to Evaluate Early and Long-Term PAH Disease Management\n(REVEAL).Circulation 2015; 132: 2403\u2013 2411.\n57 Khan MS, Usman MS, Siddiqi TJ,et al. Is anticoagulation beneficial in pulmonary arterial hypertension?Circ\nCardiovasc Qual Outcomes2018; 11: e004757.\n58 Wang P, Hu L, Yin Y, et al. Can anticoagulants improve the survival rate for patients with idiopathic\npulmonary arterial hypertension? A systematic review and meta-analysis.Thromb Res2020; 196: 251\u2013 256.", "mimetype": "text/plain", "start_char_idx": 1608, "end_char_idx": 3173, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "f55c21cd-439f-4bf5-9d28-65625c6b6150": {"__data__": {"id_": "f55c21cd-439f-4bf5-9d28-65625c6b6150", "embedding": null, "metadata": {"page_label": "18", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "96bbad54-f8ad-4af4-9292-0bc5be3d8462", "node_type": "4", "metadata": {"page_label": "18", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "630495b358d33b476c863eadbd6b1c15f0aa4791400f72b6bc0cc175d89087c0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f70ec346-0b6e-48c5-99ba-99e9db14c076", "node_type": "1", "metadata": {"page_label": "18", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "1021b3a2e747e231406323388492b928ebabd3bd884b678973651bd82320784c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f9a66bb8-404d-4cea-8fb6-ab310583e9b3", "node_type": "1", "metadata": {}, "hash": "240196ed2ccb8581dd1832490e2d250cb4e687733dfb01ad0a0e7b625ea59f69", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Can anticoagulants improve the survival rate for patients with idiopathic\npulmonary arterial hypertension? A systematic review and meta-analysis.Thromb Res2020; 196: 251\u2013 256.\n59 Adegunsoye A, Strek ME, Garrity E,et al. Comprehensive care of the lung transplant patient.Chest 2017;\n152: 150\u2013 164.\n60 Gerhardt F, Fiessler E, Olsson KM,et al. Positive vasoreactivity testing in pulmonary arterial hypertension:\ntherapeutic consequences, treatment patterns, and outcomes in the modern management era.Circulation\n2024; 149: 1549\u2013 1564.\n61 Simonneau G, Montani D, Celermajer DS, et al. Haemodynamic definitions and updated clinical\nclassification of pulmonary hypertension.Eur Respir J2019; 53: 1801913.\n62 Nathan SD, Barnett SD, King CS,et al. Impact of the new definition for pulmonary hypertension in patients\nwith lung disease: an analysis of the United Network for Organ Sharing database. Pulm Circ 2021; 11:\n2045894021999960.\n63 Pan Z, Marra AM, Benjamin N,et al. Early treatment with ambrisentan of mildly elevated mean pulmonary\narterial pressure associated with systemic sclerosis: a randomized, controlled, double-blind, parallel group\nstudy (EDITA study).Arthritis Res Ther2019; 21: 217.\n64 Saggar R, Khanna D, Shapiro S, et al. Brief report: effect of ambrisentan treatment on exercise-induced\npulmonary hypertension in systemic sclerosis: a prospective single-center, open-label pilot study.Arthritis\nRheum 2012; 64: 4072\u2013 4077.\n65 Kovacs G, Olschewski A, Berghold A, et al. Pulmonary vascular resistances during exercise in normal\nsubjects: a systematic review.Eur Respir J2012; 39: 319\u2013 328.\n66 Kovacs G, Bartolome S, Denton CP,et al. Definition, classification and diagnosis of pulmonary hypertension.\nEur Respir J2024; 64: 2401324.", "mimetype": "text/plain", "start_char_idx": 2998, "end_char_idx": 4741, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "f9a66bb8-404d-4cea-8fb6-ab310583e9b3": {"__data__": {"id_": "f9a66bb8-404d-4cea-8fb6-ab310583e9b3", "embedding": null, "metadata": {"page_label": "18", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "96bbad54-f8ad-4af4-9292-0bc5be3d8462", "node_type": "4", "metadata": {"page_label": "18", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "630495b358d33b476c863eadbd6b1c15f0aa4791400f72b6bc0cc175d89087c0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f55c21cd-439f-4bf5-9d28-65625c6b6150", "node_type": "1", "metadata": {"page_label": "18", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "10f9f6a3be0105b6ad9c3ccd770060c79b8590673ad9cc10bc2aab485df3383c", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "66 Kovacs G, Bartolome S, Denton CP,et al. Definition, classification and diagnosis of pulmonary hypertension.\nEur Respir J2024; 64: 2401324.\n67 McLaughlin V, Channick RN, Ghofrani HA, et al. Bosentan added to sildenafil therapy in patients with\npulmonary arterial hypertension.Eur Respir J2015; 46: 405\u2013 413.\nhttps://doi.org/10.1183/13993003.01325-2024 18\nEUROPEAN RESPIRATORY JOURNAL 7TH WORLD SYMPOSIUM ON PULMONARY HYPERTENSION | K.M. CHIN ET AL.", "mimetype": "text/plain", "start_char_idx": 4600, "end_char_idx": 5050, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "ef985fcc-2625-4241-817b-cdaa881c4689": {"__data__": {"id_": "ef985fcc-2625-4241-817b-cdaa881c4689", "embedding": null, "metadata": {"page_label": "19", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "35714a6b-6a03-414b-81b5-d7d8ae4d7c37", "node_type": "4", "metadata": {"page_label": "19", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "4eb3c7cb047ff4511c13725ddc151f908ff2a6d1a1fc8c3dbcb7800cf004bb57", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "54570a77-e1bf-4e4c-9fc4-9f76417f85d4", "node_type": "1", "metadata": {}, "hash": "542da48440fd698168c97b9f4b36e0185e0e496b2884dddcdc60a917e0e15bdd", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "68 Badesch DB, Tapson VF, McGoon MD, et al. Continuous intravenous epoprostenol for pulmonary\nhypertension due to the scleroderma spectrum of disease. A randomized, controlled trial.Ann Intern Med\n2000; 132: 425\u2013 434.\n69 Cascino TM, McLaughlin VV. Upfront combination therapy for pulmonary arterial hypertension: time to be\nmore ambitious than AMBITION.Am J Respir Crit Care Med2021; 204: 756\u2013 759.\n70 Savale L, Benazzo A, Corris P, et al. Transplantation, bridging, and support technologies in pulmonary\nhypertension. Eur Respir J2024; 64: 2401193.\n71 Coghlan JG, Gaine S, Channick R, et al. Early selexipag initiation and long-term outcomes: insights from\nrandomised controlled trials in pulmonary arterial hypertension.ERJ Open Res2023; 9: 00456-2022.\n72 Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC/ERS guidelines for the diagnosis and treatment of\npulmonary hypertension.Eur Heart J2022; 43: 3618\u2013 3731.\n73 Gaine S, Sitbon O, Channick RN,et al. Relationship between time from diagnosis and morbidity/mortality in\npulmonary arterial hypertension: results from the phase III GRIPHON study.Chest 2021; 160: 277\u2013 286.\n74 Pan HM, McClelland RL, Moutchia J,et al. Heterogeneity of treatment effects by risk in pulmonary arterial\nhypertension. Eur Respir J2023; 62: 2300190.\n75 Kim NH, Fisher M, Poch D, et al. Long-term outcomes in pulmonary arterial hypertension by functional\nclass: a meta-analysis of randomized controlled trials and observational registries. Pulm Circ 2020; 10:\n2045894020935291.\n76 Benza RL, Gomberg-Maitland M, Elliott CG, et al.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1554, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "54570a77-e1bf-4e4c-9fc4-9f76417f85d4": {"__data__": {"id_": "54570a77-e1bf-4e4c-9fc4-9f76417f85d4", "embedding": null, "metadata": {"page_label": "19", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "35714a6b-6a03-414b-81b5-d7d8ae4d7c37", "node_type": "4", "metadata": {"page_label": "19", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "4eb3c7cb047ff4511c13725ddc151f908ff2a6d1a1fc8c3dbcb7800cf004bb57", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ef985fcc-2625-4241-817b-cdaa881c4689", "node_type": "1", "metadata": {"page_label": "19", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "cea7a34aa7d10099232c7dd19eb475bda6bc939179596a7e64096809c190d3a7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b8b12894-9b4b-4dac-8772-a6accb1a43f0", "node_type": "1", "metadata": {}, "hash": "908e9a9fc012b6bc5a57afa01ec44d3f974d2b6fff0eb6415ad2f8a95b85e513", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Pulm Circ 2020; 10:\n2045894020935291.\n76 Benza RL, Gomberg-Maitland M, Elliott CG, et al. Predicting survival in patients with pulmonary arterial\nhypertension: the REVEAL risk score calculator 2.0 and comparison with ESC/ERS-based risk assessment\nstrategies.Chest 2019; 156: 232\u2013 337.\n77 Weatherald J, Boucly A, Chemla D,et al. Prognostic value of follow-up hemodynamic variables after initial\nmanagement in pulmonary arterial hypertension.Circulation 2018; 137: 693\u2013 704.\n78 Badagliacca R, D\u2019Alto M, Ghio S,et al. Risk reduction and hemodynamics with initial combination therapy in\npulmonary arterial hypertension.Am J Respir Crit Care Med2021; 203: 484\u2013 492.\n79 D\u2019Alto M, Badagliacca R, Argiento P, et al. Risk reduction and right heart reverse remodeling by upfront\ntriple combination therapy in pulmonary arterial hypertension.Chest 2020; 157: 376\u2013 383.\n80 Boucly A, Beurnier A, Turquier S, et al. Risk stratification refinements with inclusion of haemodynamic\nvariables at follow-up in patients with pulmonary arterial hypertension.Eur Respir J2024; 63: 2400197.\n81 van de Veerdonk MC, Kind T, Marcus JT,et al. Progressive right ventricular dysfunction in patients with\npulmonary arterial hypertension responding to therapy.J Am Coll Cardiol2011; 58: 2511\u2013 2519.\n82 Souza R, Badesch DB, Ghofrani HA,et al. Effects of sotatercept on haemodynamics and right heart function:\nanalysis of the STELLAR trial.Eur Respir J2023; 62: 2301107.\n83 McLaughlin VV, Oudiz RJ, Frost A,et al. Randomized study of adding inhaled iloprost to existing bosentan in\npulmonary arterial hypertension.Am J Respir Crit Care Med2006; 174: 1257\u2013 1263.", "mimetype": "text/plain", "start_char_idx": 1465, "end_char_idx": 3093, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "b8b12894-9b4b-4dac-8772-a6accb1a43f0": {"__data__": {"id_": "b8b12894-9b4b-4dac-8772-a6accb1a43f0", "embedding": null, "metadata": {"page_label": "19", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "35714a6b-6a03-414b-81b5-d7d8ae4d7c37", "node_type": "4", "metadata": {"page_label": "19", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "4eb3c7cb047ff4511c13725ddc151f908ff2a6d1a1fc8c3dbcb7800cf004bb57", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "54570a77-e1bf-4e4c-9fc4-9f76417f85d4", "node_type": "1", "metadata": {"page_label": "19", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "e18f5a32c621bf3a40ca3b5d7eec6f0e3a1529242bfd9db5c2153fc7b2e9d57d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a35925db-c7f1-4a62-9124-c9221eab866f", "node_type": "1", "metadata": {}, "hash": "ca58eec7b178109b09c22ebef2b0a2ded0346b9505db142afb1b5a56a9c794b3", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Randomized study of adding inhaled iloprost to existing bosentan in\npulmonary arterial hypertension.Am J Respir Crit Care Med2006; 174: 1257\u2013 1263.\n84 Picken C, Fragkos KC, Eddama M, et al. Adverse events of prostacyclin mimetics in pulmonary arterial\nhypertension: a systematic review and meta-analysis.J Clin Med2019; 8: 481.\n85 Hoeper MM, Simonneau G, Corris PA,et al.RESPITE: switching to riociguat in pulmonary arterial hypertension\npatients with inadequate response to phosphodiesterase-5 inhibitors.Eur Respir J2017; 50: 1602425.\n86 Harter ZJ, Agarwal S, Dalvi P,et al. Drug abuse and HIV-related pulmonary hypertension: double hit injury.\nAIDS 2018; 32: 2651\u2013 2667.\n87 Egan TM, Edwards LB. Effect of the lung allocation score on lung transplantation in the United States.\nJ Heart Lung Transplant2016; 35: 433\u2013 439.\n88 Kolaitis NA, Chen H, Calabrese DR,et al. The lung allocation score remains inequitable for patients with\npulmonary arterial hypertension, even after the 2015 revision.Am J Respir Crit Care Med2023; 207: 300\u2013 311.\n89 Savale L, Le Pavec J, Mercier O, et al. Impact of high-priority allocation on lung and heart-lung\ntransplantation for pulmonary hypertension.Ann Thorac Surg2017; 104: 404\u2013 411.\n90 McLaughlin VV, Vachiery JL, Oudiz RJ,et al. Patients with pulmonary arterial hypertension with and without\ncardiovascular risk factors: results from the AMBITION trial.J Heart Lung Transplant2019; 38: 1286\u2013 1295.\n91 Harder EM, Divo MJ, Washko GR,et al. Implications of mean pulmonary arterial wedge pressure trajectories\nin pulmonary arterial hypertension.Am J Respir Crit Care Med2024; 209: 316\u2013 324.", "mimetype": "text/plain", "start_char_idx": 2946, "end_char_idx": 4569, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "a35925db-c7f1-4a62-9124-c9221eab866f": {"__data__": {"id_": "a35925db-c7f1-4a62-9124-c9221eab866f", "embedding": null, "metadata": {"page_label": "19", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "35714a6b-6a03-414b-81b5-d7d8ae4d7c37", "node_type": "4", "metadata": {"page_label": "19", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "4eb3c7cb047ff4511c13725ddc151f908ff2a6d1a1fc8c3dbcb7800cf004bb57", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b8b12894-9b4b-4dac-8772-a6accb1a43f0", "node_type": "1", "metadata": {"page_label": "19", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "ee2d45d1cf2207ba522736062fb6accbf64cd6740634112babad25f5503a3aa6", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "91 Harder EM, Divo MJ, Washko GR,et al. Implications of mean pulmonary arterial wedge pressure trajectories\nin pulmonary arterial hypertension.Am J Respir Crit Care Med2024; 209: 316\u2013 324.\n92 Kianzad A, van Wezenbeek J, Celant LR,et al. Idiopathic pulmonary arterial hypertension patients with a\nhigh H2FPEF-score: insights from the Amsterdam UMC PAH-cohort. J Heart Lung Transplant 2022; 41:\n1075\u2013 1085.\n93 Rosenkranz S, Channick R, Chin KM, et al. The impact of comorbidities on selexipag treatment effect in\npatients with pulmonary arterial hypertension: insights from the GRIPHON study.Eur J Heart Fail2022; 24:\n205\u2013 214.\n94 Hoeper MM, Dwivedi K, Pausch C, et al. Phenotyping of idiopathic pulmonary arterial hypertension: a\nregistry analysis.Lancet Respir Med2022; 10: 937\u2013 948.\n95 Shlobin OA, Adir Y, Barbera JA,et al. Pulmonary hypertension associated with lung diseases.Eur Respir J\n2024; 64: 2401200.\nhttps://doi.org/10.1183/13993003.01325-2024 19\nEUROPEAN RESPIRATORY JOURNAL 7TH WORLD SYMPOSIUM ON PULMONARY HYPERTENSION | K.M. CHIN ET AL.", "mimetype": "text/plain", "start_char_idx": 4381, "end_char_idx": 5431, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "f343b160-28aa-4823-95a2-e9408e25c95f": {"__data__": {"id_": "f343b160-28aa-4823-95a2-e9408e25c95f", "embedding": null, "metadata": {"page_label": "20", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "7dd90457-d3c3-4ffb-b1a9-3ec1ccd68129", "node_type": "4", "metadata": {"page_label": "20", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "3b21afd2198aab8fec5d51ffb06364405d5a3b771be3d4d5b808ae437f2d895d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6b702833-fbdc-4732-ba97-bb023faa3e10", "node_type": "1", "metadata": {}, "hash": "72ecaa0db2adad33edb22bcd5585f38c79fff575cda6f22a182573d069fac3e2", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "96 Vachi\u00e9ry JL, Delcroix M, Al-Hiti H, et al. Macitentan in pulmonary hypertension due to left ventricular\ndysfunction. Eur Respir J2018; 51: 1701886.\n97 Hoeper MM, Pausch C, Gr\u00fcnig E,et al. Idiopathic pulmonary arterial hypertension phenotypes determined\nby cluster analysis from the COMPERA registry.J Heart Lung Transplant2020; 39: 1435\u2013 1444.\n98 Raghu G, Behr J, Brown KK,et al. Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel,\nrandomized trial.Ann Intern Med2013; 158: 641\u2013 649.\n99 Raghu G, Million-Rousseau R, Morganti A, et al. Macitentan for the treatment of idiopathic pulmonary\nfibrosis: the randomised controlled MUSIC trial.Eur Respir J2013; 42: 1622\u2013 1632.\n100 Nathan SD, Behr J, Collard HR,et al. Riociguat for idiopathic interstitial pneumonia-associated pulmonary\nhypertension (RISE-IIP): a randomised, placebo-controlled phase 2b study. Lancet Respir Med 2019; 7:\n780\u2013 790.\n101 Bermejo J, Yotti R, Garc\u00eda-Orta R,et al. Sildenafil for improving outcomes in patients with corrected valvular\nheart disease and persistent pulmonary hypertension: a multicenter, double-blind, randomized clinical trial.\nEur Heart J2018; 39: 1255\u2013 1264.\n102 Nathan SD, Barbera JA, Gaine SP,et al. Pulmonary hypertension in chronic lung disease and hypoxia.Eur\nRespir J2019; 53: 1801914.\n103 Packer M, McMurray JJV, Krum H,et al. Long-term effect of endothelin receptor antagonism with bosentan\non the morbidity and mortality of patients with severe chronic heart failure: primary results of the ENABLE\ntrials.JACC Heart Fail2017; 5: 317\u2013 326.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1560, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "6b702833-fbdc-4732-ba97-bb023faa3e10": {"__data__": {"id_": "6b702833-fbdc-4732-ba97-bb023faa3e10", "embedding": null, "metadata": {"page_label": "20", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "7dd90457-d3c3-4ffb-b1a9-3ec1ccd68129", "node_type": "4", "metadata": {"page_label": "20", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "3b21afd2198aab8fec5d51ffb06364405d5a3b771be3d4d5b808ae437f2d895d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f343b160-28aa-4823-95a2-e9408e25c95f", "node_type": "1", "metadata": {"page_label": "20", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "1cb8d26962c3936b9a6b28e6e76b11bc82d209c30b82f70e888c99ca8dc87d88", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0b425afd-fd6a-465d-9a28-cabda7071ac6", "node_type": "1", "metadata": {}, "hash": "e014c6a3d8fe3f97ffe0115fc396c3228b9ed2dbebfb4cfbbbae75e43025b53d", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "104 Machado RF, Barst RJ, Yovetich NA,et al. Hospitalization for pain in patients with sickle cell disease treated\nwith sildenafil for elevated TRV and low exercise capacity.Blood 2011; 118: 855\u2013 864.\n105 Hoeper MM, Oerke B, Wissm\u00fcller M, et al. Tadalafil for treatment of combined postcapillary and\nprecapillary pulmonary hypertension in patients with heart failure and preserved ejection fraction: a\nrandomized controlled phase 3 study.Circulation 2024; 150: 600\u2013 610.\n106 Maron BA, Bortman G, De Marco T,et al. Pulmonary hypertension associated with left heart disease.Eur\nRespir J2024; 64: 2401344.\n107 Rhee RL, Gabler NB, Sangani S,et al. Comparison of treatment response in idiopathic and connective tissue\ndisease-associated pulmonary arterial hypertension.Am J Respir Crit Care Med2015; 192: 1111\u2013 1117.\n108 Khanna D, Zhao C, Saggar R, et al. Long-term outcomes in patients with connective tissue\ndisease-associated pulmonary arterial hypertension in the modern treatment era: meta-analyses of\nrandomized, controlled trials and observational registries.Arthritis Rheumatol2021; 73: 837\u2013 847.\n109 Coghlan JG, Denton CP, Gr\u00fcnig E, et al. Evidence-based detection of pulmonary arterial hypertension in\nsystemic sclerosis: the DETECT study.Ann Rheum Dis2014; 73: 1340\u2013 1349.\n110 Xanthouli P, Jordan S, Milde N, et al. Haemodynamic phenotypes and survival in patients with systemic\nsclerosis: the impact of the new definition of pulmonary arterial hypertension.Ann Rheum Dis 2020; 79:\n370\u2013 378.\n111 Chung L, Domsic RT, Lingala B,et al.", "mimetype": "text/plain", "start_char_idx": 1561, "end_char_idx": 3099, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "0b425afd-fd6a-465d-9a28-cabda7071ac6": {"__data__": {"id_": "0b425afd-fd6a-465d-9a28-cabda7071ac6", "embedding": null, "metadata": {"page_label": "20", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "7dd90457-d3c3-4ffb-b1a9-3ec1ccd68129", "node_type": "4", "metadata": {"page_label": "20", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "3b21afd2198aab8fec5d51ffb06364405d5a3b771be3d4d5b808ae437f2d895d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6b702833-fbdc-4732-ba97-bb023faa3e10", "node_type": "1", "metadata": {"page_label": "20", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "0269a0c1a3ed64fc3ddf248a963992569066ec18198013c289f836dfa9ae8d27", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "42b1197e-485b-45b9-9b88-a4911a3021d2", "node_type": "1", "metadata": {}, "hash": "7bb95ade73c240e2e113d374c9aa798efb8daed2ceb574b40fa7c15b16529d48", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "111 Chung L, Domsic RT, Lingala B,et al. Survival and predictors of mortality in systemic sclerosis-associated\npulmonary arterial hypertension: outcomes from the pulmonary hypertension assessment and recognition\nof outcomes in scleroderma registry.Arthritis Care Res2014; 66: 489\u2013 495.\n112 Hassan HJ, Naranjo M, Ayoub N, et al. Improved survival for patients with systemic sclerosis-associated\npulmonary arterial hypertension: the Johns Hopkins registry.Am J Respir Crit Care Med2023; 207: 312\u2013 322.\n113 Mathai SC, Puhan MA, Lam D,et al. The minimal important difference in the 6-minute walk test for patients\nwith pulmonary arterial hypertension.Am J Respir Crit Care Med2012; 186: 428\u2013 433.\n114 Dorfm\u00fcller P, Humbert M, Perros F,et al. Fibrous remodeling of the pulmonary venous system in pulmonary\narterial hypertension associated with connective tissue diseases.Hum Pathol2007; 38: 893\u2013 902.\n115 G\u00fcnther S, Ja\u00efs X, Maitre S,et al. Computed tomography findings of pulmonary venoocclusive disease in\nscleroderma patients presenting with precapillary pulmonary hypertension. Arthritis Rheum 2012; 64:\n2995\u2013 3005.\n116 Kuwana M, Blair C, Takahashi T,et al.Initial combination therapy of ambrisentan and tadalafil in connective\ntissue disease-associated pulmonary arterial hypertension (CTD-PAH) in the modified intention-to-treat\npopulation of the AMBITION study:post hocanalysis. Ann Rheum Dis2020; 79: 626\u2013 634.\n117 Mullin CJ, Khair RM, Damico RL, et al. Validation of the REVEAL prognostic equation and risk score\ncalculator in incident systemic sclerosis-associated pulmonary arterial hypertension. Arthritis Rheumatol\n2019; 71: 1691\u2013 1700.\n118 Brida M, Gatzoulis MA. Pulmonary arterial hypertension in adult congenital heart disease.Heart 2018; 104:\n1568\u2013 1574.", "mimetype": "text/plain", "start_char_idx": 3059, "end_char_idx": 4824, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "42b1197e-485b-45b9-9b88-a4911a3021d2": {"__data__": {"id_": "42b1197e-485b-45b9-9b88-a4911a3021d2", "embedding": null, "metadata": {"page_label": "20", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "7dd90457-d3c3-4ffb-b1a9-3ec1ccd68129", "node_type": "4", "metadata": {"page_label": "20", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "3b21afd2198aab8fec5d51ffb06364405d5a3b771be3d4d5b808ae437f2d895d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0b425afd-fd6a-465d-9a28-cabda7071ac6", "node_type": "1", "metadata": {"page_label": "20", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "3c7c5e2c4da5940c967977e6a1fdb28580fa0fe5987bf550b30f5277c2906c9a", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "118 Brida M, Gatzoulis MA. Pulmonary arterial hypertension in adult congenital heart disease.Heart 2018; 104:\n1568\u2013 1574.\n119 Gali\u00e8 N, Beghetti M, Gatzoulis MA, et al. Bosentan therapy in patients with Eisenmenger syndrome: a\nmulticenter, double-blind, randomized, placebo-controlled study.Circulation 2006; 114: 48\u2013 54.\n120 Mukhopadhyay S, Nathani S, Yusuf J, et al. Clinical efficacy of phosphodiesterase-5 inhibitor tadalafil in\nEisenmenger syndrome \u2013 a randomized, placebo-controlled, double-blind crossover study.Congenit Heart\nDis 2011; 6: 424\u2013 431.\nhttps://doi.org/10.1183/13993003.01325-2024 20\nEUROPEAN RESPIRATORY JOURNAL 7TH WORLD SYMPOSIUM ON PULMONARY HYPERTENSION | K.M. CHIN ET AL.", "mimetype": "text/plain", "start_char_idx": 4703, "end_char_idx": 5399, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "8d6226c1-2cbf-4d5d-90bf-eb2ec99f8156": {"__data__": {"id_": "8d6226c1-2cbf-4d5d-90bf-eb2ec99f8156", "embedding": null, "metadata": {"page_label": "21", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "0aad7860-77ee-4e44-9e82-2117738954e5", "node_type": "4", "metadata": {"page_label": "21", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "885383729ee819fb817857bc67ff3475c2012a9262a21064af1932bc53219ec3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5ab467e3-7122-4b75-a9e9-a3a697961efc", "node_type": "1", "metadata": {}, "hash": "f63c8b601925c52dd7b0bf03191f60cc482fc0397006bb7232c6a8ac7fffdab0", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "121 D\u2019Alto M, Constantine A, Balint OH,et al. The effects of parenteral prostacyclin therapy as add-on treatment\nto oral compounds in Eisenmenger syndrome.Eur Respir J2019; 54: 1901401.\n122 Zhang ZN, Jiang X, Zhang R, et al. Oral sildenafil treatment for Eisenmenger syndrome: a prospective,\nopen-label, multicentre study.Heart 2011; 97: 1876\u2013 1881.\n123 Zuckerman WA, Leaderer D, Rowan CA, et al. Ambrisentan for pulmonary arterial hypertension due to\ncongenital heart disease.Am J Cardiol2011; 107: 1381\u2013 1385.\n124 Dimopoulos K, Inuzuka R, Goletto S,et al. Improved survival among patients with Eisenmenger syndrome\nreceiving advanced therapy for pulmonary arterial hypertension.Circulation 2010; 121: 20\u2013 25.\n125 Luna-Lopez R, Segura de la Cal T, Sarnago Cebada F,et al. Triple vasodilator therapy in pulmonary arterial\nhypertension associated with congenital heart disease.Heart 2024; 110: 346\u2013 352.\n126 Hasco\u00ebt S, Baruteau AE, Humbert M,et al. Long-term outcomes of pulmonary arterial hypertension under\nspecific drug therapy in Eisenmenger syndrome.J Heart Lung Transplant2017; 36: 386\u2013 398.\n127 Kaemmerer AS, Gorenflo M, Huscher D,et al. Medical treatment of pulmonary hypertension in adults with\ncongenital heart disease: updated and extended results from the International COMPERA-CHD registry.\nCardiovasc Diagn Ther2021; 11: 1255\u2013 1268.\n128 Savale L, Manes A. Pulmonary arterial hypertension populations of special interest: portopulmonary\nhypertension and pulmonary arterial hypertension associated with congenital heart disease.Eur Heart J\nSuppl 2019; 21: Suppl. K, K37\u2013 K45.\n129 Kempny A, Hjortsh\u00f8j CS, Gu H,et al.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1626, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "5ab467e3-7122-4b75-a9e9-a3a697961efc": {"__data__": {"id_": "5ab467e3-7122-4b75-a9e9-a3a697961efc", "embedding": null, "metadata": {"page_label": "21", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "0aad7860-77ee-4e44-9e82-2117738954e5", "node_type": "4", "metadata": {"page_label": "21", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "885383729ee819fb817857bc67ff3475c2012a9262a21064af1932bc53219ec3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8d6226c1-2cbf-4d5d-90bf-eb2ec99f8156", "node_type": "1", "metadata": {"page_label": "21", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "6f9a7654e5ea1d9c5ff72a3141bd5841c1cbee1eee275e7e7e4af399193178aa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "470c6f81-d686-4ef2-a5f1-2c7c1916c2a4", "node_type": "1", "metadata": {}, "hash": "b41820557b8254dfd108fd93d8451ffc9fa78df2043f0773350793275b9de19d", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "K, K37\u2013 K45.\n129 Kempny A, Hjortsh\u00f8j CS, Gu H,et al. Predictors of death in contemporary adult patients with Eisenmenger\nsyndrome: a multicenter study.Circulation 2017; 135: 1432\u2013 1440.\n130 Kearney K, Lau EM, Darley D, et al. Waitlist and post-transplant outcomes for Eisenmenger syndrome: a\ncomparison of transplant strategies.J Heart Lung Transplant2021; 40: 841\u2013 849.\n131 Wang Z, Li X, Li M, et al. The efficacy of the treat-repair-treat strategy for severe pulmonary arterial\nhypertension associated with congenital heart disease: a meta-analysis.BMC Cardiovasc Disord 2023; 23:\n569.\n132 Ivy D, Rosenzweig EB, Abman SH,et al. Embracing the challenges of neonatal and paediatric pulmonary\nhypertension. Eur Respir J2024; 64: 2401345.\n133 Weatherald J, Chaumais MC, Savale L,et al. Long-term outcomes of dasatinib-induced pulmonary arterial\nhypertension: a population-based study.Eur Respir J2017; 50: 1700217.\n134 Savale L, Chaumais MC, O\u2019Connell C, et al. Interferon-induced pulmonary hypertension: an update. Curr\nOpin Pulm Med2016; 22: 415\u2013 420.\n135 Ranchoux B, G\u00fcnther S, Quarck R,et al. Chemotherapy-induced pulmonary hypertension: role of alkylating\nagents. Am J Pathol2015; 185: 356\u2013 371.\n136 Kolaitis NA, Zamanian RT, de Jesus Perez VA, et al. Clinical differences and outcomes between\nmethamphetamine-associated and idiopathic pulmonary arterial hypertension in the pulmonary\nhypertension association registry.Ann Am Thorac Soc2021; 18: 613\u2013 622.\n137 Zamanian RT, Hedlin H, Greuenwald P, et al.", "mimetype": "text/plain", "start_char_idx": 1574, "end_char_idx": 3080, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "470c6f81-d686-4ef2-a5f1-2c7c1916c2a4": {"__data__": {"id_": "470c6f81-d686-4ef2-a5f1-2c7c1916c2a4", "embedding": null, "metadata": {"page_label": "21", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "0aad7860-77ee-4e44-9e82-2117738954e5", "node_type": "4", "metadata": {"page_label": "21", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "885383729ee819fb817857bc67ff3475c2012a9262a21064af1932bc53219ec3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5ab467e3-7122-4b75-a9e9-a3a697961efc", "node_type": "1", "metadata": {"page_label": "21", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "e046ee6b652b6864b8a6ece03137a9eb82d05b62aac76e8174f84d7d97788b55", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9577ee16-f52b-44a2-b6c5-c21c86b600d4", "node_type": "1", "metadata": {}, "hash": "543e71e6e1ee4cf183a7a7ba6173013ada49fc88af3633671abfe6242a72bdd2", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "137 Zamanian RT, Hedlin H, Greuenwald P, et al. Features and outcomes of methamphetamine-associated\npulmonary arterial hypertension.Am J Respir Crit Care Med2018; 197: 788\u2013 800.\n138 Salvador ML, Rodr\u00edguez-Padial L, Soto Ab\u00e1nades C, et al. Management and prognosis of HIV-associated\npulmonary arterial hypertension: 20 years of evidence from the REHAP registry.J Intern Med 2022; 292:\n116\u2013 126.\n139 Kolaitis NA, Lammi M, Mazimba S,et al. HIV-associated pulmonary arterial hypertension: a report from the\nPulmonary Hypertension Association Registry.Am J Respir Crit Care Med2022; 205: 1121\u2013 1124.\n140 Sitbon O, Gressin V, Speich R, et al. Bosentan for the treatment of human immunodeficiency\nvirus-associated pulmonary arterial hypertension.Am J Respir Crit Care Med2004; 170: 1212\u2013 1217.\n141 Degano B, Guillaume M, Savale L, et al. HIV-associated pulmonary arterial hypertension: survival and\nprognostic factors in the modern therapeutic era.AIDS 2010; 24: 67\u2013 75.\n142 Chinello P, Petrosillo N. Pharmacological treatment of HIV-associated pulmonary hypertension.Expert Rev\nClin Pharmacol2016; 9: 715\u2013 725.\n143 Atsukawa M, Tsubota A, Hatano M,et al. Prevalence and characteristics of portopulmonary hypertension in\ncirrhotic patients who underwent both hepatic vein and pulmonary artery catheterization.Hepatol Res2020;\n50: 1244\u2013 1254.\n144 Badesch DB, Raskob GE, Elliott CG,et al. Pulmonary arterial hypertension: baseline characteristics from the\nREVEAL registry.Chest 2010; 137: 376\u2013 387.\n145 Humbert M, Sitbon O, Chaouat A,et al. Pulmonary arterial hypertension in France: results from a national\nregistry.", "mimetype": "text/plain", "start_char_idx": 3033, "end_char_idx": 4640, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "9577ee16-f52b-44a2-b6c5-c21c86b600d4": {"__data__": {"id_": "9577ee16-f52b-44a2-b6c5-c21c86b600d4", "embedding": null, "metadata": {"page_label": "21", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "0aad7860-77ee-4e44-9e82-2117738954e5", "node_type": "4", "metadata": {"page_label": "21", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "885383729ee819fb817857bc67ff3475c2012a9262a21064af1932bc53219ec3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "470c6f81-d686-4ef2-a5f1-2c7c1916c2a4", "node_type": "1", "metadata": {"page_label": "21", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "e45efc8b50c3a101c5aae5ba5c42cc32d0d69ad9ac2da2f971726025c31f3f6b", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "145 Humbert M, Sitbon O, Chaouat A,et al. Pulmonary arterial hypertension in France: results from a national\nregistry. Am J Respir Crit Care Med2006; 173: 1023\u2013 1030.\n146 Tamura Y, Kumamaru H, Inami T,et al. Changes in the characteristics and initial treatments of pulmonary\nhypertension between 2008 and 2020 in Japan.JACC Asia2022; 2: 273\u2013 284.\n147 Hadengue A, Benhayoun MK, Lebrec D, et al. Pulmonary hypertension complicating portal hypertension:\nprevalence and relation to splanchnic hemodynamics.Gastroenterology 1991; 100: 520\u2013 528.\nhttps://doi.org/10.1183/13993003.01325-2024 21\nEUROPEAN RESPIRATORY JOURNAL 7TH WORLD SYMPOSIUM ON PULMONARY HYPERTENSION | K.M. CHIN ET AL.", "mimetype": "text/plain", "start_char_idx": 4522, "end_char_idx": 5202, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "a6913d12-efbe-4eef-8b55-e29523b00d94": {"__data__": {"id_": "a6913d12-efbe-4eef-8b55-e29523b00d94", "embedding": null, "metadata": {"page_label": "22", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "4949872a-97be-41da-9a52-628746554ae9", "node_type": "4", "metadata": {"page_label": "22", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "393048fbae41dbd2a946eaf6c7f2361823ef01dbcd0139d83ca133d783087a70", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2f2d25f0-3d35-44fc-8303-82b0baaa962d", "node_type": "1", "metadata": {}, "hash": "f7baaf0b729f38a8859007e227aa9652bde7f184722b95c9accff78be4dc176c", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "148 Colle IO, Moreau R, Godinho E, et al. Diagnosis of portopulmonary hypertension in candidates for liver\ntransplantation: a prospective study.Hepatology 2003; 37: 401\u2013 409.\n149 Castro M, Krowka MJ, Schroeder DR, et al. Frequency and clinical implications of increased pulmonary\nartery pressures in liver transplant patients.Mayo Clin Proc1996; 71: 543\u2013 551.\n150 Jose A, Kay D, Elwing JD. Treatment of portopulmonary hypertension (PoPH): a review.J Liver Transplant\n2022; 6: 100071.\n151 Savale L, Guimas M, Ebstein N, et al. Portopulmonary hypertension in the current era of pulmonary\nhypertension management.J Hepatol2020; 73: 130\u2013 139.\n152 Tamura Y, Tamura Y, Taniguchi Y, et al. Clinical management and outcomes of patients with\nportopulmonary hypertension enrolled in the Japanese Multicenter Registry.Circ Rep2022; 4: 542\u2013 549.\n153 Swanson KL, Wiesner RH, Nyberg SL,et al. Survival in portopulmonary hypertension: Mayo Clinic experience\ncategorized by treatment subgroups.Am J Transplant2008; 8: 2445\u2013 2453.\n154 Jose A, Kopras EJ, Shah SA,et al.Portopulmonary hypertension practice patterns after liver transplantation.\nLiver Transpl2023; 29: 365\u2013 376.\n155 Deroo R, Tr\u00e9po E, Holvoet T, et al. Vasomodulators and liver transplantation for portopulmonary\nhypertension: evidence from a systematic review and meta-analysis.Hepatology 2020; 72: 1701\u2013 1716.\n156 Knafl D, Gerges C, King CH,et al. Schistosomiasis-associated pulmonary arterial hypertension: a systematic\nreview. Eur Respir Rev2020; 29: 190089.\n157 Alves JL Jr, Gavilanes F, Jardim C, et al.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1555, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "2f2d25f0-3d35-44fc-8303-82b0baaa962d": {"__data__": {"id_": "2f2d25f0-3d35-44fc-8303-82b0baaa962d", "embedding": null, "metadata": {"page_label": "22", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "4949872a-97be-41da-9a52-628746554ae9", "node_type": "4", "metadata": {"page_label": "22", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "393048fbae41dbd2a946eaf6c7f2361823ef01dbcd0139d83ca133d783087a70", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a6913d12-efbe-4eef-8b55-e29523b00d94", "node_type": "1", "metadata": {"page_label": "22", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "136e868da7e61cd055a738bb6f6546a004ffc55be67b9b23c1bb2bf3ab6cfcef", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0e5717ae-80f7-4a3a-b895-e564d226412d", "node_type": "1", "metadata": {}, "hash": "a4603a3861106b72833a900cfca03cb76c8d70531f1d65708fbd476dd05d123f", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Eur Respir Rev2020; 29: 190089.\n157 Alves JL Jr, Gavilanes F, Jardim C, et al. Pulmonary arterial hypertension in the southern hemisphere:\nresults from a registry of incident Brazilian cases.Chest 2015; 147: 495\u2013 501.\n158 Graham BB, Hilton JF, Lee MH,et al. Is pulmonary arterial hypertension associated with schistosomiasis\ndistinct from pulmonary arterial hypertension associated with portal hypertension? JHLT Open 2023; 1:\n100007.\n159 Sibomana JP, Campeche A, Carvalho-Filho RJ,et al. Schistosomiasis pulmonary arterial hypertension.Front\nImmunol 2020; 11: 608883.\n160 Fernandes CJC, Piloto B, Castro M, et al. Survival of patients with schistosomiasis-associated pulmonary\narterial hypertension in the modern management era.Eur Respir J2018; 51: 1800307.\n161 Barreto AC, Franchi SM, Castro CR,et al. One-year follow-up of the effects of sildenafil on pulmonary arterial\nhypertension and veno-occlusive disease.Braz J Med Biol Res2005; 38: 185\u2013 195.\n162 Montani D, Achouh L, Dorfm\u00fcller P,et al. Pulmonary veno-occlusive disease: clinical, functional, radiologic,\nand hemodynamic characteristics and outcome of 24 cases confirmed by histology. Medicine 2008; 87:\n220\u2013 233.\n163 Montani D, Girerd B, Ja\u00efs X,et al. Clinical phenotypes and outcomes of heritable and sporadic pulmonary\nveno-occlusive disease: a population-based study.Lancet Respir Med2017; 5: 125\u2013 134.\n164 Palmer SM, Robinson LJ, Wang A,et al. Massive pulmonary edema and death after prostacyclin infusion in a\npatient with pulmonary veno-occlusive disease.Chest 1998; 113: 237\u2013 240.\n165 Boucly A, Solinas S, Beurnier A,et al.", "mimetype": "text/plain", "start_char_idx": 1477, "end_char_idx": 3070, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "0e5717ae-80f7-4a3a-b895-e564d226412d": {"__data__": {"id_": "0e5717ae-80f7-4a3a-b895-e564d226412d", "embedding": null, "metadata": {"page_label": "22", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "4949872a-97be-41da-9a52-628746554ae9", "node_type": "4", "metadata": {"page_label": "22", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "393048fbae41dbd2a946eaf6c7f2361823ef01dbcd0139d83ca133d783087a70", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2f2d25f0-3d35-44fc-8303-82b0baaa962d", "node_type": "1", "metadata": {"page_label": "22", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "08f4ea85c9b7b995711d8dae27bd2a28b6c08448dd170cc589851c5365306ce0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "030f74e5-5423-4804-8aa2-aebaf1374913", "node_type": "1", "metadata": {}, "hash": "ad9a789d2c400c42f3c9e300a7c4c8a555058c78cd43f5cd1bb9760d5484cb7b", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "165 Boucly A, Solinas S, Beurnier A,et al. Outcomes and risk assessment in pulmonary veno-occlusive disease.\nERJ Open Res2024; 10: 00612-2023.\n166 Montani D, Ja\u00efs X, Price LC,et al. Cautious epoprostenol therapy is a safe bridge to lung transplantation in\npulmonary veno-occlusive disease.Eur Respir J2009; 34: 1348\u2013 1356.\n167 Ogawa A, Sakao S, Tanabe N, et al. Use of vasodilators for the treatment of pulmonary veno-occlusive\ndisease and pulmonary capillary hemangiomatosis: a systematic review.Respir Investig2019; 57: 183\u2013 190.\n168 Khan MS, Amin E, Memon MM,et al. Meta-analysis of use of balloon pulmonary angioplasty in patients with\ninoperable chronic thromboembolic pulmonary hypertension.Int J Cardiol2019; 291: 134\u2013 139.\n169 Rubin LJ, Groves BM, Reeves JT, et al. Prostacyclin-induced acute pulmonary vasodilation in primary\npulmonary hypertension.Circulation 1982; 66: 334\u2013 338.\n170 Leuchte HH, Schwaiblmair M, Baumgartner RA,et al. Hemodynamic response to sildenafil, nitric oxide, and\niloprost in primary pulmonary hypertension.Chest 2004; 125: 580\u2013 586.\n171 McLaughlin VV, Genthner DE, Panella MM,et al. Reduction in pulmonary vascular resistance with long-term\nepoprostenol (prostacyclin) therapy in primary pulmonary hypertension.N Engl J Med1998; 338: 273\u2013 277.\n172 Farmakis IT, Baroutidou A, Patsiou V, et al. Contribution of pressure and flow changes to resistance\nreduction after pulmonary arterial hypertension treatment: a meta-analysis of 3898 patients.ERJ Open Res\n2024; 10: 00706-2023.\n173 Bartolome SD, Sood N, Shah TG,et al.", "mimetype": "text/plain", "start_char_idx": 3028, "end_char_idx": 4579, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "030f74e5-5423-4804-8aa2-aebaf1374913": {"__data__": {"id_": "030f74e5-5423-4804-8aa2-aebaf1374913", "embedding": null, "metadata": {"page_label": "22", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "4949872a-97be-41da-9a52-628746554ae9", "node_type": "4", "metadata": {"page_label": "22", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "393048fbae41dbd2a946eaf6c7f2361823ef01dbcd0139d83ca133d783087a70", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0e5717ae-80f7-4a3a-b895-e564d226412d", "node_type": "1", "metadata": {"page_label": "22", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "faf817ccfe7904d54dca1c1a242220cf4a3e6e4d83535a8e8f9ee14f5a591424", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "173 Bartolome SD, Sood N, Shah TG,et al. Mortality in patients with pulmonary arterial hypertension treated\nwith continuous prostanoids.Chest 2018; 154: 532\u2013 540.\n174 Ghofrani HA, Wiedemann R, Rose F, et al. Sildenafil for treatment of lung fibrosis and pulmonary\nhypertension: a randomised controlled trial.Lancet 2002; 360: 895\u2013 900.\n175 United States Food and Drug Administration. Sotatercept. Patient Information. www.accessdata.fda.gov/\ndrugsatfda_docs/label/2024/761363s000lbl.pdf. Date last accessed: 2 July 2024. Date last updated: March\n2024.\nhttps://doi.org/10.1183/13993003.01325-2024 22\nEUROPEAN RESPIRATORY JOURNAL 7TH WORLD SYMPOSIUM ON PULMONARY HYPERTENSION | K.M. CHIN ET AL.", "mimetype": "text/plain", "start_char_idx": 4539, "end_char_idx": 5231, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "e9309ab0-0931-4665-acaa-c8379e647e21": {"__data__": {"id_": "e9309ab0-0931-4665-acaa-c8379e647e21", "embedding": null, "metadata": {"page_label": "23", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "077e5723-f58f-475f-a396-04541c26005d", "node_type": "4", "metadata": {"page_label": "23", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "343bec9b312cd5059cedb7ec30d0ec6d6c719f24b80540dff1121f541c142f42", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "001586eb-5057-4760-8f56-7580a1b08c08", "node_type": "1", "metadata": {}, "hash": "1eb539ece38ca35345635372a4602b4c6a26d0552c0f00b45d4af74db8fbb368", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "176 Sitbon O, Humbert M, Nunes H,et al. Long-term intravenous epoprostenol infusion in primary pulmonary\nhypertension: prognostic factors and survival.J Am Coll Cardiol2002; 40: 780\u2013 788.\n177 McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of\nepoprostenol therapy.Circulation 2002; 106: 1477\u2013 1482.\n178 Oudiz RJ, Farber HW. Dosing considerations in the use of intravenous prostanoids in pulmonary arterial\nhypertension: an experience-based review.Am Heart J2009; 157: 625\u2013 635.\n179 Benza RL, Gomberg-Maitland M, Naeije R, et al. Prognostic factors associated with increased survival in\npatients with pulmonary arterial hypertension treated with subcutaneous treprostinil in randomized,\nplacebo-controlled trials.J Heart Lung Transplant2011; 30: 982\u2013 989.\n180 Akagi S, Matsubara H, Nakamura K, et al. Modern treatment to reduce pulmonary arterial pressure in\npulmonary arterial hypertension.J Cardiol2018; 72: 466\u2013 472.\n181 Tokunaga N, Ogawa A, Ito H, et al. Rapid and high-dose titration of epoprostenol improves pulmonary\nhemodynamics and clinical outcomes in patients with idiopathic and heritable pulmonary arterial\nhypertension.J Cardiol2016; 68: 542\u2013 547.\n182 Rich S, McLaughlin VV. The effects of chronic prostacyclin therapy on cardiac output and symptoms in\nprimary pulmonary hypertension.J Am Coll Cardiol1999; 34: 1184\u2013 1187.\n183 Holmboe S, Andersen A, Jensen RV,et al. Prostacyclins have no direct inotropic effect on isolated atrial\nstrips from the normal and pressure-overloaded human right heart.Pulm Circ2017; 7: 339\u2013 347.\n184 McLaughlin VV, Gaine SP, Barst RJ, et al.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1628, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "001586eb-5057-4760-8f56-7580a1b08c08": {"__data__": {"id_": "001586eb-5057-4760-8f56-7580a1b08c08", "embedding": null, "metadata": {"page_label": "23", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "077e5723-f58f-475f-a396-04541c26005d", "node_type": "4", "metadata": {"page_label": "23", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "343bec9b312cd5059cedb7ec30d0ec6d6c719f24b80540dff1121f541c142f42", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e9309ab0-0931-4665-acaa-c8379e647e21", "node_type": "1", "metadata": {"page_label": "23", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "2f38b893da05fae9a02a08ae92b2225447814cb313b09818bfc21a1c25ce3d89", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "40a81f9c-3cc7-486d-9e5b-e77d3e6d0afa", "node_type": "1", "metadata": {}, "hash": "6962738b5eb4f48a0e37dbcee2f91f3d0b1a1be43a3b4b6755894518c614ccf5", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "184 McLaughlin VV, Gaine SP, Barst RJ, et al. Efficacy and safety of treprostinil: an epoprostenol analog for\nprimary pulmonary hypertension.J Cardiovasc Pharmacol2003; 41: 293\u2013 299.\n185 Sitbon O, Manes A, Jais X,et al. Rapid switch from intravenous epoprostenol to intravenous treprostinil in\npatients with pulmonary arterial hypertension.J Cardiovasc Pharmacol2007; 49: 1\u2013 5.\n186 Gomberg-Maitland M, Tapson VF, Benza RL,et al. Transition from intravenous epoprostenol to intravenous\ntreprostinil in pulmonary hypertension.Am J Respir Crit Care Med2005; 172: 1586\u2013 1589.\n187 Rubenfire M, McLaughlin VV, Allen RP,et al. Transition from IV epoprostenol to subcutaneous treprostinil in\npulmonary arterial hypertension: a controlled trial.Chest 2007; 132: 757\u2013 763.\n188 Kikuchi H, Goda A, Takeuchi K, et al. Transition from intravenous epoprostenol to treprostinil due to\nintolerable side effects in patients with pulmonary arterial hypertension.Am J Cardiol2023; 206: 31\u2013 34.\n189 Steringer-Mascherbauer R, Maria L, Reinhold F, et al. Rapid switch from subcutaneous to intravenous\ntreprostinil in precapillary pulmonary hypertension by pump implantation.J Cardiovasc Pharmacol2021; 77:\n38\u2013 42.\n190 Kumar P, Thudium E, Laliberte K,et al. A comprehensive review of treprostinil pharmacokineticsvia four\nroutes of administration.Clin Pharmacokinet2016; 55: 1495\u2013 1505.\n191 Alkukhun L, Bair ND, Dweik RA, et al. Subcutaneous to intravenous prostacyclin analog transition in\npulmonary hypertension.J Cardiovasc Pharmacol2014; 63: 4\u2013 8.", "mimetype": "text/plain", "start_char_idx": 1583, "end_char_idx": 3110, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "40a81f9c-3cc7-486d-9e5b-e77d3e6d0afa": {"__data__": {"id_": "40a81f9c-3cc7-486d-9e5b-e77d3e6d0afa", "embedding": null, "metadata": {"page_label": "23", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "077e5723-f58f-475f-a396-04541c26005d", "node_type": "4", "metadata": {"page_label": "23", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "343bec9b312cd5059cedb7ec30d0ec6d6c719f24b80540dff1121f541c142f42", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "001586eb-5057-4760-8f56-7580a1b08c08", "node_type": "1", "metadata": {"page_label": "23", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "7c97cf8bb8ccc66b5b08660f57f3513215fa2a1e1ed7de4e66786b2ac8352180", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e89ce251-a2f9-414d-8406-8a28c5970410", "node_type": "1", "metadata": {}, "hash": "b5367ca17892526ae6b1cb59465be9495be977953e3cac529896018cca116c94", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Subcutaneous to intravenous prostacyclin analog transition in\npulmonary hypertension.J Cardiovasc Pharmacol2014; 63: 4\u2013 8.\n192 Parikh KS, Doerfler S, Shelburne N, et al. Experience in transitioning from parenteral prostacyclins to\nselexipag in pulmonary arterial hypertension.J Cardiovasc Pharmacol2020; 75: 299\u2013 304.\n193 Hinkamp C, Bartolome S, Mims E,et al. Transitioning stable patients with pulmonary arterial hypertension\nfrom parenteral prostanoids to oral selexipag.Biomed Hub2022; 7: 115\u2013 124.\n194 Frost A, Janmohamed M, Fritz JS,et al. Safety and tolerability of transition from inhaled treprostinil to oral\nselexipag in pulmonary arterial hypertension: results from the TRANSIT-1 study.J Heart Lung Transplant\n2019; 38: 43\u2013 50.\n195 Tamura Y, Furukawa A, Tamura Y,et al. Long-term safety of a structured transition protocol from parenteral\nprostanoids to selexipag in pulmonary arterial hypertension.Pulm Circ2022; 12: e12058.\n196 Chakinala MM, Feldman JP, Rischard F,et al. Transition from parenteral to oral treprostinil in pulmonary\narterial hypertension.J Heart Lung Transplant2017; 36: 193\u2013 201.\n197 MacDonald BJ, Turgeon RD. Incorporation of shared decision-making in international cardiovascular\nguidelines, 2012\u2013 2022. JAMA Netw Open2023; 6: e2332793.\n198 Tobita K, Sakamoto H, Inami T,et al. Understanding patient perspectives toward shared decision-making in\npatients with pulmonary hypertension.Am J Cardiol2024; 212: 23\u2013 29.\nhttps://doi.org/10.1183/13993003.01325-2024 23\nEUROPEAN RESPIRATORY JOURNAL 7TH WORLD SYMPOSIUM ON PULMONARY HYPERTENSION | K.M.", "mimetype": "text/plain", "start_char_idx": 2988, "end_char_idx": 4562, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "e89ce251-a2f9-414d-8406-8a28c5970410": {"__data__": {"id_": "e89ce251-a2f9-414d-8406-8a28c5970410", "embedding": null, "metadata": {"page_label": "23", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "077e5723-f58f-475f-a396-04541c26005d", "node_type": "4", "metadata": {"page_label": "23", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "343bec9b312cd5059cedb7ec30d0ec6d6c719f24b80540dff1121f541c142f42", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "40a81f9c-3cc7-486d-9e5b-e77d3e6d0afa", "node_type": "1", "metadata": {"page_label": "23", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}, "hash": "093e8c167e575ca9f93a4b4713badfcb4d51c7794b22021d6d353d8360f18d49", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CHIN ET AL.", "mimetype": "text/plain", "start_char_idx": 4563, "end_char_idx": 4574, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}}, "docstore/ref_doc_info": {"d2018a0b-99a7-4de0-b35a-6db10cebcd76": {"node_ids": ["129c4513-5ba9-4033-88ee-4075365ae992", "7510bac0-f70b-44bc-acd3-8f89e0c8a90d", "fc95755d-72c3-4a8a-a6f8-0988fb5c6be7"], "metadata": {"page_label": "1", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}}, "4faa2b7c-5f02-4209-96be-16c4ee565c75": {"node_ids": ["69ffe363-7420-452f-b2ea-e4416a5d11bb", "b50b479e-a74b-49b3-94f0-a7a58fdbc05f", "fe6f8386-4593-4649-86bf-d731c3569a66"], "metadata": {"page_label": "2", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}}, "0c51c536-373b-498e-8826-f6146e4caaf0": {"node_ids": ["fb2eaad1-718f-4616-8039-4654f96c3bf1", "4a99ebdc-8662-4dba-858c-34f555358893", "9a6b75f9-834b-410f-9884-95af32de356d", "d52fa8ce-1533-4937-8fd4-5275d850a9a1"], "metadata": {"page_label": "3", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}}, "500320de-55c2-45fa-a58d-487bc0b2179c": {"node_ids": ["d5a01f15-61ef-457c-9cdf-6dbb464e9ee1", "95a7c3ef-887d-4b09-bd0d-c0f7380ca67e", "734f87bc-cb1f-4923-b589-409732467fe7", "43a92508-3957-4e23-b58f-6e209f2b6c84"], "metadata": {"page_label": "4", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}}, "25004ac4-94a1-4f23-9f07-6ef3e4b4e22d": {"node_ids": ["e378d602-c32c-4169-ac8f-81cea7823ae9", "5575d336-dcad-4387-afd7-9cafce4f56ee", "f858374d-56da-4a0d-a4bf-b1f3db02652c", "ee57848f-ca45-4e62-b6ad-09016a2a020b"], "metadata": {"page_label": "5", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}}, "ddde90c3-b670-4525-ae1e-9a1da3042086": {"node_ids": ["5cd5875e-44f2-4c28-9991-87329308be61", "4fb65a98-6a97-4d53-a423-51d232904636", "21c86e4f-d084-4811-9a9f-0966078b0c3e", "b831a628-4982-477b-bec3-dd2f19cf7105"], "metadata": {"page_label": "6", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}}, "d1e98709-babe-4168-8e3d-b01d49bdae84": {"node_ids": ["4c8db16d-c9f9-4935-aaee-f60d563322da", "17828a4a-2f98-4535-93e3-619cd77fc02e", "e99e7c5a-2565-4d47-af8a-11c34e108d74", "44fbce5c-c656-44c8-a6dc-98f424dcfd5f"], "metadata": {"page_label": "7", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}}, "4b54fbc9-05a8-4ebd-97df-cc37d32d7c73": {"node_ids": ["2726fcf8-e00a-4887-814b-efd62ac169ac", "9f5eb2a2-a250-44a7-ad4b-a9d6cfffc8b1", "22613f8c-2fee-4a7d-ab61-63667f9d4efe"], "metadata": {"page_label": "8", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}}, "0c032fed-74ec-416f-8aed-9a47cf07898c": {"node_ids": ["52816838-5504-4684-9390-a9c8062c1a09"], "metadata": {"page_label": "9", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}}, "91470221-06ff-482c-8ce7-889eb870df07": {"node_ids": ["47ca947a-0d22-47a0-8b2f-b2390af5fc0f", "38269845-35b4-43fb-bcab-8dccea5c4519"], "metadata": {"page_label": "10", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}}, "9385da6c-c575-4c4b-bc41-8e08c17a3d81": {"node_ids": ["2298167c-0cf2-4d72-b0ad-5ddc3ec50dfd"], "metadata": {"page_label": "11", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}}, "28648416-88b7-4171-88cf-8bcec594df5c": {"node_ids": ["8245ff4d-8f14-464d-97e1-4b3260a404cb"], "metadata": {"page_label": "12", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}}, "b9068d91-e1f4-44f8-973f-cce4d54198dc": {"node_ids": ["1ea2b8db-17d4-48bc-a4e0-3420605b79fd", "ae94bd68-8960-4a33-a289-66e0d9e447dd", "c592916b-bb28-414c-b334-9d97a75633a7"], "metadata": {"page_label": "13", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}}, "eb2d3c6b-4c1f-4771-936a-acdb71e35049": {"node_ids": ["e738d045-f56d-4b27-b3e0-f26272c079ca", "0e4399ed-9517-4375-ba41-512af0d3081e", "23e20188-4ed8-4f40-88bc-122a700e77c1", "32762e5a-be01-421a-beba-d919b624ae58"], "metadata": {"page_label": "14", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}}, "978ed50c-f15e-4976-b3b8-78528ff00afa": {"node_ids": ["ca570e49-246a-4370-86bc-4075bf22f270", "0387bf00-2093-4745-8491-6814a34f8a7d", "0b026d65-5852-4739-af01-cd72f8dc336d", "4c9f8ed5-93bc-4b10-8523-a3ce12d73446"], "metadata": {"page_label": "15", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}}, "7c60562a-1161-44a9-b17b-eea513c59ccb": {"node_ids": ["70710840-8457-4145-9900-f1e37c5fa20c", "37503145-951c-430b-9ec4-2174f4b12c7f", "0ebd3a10-eb76-4604-9199-e16ecf786975"], "metadata": {"page_label": "16", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}}, "57c141a6-7490-4731-9da8-31c398d172a6": {"node_ids": ["3346480a-047a-4667-aad4-a4f4e0894fff", "8a784e94-6226-4e65-bdc4-b3fb280cb95e", "97d24af3-fef9-4879-9a1a-567f6cc5b254", "2683462d-3e8c-44ce-87f8-cd4e37d05301", "94232a86-002f-483d-80ea-a14d2df453eb", "c97a00a2-10ac-452d-b739-c91d7fd59e02"], "metadata": {"page_label": "17", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}}, "4c61839e-63a8-4b1a-8b41-a6c4b39d229c": {"node_ids": ["52e2273c-c61f-428b-8bca-3977e43dd55f", "f414c691-707e-431a-a7ae-b51486e1e3ac", "0f06968e-1c02-4a16-b7ae-bd36840247cf", "52d737c6-7b28-4e86-b401-8aaea5b65cab", "f68bd455-9fcd-4f0b-be20-cf0e453be9c2", "376e8cc1-5d2d-462a-b847-f8fe2a0965e7", "411a98cc-0f8f-48e8-b757-e97a24ef9e81"], "metadata": {"page_label": "18", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}}, "d618ddfb-b57a-425c-8f3c-cdadb780f905": {"node_ids": ["498a18fb-79a4-48a2-b3d9-bae479162cf2", "452ac336-0448-4c9f-af93-b6b0f3d2cb59"], "metadata": {"page_label": "19", "file_name": "ai in radiology.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\ai in radiology.pdf", "file_type": "application/pdf", "file_size": 1873324, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}}, "4354f20f-b099-4c4c-abae-bd50d7e5c5db": {"node_ids": ["9357125c-3523-4f3a-9018-6c08aa835279", "b8e99569-7668-4b3a-91d0-dc3e0fa95aed", "cb02e3ef-40c0-451d-a4bb-14809f01bd1b"], "metadata": {"page_label": "1", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}}, "732d36ef-8c5d-4588-962d-c4dc4204f1d8": {"node_ids": ["4e93c9be-4015-4e2f-962a-9d9bf9eeff9f", "a1022cdb-2d5a-4f2a-98f9-43b0d8f7728b", "0c185699-c838-435c-a450-466887b10bd2", "bbe4b789-2f81-4846-beff-7f53e87ce87a"], "metadata": {"page_label": "2", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}}, "d71baa71-40d8-4aab-a8c7-ba6cbee55a69": {"node_ids": ["38c5f45c-4600-431e-b195-c2937e185441", "49c02434-3b56-450b-b011-6147aaf38601"], "metadata": {"page_label": "3", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}}, "a7b50c76-9e54-4854-bd18-e3af5c016e41": {"node_ids": ["52f98438-c604-4e0b-9931-2cfeb63f68a0", "919bc9bb-5de8-40de-b5e3-2a32a52815ea", "d70ef2db-73fb-4880-aec8-cbce10c7f33e", "65f54425-2787-4a92-8ad0-0c9b5d39b3ec"], "metadata": {"page_label": "4", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}}, "7270adbc-d000-4c2e-8351-acb5ff28e3b9": {"node_ids": ["9a4ee123-20a8-4af6-92b2-934509548349", "d4280a9f-cd09-4edc-9055-b2c26aad73b1", "080b6dee-f2a0-4ae0-9bed-9e2e68969085", "27779168-4216-4731-97c6-b4cd9fe2ddd1"], "metadata": {"page_label": "5", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}}, "f0950654-0b9e-47e7-acbd-2d780485001d": {"node_ids": ["4fc2d9bf-6063-4668-ad85-e2d155197981", "bce874a3-eb71-4f83-aa21-56cea029f3c7", "113ffa4a-6837-4a51-a8d0-3973a52ba263", "5251d44c-257e-43b4-8771-bd514de0bcd1"], "metadata": {"page_label": "6", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}}, "9208caf8-3de9-4cef-8a2e-49a8017f71b4": {"node_ids": ["e51f3753-49f7-4f05-9829-0fa4fbc94aee", "850dc40e-f518-42e1-8b40-a0125bb3e783"], "metadata": {"page_label": "7", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}}, "1b3d1945-0882-4162-bf8d-3a6834fb8fbb": {"node_ids": ["c4dd69a6-1ae5-4f51-81fc-8688d6442fe0", "a83ec709-f214-43f4-ae27-589575212b80", "0ec99e8b-0b4f-4ad6-a271-ac3e3b276d29", "ed3094b4-02f4-43de-b3e3-b6a6497f80b9"], "metadata": {"page_label": "8", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}}, "5fd22f96-9a35-4f85-9010-fbf0469d9fa7": {"node_ids": ["8d2dbb2a-cce0-48db-9bb9-c083a4a74e6a", "7321ef23-f825-43e9-b1de-267d1827cdd2", "b6053ffd-5968-4596-af45-e1e403bc7b5d", "fd053964-35ce-48f8-b9d7-9a2bcdb9a194"], "metadata": {"page_label": "9", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}}, "b9da6b8c-332e-4fe7-8f05-7a7f25d2fa67": {"node_ids": ["d86e27ea-ca09-4c27-aa20-119d1cc3181f", "8e61bd17-962d-4e2d-89c2-0fdd0d06aa03", "e35d5419-adc2-4718-a662-73161e91a49e"], "metadata": {"page_label": "10", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}}, "4a1be7b9-f3dd-43d7-a3ee-65352c2eee30": {"node_ids": ["173af25e-6718-471c-9453-2755bbf24856", "a0193a14-9560-478f-a10f-a6ff357cdc1b", "377d05f6-dbd8-4adf-a793-cf0e6eb492a7", "0e9a08db-bd9f-4de7-9832-bf67acd8f1aa"], "metadata": {"page_label": "11", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}}, "31fd1866-f5e7-434f-8dae-c26972fde9a5": {"node_ids": ["1c69593e-dab1-4bf0-b41a-e15127693faf", "c5219734-fcfc-45dd-b4e2-bff802f62d82", "95b8fb2c-8110-411c-883d-9931bd220f6b"], "metadata": {"page_label": "12", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}}, "4469f94f-ee49-4d40-9fe7-1158afa84afe": {"node_ids": ["6b15ecfd-0471-4044-a275-b385ac6aac33", "e51b4e5d-ae69-4681-93df-62c0ccf0cd1c", "25b90b38-a924-452f-91bf-9ab1ba275dcd"], "metadata": {"page_label": "13", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}}, "fe46a362-7871-46bc-9d56-2a7f3396288f": {"node_ids": ["80d3ef30-a0aa-4c2d-9734-9317ee93f4b2", "dd8fd21e-6aa6-41fb-a71e-c19ceeaea478", "01513411-0fc4-4312-8653-0fe7f1e8018a"], "metadata": {"page_label": "14", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}}, "8876b368-19a7-4502-aaa9-fc8a556abbfa": {"node_ids": ["1abc359c-d314-4daa-b74c-c5084a96d351", "1749a00f-65af-4822-b802-56040b98f1ef"], "metadata": {"page_label": "15", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}}, "1ae36d76-8e88-46f5-bd67-67be78e26f04": {"node_ids": ["89fb493e-7f25-44f8-b315-b5d93164ad83", "71de077d-89cd-499a-b2ac-63926f9c45b7", "20f8b5ba-e7b0-4a72-92d0-be6915b88963", "11831bc9-8348-437c-9f5a-9a28f430d9bb"], "metadata": {"page_label": "16", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}}, "acbced89-6a78-470f-a420-ae6270eaaa32": {"node_ids": ["e90a1229-f665-4ee0-9258-eb4ae09e61bd", "3aac689d-6dc1-4c71-9127-34492b7a5f23"], "metadata": {"page_label": "17", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}}, "72bf1cf0-9d16-40d5-8ee5-808edcfdad08": {"node_ids": ["f1029f33-4d0e-4ebb-8ae1-06c4958fa132", "b4849b4e-1c07-4af1-a991-748356e851cb"], "metadata": {"page_label": "18", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}}, "3de89589-f389-4a0a-b91d-726e5db42433": {"node_ids": ["4b3d62ad-9e2a-4e3e-8dee-201c2e444af6", "277ee5cc-b685-479f-9049-5db40dcc5d72"], "metadata": {"page_label": "19", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}}, "50beb819-1b07-416c-a3ad-ef33c77c122c": {"node_ids": ["e5c76e65-8f47-44a9-aa9d-07b66c0d49ea", "94d1d91f-f86d-4b92-9ac8-800e764e1d85", "6285c43c-f238-4daf-b1c7-dd9cfa053881", "58186b1e-0a5c-4b20-a17a-131d1704cb7d"], "metadata": {"page_label": "20", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}}, "dae59523-8e69-483b-8677-6182b6742476": {"node_ids": ["b2b0f19d-434b-43e3-a65a-377732015e79", "bf28ea60-28f6-4dbb-9630-b8f27f74e46f", "21edad98-906a-4fc5-a307-7a5efe781042", "c248cdc2-9ca8-45ca-bc7b-4cb489283a5d"], "metadata": {"page_label": "21", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}}, "66d5f9dd-87a8-4e3b-9d0f-3f00f07bed8b": {"node_ids": ["ec94d3fe-330a-45e1-a133-0db27dd522dc", "c5dfe4c0-aa8a-4cc6-bbb8-05a44a77be5d", "3e092391-3ecf-4e7b-b155-116d5202646c"], "metadata": {"page_label": "22", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}}, "9f005ea6-598c-43fd-8d3d-391cb5fb6563": {"node_ids": ["04219a09-6d7a-4e24-ad68-f8595be57223", "7c5956e3-39d4-4fa1-bb96-dacf24c7946b"], "metadata": {"page_label": "23", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}}, "8a5922cc-57db-492a-a06c-5af9acfc185f": {"node_ids": ["c57ca3ae-d1f8-476a-bad9-783c79203fe3", "e51efee7-2d05-4d05-a528-e1cc0f517da6"], "metadata": {"page_label": "24", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}}, "78b95546-d2da-4e4c-9867-d8be86dd08fc": {"node_ids": ["5b8c7436-beb5-4d80-8974-897c750fd3a2", "53568206-b006-4547-a6cc-ea40852d3af5", "0e5ebb3c-e5c2-471d-9f90-092864a5f866"], "metadata": {"page_label": "25", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}}, "f2742f62-db69-4fbf-b8a2-21103d882643": {"node_ids": ["5557fe64-448f-407a-8a25-29bfb54cc617", "05383286-0878-419d-9409-525ab75fe178", "f9e95eaa-0245-4b93-a38f-208efc1cae17"], "metadata": {"page_label": "26", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}}, "601fe89c-ec16-42ba-b5a9-caddb108acd6": {"node_ids": ["753b4e40-06ba-4159-81a0-d2013e02d22f", "3d844ea4-0529-4216-a60f-9dfb8df21046", "8d3abd06-59fb-45fa-a74f-8135137ee775", "5484a62d-001c-45a6-be9f-5384e7967524"], "metadata": {"page_label": "27", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}}, "81eae37b-ccf3-4aa5-8e22-b1c75bf034bc": {"node_ids": ["48101311-136a-4e6f-8111-e2259ca6061e", "e18002bb-73a2-4836-8959-69ebb283c763", "36c133f6-a883-4cc4-aa21-95dd939027a8", "04fc74ef-0aab-4e7c-9503-6ed3095cce93"], "metadata": {"page_label": "28", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}}, "4cc40bdd-3b88-451b-8008-e1a3b76a5612": {"node_ids": ["f7d7e415-2ce9-43b4-b88a-64c1c54e396c", "fa5dfc01-2216-49b1-b848-545766f156ec", "7c67e125-f50c-49de-af00-ef22d3c673c2"], "metadata": {"page_label": "29", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}}, "7fddc816-947f-43c5-a2ce-f7e189b6c1ff": {"node_ids": ["9d481ff0-ce6d-43c3-9aed-f74d54089cda", "72bc67fb-f715-421d-98d9-0f2d20a1b7bc", "2a4f1451-4f6d-4612-b059-37c9dbb77ea1"], "metadata": {"page_label": "30", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}}, "9c603077-5325-4529-94b5-c53e270b5935": {"node_ids": ["c135bfab-49cc-4f57-b4b7-d22b49ab66e2", "4dc56958-af0d-41bb-a8a5-f8a5d250a676", "3b567437-e044-42c0-87aa-7f16a6392b25"], "metadata": {"page_label": "31", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}}, "bd29e430-dd99-46a4-b025-8ccd04ffc7fb": {"node_ids": ["90ab7808-2842-4144-bc86-2d14dbcc2a88", "26410019-c612-4421-822c-b8965ea68c03", "0cb3da40-c65c-4a91-beb4-6b33a56bc286"], "metadata": {"page_label": "32", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}}, "bccae22b-16b6-481b-b0cc-d625db6ca65f": {"node_ids": ["ef2b8976-6944-4d88-9904-3e4a378ea616", "63c9d658-6c01-4ab5-a86f-65ee121f4116"], "metadata": {"page_label": "33", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}}, "efc2184b-6b98-42fe-8c89-a4da99c9f400": {"node_ids": ["7457ec7c-4b87-4765-8a06-aed1a45137ea", "657c8563-81ec-407d-8947-453f46e704fd"], "metadata": {"page_label": "34", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}}, "0db58665-1e8e-4c84-9173-ccc828c87871": {"node_ids": ["05507c24-4f7e-4222-93b5-9c446d1d4bf9", "2b466e86-38aa-4e84-9437-402517c2d27f"], "metadata": {"page_label": "35", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}}, "79fdffcd-9489-4262-a81d-bcbe43beca14": {"node_ids": ["6ba74a3e-edbe-4c2c-a315-ef59f232b4de", "0b67ba50-2d70-4698-87b9-91f46f5d6f81", "ad03e95f-e539-4b21-9ab6-680d3e6c7cd8", "70e70abb-f1dd-4c06-b76c-0fe67463b262"], "metadata": {"page_label": "36", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}}, "8be2043a-23a5-499e-9c2e-0a960733f1e0": {"node_ids": ["48b6f1a3-a591-4faf-8416-1bf2db236587", "2fdf36ba-8f1f-4efa-9ce4-691e81026b8d", "b76cb0d6-8d86-4adf-920a-7c02794732cc", "6fbd3de0-94a0-4975-8ba1-c0f1f307ccdc", "f98e02de-48bd-46ac-b133-872bd562085d"], "metadata": {"page_label": "37", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}}, "37c094c9-4ded-4b8f-a3d5-bd6187acc8d7": {"node_ids": ["c4394a4e-dfde-49c2-8adb-8d5c3d1068f7", "e098b971-7ab2-4049-b0d8-dbcd0fb24a2b", "a546d785-06ff-40e9-8ca1-3f81a268015c", "35d12205-0bf0-4367-9963-f5a456bb95e0", "75b217c5-cccc-4a3d-a4f4-4641c8bae85c", "e2752690-4c04-4c72-94a1-d31306fc2ea1", "73f33687-ad78-4678-b4ee-e1fbee3c09cc"], "metadata": {"page_label": "38", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}}, "761bb3fe-8847-42e7-9d73-5d3d8abc6b6b": {"node_ids": ["0147068f-2e07-42cc-802a-617be82b8f48", "80824659-5661-44e0-ac9d-9ab644235cd6", "e1887e6f-82a2-432b-9db6-ecb4139d36f7", "dcd49bc2-c5d4-47a2-b545-5c6be08dcdfa", "81023747-298d-49e4-8db2-1a9cee50ba56", "a9fe4749-a380-4572-9785-5af8f66781c1", "1ae18566-0bb6-471b-bd78-d48005cd3f8a"], "metadata": {"page_label": "39", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}}, "56ff51f7-ccb5-4c78-8d0a-99145acf70e4": {"node_ids": ["d9047c34-a108-4353-92e4-3197817657a7", "397999f0-6ea0-4738-b94c-fb53b29788c0", "2e11b28c-687d-4fd4-a9e9-6475b6df4cb3", "8495d7c4-7983-453b-b9db-9d79906e58d4", "95de215d-2279-497c-9530-71d9e56a065b", "78a7702b-6022-4923-9d6f-00efdb029153", "abaaf669-00c0-4ba9-80f2-3fe711e31f81"], "metadata": {"page_label": "40", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}}, "5f99e93f-2d79-41b7-bf31-24037874c191": {"node_ids": ["a1a0c823-2afa-4689-ba11-37b67038c740", "6f4a5510-bf53-47cc-9d18-bc9077062075", "ba9642e2-6f66-4c7d-a141-be0059d06144", "77c83dc5-f3a4-4f2d-a215-0ab4fef80d41", "0953e172-4ccb-4096-bbe4-c987beb20c4a", "0fc5b0e6-01f4-40b4-8c7a-5e8904f0b753", "ff753d51-5234-4293-9c13-cd83a41377ea"], "metadata": {"page_label": "41", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}}, "a932a3d2-886d-4a41-b4eb-c9e7304ef568": {"node_ids": ["1ac810cb-ebf1-4b5c-8944-5ad981734de0", "ff116434-58e2-4e06-a625-9bede3b4144f", "bd8ec913-fbb1-4b25-bcf0-71401808fcf5", "f1a3766a-94e9-4ac2-955f-83dc8081fa4a", "fa21fca5-b7a5-4ece-8e39-be8a13c92af4", "85522ba5-68e3-49e1-853d-bc7b7fc4b540", "7abf6e28-78e8-4e28-a22a-18814cb9bf62"], "metadata": {"page_label": "42", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}}, "fdaa53d7-c08b-4351-b327-0fea1e9db34b": {"node_ids": ["04007ba2-a955-474d-b2aa-7ee4dd6ae394", "5e672d68-e79d-437e-899a-7eb42fcd09e1", "17ff836a-4198-418b-a03f-07a9995e5738", "8b83e115-7327-4950-ac95-470dec3a3065", "b5982d9f-8de0-48e7-873c-4745b0a9b979", "35783b00-240f-4ce6-b647-0336187bfd0d", "efeb9872-ea92-4132-b8e0-21c1ddb6c497"], "metadata": {"page_label": "43", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}}, "017b08de-905a-4437-b0a2-d21b6c4cde5d": {"node_ids": ["76064f35-8e07-4eb4-88fd-d4596e77ae08", "8c4b1c7c-dcf9-474d-b66e-42763db1532e", "26122383-65a0-4a19-97fc-26bd1a0c6e3c", "a49d974f-4423-4cb8-8de9-dc003050a48c", "19913503-6860-4554-b211-e3e6c41f5289", "4c0ae015-b12c-4c2d-8dd7-aa96eaadc319", "d575e133-9931-4aa0-b0b1-fd6674198764"], "metadata": {"page_label": "44", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}}, "fde648af-5d4d-4dae-b4e2-a4d334b16383": {"node_ids": ["0a23ccf6-773e-46bb-8c44-4914a99c1f15", "36eb6093-0ec7-4855-99cc-331fb872b1c2", "544028d4-67cf-4db2-a126-2ee01e438abb", "f8b2839b-5060-48af-9ac5-854dd11470ed", "cb4ad102-0f04-415c-9c6b-be9c46edd8e6", "71a74f10-4890-41ea-84d8-8e9a62626825", "ae5d7bb6-8723-48c4-867d-ff5bb7fd1a5c"], "metadata": {"page_label": "45", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}}, "efdc7e73-93b5-4b14-8f55-54d4edd305b8": {"node_ids": ["4f55e565-fc97-4a01-9f08-f8d64da59106", "f422e3e6-fd9b-4b87-a07b-a49307b5a5c6", "13141e2a-e8ab-4a32-b621-3155812403f9", "261b2be3-e88a-4660-a2e7-4ed93f0cfa86", "cf27b335-c15e-40c5-95ff-fa067d425e28", "6599f5e6-15b3-4400-9298-35e6184639fa", "58b04eb3-8626-4be7-9353-20523afad44a"], "metadata": {"page_label": "46", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}}, "ef7a8cb3-c404-4478-bfd6-d48cc93996ff": {"node_ids": ["4834e53d-2136-45a5-bee3-e350c25bc308", "b0fa056b-b183-496b-8430-1f264752c904", "ad53ef8f-c34e-4a00-8735-654440ff0bcd", "be6c3c81-dc82-429c-97a7-1b82b69f0e83", "72b34996-2125-4abb-823e-d5865aed94db", "31ba9be0-5c48-4471-9e98-73f85d7deebc", "7b656c36-d895-42d5-a60a-1bd576b871bb"], "metadata": {"page_label": "47", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}}, "27abbbdc-485a-4983-9ac7-0666588bd8f7": {"node_ids": ["6bdff43a-0693-4707-8fb1-010e9a2cdcb2", "f5f29c4e-0f26-44e5-a81c-3d879b5c49d6", "2317ffc9-03ba-438a-9367-1968cac06888", "eefdf0d9-7940-427e-b6d9-95510bf42b21", "2bc5072d-d23f-47b4-b3cf-01a85ebe6aac", "d741d7e4-1e2f-4d12-9d21-699d0e754ec8"], "metadata": {"page_label": "48", "file_name": "cancer immunotherapy.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\cancer immunotherapy.pdf", "file_type": "application/pdf", "file_size": 11932944, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}}, "793fdd24-7965-4ec3-b67b-002f28e312e3": {"node_ids": ["a42a0d5e-8326-4170-9c66-48a32c0ecf3c", "872fcdb6-1dd8-4ee6-91bf-0d5ef3ea0518", "74c8a6c7-0f05-4240-840f-3f4803bd4d90"], "metadata": {"page_label": "1", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}}, "a5cb8601-86b0-4a92-983b-21f73c7f3edb": {"node_ids": ["dd82aaed-e0ef-4be2-8b62-e7c69f37e87d", "db4ad094-a2b3-4a9a-a2f5-79169853e8cc", "aa68ae17-9430-4503-b248-dbf996def1cc", "5e14767c-7a3c-460f-8da4-7dee7e6f9d4c"], "metadata": {"page_label": "2", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}}, "36ef91a0-45ad-4de5-b37f-0347da796824": {"node_ids": ["e3eb41ec-c251-4ed7-b6dc-fb04d525dc73"], "metadata": {"page_label": "3", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}}, "9fba4c60-5030-4e2d-a80a-dc88ba2d1be1": {"node_ids": ["d3d7351e-4e9b-4121-bea7-8309bb65e827", "f1a416bc-5cce-4cb0-99a3-7f9c8c3b29d6"], "metadata": {"page_label": "4", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}}, "66af6b35-4748-45dc-b047-5db47c7454a6": {"node_ids": ["a4b9e899-3de5-405b-9d02-a1207b812d24", "04e4edc3-8fa4-437f-9e3d-ccbf8812e7ff"], "metadata": {"page_label": "5", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}}, "1a5b021a-1251-462c-88b3-0441db498c9b": {"node_ids": ["a672ec12-7596-482e-99d9-dedb5d5a6c8f", "67d15ed4-d9b4-434f-bcd6-65e6f0325a02", "240e5630-7082-4e0a-8116-f9b243f03da1", "b313e9a0-aabf-46b2-b9f6-7764a29932f5"], "metadata": {"page_label": "6", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}}, "65906fe0-97af-478d-89e7-6eb93bae2203": {"node_ids": ["cc5cd277-9217-4bbb-965c-e216757e512a", "097695a6-bd1f-4a70-9b89-136d149461bb"], "metadata": {"page_label": "7", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}}, "bfaa9764-5597-4dd1-9ad9-b29835b17ea0": {"node_ids": ["7e243e1a-a30e-42d8-907d-853e8632bbeb", "efe4bcbe-f8fc-4b43-b5a6-c74824608351", "9fb88f11-2b37-4938-8961-bb7e6b5fedad", "056517c2-e40e-42cc-8543-a2b839f432cd"], "metadata": {"page_label": "8", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}}, "b86e0623-b7c5-418e-af81-6f680a0cd825": {"node_ids": ["d791dd64-03cf-4a28-84b3-73a4bf6a98fc", "9682222d-863f-4319-b8a2-40c271a72810", "43d2c03e-3821-4049-ba1c-38429a38c5ec", "4e73f7a5-2a72-45ce-b5f6-0ff1bcf1d94d"], "metadata": {"page_label": "9", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}}, "211ae5a8-aeaf-4f78-a2a1-9bf5cde183b7": {"node_ids": ["51838432-552c-41d1-9da9-8ecaffa95b4f", "ce3a7b34-3ffd-4a7d-a7c0-86debf453268", "0fb8196a-1e04-4d67-a31d-59eddc796253", "8925c1bf-3e89-4ebf-8e63-5be315af0179"], "metadata": {"page_label": "10", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}}, "8ef58779-6977-4fb6-bb69-64d6dc4f6015": {"node_ids": ["be14fb39-8dd9-471d-baea-f11c7f5b05f8", "1dacee84-56c2-4829-a896-85985abb1444"], "metadata": {"page_label": "11", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}}, "b78963f2-1427-4e4b-bd11-712b03dd4aa9": {"node_ids": ["2d63a75e-0e47-4f72-920c-474e35d1c7d5", "75b8f2dd-5803-4d38-b795-8ea9c72c4978", "4a633ea5-b255-408a-8925-b3ce3ec8bb8d", "3da98959-7833-471c-8946-92563a61d93b"], "metadata": {"page_label": "12", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}}, "a2980ba1-b4f5-4bf3-acfc-46666d7c0419": {"node_ids": ["51eafc70-f43e-4298-8687-2409c97f3a2f", "19b7979c-cf21-43bd-9623-1247c8e3bc50", "7fee2ea4-22a8-4502-9efa-d14a97b0d633", "a56cc89d-18f9-485c-85c2-ef01d8974fea"], "metadata": {"page_label": "13", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}}, "4298f04d-6f99-48e7-bb95-9f26e912c4e1": {"node_ids": ["9b0234d0-94c3-4844-b52b-4f5046836b4c", "e7a6430e-652d-4768-acdb-141bd3422b5d", "c2826f2a-699d-460e-9b8a-7be5b47a7856", "fad729ef-da8c-4365-9be1-54dd34011692"], "metadata": {"page_label": "14", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}}, "807e3618-d7a6-4343-833b-06d85b548478": {"node_ids": ["1c302e1c-5c91-408d-a4ba-01e6c5dccd7b", "32a72e73-22c3-4743-a5a4-38d376c66bb6", "aab5d28e-1b5f-45f9-bbc1-5c3c1719de4b"], "metadata": {"page_label": "15", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}}, "e041abad-2618-46dd-a041-1dbc2e08bfcd": {"node_ids": ["497cb895-c115-479d-94e7-c0c5c6a406a0", "b1324942-3a5b-4944-b531-a1c12e9eb11d", "16ef63c1-1b3c-4b5b-9ada-5bae87f0e448", "7398bddd-d207-4501-8a69-003df36c13d9"], "metadata": {"page_label": "16", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}}, "c0f03fd7-3c41-4ff5-a615-578abb7836cb": {"node_ids": ["f09d1838-a681-4c76-893c-e5f5e69551f6", "355e5c34-3d5a-4abe-80bf-6d706a01d29d", "16dc24cd-81ef-4da7-a9bd-193de4d8e75c", "499d12d2-bcd0-4a92-9a46-be68bc255779"], "metadata": {"page_label": "17", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}}, "587dc3cd-fde2-4c71-9b40-2473b771f4ce": {"node_ids": ["c51fc633-364f-4aa8-a307-4266d6a20be4", "ae33e657-6d03-40de-81b3-86835125b63f", "821b7fc2-f9e1-451f-8ddc-a4252d3932cd", "0ef7773c-ac18-4dbb-83d1-5c81e5cec00c"], "metadata": {"page_label": "18", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}}, "98e95dbf-dafc-4247-b20b-a4d84fa6aa19": {"node_ids": ["e9d9c288-6dbd-40b6-83bd-b380240aaad1", "44e061c9-c1cc-4064-9fbf-9fefb0e36448", "d61e9618-b7c2-43ac-8c78-8c9e7c4d5b1a", "754009c1-a993-4df4-9fd8-a3d2ef5a74be"], "metadata": {"page_label": "19", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}}, "d9aebe03-7172-4603-a4b9-fc252f4f8120": {"node_ids": ["7d6ee201-e1cc-47e7-8a71-a21e3f00cead", "b64592f1-7a14-416a-9c34-7268c4b1f72b", "813ca0b5-bbc1-41c6-b45b-fc6a86bc0f62"], "metadata": {"page_label": "20", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}}, "3b2cf5c8-27eb-4c9f-adb7-bfb585a20e39": {"node_ids": ["d5099df0-2b78-417f-935c-5e9f174727f7", "5a8afcab-3188-474d-90af-ebbc0375245d", "2810d43b-63e6-4a84-aa41-015fbc903e12"], "metadata": {"page_label": "21", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}}, "69240135-82d6-4306-a1b8-5797f4d75cfd": {"node_ids": ["4eb70702-545b-4370-be43-87482225df7d", "6069e7e2-0bb5-4312-91b7-42665316ee79", "825a8cdf-50ca-4072-b42c-334eba3edc8c", "c1cd7434-5815-4c9e-a291-bb7aeebc40aa"], "metadata": {"page_label": "22", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}}, "cf63ca09-1733-45ca-8a29-5299aabac73e": {"node_ids": ["a2e90743-be84-43ba-9a7b-e15d17d8d14a", "2ebe2db7-9480-4df8-baaf-3a2c839bc5fd", "d0094173-0425-43c4-9e86-19a83eb1df01", "98cc149d-38ec-4a00-8450-0660f21c7f3c"], "metadata": {"page_label": "23", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}}, "ab208677-7742-45fd-ac0a-4cce1ba8ded8": {"node_ids": ["3dea4933-ce0e-46cc-9260-d1a1ff7cbbc7", "9bf4c4f0-985f-4a25-85f0-683694b7c8f8", "c82ed998-695d-4f5f-856b-c9d8c48712e6", "e6943aab-f624-4a93-8cd9-ba817d835cca"], "metadata": {"page_label": "24", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}}, "d8fa741f-944a-4fa7-923c-79699ba8d751": {"node_ids": ["c1c1556f-15af-4c1f-a048-8058fca21517", "6cc8055e-1837-4af9-aaa6-6c4cb5d6ff6d", "bda5a8a4-5fcf-4428-8f1f-289fe07a9d5d", "00e8b91d-05b5-46d7-9734-735a8c8eb903"], "metadata": {"page_label": "25", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}}, "45c8bb38-02a6-4db8-a11e-c0451354b3fd": {"node_ids": ["604deddb-80b6-4476-bbd3-c194ea0df1e9", "5f428a5f-5cc0-4367-96ae-a0980abe883f"], "metadata": {"page_label": "26", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}}, "ed0be872-0597-40be-a640-49c6a519b7af": {"node_ids": ["6d8f1af7-9c2e-4bb5-90f0-7142fb2ea6e7", "562e797d-544e-4aeb-8b41-d5c1f1773239", "dba13983-679f-4202-a8ea-467308c322d5"], "metadata": {"page_label": "27", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}}, "234e85aa-e810-4fe5-9151-925d4e029b6a": {"node_ids": ["3f8cab12-a567-467a-81ea-435ca37ce7ef", "76289406-e487-4837-82bc-71ef38a7dddf", "704c03a7-6576-4ae2-9c96-cc765762fcf5", "12b48709-4a6d-4a50-88f1-1f47b1f0e595", "0e02a1e4-b826-4366-bf96-7d6402142030"], "metadata": {"page_label": "28", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}}, "9365d75b-df22-4bb1-87b1-c8becc020be8": {"node_ids": ["5b0a364e-a8fb-4562-af69-91614343d2fd", "3c72cc7b-08c2-4a37-8fe4-9d6508dd1158", "4e5ac5b4-e2ec-4289-8405-3923a4891d92", "67c4f5b0-97fe-4f53-b74a-ae3bf41e473b", "55bac4dc-dd5e-40d5-a516-1b17df1f4cb5"], "metadata": {"page_label": "29", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}}, "ac87c0ae-85e3-4cf2-a730-61f926edf400": {"node_ids": ["10d4d15f-2c73-4426-a50f-71ea7f5ea9fb", "2e6fc93b-c553-43a8-ad66-44e29001d417", "a11d218c-03c3-4287-9eee-1c3152479208", "38036193-c9c7-4342-8491-e9680c2b9ad1", "7411954a-86d9-4afa-8e46-22d0b9684ea9"], "metadata": {"page_label": "30", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}}, "3d644fb7-3fee-4891-ad11-4a3c02452a32": {"node_ids": ["a96347eb-b047-4b8b-9936-2264f2903860", "ba1b3311-d8b5-4bb7-b815-180fa7982f00", "a2c40831-b334-4f94-9ef3-33b0ce88c725", "5a77cd27-44d3-46b4-a875-5f3227d74f02", "5686bf4d-0256-4464-8319-1b26b72344f7"], "metadata": {"page_label": "31", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}}, "35f0cc85-d0d6-45e8-b14f-549678a8827a": {"node_ids": ["48bd918a-35c7-4c06-9dc7-23cf1aaedbcf", "bf34aaee-81c0-402f-87c0-01e03e56d171", "0444363e-44b2-41ea-9752-86b51555eed7", "8f6e5557-84db-4f5b-bd14-dec247b4c19e", "5121ae10-e390-4da7-9d34-7d68066a37ca"], "metadata": {"page_label": "32", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}}, "9f50783a-89b7-4389-9e19-116448179aec": {"node_ids": ["c0cecdb4-4a48-4a78-8301-d3672d43571c", "16eafa85-a586-436c-8df5-132ecca5371d", "ace771a5-2f88-47d5-94a6-b20d6a50f760", "9895a5c2-2c9d-4e27-8e53-22b6d44fd9fb", "4b3ea8f9-8ae0-42d9-812a-65ddf7cf34c7"], "metadata": {"page_label": "33", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}}, "96d19885-c85b-4254-80c4-3c172b24dc5b": {"node_ids": ["83d8ea37-cc5b-461f-928b-e902185e304c", "5225cc00-9503-44bd-a2c1-04a3c1cdb9dc", "4d614c56-7196-484d-a8c0-b0ab7f0367b2", "46aedb37-db5d-4362-babf-89be3e6f1435", "a8d1690c-0990-43ac-b8fd-514d8dd018fc"], "metadata": {"page_label": "34", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}}, "1f79b2e0-32a2-45a8-b114-db0d43b38822": {"node_ids": ["016f89e3-237c-413d-8111-aa0f9a37ecd6", "dbae4752-6df0-444c-bf7f-f728a713f3dd", "6433faa6-dfdc-4130-ba33-1621c0c900eb", "67e4179a-c6ea-40a9-a364-5ffd6a5e9993", "bfb44bbc-7d0e-4ca6-a2db-643981e5d3be"], "metadata": {"page_label": "35", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}}, "ebe6da7b-2906-41d9-9edd-32ff3638114d": {"node_ids": ["12cf5b7b-a7f0-4a11-8329-a5f3788912b5", "c122fe51-0a27-4b4e-9614-dcafea5fe866", "0fc0d930-c092-440e-acd2-2e251160b7b7", "e5ad5ebf-9544-44ed-922e-2be7cfd98801", "5e4e087e-6fa0-4818-b58d-115409f2e83c"], "metadata": {"page_label": "36", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}}, "5bab9eb1-2820-4291-945b-30ae3ce9e833": {"node_ids": ["23699c03-7a89-419d-af4d-9010634a5051", "a612f6e9-e19f-49ee-b14b-b35a8582366e", "69ba9788-6c92-4601-b1ae-59266085788d", "9d87171e-e6cb-48ad-807b-d91c54c3f3cf", "a60ce069-2d6d-4c1e-8ea7-6f600b86c23a"], "metadata": {"page_label": "37", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}}, "080f72b3-c692-44bf-8b6b-e35c0a8e24ff": {"node_ids": ["586a93da-6cc5-467b-ab20-9bf860fd26c3", "b9fd9aab-7702-4258-a5ed-d2082b8d6964", "f0dd57d1-1291-4488-bce6-38a30f81b82b", "d1dd3c31-d761-4446-9874-c09a4a6180a9", "70e143c6-8c14-4800-9b1e-7b31067054df"], "metadata": {"page_label": "38", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}}, "75455cda-720f-4281-ad8d-c459a128196e": {"node_ids": ["c24ed535-7f95-4b1b-8f59-cbee02fe50fd", "32741c93-6b65-4ea4-a5bf-c7187f27ff03", "467104fb-f5db-4905-9bd1-e6f6ab56ae66", "6675e023-60b6-4e44-898e-5d59f4c4f31e", "9a7e5805-f608-4691-bd9c-b0714a308818"], "metadata": {"page_label": "39", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}}, "40a58b3d-7df0-4217-8a28-e348002a8d80": {"node_ids": ["09572bee-5327-49af-9760-3685b32ef464", "552c93a8-2f38-47cc-b3aa-6c1eddf6297b", "ca34776d-066a-4226-8723-2af30872f5e0", "fe080274-f7b4-4e97-900d-5c50cc802205", "54509ef9-e00c-47c0-a106-6ec84e7fdfa4"], "metadata": {"page_label": "40", "file_name": "covid-19.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\covid-19.pdf", "file_type": "application/pdf", "file_size": 2126972, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}}, "c5f7a6a3-9008-43b6-9d62-bd8d67c3fb4e": {"node_ids": ["e1b1819e-6c38-4e5d-bb5f-7776fddf1899", "eca16efd-d3d1-4110-81b8-0dd23cf8dd60", "c28979a0-a56d-455c-94f8-1eee57118566", "084760c7-1e6e-477f-8d56-866e153245be"], "metadata": {"page_label": "1", "file_name": "diabetes.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\diabetes.pdf", "file_type": "application/pdf", "file_size": 367943, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}}, "b5ea9a47-6efd-4bbb-a59f-d20d7c568fc0": {"node_ids": ["55df77c4-2154-48a7-873d-7d2a379ab133", "08590a5c-4710-49d6-9590-49040107a158", "b9478731-1b40-46fc-b0d7-de120548439a", "d85d410f-5469-4dc7-950e-55b38733ab8e"], "metadata": {"page_label": "2", "file_name": "diabetes.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\diabetes.pdf", "file_type": "application/pdf", "file_size": 367943, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}}, "dca39f39-0906-442f-a7e3-1281a5f2d30a": {"node_ids": ["35792614-9985-437c-a269-60be3cc60c4e", "51172858-d7ee-4a8b-aa02-f564c201792e"], "metadata": {"page_label": "3", "file_name": "diabetes.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\diabetes.pdf", "file_type": "application/pdf", "file_size": 367943, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}}, "aac21c47-5379-4e51-86de-fe537032c27f": {"node_ids": ["86e29728-680c-4951-817c-a38010f4fa7b", "8155e70a-1c8c-4820-a5d5-cb600f880e2f", "9eea549a-7051-4428-8d41-c1bbb8d3455b"], "metadata": {"page_label": "4", "file_name": "diabetes.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\diabetes.pdf", "file_type": "application/pdf", "file_size": 367943, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}}, "a844fd4c-b679-4cf6-b6f7-c4b6aa1923bb": {"node_ids": ["414e5bfe-4872-42b5-9cd6-307662e6dc0b", "184b8647-d17e-466f-9ef2-7466476f8e0c", "47907812-53e5-43ec-95dd-44fe1b6cfea0"], "metadata": {"page_label": "5", "file_name": "diabetes.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\diabetes.pdf", "file_type": "application/pdf", "file_size": 367943, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}}, "3539126f-3ec2-4806-9bd1-bd7333cf6313": {"node_ids": ["8fb71b35-2a1f-4ecc-a47b-c9b01968957f", "92f1a912-88bb-4d1b-ae5f-7dacd9a0e1e8", "b669ff45-46b9-4e4d-98d1-f8eaf5ded86e", "3963aa60-62f6-4aa0-bbf5-a376ac8c9630"], "metadata": {"page_label": "6", "file_name": "diabetes.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\diabetes.pdf", "file_type": "application/pdf", "file_size": 367943, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}}, "a1d7cf10-2bd5-4ce6-92e0-722bdf4869e1": {"node_ids": ["5aa4316d-0ebb-4717-b46f-49bd3cd4ca55", "bca466cd-6cd6-4f38-b74a-de5195810b24", "e1c61976-c09b-4a76-b40b-d2419f725813"], "metadata": {"page_label": "7", "file_name": "diabetes.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\diabetes.pdf", "file_type": "application/pdf", "file_size": 367943, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}}, "a7f203c6-f1c6-4391-9a2f-93ecbac8d1dd": {"node_ids": ["1d79b886-737a-483d-a26d-376cfc48458f", "a2a99af2-e4cc-432f-bce4-8edad3763e80", "3eafa7ba-56f5-4451-8785-c328b29ec380", "f3aa6e5d-e0e8-4ee0-bc61-708245188420", "fe81ec9e-e6e6-4483-8856-a4e2850143c9"], "metadata": {"page_label": "8", "file_name": "diabetes.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\diabetes.pdf", "file_type": "application/pdf", "file_size": 367943, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}}, "39481e14-6b63-4449-a5ee-4b06a012c44f": {"node_ids": ["ab368f89-f8c5-409b-9013-c183c28d1418", "0dce0402-7f17-4b1f-a472-d6a3d72da830", "e4fc74fc-a671-4d39-8083-3f025e8aeb39", "ea34ce3d-650b-41d0-a490-b067537189c1", "e6839b33-cc71-42a9-96b6-c2314e023cbe", "b6e2be3d-e2d6-4829-ad67-47a0c3d672cf", "0dd99e3b-76c5-4a19-95f3-981e59f654b6"], "metadata": {"page_label": "9", "file_name": "diabetes.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\diabetes.pdf", "file_type": "application/pdf", "file_size": 367943, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}}, "7827c7e0-209d-4f3c-98cd-4e7e5502aaa8": {"node_ids": ["4b6b46c6-3d6a-4af0-ad3f-7b9a69e689d9", "e4140117-03cc-4202-b9f9-fffa9720af1b", "d6489447-2c60-4546-82bb-5727e8008381", "66532eb0-3541-4668-876a-8fd4e0346f49", "71c79a8f-8287-4e48-a5d6-1ad1dabdc29a", "953758ae-18d0-4aab-8c51-e0867a21c2b5", "752fdde1-5c2f-48e1-a8fd-049456f462ce"], "metadata": {"page_label": "10", "file_name": "diabetes.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\diabetes.pdf", "file_type": "application/pdf", "file_size": 367943, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}}, "33045505-2c07-40e6-82b9-5f3306e83032": {"node_ids": ["6a838443-b8b5-4cb7-a153-0a1ec754f796", "5be15974-4aa0-4328-abdd-2ab743e97e0b"], "metadata": {"page_label": "11", "file_name": "diabetes.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\diabetes.pdf", "file_type": "application/pdf", "file_size": 367943, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}}, "dd91fae4-be27-449b-a248-277d07df1d2b": {"node_ids": ["7866a12d-ea8e-4bda-a978-6372894c2c1b", "16b8c2c7-c3a3-42c7-b179-2a778bbef49e", "80afa5aa-912c-4fd0-bb49-05fc5a3c142d"], "metadata": {"page_label": "1", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}}, "e96eecb7-db70-42f3-9855-5a5d46be4548": {"node_ids": ["71f6c3d3-5174-4810-b031-f8452bf8f1d9", "13cc55f7-6d02-4e6a-adc1-876b28b1978f", "654a5b40-f7a2-4739-bfc9-7c34c1940a93"], "metadata": {"page_label": "2", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}}, "1182aac5-628f-4dfc-8301-7bcdceca52b4": {"node_ids": ["de3de816-f2c3-4703-8b4e-f4550c230a41", "5a140d87-0202-43ed-a33d-d451e6603d91", "c5bcad1f-9701-4136-8f47-f3a809c7d7d2"], "metadata": {"page_label": "3", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}}, "1c377ee8-1469-4e10-b0b8-ba80ff296a3a": {"node_ids": ["3846a556-2d32-4516-a106-3072212efb6c", "d598ef87-fae1-4432-a1fe-21317eeb9186", "27237d82-84ff-4a1b-b944-f5fafa775657"], "metadata": {"page_label": "4", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}}, "791a0f49-b547-4d2a-9f91-edfdf60f37bb": {"node_ids": ["d5d4676e-b888-4b05-ba77-945f806a0550", "e023cf11-7e7a-43a2-8d7b-ec64206ea261", "92648530-da59-40b6-82f1-4e7f40c3ff41"], "metadata": {"page_label": "5", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}}, "10a724cc-bf62-43cb-92a1-a06be3357109": {"node_ids": ["497852dc-ae34-4097-bd60-8f9def2d1b94", "4e01d8e4-5747-4590-9030-b053b1624161", "59f7dca9-88f5-457f-8c8b-5a0e08c9f925"], "metadata": {"page_label": "6", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}}, "a5baa07e-5af2-46c6-a9a2-1afb1352c612": {"node_ids": ["824d7b93-602b-46fe-9b10-4bfc25b204d2", "c2ccfc5a-0072-402e-ba0e-cffcf5cd1ea7", "1e538796-df0c-4506-8a6c-36039334b143"], "metadata": {"page_label": "7", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}}, "aecfdb3e-ff3d-4f2c-8cc1-48157ad3b135": {"node_ids": ["41fde725-70c6-465a-a0e5-a02f9c112da8", "13456ae3-8aa7-4e2a-9037-18fe7a5ebcda", "0138a9e3-a65c-4817-9a9e-e0cc78ce9191", "bf796889-c1e7-4fd8-b0aa-517cd9178427"], "metadata": {"page_label": "8", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}}, "a4a8ac4a-99d7-4810-ba3b-e6894f3e75ae": {"node_ids": ["b5e6becb-1df3-442d-bfb2-9bb3b61fb783", "45133e3c-cd70-4d5d-a82c-afdbbe2385d7", "0ae5e854-fb4a-49a9-a284-ac5dfb4d6509"], "metadata": {"page_label": "9", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}}, "a1d5c5e6-4e47-480d-8c2c-af946efb80fb": {"node_ids": ["6879715a-a8a2-421d-9290-66a7604a7e33", "498e746c-cefd-44f5-add4-c03336001e00", "dc1b7aa9-d0c4-48e2-a54d-cf43695252bf"], "metadata": {"page_label": "10", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}}, "a1c087bc-2e51-4305-9201-5228bfb3c768": {"node_ids": ["3b303a47-137a-41cd-be1a-f40037d3ff59", "35d67d94-f935-473d-a051-e812556f9355", "71cd2865-07a0-45d1-bcaa-d3ad396dd52d"], "metadata": {"page_label": "11", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}}, "4cb35e6b-30fc-4519-9aa4-975b4b57c0c8": {"node_ids": ["20106827-6f98-4085-a815-ed964909bcad", "a772ff8e-9458-45c8-9d0b-f4f20c78032f", "03549e66-b6ba-41ad-8126-3c1b244583ce"], "metadata": {"page_label": "12", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}}, "4c17322b-c2e5-40ca-8710-f8857fb2cb81": {"node_ids": ["cacc2a75-4d8e-476e-9aa9-c80c0716b262", "a6620ad9-62c5-4854-a84e-e25dd8aa4d54", "05e4ef80-5524-42bd-9ab4-1057b69cf6fe"], "metadata": {"page_label": "13", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}}, "e5c7d5c0-71be-4ad5-9125-36dfd5ae13e4": {"node_ids": ["68799a17-b209-44e9-8512-8d4f40cec8a2", "ad70c1d4-03e3-4afc-908b-e674f2c2bcda", "7d4f5ed1-ed0b-4932-b2bf-cd6cd364d03e"], "metadata": {"page_label": "14", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}}, "8e7c1b08-1d21-4307-abcc-1e340fabac0a": {"node_ids": ["e99027de-fc48-419e-8e16-9e8d1474b75d", "1d4e135d-dfbf-4eda-9b58-35279bb92cad", "7d47a0da-dc5e-4a4b-a215-82096cf4fbda"], "metadata": {"page_label": "15", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}}, "56b81214-cfed-44aa-aaec-bdb3ee5d19e3": {"node_ids": ["996d1ae0-b8f2-4bff-bb53-0fb42c8cc539", "10a69b3c-1745-4bc7-8685-073f0c1a09d3", "2efb6bb5-ee70-4803-b291-673b3279d5d4", "0a43f452-f539-4fe3-95b7-575d8dadbf30"], "metadata": {"page_label": "16", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}}, "6656a408-9072-424b-a574-b2d5d7ae23fa": {"node_ids": ["6f3216fa-99e0-4495-b69d-bb8eb06b0efb", "363349bf-8bdf-471c-ad57-ccd1f0a3933a", "a26b4899-0d39-4ddb-adf0-9bed04d7565f", "f8f188ae-091e-477f-b425-0ce420677492"], "metadata": {"page_label": "17", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}}, "96bbad54-f8ad-4af4-9292-0bc5be3d8462": {"node_ids": ["89cab3be-0e04-44ce-abe3-405a57c41158", "f70ec346-0b6e-48c5-99ba-99e9db14c076", "f55c21cd-439f-4bf5-9d28-65625c6b6150", "f9a66bb8-404d-4cea-8fb6-ab310583e9b3"], "metadata": {"page_label": "18", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}}, "35714a6b-6a03-414b-81b5-d7d8ae4d7c37": {"node_ids": ["ef985fcc-2625-4241-817b-cdaa881c4689", "54570a77-e1bf-4e4c-9fc4-9f76417f85d4", "b8b12894-9b4b-4dac-8772-a6accb1a43f0", "a35925db-c7f1-4a62-9124-c9221eab866f"], "metadata": {"page_label": "19", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}}, "7dd90457-d3c3-4ffb-b1a9-3ec1ccd68129": {"node_ids": ["f343b160-28aa-4823-95a2-e9408e25c95f", "6b702833-fbdc-4732-ba97-bb023faa3e10", "0b425afd-fd6a-465d-9a28-cabda7071ac6", "42b1197e-485b-45b9-9b88-a4911a3021d2"], "metadata": {"page_label": "20", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}}, "0aad7860-77ee-4e44-9e82-2117738954e5": {"node_ids": ["8d6226c1-2cbf-4d5d-90bf-eb2ec99f8156", "5ab467e3-7122-4b75-a9e9-a3a697961efc", "470c6f81-d686-4ef2-a5f1-2c7c1916c2a4", "9577ee16-f52b-44a2-b6c5-c21c86b600d4"], "metadata": {"page_label": "21", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}}, "4949872a-97be-41da-9a52-628746554ae9": {"node_ids": ["a6913d12-efbe-4eef-8b55-e29523b00d94", "2f2d25f0-3d35-44fc-8303-82b0baaa962d", "0e5717ae-80f7-4a3a-b895-e564d226412d", "030f74e5-5423-4804-8aa2-aebaf1374913"], "metadata": {"page_label": "22", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}}, "077e5723-f58f-475f-a396-04541c26005d": {"node_ids": ["e9309ab0-0931-4665-acaa-c8379e647e21", "001586eb-5057-4760-8f56-7580a1b08c08", "40a81f9c-3cc7-486d-9e5b-e77d3e6d0afa", "e89ce251-a2f9-414d-8406-8a28c5970410"], "metadata": {"page_label": "23", "file_name": "Hypertension treatment.pdf", "file_path": "e:\\LLama-Index\\LlamaIndex Basics\\medical_papers\\Hypertension treatment.pdf", "file_type": "application/pdf", "file_size": 821303, "creation_date": "2025-02-24", "last_modified_date": "2025-02-24"}}}}